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The Special Issue on high grade serous ovarian cancer (HGSOC) and the contribution of the tumor
micro-environment (TME) consisted of reviews contributed by leaders in the ovarian cancer (OC)
field. As HGSOC metastases have a highly complex TME, there is an urgent need to better understand
the TME in general, its distinct components in particular, and the role of the TME in the context of
disease recurrence and development of chemoresistance. The Special Issue integrated the current
understanding of the TME components, including malignant cells, surrounding host stromal cells,
and infiltrating (recruited) immune cells. In addition to cellular contributors to the TME, the role of
ascites fluid components including soluble factors such as cytokines, chemokines, and growth factors;
cell–cell and cell–matrix adhesion molecules; extracellular matrix remodeling; and abnormal vascular
and lymphatic networks were the subject of reviews. Reviews covered the relationship between the
molecular mechanisms of HGSOC progression, including genomic, epigenomic, and transcriptomic
changes, and alterations of the immune cell landscape, as these may provide attractive new molecular
targets for HGSOC therapy.
Prof. Dr. Stack et al. [1] illustrated how the aging process has been shown to modulate the TME
in ways that are beneficial to the spread and survival of ovarian cancer. Aging hosts have been shown
to better facilitate cancer associated inflammation, invasion, and adhesion of cancer cells, while also
putting forth a weakened immune response. More research into the unique features of an aging
peritoneum is needed to better treat aging HGSOC patients.
Prof. Dr. Nephew and Prof. Dr. Klemenko illustrated how cells constituting the TME are also
involved in epigenetic crosstalk with ovarian cancer cells [2]. Ovarian cancer cells have been shown to
epigenetically reprogram a wide variety of cell types in their microenvironment to promote tumor
growth, survival, and metastasis. There is also growing evidence to suggest that cells from the tumor
microenvironment are capable of epigenetically modifying cancer cells. Prof. Dr. Mitra et al. discussed
cancer associated fibroblasts; fibroblasts that have been reprogrammed by cancer cells to support tumor
growth, survival, and spread, through the secretion of cancer promoting factors. Further research into
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their origin and identifying markers is needed in order to better characterize their function within
the TME [3].
There is still a great deal of research to be done regarding the roles of individual proteins in ovarian
cancer. As illustrated by Prof. Dr. Burdette et al. [4], the paired box protein PAX8 is overexpressed in
HGSOCs and confers advantages in growth, survival, and migration. While PAX2 has been shown
to impart similar growth advantages, expression of it is lost early on in carcinogenesis. Prof. Dr.
Hilliard’s review focused on mesothelin which is believed to play a role in survival, proliferation,
tumor progression, and adherence. Though its native biological function is poorly understood, it is
known to bind to the ovarian cancer biomarker CA125, through which it plays a role in metastasis [5].
Prof. Dr. Hudson and colleagues discussed how many of the signaling pathways implicated in HGSOC
converge on the small GTPase Rac1, which is associated not only with actin remodeling, adhesion, and
migration, but also EMT, stemness, angiogenesis, and chemoresistance [6]. Rac1’s role in such a high
number of cancer associated signaling pathways makes it an appealing target for anticancer therapies.
HGSOC presents unique challenges in the development of effective immunotherapies to combat
spread and progression. Prof. Dr. Vanderhyden et al. [7,8] showed how the low mutational burden,
recruitment of T-regs, upregulation of immune checkpoint proteins, and heterogeneity associated with
epithelial ovarian cancer have served as road blocks in the development of ovarian cancer immune
therapies. Prof. Dr. Drakes and Prof. Dr. Stiff illustrated the importance of understanding the factors
in the TME that contribute to the immunogenicity of HGSOC in the development of immune therapies
and more accurate prognosis of patients [9]. Improvements in immune therapies that result from
better characterizing immune modulating TME factors, combined with treatments targeting other
areas of the malignancy are important efforts to increase the survival of patients. In their chapter,
Prof. Dr. Khabele et al. [10,11] illustrated how macrophages in the TME represent cancer promoting
and antitumor forces in ovarian cancer. Cancer promoting M2 tumor associated macrophages (TAM)
represent an attractive target for anticancer therapies. Reprogramming of these M2 cells to M1
tumoricidal macrophages constitutes a promising means of manipulating the TME to be less amenable
to the malignancy.
HGSOC is a malignancy once thought to originate exclusively from the ovarian surface epithelium.
Prof. Dr. Kim et al. [12] reviewed current evidence that suggests HGSOC likely also originates from
serous tubal intraepithelial carcinomas (STICs) from the fallopian tube epithelium. Though STIC has
been shown to correlate with an increased risk of HGSOC, it is still important to show causation.
Additionally, it is important to elucidate the differences between STIC lesions likely to remain benign
vs those that are likely to develop into HGSOC.
Epithelial ovarian cancer is commonly associated with metastasis to the peritoneum, though
it has been shown to colonize a wide range of other tissues. Prof. Dr. Barbolina’s review focused
on the mechanisms of transcoelomic, hematogenous, and lymphatic metastasis [13]. Though most
patients typically succumb to transcoelomic, the presence of distant metastasis is associated with worse
prognosis. As treatment of transcoelomic metastasis improves, it is likely that more research will have
to be devoted to hematogenous and lymphatic spread in order to further improve patient outcomes.
Understanding the interactions between ovarian cancer and metabolites is critical to understanding
and treating the disease. In his review, Prof. Dr. Xu outlined how supportive cells have been shown to
produce cancer-promoting oncolipids [14]. Improvements to existing detection methods will be valuable
in the use of oncolipids as a diagnostic marker in gynecological cancers. Additionally, HGSOC exhibits
a reliance on oxidative phosphorylation for its energy needs, making inhibition of the OXPHOS
pathway an intriguing target for novel therapies. Prof. Dr. Patankar et al. [15] discussed how OXPHOS
inhibition slows proliferation through energy depletion and increases oxidative damage, and through
it, cell death. Development of targeted delivery systems for inhibitors of this pathway are needed.
Given the complex roles that the TME plays in supporting tumors, it follows that more
sophisticated in vitro models are needed to recapitulate the conditions in which cancer cells exist. Prof.
Dr. Kenny et al. [16] described some of the recent developments in 3D modeling of ovarian cancer.
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Models approximating in situ carcinoma in the fallopian tube, dissemination into the peritoneal cavity,
early metastatic attachment to the mesothelial-lined surfaces of the omentum, bowel, and abdominal
wall, and late chemoresistant metastases are needed.
The TME of ovarian cancer has numerous unique features that need to be considered in the study
and treatment of the disease. According to Prof. Dr. O’Hagan and colleagues [17], recent studies
have shown an association between inflammation and an increase in ovarian cancer risk. Though this
phenomenon has been well characterized in colon and pancreatic cancers, the mechanisms through
which inflammation contributes to ovarian cancer risk need further study. Prof. Dr. Hawkins et al. [18]
explained how endometriosis increases the risk of developing endometrioid, clear cell carcinoma, and
low grade serous ovarian cancers. The unique tumor microenvironment created by endometriosis
facilitates tumorigenesis through upregulation of many gene products associated with ovarian cancers.
A number of other therapeutic avenues are being explored in ovarian cancer treatment. Efficient
targeting of a chemoresistant sub-population of cancer cells known as cancer stem cells (CSC) is a
rapidly growing field in the study of high grade serous ovarian cancer. As shown by Prof. Dr. Dahl
and Prof. Dr. Roy, the PI3K/PTEN/AKT, Jak/STAT, NFkB, Notch, Wnt, and Hedgehog pathways have
all been implicated in the maintenance of cancer stem cells, many of which have therapeutics targeting
them currently undergoing clinical trials. Further study is needed to better identify cancer stem cell
populations and the mechanisms through which these pathways are involved in their maintenance.
Another treatment option, known as heated intraperitoneal chemotherapy was discussed by Prof.
Dr. Jewell et al. [19] The higher drug levels delivered through HIPEC combined with hyperthermia are
thought to increase the efficacy of chemotherapy. Studies showing the benefit of HIPEC along with CRS
have been promising, however, use of HIPEC in recurrent cancers warrants further study. The relative
safety of this treatment also warrants further investigation. Strategies for treatments targeting
supportive components of the TME outlined by Prof. Dr. Matei et al. [20] represent a promising
avenue in improving clinical outcomes in patients. Inhibition of angiogenesis, immune therapies, and
therapies targeting supportive stromal cells are being explored as therapies to improve survival in
HGSOC patients, though more research is needed to increase the efficacy of these approaches.
The planning of this special issue was motivated by the Albert Trust Midwest Ovarian Cancer
Coalition (MWOCC) biannual meeting, held in June 2018. We would like to express our deepest
gratitude to the conference sponsor, The Leo and Anne Albert Charitable Trust, Mr. Gene Pranzo
(Trustee), and Susan Brogan (organizer). We sincerely thank all the attendees and participants who
kindly contributed manuscripts of the highest quality to this issue.
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Abstract: Age is one of the biggest risk factors for ovarian cancer. Older women have higher
rates of diagnosis and death associated with the disease. In mouse models, it was shown that
aged mice had greater tumor burden than their younger counterparts when intraperitoneally
injected with ovarian tumor cells. While very few papers have been published looking at the
direct link between ovarian cancer metastasis and age, there is a wealth of information on how age
affects metastatic microenvironments. Mesothelial cells, the peritoneal extracellular matrix (ECM),
fibroblasts, adipocytes and immune cells all exhibit distinct changes with age. The aged peritoneum
hosts a higher number of senescent cells than its younger counterpart, in both the mesothelium
and the stroma. These senescent cells promote an inflammatory profile and overexpress Matrix
Metalloproteinases (MMPs), which remodel the ECM. The aged ECM is also modified by dysregulated
collagen and laminin synthesis, increases in age-related crosslinking and increasing ovarian cancer
invasion into the matrix. These changes contribute to a vastly different microenvironment in young
and aged models for circulating ovarian cancer cells, creating a more welcoming “soil”.
Keywords: ovarian cancer; age; tumor microenvironment; extracellular matrix; mesothelial cells;
immune; fibroblast; adipocytes; peritoneum
1. Introduction
Ovarian cancer (OvCa) is the deadliest gynecological cancer, with a survival rate under 50% [1].
One of the biggest risk factors for OvCa is age, where the median age of diagnosis is 63 and median
age of death is 70 [1]. Aging, as defined in the Hallmarks of Aging, is “the time-dependent functional
decline that affects most living organisms” [2]. A call for research investigating the relationship between
OvCa and aging was voiced in 1993 by Yancik after a review of epidemiologic data, showing older
women were not only more likely to be diagnosed with OvCa but were more likely to die from their
disease [3]. Yancik raised the question that has propelled the research in this field: why is there is a
difference in survival between young and aged patients? Is there a difference in treatment, or does
the cancer behave differently in older women? In 2013, epidemiological data were reviewed again by
Trillsch et al. and their data suggest that older patients often receive less radical treatment, contributing
to this disparity [4]. However, it is likely that there is more contributing to this disparity than physician
partiality alone. A separate epidemiological study showed that older OvCa patients have a two-fold
increase in peritoneal metastases relative to younger patients at time of diagnosis, suggesting that there
is more to be discovered in the relationship between OvCa and aging [5]. Here we review the aging
Cancers 2018, 10, 230; doi:10.3390/cancers10070230 www.mdpi.com/journal/cancers5
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studies in the OvCa field, as well as aging studies involving distinct components of the peritoneal
metastatic microenvironment.
OvCa metastasizes in a very unique fashion, where cells are exfoliated from the primary tumor as
either single cells or multicellular aggregates and circulate through the peritoneal cavity via diffusion
in the peritoneal fluid [6]. The circulating cells adhere to secondary sites, such as the omentum and
parietal peritoneum, via interactions with mesothelial cells [6]. The OvCa cells induce mesothelial cell
retraction, then invade into and anchor in the collagen-rich submesothelial matrix [6]. The OvCa cells
can then proliferate and form a metastatic lesion [6]. Aging can affect nearly every step of this process.
The peritoneum is a vast, serous membrane covering the interior of the abdomen and the visceral
organs. The parietal peritoneum covers the interior of the abdominal wall, then folds to form the
omentum, which lies between the parietal peritoneum and the anterior surface of the abdominal
organs. The omentum is an organ rich in adipocytes and immune cells. Both the omentum and the
parietal peritoneum are composed of a collagen-rich matrix covered by the mesothelium, separated by
a thin basement membrane. The mesothelium is a single monolayer of simple squamous epithelial-like
cells, or mesothelial cells, that cover the surface of the peritoneum. The basement membrane is a thin
layer (<100 nm) composed mostly of collagen IV and laminin that separates the mesothelium from
the elastic matrix below [7]. This matrix is comprised mostly of collagens I and III but contains other
entities such as fibroblasts, immune cells, adipocytes, lymphatics and limited cardiovasculature [7].
Each of the components has the potential to react differently to OvCa cells through age-related changes
(Figure 1).
 
Figure 1. Changes in the Aged Microenvironment. Young: In the young metastatic microenvironment,
collagens I and III form a directionally random meshwork that supports the tissue. In addition, there
are low rates of senescence in mesothelial cells, fibroblasts and adipocytes, all of which secrete factors
into the extracellular environment, forming the young secretome. The young secretome is characterized
by decreased Matrix Metalloproteinase (MMP) expression, increased cytokine expression by immune
cells, decreased cytokine expression by fibroblasts and decreased adipocyte-associated inflammatory
factors. Milky spot immune cell aggregates exist in both young and aged metastatic environments,
providing the tumor with abundant vascularization. Aged: In the aged metastatic microenvironment,
there are lower levels of collagens I and III, which are remodeled to form more aligned, linear structures.
In addition, higher levels of senescence alter the secretome, increasing inflammation and other factors
that can promote ovarian cancer (OvCa) metastasis.
The aging peritoneal microenvironment is defined in large part by two processes: extracellular
matrix (ECM) remodeling and cellular senescence. Changes in collagen, laminin and fibronectin have
the potential to alter how the metastatic OvCa cells invade into the peritoneum [8–10]. Senescence-
induced changes in fibroblasts, mesothelial cells and immune cells drastically alter the secretome of
the microenvironment, causing an increase in the transcription of factors that are associated with
inflammation and angiogenesis [11,12]. Senescence is a cell’s permanent exit from the cell cycle and was
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first attributed to telomere attrition [13]. More recently, a number of factors have been identified that
contribute to cellular senescence, including DNA damage [14,15], oxidative stress [16,17], high levels of
glucose [18,19], transforming growth factor-β (TGF-β), [18,20–22] and the tumor suppressors p16INK4a
and p53 [2]. While senescence within the tumor itself suppresses tumor growth [2,23], senescence in
the microenvironment has been shown to increase tumor growth [24,25].
Interestingly, the role of p53 also varies greatly between OvCa cells and microenvironment. It was
reported that in a C57Bl/6 model, ID8 cells with a p53 deletion showed greater tumor growth than the
ID8 parental cells [26]. However, p53 is overexpressed in the aging OvCa tumor microenvironment as
a result of oxidative stress, oncogenic stress and DNA damage [27,28]. In response to severe damage,
p53 determines cell fate, inducing either senescence or apoptosis. In epithelial and stromal cell lines,
p53 more frequently induces senescence [28]. This leads to increased Matrix Metalloproteinase (MMP)
secretion, a remodeling of the ECM and disruption of normal epithelial cell differentiation [28,29].
For reasons to be addressed, these effects contribute to increased OvCa metastasis and occur more
dramatically in aged individuals.
2. Aging Modifies the Metastatic Microenvironment
In vivo models of intraperitoneal (IP) metastasis have been utilized to demonstrate an age-related
difference in tumor burden in mice injected with ovarian tumor cells. When IP injected with syngeneic
tumor cell lines, both C57Bl/6 and FVB mice exhibited a dramatic difference in disease progression
between the young (3–6 months) and aged (20–23 months) cohort, with the aged mice harboring
greater tumor burden than their younger counterparts [26]. Transcriptome analysis of gonadal adipose
tissue from young and aged mice points to a difference in immune response in the aged mice but
it is likely that the immune system is only one of the components of the microenvironment that is
contributing to the age-related disparity in metastasis [26].
2.1. Mesothelial Cells
The mesothelium, a cobblestone monolayer of cells that exhibit characteristics of both epithelial
and mesenchymal cells, lines the surface of the peritoneum. Its function in normal tissue is to create a
barrier and limit the permeability of the peritoneum, as well as secretion of factors that are involved in
peritoneal homeostasis and launching appropriate immune responses to pathogens [30]. These cells are
very important in the adhesion of OvCa cells to secondary metastatic site. The senescent mesothelial
population increases as the host ages, due to both increased rates of senescence as well as the resistance
of senescent cells to pro-apoptotic signaling [5,31].
Senescent mesothelial cells change the cellular signaling in the tumor microenvironment,
expressing factors such as fibronectin [16,32], intercellular adhesion molecule-1 (ICAM-1) [33],
beta-galactosidase [31,34] and thymosin beta-10 [35]. Fibronectin, a mediator of cell-extracellular
matrix interaction, has been shown to be increased in aging tissues [36]. This increase has been
linked with increased OvCa cell adhesion [16] and increases tissue stiffness (which will be discussed
in more detail in Section 2.3.1) [37]. The increase in OvCa cell adhesion is partially mediated by
mesothelial ICAM-1, an adhesion molecule expressed by mesothelial cells that has been shown to be
important in other abdominal cancers that metastasize to the peritoneum [33]. In addition, profiles
of human peritoneal mesothelial cells isolated from young (mature adults under the age of 65) and
aged (over the age of 65) patients showed an increase in inflammation-associated factors, suggesting
increased inflammation in the aged mesothelium [38]. It was shown that age was associated with an
increase in both the cyclooxygenase (COX) and nitric oxide synthase (NOX) pro-inflammatory systems,
an upregulation of nuclear factor-κB (NF-κB) and inflammatory cytokines and an increase in reactive
oxygen species (ROS) in mesothelial cells [38]. ROS have been shown to be a mediator of senescence;
increased ROS results in increased cellular senescence [39]. Additional information on inflammation
and the role of the immune system is included in Section 2.4.
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Senescent mesothelial cells have been shown to interact with metastasizing OvCa cells, altering the
OvCa secretome to express angiogenic agents such as chemokine CXC ligand 2 (CXCL1), chemokine CXC
ligand 8 (CXCL8), hepatocyte growth factor (HGF) and vascular endothelial growth factor (VEGF) [40].
Mikuła-Pietrasik et al. saw increased angiogenesis in mouse models when OvCa was coinjected with
senescent human peritoneal mesothelial cells (HPMCs) [40]. This process is mediated by TGF-β1 and
IL-6, which are overexpressed in aged mesothelial cells [38,40]. When OvCa cells were incubated with
senescent mesothelial cell conditioned media, they experienced higher levels of proliferation than those
incubated with conditioned media from young cells, suggesting soluble factors released by senescent
mesothelial cells promote the proliferation of OvCa cells [40]. OvCa cells with conditioned media
from senescent mesothelial cells also showed greater migration and invasion in vitro [40]. In addition,
histological analysis of patient tumors showed the presence of senescent mesothelial cells in cancerous
tissues [40]. It is likely that an accumulation of senescent mesothelial cells, as seen in tissue from aged
patients, provides a more welcoming metastatic niche for circulating OvCa cells [5].
Hyaluronic acid, or hyaluronan (HA), is a glycosaminoglycan secreted by cells with mesenchymal
characteristics, such as mesothelial cells. It acts as a mediator of ECM organization as well as a lubricant
on the mesothelial surface [41,42]. HA is also an FDA-approved treatment for osteoarthritis and is a
popular treatment used by plastic surgeons to reverse the signs of aging of the skin [43,44]. Relevant
studies have shown two divergent lines of research: HA increasing [45–47] or decreasing [48–50] cell
adhesion. However, certain OvCa cells lines have been shown to bind directly to HA, suggesting HA
increases OvCa cell adhesion [46]. This likely contributes to the observation in ovarian and prostate
cancer patients, where overexpression of HA generally results in a poorer prognosis [11,51]. In addition,
HA has been shown to impact cell migration [52–54] and cell proliferation [54–56], to activate skin
fibroblasts [57] and to be upregulated in response to inflammation [58]. There is not much information
available on the effects of age on HA other than an observed decrease in aged tissue, likely due to the
decreased synthetic capacity of aged cells [41,59]. However, the use of HA in the treatment of age-related
diseases suggests that the role of HA in the aging microenvironment warrants further investigation.
2.2. Extracellular Matrix
The peritoneal ECM is a complex system that supports the cells of the peritoneum. Made up of
collagen, laminin and fibronection, the ECM plays an integral role in both normal peritoneal structure
as well as the metastatic success of OvCa. Directly beneath the mesothelial layer is a thin basement
membrane composed of collagen IV and laminin, covering an elastic matrix of collagens I and III,
laminin and fibronectin [60]. The ECM changes drastically with age, which can change how integrins
and syndecans bind to the ECM, thus altering the interaction between the metastasizing OvCa cells and
the tumor microenvironment [60], including increased adhesion of macrophages [61] and increased
cancer cell invasion [62].
2.2.1. Collagen
Collagen is one of the most abundant proteins in the body and forms a large portion of the
peritoneal extracellular matrix. There are multiple types of collagens; in the context of the peritoneum,
collagens I and III are the most notable, both of which are fibrous collagens [60]. On a molecular level,
both I and III have a similar amino acid structure distinct from other proteins, with glycine repeating
every third amino acid and a high percentage of prolines, which are often post-translationally modified
to become hydroxyprolines [63]. These amino acids chains come together to form the characteristic
triple helix, which are banded together in an overlapping manner to form fibrils with the distinct
D-banding pattern [63].
While little research has been done on the effects of aging on peritoneal collagen, there is a wealth
of information on skin collagen. As far back as 1975, scientists noted a significant decrease in the
amount of collagen in aged skin [64]. An immunohistochemical analysis showed amounts of collagens
I and III change as an individual ages [65]. Both collagens decrease in aged tissue but the ratio of
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collagen I/collagen III increases, suggesting that collagen I is decreasing at a slower rate than collagen
III [65]. The structure of collagen is disrupted with age, resulting in disorganization of the fibers
(Figure 2) [11]. In addition to skin, collagen extracted from human arteries, mouse tails and mouse
prostates showed alterations not only in structure but also in mRNA and protein expression, pointing
to a decrease in collagen synthesis as the culprit behind the decreasing amounts of collagen [11,66,67].
Later research showed that this decrease is likely due not only to decreased synthesis but increased
degradation as well [11,68].
Figure 2. Age-related changes in omental collagen structure. Second harmonic generation imaging
of omental tissue isolated from young and aged mice shows a distinct difference in structure.
Aged collagen forms crosslinks that result in the loss of meshwork, formation of tendon-like structures
and increased anisotropy. This causes a disruption of tissue structure that can affect how metastasizing
OvCa cells interact with the tumor microenvironment.
Matrix Metalloproteinases, or MMPs, are the main source of ECM degradation [69]. MMPs are a
family of 23 zinc-dependent enzymes that are divided into distinct groups: collagenases, gelatinases,
matrilysins and membrane-type MMPs [69]. Outside of gene regulation, MMPs are regulated in two
major ways: they require activation from the zymogen form in order to be active and active MMPs
are regulated by tissue inhibitors of metalloproteinases, or TIMPs [69,70]. MMPs are secreted from
numerous cell types within the microenvironment, such as fibroblasts and immune cells, as well as
the OvCa cells themselves [69,71]. Three MMPs have been shown to be upregulated in OvCa: MMP2,
MMP9 and MMP14 (also referred to as MT-MMP1) [13]. MMP14, a membrane-type, is present at
high levels in the tumor cells themselves, while MMP9, a gelatinase specific to collagens IV and V,
is more often upregulated in the stroma [71]. In addition, senescent cells have been shown to have
an increased expression of MMPs and addition of an MMP inhibitor reverses some senescent-specific
tissue phenotypes [72]. An upregulation of either MMP9 or MMP14 in the stroma around the tumor
cells is correlated with a more invasive phenotype, pointing to a critical role of MMPs in the tumor
microenvironment [71].
Due to its long half-life, post-translational modifications accumulate in collagenous tissue over
time [73]. Of particular interest here are modifications that create covalent crosslinks between collagen
molecules. Lysyl oxidase, or LOX, is a family of enzymes that modify lysine sidechains to form
desmosine through a Schiff base intermediate [74]. Recently, increased LOX crosslinks have been
shown to play a role in chemoresistance [75]. Advanced Glycation End-products, or AGEs, are formed
non-enzymatically as a result of glycosylation over time. These crosslinks have been shown to
9
Cancers 2018, 10, 230
change the structure and mechanical properties of collagen-rich tissues, such as the peritoneum [76].
Crosslinked collagen has higher fiber alignment, resulting in more tendon-like structures, causing the
tissue to lose elasticity and become stiffer than non-crosslinked collagen (Figure 2) [76,77]. An increase
in AGEs has been correlated with increased peritoneal permeability, which could contribute to
increased OvCa invasion [8]. In addition, stiffer matrices have been shown to increase cell motility,
proliferation and adhesion [9,10].
When AGEs occur in serum albumin, they can bind to the AGE receptor (RAGE) on monocytes and
trigger the release of tumor necrosis factor-α (TNF-α), leading to insulin resistance [78]. When bound
to RAGE on adipocytes, AGEs can induce the formation of ROS [78]. As mentioned in Section 2.1,
ROS have been shown to be a mediator of cellular senescence, where high levels cause enough cellular
damage for the cells to leave the cell cycle permanently [39]. Additionally, ROS can activate p53,
which is another pathway leading to cellular senescence [39]. In addition to their role in changing the
structure of the ECM, AGEs can also induce senescence in numerous cell types in the microenvironment
through formation of ROS and subsequent pathways [39,78].
2.2.2. Fibronectin
In contrast to the helical nature of collagen, fibronectin is a structural glycoprotein that forms
repeating beta-sheets in its folded form [37,79]. One of the main roles of fibronectin is mediating cell-cell
interactions [36]. Not only does the amount of fibronectin increase in aged tissues but aging fibronectin,
like collagen, shows an increase in anisotropy with age [36,37,79]. Fibronectin has also been shown
to stretch with age, resulting in increased stiffness [37]. In addition, fibroblasts interacting with aged
fibronectin responded differently than when interacting with young fibronectin [37]. The fibroblasts
interacting with aged fibronectin were shown to have longer β1 integrin adhesions as well as more
actin stress fibers [37]. In addition, as mentioned in Section 2.1, senescent mesothelial cells express
more fibronection, contributing to increased OvCa cell adhesion mediated by the α5β1 integrin [16].
2.2.3. Basement Membrane
The basement membrane (BM) is a component of the extracellular matrix that separates epithelial
cells from underlying connective tissue. It is primarily composed of collagen IV, intertwined with
laminin polymers [80,81]. The BM exhibits structural changes as it ages, most notably with aged cells
synthesizing less collagen IV than young cells [82,83]. While the basement membrane is understood to
thicken with age, the declined synthesis of collagen IV indicates that the thickness is due to decreased
turnover of aged tissues [82,83].
In primary ovarian tumors, collagen IV is absent on the ovarian surface [84]. This indicates
that OvCa cells must firstly degrade the ovarian BM (specifically, degrading collagen IV) to detach
from the ovary and shed into the intraperitoneal space [84]. Following this migration, cells then
alter the mesothelial BM to anchor and proliferate [85]. The mesothelial BM also has high collagen
IV and laminin content [85], so OvCa cells must again degrade collagen IV to gain entry into the
underlying ECM.
Disabled-2 (Dab2) is a signal transduction protein and tumor suppressor that also functions in
positional organization of ovarian surface cells. In OvCa, genetic and epigenetic changes to Dab2
enable tumor cells to escape ovarian BM control and proliferate in a disorganized fashion, resulting
in diffusion into the peritoneal cavity and metastasis [84]. Hypermethylation of the Dab2 promoter
results in epigenetic silencing of the gene, which is correlated with a loss of expression of collagen
IV [86]. Methylation patterns are known to change with age [87] and the effects of aging on methylation
can vary from inducing DNA hypomethylation to inducing hypermethylation. Such age-associated
deviation in methylation leads to advanced epigenetic damage in aged individuals [88]. It is possible
that DNA hyper-methylation of the Dab2 promoter may be affected by age, thereby impeding collagen
IV expression—increasing BM susceptibility to degradation.
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OvCa cells first bind to mesothelial cells to gain entry into the underlying matrix [85].
This adhesion is facilitated by ovarian cancer antigen CA125 and mesothelin interaction [89], and/or by
integrins such as β1-integrin and cell surface receptors such as CD44 (the receptor for HA) [85]. Upon
attachment to the mesothelium, OvCa cells upregulate MMP production, including that of MMP2 [85].
MMP2 preferentially interacts with collagen IV, resulting in the loss of basement membrane [90].
As aged cells are downregulated in their expression of collagen IV [83], this may lead to more efficient
BM degradation in the aged host. Additionally, in many cancers, Dab2 downregulation leads to
increased transcription of the ribonucleoprotein hnRNPK, which then enhances MMP2 transcription
by the metastatic cells [91]. Thus, downregulation of Dab2, as observed in OvCa metastatic cell lines,
may be correlated with increased MMP2 expression.
In addition to collagen IV, laminin provides structural support in the basement membrane [11,92].
Laminin is a trimeric protein with high homology between the alpha, beta and gamma trimers [11,92].
It is highly regulated in adults; the biggest changes observed in aging studies are the replacement of
fetal laminin with adult laminin [11,93]. However, in carcinogenesis, it was observed that prostate
tissues experience a loss of adult laminin, which results in disorganization of epithelial cells [11,93].
In addition, some tumor cells have been shown to increase expression of laminins, increasing cell
adhesion and invasion [92]. In the context of aging, it has been shown that there are decreased levels
of laminin in aged basement membranes [94,95]. In addition, laminins can also be AGE-modified,
leading to decreased laminin-collagen IV binding, which may make it easier for the OvCa cells to
invade through the basement membrane [94]. AGE modifications have also been shown to increase
laminin synthesis, however they also impair laminin assembly, likely contributing to the described
decrease in total laminin [94].
2.3. Fibroblasts
2.3.1. Senescent Fibroblasts
Fibroblasts are a stromal cell type, functioning in upkeep of the connective tissue environment
and ECM [96]. This upkeep is greatly altered with age in ways that promote tumorigenesis, such
as increasing angiogenesis and stimulating OvCa cell growth [97,98]. Aged fibroblasts secrete less
collagen and other proteins than their younger counterparts [96]. Furthermore, fibroblasts isolated
from older individuals had far higher rates of senescence than fibroblasts from younger individuals
with age, senescent fibroblasts accrue and replace presenescent cells (Figure 3) [24,25,96,99]—greatly
altering the function of the tissue in the process. Notably, accumulation of senescent fibroblasts in the
OvCa microenvironment is associated with increased cell proliferation and metastatic potential due to
interactions with the cancer cells [24].
Figure 3. Stromal-Epithelial Crosstalk. Active crosstalk occurs between senescent and activated
fibroblasts and OvCa cells. This induces activated fibroblasts, while concurrently inducing proliferation
and malignancy of the invading tumor.
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In a murine model, senescent fibroblasts partake in significant stromal-epithelial crosstalk
(Figure 3) [100], inducing premalignant epithelial cells to lose differentiation capacity, increase
invasiveness and eventually become fully malignant cells [99]. This can be attributed to many factors
secreted by senescent fibroblasts that alter the tissue microenvironment and stimulate growth of
epithelial cells expressing oncogenic mutations [12,101,102]. Increased fibroblast senescence results
in greater secretion of vascular endothelial growth factor (VEGF), which increases angiogenesis
of the region [97,98]. As tumors necessitate a vascular supply for efficient growth [103], increased
angiogenesis supports epithelial tumor growth. Senescent fibroblasts also secrete more MMPs [102],
which degrade collagen and the basement membrane [69,90]. These effects have been widely shown
to be correlated with increased cancer cell growth (Figure 3) [71,84]. Secretion of MMPs by senescent
fibroblasts also results in heightened microvascular permeability leading to a buildup of extracellular
fluid, which increases inflammation and damages the surrounding tissue matrix, possibly altering the
natural anti-tumorigenic nature of the presenescent microenvironment [72].
2.3.2. Fibroblast Activation
Epithelial tumor cells activate fibroblasts in the tumor stroma, stimulating a phenotypic switch
from normal fibroblasts to cancer-associated fibroblasts (CAFs) [104]. Epithelial OvCa cells secrete
factors such as chemokine growth-regulated oncogene 1 (Gro-1) [100]. Gro-1 induces the CAF
phenotype and, as Gro-1 is overexpressed in OvCa patients, there is significant evidence that Gro-1
alters the stromal environment to induce senescence in fibroblasts. This epithelial-stromal interaction
is critical in tumor initiation and proliferation. Ovarian CAFs promote tumor growth by secreting
cytokines and chemokines into the microenvironment [98,104], while non-recruited, presenescent
fibroblasts do not enhance tumorigenesis [100].
CAFs exhibit many of the same general characteristics as senescent fibroblasts [25,102]. Thus, as OvCa
cells recruit CAFs, they also induce pro-tumorigenic microenvironment changes as caused by senescent
fibroblasts described above (Figure 3). Both senescent fibroblasts and CAFs secrete CXCL12 [105], among
other pertinent factors such as IL6, IL8 and MMPs [106]. These increase inflammation and promote
angiogenesis, invasiveness and metastasis [105,106]. Secretion of chemokines—as observed in both
CAFs and senescent fibroblasts—is likely a key cancer-promoting function of fibroblasts [105]. Thus,
aging and increased senescence of fibroblasts alter the microenvironment and oncogenic cells
themselves in a way highly conducive to tumor growth (Figure 3).
2.4. Immune Cells
2.4.1. Tumor Cells Preferentially Adhere to Immune Cell Clusters
Ovarian cancer cells shed from the primary tumor and adhere preferentially to the peritoneum or
omentum in the abdominal cavity. The omentum, a visceral adipose tissue, is known to have a large
influence on peritoneal immunity due to its high quantity of lymphoid aggregates (Figure 1), often
called milky spots [107]. Within the omentum, initial attachment and growth of tumors were observed
to be most prevalent surrounding organized aggregates of immune cells [108]. Omental stem cells
exhibit a large capacity to produce angiogenic growth factors, resulting in high vascularization of the
region, particularly surrounding immune cells [103]. Avascular tumors are severely limited in growth
due to a lack of blood supply. Tumors must make an “angiogenic switch” to proliferate, where the initial
metastatic tumor initiates the formation of new vessels for increased blood supply [109]. However,
the tumor must anchor to a membrane before it can make the angiogenic switch. Studies show that
tumor cells preferentially bind to mesothelial cells directly above the omental immune cell cluster,
where the initial tumor is provided with an abundant blood supply from the existing vasculature of the
immune cell cluster. This contributes to the high survival rate of metastatic cells in the omentum [108].
Intraperitoneal injection of green fluorescent protein (GFP)-expressing tumor cells showed
localization to milky spots in the omentum [108]. This supports prior conclusions that migration
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and attachment of tumor cells to the omentum and specifically to immune aggregates, occurs from
migration from the peritoneal cavity and does not necessitate intravascular transportation. As tumor
cells metastasize, they disturb the structure of the immune cell aggregate and eventually displace
all immune cells from the metastatic tumor mass [108]. It is important to note, however, that while
hematogenous metastasis of OvCa to the peritoneal and omentum is not critical for cancer spread,
intravascular transportation of the tumor does occur with significant metastatic results [110,111].
2.4.2. Aging Affects Antitumor Macrophage Function in Peritoneum
Milky spot aggregates are comprised primarily of macrophages [112]. Studies exploring the
effect of aging on macrophage function prior to tumor exposure have yielded conflicting results,
although such discrepancies could be due to differences in sex, strain, species, or site of tissue in
macrophage isolation [113]. Isolated macrophages specifically from the peritoneum indicate lower
levels of inflammatory cytokine production with age (Table 1) [113,114]. Particularly, replicated in vitro
results indicate that macrophages of young mice produce higher amounts of tumor necrosis factor-α
(TNF-α), MMPs and have a higher phagocytic capacity than aged mice (Table 1) [115–117].
Studying the effect of decreased cytokine secretion on cancer in models of aging yields highly
conflicting results (Table 1, Figure 4). Firstly, TNF-α has both pro- and anti-tumorigenic effects. On one
hand, TNF-α could promote cancer due to its activation of cancer-promoting pathways such as NF-κB
and its correlation with increased angiogenesis, cell growth and metastasis [106,118]. On the other hand,
TNF-α also has inherent anti-tumor effects: the cytokine activates tumor-infiltrating dendritic cells and
promotes tumor stroma destruction [106,119]. Phagocytic efficiency and general cytotoxic capabilities
also decrease in aged models [120]. This could lead to increased cell proliferation in the aged host,
a hallmark of cancer [121]. However, increased cytokine secretion can lead to increased inflammation
in the tissue. This results in a mutagenic microenvironment abundant in growth factors and cytokines
that sustain angiogenesis, proliferation and invasion [122], which are three other hallmarks [121]. It is
difficult to conclude whether the anti-tumor killing abilities of the aged macrophage outweigh its
inability to provide support to the tumor (Table 1).
Notably, the innate immune response of macrophages is affected by their environment [113,115].
Peritoneal macrophage function, including cytokine secretion, was observed to be altered with age only
due to changes in the aged microenvironment, not inherent age-related dysfunction of the macrophage
itself [115]. Thus, it is possible to restore the macrophage to its full secretory phenotype by changing
its environment [113,115]. Epithelial cancer cells and stromal cells do just this–they secrete growth
factors and cytokines such as macrophage colony-stimulating factor 1 (CSF-1) to recruit macrophages,
converting their phenotype into tumor-associated macrophages (TAMs) [121,123,124]. When activated,
TAMs work similarly to cancer associated fibroblasts (CAFs). They promote metastasis by secreting
growth factors and cytokines by increasing angiogenesis and participating in cross-talk with epithelial
cells and stromal cells [121,124]. Increased CSF1 density and increased TAM occurrence are correlated
with decreased survival rates [121,124]. However, it is not understood whether cytokine secretion is
downregulated in aged TAMs, as occurs in pre-activated macrophages.
2.4.3. Tumor Infiltrating Lymphocytes: B and T cells
T-cell associated tumor infiltrating lymphocytes (TILs) are correlated with increased survival
in OvCa patients (Table 1). CD4+ and CD8+ T-lymphocytes are two types of TILs which recognize
cancer antigens and inhibit cancer proliferation. CD4+ TILs elicit dendritic cell responses, which then
induce CD8+ cells to provide extended cytotoxicity, killing tumor cells (Figure 4). Thus, an increase in
CD4+ and CD8+ T-lymphocytes is a survival advantage in OvCa patients [121,125]. One factor in this
pathway is IL-2 secretion: increased IL-2 secretion results in activated macrophages and tumor lysis
directly from CD8+ T-lymphocytes [125].
T-cell production and function is widely known to decrease with age. Notably, aged CD4+ T-cells
experience higher degrees of apoptosis and decreased function when compared to young T-cells in an
13
Cancers 2018, 10, 230
aged murine model. Aged CD4+ T-cells showed less expression of CD4 and a lower mitochondrial
mass [126]. Furthermore, aged CD4+ T-cells secreted less IL-2 than young phenotypes [127] and have
decreased memory capabilities [128]. These factors indicate that aged CD4+ TILs are inherently less
active than young TILs and therefore express less antitumorigenic capacity (Table 1).
The effect of B-cell TIL function on OvCa presents more difficult data (Table 1). In some studies,
B-cell TILs, such as CD20+, are also understood to bear a tumor survival advantage in OvCa
patients [125,129]. Studies showed that using anti-CD20+ antibodies in B-cells result in decreased CD8+
antitumor functionality, which links B-cell advantage to that of CD8+ T-cells. A lack of CD20+ secretion
results in decreased CD8+ cytotoxic capabilities, promoting cancer development [130]. While CD8+
T-cells function in antitumor activity on their own, effectiveness is shown to increase in the presence
of CD20+ [129]. Similar to T-cells, aged B-cells exhibit decreased antibody affinity and memory
responses [131]. Consequently, aging downregulates the CD20+ and CD8+ association, resulting
in decreased tumor lysis and poorer OvCa prognosis (Table 1). However, reports of certain aged
B-cells such as B1a lose many immunosuppressive functions with age but notably gain the capacity
to stimulate T-cell CD8+ tumor-killing activity [132]. Other reports on OvCa, also present data that
increased B-cell inflammatory activity in ovarian tumors is associated with poorer prognoses [133,134].
Certain populations of B-cells, such as CD138+, instead increase angiogenesis and disrupt the
T-cell lymphocyte antitumor response. Reports show reduced survival of individuals with ovarian
tumors presenting high CD138+ B-cell counts, possibly due to tumor-induced alterations of B-cell
phenotype [133]. Studies of OvCa patients also conclude that higher numbers of CD19+ B-cells are
correlated with increased tumor severity [134]. High B-cell activity is a trait generally attributed
to a younger individual [131] and thus the conflicting results of B-cell TIL contribution to OvCa
proliferation cannot be fully resolved by literature results.
Table 1. Summary of aging-related immune changes.
Immune Cell Component Effect of Aging Effect on OvCa Metastasis
T-cell Tumor Infiltrating
Lymphocytes
• Decreased cytokine secretion
• Increased apoptosis
• Decreased lymphocyte association




• Decreased cytokine secretion
• Decreased T-cell association
Possibly increased angiogenesis,
possibly decreased tumor lysis
Pre-Activated Macrophages
• Decreased cytokine secretion
• Decreased phagocytic activity Unknown, possibly mixed effects.
2.5. Adipocytes
Adipocytes make up the majority of the omentum and are present throughout the peritoneum [6].
Adipocytes are a complicated cell group that play a very important role in metabolism. In addition,
adipocytes fuel OvCa metastatic success by providing energy in the form of fatty acids and lipids [135].
In addition to this role, adipocytes have been shown to secrete IL-8 and adipokines, which help guide
OvCa cells to metastatic sites [135,136]. It has been shown that body fat percentage increases with age,
as well as the capability of adipocytes to migrate out of their normal adipose tissues and into other
sites of the body, causing site-specific alterations [136–138]. Specifically, aged adipocytes migrate to
the viscera in the abdominal cavity, which is linked with higher disease rates than fat depots in other
areas [137,139]. In fact, surgical removal of visceral fat in rats alleviated obesity-related symptoms,
such as metabolic disease and insulin resistance and lengthened the lifespan of the rats [139–141].
Epidemiologic data show that obesity is a risk factor for worse disease in women, notably age-related
diseases such as OvCa [136,142]. An in vivo pre-clinical study showed that obese mice intraperitoneally
injected with OvCa cells (either diet-induced obesity or leptin-mutant) have an increased tumor burden
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over their lean counterparts [143]. Recently, there has been a surge of research on aging adipocytes;
it has even been suggested that obesity accelerates aging, or that aging- and obesity-related processes
mirror each other [136].
Aging adipocytes have been correlated with chronic inflammation [136]. Adipose tissue
macrophages, or ATMs, have been shown to increase with age [136]. These immune cells secrete
IL-6, promoting inflammation [136]. In addition, aged adipose tissue has higher rates of cellular
senescence, as seen in the other cell types mentioned in previous sections [136]. These senescent cells
also promote inflammation through the secretion of factors such as chemokines, cytokines, growth
factors and MMPs [136]. In addition, the amount of differentiated and mature adipocytes formed
from preadipocytes decrease with age, increasing the percentage of preadipocytes in aged tissue [137].
These preadipocytes secrete a proinflammatory profile similar to senescent cells, with factors such as
PAI, IL-6 and proinflammatory cytokines and chemokines [137,144].
Figure 4. The effects of aging on the peritoneal microenvironment. (a) Tumor-Inducing Effects: Aging of
the host stimulates a vast and interconnected network of alterations to the peritoneal microenvironment.
These changes are often correlated with increased tumor burden due to heightened angiogenesis of the
region and OvCa cell adhesion, invasion, proliferation and survival. As depicted, the multifactorial
causes and results of aging present significant challenges for analysis; (b) Tumor-Suppressing Effects:
While our review generally concludes that aging alters the microenvironment in a way conducive to
tumor growth, in contrast certain aspects of aging seem to impair tumorigenesis. Aged and senescent
mesothelial cells secrete less hyaluronic acid, which is hypothesized to decrease OvCa adhesion to
the extracellular matrix (ECM). Inactivated aged macrophages are less capable of cytokine secretion,
which thereby decreases angiogenesis potential and cell invasion. The aged BM thickens due to less
collagen IV turnover, which we speculate could in theory decrease OvCa invasion (however, to our
knowledge no conclusions have been drawn regarding this). The aged basement membrane (BM)
also has a decreased laminin content, which may decrease cell adhesion. * While not shown to be
a causative link, in aged adipose tissue there is an increase in reactive oxygen species (ROS) that is
correlated with adipocytes presenting a senescent phenotype, suggesting that ROS plays the same role
in adipocytes that it does in other cell types [145]. p53 has been shown to have numerous effects on
adipose tissue and is likely also contributing to the senescent phenotype [145]. ** Aged macrophages
paradigm: aged macrophages have been shown to both induce tumorigenesis and inhibit it., we depict
both pathways. Note: Color gradients intended to help viewer differentiate between different effects of
each component of the aging microenvironment.
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In addition to inflammation, aging adipocytes have been correlated with insulin resistance [136,
145]. AGE modifications on serum albumin have been shown to cause an increase in ROS in adipocytes,
which blocks cell differentiation and leads to insulin resistance [78]. AGEs prevent cellular uptake of
glucose, which can raise glucose levels, potentially contributing to AGE-mediated collagen crosslinks
(see Section 2.2.1) [78,146]. Serum-AGE levels were shown to be higher in aged mice versus young,
contributing to more ROS and less glucose uptake [78]. In addition, serum AGEs have been shown to
stimulate TNF-α in monocytes, which causes insulin resistance [145,147].
3. Conclusions
While this review has divided the peritoneal microenvironment into distinct cellular or functional
units, in reality there is complex crosstalk between all components of the microenvironment that
is just beginning to be uncovered and understood. The end result is a vastly different metastatic
microenvironment in aged patients relative to that seen in young patients (Figure 1), reminiscent of
one of the first big debates in the field: the seed-and-soil hypothesis. Based on the research discussed
above, it is clear that the aging peritoneum provides a better “soil” for metastasizing OvCa cells.
Each component of the microenvironment has the potential to affect OvCa metastasis in a variety of
ways (Figure 4).
At every step of the establishment of metastases, we see differences in aged hosts. OvCa cells
first adhere to mesothelial cells; aged hosts have higher numbers of senescent mesothelial cells, which
increase inflammation and also increase factors such as fibronectin and ICAM-1 that mediate cell-cell
adhesion [16,33,38]. Once the OvCa cells adhere to and disrupt the mesothelial cells, they next invade
into the collagen-rich matrix below. Aged hosts have an increase in MMP activity and lower rates of
collagen synthesis, resulting in a less dense matrix that facilitates invasion. In addition, aged collagen
accumulates crosslinks, which make the tissue stiffer and more aligned, allowing OvCa cells to
adhere more readily [8,75]. The other cells present in the microenvironment, including fibroblasts,
immune cells and adipocytes, also play a large role in changing the metastatic microenvironment.
Aged fibroblasts secrete less collagen than their younger counterparts and senescent fibroblasts share
many of the characteristics of CAFs, promoting OvCa metastasis [24,96]. In the immune landscape, it is
unclear whether the effect of age on macrophages promotes or obstructs tumor growth. However, it can
be concluded T-cell lymphocytes and certain B-cell lymphocytes experience a loss of function with
age, resulting in less regulated tumor growth and increased proliferation [125]. Aged individuals have
been shown to have increased adipocyte deposits, which provide energy for the OvCa metastases [137].
Aged adipose tissue also has a chronic inflammation response, resulting in immune stimulation as well
as secretion of elements such as growth factors and MMPs, that can contribute to OvCa invasion and
proliferation [136]. These molecular processes may also represent targets for therapeutic intervention
in the aged host.
There are not many therapeutic interventions that target aging. Recent studies of senescence and
the senescent-associated secretory phenotype (SASP) illuminate the field of senolytics as a promising
anti-cancer treatment [148,149]. Many senolytic drugs have been discovered and tested in murine
models, working to selectively target the senescent cells’ anti-apoptotic pathways to induce cell
death [148]. In murine models, this decreases the SASP to decrease cancer spread [148]. Notably, this is
a selective treatment [148,149]—not every senescent cell has to be eliminated. Much work remains to
bring this field to clinical trial stages but this review supports the observation that senolytic treatments
are a propitious focus for age-associated cancers.
The studies performed in this field to date have shown that aging has multi-faceted effects on
the tumor microenvironment. However, many questions remain. Much of the work reviewed here is
not specific to the peritoneal tumor microenvironment and many studies were performed outside the
context of OvCa metastasis. Just as Yancik voiced in 1993, there is still a need for aging research in the
OvCa field. As the field progresses, integrating research on the molecular mechanisms of aging may
reveal new targets for anti-metastatic therapies for OvCa patients.
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Abstract: Metastatic dissemination of epithelial ovarian cancer (EOC) predominantly occurs through
direct cell shedding from the primary tumor into the intra-abdominal cavity that is filled with malignant
ascitic effusions. Facilitated by the fluid flow, cells distribute throughout the cavity, broadly seed
and invade through peritoneal lining, and resume secondary tumor growth in abdominal and pelvic
organs. At all steps of this unique metastatic process, cancer cells exist within a multidimensional
tumor microenvironment consisting of intraperitoneally residing cancer-reprogramed fibroblasts,
adipose, immune, mesenchymal stem, mesothelial, and vascular cells that exert miscellaneous bioactive
molecules into malignant ascites and contribute to EOC progression and metastasis via distinct
molecular mechanisms and epigenetic dysregulation. This review outlines basic epigenetic mechanisms,
including DNA methylation, histone modifications, chromatin remodeling, and non-coding RNA
regulators, and summarizes current knowledge on reciprocal interactions between each participant of
the EOC cellular milieu and tumor cells in the context of aberrant epigenetic crosstalk. Promising
research directions and potential therapeutic strategies that may encompass epigenetic tailoring as a
component of complex EOC treatment are discussed.
Keywords: ovarian cancer; epigenetics; tumor microenvironment; DNA methylation; histone
modifications; chromatin remodeling; non-coding RNAs
1. Introduction
Epithelial ovarian cancer (EOC), a histopathologically, morphologically, and molecularly
heterogeneous group of neoplasms [1], is the leading cause of gynecological malignancy-related
deaths in women, with >14,000 deaths in the United States (US) and ~152,000 deaths worldwide
yearly [2–4]. Most women have vastly disseminated intraperitoneal disease at the time of diagnosis
contributing to a five-year survival rate of only 30% [5]. Development of multidrug resistant and
essentially incurable tumor recurrence in the majority of patients after initial good response to
standard platinum/taxane-based chemotherapy are also significant factors contributing to this deadly
disease [6,7].
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1.1. Tumor Microenvironment (TME) Associated with Ovarian Neoplasms
EOC initiation results from accumulation of genetic mutations and epigenetic changes resulting in
malicious transformation of epithelial cells, stem cells, or transient metaplastic regions at the primary
site, either ovary or the fallopian tube fimbriae [8–18]. While lymph node and hematogenous metastasis
of ovarian cancer have been reported in human EOC cancer and/or model systems [19,20], the current
consensus is that expansion of ovarian neoplastic masses occurs primarily via transcoelomic route,
including the direct exfoliation of anoikis-resistant cancer cells and multi-cellular clusters from the
original tumor, ascitic fluid-facilitated intraperitoneal dissemination, subsequent mesothelial adhesion
and retraction, submesothelial extracellular matrix invasion, and ultimate establishment of secondary
lesions in peritoneum-sheathed surfaces and organs [18,21–23]. During this metastasis process,
ovarian cancer cells are confined to and nurtured by the complex host intraperitoneal cellular milieu,
encompassing cells co-existing within the tumor bulk, freely available in ascitic effusions, and residing
in peritoneal and adipose tissues—fibroblasts, mesothelial cells, adipocytes, infiltrating lymphocytes,
macrophages, plasmacytoid dendritic cells, mesenchymal stem cells, and others (Figure 1) [24–29].
Both EOC and host non-cancerous cells secrete a plethora of bioactive soluble constituents—proteins,
growth factors, phospholipids, hormones, cytokines—into the extracellular space and malignant
ascites [23,27,30–44], collectively generating a dynamic intraperitoneal TME that mediates ovarian
cancer development, metastatic progression, and therapeutic response through receptor-ligand
(autocrine, paracrine, endocrine) signaling, contact-dependent (juxtacrine) cell signaling, as well
as epigenetic regulation (Figure 1B).
1.2. Basic Epigenetic Mechanisms at a Glance
Epigenetic modifications are heritable alterations in gene expression (activation or suppression)
that occur as a result of perturbed chromatin organization and altered gene accessibility for
transcriptional machinery in the absence of changes to the DNA itself [45]. Additionally, epigenetic
mediation encompasses the modulation of gene expression at the posttranscriptional level via altered
mRNA translation into protein (Figure 2). Fundamental epigenetic regulatory mechanisms include:
1. DNA methylation—addition of methyl groups to DNA CpG sites without altering DNA
nucleotide sequence. Methylation occurs by means of enzymes called DNA methyltransferases
(DNMTs), which place methyl groups on symmetric cytosine residues in double-stranded CpG
sites [46,47]. Hypermethylation of CpG islands (nucleotide sequences enriched for CpG sites) in
the promoter regions of tumor suppressor genes (TSGs) and growth regulatory genes prompts
gene silencing [46,47] as attached methyl groups physically block binding of transcription
factors to the gene promoters. Alternatively, dense DNA methylation interferes with the proper
nucleosome positioning [48]. Within the DNMT family (including three active enzymes, DNMT1,
DNMT3a, and DNMT3b), DNMT1 exhibits high preference for hemimethylated DNA (in which
one of two complimentary DNA strands already possess attached methyl groups), and is
therefore responsible for so called “maintenance methylation” [49,50]. DNMT3a and DNMT3b
are primarily responsible for the “de novo” methylation of previously unmethylated CpG
regions [51,52], but both of these methyltransferases have been shown to carry out maintenance
methylation as well [53]. Importantly, in human neoplastic cells, it has been shown that DNMT1
provides both de novo and maintenance DNA methylation of TSGs [54–56]. The demethylating
agents (or hypomethylating agents (HMAs) that inhibit these enzymes (azacitidine or AZA;
decitabine or DAC; SGI-110 or guadecitabine) are discussed below).
2. Histone modifications—various posttranslational modifications (PTMs) at histone protein
N-terminal tails, which impair proper interactions between adjacent nucleosomes to affect the
compact packing of the chromatin and impede the binding ability of other factors/enzymes
that are involved in gene transcription [57,58]. The most common and well-characterized PTM,
histone acetylation, is a dynamic, reversible process in which positively charged histone lysine
26
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residues are neutralized via the addition of acetyl groups by histone acetyltransferases (HATs),
resulting in the attenuation of bonds between negatively charged DNA string and a histone
complex. In the reverse reaction, deacetylation, enzymes histone deacetylases (HDACs) remove
acetyl groups, and reinforce positive charge of the lysines, securing compact wrapping of
DNA around histones [59,60]. Similarly, histone (de)phosphorylation utilizes protein kinases
and phosphatases to attach or remove negatively charged phosphate groups, respectively,
influencing chemical attraction between DNA and histone tails (reviewed in [60,61]). Histone
(de)methylation—addition/removal of methyl groups by histone-specific methyltransferases
and demethylases—can either activate or silence gene transcription. Remarkably, the functional
consequences of each histone (de)methylation event depend on the histone, amino acid and
residue methylated, degree of modification (mono-, di- or tri-methylation), and attraction of
additional function-specific protein cofactors to the site, as well as existence of other methyl or
acetyl groups in close proximity (reviewed in [62]). Comprehensive analyses of currently known
histone PTMs, including those less common (ubiquitylation, sumoylation, deamination, etc.),
their functional outcomes and complex interplay between the DNA methylation and histone
modifications have been recently published [63,64].
3. Chromatin remodeling—rearrangement of chromatin organization through complete or partial
nucleosome repositioning and altering gene access for transcription. Chromatin remodeling can
occur via nucleosome sliding (movement of the core histone octamer nexus across DNA segment
with no evident disintegration of the octamer itself), nucleosome ejection (nucleosome segregation
from the chromatin chain), or histone eviction (removal of histone H2A/H2B dimers from
the DNA-associated nucleosome, sometimes with an alternative histone replacement) [65–67].
These processes are mediated by a number of ATP-dependent chromatin remodelers with high
binding affinity to modified core histone tails, as well as transcriptional enzymes, which are
extensively described in [65–67]. In particular, ARID1A and SMARCA4 are prominent chromatin
remodeler examples in ovarian cancer. ARID1A is frequently mutated in ovarian clear cell
(~50%) and low grade ovarian endometrioid (30%) carcinomas [68,69]. Most interestingly,
tumors with ARID1A mutations acquire sensitivity to pan-HDAC inhibitors, thus making
ARID1A-bearing cancers attractive for HDAC-based therapy [70]. SMARCA4 is frequently
(over 90%) mutated in ovarian small cell carcinomas of the hypercalcemic type [71,72], however,
to our knowledge, the first case of a germline SMARCA4 mutation in a patient with HGSOC was
recently reported [73]. Further investigation on the role and clinical applicability of SMARCA4
and ARID1A in HGSOC is warranted [74,75]. Altogether, the three epigenetic mechanisms that
are described above work closely to mediate DNA (un)coiling around the core histones and
ensure dynamic chromatin reassembly between heterochromatin (condensed or closed, silent)
and euchromatin (loose or open, transcription-permissive) states.
4. Non-coding RNA interference—a group of epigenetic regulatory mechanisms that involves
microRNAs (miRNAs; miR) and long non-coding RNAs (lncRNAs). MiRNAs are short
(~22 nucleotides) non-messenger RNAs that act primarily at a posttranscriptional level by base
pairing with their complimentary mRNA targets to alter mRNA translation into protein [76].
Remarkably, one miRNA may complement a variety of mRNAs, whereas the same mRNA
transcript might be a target of multiple miRNAs. Additionally, miRNAs may act as mRNA
destabilizers causing poly-A-tail shortening [77] or interfere at the gene transcriptional level
by means of PTMs (e.g., initiation of histone H3 lysine9 methylation with RNA interference
machinery, followed by DNA methylation and gene transcription repression) and heterochromatic
silencing [78]. LncRNAs are long (>200 for up to a hundred thousand nucleotides) non-messenger
RNA that execute epigenetic regulation via several mechanisms: engage in post-translational
histone modifications through association with chromatin-modifying proteins as an obligatory
active player in the complex or as a scaffold that brings different protein complexes in close
vicinity for proper functioning; serve as endogenous competitors to mRNA by base pairing with
27
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miRNAs and uncovering mRNAs for effective protein translation; or, serve as precursor RNAs
for miRNAs (all mechanisms are detailed in [79–81]).
Figure 1. Ovarian tumor-stroma bidirectional crosstalk. (A) Schematic representation of cellular diversity
within the complex ovarian tumor bulk; and, (B) Reciprocal communication between ovarian cancer
cells and intraperitoneally residing cancer-associated cellular milieu components via molecular signaling
pathways and epigenetic regulation. CAAs—cancer-associated adipocytes; CAFs—cancer-associated
fibroblasts; CSCs—cancer stem cells; EOC—epithelial ovarian cancer; MCs—mesothelial cells;
MSCs—mesenchymal stem cells; PDCs—plasmacytoid dendritic cells; TAMs—tumor-associated
macrophages; TECs—tumor-associated endothelial cells; TILs—tumor-infiltrating lymphocytes;
TME—tumor microenvironment (see main text for details).
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Figure 2. Epigenetic regulation of gene expression. (A) DNA packing in a eukaryotic cell: a DNA
molecule (chromosome) located inside the cell nucleus is composed of chromatin fibers which are made
of nucleosomes—histone octamers wrapped by a DNA helix. Condensed chromatin (heterochromatin)
is transcriptionally silent; loosely packed euchromatin allows access to DNA and active transcription
into mRNA, followed by translation into protein; (B) Major epigenetic mechanisms of gene expression
include: (1) DNA methylation; (2) histone modifications, such as histone acetylation, methylation,
phosphorylation, etc.; (3) chromatin remodeling, including nucleosome sliding, nucleosome ejection
and histone eviction; and, (4) mRNA interference with miRNAs and lncRNAs (see main text for details).
The importance of epigenetic dysregulation for cancer progression cannot be understated,
as various aberrant epigenetic modifications trigger activation of oncogenes, repression of tumor
suppressor genes, and altered transcription of protein-encoding genes that are collectively responsible
for proper expression of signaling proteins that are necessary for physiological cell life span and
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functions. In the light of significant advances in technical tools and the rapid emergence of
large “omics” data, the current knowledge in the field of cancer epigenetics and understanding
their translational potential have vastly expanded. Multiple elegant reviews illustrate a wealth of
currently available data on cancer epigenomics [46,82–87]. In the context of EOC specifically, several
recent works highlight major epigenetic players—DNA methylation [88–90], histone PTMs [88,89],
miRNAs [88,89,91,92], lncRNAs [93,94], and discuss current and potential therapeutic implication
strategies and challenges [85,95–98].
2. Epigenetic Crosstalk between EOC Cells and TME Cellular Components
The biological importance of TME as a reactive platform orchestrating diverse aspects of tumor
initiation, evolvement, metastatic progression, altered immune response, development of therapeutic
resilience, and cancer recurrence is unquestionable and continuously reaffirmed, as highlighted in a
multitude of studies [99–104]. Given the unique ovarian cancer intraperitoneal TME and the emerging
evidence of benefits from epigenetic-targeted therapeutics, we systematize epigenetic dysregulations
linked to EOC progression from the perspective of complex reciprocal relationship between ovarian
tumor cells and tumor-associated microenvironmental non-malignant cell setting. These interactions
will allow for researchers to evaluate, comprehensively, the potential for exploiting specific epigenetic
vulnerabilities in both cancerous and TME cells as molecular biomarkers, prognostic indicators,
and complementation to conventional chemotherapy and TME-targeted interventions.
2.1. Cancer-Associated Fibroblasts (CAFs)
CAFs are traditionally abundantly present within the tumor stroma (Figure 1A). They serve
a tumor-supporting role via remodeling of extracellular matrix, a scaffold for the tumor bulk.
CAFs perform endocrine/paracrine communication with the surrounding tumor and other stromal
components via the excretion of a variety of growth factors and chemokines, hence contributing to
tumor growth, immune response, angiogenesis, chemoresistance, and cell stemness; furthermore, CAFs
differentiate into other cell types, as comprehensively discussed elsewhere [105,106]. CAFs exhibit
substantial heterogeneity, which is attributed to existence of multiple proposed CAF origins, including
reprogramming of the normal resident fibroblasts, conversion from adipocytes, endothelial or epithelial
cells, or differentiation of the bone marrow derived mesenchymal or hematopoietic stem cells
(summarized in [107]). Gene expression analysis of CAFs purified from different types of cancers,
including ovarian carcinomas, revealed normal genotype, and acquisition of somatic mutations is
considered to be an extremely infrequent event [108–110]. Hence, epigenetic changes likely play an
essential role in CAF regulation.
Studies have reported altered DNA methylation status of genes (either at the gene promoter
regions or global) in stromal fibroblasts dissected from various cancer tissues that corresponded to
methylation profiles that are found in adjacent malignant cells [111,112]. In turn, as was shown by
Mathot et al. for breast cancer [113], malignant cells maintained in the presence of CAF soluble
mediators exhibit a wide gene upregulation pattern (372 genes upregulated total in the study)
epigenetically modulated via DNA hypermethylation that could be reversed by the DNMT inhibitor
decitabine. Pistone and team [114] demonstrated through global transcriptome and DNA methylation
analysis that CAF-secreted factors trigger combinatorial DNA hyper/hypomethylation changes,
collectively responsible for epithelial-to-mesenchymal transition (EMT) and stemness phenotype
in prostate cancer cells. Albrengues and colleagues [115] reported the transformation of fibroblasts
into pro-invasive CAFs in response to a cytokine termed leukemia inhibitory factor (LIF), which
triggers the continued activation of JAK1/STAT3 signaling pathway via the histone acetylation of
STAT3, followed by the activation of DNMT3b, methylation and abrogation of the Src homology
region 2 domain-containing phosphatase-1 (SHP-1), and ultimate sustained phosphorylation of JAK1.
The process is chaperoned by DNMT1, whereas the inhibition of DNMTs and JAK signaling abolishes
the CAF phenotype [115].
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Noteworthy, even brief transitory communication between cancer cells and normal fibroblasts
leads to an elevated release of transforming growth factor beta 1 (TGF-β1) by activated fibroblasts
in response to cancer cell presence [116]. This may be of particular relevance in the context of
ovarian cancer epigenetic regulation, as TGF-β is known to catalyze global DNA hypermethylation
alterations in EOC cells, promoting EMT and metastasis [117]. Moreover, Cardenas and co-workers
found that TGF-β enhances both expression and enzymatic activity of DNMT-1, -3a, and -3b in
EOC cells [117]. Importantly, the hypermethylation effect and EMT may be abrogated by treatment
with DNMT inhibitors [117]. On the other hand, TGF-β assists in the reprogramming of CAFs from
other cell types [118] and it favors further aggressive invasion of HGSOC through TGF-β-induced
secretion of prometastatic mediators by CAFs [118,119]. Collectively, these data suggest formation of a
constitutively active positive feedback loop in EOC, where initial fibroblast-malignant cell interaction
triggers secretion of TGF-β by stromal cells, followed by EMT-associated global epigenetic alterations
in EOC cells, as well as promotion of CAF phenotype and secretory activity, which closes the cycle
and further aggravates EOC. In this scenario, the combined usage of demethylating agents and drugs
targeting TGF-β signaling requires further investigation.
To our knowledge, posttranscriptional histone modifications in EOC-associated CAFs have
not been directly addressed, whereas similar studies in the context of other cancer types are very
limited. The histone mark H3K27me3 in breast CAFs was shown to be reduced, along with decreased
expression of enhancer of zeste homolog 2 (EZH2), a methyltransferase that is responsible for the
H3K27me3 histone mark [120], resulting in promotion of cancer cell invasion by CAFs via upregulated
thrombospondin type 1 motif 1 [121]. In EOC, however, EZH2 is commonly upregulated [122],
and thereby, such a mechanism is not likely. Undoubtedly, studies are needed in elucidating histone
PTMs possibly taking place during malignant cell-CAF interplay.
Malignant TME-driven implication of miRNAs in CAF phenotype and functioning has
been dissected for various cancer types (breast [123], cervical [124], gastric [125], prostate [126],
colorectal [127,128], and bladder [129]), including EOC. In an elegant gain/loss-of-function study
employing the co-transfection of multiple miRNA mimics and inhibitors, Mitra et al. [130] discovered
a combination of three dysregulated miRNAs (upregulation of miR-155 plus repression of miR-31
and miR-214) that are capable of converting quiescent fibroblasts into ovarian CAFs with extensive
expression of chemokines, in particular, direct target of miR-214 CCL-5 (C-C motif ligand 5),
CXCL-10 (C-X-C motif ligand 10), CCL-7 and CCL-8, among others, accompanied by the substantial
augmentation of ovarian tumor growth. The respective reverse experiments have shown the restoration
of wild-type fibroblast phenotype and alleviation of ovarian tumor growth in co-culture [130],
suggesting these miRNAs as novel therapeutic targets for halting EOC progression by means of
manipulating stromal signals.
Zhao and coworkers [131] have recently discerned prognostically unfavorable upregulation
of lncRNA LINC00092 in EOC cells which is induced by high CXCL-14 (C-X-C motif ligand 14)
chemokine expression in ovarian CAFs. Expressed LINC00092 binds to a glycolytic enzyme and
it facilitates glycolysis in EOC cells, boosts metastatic activity, and reciprocally supports pro-active
CAF phenotype [131]. A differential expression analysis of CAFs purified from 67 high grade serous
ovarian carcinomas (HGSOC) and 10 normal ovarian fibroblast samples identified 39 divergently
expressed lncRNAs (out of 1970 lncRNAs total analyzed) in HGSOC CAFs in comparison with
normal fibroblasts [132]. Subsequent context-specific regulatory network construction and pathway
analyses have linked the upregulation of seven lncRNAs (FLJ39739, GAS5, H19, LOC100499466,
MALAT1, NEAT1, and TUG1) and downregulation of four lncRNAs (CASC2, DLEU2, HCG18,
and LOC100133669) to the furtherance of metastasis-associated pathways in HGSOC [132]. Mechanistic
insight on the interaction of these differentially expressed lncRNAs in CAFs with proteins/pathways
is essential for the further translation of these findings into diagnostic and/or therapeutic strategies.
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2.2. Cancer-Associated Adipocytes (CAAs)
One of the distinguishing characteristics of the ovarian cancer TME is tumor cells that are in close
vicinity to adipose tissue at all stages of development and metastasis. Adipose tissue exists at the
site of the primary tumor (ovarian fat pad, mesosalpingeal/mesoovarian adipose layers) and around
the intra-abdominal cavity in the form of substantial omental adipose nodes, large adipose bundles
in the mesentery (both serve as prevalent EOC metastasis locations), as well as smaller fat depots in
the parietal and diaphragmatic peritoneum (Figure 1A). It is now commonly accepted that adipose
tissue is a highly communicative metabolic and secretory organ. Aside from functioning as energy
(lipid) storage, it produces adipokines, metabolic substrates, growth factors, hormones, and immune
mediators, and it contains other stromal components, such as fibroblasts, stromal vascular fraction,
macrophages and other immune cells, nerve tissue, and extracellular matrix [133]. In presence of
malignant setting, normal adipocytes rapidly acquire a highly active phenotype (CAAs) and respond
by metabolic and secretory profile changes, causing pro-inflammatory, pro-invasive, proliferative,
and radio- and chemoresistance effect on cancer cells [28,134–139].
There is accumulating evidence for tumor-adipocyte epigenetic interactions. During maturation,
murine preadipocytes demonstrate substantial upregulation of miR-17-92 cluster, which further
stimulates adipocyte differentiation via negative targeting of tumor-suppressor Rb2/p130 and is
known to boost cell proliferation in various cancers [140]. In breast cancer (another type of adipose
tissue-rich neoplasm), the transition of adipocytes into inflammatory CAAs in the vicinity of malignant
milieu is dependent on miRNA regulatory mechanism. In particular, in the presence of breast cancer
cells, reprogramming CAA increase expression of miR-5112, which suppresses the translation of
Cpeb1, a negative regulator of interleukin (IL)-6. As a result, the pro-inflammatory CAAs exhibit
an increased expression of IL-6 and a proliferation-promoting effect on breast cancer cells [141].
During ovarian cancer metastatic progression, omental CAAs and CAFs deliver miR-21-containing
exosomes to cancer cells. Mir-21 targets apoptotic protease activating factor 1, inhibits ovarian cancer
apoptosis, and confers paclitaxel chemoresistance [142], suggesting stromal-derived miR-21 blockade
as a potential therapeutic strategy for metastatic and refractory ovarian cancer. Profiling of miRNAs in
tumor interstitial fluid of human breast tumor tissues identified a list of 23 miRNAs that were associated
with the presence of adipocytes and immune cells in tissues, suggesting epigenetic tumor-stroma
crosstalk [143].
A genome-wide expression profiling of peri-prostate adipose tissue samples taken from prostate
cancer patients revealed shifted expression of genes collectively accounting for increased proliferative
and anti-apoptotic activity and mitigated immunosurveillance, suggesting that the peri-prostate
adipose tissue cultivates prostate cancer development [144]. A related epigenome-wide DNA
methylation pilot study of peri-prostate adipose tissue in normal weight and obese prostate cancer
patients, performed by the same research group [145], revealed abundant DNA hypermethylation
in cancer patients with excessive adiposity, with the epigenetically altered genes contributing to
altered fatty acid metabolism, immune perturbations (including those providing tumor immune
evasion), pluripotency of stem cells, and other pathways that are advantageous for cancer support.
Concordantly, analysis of DNA methylation in omental tissue of obese women revealed significant
DNA hypermethylation, whereas subsequent weight loss had a substantial hypomethylating
effect [146]. Interestingly, obesity-induced proinflammatory cytokines triggered expression of DNMT1
and methylation of adipokine gene, whereas treatment with the DNMT inhibitor reverted the process
in adipocytes [147]. Recent work by Tang et al. [148] demonstrated that treatment of adipocytes
alone with the DNMT inhibitor resulted in the re-expression of tumor suppressor genes (e.g., SUSD2,
TFP12, GREM1, TRIM29), altered expression of EMT mediators (e.g., CDH1, CDH2, FN1, and SLUG),
and diminished migrative and invasive properties of co-cultured EOC cells. These data provide clear
evidence that therapeutic tailoring of epigenetic aberrations in CAAs may, in turn, have anti-metastatic
effect on ovarian malignant cell behavior [148].
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Taking into consideration that discovery of lncRNAs as a class occurred very recently, there
is an ample gap in evidence of their regulatory role in tumor-stroma interplay. However, recent
studies report that lncRNAs are capable of mediating the expression of genes that are associated with
lipid adipogenesis and metabolism via RNA, DNA or miRNA complementation, or recruitment of
proteins involved in modulation of histone markers [149–151]. A recent study, including transcriptome
profiling of primary brown and white adipocytes, preadipocytes, and cultured adipocytes reported
a list of 175 lncRNAs that are specifically regulated during adipogenesis [152]. Given a constantly
increasing number of lncRNAs with documented significance in the development of a variety of
cancers, including ovarian [94,153,154], investigation of lncRNA-associated epigenetic modifications
in the context of interrelationship between EOC and CAAs will undoubtedly be a very fruitful and
promising direction for further basic/translational research.
2.3. Mesenchymal Stem Cells (MSCs)
MSCs encompass a diverse multipotent cell subgroup that was recruited to the tumor stroma
from such sources as bone marrow, adipose tissue, umbilical cord, endometrium (menstrual blood),
pericytes, as well as other organ-specific locations. The existence of MSCs has been reported for
the majority of organs and tissues, including ovary (Figure 1A) [155]. Due to their capacity to
differentiate into other active pro-cancerous stromal components (such as CAFs and CAAs) as well as
sustain a cancer stem cell (CSC) population, MSCs are strongly associated with cancer progression
yet retain a normal (non-malignant) genotype. In particular, ovarian carcinoma-associated MSCs
(CA-MSCs) exhibit multipotent potential and strong EOC growth-permissive and stemness-promoting
properties, increasing resistance to platinum-based chemotherapy, providing tumor stromal support
and neovascularization [156–161]. Contradictory to those reports are studies demonstrating
tumor-restricting effect of human MSCs on EOC cells via stimulation of EOC cell cycle arrest,
enhanced apoptosis, altered mitochondria membrane potential and suppressed neoangiogenesis [162],
and the inhibition of cisplatin-resistant ovarian carcinoma xenograft growth [163]. Given a wealth of
controversial data on the assisting vs restricting role of MSCs on EOC development and the extensive
interest in therapeutic applications of MSCs as vehicles for EOC-targeted drug delivery due to their
high tumor site tropism [164–168], further investigations to determine the underlying mechanisms of
MSC-EOC interactions are clearly necessary.
While the overwhelming majority of research work is focused on the elucidation of cell
signaling pathway implications, the epigenetic interplay between MSCs and EOC remains largely
unexplored. While considering the well accepted role of epigenetic aberrations in CSC reprogramming
(comprehensively outlined in [169]), emerging evidence on efficient epigenetic transformation of MSCs
into CSCs via tailoring chromatin remodeling (imbalanced DNA methylation of cancer-implicated
genes, application/loss of histone marks, etc.) [170,171], and epigenetic modulation of MSC
differentiation into diverse stromal cell lineages [172–174], the involvement of EOC-mediated
epigenetic factors on MSC phenotype and functioning, and the subsequent reciprocal effect of
reprogrammed MSCs on ovarian carcinoma, is highly plausible. Toward these possibilities,
Reza et al. [175] reported the anti-proliferative and pro-apoptotic effect of adipose-derived MSC
exosomes on ovarian cancer A2780 and SKOV3 cells; subsequent exosomal RNA sequencing identified
a list of enriched miRNAs targeting EOC cell survival pathway genes [175]. MiRNA expression
profiling in aging MSCs revealed altered expression of two miRNAs, miR-638 and miR-572, both
of which have been reported to be upregulated in ovarian carcinoma; however, distinct studies
display controversial findings on the impact of these miRNAs on EOC [176–179]. Among other
non-coding RNAs, abundant in MSC-derived extracellular vesicles and associated with ovarian
cancer development are miR-21, miR-92a and miR-221 [180]. Alternatively, Ho and colleagues [181]
demonstrated, that ovarian cancer stromal progenitor cells isolated from tumor tissues and ascitic
effusions of EOC patients displayed 40 hypermethylated tumor suppressor genes (TSGs) (with DLC1,
RASS382, CDH13, BRCA1, TIMP3, HIN-1, ESR1, CDKN2A, CCND2, CDKN2B, as most frequently
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hypermethylated and correlating with validated mRNA expression decrease in DLC1, RASSF1A,
CCND2, and CDKN2B) in comparison with matching patient ovarian cancer cells and were capable of
promoting tumor growth in vivo when co-injected with SKOV3 cells. Most importantly, treatment with
the hypomethylating agent (HMA) 5-aza-2-deoxycytidine (decitabine or DAC, a desoxyribonucloside
that exclusively incorporates into DNA and inhibits DNMTs by irreversible binding of the latter [182])
resulted in efficient demethylation of TSGs in stromal progenitor cells, repressed their self-renewal
and growth and mitigated proliferation of ovarian tumor cells [181]. Collectively, these studies
suggest a direct or indirect epigenetic relationship between MSCs and ovarian tumor cells and warrant
additional research that can potentially lead to the identification of novel therapeutic targets for
ovarian carcinomas.
2.4. Tumor-Associated Endothelial Cells (TECs)
TECs refer to endothelial cells that line the inner walls of newly formed blood vessels in tumors.
TECs support blood flow, tumor tissue trophics, and accelerate tumor progression. TECs are genetically
non-malignant cells, however, they differ from normal endothelial cells by exhibiting cytogenetic
abnormalities [183], distorted morphology [184], and altered molecular profiles [185], as well as
improper functional characteristics. TECs form a disorganized, excessively sprouted, branched, fragile,
and gap-prone endothelial network, which allows for chaotic non-laminar blood flow, increased
vascular permeability and escape of primary tumor cells into blood circulation. TECs help circulating
cancer cells overcome anoikis and escort their movement to metastatic niches [186]. Finally, TECs are
able to develop taxol resistance in the presence of surrounding malignant milieu [187].
TECs exhibit considerable heterogeneity (reviewed in [188]), and diverse features of TECs in
various tumors are attributed to the specific malignant settings [189]. In the context of epigenetic
regulation, Maishi et al. [190] implanted TECs that were isolated from the high metastatic (HM)
melanomas into low metastatic (LM) melanomas and achieved metastatic enhancement as a result of
elevated levels of proteoglycan biglycan, attracting tumor cells to intravasate. Strikingly, upregulation
of biglycan was due to DNA demethylation of its promoter region in HM-TECs as opposed to normal
endothelial cells, LM-TECs, and tumor cells [190]. Furthermore, exposure of LM-TECs to conditioned
medium from HM-tumors and treatment with the HMA decitabine proved the upregulation of biglycan
in LM-TECs via DNA demethylation triggered in the presence of HM-tumor [190]. The study elegantly
reaffirmed epigenetically-mediated bidirectional communication between tumor cells and TECs,
and further suggested epigenetic perturbations as attractive targets to manipulate neoangiogenesis
and tumor metastasis.
Epigenetic regulation of TECs has been reported. DNMT and HDAC inhibitors efficiently
mitigated TEC growth in vitro and in vivo [191,192]. Moreover, epigenetic modifications were
shown to regulate TEC-mediated immune response [193]. Downregulation of intercellular adhesion
molecule-1 (ICAM-1) in TECs due to promoter histone H3 deacetylation and the loss of histone H3
Lysine4 methylation was reported, and re-expression of ICAM-1 in TECs by DNMT and HDAC
inhibitors successfully restored leukocyte-TEC adhesion and leukocyte infiltration of vessel walls
in vitro and in vivo, respectively [193]. In a separate study, the same group identified additional
anti-angiogenesis genes (including clusterin, fibrillin 1, and quiescin Q6) downregulated in normal
endothelial cells subjected to a tumor-mimicking setting (conditioned medium) via epigenetic silencing
by promoter histone H3 deacetylation and loss of histone H3 Lysine4 methylation [194]. Furthermore,
subsequent treatment with DNMT and HDAC inhibitors reversed the gene silencing effects [194].
An influential study assessing the role of EOC on TECs was conducted by Sood group [195], who
performed a comparative genome-wide gene expression analysis of endothelial cells from five different
normal ovarian tissues and TECs isolated from 10 invasive ovarian carcinomas and revealed a list
of 400 differentially expressed genes, among which EZH2 was significantly upregulated. EZH2,
a histone-lysine N-methyltransferase, is frequently overexpressed in ovarian tumor tissues and
is a well-established epigenetic mediator (stimulator) of EOC tumor growth, invasion, metastasis,
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neoangiogenesis, platinum-resistance and ovarian cancer stem cell renewal through transcriptional
repression of signaling pathways, as well as direct/indirect interaction with multiple miRNAs
and lncRNAs (reviewed in [196]). Overexpression of EZH2 in TECs by the surrounding EOC
setting occurred in a VEGF-mediated paracrine manner, which in turn promotes EZH2 direct
binding, methylation, and transcriptional repression of vasohibin-1 (a selective negative regulator
of TEC migration, proliferation, and vessel tube formation), stimulating further angiogenesis [197].
Remarkably, the silencing of the EZH2 gene in vitro and in vivo (via systemic siRNA nanoparticle
delivery in both EOC cells and TECs in mouse EOC xenografts) substantially increased vasohibin-1
expression and reduced neoangiogenesis and tumor growth [197], underlining the additional
therapeutic potential of concomitant EZH2 targeting in TECs and EOCs. Noteworthy, the expression of
EZH2 in ovarian cancers has been shown to be regulated by different non-coding RNAs, for example
miR-298 [198] and lncRNA HOTAIR (HOX transcript antisense RNA) [199], providing additional
druggable epigenetic targets in EOC cells and TECs in order to suppress neoangiogenesis and ovarian
tumor progression.
2.5. Pericytes
Another type of vessel-associated cells, pericytes (Figure 1), play a key role in normal vasculature
development, including neoangiogenesis, and in cancer contribute to tumor development and
metastasis. These perivascular cells reside in the microvessel walls, immediately beyond the basement
membrane, and provide physical support to endothelial cells, control integrity of the vessel endothelial
layer, vascular permeability, and blood flow [200], serve as an origin of mesenchymal stem cells
(MSCs) for some human tissues [201] and as multipotent precursors for other types of cells [202],
and exert immune mediators [203]. During cancer progression, pericytes essentially contribute to
rapid neoangiogenesis and tumor growth, expansion of the CSC population, on one hand, but also
strengthen immune defense against tumor invading and restrict metastatic seeding, on the other hand,
as comprehensively outlined in [204,205]. In EOC patients, high pericyte score (carrying a pericyte
gene signature) was shown to be an unequivocal predictor of earlier relapse and poor prognosis [206].
Dual targeting of pericytes in combination with endothelial cells [207], as well as the disruption of
connections between pericytes and endothelial cells via insertion of N-cadherin blocking peptides [208],
are potential anti-angiogenesis therapeutic strategies in EOC.
Intriguingly, in a HGSOC xenograft model, injection of pericytes concomitantly with EOC cells
amplified tumor growth and metastasis rate without altering tumor vasculature, highlighting a direct
impact of perycites on EOC cells, independent of neoangiogenesis [206]. No studies have adequately
described epigenetic tumor-perycite crosstalk in ovarian carcinomas. However, proximity of the malignant
(glioblastoma) setting [209], hypoxic conditions [210] and inflammatory stimulation [211] trigger an
epigenetically mediated (through altered non-coding RNA) pericyte response. Though these findings
are quite limited, they raise the possibility of dynamic epigenetic cooperation between pericytes
and EOC cells (and other cancer-associated stromal cells) within a highly reactive, proinfammatory,
and hypoxia-prone ascitic TME. In addition, a very interesting preclinical study by Kratzsch et al. [212]
assessed the effect of 5-azacitidine (AZA; a ribonucleoside that is capable to incorporate into cellular
RNA and DNA and acts as a HMA interfering with the DNMT activity [182,213]), valproic acid
(HDAC inhibitor), temozolomide (a standard DNA alkylating chemotherapeutic positive control),
and a bevacizumab (an angiogenesis inhibitor targeted therapy positive control) on the tumor growth
and neovasculature status in the murine glioblastoma multiforme models. Strikingly, besides the
suppressive effect on glioma tumor growth, the HMA also resulted in a notable antiangiogenic effect
via the substantial diminishing of endothelial cells and the decreasing number of pericytes [212].
Contrarily, HDAC inhibitor valproic acid had no mitigating effect either on tumor growth or on the
vasculature [212]. These results suggest concordant epigenetic expression changes taking place within
the malignant tissue and the adjacent TME cells as a result of their mutual communication (as both
tumorous and angiogenesis cells selectively responded to the same epigenetic-tailoring drug, but
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not to the other). In dissonance with that is work by Karén et al. [214], who reported successful
inhibition of pericyte differentiation, migration, and proliferation in response to HDAC inhibitors
in vitro, and HDAC suppression stimulated expression of genes regulating vessel stabilization and
maturation in pericytes. Collectively, these data highlight translational potential of cancer-prone
epigenetic signatures not only in the neoplastic component per se, but in the surrounding stroma
as well.
2.6. Tumor-Associated Macrophages (TAMs)
TAMs within malignant stroma (Figure 1A) are considered to be a fundamental immune cell
subpopulation responsible for cancer-associated inflammation, matrix remodeling, tumor immune
escape, growth, invasion, angiogenesis, metastasis, cancer cell stemness, and drug resistance.
Macrophage diversity and ability to transfer between M1 (classic, host immune defense activating,
tumoricidal) and M2 (alternative, immunosuppressive, pro-tumorigenic) phenotypes are defined
by the distinct tumor microenvironments [215]. Several recent reviews [216,217] elegantly describe
bidirectional TAM interactions with cancer cells, other immune cell subpopulations and non-malignant
stromal components, such as CAFs, TECs, B cells, eosinophils, basophils, dendritic cells, natural killer
cells, and others.
In addition to ample evidence on receptor-ligand signaling interrelationship between EOC
and TAMs [218–223], a better understanding of their epigenetic cooperation has begun to accrue.
Ying et al. [224] reported initiation of M2 polarization and tumor-promoting capabilities in ovarian
TAMs by EOC-released exosomal miR-222-3p through SOCS3/STAT3 pathway. Similarly, macrophage
M2 phenotype shift was induced by exosomal miR-940 released from hypoxic epithelial ovarian
tumors [225]. Importantly, TAM-secreted exosomes suppress endothelial cell migration by targeting
miR-146b-5p/TRAF6/NF-κB/MMP2 pathway, whereas the EOC-released exosomal delivery of
lncRNAs to the site efficiently restores the endothelial cell movement [226]. Alternatively, Hu et al. [227]
observed altered expression of 19 miRNAs in TAMs exposed to tumor necrosis factor-related inducer
of apoptosis (TWEAK; commonly expressed by immune cells, such as dendritic cells and natural killer
cells) and demonstrated that the exosomal transportation of overexpressed miRNAs, and in particular,
miR-7, from TAMs to EOC cells significantly repressed their metastatic activity in vitro and in vivo via
repression of EGFR/AKT/ERK1/2 pathway. Furthermore, the insertion of antagomiR-7 into TAMs
repressed levels of miR-7 in TAMs, in released exosome vesicles and in the recipient ovarian malignant
cells, and stimulated EOC metastasis [227].
Chromatin remodeling-related epigenetic modifications resulting from TAM-EOC interaction
remain largely unknown. However, as reported for gastric cancer, TAMs are capable of silencing TSG
gelsolin in cancer cells by increased DNMT1 expression and DNA methylation of gelsolin promoter
via activation of CCL5/CCR5/STAT3 signaling [228]. Most importantly, either suppressing DNMT
enzyme activity, or treatment with demethylation agent, or interfering with CCL5/CCR5/STAT3
pathway led to decreased in vivo tumor growth, suggesting several possible routes of epigenetic
inhibition of gastric cancer development [228]. In oral cancer, interferon-γ mRNA expression in TAMs
was substantially decreased in comparison with normal or benign oral tumor specimens as a result of
promoter region methylation, with the level of methylation strongly correlating with the clinical stage,
histopathology grade, and primary tumor scale [229]. Promoter hypermethylation and downregulation
of the follistatin like-1 (FSTL-1) glycoprotein was associated with metastatic activity of nasopharyngeal
carcinomas and dysfunction of macrophages, whereas treatment with recombinant human FSTL-1
protein elevated IL-1β and tumor necrosis factor-α in TAMs and repressed cancer cell immune
evasion [230]. Using a panel of distinct cancer type cells, including cervical, hepatocellular, epidermoid
carcinomas, glioblastoma, rabdomyosarcoma, and murine melanoma, Osawa and co-authors [231]
demonstrated that cancer cell hypoxia and nutrient starvation lead to activation of histone demethylase
JMJD1A (Jumonji domain-containing 1A), followed by increased AKT phosphorylation, cancer cell
metastatic properties, increased angiogenesis, and infiltration of macrophages into cervical cancer
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and muscle sarcoma tissues in vivo. Remarkably, JMJD1A repression mitigated tumor progression
through decreased neovascularization and alleviated TAM infiltration, and importantly, enhanced
the anti-tumor effect of anti-angiogenesis agents bevacizumab and sunitinib [231]. Ishii et al. [232]
described M2 macrophage polarization via reciprocal epigenetic changes in histone H3 lysine4 and
histone H3 lysine27 methylation through STAT6 mediation, which collectively lead to transcriptional
activation of specific M2 maker genes. Altogether, these findings underline the immediate importance
of continued research accessing TAM-modulated epigenetic changes in EOC, as they may reveal novel
diagnostic and therapeutic approaches to mitigate TAM-associated pro-tumoral inflammation and
cancer progression, and boost host immune defense mechanisms.
2.7. Tumor-Infiltrating Lymphocytes (TILs)
TILs are collectively represented by varying amounts of T and B lymphocytes recruited from
the circulatory system to the tumor site to fulfill the host immune response function. In EOC,
TILs may be present in primary tumors and advanced metastatic lesions, both within malignant
(intratumoral) bulk and stromal compartment, and differential representation of certain TIL subsets
(helpers, killers, regulatory/suppressors, effectors, memory cells, and such) depends on the disease
stage, therapeutic management, chemotherapy response status, and possesses prognostic significance
(Figure 1A) [29,233–238].
The extensive evidence on signaling molecules and pathways implicated in TIL functioning and
ovarian cancer prognosis, as well as current attempts to differentially manipulate TIL subsets and
signaling networks towards boosting adequate anti-tumor immunity, have been comprehensively
summarized by Santoiemma and Powell in a recent review [239]. The epigenetic regulation of TIL
functioning in ovarian cancer and epigenetic-based immunotherapeutic strategies are emerging
areas of interest. Sehouli et al. [240] proposed the concept of “epigenetic immunophenotyping”
(identification of certain epigenetic marks) of both overall and specialized TIL populations. By using
matching healthy and cancer tissues, including ovarian, they established a strong correlation between
epigenetics and cancer prognosis [240]. In support of this concept, treatment with DNMT inhibitor
5-azacitidine led to the substantial enrichment for immunomodulatory pathways (interferon signaling,
antigen processing and presentation, and cytokines/chemokines) in ovarian and other cancers [241].
Similarly, with the use of global gene expression profiling of EOC treated with DNMT inhibitor
decitabine, Wang et al. [242] discovered prominent upregulation of immunoregulatory genes cohort in
decitabine-exposed malignant cells. The group further showed that decitabine treatment stimulated
TIL infiltration and anti-tumor function in both subcutaneous and intraperitoneal syngeneic murine
ovarian cancer models [242]. Moreover, combining a DNMT inhibitor with the standard immune
checkpoint blockade antibody stimulated conversion of naïve T cells into T effectors and contributed
to better mouse survival [242]. Based on this work, Stone et al. [243] further demonstrated that
the activation of type I interferon signaling in response to DNMT inhibitor 5-azacytidine was a key
requirement for efficient stimulation of CD45+ (leukocyte common antigen) immune cells, CD8+
cytotoxic T cells, natural killer cells, restriction of macrophages, and myeloid-derived suppressor
cells in the ovarian TME in vivo, prompting the inhibition of tumor growth and increased survival.
In support, Adair and Hogan [244] demonstrated the enhanced expression of cancer-testis antigens
and class I major histocompatibility complex (MHC)-encoded molecules in EOC cells that were treated
with DNMT inhibitors and subsequent infiltration of antigen-reactive CD8+ cytotoxic T cells to EOC.
Consistent with that, seminal work by Chiappinelli and co-authors [245] established that DNMT
inhibitors activate interferon signaling, TIL infiltration, and EOC cell death via the upregulation of
viral defense pathway, as hypomethylation of endogenous retrovirus (ERV) genes leads to upregulated
viral defense gene expression and boosts immune response.
In the context of non-coding RNA interference, two prognostic miRNA signatures—malignancy
signature and immunological signature—have been recently identified in advanced EOC [246]. Briefly,
using integrative mRNA/miRNA co-expression analysis of primary tumor tissues from advanced
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EOC patients, two modules were established: a malignancy module (let-7f, let-7g, miR-106a, miR-17,
miR200c, miR-26a, miR-26b, and miR-328), which was associated with the more aggressive EOC
growth and an immunological module (miR-197, miR-22, miR-22#, miR-28, miR-339–5p, miR-340#,
miR-628–5p, miR-629, miR-661, and miR-98), which strongly correlated with intratumoral infiltration
by T cells, natural killer cells, cytotoxic lymphocytes, and macrophages [246]. These microRNA
signatures may serve as prognostic and treatment efficacy biomarkers as well as potential targets for
epigenetic-based immunotherapy of advanced ovarian cancer [246].
2.8. Plasmacytoid Dendritic Cells (PDCs)
PDCs constitute a rare, yet critically important and highly specialized immune cell subpopulation
whose main role in immune surveillance is rapid recognition of foreign pathogens via selectively
expressed toll-like receptors and the immediate activation of both innate and acquired immune systems
(Figure 1A) [247]. Incessant stimulation of PDCs by self-DNA (a situation when PDCs, which do not
normally react to inert DNA of organism’s cells, become continually activated by the altered DNA of
transformed cells) is a characteristic of a variety of neoplasms, including ovarian carcinomas [248–250].
Accumulation of PDCs within the epithelial ovarian tumor bulk promotes vasculogenesis [251,252]
and immune tolerance [253], and it is associated with unfavorable disease prognosis [254]. Importantly,
the elimination of immature PDCs in mice bearing ovarian tumors via the targeting of specific markers
led to vascular ablation, substantially reduced tumor growth, and triggered anti-tumor immune
response and tumor re-sensitization to chemotherapeutic agents [255].
Epigenetic regulation of hematopoietic stem cell lineage commitment and subsequent differentiation
of dendritic cell precursors into specific dendritic subtypes (including PDCs) and interferon response in the
context of chromatin remodeling, miRNA and lncRNAs interference are well documented [256–260] and
not focused on herein. Meanwhile to our knowledge, the epigenetic impact on and by PDCs in relation
to EOC remains largely undefined. A single study demonstrated that exogenous supplementation of
miR-155 (which is downregulated in tumor-associated PDCs) via targeted nanoparticle delivery
to EOC-associated PDCs results in the genome-wide silencing of multiple immunosuppressive
mediators, following stimulation of immune defense mechanisms and abolishment of ovarian
carcinoma progression in vivo [261]. Importantly, a comparison of methylome profiles of dendritic
cells and myeloid-derived suppressor cells (MDSCs, an immune cell subtype bearing same progenitor
with PDCs) grown under tumor-associated conditions (exposure to prostaglandin E2 or malignant
conditioned medium) revealed MDSC-specific DNMT3A enzyme activation, DNA methylation
signature, and silencing of immunogenic-associated genes analogous to changes that were observed in
primary MDSCs dissected from ovarian cancer patients [262]. Moreover, the suppression of DNMT3A
activity abrogates MDSC-specific hypermethylation and MDSC immunosuppressive properties [262].
These findings support the epigenetic tuning of immune surveillance by ovarian TME and underline
the necessity for further investigations in this direction.
2.9. Mesothelial Cells (MCs)
MCs are simple squamous epithelial cells that line the intra-abdominal cavity as an upper single
layer (mesothelium) of the peritoneum, immediately supported by the basal membrane, underneath
which is the collagen-rich extracellular matrix (Figure 1A). MCs function as an active physical
barrier against the invasion of ovarian neoplastic cells into submesothelial matrix and metastasis
formation, and mesothelial disruption (clearance) imposes a higher level of EOC peritoneal adhesion
and dispersal [263,264]. Besides, MCs serve a secretory role by releasing bioactive soluble factors into
malignant ascites, such as phospholipid lysophosphatidic acid [265] and VEGF [266], which are known
to enhance EOC tumor growth, metastasis, apoptotic resistance, and angiogenesis [265,267–269]. MCs
also produce large amounts of tumor-associated immunostimulatory protein K90 [270], associated
with the poor prognosis in ovarian and breast cancers [271,272] and implicated in drug resistance [273].
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The bidirectional interplay between EOC cells and MCs has been recently assessed in a study by
Matte et al. [274], who reported global gene expression changes (649 altered genes primarily related to
cell growth and proliferation, apoptosis, cell cycle, cell assembly, and organization) in MCs exposed to
EOC ascitic effusions [274]; reciprocally, EOC cells exposed to EOC-associated MC setting exhibited
an enhanced resistance to induced apoptosis [274]. However, epigenetic regulation underlying these
gene expression alterations are unknown. Clearly, DNA methylation, histone modification profiling,
and non-coding RNA profiling are further key steps necessary to distinguish specific epigenetic
mechanisms responsible for gene expression switches occurring in EOC cells and cancer-affected
mesothelium because of their interdependence. Gaining better understanding of these events may
provide valuable insight on cellular adjustment during tumor-mesothelial adhesion step and suggest
novel approaches to block metastatic seeding of the peritoneum.
3. Ovarian TME: Potential Epigenomic-Based Therapeutic Strategies
The growing body of information on epigenetic control of ovarian cancer metastatic advancement
and acquisition of resistance to standard-of-care chemotherapy make epigenomic alterations attractive
prognostic markers and druggable targets to improve therapeutic outcomes in EOC patients especially
with platinum-resistant and recurrent disease. Our group and others are actively exploiting DNA
hypermethylation, modifications of histone marks, and aberrant expression of non-coding RNAs
in malignant EOC cells in an attempt to treat EOC, re-sensitize ovarian tumors to conventional
chemotherapy, and prevent/delay disease recurrence (Figure 3A). We and others aim to discern global
DNA methylation patterns and methylation states of specific candidate genes to prognosticate and
improve patient response to chemotherapies with hypomethylating agents (HMAs) [15,88,275–277].
We recently demonstrated successful in vitro and in vivo re-sensitization of multiple cisplatin-resistant
ovarian cancer cell lines using a novel small-molecule DNMT inhibitor guadecitabine (SGI-110) [275].
Efficient epigenetic targeting of ovarian CSC population by the HMA with induction of differentiation,
restriction of tumor-initiating capacity, and re-sensitization to platinum was also reported [278]. In a
recently completed phase I clinical trial, guadecitabine “priming” in combination with carboplatin
induced clinical response in patients with platinum-resistant, recurrent HGSOC [279]. Similarly,
HDAC inhibitors are being examined in advanced, refractory, and recurrent ovarian cancer [280–282].
However, despite some promising results, cell adaptation to HDAC inhibitor-mediated epigenomic
disruption has been frequently observed [283–285]. Finally, the recent identification of large miRNA
and lncRNA classes as epigenetic regulators of gene expression granted new opportunities for miRNA-
and lncRNA-employed prognostic evaluation and targeting of EOC [92–94,153,286].
Continuous accumulation of knowledge on epigenomic perturbations in ovarian TME cellular
compartments in the context of their communication with EOC cells holds great translational promise.
The fact that non-malignant stromal cells lack genetic mutations and acquire potentially reversible
tumor-specific molecular traits and cancer-indulgent functions via epigenetic reprogramming by
EOC cells suggests the epigenetic tailoring of ovarian TME as a promising strategy in ovarian cancer
management. Given the varying stroma representation in ovarian malignancies (stromal compartment
may range from 7 to 83% in different ovarian tumors [287]) and high level of TME cell heterogeneity, it
is pivotal to correctly evaluate TME composition within the tumor bulk in each disease case. Prevalence
of one or another type of TME cells may dictate activation of certain mechanistic pathways, help to
dissect “first choice” epigenetic therapy candidates, and possibly lead to the identification of epigenetic
alterations in the TME that are specific for each patient.
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Figure 3. Ovarian TME: potential epigenomic-based therapeutic strategies. (A) Main epigenetic
therapy mechanisms include: (1) DNA demethylation with hypomethylating agents (HMAs) to
re-activate transcription of silenced genes; (2) restoration of open, transcription-permissive euchromatin
state with histone deacetylase (HDAC) inhibitors preventing removal of acetyl groups from the
histone tails; (3) targeting non-coding RNA-mediated epigenetic perturbations via delivery of
exogenous miRNA inhibitors (antagomirs/blockmirs/sponges) or mimics, lncRNA siRNAs, small
molecules or peptide nucleic acid aptamers; (B) Multifaceted epigenomic targeting approach
suggests simultaneous targeting of several malignant and TME cell types using one epigenetic drug;
(C) Combinatorial epigenomic targeting involves employment of multiple epigenetic mechanisms to
revert cancer-associated phenotype in TME cells and inhibit their tumor-promoting effect on EOC
cells; (D) Epigenomic potentiation of immunotherapy involves epigenetic stimulation of cancer cell
immune gene/pathway representation which allows for increased immune surveillance efficacy.
CAA—cancer-associated adipocyte; HMA—hypomethylating agent; HDACi—histone deacetylase
inhibitor; EOC—epithelial ovarian cancer cell; MSC—mesenchymal stem cell; OCSC—ovarian cancer
stem cell; PNA—peptide nucleic acid; TAM—tumor-associated macrophage; TEC—tumor-associated
endothelial cell; TIL—tumor-infiltrating lymphocyte. Black arrows represent interactions reported in
EOC; dashed arrows designate patterns that were observed in other cancer types and may potentially
be applicable towards ovarian cancer (see main text for details).
Treatment of different stromal components with HMAs demonstrated tumor-restrictive potential.
In particular, the exposure of adipocytes to guadecitabine attenuated HGSOC cells metastasis-associated
behaviors [148]. HMA decitabine effectively inhibited the multipotent and tumor-promoting capabilities
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of ovarian cancer-associated MSCs and led to decrease in cancer cell proliferation [181]. While not
specified for EOC, treatment with the DNMT inhibitor azacitidine showed tumor-inhibiting and
anti-angiogenesis effect with a decreased amount of TECs and pericytes in other cancer types [212].
HMA therapy also showed change in immunoregulatory cell response within the tumor bulk with
increased infiltration of tumor-restrictive TIL subsets and suppression of TAM-mediated tumor
progression in EOC and other cancers [228,242–244]. Such multifaceted epigenomic targeting of
multiple stromal cell types in parallel with primary EOC cell targeting through assessing the same
epigenetic mechanism (Figure 3B) may improve efficacy, while also diminishing the toxic effects that
are associated with multi-drug treatment regimens.
Alternatively, similarly to an improved anticancer effect of a DNMT/HDAC inhibitor combination
on ovarian tumors [288] and other malignancies [284,289], the combinatorial epigenomic targeting of
ovarian TME components using several epigenomic approaches is plausible (Figure 3C). For example,
anti-angiogenesis and anti-proliferative effect of simultaneous utilization of an HDAC inhibitor to
target pro-tumorigenic histone marks and an HMA to demethylate DNA promoter CpG islands in
colon tumor-conditioned TECs was reported [194]. Analogous drug combination may have therapeutic
prospective to block ovarian cancer neovascularization. Moreover, systemic nanoparticle delivery
of siRNAs or antagomirs targeting tumor-assisting non-coding RNAs (such as EZH2, HOTAIR,
and miR-298) into ovarian TECs may provide an additional option for combinatorial blocking of
EOC tumor growth and angiogenesis [197–199]. Current data provide strong rationale for combining
HDAC and DNMT inhibitors to affect EOC-associated pericytes [212,214].
Given that CAF reprogramming is shown to repress ovarian tumor advancement [290], prevention
or reversion of CAF phenotype may potentially be accomplished through combined treatment with
a HMA [113,115] and a CAF-delivered mixture of miRNA miR-31/miR-214 mimics plus miR-155
antagonist to interfere with the EOC-associated CAF miRNA signature [130]. The recent discovery
of a number of altered lncRNAs in HGSOC CAFs [132] may suggest novel options for restricting
CAF-promoted EOC growth via targeted siRNA injections. Similarly, non-coding RNA signatures
recently identified in EOC-related immune cell populations (discussed earlier in this review) warrant
further siRNA/miRNAs targeted conveyance studies in this direction. Importantly, in contrast to CAFs,
miR-155 was downregulated in EOC-associated PDCs and its exogenous delivery to these cells, in turn,
boosted anti-tumor immune defense response and EOC suppression [261]. Taking into consideration
such drastically opposite effects of the same epigenomic regulators on different ovarian TME cell
compartments, the development of methodologies for highly specific nanoparticle transportation and
precise cell type targeting is pivotal. Several studies investigating the potential of exosome-facilitated
epigenomic (miRNA) cargo delivery for EOC treatment are also in progress [291].
Exploiting host immune system in managing ovarian cancer growth and metastatic spread has
emerged as another key research and therapeutic direction [292–296]. A number of comprehensive
analyses of epigenomic strategies employed to advance cancer immunotherapies [297–299] provide
detailed illustration on how currently available epigenetic drugs may potentially contribute to
modulation of cancer immunosurveillance and anti-tumor responses (Figure 3D). In ovarian cancer
in particular, Stone et al. [243] demonstrated while using preclinical in vivo models that combining
DNMT inhibitor and HDAC inhibitor with immune checkpoint blockade resulted in the most notable
anti-cancer effect and survival due to activation of type I interferon signaling, more efficient recruitment
of anti-tumor TIL subsets and the restriction of tumor-indulgent TAMs and myeloid-derived suppressor
cells to the ovarian TME. Alternatively, Song and coworkers [300] reported HDAC inhibitor-stimulated
increase of NKG2D ligand expression on the surface of ovarian cancer cells, which allowed for better
recognition and killing of the latter by engineered NGK2DL-specific chimeric antigen receptor T
cells. Finally, Wargo and colleagues [301] reported improved recognition of tumor cells by engineered
peripheral blood lymphocytes in response to increased cancer-testis antigen NY-ESO-1 expression
(typically expressed in the majority of epithelial tumors, including ovarian [302]), catalyzed by
DNMT inhibitor (alone or combined with HDAC inhibitor). Furthermore, the results of a recent
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phase I clinical trial by Odunsi et al. [303] showed improved efficacy of NY-ESO-1 vaccine therapy
when combined with escalated doses of HMA decitabine in patients with EOC relapse. Current
clinical trials combining immunotherapeutic approach with epigenetic drug(s) are summarized in
Table 1. In addition to epigenomic potentiation of immunotherapy by chromatin remodelers, boosting
regulatory T cell-mediated immune response may be achieved via targeting non-coding RNAs [304]
and it requires further testing for applicability in EOC (Figure 3D).
Table 1. Clinical trials evaluating safety and efficacy of immunotherapeutic agents in combination with
epigenetic drugs in patients with ovarian cancer (https://clinicaltrials.gov).
Study Name Phase Status
ClinicalTrials.gov
Identifier
Decitabine, Vaccine Therapy, and Pegylated
Liposomal Doxorubicin Hydrochloride in
Treating Patients With Recurrent Ovarian
Epithelial Cancer, Fallopian Tube Cancer, or
Peritoneal Cancer
I CompletedCompletion: June 2013 NCT01673217
Atezolizumab, Guadecitabine, and CDX-1401
Vaccine in Treating Patients With Recurrent









Guadecitabine and Pembrolizumab in Treating
Patients With Recurrent Ovarian, Primary







Genetically Modified T Cells and Decitabine in
Treating Patients With Recurrent or Refractory








Study of Azacitidine and Durvalumab in







To summarize, a deeper understanding of epigenomic involvement in reciprocal EOC tumor-stroma
interrelationship is essential and it will help to determine pharmacological routes to alter the TME,
which in turn could inhibit EOC metastatic progression and the development of chemoresistance and
tumor recurrence. Furthermore, we believe epigenetically-mediated pharmacological engagement of
certain TME players, such as immune cells, to boost immune responses towards complete malignant cell
elimination has tremendous potential.
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Abstract: Ovarian cancer is the most lethal gynecologic malignancy, and patient prognosis has not
improved significantly over the last several decades. In order to improve therapeutic approaches
and patient outcomes, there is a critical need for focused research towards better understanding of
the disease. Recent findings have revealed that the tumor microenvironment plays an essential role
in promoting cancer progression and metastasis. The tumor microenvironment consists of cancer
cells and several different types of normal cells recruited and reprogrammed by the cancer cells
to produce factors beneficial to tumor growth and spread. These normal cells present within the
tumor, along with the various extracellular matrix proteins and secreted factors, constitute the tumor
stroma and can compose 10–60% of the tumor volume. Cancer associated fibroblasts (CAFs) are
a major constituent of the tumor microenvironment, and play a critical role in promoting many
aspects of tumor function. This review will describe the various hypotheses about the origin of CAFs,
their major functions in the tumor microenvironment in ovarian cancer, and will discuss the potential
of targeting CAFs as a possible therapeutic approach.
Keywords: ovarian cancer; tumor microenvironment; cancer associated fibroblasts; fibroblast;
cross-talk; invasion; angiogenesis; ECM; chemoresistance; therapy
1. Introduction
Ovarian cancer is the deadliest of all the gynecologic malignancies, and is the fifth leading cause of
cancer related deaths among women in the United States. There has been only a modest improvement
in ovarian cancer patient prognosis over the last several decades [1,2]. Therefore, there is a critical need
for focused research to improve our understanding of the disease and develop novel therapies that are
more effective. In the past, most of the research efforts were focused on the cancer cells in isolation.
However, recent research has identified the tumor microenvironment as a key factor in promoting
cancer progression [3–7]. The cancer cells recruit various normal cells and reprogram them to produce
factors beneficial to tumor growth and spread. These normal cells present within the tumor constitute
the tumor stroma and can compose 10–60% of the tumor volume [3].
In order to survive and proliferate, the cancer cells productively interact with their
microenvironment. The tumor microenvironment is complex and contains a variety of cells constituting
the tumor stroma. Tumors however, can only grow if their complex tissue environment provides them
with a milieu of factors and conditions that can sustain their growth and spread [8]. A complicated
bidirectional interaction is therefore happening at the interface between the genetically unstable
Cancers 2018, 10, 406; doi:10.3390/cancers10110406 www.mdpi.com/journal/cancers59
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malignant cells and the genetically stable stroma, a process that will determine the degree of tumor
promotion and proliferation, invasiveness, potential for spread, and even patient prognosis [9].
The tumor stroma consists of cellular components like the cancer associated fibroblasts (CAFs),
immune cells, endothelial cells, pericytes, adipocytes, and so forth, as well as acellular components
like the extra cellular matrix proteins (ECMs) [3–7]. Each of these tumor microenvironmental elements
has been shown to play important roles in tumor growth and progression in various cancers, including
ovarian cancer. CAFs are an important constituent of the tumor stroma, and this review will
focus on providing an overview of the origin, function, and potential targeting of CAFs in ovarian
cancer therapy.
2. Origin of CAFs
There are several hypotheses about the origin of CAFs, which include the reprogramming of
the resident normal fibroblasts by the cancer cells, and differentiation of mesenchymal stem cells
(Figure 1). A less widely accepted theory is that they are already present as a small subpopulation
of normal fibroblasts, which are selected for by the cancer cells [10]. These subpopulations may
have acquired a mutation, or epigenetic alterations, independent of the tumor cells, which transform
them into activated fibroblasts. A proinflammatory microenvironment resulting in the generation
of reactive oxygen species may promote acquisition of genetic lesions [11]. As the tumor develops
in their vicinity, these subpopulations might be selected for by the cancer cells for their ability to
support tumor growth [10]. Since mutations are not commonly found in the tumor stroma, and CAFs
are not believed to have clonal populations with distinct genetic changes, this hypothesis has not
gained much traction [12]. Fibroblasts are mesenchymal cells that are generally present in the
basement membrane and serve as a scaffold, secreting ECMs, and growth and trophic factors [13,14].
They are generally in a quiescent “inactive” state, but retain some plasticity, and are capable of
getting “activated” by various physiological stimuli. During development, dermal fibroblasts play
a role in tissue patterning, and can differentiate into multiple kind of cells, including hair follicle
cells, papillary cells, reticular cells, and pre-adipocytes [15]. The fibroblasts get activated at the site
of wound healing by factors such as insulin-like growth factors (IGFs), transforming growth factor
beta 1,2,3 (TGF-β 1,2,3), and platelet-derived growth factor (PDGF), among others. These activated
fibroblasts express α-smooth muscle actin (α-SMA), which makes them contractile, and helps in wound
closure. These α-SMA expressing fibroblasts are called myofibroblasts. They secrete various ECMs and
extracellular proteases, which help in the initial wound healing and development of the scar. They also
secrete factors like TGF-β to stimulate epithelial to mesenchymal transition in the epithelial cells
around the wound. This enables the epithelial cells to move and close the wound. Thereafter, as the
wound heals, epithelialization is promoted by epidermal growth factors (EGFs) and the keratinocyte
growth factor (KGF) produced by the fibroblasts [16].
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Figure 1. Formation of cancer associated fibroblasts (CAFs) through the reprogramming of resident
normal fibroblasts or mesenchymal stem cells by ovarian cancer cells. TGF-β: transforming growth
factor beta; PDGF: platelet-derived growth factor; FGF: fibroblast growth factor; EGF: epidermal
growth factors; CXCL12: C-X-C Motif Chemokine Ligand 12; CCL5: C-C Motif Chemokine Ligand 5; ↑:
upregulated;↓: downregulated.
CAFs display several traits of the activated fibroblasts found in healing wounds, including
upregulation of TGF-β, increased secretion of ECMs, extra cellular proteases, and expression of α-SMA.
It is believed that cancer cells can recruit the resident normal fibroblasts and reprogram them into
CAFs. Several reports have demonstrated evidence in support of this hypothesis in ovarian cancer [7].
Ovarian cancer cells produce factors including TGF-β and PDGF, that can change normal fibroblasts
into “activated” CAFs. We have previously shown that ovarian cancer cells can induce a change in
expression of a set of 3 microRNAs in the resident normal omental fibroblasts, which reprograms
them into CAFs [7]. miR-214 and miR-31 were found to decrease, while miR-155 expression increased,
in the normal fibroblasts because of their interaction with the metastasizing ovarian cancer cells.
This resulted in their reprogramming into CAFs (Figure 1). It was the first report of a set of microRNAs
reprogramming normal fibroblasts into CAFs. Simultaneous inhibition of miR-214 and miR-31, along
with overexpression of miR-155, could convert normal fibroblasts into CAFs. These results supported
previous findings in other cancers, which demonstrated the absence of mutations in CAFs. Moreover,
CAFs can be isolated from tumors and cultured in vitro for several passages, and yet retain their
phenotype and their ability to support cancer cell functions. This suggested a potential role of
epigenetic regulation [17]. The role of microRNAs in reprogramming of normal fibroblasts into
CAFs further revealed a potential mechanism. Interestingly, overexpressing miR-214 and miR-31
and inhibiting miR-155 simultaneously in CAFs could revert them back into normal fibroblasts.
This offers a potential opportunity to normalize a key component of the tumor microenvironment.
Research on targeting the tumor microenvironment has revealed that the normalization of the tumor
microenvironment is a more effective approach as compared to attempts at obliterating it altogether.
The latter typically leads to the cancer cells becoming more aggressive. Depleting α-SMA positive CAFs
in a transgenic mouse model of pancreatic ductal adenocarcinoma through induction of thymidine
kinase by ganciclovir administration, either early in the tumor precursor stage or late carcinoma
stage, led to the development of undifferentiated tumors, which were highly invasive and resulted
in decreased survival [18]. Since this was observed when the CAFs were ablated in the precursor
lesions or in the late carcinomas, it indicated that irrespective of tumor stage, in the absence of the
microenvironmental support, the more aggressive cancer cell clones are selected. These findings are
similar to the increased metastasis observed upon pericyte depletion [19].
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Other hypotheses about the origin of CAFs include the recruitment of mesenchymal stem cells by
the cancer cells to the tumor [10,20]. Human pancreatic cancer cells were shown to recruit bone marrow
derived progenitors when injected in mice [21]. The resulting tumors had about 40% myofibroblasts
derived from bone marrow cells. Similarly, CAFs were shown to be derived from mesenchymal
stem cells in ovarian cancer and supported tumor growth through the secretion of the paracrine
factor IL-6 [22]. Ovarian cancer cells have been reported to secrete IL-1β that leads to the decreased
expression of p53 protein in the ovarian fibroblasts, converting them into CAFs [23]. The decreased
p53 resulted in increased secretion of IL-8, growth regulated oncogene-alpha (GRO-α), IL-6, IL-1β,
and vascular endothelial growth factor (VEGF) by the CAFs. Mesenchymal stem cell derived CAFs
were also shown to regulate ovarian cancer stem cells through bone morphogenetic protein secretion,
which resulted in resistance to chemotherapy [24,25]. The mesothelial cells lining the peritoneum and
the omentum have also been reported as a source of CAFs in ovarian cancer peritoneal and omental
metastasis [26]. The mesothelial cells have been shown to undergo mesothelial to mesenchymal
transition under the influence of ovarian cancer cell secreted TGF-β, which can form a subpopulation
of the CAFs in ovarian cancer metastatic tumors [27]. Others have demonstrated that ovarian cancer
cells interact with the mesothelial cells in a β1-integrin-dependent manner to induce mesothelial to
mesenchymal transition and convert them into CAFs [28].
3. CAF Markers
Since CAFs in the tumor microenvironment are functionally very similar to the activated
fibroblasts in healing wounds, they both share several markers. CAFs express α-SMA, which is
also a marker of myofibroblasts in wound healing [10]. Ovarian cancer CAFs also express α-SMA,
while normal fibroblasts do not [29]. However, the expression of α-SMA is only one of many changes
that occur in activated fibroblasts [30]. The levels of expression of α-SMA may also vary between
CAFs. As evidenced by the findings of Mhawech-Fauceglia et al., the CAFs in ovarian tumors are
predominantly α-SMA positive, but not all of them stain for the protein [29]. This indicates the
existence of a certain level heterogeneity within the CAF population.
In addition to α-SMA, many other markers have been reported to distinguish CAFs from normal
fibroblasts. They include fibroblast activated protein (FAP), S100A4, and platelet derived growth
factor receptor, among others [7,29,31]. FAP, a cell surface serine protease, has emerged as a specific
marker of CAFs in ovarian cancer [32]. While each of them has been shown to be an effective marker
by different groups, there is no clear consensus about a universal marker for CAFs. The probable
reason for this is that CAFs are a heterogeneous population, with some expressing one marker and
others expressing other markers. α-SMA and PDGF positive CAFs do not overlap with S100A4
positive CAFs in pancreatic cancer [33]. The mutual exclusivity and heterogeneity in CAF marker
expression may impart unique functions; for example, FAP and podoplanin positive CAFs were found
to be immunosuppressive through a nitric oxide-dependent mechanism, while FAP positive and
podoplanin negative CAFs were not immunosuppressive in lung adenocarcinoma [34]. For prostate
cancer, CAFs expressing high CD90 had greater tumor promoting capacity than CAFs expressing low
CD90 [35]. Pancreatic ductal adenocarcinomas have a subpopulation of CAFs that are distinct from
those expressing α-SMA. These CAFs express proinflammatory mediators like IL-6, and mediate a
paracrine interaction with the carcinoma cells [36]. In ovarian cancer, the expression levels of different
CAF markers, CD10, podoplanin, FAP, Platelet-derived growth factor receptor alpha (PDGFRα),
Platelet-derived growth factor receptor beta (PDGFRβ), S100 calcium binding protein A4 (S100A4),
α-SMA, snail family transcriptional repressor 2 (SNAI2, commonly known as Slug), Zinc finger
E-box-binding homeobox 1 (ZEB1), and twist family bHLH transcription factor 1 (TWIST1), clustered
the CAFs into different subgroups showing different protein expression patterns [31].
Due to the continuous reciprocal interactions of CAFs with cancer cells, it is quite possible that
the CAFs can undergo dynamic changes in their marker expression and functions depending on the
heterogeneity of the cancer cells within the tumors. A recent study identified a unique subset of CAFs
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expressing the metallo-endopeptidase CD10 and the complement anaphylatoxin receptor GPR77 [37].
These CAFs were enriched following neoadjuvant chemotherapy, and were shown to promote cancer
stem cell self-renewal through the secretion of IL-6 and IL-8. Therefore, their abundance in the tumors
of breast cancer patients predicted a poor prognosis. Similarly, the evolving ovarian cancer metastatic
tumors are metabolically reprogrammed by CAFs through the secretion of C-C Motif Chemokine
Ligand 5 (CCL5), C-X-C motif chemokine ligand 10 (CXCL10), and IL-6 to utilize glycogen [38].
The CAFs with activated p38 MAP kinase signaling were capable of inducing such reprogramming.
Therefore, considering the heterogeneity of CAFs, it is important to take into account their functional
effects in promoting tumor progression as well as the potential of dynamic changes in them.
4. CAF Functions
CAFs have multiple functions in the tumor microenvironment, which directly or indirectly
promote tumor progression. Most of these functions are mediated through the secretion of paracrine
factors, ECMs, and proteases, as well as through cell surface receptors and direct contact with cancer
cells. These functions and their underlying mechanisms are detailed below, outlined in Figure 2,
and listed in Table 1.
Figure 2. Functions of CAFs contributing towards tumor progression. ECM: extra cellular matrix; EMT:
epithelial–mesenchymal transition.
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Table 1. Functional roles of cancer associated fibroblasts (CAFs) in tumor progression.
No. Functional Role of CAF References
1 Promoting of tumor growth [39]
2 Promoting tumor invasion [3,40]
3 Inducing EMT in cancer cells [41,42]
4 Remodeling the ECM [43,44]
5 Inducing angiogenesis [45,46]
6 Inflammation and immune modulation [7,47]
7 Promoting chemoresistance and cancer stem cells [48,49]
8 Reprogramming cancer metabolism [3,4,38]
ECM: extra cellular matrix; EMT: epithelial–mesenchymal transition.
4.1. Promoting Tumor Growth
CAFs have predominantly been demonstrated to have tumor-promoting functions. They stimulate
cancer cell survival, growth, and invasion, enhance the stiffness of the extracellular matrix, contribute to
angiogenesis by releasing pro-angiogenic factors, contribute to a pro-inflammatory milieu, and impact
on the activation state of various immune cells [50]. CAFs are crucial in tumor-stroma communication
through modulation of the extracellular matrix, fibrogenesis, and chemoattraction of other stromal
cells. Several studies have demonstrated that tumor–CAF crosstalk promotes growth and invasion
of the particular cancer cells [39]. CAFs produce autocrine and paracrine cytokines that promote
the growth and biological characteristics of tumors [7]. In addition to classical growth factors,
including EGF and hepatocyte growth factor (HGF), novel CAF secreted proteins (secreted frizzled
related protein 1, and IGF like family member (IGF) 1 and 2) and membrane molecules (integrin
α11 and syndecan 1) have also been identified to possess cancer cell supporting roles. These factors
directly or indirectly stimulate tumor growth and survival, or enhance their migratory and invasive
properties [51]. Several secreted molecular regulators of CAFs have a pro-tumorigenic role, such as the
TGF-β superfamily and bone morphogenic proteins (BMPs), PDGFs, EGFs, fibroblast growth factors
(FGFs), and sonic hedgehog (SHH) [52].
Initial experiments with co-injection of CAFs with simian virus 40 (SV40)-transformed prostate
epithelial cells in mice resulted in tumors resembling prostatic intraepithelial neoplasia, whereas
normal fibroblasts did not. Similarly, co-transplantation of myofibroblasts with Ras-transformed
hepatocytes strongly enhances tumor growth through the TGF-β/PDGF axis [39]. In addition, CAFs
induce forkhead box Q1 (FOXQ1) expression; as a result, N-myc downstream-regulated gene 1
(NDRG1) is trans-activated to enhance hepatocellular carcinoma (HCC) initiation. Interestingly,
pSTAT6/CCL26 signaling is induced by the FOXQ1/NDRG1 axis, thus recruiting hepatic stellate cells
(HSCs), the main cellular source of CAFs, to the tumor microenvironment. Thereby, tumor-initiating
properties are enhanced at least partly through a positive feedback loop between CAFs and HCC
cells [53]. Taken together, these indicate that CAFs can provide growth-promoting signals to epithelial
cells, and support epithelial transformation [54].
Tumor-derived TGF-β1 has been reported to activate tumor stroma, and thereby facilitate
tumor growth and progression. Inhibition of the TGF-β pathway in mouse fibroblasts through
conditional inactivation of the TGFBR2 gene is associated with increased oncogenic potential of the
adjacent epithelia [55]. An invasive breast cancer cohort study, using a randomized tamoxifen trial,
demonstrated that TGF-β receptor type-2 expression in cancer-associated fibroblasts regulates breast
cancer cell growth and survival, and is a prognostic marker in pre-menopausal breast cancer [56].
Mesenchymal stem cell derived CAFs recruited to the stroma of the dysplastic stomach express
IL-6, Wnt5a, and bone morphogenetic protein 4, which promote tumor growth through DNA
hypomethylation [57]. In oral squamous cell carcinoma (OCC), CAFs promote the production of
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endogenous reactive oxygen species (ROS) through CCL2 expression, which induces the cell cycle
regulatory proteins, and promotes OCC proliferation, migration, and invasion [58]. CAFs have
also been reported to promote Th2 polarization of the tumor microenvironment, and stimulate
tumor growth and metastasis by recruiting tumor-associated macrophages (TAMs), myeloid derived
suppressor cells (MDSCs), and T regulatory cells (Tregs) [8,59].
In ovarian cancer, CAFs promote tumor invasion and growth through the secretion of a number
of chemokines, cytokines, and growth factors like CCL5, IL-6, IL-8, HB-EGF, and TGF-α, among
others [7]. These secreted factors were regulated by the decreased expression of miR-214 and miR-31,
and an increased expression of miR-155, in CAFs induced by ovarian cancer cells. CCL5 was a target
of miR-214 and miR-31, and was responsible for homing of the ovarian cancer cells onto plugs of CAFs
in vitro [7]. Inhibiting CCL5 with a neutralizing antibody was sufficient to reduce tumor growth of
co-injected CAFs and ovarian cancer cells in mice [7].
4.2. Promoting Tumor Invasion
Tumor invasion is a key hallmark of cancer and is essential for successful dissemination of the
cancer cells. Myofibroblasts have the inherent ability to invade through the ECM in the basement
membrane during wound healing. Similarly, CAFs have the ability to invade through matrix,
and have been widely reported to promote invasiveness of cancer cells [3]. There are several
potential mechanisms by which CAFs can directly or indirectly promote cancer cell invasiveness.
These include secretion of factors and proteases that help in the invasion. Zhu et al. (2016) [40] reported
that Gal-1-regulated CAF activation promotes breast cancer cell metastasis by upregulating MMP-9
expression in breast cancer. Recent studies have shown that breast CAFs overexpress the chemokine
CXCL1, a key regulator of tumor invasion and chemo-resistance. TGF-β negatively regulates CXCL1
expression in CAFs through Smad2/3 binding to the promoter, and through suppression of HGF/c-Met
autocrine signaling [60]. CAFs can also induce changes in the cancer cells, which helps in their
invasiveness. They have been reported to promote the metastatic activity of breast cancer cells by
activating the transcription of HOTAIR via TGF-β1 secretion [61].
CAFs can serve as engines for collective invasion of directly interacting cancer cells through
heterotypic interactions between the N-cadherin expressed on CAFs with the E-cadherin on cancer
cells [62]. Interestingly, a dual mechanism is involved. CAFs favor invasion of cancer cells by
pulling them away from the tumor, while cancer cells further enhance their spread by polarizing CAF
migration away from the tumor. Along similar lines, vimentin is reported to be necessary for lung
adenocarcinoma metastasis by maintaining heterotypic tumor cell–CAF interactions during collective
invasion [63]. Cdc42EP3—a member of the BORG family of Cdc42 effectors—is highly expressed in
CAFs, and regulates the actin and septin fibrillar networks. Coordination between the actin and the
septin networks in CAFs is required for force-mediated matrix remodeling, promoting cancer cell
invasion, angiogenesis, and tumor growth [64].
In ovarian cancer we have previously shown that CAFs can promote coordinated invasion of the
cancer cells, which promotes metastasis [7]. Using a novel 3D live confocal imaging-based co-invasion
assay, we observed that the CAFs derived from ovarian cancer omental metastasis are able to closely
interact with ovarian cancer cells and invade through matrigel by forming distinct networks of CAFs
and cancer cells, which invaded together. Cancer cells alone invaded at a slower rate and failed to form
the network consisting of cellular associations. The mechanism of CAF–cancer cell interactions reported
by Labernadie et al. [62] involving heterophilic E-cadherin/N-cadherin junctions could potentially be
playing a role in these interactions between the CAFs and ovarian cancer cells. A comparison of gene
expression profiles of CAFs from omental metastasis with normal omental fibroblasts revealed that the
CAFs secrete multiple chemokines and cytokines that can potentially regulate invasion and motility
of cancer cells [7]. Among them, CCL5 was identified as a key CAF derived mediator of metastasis,
which was itself regulated by miR-214 and miR-31. Both these microRNAs are downregulated in CAFs
during the reprogramming of normal fibroblasts by metastasizing ovarian cancer cells [7]. Zhao et al.
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(2017) identified STAT4 as a key regulator of ovarian cancer metastasis via Wnt7a-induced activation
of CAFs [65]. The concomitant increased production of CXCL12, IL6, and VEGFA by CAFs within
the tumor microenvironment could enable peritoneal metastasis of ovarian cancer via induction of
the EMT program. They also established a model of promotion of ovarian cancer metastasis by
STAT4 via tumor-derived Wnt7a-induced activation of CAFs [65]. CAFs promote ovarian cancer
cell proliferation, migration, and invasion through the paracrine FGF-1 factor. The FGF-1/FGFR-4
signaling axis regulates the stromal microenvironment in ovarian carcinomas. CAFs also activate the
expression of Snail1 and MMP3, as well as reduce the expression of E-cadherin [66].
4.3. Inducing EMT in Cancer Cells
An epithelial-mesenchymal transition (EMT) is a biological process that allows a polarized
epithelial cell, which normally interacts with the basement membrane via its basal surface, to undergo
multiple biochemical changes that enable it to assume a mesenchymal cell phenotype, which includes
enhanced migratory capacity, invasiveness, elevated resistance to apoptosis, and greatly increased
production of ECM components. The completion of an EMT is signaled by the degradation of the
underlying basement membrane and the formation of a mesenchymal cell that can migrate away from
the epithelial layer in which it originated [67]. The idea that epithelial cells can downregulate epithelial
characteristics and acquire mesenchymal characteristics arose in the early 1980s from observations
made by Elizabeth Hay [68]. Over the subsequent years, the importance of EMT in cancer progression
has been well established. The heterotypic interactions of cancer cells with the microenvironment,
including CAFs, has been shown to be a key inducer of EMT.
Coculturing CAFs with lung cancer cells can induce miR-33b downregulation and promote
epithelial cells EMT. miR-33b overexpression in lung cancer cells can counteract CAF-induced EMT.
Interestingly, Snail1 expression in fibroblasts activates the inductive effects of CAFs on lung cancer
cells. Snail1-expressing cancer-associated fibroblasts induce lung cancer cell epithelial-mesenchymal
transition through miR-33b [41]. CAF conditioned medium induced epithelial-mesenchymal
transition (EMT) by regulating the expression of EMT-associated markers E-cadherin and vimentin,
and modulated metastasis-related genes MMP-2 and VEGF, both in vitro and in vivo. Further studies
demonstrated that CAFs enhanced the metastatic potential of lung cancer cells by secreting IL-6 and
subsequently activating the JAK2/STAT3 signaling pathway [42]. TGF-β1 secreted by CAFs can
induce EMT in the interacting cancer cells and promote metastasis [69,70]. In ovarian tumors, CAF
derived exosomes contain higher levels of TGF-β1 compared to those derived from normal omental
fibroblasts [71]. Theses exosomes, upon uptake by ovarian cancer cells, induce EMT through the
activation of SMADs. Activation of STAT3 by microenvironmental IL-6 can also induce EMT in ovarian
cancer cells [72]. CAFs were reported to be the major source of IL-6 in the tumor microenvironment of
ovarian tumors [72]. Therefore, CAFs can make cancer cells more aggressive by inducing EMT in them
through various paracrine mechanisms.
4.4. Remodeling the ECM
Every organ has an ECM with unique composition, providing physical support for tissue integrity
and elasticity. It is a dynamic structure that is constantly remodeled to control tissue homeostasis [73].
Dysregulation of ECM composition, structure, stiffness, and abundance contributes to several
pathological conditions, such as fibrosis and invasive cancer. Typically, tumors have much stiffer ECMs,
causing altered dynamics of the biophysical and biochemical interactions of the cancer cells with their
microenvironment [74]. The increased stiffness of the matrix promotes invasiveness and motility of the
cancer cells through improved invadosome and lamella formation [75]. Matrix stiffness drives EMT and
metastasis through the TWIST1–G3BP2 mechanotransduction pathway in breast cancer [76]. A 9-gene
matrisome gene signature has been identified through the analysis of available databases, and is
associated with tumor progression through promotion of EMT, angiogenesis, hypoxia, inflammation,
and altered metabolism in several cancers, including ovarian cancer [43]. Altered ECMs and ECM
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remodeling enzymes, like matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases
(TIMPs), and lysyl oxidases (LOXs), work to create a stiffer microenvironment permissive for tumor
cell growth, migration, and invasion [44]. The increased secretion of fibronectin and LOXs by breast
cancer CAFs contribute towards the remodeling of the ECMs in these tumors, promoting invasion and
metastasis [77]. TGF-β activates the secretion of versican by CAFs in high-grade serous ovarian tumors,
which induces the expression of MMP9 and CD44 by the cancer cells, resulting in ECM remodeling
and invasion [78]. A recent study has demonstrated the role of ovarian cancer cell derived inhibin βA
in effectively inducing CAFs, which then secrete increased amounts of collagens and other ECMs [79].
Therefore, CAFs serve the important function of remodeling the ECMs through altered secretion of the
matrisome components, and provide the ideal microenvironmental stiffness for tumor progression.
4.5. Inducing Angiogenesis
As the tumor grows, the cancer cells are further removed from the existing blood vessels, and as
a result, experience depleted levels of oxygen and nutrients. This typically places a limit to the
tumor size, as cell proliferation in the regions well supplied by the blood vessels is balanced by cell
death in the regions deprived of oxygen and nutrients. Therefore, in order to progress, the tumors
must induce angiogenesis. It is the formation of a new vascular network to supply nutrients and
oxygen, and remove waste products. Multiple factors, like VEGF, basic fibroblast growth factor (bFGF),
interleukin-8 (IL-8), placenta-like growth factor (PLGF), TGF-β, platelet-derived endothelial growth
factor (PD-EGF), pleiotrophin, activated hypoxia-inducible factor-1α (HIF-1α), and so forth, have been
shown to trigger angiogenesis [80,81]. Many of these pro-angiogenic factors are contributed by the
tumor microenvironment [82]. CAFs induce angiogenesis directly, as well as indirectly, through VEGFA,
PDGFC, FGF2, CXCL12, osteopontin, and CSF3 secretion, ECM production, and recruitment of myeloid
cells [82]. SDF-1 secreted by breast cancer CAFs has been involved in mobilization of endothelial
precursor cells from bone marrow, thereby inducing de novo angiogenesis, as well as in tumor growth
through a paracrine effect on CXCR4 expressing cancer cells [45]. Similarly, fibroblast-derived SDF-1
synergized with IL-8 in the promotion of a complete angiogenic response in recruited endothelial
cells in pancreatic cancer [46]. SDF-1 is induced in breast cancer CAFs by oxidative stress-mediated
activation of HIF-1 [83]. Chloride intracellular channel protein 3 (CLIC3) secreted by breast cancer
CAFs induces angiogenesis through an active transglutaminase-2 (TGM2) mediated mechanism [84].
MMP-13 secreted by CAFs promotes tumor angiogenesis by releasing VEGF entrapped in the
ECM, thereby leading to increased invasion of endothelial cells in squamous cell carcinoma and
melanoma [85]. Ovarian cancer CAFs can indirectly induce angiogenesis through increased secretion
of pro-inflammatory factors IL-6, COX-2, and CXCL1 [86]. Ovarian cancer cell expression HOXA9
induces CAFs to secrete CXCL12, IL-6, and VEGF-A expression, which promotes angiogenesis [87].
Ovarian cancer CAFs have also been shown to induce angiogenesis by secreting VEGF-C as a result
of induction by Sonic Hedgehog (SHH) from ovarian cancer cells [88]. While angiogenesis can be
induced by cancer cells as well as the tumor microenvironment, CAFs are important direct or indirect
contributors to the process, and hence towards cancer progression.
4.6. Inflammation and Immune Modulation
Inflammation is a normal physiological response that is initiated in injured tissue and helps in its
healing. In clinical settings, chronic inflammation and cancer are closely related, and cancer is referred
to as “wounds that never heal”. During tissue injury associated with wounding, cell proliferation is
enhanced while the tissue regenerates; proliferation and inflammation subside after the assaulting
agent is removed or the repair completed. In contrast, proliferating neoplastic cells continue to
proliferate in microenvironments rich in inflammatory cells, and growth and survival factors,
that support their growth [89]. Pro-inflammatory cytokines are secreted by cancer cells and CAFs
to attract immune cells to the tumor. Macrophages actively attracted into tumor regions along
defined chemotactic gradients start to differentiate into tumor-associated macrophages (TAMs),
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which further enhance the growth and metastasis of cancer cells [52]. CAFs are functionally required
for mediating inflammation during squamous cell carcinogenesis, starting at the earliest pre-neoplastic
stages [90]. A recent paper demonstrated that CAFs associated to incipient neoplasia exhibit a
pro-inflammatory signature, leading them to mainly overexpress SDF-1, IL-6, and IL-1β, as well
as to recruit proangiogenic macrophages. This gene set is under the transcriptional control of nuclear
factor-κB (NF-κB) and cyclooxygenase 2 (COX-2), thereby strengthening the link between CAFs
and inflammatory mediators in tumor progression [47]. We have demonstrated that ovarian cancer
CAFs produce an array of chemokines and cytokines, which can potentially induce a proinflammatory
response [7]. These chemokines and cytokines were directly or indirectly regulated by miR-214, miR-31,
and miR-155 in CAFs [7]. Several other groups have also shown many chemokines and cytokines,
including IL-6, COX-2, and CXCL1, to be involved in tumor-related inflammation in epithelial ovarian
cancer [50,91].
CAFs in the tumor microenvironment exert immunomodulatory effects through secretion of
immunomodulatory factors that polarize responsive immune populations, such as macrophages [92].
In order for the tumor to survive, any immune response directed toward the tumor cells needs
to be suppressed [52]. CAFs play important roles in shaping the tumor immunosuppressive
microenvironment in oral squamous cell carcinoma by inducing the protumor M2 macrophages [93].
Immunosuppressive activity of CAFs has been reported in head and neck squamous cell carcinoma
through increased expression levels of IL-6, CXCL8, and TGF1 [94]. Genetic ablation of Chitinase 3-like 1
(Chi3L1) in fibroblasts in vivo attenuated tumor growth, macrophage recruitment, and reprogramming
to an M2-like phenotype, enhanced tumor infiltration by CD8+ and CD4+ T cells, and promoted a Th1
phenotype. These results indicate that CAF-derived Chi3L1 promotes tumor growth and shifts the
balance of the immune milieu towards type 2 immunity [95]. Activation of the PD1/PDL1 signaling
pathway in T-cells leads to T-cell exhaustion and immune suppression. IL6 secreted by CAFs in
hepatocellular carcinoma activates neutrophils in the tumor microenvironment, and induces PDL1
expression in them through the JAK-STAT3 pathway. The PDL1 expressing neutrophils inhibit T-cell
mediated immunity and create a protumor microenvironment [96]. Being the most abundant cellular
component of the stroma, CAFs can exert their effects indirectly on tumor progression through secreted
factors that help evolve a proinflammatory and immunosuppressive microenvironment for the cancer
cells to thrive in.
4.7. Promoting Chemoresistance and Cancer Stem Cells
The eventual development of chemoresistance is the cause of most ovarian cancer related
mortalities. The role of the tumor microenvironment in this process has generated great interest
in recent years. Glutathione and cysteine released by fibroblasts in ovarian tumors contribute
towards the depletion of platinum in the nuclei of the adjacent ovarian cancer cells, and thus impart
resistance to platinum based chemotherapies [97]. CAFs can also induce therapy resistance by
reducing the bioavailability of the drugs, by causing tumor microvessel leakiness. CAFs induce
the lipoma-preferred partner (LPP) gene in microvascular endothelial cells through a calcium-dependent
FAK/ERK/MLC2/CREB signaling pathway [48]. In one study, the increased LPP enhanced the
endothelial cell motility and permeability through increased focal adhesions and stress fiber
formation [48]. CAFs can also induce chemoresistance in cancer cells by inducing apoptosis resistance.
CAFs activate STAT3 signaling in ovarian cancer cells resulting in the development of chemoresistance
through the increased expression of the antiapoptotic survivin and Bcl-2 [49]. CAFs in pancreatic ductal
adenocarcinoma can similarly decrease apoptosis and increase the chemoresistance of the cancer cells
by the induction of transcriptional downregulation of caspases by promoter hypermethylation [98].
Ovarian cancer apoptosis was also inhibited by CAF derived exosomes that transfer miR-21 to the
cancer cells. The miR-21 then downregulated its direct target apoptotic protease activating factor 1
(APAF1), conferring chemoresistance [99].
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Cancer stem cells are known to be resistant to cytotoxic chemotherapy and can give rise to tumor
relapse. CD10 and GPR77 expressing CAFs induce cancer stem cells in breast and lung cancer through
the consistent secretion of IL-6 and IL-8 [37]. These CAFs also increase the take rate of patient derived
xenograft tumors, and inhibition of GPR77 abolishes this effect [37]. In one study, autophagic CAFs in
luminal breast cancer induced stemness in the cancer cells through the secretion of high-mobility group
box 1 (HMGB1), resulting in the activation of toll-like receptor 4 in the cancer cells [100]. In endocrine
resistant metastatic breast cancer, the transfer of CAF derived exosomes containing miR-221 activated
an ERlo/Notchhi feed-forward loop that generated CD133hi cancer stem cells [101]. In ovarian cancer,
the evidence of induction of cancer stem cells is limited, with a few reports indicating the role of
CAF derived fibroblast growth factor 4 and IL-6 in inducing cancer stem cells [102,103]. Targeting
the FHF4/FGFR2 axis that mediates the CAF-cancer stem cell signaling prevented the CAFs from
inducing cancer stem cells [102]. Insulin growth factor receptor activation in ovarian cancer cells by
CAFs, and the resulting increased Nanog expression, is also reported to promote cancer stem cells in
ovarian cancer [104]. Overall, the potential role of CAFs in providing a stem cell niche for cancer stem
cells is an idea that needs to be systematically researched.
4.8. Reprogramming Cancer Cell Metabolism
Cancer cells have an altered metabolism to cope with their different growth rate, nutrient
availability, and the hypoxia they experience as compared to normal cells. This altered metabolism is
considered one of the hallmarks of cancer, and the tumor microenvironment is a major contributor
towards this phenomenon [3,4,38,105]. CAFs have been reported to secrete vesicles, which created
hypoxia mimicking conditions in the cancer cells, causing reductive carboxylation of glutamine in
them, and decreased oxidative phosphorylation [106]. The CAF derived vesicles are also carriers
of metabolites feeding into the tricarboxylic acid cycle in the cancer cells. This brings forth a novel
mechanism by which CAFs can influence the cancer cells through the transfer of metabolites and
pushing away from an oxygen based energy metabolism. Using stable isotope labeling of amino acids
in cell culture (SILAC) in cocultures of CAFs with ovarian cancer cells, a recent study demonstrated
how the CAFs can help ovarian cancer cells switch from utilizing lipids to using glycogen reserves
for energy [38]. As the metastatic tumor grows and depletes the adipocytes in the omentum, the IL-6,
CXCL10, and CCL5 secreted by the CAFs induce the ovarian cancer cells to start utilizing glycogen.
The activation of p38 MAP kinase in the CAFs drives the cytokine secretion, which in turn activates
glycogen phosphorylase in the ovarian cancer cells [38]. This demonstrates that the dynamic changes
happening in the tumor microenvironment as the tumor progresses, forces the cancer cells to reset
their energy sources. CAFs can orchestrate this switch by turning off glycogen synthesis and activating
glycogen utilization for glycolysis. Therefore, targeting the key enzyme in this process, glycogen
phosphorylase, would be a potential therapeutic option to treat ovarian cancer metastasis.
5. Targeting CAFs Clinically
Since CAFs contribute towards so many critical aspects essential for tumor progression, strategies
targeting CAFs to treat ovarian cancer can be potentially effective. Moreover, since CAFs themselves
are genetically stable and do not have the propensity to mutate, acquiring resistance against these
therapies would be less likely. Since CAFs overexpress FAP, a humanized antibody (sibrotuzumab)
directed against human FAP has been tested in phase 1 clinical trials to demonstrate that it is safe to
administer to patients with high levels of FAP expression in their tumors [107]. However, it did not
have any beneficial effect in a phase II trial for metastatic colorectal cancer [108]. A fusion protein
consisting of an anti-FAP antibody fused with IL-2 (RO6874281) is presently under clinical trials
as a combination therapy with atezolizumab—an anti-PDL-1 antibody—for advanced or metastatic
solid tumors (ClinicalTrials.gov: NCT03386721). In addition, a phase I clinical trial is ongoing to
test RO6874281 as a single agent, or in combination with trastuzumab or cetuximab, for solid tumor,
and breast, head, and neck tumors (ClinicalTrials.gov: NCT02627274). As TGF-β plays an essential
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role in stromal-epithelial interaction and CAF induction, targeting TGF-β is a potentially promising
approach to target CAFs as well as cancer cells. Transgenic mice expressing a TGF-β antagonist were
resistant to metastasis to multiple organs while not exhibiting the adverse pathological outcomes
observed in TGF-β-null mice [109]. Transcription profiling of CAFs microdissected from ovarian cancer
patient tumors identified a subpopulation that had activation of SMAD signaling [110]. These CAFs
were markers of poor patient progression, and targeting SMAD signaling with calcitriol inhibited
tumor progression in mice. At present there are as many as 60 active clinical trials on TGF-β in cancers
(clinicaltrials.gov). However, it is very difficult to differentiate the role of CAF derived TGF-β from
other stromal sources and cancer cell autocrine TGF-β signaling. The HGF-cMet pathway, involving
the cross-talk between CAFs and cancer cells, plays a role in cancer metastasis, and is another potential
target for blocking CAF–cancer cell interaction. Targeting c-Met or HGF has shown promising tumor
growth inhibition and gemcitabine sensitization in vivo [111,112]. There are 69 active studies on cMet
listed in clinicaltrials.gov. Targeting CAF can decrease the immunosuppressive microenvironment of
the tumor, as well as lead to CD8+ T-cell activation, and enhance anti-tumor immunity [18,113].
While several strategies to target CAFs in tumors have been attempted, much remains to be
studied before it can be effectively translated to the clinic. Strategies like targeting TGF-β may benefit
from attacking both the cancer and stromal compartments. Importantly, the potential of combining
such therapies with existing platinum and taxane based chemotherapies should be tested for ovarian
cancer. However, previous experiences with targeting the tumor microenvironment have taught us
that an approach towards normalization is preferable to an eradication of the tumor stroma. This is
because the latter approach tends to give rise to more aggressive cancer cells. Therefore, targeting
CAFs should aim for reverting them back to normal fibroblasts, rather than depleting them altogether.
6. Conclusions
CAFs are an important constituent of the ovarian cancer tumor microenvironment, and have been
demonstrated to play an important role in tumor progression, metastasis, and chemoresistance. While a
universal CAF marker has not been identified, several markers have been demonstrated in unique
subpopulations, indicating that CAFs are heterogenous in this context, and this may also dictate their
function. Continuous reciprocal interactions of CAFs with cancer cells and other components of the
microenvironment shape their fate, marker expression, and function in the tumor. Continuing research
towards a better understanding of their plasticity, regulation, function, and heterogeneity would
greatly enhance the way we perceive tumors, and will determine how we treat them. Strategies to
“normalize” CAFs and deprive the cancer cells of the gamut of factors provided by them may be an
effective approach to complement existing therapies targeting the cancer cells.
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Abstract: High-grade serous ovarian cancer is a deadly disease that can originate from the
fallopian tube or the ovarian surface epithelium. The PAX (paired box) genes PAX2 and PAX8
are lineage-specific transcription factors required during development of the fallopian tube but not in
the development of the ovary. PAX2 expression is lost early in serous cancer progression, while PAX8
is expressed ubiquitously. These proteins are implicated in migration, invasion, proliferation,
cell survival, stem cell maintenance, and tumor growth. Hence, targeting PAX2 and PAX8 represents
a promising drug strategy that could inhibit these pro-tumorigenic effects. In this review, we examine
the implications of PAX2 and PAX8 expression in the cell of origin of serous cancer and their potential
efficacy as drug targets by summarizing their role in the molecular pathogenesis of ovarian cancer.
Keywords: high-grade serous ovarian carcinoma (HGSC); PAX2; PAX8; cell of origin; ovary;
fallopian tube
1. Introduction
In 2017, there were 22,440 new cases of ovarian cancer and 14,080 deaths [1]. Ovarian cancer is
the fifth leading cause of cancer related death in women and the most lethal gynecological malignancy.
High-grade serous carcinoma (HGSC) accounts for 80% of ovarian cancer cases and it is the deadliest
histological subtype of epithelial ovarian cancer (EOC). This high mortality rate is due in part to
the insidious nature of the disease, as the majority of cases are detected at an advanced stage with
distant metastases. Symptoms of HGSC, such as abdominal pressure, bloating, and urinary frequency,
are non-specific and do not present until after the tumor cells have metastasized and obstructed
organs in the peritoneum. Current treatment strategies at this late stage include surgical debulking
followed by chemotherapy with platinum and taxane drugs. While tumors are initially responsive
to chemotherapy, the 5-year survival rate remains poor because of drug resistance and subsequent
patient relapse. Patients with chemoresistant disease may receive chemotherapy in combination with
targeted therapy against PARP (Olaparib) or VEGF-A (Bevacizumab) [2,3].
While it was originally believed that the ovary was the primary site of HGSC development,
accumulating histologic, molecular, and animal model evidence suggests that the majority of cases
originate from the fallopian tube epithelium [4–7]. The PAX (paired box) genes PAX2 and PAX8 are
lineage-specific transcription factors that are involved in epithelial development of the fallopian tube
but not the ovary [8,9]. PAX8 is expressed in HGSC tumors derived from both the fallopian tube
and ovarian surface epithelium (OSE), at least in murine models where the source of the tumor is
experimentally derived. In regard to the other histotypes of EOC, PAX8 shows high expression in
clear cell and endometrioid tumors and reduced expression in mucinous tumors [10–12]. PAX2 is lost
early in the molecular progression of fallopian tube derived cancer and is absent in ~85% of HGSC.
PAX2 is detected in clear cell and mucinous tumors and absent in most endometrioid tumors [13–16].
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Studying PAX2 and PAX8 in this context provides valuable insight into the site of origin of ovarian
cancer and the tumorigenic properties that make the PAX proteins promising drug targets for treatment
of HGSC.
2. Site of Origin of HGSC
The origin of HGSC has perplexed researchers for decades and it is now known that HGSC can
originate from the fallopian tube epithelium as well as the OSE. Since PAX2 and PAX8 are expressed in
the fallopian tube, and PAX8 expression is maintained in HGSC, the expression and regulation of PAX
proteins may help to explain the source of ovarian cancer. The OSE was historically believed to be
the site of origin of serous carcinoma based on the incessant ovulation hypothesis. This hypothesis
suggests that during ovulation, fragments of the OSE get trapped within the wound created by follicle
rupture, forming an ovarian cyst [17]. The epithelium trapped within the cyst has direct contact
with the stroma and therefore has increased exposure to the stromal microenvironment, including
growth factors and cytokines [18]. As a result, cells within an ovarian cyst have a higher likelihood
of transforming into tubal-like cells that express markers of ovarian cancer, including PAX8, CA-125
and E-cadherin [18,19]. This hypothesis is supported by epidemiological data showing pregnancy and
oral contraceptive use, both of which decrease the number of ovulatory cycles, are correlated with
a decrease in ovarian cancer risk [20,21].
The OSE is unique to the female reproductive tract in that it is formed embryologically
from the mesodermally derived colemic epithelium. In contrast, other components of the female
reproductive tract, including the fallopian tube, cervix, and uterus, are Müllerian-derived structures.
These Müllerian-derived structures express PAX8, while the OSE does not. This difference in embryonic
origin has implications for adult cells. The adult OSE contains a mix of epithelial and mesenchymal-like
cells that appear to be less differentiated than the rest of the female reproductive tract. These cells do
not express molecular markers characteristic of epithelial cells, including CA-125 and E-Cadherin, but
rather express mesenchymal markers, including keratin and vimentin [18]. Serous tumors that are
derived from the OSE, however, obtain expression of these epithelial markers as well as phenotypic
characteristics of the epithelium, including papillary serous structures [22]. Thus, in mouse models,
HGSC can experimentally originate from the OSE.
The differentiated serous histology of HGSC is an interesting paradox since most cancers are less
differentiated than the tissue of origin. Cheng et al. hypothesized that the OSE is an incompletely
differentiated tissue type that can differentiate during oncogenic transformation through expression of
HOX genes [23]. HOX genes are tightly controlled genes involved in developmental programming
of the Müllerian duct, but they are not expressed in development of the OSE. This is similar to
the PAX8 gene, which is expressed in the fallopian tube and in serous tumors, but not in the
OSE. By experimentally expressing Hoxa9, researchers observed the OSE formed serous papillary
tumors. The OSE may also harbor a stem cell niche within the transitional zone of the ovarian
hilum that has increased tumorigenic properties. Researchers experimentally demonstrated that cells
within the ovarian hilum express stem cell markers that contribute to regeneration of the OSE [24].
Importantly, these stem cells had greater transformative ability after conditional inactivation of p53
and RB1. It would be interesting to examine whether these stem cells also gained developmental
markers, such as HOXA9 or PAX8 that would induce differentiation to a serous histotype.
Increasing evidence indicates that the fallopian tube epithelium serves as the main site of origin of
HGSC. Under this scenario, serous tumors found on the ovarian surface are secondary metastasis from
the fallopian tube, and thus resemble this lineage history. Piek et al. presented the first clinical evidence
supporting this hypothesis by identifying pre-neoplastic lesions with increased staining for p53 and
Ki67 in the fallopian tubes of BRCA-positive women who are predisposed to developing ovarian
carcinoma [5]. Identical p53 mutations were identified in the precursor lesions of the fallopian tube
and in concurrent ovarian carcinomas [6,25]. Molecular profiling of serous tumors identified a gene
signature in HGSC tumors that more closely correlated with the normal fallopian tube epithelium than
78
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the normal OSE [26,27]. Clinically, bilateral salpingectomy reduced the risk of serous carcinoma by
61% and prophylactic salpingo-oophorectomy in BRCA-positive women reduced the risk of serous
carcinoma by 80% [28,29]. Therefore, the current recommendation states that BRCA-positive women
after child bearing age should undergo prophylactic salpingo-oophorectomy [30].
The fallopian tube origin for ovarian cancer is further supported by multiple animal models.
Immortalized fallopian tube secretory epithelial cells are transformed into HGSC through H-RasV12
mutation or c-Myc expression [31]. Dicer-Pten deletion from the reproductive tract resulted in HGSC
formation, even after bilateral removal of the ovaries, demonstrating that these tumors originated
in the fallopian tube [7]. Pax8 promoter-driven deletion of Brca, Tp53, and Pten in the fallopian
tube also led to HGSC development [32]. Since a common molecular alteration in these models is
loss of Pten, Russo and colleagues examined the effects of Pten loss alone from the fallopian tube
epithelium. Homozygous loss of Pten was sufficient to drive the development of borderline serous
and endometrioid carcinoma that could metastasize to the ovary [33]. Interestingly, in a cell-based
model, Pten loss in combination with Kras mutation formed highly aggressive tumors, while addition
of constitutively active Akt attenuated this phenotype [34]. Research from the Cho laboratory
demonstrated how serous carcinoma progresses from serous tubal intraepithelial carcinoma (STIC)
to HGSC using various combinatorial deletions in Rb1, Brca1, p53, Nf1 [35]. These tumor models
derived from the fallopian tube epithelium provide researchers with the tools to study the molecular
progression from pre-neoplastic lesion to aggressive serous carcinoma.
Careful examination and sequencing of patients with HGSC paints a more nuanced picture of
the cell of origin debate. Laser-capture tumor microdissection of multiple anatomic sites in patients
with HGSC showed an identical p53 mutation at all sites [36]. The metastatic trajectory of HGSC was
elucidated using phylogenetic clustering that compared tumor mutations to a patient’s germline DNA.
While the majority of patient tumors clustered in the “basal STIC” category, with the STIC showing
the highest similarity to germline DNA, some tumors showed “STIC metastases”. These findings
call into question the assumption that the presence of STICs is always evidence for a fallopian tube
origin for HGSC. A separate evolutionary analysis study that sequenced STICs, ovarian cancer, and
metastases in nine patients found tumor-specific alterations in p53, BRCA1, BRCA2, or PTEN to be
present in STICs [37]. This finding implies that in the majority of cases, mutations that drive HGSC
occur early, before metastasis to the ovary. In a proteomic study of HGSC cell lines and patient tumor
samples, 26 ovarian cancer cell lines and five HGSC tumors were grouped into three distinct categories:
epithelial, clear cell, and mesenchymal [38]. While most cell lines and tumors in this study clustered in
the epithelial group, suggesting a fallopian tube cell of origin, the authors identified a subset of cell
lines and one HGSC tumor that grouped in the mesenchymal category, suggesting an ovarian cell of
origin [38]. This demonstrates HGSC may arise from both the fallopian tube and OSE or that cells may
acquire markers during tumorigenesis that resemble different tissues.
PAX2 and PAX8 are expressed in the fallopian tube epithelium, however, PAX2 is lost in ~85%
HGSC and it has been shown that mutant p53 and loss of PTEN represses PAX2 expression in a fallopian
tube-derived mode of ovarian cancer [39]. On the contrary, PAX8 is expressed in 85–90% of HGSC and
is a widely used biomarker for HGSC [4,16,40]. PAX2 and PAX8 are differentially regulated in HGSC
and it will be interesting to know whether loss of PAX2 during HGSC progression leads to dependence
of HGSC on PAX8. Thus, studying the shared regulatory mechanisms of PAX2 and PAX8 expression
between the fallopian tube and ovary will be essential to developing effective treatment therapies until
the site of origin of a patient’s tumor can be definitively identified.
3. Role of PAX2 and PAX8 in Development and Adult Tissues
The PAX genes are a set of developmental transcription factors that are key regulators for proper
tissue formation and cellular differentiation [41]. This is convincingly supported by mouse models
with Pax gene deletions. PAX2 is required for mesenchymal-to-epithelial transition of the intermediate
mesoderm into the epithelial structures of the inner ear, kidneys, ureters, Wolffian and Müllerian
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ducts, including the oviducts, uterus, and vagina [42]. Mice with Pax2 homozygous mutation do not
develop these structures. Research has shown that Pax2 is a tissue-specific epigenetic regulatory gene
that ensures proper temporal and spatial development of these epithelial structures. The Hashino
laboratory demonstrated that in progenitor cells of the inner ear, the histone demethylase LSD1 recruits
the NuRD co-repressor complex to bind and repress PAX2 target genes. This inhibition ensures
tight temporal control of PAX2-regulated genes. Once cells enter the differentiated state to become
epithelial cells, LSD1 and the NuRD complex are released from the PAX2 binding site, and transcription
can occur. This switch from progenitor intermediate mesoderm to differentiated epithelium is
irreversible and is maintained over rapidly dividing cell populations through PAX2-regulated
epigenetic modifications [43]. Research from the Dressler laboratory demonstrated that PAX2
promotes assembly of the histone H3K4 methylation complex by recruiting PTIP (PAX transcription
activation domain interacting protein) at PAX2 binding elements [44]. This histone modification is
associated with active promoters and increased transcription. PTIP deletion inhibits histone H3K4
methylation, even though PAX2 still binds to the chromosome. These data suggest that PTIP regulates
epigenetic modifications required for activation of PAX2 targets that are essential for development and
maintenance of epithelial structures.
PAX2 expression persists in adult reproductive tissues (epididymis, vas deferens, oviduct), ureters,
bladder, kidneys, and mammary glands [45]. Cai et al. demonstrated that PAX2 levels are osmotically
regulated [46]. Exposing medullary epithelial cells in vitro to high levels of NaCl increased PAX2
levels, while reducing in vivo renal inner-medullary interstitial NaCl levels decreased PAX2 levels.
This increase in PAX2 appears to protect against cell death induced by osmotic stress. The stem cells of
the mammary duct also express PAX2 where it may protect against apoptosis [47]. This is supported by
research in C. elegans which demonstrates PAX2/5/8 can upregulate transcription of the anti-apoptotic
Bcl2 [48].
PAX8 is a closely related paralog to PAX2 that is expressed during embryogenesis in the thyroid,
metanephros, central nervous system, and Müllerian duct. Inactivation of the Pax8 gene in mice leads to
complete loss of thyroid follicular cells, severe growth retardation, and death in the perinatal period [49].
Providing exogenous thyroid hormone to Pax8−/− mice rescued the hypothyroid phenotype, but these
mice remained infertile due to nonfunctional uteri and closed vaginal openings [50].
PAX8 continues to be expressed in the adult kidneys, cervix, endometrium, fallopian tube, seminal
vesicle, epididymis, thyroid, pancreas, and lymphoid cells [10,51]. There is also evidence that a subset
of cells in the OSE express PAX8, but further research will need to examine the mechanism for this
acquired expression [51,52]. The majority of our understanding of PAX8 function in adults is based
on studies in the thyroid. Zannini and colleagues demonstrated that PAX8 is required for expression
of the thyroid-specific genes: thyroglobulin, thyroperoxidase, and sodium/iodide symporter [53,54].
Interestingly, ChIP-Seq demonstrated PAX8 tends to bind in intronic regions (82%) over 5’-UTR
regulatory regions (2%) [55]. This suggests PAX8 may bind alternative promoters or ncRNAs that
regulate gene expression. Additionally, immunoprecipitation studies demonstrated that PAX8 binds
CTCF and SP1, both of which are involved in chromatin remodeling [55]. These data suggest PAX8
functions both to directly increase transcription and to remodel the chromatin landscape.
4. Role of PAX2 and PAX8 in HGSC
Examining the histologic and molecular events that give rise to serous carcinoma is crucial to
understanding the drivers of ovarian cancer. Secretory cell outgrowths (SCOUTs) are precursor lesions
of serous carcinoma that can be found in the proximal and distal fallopian tube. Normal fallopian
tube epithelial cells express high levels of PAX2 but approximately 90% of SCOUTs have lost PAX2
expression [16]. Almost all serous tumor cells also have mutation in the tumor suppressor p53, yet only
25% of SCOUTs have p53 mutation that can be detected histologically [16,56]. SCOUTs located at the
fimbrial edge with p53 mutation are coined ‘p53 signatures’ [16]. Cells with the p53 signature have
PAX2 loss, suggesting a step-wise progression from PAX2 loss to p53 signature to STIC to metastatic
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serous carcinoma. This progression has been extensively researched, and there are many excellent
reviews detailing these findings [4,30,57,58].
Through molecular characterization of SCOUTs, Ning and colleagues demonstrated that PAX2
loss is associated with an increased stem cell phenotype [59]. They show through in vitro culture of
SCOUTs that these cells can differentiate into both ciliated and basal cell histotypes. PAX2 knockdown
in fallopian tube epithelial cell lines increased expression of the stem cell markers CD44 and SCA1
and decreased the capability of these cells to form differentiated epithelial luminal structures [60].
Modi et al. demonstrated in murine oviductal epithelial cells that Pax2 loss and p53 mutation
increased proliferation and migration, but was insufficient to drive tumorigenesis [39]. This is
consistent with human histological findings that p53 signatures are benign secretory outgrowths.
ChIP analysis revealed wild type p53 enhances Pax2 transcription while mutant p53 decreases Pax2
transcription, suggesting a mechanism for sustained Pax2 loss in neoplastic lesions [39]. Interestingly,
cells lost Pax2 expression in a fallopian tube model of ovarian cancer derived through loss of Pten [39].
Re-expression of Pax2 inhibited the tumorigenic properties of these cells and prolonged survival
(Figure 1). Alternatively, Pax2 expression in a spontaneous OSE derived model of HGSC (called
STOSE) reduced proliferation and metastasis by increasing COX2 and reducing HTRA1 expression [61].
Taken together, these findings suggest Pax2 loss is an early molecular event in ovarian cancer
progression that predisposes cells to further mutations that can drive tumorigenesis, regardless of
cell of origin. Further research should examine the mechanistic requirement for Pax2 loss in HGSC
progression, especially considering that there is increased hypomethylation and activation of Pax2
in endometrial and renal carcinoma, yet The Cancer Genome Atlas (TCGA) does not find increased
methylation at this locus in HGSC tumor samples [47,62,63].
Figure 1. PAX2 and PAX8 regulate tumor formation in HGSC in an opposing manner. Serous tubal
intraepithelial carcinomas (STICs) express PAX8, but not PAX2. Similarly, epithelial cells in cortical
inclusion cysts express PAX8. HGSC tumor cells express PAX8 and it has been experimentally shown
that PAX8 reduction decreases characteristics that enhance tumor formation. PAX2 is not expressed in
HGSC and re-expression of PAX2 inhibits the tumorigenic properties of tumor cells.
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Pathologists have used PAX8 for decades as a histologic marker to define HGSC,
but a genome-wide RNA interference screen of cancer cell lines was the first to identify the importance
of PAX8 in ovarian cancer [64]. PAX8 was the top-ranked differentially expressed gene in the screen
between ovarian and non-ovarian cancer cell lines. PAX8 knockdown reduced proliferation, migration
and invasion and increased apoptosis in ovarian cancer cells [65]. Pax8 was shown to directly bind
and increase the transcription of p53, which then increased p21 to induce proliferation [66]. Pax8 also
promoted tumor cell growth by increasing transcription of the cell cycle regulator E2f1 through
direct binding to the E2f1 promoter in a complex with the RB protein [67]. In thyroid follicular
carcinoma, a translocation event results in PAX8-PPARγ1 fusion [68], but this genetic event is not
observed in HGSC (regulation of PAX2 and PAX8 in specific cancers is summarized in Table 1).
To better understand the mechanism of PAX8 oncogenesis in HGSC despite its normal expression
in the fallopian tube, several research groups have examined the role of PAX8 in the ovary and
fallopian tube. Serial passaging of the normal OSE transforms cells into serous carcinoma with
PAX8 expressed [22]. Loss of LKB1 and PTEN in the OSE also leads to a HGSC cell line with
acquired PAX8 expression [69]. Rodgers and colleagues demonstrated that forced PAX8 expression
in normal OSE increases proliferation, migration, and epithelial-mesenchymal transition through
upregulation of the FOXM1 pathway [70]. Correspondingly, PAX8 knockdown in three human HGSC
cell lines decreased expression of FOXM1, decreased proliferation, and increased apoptosis [70].
Reducing PAX8 expression in the normal fallopian tube, however, did not produce noticeable
phenotypic effects, suggesting that targeting PAX8 pharmacologically would not affect normal tissues.
These phenotypic observations were corroborated by Elias and colleagues who performed an RNA
sequencing experiment demonstrating few transcripts altered in the fallopian tube but increased
transcript alterations in serous tumors after PAX8 knockdown. The authors suggest alterations to
the PAX8 cistrome are responsible for changes in gene expression leading to HGSC derived from the
fallopian tube. The PAX8 consensus binding motif is altered between the fallopian tube and serous
tumor cells that may affect downstream regulated genes. Elias et al. show differential association
between PAX8 and Yes-associated protein (YAP1), a major downstream regulator of the evolutionarily
conserved Hippo pathway that regulates organ size, cell proliferation, and apoptosis [71]. Interestingly,
ChIP-Seq identified PAX8 mostly binds at non-promoter sites and is enriched at super-enhancers,
where PAX8 can globally regulate genes involved in tumorigenesis [72]. Taken together, these findings
suggest PAX8 could be targeted for drug development to reduce proliferation, migration and survival
of tumor cells while leaving other organs unaffected (Figure 1).
Table 1. Mechanism of PAX2 and PAX8 regulation in specific cancer types.
Cancer Type PAX2 Regulation PAX8 Regulation References
HGSC Transcriptional downregulation No change [39]
Endometrial Promoter hypomethylation No change [62]
Thyroid No change PAX8-PPARγ1 fusion [68]
Renal Promoter hypomethylation Increased protein levels [63,73]
Wilms tumor Transcriptional upregulation Transcriptional upregulation [74,75]
Breast Transcriptional upregulation No change [76]
Glioma Transcriptional upregulation Transcriptional upregulation [77,78]
5. Clinical Strategies to Target PAX2 and PAX8
Ovarian cancer is a heterogeneous disease with few common molecular alterations [56].
Developing therapeutic strategies that target common molecular alterations, such as loss of PAX2 or
gain of PAX8, may produce greater therapeutic benefits. A promoter activation screen identified
luteolin as a small molecule that restores PAX2 expression in cells with wild type p53 [39].
Luteolin could be taken as a preventative supplement to decrease the occurrence of SCOUTs, but it
would be ineffective in treating serous tumors with p53 mutation. Further screens or combination
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therapy studies should be performed in HGSC cells to identify molecules that increase PAX2 in
tumors. The effect of these molecules on the homologue PAX8 should also be explored. Molecules
that increase expression of PAX2 may also increase expression of PAX8, which could then increase
the aggressive properties of a tumor cell. Therapies that reduce transcription of these PAX proteins,
however, may significantly mediate the deleterious effect of PAX8 while maintaining the already
decreased PAX2 levels.
PAX8 seems to have little functional effect in the fully differentiated adult fallopian tube,
but mediates several tumorigenic effects in HGSC, including proliferation, migration, angiogenesis,
and apoptosis [65,70–72,79]. Reducing PAX8 levels or disrupting the transcriptional activity of PAX8
may inhibit these pro-cancerous effects while leaving the normal fallopian tube epithelium unaffected.
Using a virtual screen that modeled paired domain binding to DNA, Grimley and colleagues identified
small molecules that disrupt binding of the paired domain of PAX2/5/8 to DNA [80]. Other potential
drug targets include the adapter proteins that bind to the chromosome in a complex with PAX8.
PAX8 requires interactions with YAP1, CTCF and SP1 to initiate transcription, as discussed earlier.
Disrupting these interactions may mediate the deleterious effects of PAX8 in serous carcinoma.
6. Concluding Remarks
Proper temporal and spatial expression of the PAX protein family is essential for embryonic
development. PAX2 and PAX8 are co-expressed during mesenchymal-to-epithelial transition of the
Müllerian duct and they continue to be expressed in adult structures, such as the fallopian tube.
These proteins maintain a regenerative stem cell population in adult tissues. In HGSC, PAX8 provides
growth advantages by enhancing the proliferative, migratory, and survival capabilities of cancer cells
from the fallopian tube and ovary. The OSE does not normally express PAX8, yet it acquires PAX8
expression during malignant transformation in certain mouse models. More work is required to tease
apart the role of PAX8 in tumors derived from the fallopian tube or OSE. PAX2 is a homolog of PAX8
that has been shown to impart similar growth advantages, yet tumors derived from the fallopian tube
epithelium lose PAX2 expression during malignant transformation. Further research is required to
understand the importance and regulatory machinery that leads to PAX2 loss and PAX8 dependence
in HGSC.
Identifying drug targets for novel cancer treatments in HGSC has been challenging because it is
a heterogeneous disease with few shared mutations. The PAX proteins are promising because PAX8
is ubiquitously expressed in serous tumors and PAX2 loss is an early molecular event shared in the
progression from benign to malignant carcinoma. Targeting these proteins may hold promise in reducing
tumor growth and progression in a majority of patients and significantly improving patient survival.
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Abstract: Ovarian cancer is the deadliest gynecological disease among U.S. women. Poor 5-year
survival rates (<30%) are due to presentation of most women at diagnosis with advanced stage disease
with widely disseminated intraperitoneal metastasis. However, when diagnosed before metastatic
propagation the overall 5-year survival rate is >90%. Metastasizing tumor cells grow rapidly and
aggressively attach to the mesothelium of all organs within the peritoneal cavity, including the
parietal peritoneum and the omentum, producing secondary lesions. In this review, the involvement
of mesothelin (MSLN) in the tumor microenvironment is discussed. MSLN, a 40kDa glycoprotein that
is overexpressed in many cancers including ovarian and mesotheliomas is suggested to play a role in
cell survival, proliferation, tumor progression, and adherence. However, the biological function of
MSLN is not fully understood as MSLN knockout mice do not present with an abnormal phenotype.
Conversely, MSLN has been shown to bind to the ovarian cancer antigen, CA-125, and thought to
play a role in the peritoneal diffusion of ovarian tumor cells. Although the cancer-specific expression
of MSLN makes it a potential therapeutic target, more studies are needed to validate the role of
MSLN in tumor metastasis.
Keywords: ovarian cancer; mesothelin; CA125; tumor microenvironment
1. Introduction
Ovarian cancer is the fifth leading cause of cancer death in U.S. women, making it the most lethal
gynecological malignancy. The American Cancer Society estimates that about 22,240 new cases of
ovarian cancer will be diagnosed in the United States in 2018, of which 14,070 (>60%) women will
die of the disease [1]. The overall 5-year survival rate of women diagnosed with ovarian cancer is
47% and for women diagnosed with advanced stage disease, presenting with intraperitoneal metastasis,
the 5-year survival rate is only 29% [1,2]. Ovarian cancer is a heterogeneous disease composed of
seven histological subtypes: high-grade serous, low-grade serous, mucinous, endometrioid, clear cell,
carcinosarcoma, and Brenner tumors [3]. Approximately 90% of ovarian cancers are classified as
malignant epithelial ovarian carcinomas (EOCs), of which high-grade serous carcinomas (HGSC)
account for 70% of tumor types [4–7]. Early signs or symptoms of ovarian cancer are often subtle and
nonspecific which are frequently ignored or treated with medicine to relieve discomfort. In 50–80% of
high-grade serous carcinomas, the most frequent genetic change is a p53 mutation found in tumors
of all stages [8–10]. Mutations in BRCA1 and BRCA2, tumor suppressor genes, are found in about
50% and 70% of ovarian cancer patients with a family history of ovarian cancer, but 95% of ovarian
cancer cases are sporadic [11–13].
The major cause of death is due to therapy-resistant metastasis from the primary tumor to the
peritoneum [14–18]. The lack of successful eradication of the disease can be owing to the various
complex overlapping signaling networks, together with the peritoneal tumor microenvironment
composed of mesothelial cells, the submesothelial matrix, and adipose. Unlike other cancers,
Cancers 2018, 10, 277; doi:10.3390/cancers10090277 www.mdpi.com/journal/cancers88
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ovarian cancer uniquely metastasizes by the detachment of tumor cells, either single or multicellular
aggregates, from the primary ovarian/fallopian tube tumor instead of the classically studied pattern
of hematogenous metastasis (Figure 1A,B) [15,16,18,19]. Recent studies have challenged this mode of
metastasis, suggesting that hematogenous spread of ovarian cancer may play a larger role in ovarian
cancer cell metastasis; however, for the purpose of this review, ovarian cancer metastasis will be
discussed as direct shedding of tumor cells [20,21]. This distinctive process bypasses several steps of
intra- and extravasation before metastasis to other organs [19]. These detached cells undergo epithelial
to mesenchymal transition before detaching, resulting in the loss of E-cadherin, a glycoprotein located
at cellular junctions, and an invasive phenotype [22]. The metastatic cells disseminate throughout the
peritoneal cavity, facilitated by natural fluid flow and preferentially attach to the mesothelium that
covers all the organs in the peritoneal cavity including the omentum, abdominal peritoneum and the
contralateral ovary (Figure 1C,D) [14,23,24]. Proliferation of disseminated tumor cells on the omentum
eventually results in the obstruction of the bowel and stomach [25,26]. It is unknown if the primary
tumor prepares secondary metastatic sites, including the omentum and peritoneum, for colonization,
a process that has been implicated in other cancers [19].
Figure 1. Model for peritoneal metastasis of ovarian tumors. Ovarian cancer metastasis is unique as
tumor cells shed from the primary tumor and spread throughout the peritoneal cavity. MSLN:CA125
interaction mediates heterotypic and homotypic cellular adhesion.
Currently, there are no simple screening tests available to detect ovarian cancer. However,
available diagnostic testing includes pelvic examinations, transvaginal ultrasonography and serum
measurements of cancer antigen-125 (CA125) [27]. Identification of additional screening strategies to
accurately diagnose patients in early stages are of great need. Moreover, mesothelin, a glycoprotein
expressed in mesothelial cells and overexpressed in EOCs, could be useful as both a screening
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biomarker as well as a therapeutic target [28]. Understanding the interaction of the tumor and
mesothelium and regulating the molecules that modify the metastatic tumor microenvironment
is of great importance for the development of future therapeutics.
2. CA125
CA125, a repeating peptide epitope of the mucin 16 (MUC16), is a large membrane-bound cell
surface mucin, discovered in 1981 by a monoclonal antibody OC125 developed from mice immunized
with human ovarian cancer cells [29]. CA125 is a heavily glycosylated type I transmembrane protein
belonging to the family of tethered mucins containing both O-linked and N-linked oligosaccharides [30].
CA125 is overexpressed in many tumors of epithelial origin suggesting that it plays an important role
in tumorigenesis [30,31]. CA125 is commonly used as a biomarker to monitor ovarian cancer disease
progression and relapse as it is highly expressed in ovarian carcinomas yet minimally expressed in
normal ovarian tissues [32–34]. CA125/MUC16 has been shown to inhibit cytolytic responses of human
natural killer cells in ovarian cancer, therefore acting as a suppressor of the immune response directed
against the ovarian tumors [35,36]. CA125 has been shown to promote cancer cell proliferation [37].
Although the role of CA125 is mainly studied in ovarian cancer, recent studies have shown that CA125
is also highly expressed in other cancers including peritoneal mesotheliomas, pancreatic, and colorectal
cancer, implicating a mesothelial cell interaction [38–40].
3. Mesothelial Cells
All organs of the abdominal cavity are covered by the mesothelium, a monolayer of mesothelial
cells covering a basement membrane composed of fibronectin, collagen I and IV and laminin [41,42].
Mesothelial cells are flattened squamous-like cells derived from the mesoderm and possess both
epithelial and mesenchymal characteristics [43,44]. Mesothelial cells have well-developed cell–cell
junction complexes, including tight junctions, that are critical for cell surface polarity and the
formation and maintenance of a semi-permeable diffusion barrier. The mesothelium functions to
provide a protective barrier as well as a frictionless interface for the free movement of organs and
tissues [45]. The mesothelium also plays an important role in contributing to the homeostasis of the
peritoneal cavity, fluid and cell transport, tissue repair, initiation and resolution of inflammation
and possibly tumor dissemination [46,47]. In the tumor microenvironment, mesothelial cells are
preconditioned by the cancer cell secretome to induce the expression of multiple pro-inflammatory
factors [48]. Mesothelial cells are implicated in both epithelial-to-mesenchymal transition (EMT) and
mesothelial-to-mesenchymal transition (MMT), an EMT-like process [49–51]. EMT is the biological
process by which epithelial cells lose cell–cell adhesion and gain migratory properties and MMT
is a biologic process in which mesothelial cells of the peritoneal cavity acquire a fibroblast-like
phenotype, with increased migratory capabilities [50,52]. Mesothelial cells, expressing mesothelin,
line the peritoneal wall and all the organs of the peritoneal cavity that is susceptible to ovarian
cancer metastasis.
4. Mesothelin
Mesothelin (MSLN), first identified in 1992 [53], is synthesized as a 70 kDa precursor that is
proteolytically cleaved at Arg295, resulting in an approximately 30 kDa fragment called megakaryocyte
potentiating factor (MPF) and the 40 kDa MSLN membrane-bound fragment (Figure 2) [54,55].
Both MSLN and MPF are biologically active; however, the exact function remains unknown [56].
MSLN is a glycosylphosphatidylinositol (GPI)-anchored membrane glycoprotein that is physiologically
expressed at the cell surface of mesothelial cells lining the pleura, pericardium, and peritoneum [57,58].
Composed of 16 exons spanning 7733 bp, the human MSLN gene occupies approximately 8 kb located
at chromosome 16 p 13.3. Alternative splicing results in the predominant variant 1 encoded by MSLN1,
variant 2 (24 bp insert), and variant 3 (82 bp insert) [55,57,59,60].
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Figure 2. Structure of mesothelin (MSLN). The 70 kDa MSLN precursor protein is proteolytically
cleaved to release the 30 kDa N-terminal megakaryocyte potentiating factor (MPF) and is displayed as
mature MSLN on the cell surface.
Although many prediction programs have attempted to predict the three-dimensional structure
of the MSLN precursor and mature MSLN, the structure still remains unknown [61]. MSLN1 was
found by Hellstrom et al. to be primarily expressed at the cell surface and was also released into body
fluids of patients of several tumor types. Soluble MSLN results from a cleavage of variants 1 at the
C-terminal domain [60]. An 18-bp enhancer sequence, CanScript, located −65 to −46 bp 5′ of one
of three transcriptional start sites in the promoter region of the MSLN gene, was identified in cancer
cell lines with aberrant overexpression of MSLN. The CanScript sequence enhancer consists of two
functionally putative binding motifs: the conventional MCAT element and a SP1-like element [62].
All eight nucleotides in the MCAT element were shown to be essential for its function; conversely,
the SP1-like element was shown to have two mutations suggesting, that the cancer-specific expression
of MSLN is thought to occur through the binding of an unknown transcription factor. Transcription
factors such as KLF6 and YAP1 have been investigated but binding of these factors are not adequate
for MSLN overexpression in certain cancer types [63]. Nonetheless, the essential transcriptional factor
that regulates the MSLN overexpression in human cancers has not been identified.
MSLN is normally expressed in mesothelial cells in trace amounts. In contrast, MSLN is
highly expressed in human cancers including 70% of ovarian cancers [54,64–66], mesotheliomas [54],
and pancreatic adenocarcinoma [67,68] and therefore identified as a tumor-associated marker.
The biological function of MSLN is not fully understood as MSLN knockout mice do not present with
an abnormal phenotype, suggesting that MSLN is a non-essential protein [58]. Furthermore, MSLN is
reported to play a role in cell adhesion [69], tumor progression [65,70–73], and chemoresistance [73–76].
Specifically, MSLN has been shown to have oncogenic properties by increasing ovarian cancer invasion
by inducing MMP-7 through MAPK/ERK and JNK pathways and by inducing drug resistance through
PI3K/AKT and MAPK/ERK signaling pathways [65,74]. Albeit, mechanisms that regulate MSLN
cell-surface expression are not well understood.
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5. MSLN and CA125
CA125, the ovarian cancer antigen/biomarker, has been identified as a MSLN ligand and
could potentially mediate cell adhesion [69]. Rump et al. demonstrated MSLN–CA125 interaction
mediates heterotypic cellular adhesion (Figure 1C) of the human ovarian cancer cell line, OVCAR3,
expressing CA125 to a MSLN expressing endothelial-like cell line [69]. Additionally, Gubbels et al.
established that MSLN binds to CA125 in a specific and N-linked glycan-dependent manner,
thus CA125-expressing ovarian tumor cells could bind specifically to the mesothelin-expressing
peritoneal lining (Figure 1D) [77]. The N-linked oligosaccharides of CA125 are necessary for the
binding to MSLN with MSLN having a strong affinity to CA125 with an apparent dissociation constant
(Kd) of 5 nM [77–79]. Consequently, MSLN:CA125-dependent cell attachment may play an important
role in the peritoneal implantation of ovarian tumor cells [54,80]. The MSLN:CA125 role in cell
attachment is supported by work from Bruney et al., demonstrating the overexpression of membrane
type 1 matrix metalloproteinase (MT1-MMP) in human ovarian cancer cells (OVCA433-MT)-decreased
cell surface expression of CA125/MUC16, subsequently increasing CA125/MUC16 ectodomain
shedding, resulting in the release of CA125 from the cell surface. Additionally, there was decreased
adhesion of OVCA433-MT to human mesothelial cells (LP9) and to intact peritoneal explants,
suggesting the importance of MSLN:CA125 initial adhesion of [81]. After initial attachment of
ovarian cancer cells to the peritoneal mesothelium, the co-overexpression of both MSLN and CA125
can lead to recruitment of other ovarian cancer cells being sloughed off from the primary site
(Figure 1B,C) [82]. Therefore, the tumor load at secondary sites could be a combination of excessive
proliferation and adhesion of circulating single or multicellular aggregates in peritoneal ascites
fluid [77,83]. Conversely, the exact function of MSLN in tumor progression remains unclear [84];
however, understanding the importance of CA125:mesothelin binding may lead to novel therapies to
control ovarian peritoneal metastasis.
6. Targeting MSLN
Clarifying the function of MSLN will enhance its clinical application in ovarian cancer, including
early detection, chemo-response, prognosis and therapeutic targeting. Several features of MSLN
make it a useful candidate for cancer therapy, including that it is well-internalized, enabling it to
be a good target for immunotoxins [85]. Additionally, MSLN is actively shed from the cell surface
generating a pool of antigens in ascites or blood circulation allowing for the quantification of circulating
serum MSLN levels potentially used for diagnosis of ovarian cancer patients [28,86–88]. The use of
MSLN as a plasma biomarker has been investigated by several groups using blood ELISA tests and
demonstrated that serum MSLN levels decrease after surgical therapy and, therefore, may be useful
in monitoring treatment response in MSLN expression cancers [86,89]. Pools of antigens, from shed
MSLN, in the tumor interstitial space will unavoidably interact with a targeting agent during tumor
dissemination [60,85,87]. The first identified sheddase, TNF-α converting enzyme (TACE) was shown
to mediate MSLN shedding. TACE is a transmembrane glycoprotein, known for its role in releasing
EGFR ligands from the cell surface, therefore regulating the activation of the EGFR pathway [60,90].
Tumor targeting is a complex process and, furthermore, modulation of MSLN shedding could have
an influence on drug kinetics in both circulation and tumor tissue. However, shedding is not the
only way MSLN could be modulated. The expression levels of MSLN could potentially be regulated
similarly to other antigens by trogocytosis [91] or antigen masking [92]; however, the role of these
antigens remains to be elucidated. Furthermore, MSLN is expressed in dispensable mesothelial cells
so the risk of non-specific toxicity is decreased.
6.1. Molecular Imaging for the Detection of MSLN
Mesothelin has recently been investigated as a target for molecular imaging probes. These probes
are designed to guide antibody-based treatments that can be used to assess tumor uptake, response to
92
Cancers 2018, 10, 277
treatment and the distribution in primary tumors and secondary sites. Prantner et al. identified and
characterized an antimesothelin nanobody (NbG3a) used for in vitro diagnostic applications [93].
Further studies from the same group established the potential use of NbG3a for a novel molecular
imaging probe with promising results for human imaging and therapeutic applications [94].
Terwisscha van Scheltinga et al. investigated the use of an antibody–drug conjugate (anti-mesothelin
antibody-monomethyl auristatin E) coupled to molecular imaging with 89Zr immuno-positive emission
tomography (PET). Using this technique, quantitative immuno-PET measurement of relative antibody
uptake was determined to correlate with tumor growth inhibition [95]. Furthermore, non-antibody
protein scaffolds have successfully been engineered to bind to mesothelin with high affinity [96].
Unlike antibodies that are large in size and have slow clearance from circulation, non-antibody protein
scaffolds have demonstrated specific binding to identify tumors expressing the molecular target in
murine models [97–99] and have demonstrated promising results in both preclinical and clinical
evaluations [100]. The use of these techniques demonstrates the translational potential of MSLN.
6.2. Clinical Trials
There are many clinical trials testing MSLN-targeting agents using strategies such as antibody-based
immunotoxins such as SS1P, consisting of an anti-MLSN Fv obtained from a phage display library of
immunized mice with recombinant MSLN fused to a truncated form of the Pseudomonas Exotoxin
PE38 that mediates cell death. The mechanism of action of an immunotoxin is threefold. First,
the immunotoxin binds to cell-bound MSLN; second, this complex is internalized by endocytosis,
undergoes retrograde transport to the endoplasmic reticulum and the PE portion is translocated
to the cytosol; and third, the PE catalyzes ADP-ribosylation of the elongation factor-2, halting
protein synthesis and activating apoptosis [85,101]. There have been two Phase I clinical trials with
different modes of administration using either continuous infusion or as bolus intravenous infusions
in mesotheliomas, ovarian, and pancreatic cancers. Continuous infusion was well tolerated and
showed modest clinical activity; however, there was advantage seen over bolus dosing [102,103].
Additionally, there is a high affinity chimeric antibody, amatuximab (MORAb-009), with high affinity
and specificity for mesothelin that is under investigation in clinical trials. Amatuximab works by
inducing antibody-dependent cellular cytoxicity [104]. It was observed that upon treatment with
amatuximab, patients had an increase in CA125 levels suggesting that amatuximab interferes with
the MSLN:CA125 interaction [105]. A tumor vaccine CRS-207 utilizing a live attenuated strain of
bacterium Listeria monocytogenes (Lm) expressing human MSLN has shown good tolerance and
MSLN-specific T-cell response in a phase I study of safety clinical trial. This phase I study not
only demonstrated that vaccines are safe and tolerable but also showed that a tumor antigen-modified
Lm can induce tumor antigen-specific T-cell responses in patients with advanced cancer, suggesting
that further evaluation of Lm vaccine as a candidate biomarker of improved clinical outcomes is
needed [106]. A two-part phase I/II trial is underway using combination therapy with CRS-207,
epacadostat, and pembrolizumab (keytruda) in patients with platinum-resistant ovarian, fallopian tube,
and peritoneal cancers using different combinations of the three treatments (ClinicalTrials.gov Identifier
NCT02575807). Antibody–drug conjugates is another strategy used to target MSLN. An ongoing
phase I clinical trial with anetumab ravtansine (BAY94-9343) to determine the safety and maximum
tolerated dose for patients with advanced solid tumors including ovarian carcinoma and mesothelioma
opened in 2011 (ClinicalTrials.gov Identifier NCT01439152). Anetumab ravtansine consists of the
fully human anti-MSLN IgG1 linked to a potent tubulin-binding drug, DM4. In preclinical trials,
anetumab ravtansine inhibited both subcutaneous and orthotopic tumor growth in xenograft models
of ovarian, pancreatic, and mesothelioma cancers [107]. In patients with recurrent MSLN-expressing
platinum-resistant recurrent ovarian, fallopian tube or primary peritoneal cancer, a phase Ib clinical trial
to determine the maximum tolerated dose of anetumab ravtansine that could be safely combined with
pegylated liposomal doxorubicin is underway (ClinicalTrials.gov Identifier NCT02751918). Several
ongoing clinical trials are utilizing anti-MSLN CAR-modified T cells as MSLN targeting agent. The T
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cells are obtained by apheresis and introduced to a temporary gene which will cause them to make
a new type of antibody that will attach to MSLN. Once attached, the cells will become activated and
stimulate the host immune system to attack the MSLN-expressing cells [108]. The above clinical trials
have confirmed that targeting MSLN could be beneficial in improving existing therapeutic options for
patients diagnosed with a MSLN-expressing cancer, including ovarian cancer.
7. Conclusions
Ovarian cancer is the deadliest gynecological malignancy among U.S. women and is often
diagnosed at a late stage when the disease has metastasized into the peritoneal cavity. Mesothelin,
a glycoprotein normally expressed in mesothelial cells, is highly expressed in several cancers including
ovarian, pancreatic, and mesotheliomas. It has been shown that MSLN binds to the ovarian cancer
biomarker CA125 and this interaction plays a role in the peritoneal metastasis of ovarian cancer.
The differential expression of mesothelin in normal and cancer tissues makes it a promising candidate
for targeted therapeutics. Several candidate immunotherapies targeting MSLN are in ongoing
clinical trials. New strategies to disrupt the MSLN:CA125 interaction are emerging. Although MSLN
is implicated in many cancers, the role of MSLN is still poorly understood warranting further
investigation and clinical trial studies. Future advances in ovarian cancer therapy depend on novel
treatment mechanisms in combination with current chemotherapeutic approaches that will result in
cytotoxicity, inhibition of metastasis and angiogenesis, and increasing the immunological detection
of tumors. Further mechanistic studies on MSLN are needed to validate the potential role of MSLN
in tumor metastasis that possibly will provide insight for effective MSLN-targeting therapies for
several cancers.
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Abstract: The tumor microenvironment for epithelial ovarian cancer is complex and rich in bioactive
molecules that modulate cell-cell interactions and stimulate numerous signal transduction cascades.
These signals ultimately modulate all aspects of tumor behavior including progression, metastasis
and therapeutic response. Many of the signaling pathways converge on the small GTPase Ras-related
C3 botulinum toxin substrate (Rac)1. In addition to regulating actin cytoskeleton remodeling
necessary for tumor cell adhesion, migration and invasion, Rac1 through its downstream effectors,
regulates cancer cell survival, tumor angiogenesis, phenotypic plasticity, quiescence, and resistance
to therapeutics. In this review we discuss evidence for Rac1 activation within the ovarian tumor
microenvironment, mechanisms of Rac1 dysregulation as they apply to ovarian cancer, and the
potential benefits of targeting aberrant Rac1 activity in this disease. The potential for Rac1 contribution
to extraperitoneal dissemination of ovarian cancer is addressed.
Keywords: Rho-GTPase; Rac1; guanine nucleotide exchange factors (GEFs); GTPase activating
proteins (GAPs); oncogene; oncoprotein; ovarian cancer; tumor microenvironment; bone niche;
therapeutic targeting
1. Introduction
Despite advances in treatment, long-term outcomes for epithelial ovarian cancer (EOC) patients
remain discouraging. Challenges to effective treatment include factors such as diagnosis after
tumor dissemination, presence of residual disease after treatment, a limited number of identified
targets for maintenance therapy, and acquired chemoresistance leading to relapse after initial clinical
remission [1,2]. EOC displays a high degree of genomic heterogeneity [3,4] and it has been proposed
that tumor microenvironmental factors may also contribute to tumor heterogeneity [5].
EOC dissemination occurs predominantly through tumor cell exfoliation into the peritoneal cavity
thereby providing a unique environment for tumor growth and metastasis when compared to the
majority of solid tumors [6–10]. There is heterogeneity of sites within the peritoneal cavity leading
to diverse localized environments. For example, the omentum is rich in adipocytes and provides a
distinct niche when compared to the mesothelium of the peritoneal wall [10–18]. Furthermore, the
tissue underlying the mesothelial lining at various locations differs in architecture and local production
of chemotactic factors thus promoting different adhesive and invasive behaviors [11]. It may be more
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accurate to consider the peritoneal cavity as home to multiple tumor microenvironments (TMEs)
presenting additional challenges to effective treatment.
Tumor cells within the ovarian cancer TME are exposed to a variety of regulatory signals.
Tumor cells interact with mesothelium, fibroblasts, endothelium, immune cells and other cells in
the TME [6–10,19,20]. Invasive cells come into contact with the extracellular matrix (ECM) underlying
the mesothelium. This leads to intracellular signaling due to integrin engagement and exposure to
ECM-associated growth factors. Each cell type in the TME, as well as the tumor cells themselves,
secrete bioactive molecules that accumulate in the peritoneal fluids and drive adverse tumor cell
behaviors such as proliferation, invasion, and phenotypes promoting chemoresistance. These cell-cell
interactions between tumor cells or other cells in the TME, cell-matrix interactions, and exposure to
growth factors and cytokines present in peritoneal fluids all stimulate signaling cascades that dictate
aspects of tumor cell function. Many of these diverse signals converge upon, and are integrated
through, the small GTPase Ras-related C3 botulinum toxin substrate (Rac) 1 (Figure 1) [21–26].
Figure 1. Bioactive molecules in the tumor microenvironment (TME) activate multiple receptors that
converge on Rac1. (A) Examples of receptors that activate Rac1 in response to bioactive molecules in
the TME are shown (GPCR = G protein-coupled receptor; RTK = receptor tyrosine kinase). Rac1 activity
is balanced through multiple regulatory mechanisms discussed in this review that serve to control
diverse physiological outcomes. (B) Cell-cell interactions between tumor cells themselves or with cells
in the TME (adipocytes, cancer-associated fibroblasts, mesothelia) can also cause Rac1 activation and
further modulate the TME. See Section 3.3 for further detail.
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The Rac subfamily of Rho family small GTPases has three members. Rac1 is the best-characterized
member of this subfamily with strong evidence for Rac1 dysregulation in cancer [21,23–25,27,28].
Rac2 expression is confined to hematopoietic cells [29] and Rac3 has not been studied in the context
of ovarian cancer so these two proteins will not be discussed further in this review. Rac1 acts as a
molecular switch by cycling between active and inactive states that depend upon nucleotide binding
(Figure 1A) and other regulatory mechanisms discussed below. As a focal point for multiple signaling
pathways, Rac1 is capable of shunting cells between proliferation, apoptosis or quiescence, altering
cell differentiation and transcription, and modulating cell-environment interactions. Based on the
known activities of Rac1, this protein can play important roles in multiple steps of tumor development,
dissemination and disease recurrence.
2. Consequences of Rac1 Activation in Cancer
Rac1 cycles between an active GTP-bound state and an inactive GDP-bound conformation
(Figure 1A) regulated by guanine nucleotide exchange factors (GEFs), GTPase-activating proteins
(GAPs) and guanine nucleotide dissociation inhibitors (GDIs) [24]. Aberrant activation of Rac1
is implicated in numerous aspects of tumor development and progression and is the subject of
several recent reviews [25,26,30,31]. Rac1 is best recognized for translating extracellular signaling into
downstream changes in actin remodeling, cell adhesion, motility and invasion [23,26,32]. There is
strong emerging evidence that Rac1 also contributes to the tumor stem cell phenotype, epithelial to
mesenchymal transition (EMT), angiogenesis, and chemoresistance [33–38]. Elevated Rac1 activity is
associated with enhanced stem cell characteristics in multiple cancers and its inhibition attenuates the
stem cell phenotype [34,36,39]. Although the relationship between Rac1 expression and/or elevated
activity and cancer stem cells has been reported for several cancer types, there is little information for
ovarian cancer. However, a splice variant of Vav3, a GEF and enhancer of Rac1 activity, is overexpressed
in multi-drug resistant stem cell-like fractions of ovarian cancer cells [40]. This finding suggests that
elevated Rac1 activity may promote stem cell characteristics in ovarian cancer similar to the reports for
other tumor types.
Ovarian cancer cells display phenotypic plasticity with gains and losses of epithelial characteristics
during tumor development and peritoneal metastasis [41–43]. EMT is viewed as a critical aspect of
tumor invasion and metastasis [44,45] and Rac1 is implicated in promoting EMT in a number of
cancers [25]. Experimental evidence demonstrates that elevated Rac1 activity is sufficient to drive
aspects of EMT in ovarian tumor cells. When a mutationally activated form of Rac1 (Rac1G12V)
was introduced into ovarian tumor cells with an epithelial phenotype, cells displayed morphologic
characteristics of EMT including down-regulation of the epithelial marker E-cadherin, up-regulation of
the mesenchymal marker vimentin, and increased invasive capacity [46]. Inhibition of Rac1 activity or
knockdown of Rac1 expression restored epithelial characteristics to ovarian tumor cells [13,46,47] and
inhibited migration and invasion [47–49]. The significance of EMT in ovarian cancer is demonstrated
by the presence of ovarian cancer cells in extraperitoneal sites [50–52] and the circulation [50,53–55]
where the circulating tumor cells display mesenchymal characteristics [54,56]
Tumor angiogenesis supplies necessary nutrients and fosters tumor growth [22]. Angiogenesis is
a critical aspect of ovarian cancer and this process is targeted by therapeutics in current care [57–59].
Rac1 is involved in angiogenesis and required for vascular integrity and blood vessel sprouting as
demonstrated in a conditional Rac1 knockout mouse model [60]. In humans, Rac1 expression correlated
with blood vessel invasion in a meta-analysis of multiple cancer studies [38]. Rac1 is activated by the
angiogenic factors vascular endothelial growth factor (VEGF)-A, angiopoietin 1, basic fibroblast growth
factor (FGF) and others [61]. Activation of Rac1 in endothelial cells regulates adhesion, filopodia,
morphogenesis, cell proliferation and migration [33,62–65]. Two different Rac1 inhibitors displayed
anti-angiogenic activity in breast cancer models in vivo [66,67] supporting a potential benefit of Rac1
inhibition as an alternate anti-angiogenic strategy in cancer, including ovarian cancer.
103
Cancers 2018, 10, 358
Lymphangiogenesis is driven by the VEGF-C ligand and its high affinity receptor VEGFR3 [68,69].
The well-established omental niche site has vessels that express high levels of the neoangiogenic
VEGFR3, which serve to recruit ovarian tumor cells and offer a supportive environment for
neovascularization [70]. High VEGF-C expression is associated with worse overall survival in
ovarian cancer patients and tumor cell expression of VEGF-C is critical for lymphatic invasion and
lymphangiogenesis [71,72]. Mechanistic studies show VEGF-C signaling to Rac1 requires VEGFR3
endocytosis mediated by EphrinB2 [73]. In colorectal and lung cancers, lymph node metastasis
mediated by VEGF-C is linked to high expression of the Rac1 activating GEF Tiam1 [74,75]. Conversely,
a chemical library screen identified statins as potent inhibitors of lymphangiogenesis by blocking Rac1
prenylation and plasma membrane recruitment [69]. In this regard it is worth noting that inhibition of
VEGFR3 signaling in OVCAR8 cells, via Maz51, induced chemosensitization through downregulation
of BRCA gene expression. This finding suggests that combined targeting of VEGFR3 and Rac1 may
have benefit for dually blocking metastasis and enhancing tumor cell killing [76].
Rac1 is gaining substantial attention as a mediator of chemoresistance [37,77,78]. Rac1 is
implicated in treatment resistance in multiple cancers [37] and Rac1 inhibition increases sensitivity to
doxorubicin for squamous cell carcinoma cells, 5-fluorouracil and cisplatin in gastric adenocarcinoma
spheroids, and fludarabine for chronic lymphocytic leukemia (reviewed in [37]). In addition to these
conventional chemotherapies, Rac1 is suspected in resistance to a number of targeted therapies through
regulation of compensatory mechanisms. These include therapies directed against the epidermal
growth factor (EGF) receptor and human epidermal growth factor receptor (HER)-2 for lung and
breast cancers, B-RAF protein inhibitors in melanoma, estrogen targeted therapies in breast cancer
and VEGF/VEGFR targeted therapies in prostate cancer (reviewed in [30]). In many cases sensitivity
to the targeted therapeutic is restored upon Rac1 inhibition. The contributions of Rac1 activation
to chemoresistance is likely multifaceted based on specific mechanisms along distinct drug action
pathways, as well as non-specific mechanisms related to Rac1 promotion of EMT and stem cell
characteristics [42,79–81].
3. Pathways for Rac1 Activation by the Ovarian Tumor Microenvironment
Extracellular signals mediated by various cell surface receptors such as integrins, cadherins,
cytokine receptors, G-protein-coupled receptors (GPCRs) and receptor tyrosine kinases (RTKs) activate
GEFs and recruit Rac1 (sequestered with GDIs) from the cytosol to the plasma membrane or other
cellular locations (Figure 3A [21,30,82,83]). Rac1 then activates effector molecules including proteins
involved in actin remodeling, kinases, and adapter proteins that are responsible for propagating
Rac1-dependent signals and subsequent biological responses. The specific stimulus can dictate distinct
responses to Rac1 activation based on post-translational modifications of Rac1, GEFs or other Rac1
modulatory molecules or effectors [21]. Because Rac1 is responsive to an array of signals, Rac1
is capable of driving multiple steps of tumor development, dissemination and recurrence. A few
examples of Rac1 activation by common components of ascitic fluids are described in more detail below.
3.1. Activators of G-Protein Coupled Receptors and Rac1 Activity
The bioactive lipids lysophosphatidic acid (LPA) and sphingosine-1-phosphate (S1P) are present
in ascitic fluid of ovarian cancer patients and activate GPCRs upstream of Rac1. Elevated levels of
LPA and S1P are both associated with ovarian tumor cell migration, invasion and metastasis [6,84]
and these processes require Rac1-dependent actin remodeling. Pharmacologic inhibition of Rac1
decreased S1P-dependent ovarian tumor cell invasion [85]. When multiple ovarian tumor cell lines
were studied, the ability of LPA to stimulate migration was highly correlated with LPA-dependent Rac1
activation [86]. Expression of a dominant negative form of Rac1 ablated LPA-stimulated cell migration
and in vivo metastatic colonization in responsive cell lines. Conversely, expression of a constitutively
active form of Rac1 conferred migration and in vivo implantation to cell lines non-responsive to
LPA [86]. Knock-down strategies determined that a Rac1-activating SOS1/EPS8/ABI1 complex unique
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to metastatic cells was responsible for the LPA stimulated migration and invasive implantation in
mice [86]. LPA activation of Rac1 has also been reported to be dependent on a Src/p130Cas pathway
for ovarian cell migration [87] and the Rac1 GEF βPIX was necessary for LPA-induced invadopodia
formation [88] although βPIX knock-down did not disrupt LPA-stimulated migration in certain ovarian
tumor cell lines [86]. The reported observations indicate that distinct Rac1 regulatory mechanisms are
responsible for different functional outputs and there may be cell-specific differences based on the
expression or activity of Rac1 regulators.
3.2. Activators of Tyrosine Kinases and Rac1 Activity
Ligands for RTKs such as the EGF receptor and VEGF receptor are prevalent in ovarian cancer
ascites and regulate Rac1 activation through multiple mechanisms. Signaling through RTKs activate
phosphatidylinositol-3 kinase and phospholipase C-γ to modulate targeting of Rac1 regulatory
proteins such as GEFs and GAPs and recruit GEFs to signaling complexes through post-translational
modifications (reviewed in [21,89]). In certain cases, signaling receptors can modify Rac1 activity
directly. For example, EGF receptor-stimulated ERK phosphorylation of Rac1 on T108 targets Rac1 for
nuclear translocation [21]. Rac1 has been shown to be an essential component of EGF receptor signaling
in different tumor types [90,91] and implicated in EGF receptor driven tumorigenesis [91]. Ligands
present in the ovarian TME are likely to activate Rac1 by impinging on ErbB3, ErbB4 and MET receptors,
which are expressed in 76–98% of ovarian tumors [92]. For example, heregulin stimulation of ErbB3 and
ErbB4 causes upregulation of C-X-C chemokine receptor type 4 (CXCR4) and increases Rac1 activation
through a stromal cell-derived factor (SDF)-1-CXCR4 mediated PREX1 GEF mechanism in breast
cancer cells [93]. Hepatocyte growth factor (HGF) induces a MET-AXL-ELMO2-DOCK180 complex
that activates Rac1-dependent cancer cell migration and invasion [94]. Pharmacologic inhibition of
Rac1 inhibited EGF-stimulated p21-activating kinase (PAK) phosphorylation, filopodia formation and
invadopodia [48,95] in ovarian tumor cell lines indicating contributions of Rac1 in cancer-relevant
functions. Although specific mechanisms of Rac1 activation by VEGF have not been explored in
ovarian cancer models, there is abundant evidence that Rac1 is a component of VEGF signaling to
angiogenesis. Ablation of Rac1 in endothelial cells in development is embryonic lethal due to lack of
neovascularization [96]. Studies show that Rac1 activation is critical for normal in vivo angiogenesis in
adult mice due to junctional stabilization required for mature vessels [97]. More recent work indicates
that lumen formation and stable cell:cell contacts are mediated through the GEF DOCK4 activation
of Rac1 [62]. The combined data indicate that further study of Rac1 activation in ovarian cancer by
tyrosine kinase receptors and their interfaces with G-protein coupled receptors is warranted.
3.3. Cell Interactions Leading to Rac1 Activation
An article in the present series and other recent reviews provide an in depth analysis of cell-cell
interactions in the ovarian tumor microenvironment that drive ovarian cancer progression [9,57,98].
Here, we briefly highlight how some of these interactions may promote ovarian cancer metastasis
through Rac1-dependent mechanisms (Figure 1B).
3.3.1. Tumor Cell-Cell Adhesion
Rac1 signaling is important for cell-cell adhesion. Ovarian cancer cells in the ascites fluid form
multicellular aggregates (spheroids) that facilitate angiogenesis and invasion of various peritoneal
organs [11]. Tumor cell-cell adhesions are mediated by E-cadherin maintenance of cell-cell junctions
that depend on a Rac1-Tiam1 GEF-IQGAP1 effector complex and promote an anti-migratory
phenotype [99]. Ovarian cancer spheroids with high E-cadherin expression are less sensitive to cisplatin
treatment suggesting an important role for cell-cell adhesions in spheroid chemoresistance [100].
105
Cancers 2018, 10, 358
3.3.2. Mesothelial Cells
Ovarian cancer frequently metastasizes to the peritoneal wall, which is lined with mesothelial
cells. Ovarian cancer cell interactions with mesothelial cells can stimulate mesothelial cell production
of fibronectin through the autocrine secretion of transforming growth factor (TGF)-β1. This activates a
TGF-βR1/Rac1/SMAD-dependent signaling pathway in mesothelial cells. The activated mesothelial
cells and production of fibronectin contributes to metastasis by supporting tumor cell adhesion,
invasion, and proliferation [13,57]. Co-culture of ovarian cancer cell lines with mesothelial cells led
to upregulated expression of the hyaluronan receptor and stem cell marker CD44 and promoted
tumorigenesis in a xenograft model [101]. CD44 promotes ovarian tumor cell-peritoneal cell adhesion
through binding of its ligand hyaluronan in complex with versican [102] and is generally known to
signal through multiple pathways downstream of Rac1 to promote tumor cell invasion [103].
3.3.3. Fibroblasts
Ovarian tumor cell-fibroblast interactions cause conversion of normal fibroblasts to
cancer-associated fibroblasts (CAFs, distinguished by smooth muscle actin expression) and lead to
increased tumor cell adhesion and overexpression of HGF and matrix metalloproteinase (MMP) [104].
MET receptor activation by HGF induced recruitment of the bipartite Rac1 GEF Elmo2/Dock180 and
promoted Rac1-dependent migration and invasion of multiple cancer cell lines in vitro, though ovarian
cell lines were not specifically tested [94]. Interactions between human omental CAF and ovarian
tumor cells also result in an integrin/p38/Rac1-dependent activation of cytokine secretion by CAFs,
which in turn promotes tumor cell proliferation and metastasis through activated glycogen breakdown
and glycolysis [105].
3.3.4. Adipocytes
The omentum is a favored ovarian tumor cell niche based on initial chemoattraction by adipocyte
secreted factors that can stimulate Stat3-mediated Rac1 activation [106]. In turn, the activation of these
pathways can strengthen cadherin-dependent binding of tumor cells, provide tumor cells with an
energy source through mutual changes in lipid metabolism, and promote invasion [14,106].
The selected illustrations do not capture the entire scope of potential ovarian cancer TME
regulation of Rac1 activity. Inflammatory cytokines such as interleukins 6 and 8, tumor necrosis
factor (TNF) α, and TGFβ are among the additional soluble factors in ascites fluids that are associated
with worse prognosis and variously associated with proliferation, metastatic spread, angiogenesis,
EMT and treatment resistance [6,107]. Each of these bioactive molecules is capable of stimulating
signaling cascades leading to Rac1 activation through direct or indirect mechanisms [24]. In addition,
integrin engagement and focal adhesion kinase activation recruits Rac1 to regulate spreading and
adhesion on the extracellular matrix [26,89,108]. Immune cells are an integral part of the ovarian
cancer TME and perform immune suppressive and activating functions that are pivotal in disease
pathology [109,110] and these cells serve as important therapeutic targets [111,112]. The best-studied
example of immune cell coupling to Rac1 activation in ovarian cancer is through cytokine activation of
CXCR4 as detailed in Sections 4.2 and 6. A more complete understanding of the complexities of Rac1
regulation by the ovarian cancer TME will require further study.
4. Mechanisms of Rac1 Dysregulation and Evidence in Ovarian Cancer
We reported that Rac1 protein is overexpressed and hyperactivated in ovarian cancer patient
samples [113]. Addressing the function of Rac1 hyperactivation in ovarian cancer is an important
research area because of the known roles of Rac1 in cancer metastasis and recurrence. In cancer, Rac1 is
frequently released from normal control mechanisms through mutation [114–118], aberrant regulation
of nucleotide binding and hydrolysis [26,30,119], and altered splicing [120–130]. Insight into possible
mechanisms leading to Rac1 overexpression and hyperactivation in ovarian cancer is garnered from
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analyses of the Catalogue of Somatic Mutations in Cancer (COSMIC) and The Cancer Genome Atlas
(TCGA) databases as detailed below.
4.1. Rac1 Overexpression and Somatic Mutation
There are 239 pathogenic missense mutations across diverse cancer types affecting 46 of the 192
amino acids in RAC1 (COSMIC v86 database updated in August 2018, https://cancer.sanger.ac.uk/
cosmic/download). The mutants are clustered in conserved residues relevant to GTPase activity or
affect residues close in 3D space that are important to Rac1 function (Figure 2A,B [117,118,131–133]).
Select point mutants are the primary cause of constitutive Rac1 activation in some cancer types
(melanoma, lung and germ cell cancers) (Figure 2A [114–118,132,134]). The highest prevalence (9%) of
the constitutively active, fast cycling P29S mutant is found in melanoma [115]. To date, the functionally
characterized Rac1 missense mutants (P29S, A159V, C18S and G15) all increase Rac1 activation and
possibly expression [118,135]. Rac1 is not found mutant in the 315 serous ovarian cancer patient
samples in the TCGA. However, given the low frequency of Rac1 missense mutants (0.01–0.02% for
G15, C18 [118]) such rare mutations would be undetectable in the sample size and should not be taken
as lack of evidence for the importance of Rac1 in ovarian cancer. For example, an shRNA essentiality
screen of 29 ovarian cancer cell lines showed SKOV3, COV362, JHM + OM1 and SNU840 to have
significantly decreased growth fitness with the loss of Rac1 (Harmonizome Achilles [136,137]. As
another case in point, Rac1 is overexpressed due to gene amplification or mRNA upregulation in 21%
(66/316) of the primary tumors in TCGA [138]. Despite the low frequency of RAC1 gene mutations,
RAC1 is similar to well-known oncogenes and tumor suppressors in being categorized as a Tier 1
cancer-causing gene in the COSMIC cancer gene census. Therefore, further systematic study of the
239 Rac1 missense mutations is warranted. In contrast to tumor suppressor genes, where truncating
mutations are prevalent and cause loss of function, the Rac1 mutations are like those in the oncoprotein
Ras. The mutations appear in hotspots and tend to be activating mutations [139]. Thus, RAC1 is a Tier
1 cancer-causing gene and the mutational patterns in Rac1 are similar to many well-known oncogenes
which are positive drivers of cancer.
4.2. Rac1 Regulators
The activity of Rac1 is tightly controlled through a large network of GEF and GAP regulatory
factors (Figure 3A,B [30,131,140–143]). This network is much greater than most other Ras-related
GTPases. Rac1 GEF and GAP regulatory factors are mutant or exhibit altered expression in
ovarian serous adenocarcinoma with a frequency of 0.3–1.6% based on our analyses of 28 relevant
regulatory proteins in COSMIC v86 [144] and the cBioPortal platform for TCGA data viewing [19,131]
(Figure 4 [20,83,118,138,144–147]).
Notably, the regulatory protein mutants show a high level of concurrent expression in tumor cells,
suggesting that hitting multiple nodes releases key Rac1-regulated pathways from normal control.
Even while the identified mutations often lie in known GEF and GAP regulatory domains, as well as in
lipid or protein interaction domains, no systematic analyses have been completed to identify hotspot
mutations or determine their pathogenicity in ovarian cancer. Nevertheless, some insights can be
drawn from a handful of analyses of regulatory protein overexpression [109,148,149], truncation [150]
or altered splice variants [40]; see also review [30].
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Figure 2. Pathogenic Cancer Mutations in Rac1. Rac1 gain of function mutations occur with low
frequency (0.2–1%) in multiple cancer types, though as yet none have been found in serous ovarian
cancer. (A) There are 239 pathogenic mutations in Rac1, resulting in missense substitutions at 46 amino
acid residues. Melanoma has the highest frequency of Rac1 mutations, leading to substitutions at
proline 29 and constitutive activation through GEF-independent fast nucleotide exchange. (B) Thirteen
of the missense mutants are likely oncogenic (G12R/V/E, G15S, C18S/Y, P29F/L/S/T, Q61R/K,
A159V) evidenced by recurrence at hotspots, paralogous with oncogenic mutations in Ras, or affecting
residues that are clustered in the 3D structure close to the nucleotide binding site. Shown is the
proximity of 4 point mutants in the crystal structure of wild-type Rac1 (PDB 3th5) rendered with
MacPyMOL: PyMOL v1.5.0.5 (Schrödinger LLC).
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Figure 3. Rac1 Regulatory Network in Ovarian Cancer. Rac1 integrates signals downstream of tyrosine
kinase receptors, adhesion molecules and G-protein coupled receptors and has nuclear functions.
(A) There are over 40 GEF and GAP proteins involved in the regulation of Rac1 activity through the
stimulation of nucleotide binding (GEFs) and hydrolysis (GAPs). Activated Rac1 binds to effectors that
recognize the unique conformation of the GTP-bound GTPase and mediate downstream physiologic
responses to receptor signaling. Activated Rac1 is ubiquitinated by HACE1 or FBXW7 and targeted
for proteasomal degradation, further controlling protein levels and activity. (B) Twenty-six Rac1 GEF
and GAP proteins, HACE1 and FBXW7 ubiquitin ligases have somatic mutations in serous ovarian
cancer patient samples. String network analysis places Rac1 at the core with a large array of close
functional associations with Rac1 regulatory proteins whose functions in ovarian cancer largely remain
to be determined.
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Figure 4. Rac1 regulators and effectors are part of the long tail of oncogenic drivers in ovarian cancer.
A list of 54 genes with frequent missense mutations in cancers was derived from OncoKB: A precision
oncology knowledge base and two recent publications on rare mutations. The cancer gene list was
combined with a selected list of 28 Rac1 regulatory proteins (GEFs, GAPs, ubiquitin ligases). Plotted is
the frequency of missense mutations in genes with mutation frequencies above 0 (58 of 82 analyzed)
among 315 serous ovarian cancer patient samples in TCGA. The frequency for BRCA1 and BRCA2 gene
mutations is the sum of somatic and germline missense mutations. For all other genes no germ line
mutations are reported. Among the analyzed genes, 53 (9.2%) are Tier 1 of 574 reported in COSMIC v86;
Tier 1 genes have “documented activity relevant to cancer, plus evidence of mutations in cancer, which change
the activity of the gene product in a way that promotes oncogenic transformation”. Among the Rac1 regulators
only ARHGEF12 and ARHGEF10L are validated as Tier 1 and Tier 2 (“strong indication of a role in
cancer”), respectively. Cancer genes (black and gray), Rac1 GEFs (green), Rac1 GAPs (red), ubiquitin
ligases (yellow). The data show that even though missense mutations in individual Rac1 regulators
occur with low frequency, there are at least 26 possible targets (10 with co-occurring alterations, p < 0.05)
that might lead to Rac1 activation or inactivation in ovarian cancer.
Overexpression of the Rac1 GEF DOCK180 drives glioblastoma invasion through the activation
of a Rac1-dependent kinase pathway [149]. A truncating mutant of PREX2 in melanoma has increased
Rac1 GEF activity, and activates PI3K/AKT signaling, while abolishing binding to the PTEN tumor
suppressor in melanoma [150]. An N-terminally truncated splice variant of the Vav3 GEF (Vav3.1)
is a predictor of poor prognosis and platinum-response and highly expressed in ovarian cancer
stem-like cell populations isolated from established cell lines [40]. These examples are supportive of
a requirement for Rac1 activation in multiple cancers. Recent analyses of the metastatic TME using
omental samples from patients with high grade serous ovarian cancer characterized secreted, matrix
and cellular components [109]. Multivariate regression analyses of data were used to model the
relationships between all TME components. Comprehensive RNA seq analysis of the TME identified
31 Rac1 GEFs, GAPS and ubiquitin ligases significantly associated with disease score by Pearson’s
and Spearman’s tests; five GEFs and GAPs were significant based on Pearson’s only (supplementary
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Table 13 in [109]). Recent analyses of a large cohort of Canadian ovarian cancer patients identified
variants in ARHGEF10L to be significantly associated with invasive disease [151] and three somatic
missense mutations have been identified in ovarian cancer patient samples (COSMIC v86). The limited
information on ARHGEF10L suggests in vitro GEF activity for RhoA, but not Rac1 or Cdc42 [152]. Since
RhoA and Rac1 are often reciprocally active, connections between the two GTPases may need further
analysis in ovarian cancer. Alterations in GAP expression in vivo have both activating and inhibitory
effects on tumorigenesis and metastasis, likely due to dual roles as scaffolding proteins and GTP
hydrolysis regulators [30]. When considering how to tackle prioritization of GEF and GAP proteins for
study, categorizing potential tumor suppressive vs. promoting activity might be gained by using a
ratiometric analysis of truncating/frameshift vs. missense mutations [139]. Additionally, functional
analyses of select point mutants in key regulatory domains is an essential complementary effort that
is necessary to understand effects on regulatory protein activity and pathway interconnections. The
composite data are suggestive that Rac1 hyperactivation is an important driver in ovarian cancer and
may result largely from the misregulation of GEF and GAP regulatory cascades rather than through
activating mutations in Rac1 itself.
Emerging evidence suggests that Rac1 regulatory proteins function in spatially localized molecular
assemblies. Such assemblies restrict Rac1 activity temporally and spatially to specific subcellular
domains, which in turn restricts what downstream pathways are triggered by Rac1. In ovarian cancer,
a recently described tripartite complex that includes the SOS1 GEF is essential for LPA-mediated Rac1
activation and metastasis [86]. Activation of Rac1 by the Tiam1 or PREX1 GEF proteins is spatially
distinct in the cell and dictates anti- or pro-migratory responses in ovarian cancer cells [99]. The
translocation of Rac1 in response to signaling and transient assembly of Rac1 GEFs at the plasma
membrane can also occur through specific actin and protein based recruitment [82]. On the other hand,
Rac1 forms a stable plasma membrane complex with CXCR4 independent of GTP-bound status, which
is important for maintaining CXCR4 in a signaling competent conformation [153]. The PREX1 GEF is
speculated to enable rapid response of Rac1 activation downstream of CXCR4 signaling. Therefore,
functional studies of Rac1 and associated regulatory factors in the ovarian metastatic cascade will need
to carefully consider spatiotemporal organization.
4.3. Rac1b Splice Variant
The constitutively active Rac1b splice variant mRNA level [113] and protein levels are moderate
to high in the majority of serous papillary ovarian adenocarcinoma cells (Figure 5). Interestingly,
Rac1b is also differentially expressed in underlying stromal cells in malignant serous papillary ovarian
adenocarcinoma tissue as compared to normal ovary. The prognostic or diagnostic significance of
overexpression of canonical Rac1 in ovarian cancer and/or the potential role(s) of the hyperactivated,
fast cycling Rac1b isoform remain open questions. We analyzed RAC1 mRNA expression data for 298
Stage III primary serous ovarian cancer patient samples in TCGA using isoform analysis tools [154,155].
The results demonstrate that high total RAC1 mRNA expression is associated with worse outcomes
(Figure 6A,B) and concur with a report that analyzed Rac1 as a risk factor in a cohort of 150 Chinese
ovarian cancer patients [47]. High expression of the canonical RAC1 isoform also trended to worse
outcomes but was not statistically significant (Figure 6C). The impact of RAC1b isoform expression on
ovarian patient survival has not been reported and was of particular interest. Rac1b protein drives
tumor cell proliferation and EMT and is upregulated by MMP3, a known survival risk factor in
breast, lung, and pancreatic cancers [124,156–158]. High mRNA expression of the fast cycling and
constitutively active RAC1b isoform does not predict ovarian cancer patient survival and trended
toward higher survival probability (Figure 6D [113,120–122,129,130,155]); the finding was consistent
irrespective of various groupings, treatment as a continuous variable or when expressed as a fraction
of total RAC1 mRNA expression. The only other study assessing the significance of RAC1b isoform
expression measured the prognostic value of RAC1b in progression free and overall survival [159].
Findings were based on quantitative RT-PCR analyses of 157 metastatic colorectal cancer patient
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samples following relapse after first line chemotherapy. In contrast to our findings in primary ovarian
tumors, fractional RAC1b overexpression was significantly associated with poor progression free
(HR 0.54, p = 0.49) and overall survival (HR 0.53, p = 0.039) in metastatic colorectal cancer patients.
Similar to the ovarian cancer patients, RAC1b expression was not mutually exclusive and 152/157 (97%)
of the metastatic colorectal patients had higher canonical RAC1 than RAC1b expression. To date there
are no studies that have distinguished the functions of Rac1 and Rac1b overexpression or activity in
the absence of endogenous protein, in part due to the essentiality of Rac1 function [128,160]. Together,
these data indicate that overexpression and aberrant Rac1 and/or Rac1b activity are closely tied to
malignant ovarian cancer and further dissection of their respective roles in tumor microenvironment
responsiveness, metastasis and relapse is warranted.
 
Figure 5. The constitutively active Rac1b splice variant is overexpressed in ovarian cancer. Ovarian
cancer tissue microarrays were stained for Rac1b, a constitutively active Rac1 splice variant. Slides
were imaged using an Aperio slide scanner and analysis was performed using HALO software. (A) Top
panel: Malignant tissue stained with DAB for Rac1b. Analysis to identify tumor cells (red) and
stromal cells (green). Middle panel: Quantification of the amount of Rac1b expression in tumor
cells (right) vs. stromal cells (left) in malignant tissue. Blue-no staining, yellow-weak staining,
orange-moderate staining, red-strong staining. Bottom panel: Quantification of Rac1b expression
in stromal cells in normal ovary tissue, colors as for middle panel. (B) The majority of serous papillary
ovarian adenocarcinoma cells were moderately to strongly positive for Rac1b, while stromal cells were
weakly positive. (C) Quantitative comparisons of normal ovary tissue and serous papillary ovarian
adenocarcinoma tissue evidences an elevated expression of Rac1b in the stromal cells adjacent to the
malignant tumor cells relative to normal tissue.
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Figure 6. High total RAC1 expression predicts reduced ovarian cancer patient survival. (A) Rac1
undergoes regulated splicing in response to growth factor signaling, which is subject to positive and
negative regulation by hnRNP A1 and SR protein. The resulting splice variant is called Rac1b and
contains a 19 amino acid insert adjacent to the Switch II region. Rac1b is a fast cycling, constitutively
active and frequently overexpressed in cancer, including ovarian cancer. (B) Kaplan-Meier plot of high
vs. low total RAC1 mRNA expression. TCGA datasets for total and RAC1 isoform mRNA expression
in ovarian cancer patients from ISOexpresso; uc003spx.3 (canonical RAC1) and uc003spw.3 (RAC1b
containing exon 3b/4). Analyses were restricted to 298 patients with Stage III and Stage IV disease.
Patients were divided into 3 groups based on total Rac1 expression. Upper tertile values represent
high total Rac1 expression and lower tertile values represent low expression, middle values were
excluded. Patients with high RAC1 expression have worse survival outcomes than those with low
RAC1 expression (HR = 1.5, p = 0.0325); analogous results obtained using data direct from TCGA and
CASViewer. No evidence for an association between isoform RAC1b and survival outcomes (HR = 0.96,
p = 0.82, not shown). Higher expression of the canonical RAC1 isoform trended to lower survival
probability, though was not statistically significant (HR = 1.37, p = 0.121). (C) Plot of total RAC1 (green
line), canonical RAC1c (blue diamond), and RAC1b (red square) expression in each patient ranked
according to expression levels. (D) Kaplan-Meier plot of RAC1b as a fraction of total RAC1, with two
groups defined based on median expression. High RAC1b expression (HR = 0.76, p = 0.0913).
5. Potential Benefits of Targeting Aberrant Rac1 Activity in Ovarian Cancer
The broad impact of Rac1 on tumor cell behavior has led to consideration of Rac1 as a potential
therapeutic target [25,28,95,161–163]. In ovarian cancer cell lines, knock down of Rac1 expression
decreased fibronectin production [13], reversed EMT as measured by increased E-cadherin and
decreased vimentin expression [46,47], inhibited tumor cell migration and invasion [47] and reduced
tumor growth in a xenograft model [47]. An inhibitor of Rac1 (NSC23766) decreased ovarian tumor
cell migration, invasion and matrix-metalloproteinase production [48,49,95].
Although a number of small molecule inhibitors have been developed to inhibit Rac1 activity
(e.g., NSC23766, EHT 1864, EHop-016 and its derivative MBQ-167), these agents have not been
translated to human use [66,164–166]. A high-throughput screen of the Prestwick library of off
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patent, FDA-approved drugs identified activators and inhibitors of Rho GTPases [95]. The resultant
findings coupled with cheminformatics approaches identified the R-enantiomers of a limited number
of non-steroidal anti-inflammatory drugs (NSAIDs), R-naproxen and R-ketorolac, as inhibitors of
Rac1 [95]. The S-enantiomers are pharmacologic NSAIDs based on cyclooxygenase (COX) inhibition.
GTPase inhibition by the R-enantiomers represents a previously unidentified pharmacologic activity.
R-naproxen and R-ketorolac inhibit serum and EGF-stimulated Rac1 and Cdc42 activation and
downstream signaling through a proposed allosteric mechanism [48,95]. R-ketorolac was tested
using ovarian tumor cell lines and primary ovarian tumor cells isolated from patient ascites fluids [48].
R-ketorolac was an effective Rac1 inhibitor and decreased downstream signaling as demonstrated
by reduction of PAK1 and PAK2 phosphorylation. R-ketorolac inhibited Rac1-dependent cellular
functions in ovarian cancer cell lines and primary cells including inhibition of growth factor-stimulated
formation of filopodia, cell adhesion to fibronectin and type I collagen, development of invadopodia
and tumor cell migration [48]. The inhibitory effects of R-ketorolac in cells are comparable to those of
established Rac1 and Cdc42 selective inhibitors [48,167].
In Phase 0 human studies, ovarian cancer patients received racemic ketorolac for its FDA-approved
indication in postoperative analgesia [113] then blood and peritoneal fluids were collected at intervals
for 24h. After administration of the racemic drug, R-ketorolac was detected in patient peritoneal fluids.
The concentration of R-ketorolac was sufficient to inhibit Rac1 activity in cells retrieved from the
peritoneal compartment of these post-surgical ovarian cancer patients. Potential benefit of R-ketorolac
is suggested by the results of a medical record review to compare the ovarian cancer–specific survival of
ovarian cancer patients who did or did not receive ketorolac [113]. The medical record review revealed
increased survival of patients receiving ketorolac and this observation is consistent with other reports
of improved clinical outcomes associated with ketorolac usage in breast cancer patients [168–170].
The overall findings suggest that ovarian cancer patients may benefit from inhibition of Rac1 in the
clinical setting.
6. Other Ovarian Tumor Microenvironments: Extraperitoneal Dissemination and Bone Niche as a
Sanctuary Site and Potential Reservoir for Relapse
While ovarian cancer metastasis is largely confined to the peritoneal cavity and localized to the
omentum, there is strong evidence for extra-peritoneal dissemination [171,172]. As illustrated in
preceding sections, Rac1 plays a critical role in the key processes that impact tumor dissemination
and as such, Rac1 may contribute to ovarian tumor cell escape from the peritonium. Particularly
in advanced disease, ovarian carcinoma can spread to distant organs by both hematogenous
dissemination and lymphatic invasion [173]. In a well-designed parabiosis study, ovarian tumor cells
were found to spread in anastomosed mice within two weeks of ovary injection [18], clearly illustrating
hematogenous spread of the disease. Additionally, circulating tumor cells (CTCs) are frequently
detected in patients [53,174]. In fact, CTCs were detected in 90% (98/109) of newly diagnosed ovarian
cancer patients, where the number of CTCs correlated with disease stage and was altered with
treatment [175]. Lymph node involvement of the disease is also common and has been proposed as
a potential prognostic factor with site-specific prognostic differences identified between the ovary
and lymph node [176]. However, this study was unable to rule out the “safe haven” hypothesis
for metastatic ovarian tumor cells in retroperitoneal lymph nodes and suggested that lymph node
dissection after complete cytoreduction is warranted pending further prospective data collection [176].
Interestingly, recent work comparing the survival of patients with distant lymph node metastases to
patients with pleural metastases or other distant ovarian cancer metastases found increased survival in
women having lymph nodes as their only distant metastatic site [177]. A follow up study investigating
the relationship between site-specific patterns of distant metastases and overall survival also found
that patients with lymph node metastasis had the longest survival when compared to women with
other metastatic disease [173]. Collectively, these data suggest that disease dissemination through the
lymphatics may have a less aggressive phenotype than disease that spreads hematogenously. Future
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studies will be necessary to quantitatively compare the aggressive nature of ovarian cancer cells with
respect to their route of disease dissemination.
Once outside the peritoneum, other common sites of distant metastatic ovarian cancer include the
liver, lung, and bone [6]. While frank bone metastases are rare in ovarian cancer [173,178], prognosis of
cases with bone metastasis is poor. A recent publication [179] followed up on previous observations of
bone marrow disseminated tumor cells (DTCs) in ovarian cancer patients [51,52,180,181] and affirmed
that bone DTCs correlated with reduced progression free and overall survival [182,183]. Bone marrow
was isolated from 79 ovarian cancer patients pre- and post-platinum-based chemotherapy. Bone DTCs
were detected in 42% and 41% of patients before and after chemotherapy, respectively, illustrating the
chemoresistance of cells in the bone niche [179]. Alterations in the bone microenvironment caused
by irradiation and cisplatin therapy can further promote and increase metastatic spread that may be
ameliorated by non-steroidal anti-inflammatory agents [184]. Additionally, tumor secreted factors
such as CCL2 can activate cells in the bone marrow promoting a premetastatic niche and paving the
way for successful tumor dissemination at a secondary site [98]. The predominant signaling axis that
promotes bone marrow homing is the CXCR4/SDF-1α signaling cascade [185]. The expression and
secretion of SDF-1α is abundant in the bone marrow microenvironment (expressed by osteoblasts
and endothelial cells) and promotes the homing and maintenance of CXCR4+ cells within the bone
marrow. In addition to driving hematopoietic cells as well as breast and prostate cancer cells to the
bone [186–189], CXCR4/SDF-1α signaling has also been shown to promote ovarian cancer metastasis
and is a predictor of poor prognosis in ovarian cancer [190,191]. Overexpression of CXCR4 is associated
with cisplatin resistant ovarian cancer [192] as well as the peritoneal [193], hematogenous [194] and
lymph node [195] dissemination of the disease. Moreover, CXCR4 can modulate cancer cell migration
through interactions with the downstream effector Rac1 [196]. In fact, blocking or silencing of CXCR4
was found to significantly reduce RhoA and Rac-1/Cdc42 expression levels and decrease ovarian
cancer cell migration [197]. Additionally, CXCR4 blockade reduced ovarian tumor growth in animal
models [198,199]. Therefore, CXCR4 appears to be a shared signaling mechanism that facilitates
homing and engraftment within the peritoneal cavity and the bone marrow microenvironment. How
Rac1 specifically influences ovarian tumor cells within these two separate environments remains to
be explored.
Ovarian cancer metastasis has long been studied in the context of the peritoneal compartment
where the bulk of the tumor grows. However, as we improve our systemic and palliative therapy
for ovarian cancer patients, an increasing occurrence of unusual distant metastases is being reported.
Despite compelling human findings, the overall significance of the bone niche with respect to ovarian
cancer prognosis remains ill-defined and suggests that a shift in research focus to understudied
metastatic sites such as the bone will be critical to improving patient outcomes. Moreover, the bone
marrow dissemination of ovarian cancer cells has been largely overlooked as a potential mechanism
for relapse, where the persistence of tumor cells in the protected bone niche could contribute to disease
recurrence. Therefore, future studies should be directed at identifying factors that enable tumor cells to
be harbored in specialized niche sites that include the bone. By targeting bone marrow-resident tumor
cells, we may uncover mechanistic strategies to eradicate distant tumor cell reservoirs that contribute
to ovarian cancer relapse and poor overall patient survival.
7. Conclusions
Ovarian cancer remains a leading cause of death in women resulting from gynecologic malignancy
principally due to recurrent, drug resistant disease, and limited options for targeted therapies. Greater
understanding of signaling proteins that mediate tumor microenvironmental drivers of disease and
resistance may provide new avenues for therapeutic development. Rac1 is at the nexus of numerous
signaling pathways stimulated by the ovarian cancer TME and has broad roles in cancer beyond the
well-recognized regulation of actin remodeling, tumor cell adhesion and migration. Rac1-dependent
functions in EMT, stem cell phenotypes, angiogenesis and chemoresistance all have high relevance to
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ovarian cancer. Although more research is needed regarding specific contributions of aberrant Rac1
activity in ovarian cancer and disease dissemination with respect to specialized microenvironments,
current knowledge suggests benefits of targeting Rac1, alone or in combination, for disease treatment.
Author Contributions: Conceptualization, L.G.H., J.M.G. and A.W.-N.; Methodology, A.W.-N.; Formal Analysis,
H.K.; Investigation, M.R.R.; Data Curation, A.W.-N.; Writing—Original Draft Preparation, L.G.H., J.M.G. and
A.W.-N.; Writing—Review & Editing, L.G.H., J.M.G., H.K., M.R.R., A.W.-N.; Visualization, H.K., A.W.-N., M.R.R.;
Supervision, L.G.H., J.M.G. and A.W.-N.; Project Administration, L.G.H., J.M.G. and A.W.-N.; Funding Acquisition,
L.G.H., J.M.G. and A.W.-N.
Funding: This research was funded by the National Institutes of Health; grant numbers are R21 TR001731, P50
GM085273 and P30 CA118100.
Acknowledgments: Rac1b imaging and analyses were conducted using the University of New Mexico Pathology
Dept. & Comprehensive Cancer Center Human Tissue Repository & Tissue Analysis Shared Resource. We thank
Fred Schultz, M.A. for Aperio scanning of IHC slides and training in the use of Halo quantitative imaging software
(Indica Labs).
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Christie, E.L.; Bowtell, D.D.L. Acquired chemotherapy resistance in ovarian cancer. Ann. Oncol. 2017, 28,
viii13–viii15. [CrossRef] [PubMed]
2. DiSilvestro, P.; Alvarez Secord, A. Maintenance treatment of recurrent ovarian cancer: Is it ready for prime
time? Cancer Treat. Rev. 2018, 69, 53–65. [CrossRef] [PubMed]
3. Kroeger, P.T., Jr.; Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr. Opin. Obstet. Gynecol.
2017, 29, 26–34. [CrossRef] [PubMed]
4. Previs, R.A.; Sood, A.K.; Mills, G.B.; Westin, S.N. The rise of genomic profiling in ovarian cancer.
Expert Rev. Mol. Diagn. 2016, 16, 1337–1351. [CrossRef] [PubMed]
5. Kim, S.; Kim, B.; Song, Y.S. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in
ovarian cancer. Cancer Sci. 2016, 107, 1173–1178. [CrossRef] [PubMed]
6. Thibault, B.; Castells, M.; Delord, J.P.; Couderc, B. Ovarian cancer microenvironment: Implications for cancer
dissemination and chemoresistance acquisition. Cancer Metastasis Rev. 2014, 33, 17–39. [CrossRef] [PubMed]
7. Ghoneum, A.; Afify, H.; Salih, Z.; Kelly, M.; Said, N. Role of tumor microenvironment in ovarian cancer
pathobiology. Oncotarget 2018, 9, 22832–22849. [CrossRef] [PubMed]
8. Ghoneum, A.; Afify, H.; Salih, Z.; Kelly, M.; Said, N. Role of tumor microenvironment in the pathobiology of
ovarian cancer: Insights and therapeutic opportunities. Cancer Med. 2018. [CrossRef] [PubMed]
9. Weidle, U.H.; Birzele, F.; Kollmorgen, G.; Rueger, R. Mechanisms and Targets Involved in Dissemination of
Ovarian Cancer. Cancer Genom. Proteom. 2016, 13, 407–423. [CrossRef]
10. Worzfeld, T.; Pogge von Strandmann, E.; Huber, M.; Adhikary, T.; Wagner, U.; Reinartz, S.; Muller, R. The
Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front. Oncol. 2017, 7, 24. [CrossRef]
[PubMed]
11. Steinkamp, M.P.; Winner, K.K.; Davies, S.; Muller, C.; Zhang, Y.; Hoffman, R.M.; Shirinifard, A.;
Moses, M.; Jiang, Y.; Wilson, B.S. Ovarian tumor attachment, invasion, and vascularization reflect unique
microenvironments in the peritoneum: Insights from xenograft and mathematical models. Front. Oncol 2013,
3, 97. [CrossRef] [PubMed]
12. Giridhar, P.V.; Funk, H.M.; Gallo, C.A.; Porollo, A.; Mercer, C.A.; Plas, D.R.; Drew, A.F. Interleukin-6 receptor
enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in
ovarian tumor cells. Clin. Exp. Metastasis 2011, 28, 887–897. [CrossRef] [PubMed]
13. Kenny, H.A.; Chiang, C.Y.; White, E.A.; Schryver, E.M.; Habis, M.; Romero, I.L.; Ladanyi, A.; Penicka, C.V.;
George, J.; Matlin, K.; et al. Mesothelial cells promote early ovarian cancer metastasis through fibronectin
secretion. J. Clin. Investig. 2014, 124, 4614–4628. [CrossRef] [PubMed]
14. Nieman, K.M.; Kenny, H.A.; Penicka, C.V.; Ladanyi, A.; Buell-Gutbrod, R.; Zillhardt, M.R.; Romero, I.L.;
Carey, M.S.; Mills, G.B.; Hotamisligil, G.S.; et al. Adipocytes promote ovarian cancer metastasis and provide
energy for rapid tumor growth. Nat. Med. 2011, 17, 1498–1503. [CrossRef] [PubMed]
116
Cancers 2018, 10, 358
15. McGrail, D.J.; Kieu, Q.M.; Dawson, M.R. The malignancy of metastatic ovarian cancer cells is increased on
soft matrices through a mechanosensitive Rho-ROCK pathway. J. Cell Sci. 2014, 127, 2621–2626. [CrossRef]
[PubMed]
16. Lungchukiet, P.; Sun, Y.; Kasiappan, R.; Quarni, W.; Nicosia, S.V.; Zhang, X.; Bai, W. Suppression of
epithelial ovarian cancer invasion into the omentum by 1alpha,25-dihydroxyvitamin D3 and its receptor.
J. Steroid Biochem. Mol. Biol. 2015, 148, 138–147. [CrossRef] [PubMed]
17. Khan, S.M.; Funk, H.M.; Thiolloy, S.; Lotan, T.L.; Hickson, J.; Prins, G.S.; Drew, A.F.; Rinker-Schaeffer, C.W.
In vitro metastatic colonization of human ovarian cancer cells to the omentum. Clin. Exp. Metastasis 2010, 27,
185–196. [CrossRef] [PubMed]
18. Pradeep, S.; Kim, S.W.; Wu, S.Y.; Nishimura, M.; Chaluvally-Raghavan, P.; Miyake, T.; Pecot, C.V.; Kim, S.J.;
Choi, H.J.; Bischoff, F.Z.; et al. Hematogenous metastasis of ovarian cancer: Rethinking mode of spread.
Cancer Cell 2014, 26, 77–91. [CrossRef] [PubMed]
19. Cerami, E.; Gao, J.; Dogrusoz, U.; Gross, B.E.; Sumer, S.O.; Aksoy, B.A.; Jacobsen, A.; Byrne, C.J.; Heuer, M.L.;
Larsson, E.; et al. The cBio cancer genomics portal: An open platform for exploring multidimensional cancer
genomics data. Cancer Discov. 2012, 2, 401–404. [CrossRef] [PubMed]
20. Cook, D.R.; Rossman, K.L.; Der, C.J. Rho guanine nucleotide exchange factors: Regulators of Rho GTPase
activity in development and disease. Oncogene 2014, 33, 4021–4035. [CrossRef] [PubMed]
21. Haga, R.B.; Ridley, A.J. Rho GTPases: Regulation and roles in cancer cell biology. Small GTPases 2016, 7,
207–221. [CrossRef] [PubMed]
22. Bid, H.K.; Roberts, R.D.; Manchanda, P.K.; Houghton, P.J. RAC1: An emerging therapeutic option for
targeting cancer angiogenesis and metastasis. Mol. Cancer Ther. 2013, 12, 1925–1934. [CrossRef] [PubMed]
23. Cardama, G.A.; Gonzalez, N.; Maggio, J.; Menna, P.L.; Gomez, D.E. Rho GTPases as therapeutic targets in
cancer (Review). Int. J. Oncol. 2017, 51, 1025–1034. [CrossRef] [PubMed]
24. Hodge, R.G.; Ridley, A.J. Regulating Rho GTPases and their regulators. Nat. Rev. Mol. Cell Biol. 2016, 17,
496–510. [CrossRef] [PubMed]
25. Jansen, S.; Gosens, R.; Wieland, T.; Schmidt, M. Paving the Rho in cancer metastasis: Rho GTPases and
beyond. Pharmacol. Ther. 2018, 183, 1–21. [CrossRef] [PubMed]
26. Lawson, C.D.; Ridley, A.J. Rho GTPase signaling complexes in cell migration and invasion. J. Cell Biol. 2018,
217, 447–457. [CrossRef] [PubMed]
27. Porter, A.P.; Papaioannou, A.; Malliri, A. Deregulation of Rho GTPases in cancer. Small GTPases 2016, 7,
123–138. [CrossRef] [PubMed]
28. Zandvakili, I.; Lin, Y.; Morris, J.C.; Zheng, Y. Rho GTPases: Anti- or pro-neoplastic targets? Oncogene 2017,
36, 3213–3222. [CrossRef] [PubMed]
29. Troeger, A.; Williams, D.A. Hematopoietic-specific Rho GTPases Rac2 and RhoH and human blood disorders.
Exp. Cell Res. 2013, 319, 2375–2383. [CrossRef] [PubMed]
30. Kazanietz, M.G.; Caloca, M.J. The Rac GTPase in Cancer: From Old Concepts to New Paradigms. Cancer Res.
2017, 77, 5445–5451. [CrossRef] [PubMed]
31. Maldonado, M.D.M.; Dharmawardhane, S. Targeting Rac and Cdc42 GTPases in Cancer. Cancer Res. 2018,
78, 3101–3111. [CrossRef] [PubMed]
32. Sadok, A.; Marshall, C.J. Rho GTPases: Masters of cell migration. Small GTPases 2014, 5, e29710. [CrossRef]
[PubMed]
33. Orgaz, J.L.; Herraiz, C.; Sanz-Moreno, V. Rho GTPases modulate malignant transformation of tumor cells.
Small GTPases 2014, 5, e29019. [CrossRef] [PubMed]
34. Akunuru, S.; Palumbo, J.; Zhai, Q.J.; Zheng, Y. Rac1 targeting suppresses human non-small cell lung
adenocarcinoma cancer stem cell activity. PLoS ONE 2011, 6, e16951. [CrossRef] [PubMed]
35. Wang, J.Y.; Yu, P.; Chen, S.; Xing, H.; Chen, Y.; Wang, M.; Tang, K.; Tian, Z.; Rao, Q.; Wang, J. Activation of
Rac1 GTPase promotes leukemia cell chemotherapy resistance, quiescence and niche interaction. Mol. Oncol.
2013, 7, 907–916. [CrossRef] [PubMed]
36. Yoon, C.H.; Hyun, K.H.; Kim, R.K.; Lee, H.; Lim, E.J.; Chung, H.Y.; An, S.; Park, M.J.; Suh, Y.; Kim, M.J.; et al.
The small GTPase Rac1 is involved in the maintenance of stemness and malignancies in glioma stem-like
cells. FEBS Lett. 2011, 585, 2331–2338. [CrossRef] [PubMed]
117
Cancers 2018, 10, 358
37. Cardama, G.A.; Alonso, D.F.; Gonzalez, N.; Maggio, J.; Gomez, D.E.; Rolfo, C.; Menna, P.L. Relevance of
small GTPase Rac1 pathway in drug and radio-resistance mechanisms: Opportunities in cancer therapeutics.
Crit. Rev. Oncol. Hematol. 2018, 124, 29–36. [CrossRef] [PubMed]
38. Lou, S.; Wang, P.; Yang, J.; Ma, J.; Liu, C.; Zhou, M. Prognostic and Clinicopathological Value of Rac1 in
Cancer Survival: Evidence from a Meta-Analysis. J. Cancer 2018, 9, 2571–2579. [CrossRef] [PubMed]
39. Nayak, R.C.; Chang, K.H.; Vaitinadin, N.S.; Cancelas, J.A. Rho GTPases control specific
cytoskeleton-dependent functions of hematopoietic stem cells. Immunol. Rev. 2013, 256, 255–268. [CrossRef]
[PubMed]
40. Reimer, D.; Boesch, M.; Wolf, D.; Marth, C.; Sopper, S.; Hatina, J.; Altevogt, P.; Parson, W.; Hackl, H.;
Zeimet, A.G. Truncated isoform Vav3.1 is highly expressed in ovarian cancer stem cells and clinically
relevant in predicting prognosis and platinum-response. Int. J. Cancer 2018, 142, 1640–1651. [CrossRef]
[PubMed]
41. Klymenko, Y.; Kim, O.; Stack, M.S. Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity
in Ovarian Cancer. Cancers 2017, 9, 104. [CrossRef] [PubMed]
42. Deng, J.; Wang, L.; Chen, H.; Hao, J.; Ni, J.; Chang, L.; Duan, W.; Graham, P.; Li, Y. Targeting
epithelial-mesenchymal transition and cancer stem cells for chemoresistant ovarian cancer. Oncotarget
2016, 7, 55771–55788. [CrossRef] [PubMed]
43. Barbolina, M.V.; Moss, N.M.; Westfall, S.D.; Liu, Y.; Burkhalter, R.J.; Marga, F.; Forgacs, G.; Hudson, L.G.;
Stack, M.S. Microenvironmental regulation of ovarian cancer metastasis. Cancer Treat. Res. 2009, 149, 319–334.
[PubMed]
44. da Silva-Diz, V.; Lorenzo-Sanz, L.; Bernat-Peguera, A.; Lopez-Cerda, M.; Munoz, P. Cancer cell plasticity:
Impact on tumor progression and therapy response. Semin. Cancer Biol. 2018. [CrossRef] [PubMed]
45. Zhang, Y.; Weinberg, R.A. Epithelial-to-mesenchymal transition in cancer: Complexity and opportunities.
Front. Med. 2018. [CrossRef] [PubMed]
46. Fang, D.; Chen, H.; Zhu, J.Y.; Wang, W.; Teng, Y.; Ding, H.F.; Jing, Q.; Su, S.B.; Huang, S.
Epithelial-mesenchymal transition of ovarian cancer cells is sustained by Rac1 through simultaneous
activation of MEK1/2 and Src signaling pathways. Oncogene 2017, 36, 1546–1558. [CrossRef] [PubMed]
47. Leng, R.; Liao, G.; Wang, H.; Kuang, J.; Tang, L. Rac1 expression in epithelial ovarian cancer: Effect on cell
EMT and clinical outcome. Med. Oncol. 2015, 32, 329. [CrossRef] [PubMed]
48. Guo, Y.; Kenney, S.R.; Muller, C.Y.; Adams, S.; Rutledge, T.; Romero, E.; Murray-Krezan, C.; Prekeris, R.;
Sklar, L.A.; Hudson, L.G.; et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell
Behaviors Critical for Invasion and Metastasis. Mol. Cancer Ther. 2015, 14, 2215–2227. [CrossRef] [PubMed]
49. Zhou, G.; Peng, F.; Zhong, Y.; Chen, Y.; Tang, M.; Li, D. Rhein suppresses matrix metalloproteinase production
by regulating the Rac1/ROS/MAPK/AP-1 pathway in human ovarian carcinoma cells. Int. J. Oncol. 2017,
50, 933–941. [CrossRef] [PubMed]
50. Romero-Laorden, N.; Olmos, D.; Fehm, T.; Garcia-Donas, J.; Diaz-Padilla, I. Circulating and disseminated
tumor cells in ovarian cancer: A systematic review. Gynecol. Oncol. 2014, 133, 632–639. [CrossRef] [PubMed]
51. Fehm, T.; Banys, M.; Rack, B.; Janni, W.; Marth, C.; Blassl, C.; Hartkopf, A.; Trope, C.; Kimmig, R.;
Krawczyk, N.; et al. Pooled analysis of the prognostic relevance of disseminated tumor cells in the bone
marrow of patients with ovarian cancer. Int. J. Gynecol. Cancer 2013, 23, 839–845. [CrossRef] [PubMed]
52. Fehm, T.; Becker, S.; Bachmann, C.; Beck, V.; Gebauer, G.; Banys, M.; Wallwiener, D.; Solomayer, E.F. Detection
of disseminated tumor cells in patients with gynecological cancers. Gynecol. Oncol. 2006, 103, 942–947.
[CrossRef] [PubMed]
53. Gasparri, M.L.; Savone, D.; Besharat, R.A.; Farooqi, A.A.; Bellati, F.; Ruscito, I.; Panici, P.B.; Papadia, A.
Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis
in ovarian cancer. Tumour Biol. J. Int. Soc. Oncodev. Biol. Med. 2016, 37, 71–75. [CrossRef] [PubMed]
54. Yeung, T.L.; Leung, C.S.; Yip, K.P.; Au Yeung, C.L.; Wong, S.T.; Mok, S.C. Cellular and molecular processes
in ovarian cancer metastasis. A Review in the Theme: Cell and Molecular Processes in Cancer Metastasis.
Am. J. Physiol. Cell Physiol. 2015, 309, C444–C456. [CrossRef] [PubMed]
55. Zhou, Y.; Bian, B.; Yuan, X.; Xie, G.; Ma, Y.; Shen, L. Prognostic Value of Circulating Tumor Cells in Ovarian
Cancer: A Meta-Analysis. PLoS ONE 2015, 10, e0130873. [CrossRef] [PubMed]
118
Cancers 2018, 10, 358
56. Blassl, C.; Kuhlmann, J.D.; Webers, A.; Wimberger, P.; Fehm, T.; Neubauer, H. Gene expression profiling of
single circulating tumor cells in ovarian cancer—Establishment of a multi-marker gene panel. Mol. Oncol.
2016, 10, 1030–1042. [CrossRef] [PubMed]
57. Nwani, N.G.; Sima, L.E.; Nieves-Neira, W.; Matei, D. Targeting the Microenvironment in High Grade Serous
Ovarian Cancer. Cancers 2018, 10, 266. [CrossRef] [PubMed]
58. Monk, B.J.; Minion, L.E.; Coleman, R.L. Anti-angiogenic agents in ovarian cancer: Past, present, and future.
Ann. Oncol. 2016, 27, i33–i39. [CrossRef] [PubMed]
59. Hansen, J.M.; Coleman, R.L.; Sood, A.K. Targeting the tumour microenvironment in ovarian cancer.
Eur. J. Cancer 2016, 56, 131–143. [CrossRef] [PubMed]
60. Nohata, N.; Uchida, Y.; Stratman, A.N.; Adams, R.H.; Zheng, Y.; Weinstein, B.M.; Mukouyama, Y.S.;
Gutkind, J.S. Temporal-specific roles of Rac1 during vascular development and retinal angiogenesis. Dev. Biol.
2016, 411, 183–194. [CrossRef] [PubMed]
61. Galan Moya, E.M.; Le Guelte, A.; Gavard, J. PAKing up to the endothelium. Cell. Signal. 2009, 21, 1727–1737.
[CrossRef] [PubMed]
62. Abraham, S.; Scarcia, M.; Bagshaw, R.D.; McMahon, K.; Grant, G.; Harvey, T.; Yeo, M.; Esteves, F.O.;
Thygesen, H.H.; Jones, P.F.; et al. A Rac/Cdc42 exchange factor complex promotes formation of lateral
filopodia and blood vessel lumen morphogenesis. Nat. Commun. 2015, 6, 7286. [CrossRef] [PubMed]
63. Fryer, B.H.; Field, J. Rho, Rac, Pak and angiogenesis: Old roles and newly identified responsibilities in
endothelial cells. Cancer Lett. 2005, 229, 13–23. [CrossRef] [PubMed]
64. Soga, N.; Connolly, J.O.; Chellaiah, M.; Kawamura, J.; Hruska, K.A. Rac regulates vascular endothelial
growth factor stimulated motility. Cell Commun. Adhes. 2001, 8, 1–13. [CrossRef] [PubMed]
65. Xue, Y.; Bi, F.; Zhang, X.; Pan, Y.; Liu, N.; Zheng, Y.; Fan, D. Inhibition of endothelial cell proliferation by
targeting Rac1 GTPase with small interference RNA in tumor cells. Biochem. Biophys. Res. Commun. 2004,
320, 1309–1315. [CrossRef] [PubMed]
66. Humphries-Bickley, T.; Castillo-Pichardo, L.; Hernandez-O’Farrill, E.; Borrero-Garcia, L.D.;
Forestier-Roman, I.; Gerena, Y.; Blanco, M.; Rivera-Robles, M.J.; Rodriguez-Medina, J.R.; Cubano, L.A.; et al.
Characterization of a Dual Rac/Cdc42 Inhibitor MBQ-167 in Metastatic Cancer. Mol. Cancer Ther. 2017, 16,
805–818. [CrossRef] [PubMed]
67. Castillo-Pichardo, L.; Humphries-Bickley, T.; De La Parra, C.; Forestier-Roman, I.; Martinez-Ferrer, M.;
Hernandez, E.; Vlaar, C.; Ferrer-Acosta, Y.; Washington, A.V.; Cubano, L.A.; et al. The Rac Inhibitor
EHop-016 Inhibits Mammary Tumor Growth and Metastasis in a Nude Mouse Model. Transl. Oncol. 2014, 7,
546–555. [CrossRef] [PubMed]
68. Nagahashi, M.; Ramachandran, S.; Rashid, O.M.; Takabe, K. Lymphangiogenesis: A new player in cancer
progression. World J. Gastroenterol. 2010, 16, 4003–4012. [CrossRef] [PubMed]
69. Schulz, M.M.; Reisen, F.; Zgraggen, S.; Fischer, S.; Yuen, D.; Kang, G.J.; Chen, L.; Schneider, G.;
Detmar, M. Phenotype-based high-content chemical library screening identifies statins as inhibitors of
in vivo lymphangiogenesis. Proc. Natl. Acad. Sci. USA 2012, 109, E2665–E2674. [CrossRef] [PubMed]
70. Sorensen, E.W.; Gerber, S.A.; Sedlacek, A.L.; Rybalko, V.Y.; Chan, W.M.; Lord, E.M. Omental immune
aggregates and tumor metastasis within the peritoneal cavity. Immunol. Res. 2009, 45, 185–194. [CrossRef]
[PubMed]
71. Kuerti, S.; Oliveira-Ferrer, L.; Milde-Langosch, K.; Schmalfeldt, B.; Legler, K.; Woelber, L.; Prieske, K.;
Mahner, S.; Trillsch, F. VEGF-C expression attributes the risk for lymphatic metastases to ovarian cancer
patients. Oncotarget 2017, 8, 43218–43227. [CrossRef] [PubMed]
72. Hisamatsu, T.; Mabuchi, S.; Sasano, T.; Kuroda, H.; Takahashi, R.; Matsumoto, Y.; Kawano, M.; Kozasa, K.;
Takahashi, K.; Sawada, K.; et al. The significance of lymphatic space invasion and its association with
vascular endothelial growth factor-C expression in ovarian cancer. Clin. Exp. Metastasis 2015, 32, 789–798.
[CrossRef] [PubMed]
73. Wang, Y.; Nakayama, M.; Pitulescu, M.E.; Schmidt, T.S.; Bochenek, M.L.; Sakakibara, A.; Adams, S.; Davy, A.;
Deutsch, U.; Luthi, U.; et al. Ephrin-B2 controls VEGF-induced angiogenesis and lymphangiogenesis. Nature
2010, 465, 483–486. [CrossRef] [PubMed]
74. Liu, S.; Li, Y.; Qi, W.; Zhao, Y.; Huang, A.; Sheng, W.; Lei, B.; Lin, P.; Zhu, H.; Li, W.; et al. Expression of
Tiam1 predicts lymph node metastasis and poor survival of lung adenocarcinoma patients. Diagn. Pathol.
2014, 9, 69. [CrossRef] [PubMed]
119
Cancers 2018, 10, 358
75. Zhong, D.; Li, Y.; Peng, Q.; Zhou, J.; Zhou, Q.; Zhang, R.; Liang, H. Expression of Tiam1 and VEGF-C
correlates with lymphangiogenesis in human colorectal carcinoma. Cancer Biol. Ther. 2009, 8, 689–695.
[CrossRef] [PubMed]
76. Lim, J.J.; Yang, K.; Taylor-Harding, B.; Wiedemeyer, W.R.; Buckanovich, R.J. VEGFR3 inhibition
chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2. Neoplasia
2014, 16, 343–353. [CrossRef] [PubMed]
77. Hofbauer, S.W.; Krenn, P.W.; Ganghammer, S.; Asslaber, D.; Pichler, U.; Oberascher, K.; Henschler, R.;
Wallner, M.; Kerschbaum, H.; Greil, R.; et al. Tiam1/Rac1 signals contribute to the proliferation and
chemoresistance, but not motility, of chronic lymphocytic leukemia cells. Blood 2014, 123, 2181–2188.
[CrossRef] [PubMed]
78. Ikram, M.; Lim, Y.; Baek, S.Y.; Jin, S.; Jeong, Y.H.; Kwak, J.Y.; Yoon, S. Co-targeting of Tiam1/Rac1 and Notch
ameliorates chemoresistance against doxorubicin in a biomimetic 3D lymphoma model. Oncotarget 2018, 9,
2058–2075. [CrossRef] [PubMed]
79. Steg, A.D.; Bevis, K.S.; Katre, A.A.; Ziebarth, A.; Dobbin, Z.C.; Alvarez, R.D.; Zhang, K.; Conner, M.;
Landen, C.N. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin. Cancer Res.
2012, 18, 869–881. [CrossRef] [PubMed]
80. Huang, R.Y.; Chung, V.Y.; Thiery, J.P. Targeting pathways contributing to epithelial-mesenchymal transition
(EMT) in epithelial ovarian cancer. Curr. Drug Targets 2012, 13, 1649–1653. [CrossRef] [PubMed]
81. Ahmed, N.; Abubaker, K.; Findlay, J.; Quinn, M. Epithelial mesenchymal transition and cancer stem cell-like
phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr. Cancer Drug Targets 2010, 10, 268–278.
[CrossRef] [PubMed]
82. Bustelo, X.R.; Ojeda, V.; Barreira, M.; Sauzeau, V.; Castro-Castro, A. Rac-ing to the plasma membrane: The
long and complex work commute of Rac1 during cell signaling. Small GTPases 2012, 3, 60–66. [CrossRef]
[PubMed]
83. Vazquez-Prado, J.; Bracho-Valdes, I.; Cervantes-Villagrana, R.D.; Reyes-Cruz, G. Gbetagamma Pathways
in Cell Polarity and Migration Linked to Oncogenic GPCR Signaling: Potential Relevance in Tumor
Microenvironment. Mol. Pharmacol. 2016, 90, 573–586. [CrossRef] [PubMed]
84. Xu, Y. Lysophospholipid Signaling in the Epithelial Ovarian Cancer Tumor Microenvironment. Cancers 2018,
10, 227. [CrossRef] [PubMed]
85. Devine, K.M.; Smicun, Y.; Hope, J.M.; Fishman, D.A. S1P induced changes in epithelial ovarian cancer
proteolysis, invasion, and attachment are mediated by Gi and Rac. Gynecol. Oncol. 2008, 110, 237–245.
[CrossRef] [PubMed]
86. Chen, H.; Wu, X.; Pan, Z.K.; Huang, S. Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer
metastasis. Cancer Res. 2010, 70, 9979–9990. [CrossRef] [PubMed]
87. Ward, J.D.; Dhanasekaran, D.N. LPA Stimulates the Phosphorylation of p130Cas via Galphai2 in Ovarian
Cancer Cells. Genes Cancer 2012, 3, 578–591. [CrossRef] [PubMed]
88. Ward, J.D.; Ha, J.H.; Jayaraman, M.; Dhanasekaran, D.N. LPA-mediated migration of ovarian cancer cells
involves translocalization of Galphai2 to invadopodia and association with Src and beta-pix. Cancer Lett.
2015, 356, 382–391. [CrossRef] [PubMed]
89. Fritz, R.D.; Pertz, O. The dynamics of spatio-temporal Rho GTPase signaling: Formation of signaling patterns.
F1000Research 2016, 5. [CrossRef] [PubMed]
90. Yang, C.; Liu, Y.; Lemmon, M.A.; Kazanietz, M.G. Essential role for Rac in heregulin beta1 mitogenic
signaling: A mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
Mol. Cell. Biol. 2006, 26, 831–842. [CrossRef] [PubMed]
91. Zhu, G.; Fan, Z.; Ding, M.; Zhang, H.; Mu, L.; Ding, Y.; Zhang, Y.; Jia, B.; Chen, L.; Chang, Z.; et al.
An EGFR/PI3K/AKT axis promotes accumulation of the Rac1-GEF Tiam1 that is critical in EGFR-driven
tumorigenesis. Oncogene 2015, 34, 5971–5982. [CrossRef] [PubMed]
92. Davies, S.; Holmes, A.; Lomo, L.; Steinkamp, M.P.; Kang, H.; Muller, C.Y.; Wilson, B.S. High incidence of
ErbB3, ErbB4, and MET expression in ovarian cancer. Int. J. Gynecol. Pathol. 2014, 33, 402–410. [CrossRef]
[PubMed]
93. Lopez-Haber, C.; Barrio-Real, L.; Casado-Medrano, V.; Kazanietz, M.G. Heregulin/ErbB3 Signaling Enhances
CXCR4-Driven Rac1 Activation and Breast Cancer Cell Motility via Hypoxia-Inducible Factor 1alpha.
Mol. Cell. Biol. 2016, 36, 2011–2026. [CrossRef] [PubMed]
120
Cancers 2018, 10, 358
94. Li, W.; Xiong, X.; Abdalla, A.; Alejo, S.; Zhu, L.; Lu, F.; Sun, H. HGF-induced formation of the
MET-AXL-ELMO2-DOCK180 complex promotes RAC1 activation, receptor clustering, and cancer cell
migration and invasion. J. Biol. Chem. 2018. [CrossRef] [PubMed]
95. Oprea, T.I.; Sklar, L.A.; Agola, J.O.; Guo, Y.; Silberberg, M.; Roxby, J.; Vestling, A.; Romero, E.; Surviladze, Z.;
Waller, A.; et al. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLoS ONE
2015, 10, e0142812. [CrossRef] [PubMed]
96. Tan, W.; Palmby, T.R.; Gavard, J.; Amornphimoltham, P.; Zheng, Y.; Gutkind, J.S. An essential role for Rac1 in
endothelial cell function and vascular development. FASEB J. 2008, 22, 1829–1838. [CrossRef] [PubMed]
97. Hoang, M.V.; Nagy, J.A.; Senger, D.R. Active Rac1 improves pathologic VEGF neovessel architecture and
reduces vascular leak: Mechanistic similarities with angiopoietin-1. Blood 2011, 117, 1751–1760. [CrossRef]
[PubMed]
98. Peinado, H.; Zhang, H.; Matei, I.R.; Costa-Silva, B.; Hoshino, A.; Rodrigues, G.; Psaila, B.; Kaplan, R.N.;
Bromberg, J.F.; Kang, Y.; et al. Pre-metastatic niches: Organ-specific homes for metastases. Nat. Rev. Cancer
2017, 17, 302–317. [CrossRef] [PubMed]
99. Marei, H.; Carpy, A.; Woroniuk, A.; Vennin, C.; White, G.; Timpson, P.; Macek, B.; Malliri, A. Differential Rac1
signalling by guanine nucleotide exchange factors implicates FLII in regulating Rac1-driven cell migration.
Nat. Commun. 2016, 7, 10664. [CrossRef] [PubMed]
100. Xu, S.; Yang, Y.; Dong, L.; Qiu, W.; Yang, L.; Wang, X.; Liu, L. Construction and characteristics of an
E-cadherin-related three-dimensional suspension growth model of ovarian cancer. Sci. Rep. 2014, 4, 5646.
[CrossRef] [PubMed]
101. Shishido, A.; Mori, S.; Yokoyama, Y.; Hamada, Y.; Minami, K.; Qian, Y.; Wang, J.; Hirose, H.; Wu, X.;
Kawaguchi, N.; et al. Mesothelial cells facilitate cancer stemlike properties in spheroids of ovarian cancer
cells. Oncol. Rep. 2018, 40, 2105–2114. [PubMed]
102. Ween, M.P.; Oehler, M.K.; Ricciardelli, C. Role of versican, hyaluronan and CD44 in ovarian cancer metastasis.
Int. J. Mol. Sci. 2011, 12, 1009–1029. [CrossRef] [PubMed]
103. Chen, C.; Zhao, S.; Karnad, A.; Freeman, J.W. The biology and role of CD44 in cancer progression: Therapeutic
implications. J. Hematol. Oncol. 2018, 11, 64. [CrossRef] [PubMed]
104. Cai, J.; Tang, H.; Xu, L.; Wang, X.; Yang, C.; Ruan, S.; Guo, J.; Hu, S.; Wang, Z. Fibroblasts in omentum
activated by tumor cells promote ovarian cancer growth, adhesion and invasiveness. Carcinogenesis 2012, 33,
20–29. [CrossRef] [PubMed]
105. Curtis, M.; Kenny, H.A.; Ashcroft, B.; Mukherjee, A.; Johnson, A.; Zhang, Y.; Helou, Y.; Batlle, R.; Liu, X.;
Gutierrez, N.; et al. Fibroblasts Mobilize Tumor Cell Glycogen to Promote Proliferation and Metastasis.
Cell MeTable 2018. [CrossRef] [PubMed]
106. Raptis, L.; Arulanandam, R.; Geletu, M.; Turkson, J. The R(h)oads to Stat3: Stat3 activation by the Rho
GTPases. Exp. Cell Res. 2011, 317, 1787–1795. [CrossRef] [PubMed]
107. Savant, S.S.; Sriramkumar, S.; O’Hagan, H.M. The Role of Inflammation and Inflammatory Mediators in the
Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. Cancers 2018, 10,
251. [CrossRef] [PubMed]
108. Lawson, C.D.; Burridge, K. The on-off relationship of Rho and Rac during integrin-mediated adhesion and
cell migration. Small GTPases 2014, 5, e27958. [CrossRef] [PubMed]
109. Pearce, O.M.T.; Delaine-Smith, R.M.; Maniati, E.; Nichols, S.; Wang, J.; Bohm, S.; Rajeeve, V.; Ullah, D.;
Chakravarty, P.; Jones, R.R.; et al. Deconstruction of a Metastatic Tumor Microenvironment Reveals a
Common Matrix Response in Human Cancers. Cancer Discov. 2018, 8, 304–319. [CrossRef] [PubMed]
110. Montfort, A.; Pearce, O.; Maniati, E.; Vincent, B.G.; Bixby, L.; Bohm, S.; Dowe, T.; Wilkes, E.H.; Chakravarty, P.;
Thompson, R.; et al. A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade
Serous Ovarian Metastases. Clin. Cancer Res. 2017, 23, 250–262. [CrossRef] [PubMed]
111. Flies, D.B.; Higuchi, T.; Harris, J.C.; Jha, V.; Gimotty, P.A.; Adams, S.F. Immune checkpoint blockade
reveals the stimulatory capacity of tumor-associated CD103(+) dendritic cells in late-stage ovarian cancer.
Oncoimmunology 2016, 5, e1185583. [CrossRef] [PubMed]
112. Higuchi, T.; Flies, D.B.; Marjon, N.A.; Mantia-Smaldone, G.; Ronner, L.; Gimotty, P.A.; Adams, S.F.
CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer.
Cancer Immunol. Res. 2015, 3, 1257–1268. [CrossRef] [PubMed]
121
Cancers 2018, 10, 358
113. Guo, Y.; Kenney, S.R.; Cook, L.; Adams, S.F.; Rutledge, T.; Romero, E.; Oprea, T.I.; Sklar, L.A.; Bedrick, E.;
Wiggins, C.L.; et al. A Novel Pharmacologic Activity of Ketorolac for Therapeutic Benefit in Ovarian Cancer
Patients. Clin. Cancer Res. 2015, 21, 5064–5072. [CrossRef] [PubMed]
114. Hodis, E.; Watson, I.R.; Kryukov, G.V.; Arold, S.T.; Imielinski, M.; Theurillat, J.P.; Nickerson, E.; Auclair, D.;
Li, L.; Place, C.; et al. A landscape of driver mutations in melanoma. Cell 2012, 150, 251–263. [CrossRef]
[PubMed]
115. Davis, M.J.; Ha, B.H.; Holman, E.C.; Halaban, R.; Schlessinger, J.; Boggon, T.J. RAC1P29S is a spontaneously
activating cancer-associated GTPase. Proc. Natl. Acad. Sci. USA 2013, 110, 912–917. [CrossRef] [PubMed]
116. Kumar, A.; Rajendran, V.; Sethumadhavan, R.; Purohit, R. Molecular dynamic simulation reveals damaging
impact of RAC1 F28L mutation in the switch I region. PLoS ONE 2013, 8, e77453. [CrossRef] [PubMed]
117. Chang, M.T.; Asthana, S.; Gao, S.P.; Lee, B.H.; Chapman, J.S.; Kandoth, C.; Gao, J.; Socci, N.D.; Solit, D.B.;
Olshen, A.B.; et al. Identifying recurrent mutations in cancer reveals widespread lineage diversity and
mutational specificity. Nat. Biotechnol. 2016, 34, 155–163. [CrossRef] [PubMed]
118. Gao, J.; Chang, M.T.; Johnsen, H.C.; Gao, S.P.; Sylvester, B.E.; Sumer, S.O.; Zhang, H.; Solit, D.B.; Taylor, B.S.;
Schultz, N.; et al. 3D clusters of somatic mutations in cancer reveal numerous rare mutations as functional
targets. Genome Med. 2017, 9, 4. [CrossRef] [PubMed]
119. Marei, H.; Malliri, A. GEFs: Dual regulation of Rac1 signaling. Small GTPases 2017, 8, 90–99. [CrossRef]
[PubMed]
120. Jordan, P.; Brazao, R.; Boavida, M.G.; Gespach, C.; Chastre, E. Cloning of a novel human Rac1b splice variant
with increased expression in colorectal tumors. Oncogene 1999, 18, 6835–6839. [CrossRef] [PubMed]
121. Schnelzer, A.; Prechtel, D.; Knaus, U.; Dehne, K.; Gerhard, M.; Graeff, H.; Harbeck, N.; Schmitt, M.; Lengyel, E.
Rac1 in human breast cancer: Overexpression, mutation analysis, and characterization of a new isoform,
Rac1b. Oncogene 2000, 19, 3013–3020. [CrossRef] [PubMed]
122. Singh, A.; Karnoub, A.E.; Palmby, T.R.; Lengyel, E.; Sondek, J.; Der, C.J. Rac1b, a tumor associated,
constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004, 23, 9369–9380.
[CrossRef] [PubMed]
123. Matos, P.; Jordan, P. Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression.
Exp. Cell Res. 2005, 305, 292–299. [CrossRef] [PubMed]
124. Radisky, D.C.; Levy, D.D.; Littlepage, L.E.; Liu, H.; Nelson, C.M.; Fata, J.E.; Leake, D.; Godden, E.L.;
Albertson, D.G.; Nieto, M.A.; et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and
genomic instability. Nature 2005, 436, 123–127. [CrossRef] [PubMed]
125. Orlichenko, L.; Geyer, R.; Yanagisawa, M.; Khauv, D.; Radisky, E.S.; Anastasiadis, P.Z.; Radisky, D.C. The
19-amino acid insertion in the tumor-associated splice isoform Rac1b confers specific binding to p120 catenin.
J. Biol. Chem. 2010, 285, 19153–19161. [CrossRef] [PubMed]
126. Silva, A.L.; Carmo, F.; Bugalho, M.J. RAC1b overexpression in papillary thyroid carcinoma: A role to unravel.
Eur. J. Endocrinol. Eur. Fed. Endocr. Soc. 2013, 168, 795–804. [CrossRef] [PubMed]
127. Zhou, C.; Licciulli, S.; Avila, J.L.; Cho, M.; Troutman, S.; Jiang, P.; Kossenkov, A.V.; Showe, L.C.; Liu, Q.;
Vachani, A.; et al. The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis. Oncogene 2013,
32, 903–909. [CrossRef] [PubMed]
128. Li, G.; Ying, L.; Wang, H.; Wei, S.S.; Chen, J.; Chen, Y.H.; Xu, W.P.; Jie, Q.Q.; Zhou, Q.; Li, Y.G.; et al.
Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways.
Oncotarget 2016, 7, 17970–17985. [CrossRef] [PubMed]
129. Fu, X.D. Both sides of the same coin: Rac1 splicing regulating by EGF signaling. Cell Res. 2017, 27, 455–456.
[CrossRef] [PubMed]
130. Wang, F.; Fu, X.; Chen, P.; Wu, P.; Fan, X.; Li, N.; Zhu, H.; Jia, T.T.; Ji, H.; Wang, Z.; et al. SPSB1-mediated
HnRNP A1 ubiquitylation regulates alternative splicing and cell migration in EGF signaling. Cell Res. 2017,
27, 540–558. [CrossRef] [PubMed]
131. Gao, J.; Aksoy, B.A.; Dogrusoz, U.; Dresdner, G.; Gross, B.; Sumer, S.O.; Sun, Y.; Jacobsen, A.; Sinha, R.;
Larsson, E.; et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal.
Sci. Signal. 2013, 6, pl1. [CrossRef] [PubMed]
132. Krauthammer, M.; Kong, Y.; Ha, B.H.; Evans, P.; Bacchiocchi, A.; McCusker, J.P.; Cheng, E.; Davis, M.J.;
Goh, G.; Choi, M.; et al. Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma.
Nat. Genet. 2012, 44, 1006–1014. [CrossRef] [PubMed]
122
Cancers 2018, 10, 358
133. DeLano, W.L. PyMOL: An Open-Source Molecular Graphics Tool; Delano Scientific: San Carlos, CA, USA, 2002.
134. Kawazu, M.; Ueno, T.; Kontani, K.; Ogita, Y.; Ando, M.; Fukumura, K.; Yamato, A.; Soda, M.;
Takeuchi, K.; Miki, Y.; et al. Transforming mutations of RAC guanosine triphosphatases in human cancers.
Proc. Natl. Acad. Sci. USA 2013, 110, 3029–3034. [CrossRef] [PubMed]
135. Watson, I.R.; Li, L.; Cabeceiras, P.K.; Mahdavi, M.; Gutschner, T.; Genovese, G.; Wang, G.; Fang, Z.;
Tepper, J.M.; Stemke-Hale, K.; et al. The RAC1 P29S hotspot mutation in melanoma confers resistance
to pharmacological inhibition of RAF. Cancer Res. 2014, 74, 4845–4852. [CrossRef] [PubMed]
136. Cheung, H.W.; Cowley, G.S.; Weir, B.A.; Boehm, J.S.; Rusin, S.; Scott, J.A.; East, A.; Ali, L.D.; Lizotte, P.H.;
Wong, T.C.; et al. Systematic investigation of genetic vulnerabilities across cancer cell lines reveals
lineage-specific dependencies in ovarian cancer. Proc. Natl. Acad. Sci. USA 2011, 108, 12372–12377.
[CrossRef] [PubMed]
137. Cowley, G.S.; Weir, B.A.; Vazquez, F.; Tamayo, P.; Scott, J.A.; Rusin, S.; East-Seletsky, A.; Ali, L.D.; Gerath, W.F.;
Pantel, S.E.; et al. Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification
of context-specific genetic dependencies. Sci. Data 2014, 1, 140035. [CrossRef] [PubMed]
138. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011,
474, 609–615. [CrossRef] [PubMed]
139. Vogelstein, B.; Papadopoulos, N.; Velculescu, V.E.; Zhou, S.; Diaz, L.A., Jr.; Kinzler, K.W. Cancer genome
landscapes. Science 2013, 339, 1546–1558. [CrossRef] [PubMed]
140. Zoughlami, Y.; van Stalborgh, A.M.; van Hennik, P.B.; Hordijk, P.L. Nucleophosmin1 is a negative regulator
of the small GTPase Rac1. PLoS ONE 2013, 8, e68477. [CrossRef] [PubMed]
141. Payapilly, A.; Malliri, A. Compartmentalisation of RAC1 signalling. Curr. Opin. Cell Biol. 2018, 54, 50–56.
[CrossRef] [PubMed]
142. Mettouchi, A.; Lemichez, E. Ubiquitylation of active Rac1 by the E3 ubiquitin-ligase HACE1. Small GTPases
2012, 3, 102–106. [CrossRef] [PubMed]
143. Szklarczyk, D.; Franceschini, A.; Wyder, S.; Forslund, K.; Heller, D.; Huerta-Cepas, J.; Simonovic, M.; Roth, A.;
Santos, A.; Tsafou, K.P.; et al. STRING v10: Protein-protein interaction networks, integrated over the tree of
life. Nucleic Acids Res. 2015, 43, D447–D452. [CrossRef] [PubMed]
144. Bamford, S.; Dawson, E.; Forbes, S.; Clements, J.; Pettett, R.; Dogan, A.; Flanagan, A.; Teague, J.; Futreal, P.A.;
Stratton, M.R.; et al. The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website.
Br. J. Cancer 2004, 91, 355–358. [CrossRef] [PubMed]
145. Chakravarty, D.; Gao, J.; Phillips, S.M.; Kundra, R.; Zhang, H.; Wang, J.; Rudolph, J.E.; Yaeger, R.; Soumerai, T.;
Nissan, M.H.; et al. OncoKB: A Precision Oncology Knowledge Base. JCO Precis. Oncol. 2017, 2017.
[CrossRef] [PubMed]
146. Armenia, J.; Wankowicz, S.A.M.; Liu, D.; Gao, J.; Kundra, R.; Reznik, E.; Chatila, W.K.; Chakravarty, D.;
Han, G.C.; Coleman, I.; et al. The long tail of oncogenic drivers in prostate cancer. Nat. Genet. 2018, 50,
645–651. [CrossRef] [PubMed]
147. Futreal, P.A.; Coin, L.; Marshall, M.; Down, T.; Hubbard, T.; Wooster, R.; Rahman, N.; Stratton, M.R. A census
of human cancer genes. Nat. Rev. Cancer 2004, 4, 177–183. [CrossRef] [PubMed]
148. Ryan, M.B.; Finn, A.J.; Pedone, K.H.; Thomas, N.E.; Der, C.J.; Cox, A.D. ERK/MAPK Signaling Drives
Overexpression of the Rac-GEF, PREX1, in BRAF- and NRAS-Mutant Melanoma. Mol. Cancer Res. MCR
2016, 14, 1009–1018. [CrossRef] [PubMed]
149. Misek, S.A.; Chen, J.; Schroeder, L.; Rattanasinchai, C.; Sample, A.; Sarkaria, J.N.; Gallo, K.A. EGFR Signals
through a DOCK180-MLK3 Axis to Drive Glioblastoma Cell Invasion. Mol. Cancer Res. MCR 2017, 15,
1085–1095. [CrossRef] [PubMed]
150. Lissanu Deribe, Y.; Shi, Y.; Rai, K.; Nezi, L.; Amin, S.B.; Wu, C.C.; Akdemir, K.C.; Mahdavi, M.; Peng, Q.;
Chang, Q.E.; et al. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation
in NRAS-mutant melanoma. Proc. Natl. Acad. Sci. USA 2016, 113, E1296–E1305. [CrossRef] [PubMed]
151. Earp, M.; Tyrer, J.P.; Winham, S.J.; Lin, H.Y.; Chornokur, G.; Dennis, J.; Aben, K.K.H.; Anton-Culver, H.;
Antonenkova, N.; Bandera, E.V.; et al. Variants in genes encoding small GTPases and association with
epithelial ovarian cancer susceptibility. PLoS ONE 2018, 13, e0197561. [CrossRef] [PubMed]
152. Winkler, S.; Mohl, M.; Wieland, T.; Lutz, S. GrinchGEF—A novel Rho-specific guanine nucleotide exchange
factor. Biochem. Biophys. Res. Commun. 2005, 335, 1280–1286. [CrossRef] [PubMed]
123
Cancers 2018, 10, 358
153. Zoughlami, Y.; Voermans, C.; Brussen, K.; van Dort, K.A.; Kootstra, N.A.; Maussang, D.; Smit, M.J.;
Hordijk, P.L.; van Hennik, P.B. Regulation of CXCR4 conformation by the small GTPase Rac1: Implications
for HIV infection. Blood 2012, 119, 2024–2032. [CrossRef] [PubMed]
154. Han, S.; Kim, D.; Kim, Y.; Choi, K.; Miller, J.E.; Kim, D.; Lee, Y. CAS-viewer: Web-based tool for
splicing-guided integrative analysis of multi-omics cancer data. BMC Med Genom. 2018, 11, 25. [CrossRef]
[PubMed]
155. Yang, I.S.; Son, H.; Kim, S.; Kim, S. ISOexpresso: A web-based platform for isoform-level expression analysis
in human cancer. BMC Genom. 2016, 17, 631. [CrossRef] [PubMed]
156. Mehner, C.; Miller, E.; Khauv, D.; Nassar, A.; Oberg, A.L.; Bamlet, W.R.; Zhang, L.; Waldmann, J.; Radisky, E.S.;
Crawford, H.C.; et al. Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote
pancreatic adenocarcinoma. Mol. Cancer Res. MCR 2014, 12, 1430–1439. [CrossRef] [PubMed]
157. Mehner, C.; Miller, E.; Nassar, A.; Bamlet, W.R.; Radisky, E.S.; Radisky, D.C. Tumor cell expression of MMP3
as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma. Genes Cancer
2015, 6, 480–489. [PubMed]
158. Stallings-Mann, M.L.; Waldmann, J.; Zhang, Y.; Miller, E.; Gauthier, M.L.; Visscher, D.W.; Downey, G.P.;
Radisky, E.S.; Fields, A.P.; Radisky, D.C. Matrix metalloproteinase induction of Rac1b, a key effector of lung
cancer progression. Sci. Transl. Med. 2012, 4, 142ra195. [CrossRef] [PubMed]
159. Alonso-Espinaco, V.; Cuatrecasas, M.; Alonso, V.; Escudero, P.; Marmol, M.; Horndler, C.; Ortego, J.;
Gallego, R.; Codony-Servat, J.; Garcia-Albeniz, X.; et al. RAC1b overexpression correlates with poor
prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX
chemotherapy. Eur. J. Cancer 2014, 50, 1973–1981. [CrossRef] [PubMed]
160. Huff, L.P.; Decristo, M.J.; Trembath, D.; Kuan, P.F.; Yim, M.; Liu, J.; Cook, D.R.; Miller, C.R.; Der, C.J.; Cox, A.D.
The Role of Ect2 Nuclear RhoGEF Activity in Ovarian Cancer Cell Transformation. Genes Cancer 2013, 4,
460–475. [CrossRef] [PubMed]
161. Lin, Y.; Zheng, Y. Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin. Drug Discov.
2015, 10, 991–1010. [CrossRef] [PubMed]
162. Pajic, M.; Herrmann, D.; Vennin, C.; Conway, J.R.; Chin, V.T.; Johnsson, A.K.; Welch, H.C.; Timpson, P. The
dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment.
Small GTPases 2015, 6, 123–133. [CrossRef] [PubMed]
163. Smithers, C.C.; Overduin, M. Structural Mechanisms and Drug Discovery Prospects of Rho GTPases. Cells
2016, 5, 26. [CrossRef] [PubMed]
164. Nassar, N.; Cancelas, J.; Zheng, J.; Williams, D.A.; Zheng, Y. Structure-function based design of small
molecule inhibitors targeting Rho family GTPases. Curr. Top. Med. Chem. 2006, 6, 1109–1116. [CrossRef]
[PubMed]
165. Dharmawardhane, S.; Hernandez, E.; Vlaar, C. Development of EHop-016: A small molecule inhibitor of
Rac. Enzymes 2013, 33 Pt A, 117–146.
166. Shutes, A.; Onesto, C.; Picard, V.; Leblond, B.; Schweighoffer, F.; Der, C.J. Specificity and mechanism of
action of EHT 1864, a novel small molecule inhibitor of Rac family small GTPases. J. Biol. Chem. 2007, 282,
35666–35678. [CrossRef] [PubMed]
167. Hong, L.; Kenney, S.R.; Phillips, G.K.; Simpson, D.; Schroeder, C.E.; Noth, J.; Romero, E.; Swanson, S.;
Waller, A.; Strouse, J.J.; et al. Characterization of a Cdc42 protein inhibitor and its use as a molecular probe.
J. Biol. Chem. 2013, 288, 8531–8543. [CrossRef] [PubMed]
168. Forget, P.; Bentin, C.; Machiels, J.P.; Berliere, M.; Coulie, P.G.; De Kock, M. Intraoperative use of ketorolac
or diclofenac is associated with improved disease-free survival and overall survival in conservative breast
cancer surgery. Br. J. Anaesth. 2014. [CrossRef] [PubMed]
169. Retsky, M.; Demicheli, R.; Hrushesky, W.J.; Forget, P.; De Kock, M.; Gukas, I.; Rogers, R.A.;
Baum, M.; Sukhatme, V.; Vaidya, J.S. Reduction of breast cancer relapses with perioperative non-steroidal
anti-inflammatory drugs: New findings and a review. Curr. Med. Chem. 2013, 20, 4163–4176. [CrossRef]
[PubMed]
170. Forget, P.; Vandenhende, J.; Berliere, M.; Machiels, J.P.; Nussbaum, B.; Legrand, C.; De Kock, M. Do
intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
Anesth. Analg. 2010, 110, 1630–1635. [CrossRef] [PubMed]
124
Cancers 2018, 10, 358
171. Bowtell, D.D.; Bohm, S.; Ahmed, A.A.; Aspuria, P.J.; Bast, R.C., Jr.; Beral, V.; Berek, J.S.; Birrer, M.J.; Blagden, S.;
Bookman, M.A.; et al. Rethinking ovarian cancer II: Reducing mortality from high-grade serous ovarian
cancer. Nat. Rev. Cancer 2015, 15, 668–679. [CrossRef] [PubMed]
172. Lengyel, E. Ovarian cancer development and metastasis. Am. J. Pathol. 2010, 177, 1053–1064. [CrossRef]
[PubMed]
173. Deng, K.; Yang, C.; Tan, Q.; Song, W.; Lu, M.; Zhao, W.; Lou, G.; Li, Z.; Li, K.; Hou, Y. Sites of distant
metastases and overall survival in ovarian cancer: A study of 1481 patients. Gynecol. Oncol. 2018, 150,
460–465. [CrossRef] [PubMed]
174. Obermayr, E.; Bednarz-Knoll, N.; Orsetti, B.; Weier, H.U.; Lambrechts, S.; Castillo-Tong, D.C.; Reinthaller, A.;
Braicu, E.I.; Mahner, S.; Sehouli, J.; et al. Circulating tumor cells: Potential markers of minimal residual
disease in ovarian cancer? a study of the OVCAD consortium. Oncotarget 2017, 8, 106415–106428. [CrossRef]
[PubMed]
175. Zhang, X.; Li, H.; Yu, X.; Li, S.; Lei, Z.; Li, C.; Zhang, Q.; Han, Q.; Li, Y.; Zhang, K.; et al. Analysis of
Circulating Tumor Cells in Ovarian Cancer and Their Clinical Value as a Biomarker. Cell. Physiol. Biochem.
Int. J. Exp. Cell. Physiol. Biochem. Pharmacol. 2018, 48, 1983–1994. [CrossRef] [PubMed]
176. Keyver-Paik, M.D.; Arden, J.M.; Luders, C.; Thiesler, T.; Abramian, A.; Hoeller, T.; Hecking, T.; Ayub, T.H.;
Doeser, A.; Kaiser, C.; et al. Impact of Chemotherapy on Retroperitoneal Lymph Nodes in Ovarian Cancer.
Anticancer Res. 2016, 36, 1815–1824. [PubMed]
177. Hjerpe, E.; Staf, C.; Dahm-Kahler, P.; Stalberg, K.; Bjurberg, M.; Holmberg, E.; Borgfeldt, C.; Tholander, B.;
Hellman, K.; Kjolhede, P.; et al. Lymph node metastases as only qualifier for stage IV serous ovarian cancer
confers longer survival than other sites of distant disease—A Swedish Gynecologic Cancer Group (SweGCG)
study. Acta Oncol. 2018, 57, 331–337. [CrossRef] [PubMed]
178. Sehouli, J.; Olschewski, J.; Schotters, V.; Fotopoulou, C.; Pietzner, K. Prognostic role of early versus late onset
of bone metastasis in patients with carcinoma of the ovary, peritoneum and fallopian tube. Ann. Oncol. 2013,
24, 3024–3028. [CrossRef] [PubMed]
179. Chebouti, I.; Blassl, C.; Wimberger, P.; Neubauer, H.; Fehm, T.; Kimmig, R.; Kasimir-Bauer, S. Analysis of
disseminated tumor cells before and after platinum based chemotherapy in primary ovarian cancer. Do stem
cell like cells predict prognosis? Oncotarget 2016. [CrossRef] [PubMed]
180. Pantel, K.; Alix-Panabieres, C. Bone marrow as a reservoir for disseminated tumor cells: A special source for
liquid biopsy in cancer patients. BoneKEy Rep. 2014, 3, 584. [CrossRef] [PubMed]
181. Banys, M.; Solomayer, E.F.; Becker, S.; Krawczyk, N.; Gardanis, K.; Staebler, A.; Neubauer, H.; Wallwiener, D.;
Fehm, T. Disseminated tumor cells in bone marrow may affect prognosis of patients with gynecologic
malignancies. Int. J. Gynecol. Cancer 2009, 19, 948–952. [CrossRef] [PubMed]
182. Wimberger, P.; Heubner, M.; Otterbach, F.; Fehm, T.; Kimmig, R.; Kasimir-Bauer, S. Influence of
platinum-based chemotherapy on disseminated tumor cells in blood and bone marrow of patients with
ovarian cancer. Gynecol. Oncol. 2007, 107, 331–338. [CrossRef] [PubMed]
183. Wimberger, P.; Roth, C.; Pantel, K.; Kasimir-Bauer, S.; Kimmig, R.; Schwarzenbach, H. Impact of
platinum-based chemotherapy on circulating nucleic acid levels, protease activities in blood and
disseminated tumor cells in bone marrow of ovarian cancer patients. Int. J. Cancer 2011, 128, 2572–2580.
[CrossRef] [PubMed]
184. Gunjal, P.M.; Schneider, G.; Ismail, A.A.; Kakar, S.S.; Kucia, M.; Ratajczak, M.Z. Evidence for induction of a
tumor metastasis-receptive microenvironment for ovarian cancer cells in bone marrow and other organs
as an unwanted and underestimated side effect of chemotherapy/radiotherapy. J. Ovarian Res. 2015, 8, 20.
[CrossRef] [PubMed]
185. Sharma, M.; Afrin, F.; Satija, N.; Tripathi, R.P.; Gangenahalli, G.U. Stromal-derived factor-1/CXCR4 signaling:
Indispensable role in homing and engraftment of hematopoietic stem cells in bone marrow. Stem Cells Dev.
2011, 20, 933–946. [CrossRef] [PubMed]
186. Gupta, N.; Duda, D.G. Role of stromal cell-derived factor 1alpha pathway in bone metastatic prostate cancer.
J. Biomed. Res. 2016, 30, 181–185. [PubMed]
187. Lapidot, T.; Kollet, O. The essential roles of the chemokine SDF-1 and its receptor CXCR4 in human stem cell
homing and repopulation of transplanted immune-deficient NOD/SCID and NOD/SCID/B2m(null) mice.
Leukemia 2002, 16, 1992–2003. [CrossRef] [PubMed]
125
Cancers 2018, 10, 358
188. Peled, A.; Petit, I.; Kollet, O.; Magid, M.; Ponomaryov, T.; Byk, T.; Nagler, A.; Ben-Hur, H.; Many, A.; Shultz, L.;
et al. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science
1999, 283, 845–848. [CrossRef] [PubMed]
189. Price, T.T.; Burness, M.L.; Sivan, A.; Warner, M.J.; Cheng, R.; Lee, C.H.; Olivere, L.; Comatas, K.; Magnani, J.;
Kim Lyerly, H.; et al. Dormant breast cancer micrometastases reside in specific bone marrow niches that
regulate their transit to and from bone. Sci. Transl. Med. 2016, 8, 340ra373. [CrossRef] [PubMed]
190. Liu, C.F.; Liu, S.Y.; Min, X.Y.; Ji, Y.Y.; Wang, N.; Liu, D.; Ma, N.; Li, Z.F.; Li, K. The prognostic value of CXCR4
in ovarian cancer: A meta-analysis. PLoS ONE 2014, 9, e92629. [CrossRef] [PubMed]
191. Guo, Q.; Gao, B.L.; Zhang, X.J.; Liu, G.C.; Xu, F.; Fan, Q.Y.; Zhang, S.J.; Yang, B.; Wu, X.H. CXCL12-CXCR4
Axis Promotes Proliferation, Migration, Invasion, and Metastasis of Ovarian Cancer. Oncol. Res. 2015, 22,
247–258. [CrossRef] [PubMed]
192. Li, J.; Jiang, K.; Qiu, X.; Li, M.; Hao, Q.; Wei, L.; Zhang, W.; Chen, B.; Xin, X. Overexpression of CXCR4
is significantly associated with cisplatin-based chemotherapy resistance and can be a prognostic factor in
epithelial ovarian cancer. BMB Rep. 2014, 47, 33–38. [CrossRef] [PubMed]
193. Kajiyama, H.; Shibata, K.; Terauchi, M.; Ino, K.; Nawa, A.; Kikkawa, F. Involvement of SDF-1alpha/CXCR4
axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int. J. Cancer 2008, 122, 91–99.
[CrossRef] [PubMed]
194. Figueras, A.; Alsina-Sanchis, E.; Lahiguera, A.; Abreu, M.; Muinelo-Romay, L.; Moreno-Bueno, G.;
Casanovas, O.; Graupera, M.; Matias-Guiu, X.; Vidal, A.; et al. A Role for CXCR4 in Peritoneal and
Hematogenous Ovarian Cancer Dissemination. Mol. Cancer Ther. 2018, 17, 532–543. [CrossRef] [PubMed]
195. Guo, L.; Cui, Z.M.; Zhang, J.; Huang, Y. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate
with lymph node metastasis in epithelial ovarian carcinoma. Chin. J. Cancer 2011, 30, 336–343. [CrossRef]
[PubMed]
196. Arnaud, M.P.; Vallee, A.; Robert, G.; Bonneau, J.; Leroy, C.; Varin-Blank, N.; Rio, A.G.; Troadec, M.B.;
Galibert, M.D.; Gandemer, V. CD9, a key actor in the dissemination of lymphoblastic leukemia, modulating
CXCR4-mediated migration via RAC1 signaling. Blood 2015, 126, 1802–1812. [CrossRef] [PubMed]
197. Mao, T.L.; Fan, K.F.; Liu, C.L. Targeting the CXCR4/CXCL12 axis in treating epithelial ovarian cancer.
Gene Ther. 2017, 24, 621–629. [CrossRef] [PubMed]
198. Ray, P.; Lewin, S.A.; Mihalko, L.A.; Schmidt, B.T.; Luker, K.E.; Luker, G.D. Noninvasive imaging reveals
inhibition of ovarian cancer by targeting CXCL12-CXCR4. Neoplasia 2011, 13, 1152–1161. [CrossRef]
[PubMed]
199. Righi, E.; Kashiwagi, S.; Yuan, J.; Santosuosso, M.; Leblanc, P.; Ingraham, R.; Forbes, B.; Edelblute, B.;
Collette, B.; Xing, D.; et al. CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong
survival in an immunocompetent mouse model of ovarian cancer. Cancer Res. 2011, 71, 5522–5534. [CrossRef]
[PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




The Tumor Microenvironment of Epithelial Ovarian
Cancer and Its Influence on Response
to Immunotherapy
Galaxia M. Rodriguez 1,2, Kristianne J. C. Galpin 1,2, Curtis W. McCloskey 1,2
and Barbara C. Vanderhyden 1,2,*
1 Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road,
Ottawa, ON K1H 8L6, Canada; garodriguez@toh.ca (G.M.R.); kgalpin@ohri.ca (K.J.C.G.);
cmccloskey@ohri.ca (C.W.M.)
2 Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road,
Ottawa, ON K1H 8M5, Canada
* Correspondence: bvanderhyden@ohri.ca; Tel.: +1-613-737-7700 (ext. 70330)
Received: 23 June 2018; Accepted: 20 July 2018; Published: 24 July 2018
Abstract: Immunotherapy as a treatment for cancer is a growing field of endeavor but reports of
success have been limited for epithelial ovarian cancer. Overcoming the challenges to developing
more effective therapeutic approaches lies in a better understanding of the factors in cancer cells and
the surrounding tumor microenvironment that limit response to immunotherapies. This article
provides an overview of some ovarian cancer cell features such as tumor-associated antigens,
ovarian cancer-derived exosomes, tumor mutational burden and overexpression of immunoinhibitory
molecules. Moreover, we describe relevant cell types found in epithelial ovarian tumors including
immune cells (T and B lymphocytes, Tregs, NK cells, TAMs, MDSCs) and other components found in
the tumor microenvironment including fibroblasts and the adipocytes in the omentum. We focus on
how those components may influence responses to standard treatments or immunotherapies.
Keywords: epithelial ovarian cancer; tumor microenvironment; tumor infiltrating lymphocytes;
tumor-associated antigens; ascites; immunosuppression; prognostic factors; cancer-associated
fibroblasts; exosomes; adipocytes
1. Introduction
An increasing body of evidence strongly suggests that the immune system is able to identify,
control and eliminate nascent neoplastic cells in a process known as cancer immunosurveillance [1].
Epithelial ovarian cancers (EOCs) are “immunogenic tumors” that produce spontaneous antitumor
immune responses detectable in peripheral blood, tumors and ascites of patients [2–4]. The resulting
presence of tumor infiltrating lymphocytes (TILs) is associated with improved survival in EOC [5].
Unfortunately, there are a number of factors in the tumor microenvironment (TME) that can impair the
presence or activity of TILs, thereby facilitating cancer progression.
Various immunotherapeutic strategies are attempting to address the challenges posed by the
highly immunosuppressive EOC TME. Immunotherapies encompass many modalities, including
immune checkpoint blockade, antibody-based therapies, cancer vaccines, cytokines, adoptive
cell transfer, and chimeric antigen receptor-modified T cells [6]. However, emerging cancer
immunotherapies (blocking antibodies for checkpoint inhibitors) have shown low rates of responses in
EOC (reviewed in [2]). Improving this response rate is a major goal, which can only be achieved with a
better understanding of the elements in the TME that contribute to treatment failure. Immune cells are
the main players in the development of antitumor immunity or tumor progression, but there are also
Cancers 2018, 10, 242; doi:10.3390/cancers10080242 www.mdpi.com/journal/cancers127
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other components in the TME that should be taken into consideration when designing new therapeutic
strategies. Those components include EOC-derived exosomes, cancer-associated fibroblasts (CAFs)
and adipocytes residing in the omentum.
In this review we will describe those elements of the TME, how they influence the burden of the
tumor, the responses to therapies, and their relevance in designing cancer immunotherapies for EOC.
2. Cancer Cells and Tumor Antigens
The success of cancer immunotherapy hinges on the ability to generate cancer-specific antitumor
T-cell responses, to both recognize tumor-associated antigens (TAAs) and kill tumor cells, and to
generate memory responses. TAAs can be classified into different categories: tissue differentiation,
cancer testes antigens (CTAs), neoantigens derived from mutations, overexpressed cellular,
splice variant, glycolipid, and viral antigens [7,8]. Ideal TAAs for immunotherapy targets are
immunogenic and are expressed or overexpressed in tumor tissue, with restricted expression
in associated normal tissues, in a significant percentage of patients [9]. Positive responses to
immunotherapies such as immune checkpoint inhibitors [blocking programmed cell death protein
1 (PD-l), programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated antigen 4
(CTLA-4)], have been associated with high mutation/neoantigen burden [10,11]. The initial clinical
studies of small numbers of EOC patients treated with immune checkpoint inhibitors have resulted in
clinical benefits in less than 20% of patients (Table 1). Unfortunately, little is known about the TME at
the start of treatment in most studies, making it impossible to discern the factors that may have blocked
any response. The failure to respond could be related to the neoantigen burden in EOC, which may be
insufficient to generate a significant antitumoral response [12,13]. There are currently intense research
efforts to understand other TAAs (Table 2) recognized by TILs to design informed immunotherapy
targets (Table 3).
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2.1. Neoantigens
Ovarian cancer has been shown to harbor an intermediate neoantigen load by whole exome
sequencing/next generation sequencing [12,59]. Whole exome sequencing of tumor cells from ascites
samples of three high-grade serous ovarian cancer (HGSC) patients revealed a tumor mutation burden
(TMB) of approximately 20–40 mutations across all patients, however only 1/79 mutations (1.3%)
were recognized by autologous tumor-associated T cells [60]. Comprehensive genomic profiling of
ovarian cancer revealed low overall TMB among subtypes: HGSC (3.6), low-grade serous (LGSOC)
(2.7), endometrioid (2.7), mucinous (2.7), and clear cell (2.7). Only a small percentage of patients
had a significant TMB (20 or more mutations per Mb), meaning only a small percentage of patients
would be predicted to show favorable response to immune therapy [12]. Consequently, in clinical
trials of checkpoint inhibitors in EOC, CTLA-4 inhibitors (Ipilimumab), PD1 inhibitors (Nivolumab
and Pembrolizumab), and PD-L1 inhibitors (MS-936559 and Avelumab) had response rates of
5–20% [14,20,61] (Table 1). A notable exception is the highly aggressive small cell carcinoma of the
ovary, hypercalcemic type which, despite being a monogenic cancer, has responsiveness to anti-PD1
immunotherapy [62].
Neoantigen depletion [63], intratumoral heterogeneity, and clonal evolution of primary tumors
and metastases may influence immunosurveillance and response to immunotherapy [64,65]. Epithelial
T-cell rich tumors show the lowest amount of clonal diversity, neoantigen diversity and greatest loss of
human leukocyte antigen (HLA) expression, which suggests immunoediting in the TME. T-cell poor
tumors or “cold tumors” have a higher predicted and more diverse neoantigen load (unedited) [63].
2.2. Cancer Testes Antigens
CTAs are encoded by ~140 genes that are normally only expressed in germ cells (testes, placenta,
fetal ovary) and not normal somatic adult cells, but often highly expressed in tumors. This along with
their immunogenicity makes them significant targets for cancer immunotherapy [9,66,67]. Vaccination
with recombinant MAGE-A3 antigen has been used in Phase I/II clinical trials for melanoma [68] and
non-small-cell lung cancer (NSCLC) [69] with a good safety profile and observed humoral response,
but only slight effects on survival.
Several CTAs have been described in EOC (Table 2) and have been proposed as immunotherapy
targets (Table 3) based on their tissue specificity and high expression in a significant number of EOCs
of all subtypes. NY-ESO-1 (ESO157–165) specific CD8+ T cells were found in TILs of 71% of (10/14)
vaccination naïve seropositive patients, and ex vivo proliferation of NY-ESO-1 specific peripheral
blood lymphocytes in 65% of patients suggested that an adaptive immune response against this CTA
can be achieved [70,71]. Clinical trials have subsequently tested the feasibility of generating NY-ESO-1
specific immune responses (Table 3). These approaches have generated humoral and CD4+ and
CD8+ antigen specific T-cell responses, and in some cases, long lasting/complete responses [44–47].
NY-ESO-1 was not expressed in some recurrent tumors, raising the possibility of immune escape [44].
Furthermore, NY-ESO-1 reactive CD8+ T cells often express higher levels of inhibitory molecules
lymphocyte-activation gene 3 (LAG3), PD-1 and CTLA-4, suggesting immunosuppression as a reason
for lack of complete response during clinical trials [71].
Many characteristics of CTA epitopes and all TAAs such as (i) immunogenicity; (ii) restriction
to HLA-I or -II; (iii) natural processing; (iv) expression; and (v) role in tumor progression remain
to be elucidated and require validation in larger sample sizes. While the expression of CTAs does
not often correlate with improved survival, their tissue specificity makes CTAs attractive targets
for immunotherapies (Table 3) such as peptide vaccines [44,70], antigen-loaded dendritic cell (DC)
vaccines [72], or oncolytic viral platforms, and for combined interventions with immune checkpoint
inhibitors [73] or chemotherapy [74], in order to overcome tumor escape mechanisms.
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2.3. Other TAAs
Genetic and epigenetic aberrations in cancer cells, resulting from mutations, amplifications or
deletions in genes, provide both therapeutic targets and potential TAAs for immunotherapy design
(Table 2). However, the greatest hurdles still remain in designing immunotherapeutic targets for
a disease in which such aberrations, with the exception of p53 mutation (95% of HGSC [33,75]),
are relatively uncommon (<20% frequency in HGSC cases) and lack antigen specificity to the tumor.
Immunogenic oncogenes p53, Her2-neu and WT1 are broadly overexpressed in EOC, particularly
HGSC, and targeted immunotherapies have been explored in clinical trials (Table 3). Other common
but infrequent amplifications, mutations or deletions occur in CCNE1, NF1, PTEN, KRAS, RB,
CDK2NA, PIK3CA and AKT1/2 and provide potential therapeutic targets for EOC immunotherapy [33].
The DCs, T-cells, and peptide-based vaccine strategies against proteins described above have largely
demonstrated immunological responses including CD4+ and CD8+ T-cell responses in preliminary
clinical trials following vaccination, but often in the absence of clinical responses. This is perhaps
due to widespread immunosuppression in the TME preventing T-cell activation and proliferation,
as well as tumor heterogeneity and immunogenicity that impede proper TAA presentation to the
immune cells.
The EOC immunopeptidome was profiled by isolating HLA molecules primarily from HGSC
tumors and which were analyzed by mass spectrometry [57]. The analysis identified relevant proteins
including CRABP1/2, FOLR1, and KLK10 presented on major histocompatibility complex (MHC)
I molecules, and mesothelin, PTPRS and UBB presented on MHC-II molecules [57]. The most
abundantly detected protein presented on MHC-I molecules was MUC16 (CA-125), with 113
different peptides expressed in approximately 80% of patients. MUC16-derived peptides were
highly immunogenic (85% T-cell responses in vitro), and consequently it was proposed as the top
candidate for targeted immunotherapy moving forward [57]. Although CA-125 is immunogenic,
the large number of trials with a monoclonal antibody targeting CA-125 (Table 3) have been mostly
unsuccessful as a monotherapy [76]. This failure could be explained by the weak magnitude of the
immune response generated, the loss of expression or down-regulation of CA-125 on EOC cells to
avoid immune recognition, or the overgrowth of CA-125(-) EOC cells as a consequence of cancer
immunoediting process.
A single TAA is generally only expressed in a subset of patients, making the design of a universal
immunotherapy challenging. The main barrier of targeting a single TAA is cancer immunoediting,
which enables the enrichment of neoplastic cells in tumors that do not express the targeted TAA over
time. Chimeric antigen receptor T (CAR-T) cells provides the option of combining multiple antigen
specificities, and delivering direct cytokine stimulation (GM-CSF, IL-12) to the TME, irrespective of the
MHC status of the patient [8].
2.4. Tumor Immunogenicity and Other Immunoinhibitory Molecules
Loss of immunogenicity is an immune hallmark of cancer that is exploited by tumors to evade
immune recognition. This can be triggered by down-regulation or loss of expression of MHC-I and -II,
and the antigen processing and presentation machinery (APM) [77–80]. Expression of MHC-I genes is
altered by 60–90%, depending on the cancer type. These impairments reduce the antigens presented on
the cell surface leading to decreased or lack of recognition and elimination by cytotoxic T lymphocytes.
The mechanisms that are related to immune cell infiltration in EOC are dependent on MHC-I
and -II status [3,81]. The presence of neoantigen-reactive T cells in patients with EOC can improve
survival [82]. However, as mentioned before, since ovarian tumors possess intermediate/low
mutation burdens, the incidence of naturally processed and presented neoantigens generating a
significant antitumoral response is very low [13]. The expression of APM components and the
presence of intratumoral T-cell infiltrates were significantly associated with improved survival [81].
Han. et al. demonstrated that the majority of ovarian carcinomas analyzed had either heterogeneous
or positive expression of peptide transporter 1 (TAP1), TAP2, HLA class I heavy chain, and beta-2
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microglobulin [81]. Concurrent expression of HLA-DR and CA-125 on cancer cells correlated with
higher frequency of CD8+ TILs and increased survival [83]. Similarly, tumor cell expression of
HLA-DMB was associated with increased numbers of CD8+ TILs and both were associated with
improved survival in advanced-stage serous EOC [84]. The regulation of APM components and MHC
molecules in human cancers is a significant area of research but is beyond the scope of this review
(reviewed in [85,86]).
The mutational profile of EOC can also predict immunogenicity. Tumors with deficient
homologous recombination (HR) machinery occur with a frequency of up to 50% [33]. These include
mutations in BRCA1/BRCA2 (20% frequency) or non-BRCA HR deficiencies (Fanconi anemia genes,
restriction site associated DNA genes, and DNA damage response genes) [33]. HR deficient tumors
have higher predicted neoantigen load, and infiltrating and peritumoral lymphocytes in these
tumors have increased PD-1/PD-L1 expression [43], which may enhance susceptibility to immune
checkpoint therapy. BRCA1/2 mutated HGSC tumors have more CD3+ and CD8+ TILs compared to
HR-proficient tumors, a signature associated with higher overall survival [43,87]. p53 mutations
are also associated with higher levels of TILs [87,88]. Non-HR deficient tumors therefore have
poorer overall survival [43] and may be less immunogenic, making them more difficult to target
with immunotherapies. Alternative strategies and TAAs to target this group of EOC tumors need
further investigation.
The expression of immunoinhibitory molecules on cancer cells, including PD-L1 and Indoleamine
2,3-dioxygenase (IDO) are associated with patient prognosis. Higher expression of PD-L1 on tumor
cells correlates with poorer prognosis, suggesting that the PD-1/PD-L pathway can be a good target for
restoring antitumor immunity in EOC [89,90], although others have suggested that high PD-1/PD-L1
expression in primary tumors may be associated with a favorable progression-free survival [91,92].
Increased infiltration of CD8+ T cells is associated with high PD-L1 expression likely as a result of an
adaptive response where infiltrating CD8+ T cells secrete interferon gamma (IFNγ) that subsequently
induces PD-L1 expression on cancer cells. This in turn inhibits T-cell activation and proliferation,
preventing successful targeting and clearance of the tumor. Immune checkpoint inhibitors (anti-PD-L1
and PD-1) have been FDA approved for melanoma and NSCLC, but only a small percentage (10–33%)
of ovarian cancers express PD-L1 [61,92,93], thus only a small percentage of patients may respond
to anti-PD-L1 immunotherapy (Table 1). The enzyme IDO is often overexpressed by cancer cells,
but is also produced by DCs and macrophages [94,95] in the TME. IDO catabolizes tryptophan,
which leads to cell cycle arrest or apoptosis in NK and CD4 T cells [96], and skewed differentiation
of regulatory T cells (Tregs) induced by plasmacytoid DCs, leading to immunosuppression in the
TME [97]. Positive staining for IDO, observed in 24–57% of patient samples, is associated with poor
prognosis of HGSC, decreased CD8+ TILs, as well as resistance to chemotherapy [98,99]. Targeting
IDO with inhibitors may improve outcome [100,101].
3. Immune Cells
Most solid tumors are infiltrated by myeloid- and lymphoid lineage-derived immune cells that
are differentially distributed within the TME with a crucial role in the establishment of antitumoral
responses or tumor progression [1]. Growing tumor cells release “danger signals” that enable the
recruitment of immune cells into the tumor niche. TILs such as CD4+ and CD8+ T cells, B lymphocytes,
Natural Killer (NK)-T cells, as well as innate immune cells such as NK cells, macrophages and DCs,
are then recruited in order to eliminate nascent neoplastic cells, acting as an extrinsic tumor suppression
mechanism [102]. However, immunosurveillance promotes the selection of poorly immunogenic cancer
cells through cancer immunoediting where neoplastic cells that resist the elimination phase can persist
in equilibrium with effector CD4+ and CD8+ T cells under a pro-inflammatory milieu. Over time,
cancer cells with the most immunoevasive characteristics are selected, enabling them to eventually
escape immune attack [102]. Finally, immunoedited tumors become clinically apparent with variants
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that trigger the establishment of an immunosuppressive TME containing immunosuppressive immune
cells such as myeloid-derived suppressor cells (MDSCs), Tregs, and others [2,103].
3.1. Immune Modulators and Adaptive Immune Cells in the Ovarian Cancer TME
3.1.1. TILs
TILs can localize into the tumor islet (intraepithelial) and in the peritumoral space (stromal) [2].
Several studies have shown a positive correlation between the presence of intraepithelial TILs and
tumor regression in many solid cancers [4,5,104–107]. T cells can be found in primary tumor tissue
and omental metastases [4,104,105,107–111] and their presence has been correlated with positive
prognosis. Dadmarz et al. demonstrated that TILs isolated from EOC patients (primary tumor,
metastases or ascites) were tumor-specific and could recognize autologous TAAs. Antitumoral
responses were mainly characterized by the secretion of tumor necrosis factor-alpha (TNFα) and
granulocyte macrophage-colony stimulating factor (GM-CSF) when stimulated with autologous
tumor [112]. Later, Zhang and colleagues showed that intraepithelial CD3+ TILs can be found in
>50% of advanced-stage EOC with their presence correlating with a five-year overall survival rate of
38% in contrast to 4.5% in patients whose tumors contained no T cells [5]. Even after debulking and
platinum-based chemotherapy, the presence of intraepithelial CD3+ TILs increased the five-year overall
survival rate (>70%) in comparison to patients whose tumors contained no T cells in islets (11%) [5].
T cell-rich tumors correlated with delayed recurrence or death and were associated with increased
expression of Interleukin-2 (IL-2), IFNγ and lymphocyte-attracting chemokines within the tumor such
as CXCL9 [113], CCL21, and CCL22 [5]. Conversely, tumors with no T cells in islets were associated
with an increased level of vascular endothelial growth factor (VEGF), an angiogenic regulatory factor
in the TME associated with early recurrence and short survival [5]. A more recent study showed
that intratumoral accumulation of CXCR3 ligands such as CXCL9 and CXCL10, predicts survival in
advanced HGSC [113] (Figure 1). This study also identified the cyclooxygenase (COX) metabolite
Prostaglandin E2 as a negative regulator of chemokine secretion that contributes to tumor progression
by impeding TILs recruitment in ovarian cancer [113]. Further investigation showed that expression
of both COX-1 and COX-2 were negatively correlated with intraepithelial CD8+ TILs as well as with
EOC patient survival [114].
While some studies have reported that the presence of both intraepithelial CD3+ and CD8+
T-cells correlates with improved disease-specific survival for EOC patients [81,87] others have shown
that this beneficial characteristic is attributed to intraepithelial CD8+ TILs [4,104,105,107–110,115].
No association was found for CD3+ TILs or other subtypes of intraepithelial or stromal TILs in
EOC overall patient survival. Interestingly, the subgroups displaying high versus low intraepithelial
CD8+/CD4+ TIL ratios had favorable survival prognosis (median = 58 versus 23 months) [106].
This was due to the unfavorable effect of CD4+ CD25+ forkhead box P3+ (FOXP3) Tregs [88,104,106]
that will be discussed later.
In 2012, a meta-analysis of ten studies with 1815 ovarian cancer patients confirmed the
prognostic value of intraepithelial CD8+ TILs in EOC specimens regardless of the tumor grade,
stage, or histologic subtype studied [111]. Their presence suggests that spontaneously activated
antitumoral responses are present in the tumor niche to control tumor outgrowth [111] as observed
by the presence of tumor-reactive antibodies and T cells found in the peripheral blood of advanced
stage EOC patients [116–118], and oligoclonal tumor-reactive T cells isolated from blood, ascites or
tumors [88,119–123]. Conversely, the lack of intraepithelial TILs is significantly associated with poor
survival among EOC patients [111]. Thus, immunotherapies aiming to increase the effector functions
of pre-existing antitumoral CD8+ TILs and triggering effector T cell-trafficking to the TME are the holy
grail of cancer immunotherapy.
CD4+ T cells as well as CD8+ T cells can specifically recognize TAAs from malignant cells. CD4+
T helper (Th) cells provide cytokine support for CD8+ T-cell proliferation and expansion to eliminate
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cancer cells and trigger antitumoral responses. In an analysis of ovarian tumors, Tsiatas et al. found
that a high percentage of CD4+ CD25hi cells and activated CD4+ T cells were significantly associated
with improved median overall survival [124]. Two other studies also showed a positive correlation of
the high frequency of CD4+ TILs and EOC patient survival [110,125]. Nesbeth et al., using an animal
model for EOC, found that tumor-primed CD4+ T cells produce high levels of CCL5 that enables the
recruitment and activation of DCs to the TME. Mature DCs were then able to prime tumor-specific
CD8+ T cells and confer long-term protection [126]. Hence, immunotherapies stimulating both effector
CD4+ and CD8+ T cells could confer synergistic antitumoral responses.
 
Figure 1. Antitumoral responses in the EOC TME. Immunogenic cell death induces the release of
DAMPs mediating the recruitment of innate cells and APCs. Lympho-attracting chemokines produced
by APCs such as macrophages enable the recruitment of CD8+ T cells to the tumor niche. DCs are also
attracted by the production of CCL5 derived from NK cells and CD4+ T cells. The pro-inflammatory
milieu enables TAA sampling and presentation by APCs to T cells to induce their activation and
expansion. Pro-inflammatory cytokines released by activated effector T cells, M1 macrophages and
DCs allow the amplification of the antitumoral response, enabling the cytolytic death of EOC targeted
by CD8+ TILs and NK cells. B cells also participate in antitumor immunity by presenting TAAs to CD8+
T cells, by facilitating Th1 polarization, T-cell expansion and by producing tumor specific antibodies.
Danger-associated molecular patterns (DAMPs), Antigen presenting cells (APCs), tumor-associated
antigens (TAAs), dendritic cells (DCs), natural killer cells (NKs), CD4+ T helper cell (Th1).
3.1.2. Regulatory T lymphocytes
Tregs negatively regulate antitumoral responses in both a direct and indirect manner, highlighting
that Tregs are a fundamental means of tumor immune evasion [127,128]. In healthy tissues,
Tregs mediate tolerance by suppressing autoreactive T cells to protect and prevent excessive tissue
destruction. Since most TAAs are composed by self-peptides, Tregs are often found in tumors to
dampen antitumoral responses. Tregs accumulate and are more frequently present in tumors, with a
shift in the median ratio of Tregs to TILs from 3–8% in healthy tissue to 18–25% in all analyzed cancers,
including EOC [129]. Curiel et al. analyzed 104 EOC specimens and found that CD4+ CD25+ FOXP3+
Tregs specifically suppress antitumoral T cells in vivo, contributing to tumor growth. In addition,
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their presence correlates with poor patient outcome [130]. CD4+ Tregs preferentially migrated
to tumor and ascites and were rarely found in draining lymph nodes at later cancer stages [131].
Immunotherapies impeding Treg trafficking could release the TME immunosuppression and promote
the development of antitumoral responses.
FOXP3+ Tregs express minimal levels of effector cytokines and granzyme B, but are able to induce
inhibitory activities through IL-10 and transforming growth factor beta (TGF-β) production [132] and
cell–cell interactions [127] (Figure 2). Barnett et al. showed that EOC tumors highly infiltrated by Tregs
were associated with poor survival, advanced stage and suboptimal debulking [109]. Investigation of
the influence of cytoreduction on the immune system of primary and recurrent EOC found that the
ratio of CD4/CD8 is increased in primary but not in recurrent tumors [133]. Primary cytoreduction
increased circulating effector CD4+ and CD8+ T cells, but circulating CD4+ Tregs were decreased as
well as IL-10 serum levels, but not TGFβ and IL-6 [133]. CD4+ Tregs were also decreased after chemical
debulking in patients treated with neoadjuvant chemotherapy. The reduction of the systemic and TME
immunosuppression triggered by surgical debulking resulted in an increased capacity of CD8+ T cells
to respond to the recall antigens, but not in patients who were previously subjected to chemotherapy
or affected by recurrent EOC [133].
Fialová and colleagues studied the dynamics of the tumor-infiltrating immune cells during
different stages of EOC [134]. Early stage disease displayed a strong Th17 immune response while
stage II patients had responses characterized by the recruitment of Th1 cells. Disseminated disease
(stages III and IV) were characterized by high amounts of Tregs, tumor-associated macrophages
(TAMs), DCs, and high levels of CCL22, which is secreted by tumor cells, TAMs and DCs to enable
further recruitment of Tregs and immunosuppression [134]. Other studies have shown the importance
of the TME in facilitating the establishment of tolerance and recruitment of Tregs to sustain tumor
growth. Using EOC cell lines in vitro, Facciabene et al. found that tumor hypoxia induces the
expression of chemokine ligands such as CCL28, enabling the recruitment of Tregs and triggering
angiogenesis [135]. CCL28 overexpression was associated with a poor outcome in patients with
EOC [135]. Similarly, CCL22 production by TAMs enabled the recruitment of Tregs [130,134] that
induced B7-H4 on antigen-presenting cells including macrophages [136]. CXCR3+ Tregs, able to
control type-I T-cell responses, are highly enriched in EOC and represent the majority of Tregs [137].
These Tregs were able to suppress T-cell proliferation and IFNγ secretion [137].
An interesting study analyzed 22 EOC ascites specimens and found significantly elevated levels
of IL-6, IL-8, IL-10, IL-15, IP-10, MCP-1, MIP-1β and VEGF and significantly reduced levels of
IL-2, IL-5, IL-7, IL-17, PDGF-BB, and CCL5 compared to plasma. Moreover, T cells derived from
EOC-associated ascites displayed poor responsiveness when expanded in vitro [138]. The authors
claimed that this non-responsiveness could be explained by a high CD4/CD8 ratio that may indicate the
presence of Tregs, reduced IL-2 and elevated IL-6 and IL-10 levels triggering a Th2 inhibitory immune
response [138]. This high CD4/CD8 ratio was also associated with poor outcome [109,115,136,139],
consistent with other studies [124,140,141]. In contrast, a positive correlation between Tregs and
patient prognosis has been reported [140]. High tumor grade correlated with higher frequencies of
CD3+, CD68+ CD163+ TAMs, and CD25+ FOXP3+ Treg cells, but Treg frequencies were significant
predictors of favorable prognosis in patients with familial ovarian cancer (11/73 patients with BRCA
mutation) [140]. The presence of FOXP3+ TILs may be linked to positive prognostic factors in optimally
debulked HGSC patients [141]. Nevertheless, this disease-specific survival was positively associated
along with other TIL markers such as CD8, CD3, TIA-1, CD20 (a B cell surface marker), MHC class I
and class II [141].
CD8+ Tregs are also found in EOC [142,143]. They regulate the immunosuppressive TME by
limiting immunosurveillance mechanisms and contributing to cancer progression [144]. Recently,
Zhang and colleagues showed that CD8+ Tregs are found in the stroma and intraepithelial areas of
EOC tumors [143]. CD8+ Tregs are characterized by the expression of FOXP3, CTLA-4, and CD25,
but decreased expression of CD28 [143]. CD8+ Tregs were able to convert effector CD8+ T cells
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into suppressor cells [143]. CD8+ Tregs exert their suppressive function through the secretion of
TGF-β1 [142].
Overall, Tregs are considered a critical barrier against antitumoral responses along with
tolerance-inducing plasmacytoid DCs, B7-H4+ TAMs, MDSCs, IL-10, TGFβ, and VEGF. All these
processes act in concert as a tumor evasion mechanism resulting in tumor progression [145]. Barriers
to antitumoral responses are summarized in Figure 2.
 
Figure 2. Tumor promoting network in the EOC TME. Outgrowth of EOC provokes hypoxia that
induces the expression of chemokines to recruit MDSCs, Tregs, and TAMs. Tregs induce B7-H4
expression on APCs, subsequently blocking cytokine secretion, cytolytic activity, T-cell proliferation
and promoting an immunosuppressive TME. EOC cells and MDSCs produce IDO that catabolizes
tryptophan, rendering T cells anergic and dysfunctional. MDSCs and TAMs contribute to tumor growth,
malignancy, metastasis and stemness. Several tumor promoting cytokines such as IL-6, IL-10 and TGFβ
are prominent in the TME. VEGF released by EOC cells and CAFs stimulates angiogenic factors in
the TME. CAFs also secrete many factors that mediate tumor cell migration, proliferation, invasion
and chemoresistance, and contribute to the immunosuppressive TME. Adipocytes produce FA and
cytokines that fuel tumor growth and omental metastasis. Myeloid-derived suppressor cells (MDSCs),
tumor-associated macrophages (TAMs), regulatory T cells (Tregs), cancer-associated fibroblasts (CAFs),
fatty acids (FA).
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3.1.3. B Lymphocytes
B lymphocytes have been reported to have pivotal roles in cancer immunity [146]. Stromal or
intraepithelial B lymphocytes have been found in EOC [141]; however their function in tumor
development is not yet clear. Their presence is proposed to be associated with a good prognosis
depending on the tumor stage and the TME where they are found [4,108,141]. The presence of B
cells and CD8+ TILs correlates with increased patient survival compared to CD8+ TILs alone [108].
Nielsen et al. analyzed tumor and serum specimens obtained from patients with HGSC and found that
the majority of CD20+ TILs were antigen experienced and suggested to accomplish TAA presentation in
the TME since they often co-localized with CD8+ TILs and expressed markers such as MHC-I, MHC-II,
CD40, CD80, and CD86 [108]. B cells can achieve antitumor immunity by secreting IFNγ, facilitating
CD4+ Th cells to polarize to Th1 responses, and promote T-cell expansion by presenting TAAs [146].
Recently, the positive role of B cells among TILs at metastatic sites from patients with HGSC was
reported [147]. B cells were often found in the stroma of metastases and were characterized by a strong
memory response against TAAs by production of tumor-specific IgGs (Figure 1). Interestingly, these
responses were amplified by chemotherapy [147].
Conversely, a new subset of B cells, regulatory B cells (Bregs), has been recently designated as
immunosuppressive cells able to secrete anti-inflammatory mediators such as IL-10, IL-35, and TGF-β,
triggering T-cell conversion to Tregs [148] (Figure 2). Indeed, a study that analyzed EOC tumor
tissue and omental metastases found that high B cell infiltration negatively correlates with patient
survival [149]. High CD20 and CD138 expression correlated with high tumor grade [149]. Analysis of
omental specimens from patients with HGSC found that overall survival was 160.6 months in patients
with low B-cell expression vs. 47.3 months in those with high B-cell expression, associating increased
B-cell infiltration with poorer survival [150]. Similarly, the analysis of post-chemotherapy effusions
from ovarian carcinomas revealed that a higher percentage of CD19+ cells (B cell marker) and stage IV
disease predicted poor survival for patients [151].
Taken together, it is important to consider that several B-cell subsets with different phenotypes
and functions exist, and they may have various roles in modifying the ability of tumors to respond
to treatment [146]. Thus, a deep characterization of B-cell subpopulations within the TILs, ascites,
and peripheral blood at different stages is crucial in order to provide a better understanding of the
capability, importance and therapeutic potential of these cells in EOC.
3.1.4. NK-T Lymphocytes
NK-T cells possess dual-functional capability: as T-cell subsets with a T-cell receptor
(TCR)-mediated specific cytotoxicity and as NK cells with acquired killer functions [152,153]. NK-T
cells have been found in increased frequencies in EOC tumor ascites compared to blood, but they were
decreased at higher tumor grade and in cases of platinum resistance [154]. Moreover, the presence of
NK-T cells was inversely correlated with VEGF ascites levels [155]. Since these cells display the most
potent cytotoxicity profile, they might be promising agents for adoptive cell immunotherapy [156].
Further studies are needed to better understand the potential antitumoral capacity of these cells and
their role in the different EOC TMEs.
3.2. Innate Immune Cells in the Ovarian Cancer TME
3.2.1. NK Cells
Many studies have reported the presence of innate immune cells such as NKs, macrophages
and DCs playing important roles in EOC tumorigenesis [103,124,154]. NK cells are crucial
effectors in cancer immunosurveillance, recognizing and spontaneously killing virus-infected cells,
cancer, and foreign cells hazardous to the host [157]. NK cells mediate antitumoral responses by
secreting pro-inflammatory cytokines and chemokines such as IFNγ, TNF, IL-6, GM-CSF and CCL5,
which influence antitumor activity and promote innate and adaptive responses in the TME [157–159]
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(Figure 1). Tsiatas et al. analyzed 45 fresh specimens from different EOC and found an increased
amount of CD56+ NK and NK-T cells along with activated CD4+ and CD8+ CD25+ T cells in serous
and endometrioid carcinomas compared with mucinous and clear cell carcinomas [124]. Despite
the high concentration of NKs found in ascites compared to peripheral blood, they are functionally
impaired [121,160,161]. The influence of infiltrating NK cells on patient outcome is also debated.
Analysis of ovarian carcinoma effusions showed that the presence of NK cells at an advanced stage (IV)
predicted worse overall survival [151]. However, a positive antitumoral role for NK cells along with
effector CD8+ T cells has been reported [162], and NK cell activity of peripheral blood lymphocytes
was related to a significant progression-free survival of EOC patients [163]. Importantly, NK cells
are activated or not, according to the balance between inhibitory and activating signals through
different NK receptors [157]. Like many other cancers, EOC tumors express NK cell receptor ligand
ULBP2, which is an indicator of poor prognosis and could promote T-cell dysfunction in the TME [164]
(Figure 2). Since NK cells are important players in antitumoral immunity, more studies aiding to
characterize their function, phenotypes, incidence and role in the EOC TME are needed to provide
new rational for immunotherapies.
3.2.2. Tumor-Associated Macrophages
Both TAMs and MDSCs constitute up to 20% of the EOC TME and are known to maintain and
promote an immunosuppressive TME [103] (Figure 2). TAMs are considered the most abundant
infiltrating immune cells in EOC tissue and ascites [165,166]. They possess an immunosuppressive M2
phenotype characterized by the expression of CD163, CD204, CD206, and IL-10 [165], and their presence
correlates with tumor progression [140,167]. M2 TAMs secrete colony-stimulating factor 1 (CSF-1) that
has been found in high levels in malignant EOC [167], and contributes to tumor growth, invasion,
and metastasis. Moreover, EOC cells are able to induce an M2 TAM phenotype [168]. TAMs produce
the chemokine CCL22 enabling the trafficking of Tregs to the ovarian tumors [130]. EOC cells as well
as TAMs are known to express the coinhibitory molecule B7-H4 [169], a member of the B7 family
that has a profound inhibitory effect on the growth, cytokine secretion, and development of T-cell
cytotoxicity [169]. B7-H4+ TAMs are able to suppress antitumoral responses in EOC [136]. A study
of 103 EOC patients showed that enhanced B7-H4 expression in macrophages correlated with Treg
cell numbers in the tumor [136]. Tregs and B7-H4+ TAMs were associated with poor patient outcome.
Tregs in the TME can induce B7-H4+ TAMs to produce IL-10 and IL-6 [136], further supporting
an immunosuppressive milieu. Higher tumor grade correlated with higher frequencies of CD163+
TAMs [140] and worse progression-free survival [170,171]. Importantly, two studies evaluating M1-
(HLA-DR, iNOS) and M2-polarization (CD163, VEGF) markers showed that higher M1/M2 TAMs
ratio in tumors was associated with a favorable overall survival [172,173], and high serum levels
of CD163 predicts poor EOC patient prognosis [174]. In addition, monocyte-derived macrophages
in EOC displayed an altered morphology and defective antitumoral functions including defective
antibody-dependent cell-mediated cytotoxicity and phagocytosis [175]. Thus, EOC cells and the TME
provoke and maintain a strong immunosuppressive M2 phenotype supportive of tumor progression.
Immunotherapeutic approaches aiming to switch TAM phenotypes [176] could help the evolution of
antitumoral responses and improve patient outcome.
3.2.3. Myeloid-Derived Suppressor Cells
MDSCs are composed of a heterogeneous population of immature myeloid cells that arise in
pathologic conditions such as cancer, inflammation and infection, and possess a potent capacity to
dampen T-cell responses [177]. MDSCs are considered key inducers of tumor immune evasion and
impaired immunity by upregulating arginase-1, nitric oxide, and reactive oxygen species, and by
generating reactive nitrogen species [178] (Figure 2). MDSCs also deplete cysteine, induce Tregs,
inhibit T-cell activation and proliferation, attenuate the cytolytic ability of NK cells, and trigger a M2
phenotype [103]. Obermajer et al. showed that the frequencies of CD11b+ CD14+ CD33+ CXCR4+
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MDSCs in EOC ascites correlated with CXCL12 and prostaglandin E(2) levels [179]. MDSCs derived
from EOC patients also increased gene expression of cancer stem cells, sphere formation and metastasis
of EOC [180]. Wu et al. characterized typical monocytic CD14+ HLA-DR-/lo MDSCs in peripheral blood
and ascites derived from EOC patients and found that MDSCs are enriched in both compartments [181].
Moreover, the density of MDSCs correlated with poor patient prognosis and elevated levels of
IL-6 and IL-10 [181,182]. VEGF expression in EOC induced MDSCs recruitment, inhibiting local
immunity [182]. A recent study with mouse EOC cells found that Snai1, a major transcription factor
that induces epithelial-mesenchymal transition (EMT), mediates EOC progression by upregulating
CXCR2 ligands, enabling the recruitment of MDSCs [183]. EOC cells also attracts myeloid cells
by producing adenosine [184]. Hence, strategies targeting MDSCs could release the brakes against
antitumoral responses. Metformin, a drug used to treat type 2 diabetes, may trigger EOC clinical
benefit by improving antitumoral T-cell responses that are impeded by MDSCs in the TME, since this
drug can block MDSC suppressor functions by decreasing CD39 and CD73 expression [185].
4. Exosomes
Highly proliferating cells such as cancer cells produce large amounts of exosomes which are small
(40–100 nm) extracellular vesicles [186]. EOC tumor-derived exosomes carry cell membrane proteins
and cargo proteins that could be used for diagnostics (EP-CAM) and immunotherapeutic targeting
such as neoantigens and TAAs (Her2-neu, CA-125) [186], proteins (TGF-β1) [187], and miRNAs
(miR-21) [188] that are involved in disease progression, metastasis, and chemoresistance [186],
as well as immunomodulatory proteins (FAS-L) [189]. Exosomes can be taken up by other cancer
cells, CAFs, and immune cells, therefore playing an important role in intercellular communication.
Thus far, 2035 exosome cargo molecules have been identified from EOC cells in ExoCarta, a database for
exosome cargo [190,191]. Exosomes derived from human patient ascites promotes tumor progression
in vivo [189,192], and are proposed to have direct and indirect roles in modulating the immune
TME, as exosomes could also be taken up by NKs and B cells [192] (Figure 2). In other disease
models, such as melanoma and colorectal cancer, exosomes mediate immunosuppression and immune
tolerance by suppressing the activation of T and NK cells, monocytes, modulating T-cell inhibitory
molecules expression, and inducing CD8+ T-cell apoptosis [193,194]. FAS-L and TRAIL expression
on EOC-derived exosomes inhibit activation of peripheral blood mononuclear cells by DCs through
induction of apoptosis [189]. EOC-derived exosomes express ligands (MICA/B and ULBP1-3) for the
NK receptor NKG2D, acting as a decoy and interfering with NK-mediated targeting of tumor cells [195].
Greater understanding of the complex network of the intercellular communication between EOC
cells, CAFs, and immune cells is needed for the rational design of immunotherapeutic interventions,
or leveraged for nanomedicine applications such as TAA loaded-DC-derived exosomes [196] and drug
delivery systems [186].
5. Cancer-Associated Fibroblasts
CAFs are activated fibroblasts that express α-smooth muscle actin and fibroblast activation
protein. They make up 7–85% [197] of the tumor and are the primary stromal cell type in the TME.
Cross-talk between epithelial and stromal compartments creates a positive feedback loop, a supportive
hyper-activated storm of cytokines, chemokines, angiogenetic factors, and EMT-promoting factors,
to promote tumor progression and chemoresistance (Figure 2). CAFs from ovarian cancer patients
secrete high levels of hepatocyte growth factor (HGF) that promotes cancer cell proliferation,
chemoresistance, invasion, and migration though constitutive activation of cMet/PI3K/Akt pathways
and glucose-regulated protein 78 (GRP78) [198,199]. CAFs produce pro-inflammatory cytokines COX-2
and CXCL1 [200], CCL5 [201], CXCL11 [202], and IL-6 [203], which can promote proliferation and
EMT. In addition to their direct actions on cancer cells, CAFs also produce exosomes with high levels
of TGF-β1 that subsequently activates normal fibroblasts [187]. Interestingly, Givel et al. identified
four CAFs subsets in HGSC, finding an accumulation of one subset, CAF-S1, in the mesenchymal
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molecular subtype of HGSC. CAF-S1 is associated with an immunosuppressive TME, due to its high
levels of expression of CXCL12β, which recruits Tregs to the tumor. The CAF-S1 cells also express
CD73, B7-H3 and IL-6, which subsequently promote survival and proliferation of Tregs [204]. Thus,
CAFs can make major contributions to the creation of an immunosuppressive TME.
On the other hand, EOC cells can stimulate the activation of CAFs by producing high levels
of interleukin-1β (IL-1β) [205] and TGF-β [206], which subsequently induces secretion of IL-8,
IL-6, IL-1β, VEGF, and growth regulated oncogene-alpha (GRO-α) by CAFs to promote tumor
progression [205]. EOC cells release exosomes not only to activate tumor cells, but also to reprogram
normal fibroblasts into CAFs [207]. Furthermore, CAFs act on endothelial cells via the secretion of
VEGF-C [208] or by upregulating genes such as lipoma-preferred partner, to promote angiogenesis,
which leads to tumor progression and chemoresistance [209]. Cross-talk between CAFs and cancer
cells, as well as endothelial cells and immune cells, suggests that targeting signaling mechanisms in
this relationship may combat chemoresistance and immune modulation better than singly targeting
the epithelial compartment.
6. Adipocytes and the Omentum
The unique TME of the omentum, a large visceral fat pad that covers the bowel and abdomen
cavities [210,211], suggests a two-step model of omental metastasis and tumorigenesis where ovarian
cancer cells preferentially and rapidly home to “milky spots” [212] in the omentum, prior to spreading
throughout non-“milky spot” areas of the omentum and peritoneal cavity [213–217]. “Milky spots” are
highly vascularized regions with aggregates of immune cells, capable of innate and adaptive immune
functions, and antigen presentation similar to lymph node structures [212]. The involvement of the
omentum and adipose tissue suggests the need to develop intraperitoneal immunotherapy similar to
the advances seen with intraperitoneal chemotherapy.
Adipocytes in the omentum produce cytokines and chemokines, including highly secreted IL-6,
IL-8, MCP-1, tissue inhibitor of metalloproteinases-1 (TIMP-1) and adiponectin, to promote cancer
growth and omental metastases. Adipocytes can alter their lipid metabolism via Fatty acid–binding
protein 4 (FAB4) to undergo lipolysis providing fatty acids (FA) to cancer cells as a fuel source for rapid
tumor growth [216]. Cancer cells themselves can also alter lipid metabolism, often by upregulating FA
receptor CD36 [218] and FAB4 in omental metastases at the tumor/adipocyte interface to promote FA
and cholesterol uptake from adipocytes [216] to fuel tumor progression.
Many studies have suggested an association between obesity and the incidence of ovarian cancer
as well as an association with poor prognosis [219]. Indeed, in a murine model of ovarian cancer,
metastasis and tumor growth is supported in obese mice through altered regulation of FA pathway
and increased immunosuppression, demonstrated by a decreased ratio of M1/M2 macrophages [220]
(Figure 2). Improved understanding of how adipocytes and the omentum support ovarian cancer
growth and promote peritoneal metastases will reveal therapeutic targets for both conventional therapy
and immunotherapy. It will be important to consider how age and obesity [221–223] may dictate
differences in response to immunotherapy and how current models with young, lean mice may fail to
accurately model responses to immunotherapy.
7. Conclusions
In summary, in order to develop better immunotherapies for EOC we need to identify and consider
all key elements found in the TME of not only primary tumors but also in ascites and metastases
with a focus on how these features affect and are affected by different cancer therapies. It is crucial to
take into account the quality of the TME (immune-activating vs. immune-suppressing mechanisms),
tumor immunogenicity, tumor burden mutations, tumor stage, patient overall condition, and age,
as well as treatment effects on the TME (chemotherapy, neoadjuvant chemotherapy, surgery debulking).
Each of these factors may influence the outcome of EOC and the responses to cancer immunotherapies.
Moreover, to avoid tumor recurrence, EOC characteristics such as TAA presentation, expression of
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coinhibitory molecules, production of immunosuppressive cytokines and chemokines should all be
considered to find therapeutic combinations that could synergize and achieve maximal benefits to
eliminate EOC. Other articles in this special issue will address some of these topics, including the
exploration of promising immunotherapies for HGSC that are currently under investigation [224].
Author Contributions: All authors contributed to the research, writing, and editing of this review article.
Funding: The authors’ research relevant to this article is funded by grants to BCV from BioCanRx and the
Canadian Institutes of Health Research, as well as a fellowship from the Fonds de recherche du Québec—Santé
(GMR), and a Vanier Canada Graduate Scholarship (CM).
Acknowledgments: The authors are grateful for the donations and support from the local community of ovarian
cancer patients, especially the late Margaret Craig, and the Carol Annibale Ovarian Cancer Foundation.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Vesely, M.D.; Schreiber, R.D. Cancer immunoediting: Antigens, mechanisms, and implications to cancer
immunotherapy. Ann. N. Y. Acad. Sci. 2013, 1284, 1–5. [CrossRef] [PubMed]
2. Santoiemma, P.P.; Powell, D.J. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol. Ther. 2015, 16,
807–820. [CrossRef] [PubMed]
3. Santoiemma, P.P.; Reyes, C.; Wang, L.-P.; McLane, M.W.; Feldman, M.D.; Tanyi, J.L.; Powell, D.J. Systematic
evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol. Oncol. 2016,
143, 120–127. [CrossRef] [PubMed]
4. Stumpf, M.; Hasenburg, A.; Riener, M.-O.; Jütting, U.; Wang, C.; Shen, Y.; Orlowska-Volk, M.; Fisch, P.;
Wang, Z.; Gitsch, G.; et al. Intraepithelial CD8-positive T lymphocytes predict survival for patients with
serous stage III ovarian carcinomas: Relevance of clonal selection of T lymphocytes. Br. J. Cancer 2009, 101,
1513–1521. [CrossRef] [PubMed]
5. Zhang, L.; Conejo-Garcia, J.R.; Katsaros, D.; Gimotty, P.A.; Massobrio, M.; Regnani, G.; Makrigiannakis, A.;
Gray, H.; Schlienger, K.; Liebman, M.N.; et al. Intratumoral T cells, recurrence, and survival in epithelial
ovarian cancer. N. Engl. J. Med. 2003, 348, 203–213. [CrossRef] [PubMed]
6. Coukos, G.; Tanyi, J.; Kandalaft, L.E. Opportunities in immunotherapy of ovarian cancer. Ann. Oncol. Off. J.
Eur. Soc. Med. Oncol. 2016, 27 (Suppl. 1), i11–i15. [CrossRef] [PubMed]
7. Odunsi, K. Immunotherapy in ovarian cancer. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2017, 28, viii1–viii7.
[CrossRef] [PubMed]
8. Wang, R.-F.; Wang, H.Y. Immune targets and neoantigens for cancer immunotherapy and precision medicine.
Cell Res. 2017, 27, 11–37. [CrossRef] [PubMed]
9. Ilyas, S.; Yang, J.C. Landscape of Tumor Antigens in T-Cell Immunotherapy. J. Immunol. 2015, 195, 5117–5122.
[CrossRef] [PubMed]
10. Rizvi, N.A.; Hellmann, M.D.; Snyder, A.; Kvistborg, P.; Makarov, V.; Havel, J.J.; Lee, W.; Yuan, J.; Wong, P.;
Ho, T.S.; et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in
non-small cell lung cancer. Science 2015, 348, 124–128. [CrossRef] [PubMed]
11. Van Allen, E.M.; Miao, D.; Schilling, B.; Shukla, S.A.; Blank, C.; Zimmer, L.; Sucker, A.; Hillen, U.;
Foppen, M.H.G.; Goldinger, S.M.; et al. Genomic correlates of response to CTLA-4 blockade in metastatic
melanoma. Science 2015, 350, 207–211. [CrossRef] [PubMed]
12. Chalmers, Z.R.; Connelly, C.F.; Fabrizio, D.; Gay, L.; Ali, S.M.; Ennis, R.; Schrock, A.; Campbell, B.; Shlien, A.;
Chmielecki, J.; et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational
burden. Genome Med. 2017, 9, 34. [CrossRef] [PubMed]
13. Martin, S.D.; Brown, S.D.; Wick, D.A.; Nielsen, J.S.; Kroeger, D.R.; Twumasi-Boateng, K.; Holt, R.A.;
Nelson, B.H. Low mutation burden in ovarian cancer may limit the utility of neoantigen-targeted vaccines.
PLoS ONE 2016, 11, e0155189. [CrossRef] [PubMed]
14. Hamanishi, J.; Mandai, M.; Ikeda, T.; Minami, M.; Kawaguchi, A.; Murayama, T.; Kanai, M.; Mori, Y.;
Matsumoto, S.; Chikuma, S.; et al. Safety and antitumor activity of anti-PD-1 antibody, Nivolumab, in patients
with platinum-resistant Ovarian Cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2015, 33, 4015–4022.
[CrossRef] [PubMed]
143
Cancers 2018, 10, 242
15. Varga, A.; Piha-Paul, S.A.; Ott, P.A.; Mehnert, J.M.; Berton-Rigaud, D.; Johnson, E.A.; Cheng, J.D.; Yuan, S.;
Rubin, E.H.; Matei, D.E. Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive
advanced ovarian cancer: Interim results from a phase Ib study. J. Clin. Oncol. 2015, 33, 5510. [CrossRef]
16. Donahue, R.N.; Lepone, L.M.; Grenga, I.; Jochems, C.; Fantini, M.; Madan, R.A.; Heery, C.R.; Gulley, J.L.;
Schlom, J. Analyses of the peripheral immunome following multiple administrations of avelumab, a human
IgG1 anti-PD-L1 monoclonal antibody. J. Immunother. Cancer 2017, 5, 20. [CrossRef] [PubMed]
17. Disis, M.L.; Patel, M.R.; Pant, S.; Hamilton, E.P.; Lockhart, A.C.; Kelly, K.; Beck, J.T.; Gordon, M.S.; Weiss, G.J.;
Taylor, M.H.; et al. Avelumab (MSB0010718C; anti-PD-L1) in patients with recurrent/refractory ovarian cancer
from the JAVELIN Solid Tumor phase Ib trial: Safety and clinical activity. J. Clin. Oncol. 2016, 34, 5533. [CrossRef]
18. Brahmer, J.R.; Tykodi, S.S.; Chow, L.Q.M.; Hwu, W.-J.; Topalian, S.L.; Hwu, P.; Drake, C.G.; Camacho, L.H.;
Kauh, J.; Odunsi, K.; et al. Safety and activity of anti–PD-L1 antibody in patients with advanced cancer. N.
Engl. J. Med. 2012, 366, 2455–2465. [CrossRef] [PubMed]
19. Hodi, F.S.; Mihm, M.C.; Soiffer, R.J.; Haluska, F.G.; Butler, M.; Seiden, M.V.; Davis, T.; Henry-Spires, R.;
MacRae, S.; Willman, A.; et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody
blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad.
Sci. USA 2003, 100, 4712–4717. [CrossRef] [PubMed]
20. Hodi, F.S.; Butler, M.; Oble, D.A.; Seiden, M.V.; Haluska, F.G.; Kruse, A.; MacRae, S.; Nelson, M.; Canning, C.;
Lowy, I.; et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated
antigen 4 in previously vaccinated cancer patients. Proc. Natl. Acad. Sci. USA 2008, 105, 3005–3010.
[CrossRef] [PubMed]
21. Bellone, S.; Buza, N.; Choi, J.; Zammataro, L.; Gay, L.; Elvin, J.; Rimm, D.L.; Liu, Y.; Ratner, E.S.; Schwartz, P.E.;
et al. Exceptional response to Pembrolizumab in a metastatic, chemotherapy/radiation-resistant ovarian
cancer patient harboring a PD-L1-genetic rearrangement. Clin. Cancer Res. 2018. [CrossRef] [PubMed]
22. Huang, J.; Jochems, C.; Anderson, A.M.; Talaie, T.; Jales, A.; Madan, R.A.; Hodge, J.W.; Tsang, K.Y.;
Liewehr, D.J.; Steinberg, S.M.; et al. Soluble CD27-pool in humans may contribute to T cell activation
and tumor immunity. J. Immunol. 2013, 190, 6250–6258. [CrossRef] [PubMed]
23. Huang, J.; Jochems, C.; Talaie, T.; Anderson, A.; Jales, A.; Tsang, K.Y.; Madan, R.A.; Gulley, J.L.; Schlom, J.
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood 2012,
120, 3030–3038. [CrossRef] [PubMed]
24. Tammela, J.; Uenaka, A.; Ono, T.; Noguchi, Y.; Jungbluth, A.A.; Mhawech-Fauceglia, P.; Qian, F.; Schneider, S.;
Sharma, S.; Driscoll, D.; et al. OY-TES-1 expression and serum immunoreactivity in epithelial ovarian cancer.
Int. J. Oncol. 2006, 29, 903–910. [CrossRef] [PubMed]
25. Tammela, J.; Jungbluth, A.A.; Qian, F.; Santiago, D.; Scanlan, M.J.; Keitz, B.; Driscoll, D.; Rodabaugh, K.;
Lele, S.; Old, L.J.; et al. SCP-1 cancer/testis antigen is a prognostic indicator and a candidate target for
immunotherapy in epithelial ovarian cancer. Cancer Immun. 2004, 4, 10. [PubMed]
26. Garg, M.; Chaurasiya, D.; Rana, R.; Jagadish, N.; Kanojia, D.; Dudha, N.; Kamran, N.; Salhan, S.; Bhatnagar, A.;
Suri, S.; et al. Sperm-associated antigen 9, a novel cancer testis antigen, is a potential target for immunotherapy in
epithelial ovarian cancer. Clin. Cancer Res. 2007, 13, 1421–1428. [CrossRef] [PubMed]
27. Agarwal, S.; Saini, S.; Parashar, D.; Verma, A.; Sinha, A.; Jagadish, N.; Batra, A.; Suri, S.; Gupta, A.;
Ansari, A.S.; et al. The novel cancer-testis antigen A-kinase anchor protein 4 (AKAP4) is a potential target
for immunotherapy of ovarian serous carcinoma. Oncoimmunology 2013, 2. [CrossRef] [PubMed]
28. Odunsi, K.; Jungbluth, A.A.; Stockert, E.; Qian, F.; Gnjatic, S.; Tammela, J.; Intengan, M.; Beck, A.; Keitz, B.;
Santiago, D.; et al. NY-ESO-1 and LAGE-1 Cancer-Testis Antigens Are Potential Targets for Immunotherapy
in Epithelial Ovarian Cancer. Cancer Res. 2003, 63, 6076–6083. [PubMed]
29. Daudi, S.; Eng, K.H.; Mhawech-Fauceglia, P.; Morrison, C.; Miliotto, A.; Beck, A.; Matsuzaki, J.; Tsuji, T.;
Groman, A.; Gnjatic, S.; et al. Expression and immune responses to MAGE antigens predict survival in
epithelial ovarian cancer. PLoS ONE 2014, 9, e104099. [CrossRef] [PubMed]
30. Gillespie, A.M.; Rodgers, S.; Wilson, A.P.; Tidy, J.; Rees, R.C.; Coleman, R.E.; Murray, A.K. MAGE, BAGE and
GAGE: Tumour antigen expression in benign and malignant ovarian tissue. Br. J. Cancer 1998, 78, 816–821.
[CrossRef] [PubMed]
31. Yamada, A.; Kataoka, A.; Shichijo, S.; Kamura, T.; Imai, Y.; Nishida, T.; Itoh, K. Expression of MAGE-1,
MAGE-2, MAGE-3/-6 and MAGE-4A/-4B genes in ovarian tumors. Int. J. Cancer 1995, 64, 388–393.
[CrossRef] [PubMed]
144
Cancers 2018, 10, 242
32. Hardwick, N.; Chung, V.; Cristea, M.; Ellenhorn, J.D.; Diamond, D.J. Overcoming immunosuppression to
enhance a p53MVA vaccine. Oncoimmunology 2014, 3, e958949. [CrossRef] [PubMed]
33. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature
2011, 474, 609–615. [CrossRef]
34. Fajac, A.; Benard, J.; Lhomme, C.; Rey, A.; Duvillard, P.; Rochard, F.; Bernaudin, J.F.; Riou, G. c-erbB2 gene
amplification and protein expression in ovarian epithelial tumors: Evaluation of their respective prognostic
significance by multivariate analysis. Int. J. Cancer 1995, 64, 146–151. [CrossRef] [PubMed]
35. Ioannides, C.G.; Fisk, B.; Fan, D.; Biddison, W.E.; Wharton, J.T.; O’brian, C.A. Cytotoxic T cells isolated from
ovarian malignant ascites recognize a peptide derived from the HER-2/neu proto-oncogene. Cell. Immunol.
1993, 151, 225–234. [CrossRef] [PubMed]
36. Lanitis, E.; Dangaj, D.; Hagemann, I.S.; Song, D.-G.; Best, A.; Sandaltzopoulos, R.; Coukos, G.; Powell, D.J.
Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically-detectable levels.
PLoS ONE 2012, 7, e49829. [CrossRef] [PubMed]
37. Nielsen, J.S.; Jakobsen, E.; HOlund, B.; Bertelsen, K.; Jakobsen, A. Prognostic significance of p53, Her-2, and
EGFR overexpression in borderline and epithelial ovarian cancer. Int. J. Gynecol. Cancer 2004, 14, 1086–1096.
[CrossRef] [PubMed]
38. Netinatsunthorn, W.; Hanprasertpong, J.; Dechsukhum, C.; Leetanaporn, R.; Geater, A. WT1 gene expression
as a prognostic marker in advanced serous epithelial ovarian carcinoma: An immunohistochemical study.
BMC Cancer 2006, 6, 90. [CrossRef] [PubMed]
39. Sallum, L.F.; Andrade, L.; Ramalho, S.; Ferracini, A.C.; de Andrade Natal, R.; Brito, A.B.C.; Sarian, L.O.;
Derchain, S. WT1, p53 and p16 expression in the diagnosis of low- and high-grade serous ovarian carcinomas
and their relation to prognosis. Oncotarget 2018, 9, 15818–15827. [CrossRef] [PubMed]
40. Hassan, R.; Kreitman, R.J.; Pastan, I.; Willingham, M.C. Localization of mesothelin in epithelial ovarian
cancer. Appl. Immunohistochem. Mol. Morphol. AIMM 2005, 13, 243–247. [CrossRef] [PubMed]
41. Tanyi, J.L.; Haas, A.R.; Beatty, G.L.; Stashwick, C.J.; O’Hara, M.H.; Morgan, M.A.; Porter, D.L.; Melenhorst, J.J.;
Plesa, G.; Lacey, S.F.; et al. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial
ovarian cancer. J. Clin. Oncol. 2016, 34, 5511. [CrossRef]
42. Felder, M.; Kapur, A.; Gonzalez-Bosquet, J.; Horibata, S.; Heintz, J.; Albrecht, R.; Fass, L.; Kaur, J.; Hu, K.;
Shojaei, H.; et al. MUC16 (CA125): Tumor biomarker to cancer therapy, a work in progress. Mol. Cancer 2014,
13, 129. [CrossRef] [PubMed]
43. Strickland, K.C.; Howitt, B.E.; Shukla, S.A.; Rodig, S.; Ritterhouse, L.L.; Liu, J.F.; Garber, J.E.; Chowdhury, D.;
Wu, C.J.; D’Andrea, A.D.; et al. Association and prognostic significance of BRCA1/2-mutation status with
neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade
serous ovarian cancer. Oncotarget 2016, 7, 13587–13598. [CrossRef] [PubMed]
44. Odunsi, K.; Qian, F.; Matsuzaki, J.; Mhawech-Fauceglia, P.; Andrews, C.; Hoffman, E.W.; Pan, L.; Ritter, G.;
Villella, J.; Thomas, B.; et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces
integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 12837–12842.
[CrossRef] [PubMed]
45. Sabbatini, P.; Tsuji, T.; Ferran, L.; Ritter, E.; Sedrak, C.; Tuballes, K.; Jungbluth, A.A.; Ritter, G.; Aghajanian, C.;
Bell-McGuinn, K.; et al. Phase I trial of overlapping long peptides from a tumor self-antigen and poly-ICLC
shows rapid induction of integrated immune response in ovarian cancer patients. Clin. Cancer Res. 2012, 18,
6497–6508. [CrossRef] [PubMed]
46. Diefenbach, C.S.M.; Gnjatic, S.; Sabbatini, P.; Aghajanian, C.; Hensley, M.L.; Spriggs, D.R.; Iasonos, A.; Lee, H.;
Dupont, B.; Pezzulli, S.; et al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide
ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res.
2008, 14, 2740–2748. [CrossRef] [PubMed]
47. Odunsi, K.; Matsuzaki, J.; Karbach, J.; Neumann, A.; Mhawech-Fauceglia, P.; Miller, A.; Beck, A.;
Morrison, C.D.; Ritter, G.; Godoy, H.; et al. Efficacy of vaccination with recombinant vaccinia and fowlpox
vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc. Natl. Acad. Sci. USA
2012, 109, 5797–5802. [CrossRef] [PubMed]
145
Cancers 2018, 10, 242
48. Hardwick, N.R.; Frankel, P.; Ruel, C.; Kilpatrick, J.; Tsai, W.; Kos, F.; Kaltcheva, T.; Leong, L.;
Morgan, R.; Chung, V.; et al. p53-reactive T cells are associated with clinical benefit in patients
with platinum-resistant epithelial ovarian cancer after treatment with a p53 vaccine and Gemcitabine
chemotherapy. Clin. Cancer Res. 2018. [CrossRef] [PubMed]
49. Leffers, N.; Vermeij, R.; Hoogeboom, B.-N.; Schulze, U.R.; Wolf, R.; Hamming, I.E.; van der Zee, A.G.;
Melief, K.J.; van der Burg, S.H.; Daemen, T.; et al. Long-term clinical and immunological effects of p53-SLP®
vaccine in patients with ovarian cancer. Int. J. Cancer 2012, 130, 105–112. [CrossRef] [PubMed]
50. Coosemans, A.; Vanderstraeten, A.; Tuyaerts, S.; Verschuere, T.; Moerman, P.; Berneman, Z.; Vergote, I.;
Amant, F.; Gool, S.W.V. Immunological response after WT1 mRNA-loaded dendritic cell immunotherapy in
ovarian carcinoma and carcinosarcoma. Anticancer Res. 2013, 33, 3855–3859. [PubMed]
51. Miyatake, T.; Ueda, Y.; Morimoto, A.; Enomoto, T.; Nishida, S.; Shirakata, T.; Oka, Y.; Tsuboi, A.; Oji, Y.;
Hosen, N.; et al. WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional
therapies: A phase II trial. J. Cancer Res. Clin. Oncol. 2013, 139, 457–463. [CrossRef] [PubMed]
52. Sabbatini, P.; Harter, P.; Scambia, G.; Sehouli, J.; Meier, W.; Wimberger, P.; Baumann, K.H.; Kurzeder, C.;
Schmalfeldt, B.; Cibula, D.; et al. Abagovomab as maintenance therapy in patients with epithelial ovarian
cancer: A phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA study. J. Clin.
Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31, 1554–1561. [CrossRef] [PubMed]
53. Braly, P.; Nicodemus, C.F.; Chu, C.; Collins, Y.; Edwards, R.; Gordon, A.; McGuire, W.; Schoonmaker, C.;
Whiteside, T.; Smith, L.M.; et al. The immune adjuvant properties of front-line carboplatin-paclitaxel:
A randomized phase 2 study of alternative schedules of intravenous oregovomab chemoimmunotherapy in
advanced ovarian cancer. J. Immunother. 2009, 32, 54–65. [CrossRef] [PubMed]
54. Berek, J.; Taylor, P.; McGuire, W.; Smith, L.M.; Schultes, B.; Nicodemus, C.F. Oregovomab maintenance
monoimmunotherapy does not improve outcomes in advanced ovarian cancer. J. Clin. Oncol. Off. J. Am. Soc.
Clin. Oncol. 2009, 27, 418–425. [CrossRef] [PubMed]
55. Reinartz, S.; Köhler, S.; Schlebusch, H.; Krista, K.; Giffels, P.; Renke, K.; Huober, J.; Möbus, V.; Kreienberg, R.;
DuBois, A.; et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125:
Immunological response and survival (phase Ib/II). Clin. Cancer Res. 2004, 10, 1580–1587. [CrossRef] [PubMed]
56. Koneru, M.; O’Cearbhaill, R.; Pendharkar, S.; Spriggs, D.R.; Brentjens, R.J. A phase I clinical trial of adoptive
T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian
cancer. J. Transl. Med. 2015, 13, 102. [CrossRef] [PubMed]
57. Schuster, H.; Peper, J.K.; Bösmüller, H.-C.; Röhle, K.; Backert, L.; Bilich, T.; Ney, B.; Löffler, M.W.;
Kowalewski, D.J.; Trautwein, N.; et al. The immunopeptidomic landscape of ovarian carcinomas. Proc. Natl.
Acad. Sci. USA 2017, 114, E9942–E9951. [CrossRef] [PubMed]
58. Tanyi, J.L.; Bobisse, S.; Ophir, E.; Tuyaerts, S.; Roberti, A.; Genolet, R.; Baumgartner, P.; Stevenson, B.J.;
Iseli, C.; Dangaj, D.; et al. Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in
ovarian cancer. Sci. Transl. Med. 2018, 10, eaao5931. [CrossRef] [PubMed]
59. Alexandrov, L.B.; Nik-Zainal, S.; Wedge, D.C.; Aparicio, S.A.J.R.; Behjati, S.; Biankin, A.V.; Bignell, G.R.;
Bolli, N.; Borg, A.; Børresen-Dale, A.-L.; et al. Signatures of mutational processes in human cancer. Nature
2013, 500, 415–421. [CrossRef] [PubMed]
60. Wick, D.A.; Webb, J.R.; Nielsen, J.S.; Martin, S.D.; Kroeger, D.R.; Milne, K.; Castellarin, M.;
Twumasi-Boateng, K.; Watson, P.H.; Holt, R.A.; et al. Surveillance of the tumor mutanome by T cells during
progression from primary to recurrent ovarian cancer. Clin. Cancer Res. 2014, 20, 1125–1134. [CrossRef]
[PubMed]
61. Hamanishi, J.; Mandai, M.; Konishi, I. Immune checkpoint inhibition in ovarian cancer. Int. Immunol. 2016,
28, 339–348. [CrossRef] [PubMed]
62. Jelinic, P.; Ricca, J.; Van Oudenhove, E.; Olvera, N.; Merghoub, T.; Levine, D.A.; Zamarin, D. Immune-active
microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for immune
checkpoint blockade. JNCI J. Natl. Cancer Inst. 2018. [CrossRef] [PubMed]
63. Zhang, A.W.; McPherson, A.; Milne, K.; Kroeger, D.R.; Hamilton, P.T.; Miranda, A.; Funnell, T.; Little, N.;
de Souza, C.P.E.; Laan, S.; et al. Interfaces of malignant and immunologic clonal dynamics in ovarian cancer.
Cell 2018, 173, 1755–1769. [CrossRef] [PubMed]
64. McGranahan, N.; Swanton, C. Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell
2017, 168, 613–628. [CrossRef] [PubMed]
146
Cancers 2018, 10, 242
65. Bashashati, A.; Ha, G.; Tone, A.; Ding, J.; Prentice, L.M.; Roth, A.; Rosner, J.; Shumansky, K.; Kalloger, S.;
Senz, J.; et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed
through spatial mutational profiling. J. Pathol. 2013, 231, 21–34. [CrossRef] [PubMed]
66. Caballero, O.L.; Chen, Y.-T. Cancer/testis (CT) antigens: Potential targets for immunotherapy. Cancer Sci.
2009, 100, 2014–2021. [CrossRef] [PubMed]
67. Want, M.Y.; Lugade, A.A.; Battaglia, S.; Odunsi, K. Nature of tumor rejection antigens in ovarian cancer.
Immunology 2018. [CrossRef] [PubMed]
68. Grob, J.-J.; Mortier, L.; D’Hondt, L.; Grange, F.; Baurain, J.F.; Dréno, B.; Lebbe, C.; Robert, C.; Dompmartin, A.;
Neyns, B.; et al. Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in
patients with MAGE-A3-positive metastatic cutaneous melanoma: An open phase I/II study with a first
assessment of a predictive gene signature. ESMO Open 2017, 2, e000203. [CrossRef] [PubMed]
69. Vansteenkiste, J.; Zielinski, M.; Linder, A.; Dahabreh, J.; Gonzalez, E.E.; Malinowski, W.; Lopez-Brea, M.;
Vanakesa, T.; Jassem, J.; Kalofonos, H.; et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell
lung cancer: Phase II randomized study results. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2013, 31,
2396–2403. [CrossRef] [PubMed]
70. Matsuzaki, J.; Qian, F.; Luescher, I.; Lele, S.; Ritter, G.; Shrikant, P.A.; Gnjatic, S.; Old, L.J.; Odunsi, K.
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous
HLA class II T-helper region of NY-ESO-1. Cancer Immunol. Immunother. CII 2008, 57, 1185–1195. [CrossRef]
[PubMed]
71. Matsuzaki, J.; Gnjatic, S.; Mhawech-Fauceglia, P.; Beck, A.; Miller, A.; Tsuji, T.; Eppolito, C.; Qian, F.; Lele, S.;
Shrikant, P.; et al. Tumor-infiltrating NY-ESO-1–specific CD8+ T cells are negatively regulated by LAG-3 and
PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. USA 2010, 107, 7875–7880. [CrossRef] [PubMed]
72. Hanlon, D.J.; Aldo, P.B.; Devine, L.; Alvero, A.B.; Engberg, A.K.; Edelson, R.; Mor, G. Enhanced stimulation
of anti-ovarian cancer CD8(+) T cells by dendritic cells loaded with nanoparticle encapsulated tumor antigen.
Am. J. Reprod. Immunol. 2011, 65, 597–609. [CrossRef] [PubMed]
73. Xue, W.; Metheringham, R.L.; Brentville, V.A.; Gunn, B.; Symonds, P.; Yagita, H.; Ramage, J.M.; Durrant, L.G.
SCIB2, an antibody DNA vaccine encoding NY-ESO-1 epitopes, induces potent antitumor immunity which
is further enhanced by checkpoint blockade. Oncoimmunology 2016, 5, e1169353. [CrossRef] [PubMed]
74. Odunsi, K.; Matsuzaki, J.; James, S.R.; Mhawech-Fauceglia, P.; Tsuji, T.; Miller, A.; Zhang, W.; Akers, S.N.;
Griffiths, E.A.; Miliotto, A.; et al. Epigenetic potentiation of NY-ESO-1 vaccine therapy in human ovarian
cancer. Cancer Immunol. Res. 2014, 2, 37–49. [CrossRef] [PubMed]
75. Reid, B.M.; Permuth, J.B.; Sellers, T.A. Epidemiology of ovarian cancer: A review. Cancer Biol. Med. 2017, 14,
9–32. [CrossRef] [PubMed]
76. Leffers, N.; Daemen, T.; Helfrich, W.; Boezen, H.M.; Cohlen, B.J.; Melief, C.J.; Nijman, H.W. Antigen-specific
active immunotherapy for ovarian cancer. In The Cochrane Library; John Wiley & Sons, Ltd.: Hoboken, NJ,
USA, 2014.
77. Marincola, F.M.; Jaffee, E.M.; Hicklin, D.J.; Ferrone, S. Escape of human solid tumors from T-cell recognition:
Molecular mechanisms and functional significance. Adv. Immunol. 2000, 74, 181–273. [PubMed]
78. Campoli, M.; Chang, C.-C.; Ferrone, S. HLA class I antigen loss, tumor immune escape and immune selection.
Vaccine 2002, 20 (Suppl. 4), 40–45. [CrossRef]
79. Chang, C.-C.; Campoli, M.; Ferrone, S. Classical and nonclassical HLA class I antigen and NK Cell-activating
ligand changes in malignant cells: Current challenges and future directions. Adv. Cancer Res. 2005, 93,
189–234. [CrossRef] [PubMed]
80. Aptsiauri, N.; Cabrera, T.; Mendez, R.; Garcia-Lora, A.; Ruiz-Cabello, F.; Garrido, F. Role of altered expression
of HLA class I molecules in cancer progression. Adv. Exp. Med. Biol. 2007, 601, 123–131. [PubMed]
81. Han, L.Y.; Fletcher, M.S.; Urbauer, D.L.; Mueller, P.; Landen, C.N.; Kamat, A.A.; Lin, Y.G.; Merritt, W.M.;
Spannuth, W.A.; Deavers, M.T.; et al. HLA class I antigen processing machinery component expression and
intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin. Cancer Res.
2008, 14, 3372–3379. [CrossRef] [PubMed]
82. Brown, S.D.; Warren, R.L.; Gibb, E.A.; Martin, S.D.; Spinelli, J.J.; Nelson, B.H.; Holt, R.A. Neo-antigens
predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014, 24,
743–750. [CrossRef] [PubMed]
147
Cancers 2018, 10, 242
83. Matsushita, N.; Ghazizadeh, M.; Konishi, H.; Araki, T. Association of ovarian tumor epithelium coexpressing
HLA-DR and CA-125 antigens with tumor infiltrating cytotoxic T lymphocytes. J. Nippon Med. Sch. Nippon
Ika Daigaku Zasshi 2003, 70, 40–44. [CrossRef] [PubMed]
84. Callahan, M.J.; Nagymanyoki, Z.; Bonome, T.; Johnson, M.E.; Litkouhi, B.; Sullivan, E.H.; Hirsch, M.S.;
Matulonis, U.A.; Liu, J.; Birrer, M.J.; et al. Increased HLA-DMB expression in the tumor epithelium is
associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.
Clin. Cancer Res. 2008, 14, 7667–7673. [CrossRef] [PubMed]
85. Garrido, F.; Perea, F.; Bernal, M.; Sánchez-Palencia, A.; Aptsiauri, N.; Ruiz-Cabello, F. The escape of cancer
from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture. Vaccines 2017,
5, 7. [CrossRef] [PubMed]
86. Garrido, F.; Ruiz-Cabello, F.; Aptsiauri, N. Rejection versus escape: The tumor MHC dilemma.
Cancer Immunol. Immunother. 2017, 66, 259–271. [CrossRef] [PubMed]
87. Clarke, B.; Tinker, A.V.; Lee, C.-H.; Subramanian, S.; van de Rijn, M.; Turbin, D.; Kalloger, S.; Han, G.;
Ceballos, K.; Cadungog, M.G.; et al. Intraepithelial T cells and prognosis in ovarian carcinoma: Novel
associations with stage, tumor type, and BRCA1 loss. Mod. Pathol. 2009, 22, 393–402. [CrossRef] [PubMed]
88. Shah, C.A.; Allison, K.H.; Garcia, R.L.; Gray, H.J.; Goff, B.A.; Swisher, E.M. Intratumoral T cells,
tumor-associated macrophages, and regulatory T cells: Association with p53 mutations, circulating tumor
DNA and survival in women with ovarian cancer. Gynecol. Oncol. 2008, 109, 215–219. [CrossRef] [PubMed]
89. Abiko, K.; Matsumura, N.; Hamanishi, J.; Horikawa, N.; Murakami, R.; Yamaguchi, K.; Yoshioka, Y.; Baba, T.;
Konishi, I.; Mandai, M. IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of
ovarian cancer. Br. J. Cancer 2015, 112, 1501–1509. [CrossRef] [PubMed]
90. Hamanishi, J.; Mandai, M.; Iwasaki, M.; Okazaki, T.; Tanaka, Y.; Yamaguchi, K.; Higuchi, T.; Yagi, H.;
Takakura, K.; Minato, N.; et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes
are prognostic factors of human ovarian cancer. Proc. Natl. Acad. Sci. USA 2007, 104, 3360–3365. [CrossRef]
[PubMed]
91. Darb-Esfahani, S.; Kunze, C.A.; Kulbe, H.; Sehouli, J.; Wienert, S.; Lindner, J.; Budczies, J.; Bockmayr, M.;
Dietel, M.; Denkert, C.; et al. Prognostic impact of programmed cell death-1 (PD-1) and PD-ligand 1 (PD-L1)
expression in cancer cells and tumor-infiltrating lymphocytes in ovarian high grade serous carcinoma.
Oncotarget 2016, 7, 1486–1499. [CrossRef] [PubMed]
92. Webb, J.R.; Milne, K.; Kroeger, D.R.; Nelson, B.H. PD-L1 expression is associated with tumor-infiltrating
T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol. Oncol. 2016, 141, 293–302.
[CrossRef] [PubMed]
93. Drakes, M.L.; Mehrotra, S.; Aldulescu, M.; Potkul, R.K.; Liu, Y.; Grisoli, A.; Joyce, C.; O’Brien, T.E.; Stack, M.S.;
Stiff, P.J. Stratification of ovarian tumor pathology by expression of programmed cell death-1 (PD-1) and
PD-ligand-1 (PD-L1) in ovarian cancer. J. Ovarian Res. 2018, 11. [CrossRef] [PubMed]
94. Goyne, H.E.; Stone, P.J.B.; Burnett, A.F.; Cannon, M.J. Ovarian tumor ascites CD14+ cells suppress dendritic
cell-activated CD4+ T-cell responses through IL-10 secretion and indoleamine 2,3-dioxygenase. J. Immunother.
2014, 37, 163–169. [CrossRef] [PubMed]
95. Hennequart, M.; Pilotte, L.; Cane, S.; Hoffmann, D.; Stroobant, V.; Plaen, E.D.; Eynde, B.J.V. den Constitutive
IDO1 expression in human tumors is driven by Cyclooxygenase-2 and mediates intrinsic immune resistance.
Cancer Immunol. Res. 2017. [CrossRef] [PubMed]
96. Tanizaki, Y.; Kobayashi, A.; Toujima, S.; Shiro, M.; Mizoguchi, M.; Mabuchi, Y.; Yagi, S.; Minami, S.;
Takikawa, O.; Ino, K. Indoleamine 2,3-dioxygenase promotes peritoneal metastasis of ovarian cancer by
inducing an immunosuppressive environment. Cancer Sci. 2014, 105, 966–973. [CrossRef] [PubMed]
97. Ino, K. Indoleamine 2,3-dioxygenase and immune tolerance in ovarian cancer. Curr. Opin. Obstet. Gynecol.
2011, 23, 13–18. [CrossRef] [PubMed]
98. Inaba, T.; Ino, K.; Kajiyama, H.; Yamamoto, E.; Shibata, K.; Nawa, A.; Nagasaka, T.; Akimoto, H.; Takikawa, O.;
Kikkawa, F. Role of the immunosuppressive enzyme indoleamine 2,3-dioxygenase in the progression of
ovarian carcinoma. Gynecol. Oncol. 2009, 115, 185–192. [CrossRef] [PubMed]
99. Takao, M.; Okamoto, A.; Nikaido, T.; Urashima, M.; Takakura, S.; Saito, M.; Saito, M.; Okamoto, S.;
Takikawa, O.; Sasaki, H.; et al. Increased synthesis of indoleamine-2,3-dioxygenase protein is positively
associated with impaired survival in patients with serous-type, but not with other types of, ovarian cancer.
Oncol. Rep. 2007, 17, 1333–1339. [CrossRef] [PubMed]
148
Cancers 2018, 10, 242
100. Qian, F.; Villella, J.; Wallace, P.K.; Mhawech-Fauceglia, P.; Tario, J.D.; Andrews, C.; Matsuzaki, J.; Valmori, D.;
Ayyoub, M.; Frederick, P.J.; et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in
reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian
cancer. Cancer Res. 2009, 69, 5498–5504. [CrossRef] [PubMed]
101. Sheridan, C. IDO inhibitors move center stage in immuno-oncology. Nat. Biotechnol. 2015, 33, 321–322.
[CrossRef] [PubMed]
102. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity’s roles in cancer
suppression and promotion. Science 2011, 331, 1565–1570. [CrossRef] [PubMed]
103. Okła, K.; Wertel, I.; Polak, G.; Surówka, J.; Wawruszak, A.; Kotarski, J. Tumor-associated macrophages and
myeloid-derived suppressor cells as immunosuppressive mechanism in ovarian cancer patients: Progress
and challenges. Int. Rev. Immunol. 2016, 35, 372–385. [CrossRef] [PubMed]
104. Leffers, N.; Gooden, M.J.M.; de Jong, R.A.; Hoogeboom, B.-N.; ten Hoor, K.A.; Hollema, H.; Boezen, H.M.;
van der Zee, A.G.J.; Daemen, T.; Nijman, H.W. Prognostic significance of tumor-infiltrating T-lymphocytes in
primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol. Immunother. CII 2009, 58,
449–459. [CrossRef] [PubMed]
105. Raspollini, M.R.; Castiglione, F.; Rossi Degl’innocenti, D.; Amunni, G.; Villanucci, A.; Garbini, F.; Baroni, G.;
Taddei, G.L. Tumour-infiltrating gamma/delta T-lymphocytes are correlated with a brief disease-free interval
in advanced ovarian serous carcinoma. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2005, 16, 590–596. [CrossRef]
[PubMed]
106. Sato, E.; Olson, S.H.; Ahn, J.; Bundy, B.; Nishikawa, H.; Qian, F.; Jungbluth, A.A.; Frosina, D.; Gnjatic, S.;
Ambrosone, C.; et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T
cell ratio are associated with favorable prognosis in ovarian cancer. Proc. Natl. Acad. Sci. USA 2005, 102,
18538–18543. [CrossRef] [PubMed]
107. Tomsová, M.; Melichar, B.; Sedláková, I.; Steiner, I. Prognostic significance of CD3+ tumor-infiltrating
lymphocytes in ovarian carcinoma. Gynecol. Oncol. 2008, 108, 415–420. [CrossRef] [PubMed]
108. Nielsen, J.S.; Sahota, R.A.; Milne, K.; Kost, S.E.; Nesslinger, N.J.; Watson, P.H.; Nelson, B.H. CD20+
tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T
cells promote favorable prognosis in ovarian cancer. Clin. Cancer Res. 2012, 18, 3281–3292. [CrossRef]
[PubMed]
109. Barnett, J.C.; Bean, S.M.; Whitaker, R.S.; Kondoh, E.; Baba, T.; Fujii, S.; Marks, J.R.; Dressman, H.K.;
Murphy, S.K.; Berchuck, A. Ovarian cancer tumor infiltrating T-regulatory (T(reg)) cells are associated
with a metastatic phenotype. Gynecol. Oncol. 2010, 116, 556–562. [CrossRef] [PubMed]
110. Hamanishi, J.; Mandai, M.; Abiko, K.; Matsumura, N.; Baba, T.; Yoshioka, Y.; Kosaka, K.; Konishi, I.
The comprehensive assessment of local immune status of ovarian cancer by the clustering of multiple
immune factors. Clin. Immunol. 2011, 141, 338–347. [CrossRef] [PubMed]
111. Hwang, W.-T.; Adams, S.F.; Tahirovic, E.; Hagemann, I.S.; Coukos, G. Prognostic significance of
tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol. Oncol. 2012, 124, 192–198. [CrossRef]
[PubMed]
112. Dadmarz, R.D.; Ordoubadi, A.; Mixon, A.; Thompson, C.O.; Barracchini, K.C.; Hijazi, Y.M.; Steller, M.A.;
Rosenberg, S.A.; Schwartzentruber, D.J. Tumor-infiltrating lymphocytes from human ovarian cancer patients
recognize autologous tumor in an MHC class II-restricted fashion. Cancer J. Sci. Am. 1996, 2, 263–272.
[PubMed]
113. Bronger, H.; Singer, J.; Windmüller, C.; Reuning, U.; Zech, D.; Delbridge, C.; Dorn, J.; Kiechle, M.;
Schmalfeldt, B.; Schmitt, M.; et al. CXCL9 and CXCL10 predict survival and are regulated by cyclooxygenase
inhibition in advanced serous ovarian cancer. Br. J. Cancer 2016, 115, 553–563. [CrossRef] [PubMed]
114. Liu, M.; Matsumura, N.; Mandai, M.; Li, K.; Yagi, H.; Baba, T.; Suzuki, A.; Hamanishi, J.; Fukuhara, K.;
Konishi, I. Classification using hierarchical clustering of tumor-infiltrating immune cells identifies poor
prognostic ovarian cancers with high levels of COX expression. Mod. Pathol. 2009, 22, 373–384. [CrossRef]
[PubMed]
115. Hermans, C.; Anz, D.; Engel, J.; Kirchner, T.; Endres, S.; Mayr, D. Analysis of FoxP3+ T-regulatory cells and
CD8+ T-cells in ovarian carcinoma: Location and tumor infiltration patterns are key prognostic markers.
PLoS ONE 2014, 9, e111757. [CrossRef] [PubMed]
149
Cancers 2018, 10, 242
116. Shi, J.-X.; Qin, J.-J.; Ye, H.; Wang, P.; Wang, K.-J.; Zhang, J.-Y. Tumor associated antigens or anti-TAA
autoantibodies as biomarkers in the diagnosis of ovarian cancer: A systematic review with meta-analysis.
Expert Rev. Mol. Diagn. 2015, 15, 829–852. [CrossRef] [PubMed]
117. Taylor, D.D.; Gercel-Taylor, C.; Parker, L.P. Patient-derived tumor-reactive antibodies as diagnostic markers
for ovarian cancer. Gynecol. Oncol. 2009, 115, 112–120. [CrossRef] [PubMed]
118. Taylor, D.D.; Atay, S.; Metzinger, D.S.; Gercel-Taylor, C. Characterization of humoral responses of ovarian
cancer patients: Antibody subclasses and antigenic components. Gynecol. Oncol. 2010, 116, 213–221.
[CrossRef] [PubMed]
119. Jang, M.; Yew, P.-Y.; Hasegawa, K.; Ikeda, Y.; Fujiwara, K.; Fleming, G.F.; Nakamura, Y.; Park, J.-H.
Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next
generation sequencing. Oncoimmunology 2015, 4, e1030561. [CrossRef] [PubMed]
120. Landskron, J.; Helland, Ø.; Torgersen, K.M.; Aandahl, E.M.; Gjertsen, B.T.; Bjørge, L.; Taskén, K.
Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.
Cancer Immunol. Immunother. 2015, 64, 337–347. [CrossRef] [PubMed]
121. Lukesova, S.; Vroblova, V.; Tosner, J.; Kopecky, J.; Sedlakova, I.; Čermáková, E.; Vokurkova, D.; Kopecky, O.
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Abstract: Immunotherapy has emerged as one of the most promising approaches for ovarian
cancer treatment. The tumor microenvironment (TME) is a key factor to consider when stimulating
antitumoral responses as it consists largely of tumor promoting immunosuppressive cell types that
attenuate antitumor immunity. As our understanding of the determinants of the TME composition
grows, we have begun to appreciate the need to address both inter- and intra-tumor heterogeneity,
mutation/neoantigen burden, immune landscape, and stromal cell contributions. The majority of
immunotherapy studies in ovarian cancer have been performed using the well-characterized murine
ID8 ovarian carcinoma model. Numerous other animal models of ovarian cancer exist, but have
been underutilized because of their narrow initial characterizations in this context. Here, we describe
animal models that may be untapped resources for the immunotherapy field because of their shared
genomic alterations and histopathology with human ovarian cancer. We also shed light on the
strengths and limitations of these models, and the knowledge gaps that need to be addressed to
enhance the utility of preclinical models for testing novel immunotherapeutic approaches.
Keywords: ovarian cancer; tumor microenvironment; immune infiltrating cells; chemotherapy;
immunotherapy; syngeneic; transgenic models; hot vs. cold tumors; immunosuppression
1. Introduction
At present, there are no approved immune therapies for epithelial ovarian cancer (EOC)
patients. As EOC is often detected at a late stage, research has mainly focused on the discovery
of new treatments. Current first-line treatment is debulking surgery and adjuvant or neoadjuvant
chemotherapy. Even though >80% of patients show a positive response to this initial therapy,
most patients will relapse with chemotherapy-resistant disease [1]. As the presence of tumor infiltrating
lymphocytes (TILs) correlates with increased EOC patient survival [2–9], immunotherapies hold great
potential for improving EOC outcomes, as they have for several other types of cancers. The U.S.
Food and Drug Administration has approved the use of several immune checkpoint inhibitors for
non-small-cell lung cancer (NSCLC), melanoma, bladder cancer, renal cell carcinomas, and Hodgkin
lymphoma and recently approved the first chimeric antigen receptor (CAR)-T-cell therapy to treat
children with B-cell acute lymphoblastic leukemia [10,11].
Antitumor immunity in EOC patients is robustly attenuated because of the immunosuppressive
cells within the tumor microenvironment (TME), as reviewed in the literature [12,13]. Several cell
types are found in the tumor niche, including immune cells [effector T and B lymphocytes, regulatory
T and B cells, natural killer cells (NKs), tumor-associated macrophages (TAMs), and myeloid-derived
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suppressor cells (MDSCs), among many others (Table 1)], as well as other components found in the
TME, including fibroblasts and the adipocytes in the omentum [12]. MDSCs, TAMs, and regulatory
T cells (Tregs) play a critical role in maintaining a highly immunosuppressive TME by producing
immunomodulatory molecules [transforming growth factor beta (TGFβ), interleukin (IL)-10, IL-6,
etc.] and inducing and recruiting immunoinhibitory cells, which dampens antitumoral immunity
and supports tumor promotion [12,14]. Therefore, EOC immunotherapy must combine approaches
that aim to reduce the highly immunosuppressive TME, as well as stimulate immune-activating
antitumoral responses. This review describes encouraging results from both preclinical and clinical
trials and highlights the immunotherapies that offer innovative and combinatorial approaches to
circumvent the antitumoral barriers within the TME.
Table 1. Main subsets of immune infiltrating cells in epithelial ovarian cancer (EOC) tumor
microenvironment (TME).
Immune Cell Type Antitumoral Function Tumor-Promoting Function
CD4+ Th1 cells
Help to CTLs in tumor rejection
and production of TNFα, IFNγ,
and IL-2
Production of cytokines
CD4+ Th2 cells Education of macrophages, production of cytokines, B cell activation
CD4+ Treg Cells
Suppression of inflammation
(cytokines and other suppressive
mechanisms)
Immunosuppression: causes IL-2 and other cytokine deprivation,
production of TGFβ, IL-10, impaired activation of CTLs
CD8+ T Cells
Direct lysis of cancer cells and
production of pro-inflammatory
cytokines TNFα, IFNγ, and IL-2
FOXP3+ CTLA-4+ CD25+, convert effector CD8+ T cells into
suppressor cells, suppressive function through TGF-β1
B Cells
Production of tumor specific
antibodies, IFNγ, TAA
presentation, Th1 polarization,
promotes T cell expansion
Production of IL-6, IL-10, IL-35, TGFβ, CCL22, immunosuppression,
T cell conversion to Tregs, promotes Th2 inhibitory responses
Macrophages, DCs
TAA sampling and presentation;
T-cell priming; and production of
IL-12 and type I IFN,
lympho-attracting chemokines
CXCL9, CXCL10, CXCL11
Promotes metastasis and invasion. Produces CSF-1, arginase, IL-6,
IL-10, and CCL22. B7-H4+ TAMs suppress antitumoral responses.
MDSCs
Immunosuppression, induces Tregs differentiation, M2 TAM, cancer
stemness, sphere formation, and metastasis. Defective TAA
presentation. Production of arginase-1, nitric oxide, reactive oxygen
and nitrogen species, prostaglandin E2, CXCL12. Deplete cysteine,
induce Tregs, inhibit T-cell activation and proliferation, and
attenuate the cytolytic ability of NK cells.
NK Cells
Direct cytotoxicity toward cancer
cells and production of
pro-inflammatory cytokines
GM-CSF, TNFα, IFNγ, IL-2 and
chemokine CCL5
CD4+ helper T cells (Th), cytotoxic T lymphocytes (CTLs), interferon (IFN), interleukin (IL), transforming
growth factor beta (TGFβ), forkhead box P3 (FoxP3), cytotoxic T-lymphocyte associated protein 4 (CTLA-4),
tumor-associated antigens (TAAs), tumor-associated macrophages (TAMs), dendritic cells (DCs), colony stimulating
factor 1 (CSF1), granulocyte-macrophage colony-stimulating factor (GM-CSF), myeloid-derived suppressor cells
(MDSCs), natural killer cells (NKs), regulatory T cells (Tregs). See the literature [12] for details.
2. Adoptive Cell Therapy
Adoptive cell therapy (ACT) aims to boost the antitumoral activity of autologous (patient) or
allogeneic (from healthy donors) lymphocytes [15]. ACT consists of the isolation of T cells from
a patient’s tumor or peripheral blood to expand or manipulate those cells ex vivo, away from the
influence of the immunosuppressive TME. These ex vivo expanded T cells are reintroduced into the
patient along with recombinant IL-2 (rIL-2) after a lympho-depleting chemotherapy regimen [15].
ACT has resulted in complete and durable regressions in patients with melanoma [16,17]. In 1995,
Fujita and colleagues used ACT of TILs in 13 patients with advanced-stage EOC who did not show
any detectable lesions after primary surgery and cisplatin-containing chemotherapy [18]. All patients
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who received TILs following post-surgery chemotherapy survived three years, compared with only
67.5% of patients receiving chemotherapy alone. Interestingly, TILs promoted tumor regression even
in patients with advanced disease or recurrent platinum-resistant EOC [18]. Among TILs, CD8+ T cells
have been shown to migrate and infiltrate tumors and mediate antitumoral responses [19]. An early
trial in EOC patients that used ACT with TILs following a single injection of cyclophosphamide
showed tumor regression in primary tumors and metastases (ovary, liver, lung, and lymph node),
which was stable for up to five months with one out of seven patients showing complete response
and four out of seven with >50% reduction in tumor burden [20]. When this study was expanded
with 10 additional patients, seven cases showed complete regression without recurrence for up to 15
months [20]. This highlighted the prospect of combined therapy using TILs and cisplatin without rIL-2
administration that has unfavorable toxicity in many cases [20].
In another study, 11 patients with advanced platinum-resistant EOC received intraperitoneal (IP)
TILs and low doses of rIL-2 IP [21]. Grade 3 clinical toxicity (peritonitis) and anemia were observed
without a significant clinical response in any patient. However, 50% of treated patients had regression
of ascites (two patients), tumor and carcinoma antigen (CA)-125 (one patient), and surgically confirmed
stable tumor and CA-125 values (one patient) [21]. Thus, ACT efficacy has shown conflicting results
depending on the study (reviewed in the literature [22]). Importantly, the most encouraging clinical
responses were observed when patients were stratified according to the presence or absence of TILs,
with the best clinical response in patients who had TILs or ‘hot’ tumors, a property known to improve
survival [22]. As discussed by Santoiemma and Powell, these early studies were executed prior
to our advanced understanding of TIL quality, persistence and specificity, patient disease burden,
and pre-conditioning regimens, which have since been significantly improved [22].
As ACT has resulted in response rates up to 72% in metastatic melanoma occurring at all sites
and has been durable beyond three years in many patients [17], there remains considerable promise in
identifying and optimizing conditions whereby ACT can be consistently successful in EOC.
Chimeric Antigen Receptor T Cells (CAR-T)
New approaches, such as genetically engineered T cells, build on the promising early ACT
trials that are constrained by the need to isolate and expand functional tumor-reactive T cells [23].
Genetic engineering of T cells has become a powerful approach to increase tumor immunity [24].
The T-cell receptor (TCR) from lymphocytes and chimeric antigen receptors (CARs) can be adapted
to specifically target patient tumor cells. CAR-T cells allow for the recognition of tumor cells in a
major histocompatibility complex (MHC)-unrestricted manner, combining antigen-specificity and
T-cell activating properties in a single fusion molecule [25]. The first generation of CARs was tested in
several cancers, including EOC [26], renal cancer, lymphoma, and neuroblastoma, inducing modest
responses [25]. In the first study of CAR-T cells in EOC, autologous T cells specific to the EOC tumor
associated antigen (TAA) α-folate receptor (FRα) were generated with a chimeric gene composed of an
anti-FRα single-chain antibody linked to the signaling domain of the Fc receptor gamma chain [26].
From this study, no reduction in tumor burden was seen in any patient. Although large numbers of
CAR-T cells were well tolerated, they did not persist long-term [26]. Some promising TAAs related to
EOC for the generation of CARs are FRα [27], human epidermal growth factor receptor 2 (HER-2) [28],
CA-125 (MUC16) [29,30], and mesothelin [31]. Moreover, CAR-T cells can be redirected against NKG2D
ligands, which are widely expressed on EOC [32], as well as the epithelial cell adhesion molecule
(EpCAM) [33] and 5T4 [34].
CAR translation to solid tumors is actively being investigated at present; however, few facilities
have the capacity to produce CARs and many trials have achieved less than expected efficacy.
This could be explained by the highly immunosuppressive TME [35]. Koneru and colleagues generated
T cells engineered to specifically recognize the MUC-16ecto TAA that is expressed in the majority of
ovarian tumors and derived from the cleavage of CA-125 [29,36]. As a strategy to overcome the TME,
they developed a construct that co-expressed both MUC16ecto CAR and IL-12, a pro-inflammatory
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cytokine that has potential roles in anticancer therapy [37]. Some immune cells such as NK cells,
dendritic cells (DCs), and macrophages normally produce IL-12 to induce T-cell proliferation and
inhibit Tregs. The IL-12 secreting CAR-T cells displayed enhanced antitumor efficacy as determined by
increased survival, prolonged persistence of T cells, and higher systemic interferon gamma (IFNγ) in
mice with human EOC xenografts [36]. These observations suggest that IP delivery of CAR-T cells may
be most beneficial for EOC treatment [38]. The peritoneal cavity is the main locus for EOC metastases,
and local treatment seems to be a safer option for patients, because adverse reactions induced by
‘on-target off-tumor’ toxicities, such as cytokine release syndrome, were reported in a study that used
ACT of autologous mesothelin-redirected CAR-T cells in a patient with BRCA1+ advanced recurrent
serous EOC [39]. By local administration of CARs, antigens expressed by both EOC and healthy tissue,
such as EpCAM, can be targeted in a safer way [40]. Indeed, there is a long-term survival advantage
associated with IP chemotherapy in advanced EOC disease [41]. Recent studies have shown that
CAR-T cells could be administrated along with cytokines such as IL-2, IL-7, IL-15, and IL-21 to increase
their efficacy against hematologic and solid tumors [42].
There are still many barriers to overcome for CAR-T therapy effectiveness, such as T-cell trafficking
into the tumor niche, patient selection, cancer-specific TAAs, and the highly immunosuppressive TME,
as well as the dose and route of administration [35,43,44]. Combinatorial strategies to circumvent these
barriers, such as incorporating immune checkpoint inhibitors into CAR-T cells [45], may be the new
frontier in enhancing the tumor elimination efficacy of CAR-T cells for EOC patients.
3. Strategies Targeting Immunosuppression in the TME
Regulatory T cells (Tregs) participate in the establishment of the immunosuppressive TME,
attenuating antitumor immunity. Neoplastic cells and TAMs produce CCL22 that mediates Treg
tumor infiltration, a mechanism that could be blocked to decrease immunosuppression and enhance
antitumoral immunity [46,47]. T cells transduced to express chemokine receptors matching the TME
chemokines can improve tumor homing after ACT, as shown by improved migration of tumor ascites
lymphocytes to the EOC microenvironment by T-cell CXCR2 transduction [48].
Highly immunosuppressive MDSCs are attractive targets to enhance the efficacy of cancer
immunotherapy. Immunizing mice with microparticles containing TLR9 and NOD-2 ligands (MIS416),
followed by anti-CD11b administration, was shown to abrogate the immunosuppressive capacity
of MDSCs in the ID8 murine model of EOC [49]. This treatment significantly prolonged survival,
highlighting the need for more immunotherapies targeting innate immunity within the TME [49].
However, there are still many unknowns concerning the different MDSC phenotypes and levels in
tumor tissue, peripheral blood, and/or ascites fluid, and how their presence influences the TME [50].
TGF-β plays a key role in EOC TME by preventing antitumoral T cell responses. Recent studies
have identified stromal TGF-β signaling as a determinant of immune exclusion [51,52]. In a model
of colorectal cancer, Tauriello and colleagues recently showed that TGF-β inhibition prevents tumor
metastasis by increasing cytotoxic T-cell responses [53]. Thus, blocking TGF-β production along with
immunotherapy could be a promising pro-immunogenic approach in EOC by promoting strong T cell
infiltration and antitumoral immunity [51,54].
A recent study found that the accumulation of effector memory CD8+ T cells (TEM) in EOC
ascites was mediated by TAM-derived CXCL9. This accumulation of CD8+ T cells correlated with
increased patient survival. However, ascites-derived factors can suppress TEM effector functions
through the production of IFNγ and TNFα, and CD107a expression, shortening relapse-free survival
of patients. Inducing TAMs to produce CXCL9, CXCL10, and CXCL-11 chemokines may potentially be
therapeutic [55]. COX inhibitors also enhance chemokine release, suggesting their use in combinatorial
strategies to increase TILs within the EOC TME [56].
Increased expression of immune checkpoint molecules on cancer cells, antigen-presenting cells
(APCs), and T cells in the EOC TME leads to immunosuppression upon binding of their corresponding
receptor/ligand, effectively putting the brakes on CD8+ effector T and NK cells. Blockage of
159
Cancers 2018, 10, 244
co-inhibitory molecules has now been exploited in many cancer types to increase pre-existing patient
antitumoral responses (reviewed in the literature [57]). These co-inhibitory molecules include cytotoxic
T-lymphocyte associated protein 4 (CTLA-4; on T cells to control T cell activation, and binds to CD80 or
CD86 on APCs or tumor cells), lymphocyte-activation gene 3 (LAG-3; on T and NK cells, and binds to
MHC-II and LSECtin on APCs or tumor cells [58]), programmed cell death protein 1 (PD-1; on activated
T, B, and NK cells, and binds to PD-L1 or PD-L2 on APCs or tumor cells), and PD-L1 (on APC or tumor
cells, and binds to PD-1 on T cells or CD80 on APC or tumor cells).
Anti-PD-1 and anti-LAG-3 synergized in the ID8-OT-I murine model to prolong survival, reduce
tumor burden, and reduce Tregs, while increasing CD4+ and CD8+ TILs [59]. Therefore, blockade of
immune inhibitory molecules, such as LAG-3, T cell immunoglobulin and mucin domain 3 (TIM-3);
or T cell immunoreceptor with Ig and ITIM domains (TIGIT); as well as fibrinogen-like protein 2
(FGL-2) [60–62], may synergize with PD-1/PD-L1 to target multiple cell types and more potently relieve
immunosuppression [58,63]. Interestingly, Lin and colleagues found that the efficacy of anti-PD-L1
therapy was unaltered by tumor cell expression of PD-L1 and instead, DC and macrophage PD-L1
expression was likely to underlie response [64]. Thus, more studies need to explore how these
immunotherapies abrogate immunosuppression and the cell types underlying responses.
Beyond the immunosuppressive cytokine milieu present in the TME, antigen persistence also
contributes to long-lasting T cell exhaustion (reviewed in the literature [65]), in part through
increasing PD-1 expression and through de novo methylation of effector function genes [66]. Thus,
targeting aberrant methylation using epigenetic modifiers such as the DNA methyltransferase inhibitor,
azacytidine, has offered promising results in rejuvenating T cell responses [66]. Further, azacytidine
induces the expression of antigen processing machinery and activates the interferon response in
cancer cells by inducing viral mimicry through the MDA5/MAVS/IRF7 pathway [67,68]. However,
azacytidine can also upregulate PD-L1 on cancer cells [69], and thus shift the balance from antitumor
immunity toward immunosuppression. Combinatorial approaches with epigenetic therapies and
immune checkpoint blockade (anti-PD-1) have been employed and shown to enhance CD8+ T and NK
cell recruitment and function, and overall survival in murine models [66,70].
4. Increasing Tumor Immunogenicity
4.1. Chemotherapy
Chemotherapeutic agents used in standard EOC treatment can induce an immunogenic cell death
of cancer cells by the release of danger signals known as damage-associated molecular patterns
(DAMPs) [71,72]. Memory T cells derived from peripheral blood mononuclear cells from EOC
patients after cytoreductive surgery and platinum and taxane chemotherapy recognized antigens
associated with apoptotic EOC cells, and their presence was correlated with prolonged survival [73].
Responders displayed significant IFNγ or IL-17 functions by both CD4+ and CD8+ T cells in response
to apoptotic EOC antigens [73]. Exposure to platinum-based drugs can disrupt the STAT6-mediated
immunosuppression in the TME by decreasing the expression of PD-L2 on both human DCs and tumor
cells, enhancing antigen-specific proliferation and Th1 cytokine secretion, as well as increasing tumor
T cell recognition [74,75]. CD8+ T-cell function is not permanently suppressed in advanced EOC and
successful carboplatin/paclitaxel chemotherapy is associated with improved antigen-specific T cell
reactivity [76].
Paclitaxel has been previously reported to be a ligand to Toll-like receptor 4 (TLR4), normally
found on normal and neoplastic cells, which, under ligation, significantly increase the secretion of IL-6
and IL-8 by human EOC cell lines (SKOV3, OVCAR3), abrogating paclitaxel effects on cell proliferation,
and promoting tumor survival and chemoresistance [77–79]. MyD88 expression is more restricted to
EOC cells, independent of tumor grade, and is associated with reduced progression-free and overall
survival [80]. Strategies aiming to target the TLR4 signaling pathway on TLR4/MyD88(+) EOC patients
may hold promise for the treatment of paclitaxel-resistant EOC. For example, atractylenolide-I (AO-I),
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a naturally occurring sesquiterpene lactone and TLR4-antagonizing agent, inhibits TLR4 signaling
by interfering with the binding of paclitaxel to membrane TLR4, thus sensitizing the response of
MyD88(+) EOC cells to paclitaxel [81]. AO-I indirectly downregulates MyD88/NF-κB signaling;
reduces activation of NF-κB, Akt, and indoleamine 2,3-dioxygenase (IDO)-1; and attenuates the
secretion of IL-6, TGF-β1, VEGF, and IL-17A by SKOV3 cells [82]. In another study, Peng and colleagues
found that chemotherapy induces local immune suppression by increasing PD-L1 expression in ovarian
tumor cells [83]. Paclitaxel treatment is able to increase CD8+ T-cell infiltration of ovarian tumors in
a mouse model of ovarian cancer by upregulating MHC-I expression, as well as PD-L1 expression,
in an NF-κB-dependent manner [83]. Thus, the authors showed that by combining paclitaxel treatment
with anti-PD-L1 or anti-PD1 antibodies, the immunosuppressive TME is attenuated, enabling the
achievement of maximal antitumoral responses and increasing survival of ovarian tumor-bearing
mice [83].
Agents such as cyclophosphamide can also be used in combination with immune checkpoint
inhibitors, such as anti-PD-1, to gain therapeutic synergy by decreasing Treg infiltration and stimulating
the generation of CD8+ TILs [84]. Gemcitabine chemotherapy combined with CTLA-4 blockade
results in a potent antitumor immune response that is CD4+ and CD8+ T-cell dependent [85].
Oxaliplatin treatment can enhance susceptibility of human EOC cells to NK cell-mediated cytolysis by
inducing the production of type I IFN and chemokines, and enhance MHC class I-related chains A/B,
UL16-binding protein (ULBP)-3, CD155, and TNF-related apoptosis-inducing ligand (TRAIL)-R1/R2
expression [86].
Chemotherapy possesses immunomodulatory properties by augmenting pre-existing TIL
responses in high-grade serous ovarian cancer (HGSC) patients; however, this increase fails to confer
significant prognostic benefit [87]. In contrast, platinum-resistant EOC has been shown to generate
poor immunologic responses [88]. Several studies have assessed the clinical and cost-effectiveness of
different combined chemotherapeutic approaches for advanced recurrent or refractory EOC [89,90].
By combining standard chemotherapeutic agents with immunotherapies, chemotherapy-induced
apoptosis can be exploited as an adjuvant to synergistically enhance antitumoral immunity.
EOC-derived ascites offers accessible and plentiful tumor tissue to identify and target molecules
that shape the TME. Both the cellular and fluid compartments allow for the investigation of prognostic
and predictive biomarkers, pharmacodynamic markers, and molecular profiling analysis [91].
Moreover, ascites may be a useful tool to reveal the immune status of the TME within the peritoneal
cavity. For example, IL-6 is enriched in the malignant EOC ascites, enhancing the invasive properties
of EOC cells [92]. IL-6 levels are elevated in recurrent compared with primary advanced EOC [93],
and because the IL-6R/STAT3/miR-204 feedback loop contributes to cisplatin resistance of EOC [94],
targeting IL-6 or IL6R with neutralizing antibodies could increase EOC sensitivity to cisplatin.
IL-6 levels can also be modulated using NF-κB inhibitors, like dehydroxymethylepoxyquinomicin
(DHMEQ), as showed by Nishio and colleagues, who evaluated the effects of DHMEQ in vitro
on human EOC cells and macrophages [95]. DHMEQ was able to inhibit the production of IL-6
and IL-8 by EOC cell lines and enable the release of immunosuppression of human DCs and
macrophages incubated with culture supernatant of EOC pretreated cells. In vivo studies in nude
mice implanted with human EOC cells showed a reduction of arginase expression and tumor
accumulation of MDSCs, demonstrating the important role of NF-κB in maintaining EOC TME
immunosuppression [95]. Given NF-κB is a pleiotropic transcription factor and also possesses
anti-inflammatory properties [96], further studies are needed to evaluate the therapeutic potential of
DHMEQ in EOC in immunocompetent hosts to better evaluate its impact on all the components of the
EOC TME.
4.2. Oncolytic Viruses
Oncolytic viruses (OV) can be engineered for transgene expression to enhance their tumor
specificity, safety, drug susceptibility, immunogenicity, and oncolytic potency [97]. They can be
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administered locally or intravenously and spread to the tumor and metastases [98,99]. OVs trigger at
least two modes of cancer cell killing: direct oncolysis of infected cells or indirect cell death elicited
by the host immune system [97,100]. These phenomena allow the release of viral antigens, DAMPs,
and TAAs, which, under a proper inflammatory milieu, enable their recognition and phagocytosis
by immune cells, such as macrophages and DCs, to eventually activate T cells in the draining lymph
nodes [97,100,101]. OV have tumor specificity because, unlike malignant cells, healthy cells can
respond to infection by inducing antiviral IFNs, though tumor heterogeneity in IFN expression has
been identified as means of OV resistance [102].
OVs are a new class of immunotherapy that have shown promising results in clinical studies,
leading to the approval of the first OV, talimogene laherparepvec (Imlygic®, Amgen, Thousand Oaks,
CA, USA) T-VEC, for treatment of metastatic melanoma [103–106]. Notably, OVs have shown synergy
when combined with other immunotherapies, such as checkpoint inhibitor antibodies [103,104,106].
IL-12 expressing oncolytic herpes simplex virus was shown to promote eradication of both murine and
human ovarian cancer cell lines and promote TAA-specific CD8+ T-cell responses in the peritoneal
cavity and omentum, leading to reduced peritoneal metastasis and improved survival in the mouse
model tgMISIIRTAg [107]. Thus, the use of OV immunotherapy alone or combined with approaches to
increase immunostimulatory or immunogenic responses offers promising strategies for investigation
as novel treatments for EOC patients.
In addition to cancer cells, OVs can infect and lyse CAFs [108] and endothelial cells in the
TME [109,110], leading to the destruction of these cells and immune infiltration [111]. At present,
several viruses are under active investigation in preclinical [112–117] and clinical trials (NCT02028117,
NCT00408590, NCT02759588, NCT02068794, NCT03225989, NCT01199263, NCT02285816) as potential
therapies for various cancers, including EOC, as well as in combinatorial strategies with other
immunotherapies such as checkpoint inhibitors.
A promising new strategy for cancer immunotherapy is to exploit autologous tumor cells as
carriers of viruses to the tumor niche [118]. Such oncolytic vaccine platforms consisting of tumor cells
infected with OV have been shown to be a favorable strategy in murine models of melanoma and
other solid cancers [101,103]. An infected cell vaccine (ICV) platform was developed using irradiated
autologous tumor cells infected with oncolytic Maraba (MG1) virus that is engineered to express the
immune stimulatory cytokine IL-12 [119]. When delivered directly into the peritoneal cavity in a
model of peritoneal carcinomatosis, the vaccine promoted the migration of IFNγ-secreting NK cells,
decreased tumor burden, and improved survival. Importantly, the enhanced NK-cell cytotoxicity
and migratory capacity driven by ICV-MG1-IL12 was also observed in human lymphocytes exposed
to human tumor cell lines infected with MG1-IL12, highlighting the benefit of this approach in
patients with abdominal cancers [119]. MG1 is currently being evaluated in phase I/II clinical trials
as a stand-alone therapy and in a vaccination strategy for the treatment of late-stage disseminated
disease (NCT02285816, NCT02879760). Thus, by using tumor cells as virus carriers, the TME can
be remodeled, making a “cold” tumor into an inflamed or “hot” tumor that could support and
sustain the generation of significant antitumoral responses. This approach could be advantageous to
EOC patients whose tumors have suboptimal immune infiltration and do not respond to standard
therapies. Additional studies are needed to assess the conditions (TME quality, tumor grade, etc.)
under which this approach could benefit those EOC patients, as well as to determine if this rationale
could be exploited with tumor cells derived from EOC ascites. Figure 1 summarizes some emerging
EOC immunotherapies.
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Figure 1. Emerging ovarian cancer immunotherapies. T cell infiltrated EOCs (>50% EOCs [120] can
be targeted with therapies such as ACT, CARs cells, co-stimulatory mAbs [121] (like anti-CD137),
oncolytic virotherapies, and DC-based vaccines [122], aiming to increase the effector functions
of the pre-existing antitumoral immunity. Conversely, strategies aiming to decrease the highly
immunosuppressive TME [checkpoint blockers mAbs (anti-PD-L1), IDO inhibitors [123], etc.] can be
exploited for ‘cold’ tumors and/or for advanced stages EOC, to decrease the immunosuppressive
functions of MDSCs, TAMs, and Tregs. Radiotherapy and chemotherapy are immunogenic cell death
inducers increasing the release of TAAs in the TME, thus augmenting the NK-cell mediated killing,
the incidence of TAA presentation by APCs, and eventually T cell priming. Also, chemotherapy can
target MDSCs (gemcitabine [124], 5-fluorouracil [125]). EOC cells and TAMs can be targeted with
trabectedin, which inhibits CCL2 production and decreases monocyte recruitment in tumors [126].
OVs can infect tumor cells, as well as CAFs and endothelial cells, thereby helping to decrease their
immunosuppressive action in the TME. Many approaches can be combined, such as administration
of costimulatory cytokines (IL-2, IL-7, IL-15 and IL-21) along with approaches such as CARs, OVs,
and ACT. Tumor cells derived from ascites can be exploited for the production of infected cell vaccines
with OVs delivering IL-12. Simultaneous targeting of CD137 and PD-1 [127] or TIM-3 [128] with
mAbs along with cisplatin treatment [129] can achieve significant antitumoral responses. Adoptive cell
transfer (ACT), cancer-associated fibroblasts (CAFs), chimeric antigen receptor (CAR), monoclonal
antibodies (mAbs), natural killer (NK), myeloid-derived suppressor cell (MDSC), tumor associated
macrophage (TAM), regulatory T cells (Tregs), tumor associated antigen (TAA), antigen presenting
cell (APC), oncolytic virus (OV), programmed cell death 1 (PD-1), T-cell immunoglobulin and mucin
domain 3 (TIM-3), metastasis (Mets).
5. Preclinical Models for Ovarian Cancer Immunotherapy
The ovarian cancer field has accelerated rapidly since the discovery that ovarian cancer is not one
disease, but exists as numerous subtypes that behave differently. For the most common EOC subtype,
HGSC, we have only recently begun to appreciate the role of the fallopian tube secretory epithelium
(murine oviductal epithelium) as one of the origins of HGSC. These discoveries led researchers
to focus on modeling ovarian cancer after specific subtypes or origin(s) of disease, leading to a
narrow characterization of many of these preclinical models in relation to their origin and common
genomic alterations with HGSC. Commonly studied features include growth rate, tumorigenic
potential, immunohistochemical markers, DNA mutations, BRCAness, RNA expression, and copy
number variation, with the results correlated to The Cancer Genome Atlas (TCGA) or other large
datasets on HGSC. Since the emergence of immunotherapies as promising agents for ovarian cancer
treatment, we have a rich reservoir of human and murine-derived ovarian cancer models that have
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limited characterization for the features that we have come to appreciate as important indicators of
immunotherapeutic efficacy. Such features include MHC status and PD-L1/2 expression on cancer
cells, total mutational and neoantigen burden, ascites composition, hot versus cold immune landscape,
and the contribution of tumor stroma (cancer-associated fibroblasts) to tumor immunosuppression.
Given that the current clinical efficacy of immune checkpoint blockade for HGSC ranges from 9.7 to
15% [35], preclinical models will be of great importance as we seek better indicators of response, as well
as new immunotherapy development. In this section, we summarize the current knowledge of ovarian
cancer models and highlight the models that may be untapped resources for the immunotherapy field.
5.1. Syngeneic Murine Models
A syngeneic model is defined by its immunological compatibility such that the host does not reject
either the outgrowth or transplant of cancer cells in immunocompetent animals. We have divided
syngeneic models into spontaneously occurring and genetically engineered models, as described below.
5.1.1. Spontaneously Transformed Syngeneic Models
The only two non-human animals that are known to spontaneously develop EOC are the
egg-laying hen and the jaguar (Table 2). Up to 35% of egg-laying hens develop EOC with similar
risk factors to humans such as age and ovulation number, reviewed in the literature [130]. The hen
model has yet to be used for immunotherapy development, but has features that make it an exciting
candidate for future use. The first evidence that spontaneous hen tumors are immunogenic was
the observation of mesothelin auto-antibodies and mRNA in 44% of hens harboring tumors [131].
Serous histology hen tumors contain the most TILs characterized by T and B cell infiltration [132],
and highly express immunosuppressive ILT3, which functions to limit T cell proliferation and
differentiation, suggesting perturbed antitumor adaptive immunity within the TME [133]. Barua and
colleagues showed elevated expression of DR6, a known inhibitor of DC function, with increasing stage
of disease, suggesting perturbed innate immunity, as well as adaptive immunity [134]. This group
then showed that increased immune infiltration in late-stage disease is restricted to the tumor stroma,
while intratumoral immune infiltration largely decreases with the stage, indicating that late-stage
tumors acquire mechanisms to limit immune trafficking [135]. These studies support the presence of
immunosuppression within the hen TME and highlight the hen model’s promise for immunotherapy
development. Profiling immune checkpoint expression, total mutation, and neoantigen burden in hen
tumors would be an exciting addition to the hen model dataset.
Interestingly, 40% of captive jaguars develop ovarian carcinoma with non-synonymous mutations
in BRCA1 [136,137]. The endangered nature of this species prevents its use as an ovarian cancer model,
though immunotherapies that enhance survival of patients with BRCA1-associated cancers could later
play a role in the conservation of this species.
The ID8 and STOSE models (in the C57BL/6 and FVB/N strains, respectively) are two incidences
of spontaneous transformation of primary murine ovarian surface epithelial cell cultures. Both of
these models share similar epithelial markers [cytokeratin(+), WT1(+), inhibin(−)], growth rates,
expression profiles similar to human HGSC, and tumorigenicity in syngeneic xenografts [138,139],
and they both form malignant ascites and disseminated disease following orthotopic intrabursal
injection [138,140]. The ID8 model, established by Roby and colleagues in 2000, has been the most
commonly used model for immunotherapy development based on its established characterization
and reliability in forming syngeneic tumors. Peritoneal tumors generated by IP injection of ID8 cells
develop a complex microenvironment with SMA+ fibroblasts, CD3+ T cells, CD68+ macrophages,
and neo-vasculature [140]. ID8 cells have been employed in the development of epigenetic
modifiers, immune checkpoint inhibitor and oncolytic virus studies, DC and microparticle vaccines,
and numerous emerging immunotherapies [112,129,141–144].
Antibody monotherapy has shown little promise in the ID8 model, as neither immune
checkpoint inhibitors (anti-PD-1, anti-CTLA-4) or activating antibodies (anti-OX40, anti-CD137) used
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as monotherapies had any impact on survival [129,142]. Two studies using combination antibody
immunotherapy, anti-PD-1 and -OX40 [142] or anti-PD-1 and -CTLA-4 and -CD137 [129] have shown
prolonged survival of ID8 tumor-bearing mice and a shift from a CD4+ T helper 2 (Th2) cell milieu
to an antitumor Th1 response characterized by an increased ratio of CD8+ and CD4+ T cells over
immunosuppressive CD4+FOXP3+ Tregs, and a reduction in CD11b+Gr-1+ MDSCs. In both studies,
antibodies were administered within 15 days of ID8 injection, representing early-stage disease before
robust tumor formation and ascites develops. It remains to be determined if these therapies promote
regression of late-stage disease in the presence of ascites. Turner and colleagues reported enhanced
MHC class II expression in subcutaneous ID8 tumors and restricted tumor growth with a combined
epigenetic therapy using a histone deacetylase inhibitor (entinostat) and DNA methyltransferase
inhibitor (azacytidine). Furthermore, azacytidine enhances recruitment of CD8 T and NK cells in the
ID8 model, and shows synergy with anti-PD-1 checkpoint blockade, offering an alternative approach
to modify the immune landscape of the TME [70,144].
Numerous OV platforms have been tested in the ID8 model including reovirus, vaccinia,
myxoma, vesicular stomatitis, and herpes simplex viruses [109,112,141,143,145]. Many of these
OV platforms have been shown to prolong survival, enhance CD8+ T-cell infiltration, and reduce
immunosuppression. Oncolytic vaccinia virus encoding a CXCR4 antagonist helped prevent peritoneal
spread and reduced Treg recruitment in ID8 tumors [112]. Although promising, this monotherapy
failed to cure the ID8 model, highlighting the need for combinatorial therapies [112]. Synergy was
observed when myxoma virus was administered prior to cisplatin treatment in an IP ID8 model,
generating a T-cell response that could recognize TAAs from ID8 cell lysates [143]. A recent study by
Liu and colleagues reported synergy between anti-PD-1 antibody therapy and oncolytic vaccinia virus
in the ID8 model [146], opening the door to combining oncolytic platforms and immune checkpoint
inhibition or novel antibody therapies.
Among the studies using ID8 cells, none have identified a full curative therapy that generates
a robust memory response that can protect against ID8 cell re-challenge, a sought-after goal
of immunotherapies. This could be because of the poor immunogenicity of ID8 cells; out of
their mutational burden of 92 somatic mutations, only 17 are predicted to generate transcribed
neoantigens. Upon vaccination with synthetic peptides carrying these 17 mutations, none induced
a neoantigen-specific T-cell response, indicating that they likely do not yield MHC presented
epitopes [147]. The use of modified ID8 cell lines may better phenocopy human HGSC, given that
parental ID8 cells have a relatively low mutational burden compared with human HGSC [147].
One of the first modifications to ID8 cells was the stable expression of beta-defensin,
Defb29, and Vegf-A yielding ID8-Defb29/Veg-A cells that had increased pro-tumor DC recruitment,
neovasculature, and a more aggressive phenotype with reduced survival compared with parental
ID8 cells [148]. ID8-Defb29/Veg-A derived tumors are good models for DC dysfunction and recently,
Cubillos-Ruiz and colleagues identified the role of the endoplasmic reticulum stress sensor XBP1
in mediating DC dysfunction in this model [149]. A second modification was the addition of the
ovalbumin (OVA) peptide, ID8-OVA, a useful tool to assess antitumoral responses mediated by OT-I
CD8+ T cells or OT-II CD4+ T cells derived from the transgenic mouse models OT-I and OT-II, where
the TCRs were designed to specifically recognize OVA peptides in the context of H2Kb and I-A b,
respectively [141,150]. Using a reovirus platform, Chiang and colleagues showed prolonged survival,
enhanced expression of MHC class I antigen presentation machinery (beta-2-microglobulin, TAP-1,
and TAP-2), reduction of MDSCs and Tregs, and enhanced DC-activation of OVA-specific CD8+ T cells
in the ID8-OVA model [141].
One of the notable weaknesses of the ID8 model is that it does not contain a Trp53 mutation,
which is characteristic of 94% of human HGSC [151]. Walton and colleagues generated ID8 cells
with both a Trp53 and Brca2 mutation using CRISPR-Cas9 [152,153]. ID8-Trp53−/− tumors had
increased MDSCs recruitment, possibly through increased CCL2 expression. With the addition of
Brca2 deletion, the tumors gained intraepithelial lymphoid aggregates, characteristic of hereditary
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human HGSC (~9% of cases), making this model relevant to the study of BRCA-associated HGSC [154].
Given the observed increase in mutational burden in HGSC of BRCA mutation carriers [155], it would
be interesting to profile neoantigen burden and TAA-specific T-cell responses in ID8-Trp53-Brca2 cells,
as well as ID8-Defb29/Vegf-A, to further enhance their relevance to HGSC. These modified ID8 cell
lines may offer more relevant models for ovarian cancer immunotherapy as they better phenocopy the
TME found in human HGSC. Roberts and colleagues have also published a spontaneously transformed
murine ovarian surface epithelial cell line, MOSE-L cells, which were highly proliferative, expressed
epithelial markers, and are tumorigenic in syngeneic C57BL/6 mice, though uptake of this model has
been sparse, likely because of the well-established characterization of the ID8 model [156].
In 2014, our group published the second spontaneously transformed syngeneic model of
HGSC-like cancer, the STOSE model, which reliably generates tumors in syngeneic FVB/N mice.
Our initial characterization profiled the growth rate, genomic instability, and immunohistochemical
markers relevant to human HGSC [138]. Recently, we have expanded the characterization of
the STOSE model by profiling the immune landscape of orthotopic intrabursal-derived STOSE
tumors and have found STOSE tumors have increased T-cell infiltration and a larger CD4+ Treg
population than ID8 tumors (data not shown), suggesting STOSE tumors contain a T-cell-rich or ‘hot’
TME. In contrast, orthotopic ID8 tumors generate a more myeloid-rich or ‘cold’ TME. Given their
susceptibility to oncolytic virus infection in vitro [107], it will be important to compare the efficacy of
immunotherapeutic approaches in these two models, which generate tumors in different murine strains
and have contrasting immune landscapes within the TME, and may better reflect the heterogeneity of
HGSC seen in the clinic. Characterization of the STOSE model for copy number and mutational and
neoantigen burden must be done to assess the utility of the STOSE model.
Both ID8 and STOSE models are derived from the ovarian surface epithelium. Given the
contribution of the fallopian tube epithelium to human HGSC, spontaneous and transplantable
syngeneic models derived from murine oviductal epithelium are much needed. Endsley and colleagues
described spontaneously transformed murine oviductal epithelial cells derived from CD1 mice that
exhibited features of transformation, but only generated subcutaneous tumors in athymic nude mice,
limiting their use as a syngeneic model for cancer immunotherapy studies [157]. The addition of PTEN
loss in these cells resulted in the first and, currently, the only syngeneic model of fallopian tube-derived
EOC [158].
5.1.2. Genetically Engineered Mouse Models (GEMM)
The majority of GEMM models were generated to improve our understanding of the origin(s)
of ovarian cancer. Consequently, most of the characterization of these models has placed primary
emphasis on identifying the location of early lesions and an immunohistochemical panel assessing
positivity for PAX8, P53, WT1, and cytokeratins with a lack of inhibin and calretinin staining.
With emerging immunotherapies targeting the TME, characterization of the majority of GEMM models
has been too narrow to assess their use for testing immunotherapies, although many models may
be ideal because of their shared genomic alterations and TME complexity that phenocopy HGSC.
The various GEMM models of ovarian cancer have been comprehensively reviewed [159,160]. Here,
we discuss some important considerations in using GEMM models for immunotherapy development.
Many models have been made using oncogenic simian-virus 40 T-antigen (SV40TAg) driven
from the ovarian or oviductal epithelium (Table 3). These models include the TgMISIIRTAg model,
which drives SV40TAg expression from the MISIIR gene, leading to ovarian tumor development
in 50% of mice at 6–13 weeks of age [161]. The use of this model has revealed a synergistic
effect of the viral sensitizer colchicine and vaccinia virotherapy [109]. Epigenetic combination
therapy, entinostat and azacytidine, was shown to enhance MHC class II expression in TgMISIIRTAg
tumors [144]. The TgCAG-LS-TAg model that drives SV40TAg from the chicken β-actin promoter
was used to show that estrogen can accelerate EOC development, though an immune basis for this
acceleration was not explored [162]. Another model used the oviduct-specific gene, Ovgp1, to drive
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SV40TAg expression generating tumors derived from oviductal epithelial cells [163]. Although these
results showed promise, the use of SV40TAg for immunotherapy studies should proceed with
caution as SV40TAg is both an oncogenic driver and a dominant immunogen. Schietinger and
colleagues designed a sophisticated experiment in which SV40TAg-specific T cells (TCRSV40-1) and
OT-I T cells were co-injected into liver tumor-bearing ASTxAlb–Cre mice that constitutively express
SV40TAg. Only TCRSV40-1 cells became dysfunctional in the presence of cognate SV40TAg with
enhanced expression of PD-1, TIM-3, LAG-3, and 2B4, while OT-I T cells maintained their functional
expression of IFNγ and TNFα [164]. This showed that SV40TAg expression strongly inhibited effective
T cell responses with little contribution from the immunosuppressive TME, because OT-I T cells
maintained their functional phenotype within the TME. Thus, a strong clonal response to a persistent
dominant antigen was enough to reduce the influence of the TME, which does not reflect the normal
contribution of the TME in suppressing antitumor immunity in HGSC (reviewed in the literature [165]).
Further, McGranahan and colleagues recently showed that effective cancer immunotherapy goes
beyond total mutational burden and requires a clonal neoantigen T-cell response [166]. Patients who
exhibit increased intratumoral neoantigen heterogeneity (subclonality) have reduced clinical benefit
to immune checkpoint inhibition. They further showed that chemotherapy can induce neoantigen
heterogeneity [166]. Thus, using models with a dominant antigen, such as SV40TAg, which can
abrogate the effects of the TME, could confound the interpretation of an immunotherapy’s efficacy.
Models that have neoantigen heterogeneity or lack authentic neoantigens (like the ID8 cells) may better
phenocopy HGSC, as only 12% of HGSC are likely to express ≥ 1 neoantigen [147].
Given that 94% of HGSCs possess TP53 mutations, with 35% of tumors expressing high levels of
TP53 and 62% expressing little to no detectable TP53 [151], immunotherapies should be tested in models
that represent both high and low p53 expression. Multiple GEMMs have either Trp53 knockout or Trp53
mutation, driven from both the ovarian and oviductal epithelium [167–170]. HGSCs with mutant TP53
have higher PD-L1 expression than tumors with wild-type TP53, indicating a role for mutant TP53 in
modulating the TME, though the exact TP53 mutations were not specified [171]. The effect of TP53
loss was further corroborated by Son and colleagues who showed p53 loss enhanced pro-inflammatory
cytokine (CXCL1, CXCL2, CXCL3, and CXCL8; and TNFα) expression in HGSC [172]. More studies
are needed to elucidate the effects of specific TP53 mutations on the ovarian cancer TME.
Interestingly, hereditary BRCA1/2 mutations lead to higher mutational burden and neoantigen
burden that correlates with improved survival, increased TILs, and increased PD-1/PD-L1 expression,
indicating that these tumors may especially benefit from immune checkpoint inhibition [155,171].
Perets and colleagues generated GEMMs with doxycycline-inducible Cre-recombinase mediated
deletion of Brca1 or 2 and Pten, and Trp53 loss or mutation, driven from the oviductal
epithelium-specific Pax8 promoter. All combinations yielded HGSC-like tumors with high mutational
burden and genomic alterations similar to the TCGA dataset on ovarian carcinoma such as c-myc
amplification [169]. Similarly, Zhai and colleagues characterized a model of tamoxifen-inducible
deletion of Brca1, Pten, Rb1, and Nf1 driven from the Ovgp1 promoter, which generated serous-tubal
intraepithelial carcinomas that progressed to HGSC. They also characterized a similar model with
deletion of Brca1, Pten, and p53 that also developed precursor lesions and HGSC, but with a mixed
tumor phenotype with mucinous metaplasia [173]. These models have numerous features relevant to
human disease and profiling the immune landscape and mutational and neoantigen burden would be
exciting additions to extend the use of these models into the realm of cancer immunotherapy.
One GEMM study that profiled the TME was done by Budiu and colleagues, using mice that
express human MUC1 from the endogenous promoter that were then crossed with mice containing
conditional alleles for Pten deletion and activation of KrasG12D [174]. MUC1 is overexpressed in
75–90% of human EOC and, interestingly, tumor-associated MUC1 is more immunogenic because of
the loss of glycosylation, revealing epitopes that can be targeted by antibodies and specific CD8+ T cell
responses [175–177]. The MUC1KrasPTEN model generates ovarian tumors with high serum levels of
human MUC1, robust CD4+FOXP3+ TILs, and dysfunctional DCs [174]. Mice that expressed human
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MUC1 had a larger splenic Treg population than KrasPTEN mice alone. Using a MUC1 vaccination
strategy along with a type 1 DC polarizing cocktail, they were able to reduce Tregs and enhance
survival in MUC1KrasPTEN tumor-bearing mice [174]. This model allows for a MUC1-directed
antitumor response that could be modulated by a vaccination strategy targeting the TME. In this
aspect, this model improves upon SV40TAg models where the immunogen is too dominant to see any
effect of the TME modulation [164].
Although GEMM models enable us to better model the origins of disease and genomic alterations
characteristic of HGSC, they have two weaknesses that limit their use for immunotherapy. Firstly,
most GEMMs have been generated on a mixed strain background, preventing the generation of
transplantable syngeneic cell lines. Secondly, although GEMMs may reproducibly generate tumors,
they tend to arise over a wide course of time. The difficulty in controlling tumor onset and size in
GEMMs introduces a logistical challenge for immunotherapy studies that rely on flow cytometric
analysis of immune populations that are generally performed simultaneously at one point in time. In
contrast, this limitation is easily overcome with transplantable syngeneic models, such as the ID8 and
STOSE models, where tumor onset is uniform and controlled.
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6. Human-Derived and Autologous Cultures
Numerous ovarian cancer cell lines have been used historically with inconsistencies in their
relevance to human HGSC, particularly A2780 and SKOV3 cells, which are unlikely to represent
HGSC (reviewed in the literature [185]). Recently, HGSC primary cultures have been established
that have genomic alterations, TAA expression, and gene expression profiles consistent with TCGA
datasets [186–188]. These primary cultures offer resources for TAA discovery, infectivity with oncolytic
viruses, and developing methods to increase immunogenicity. The major weakness of using primary
cultures is that tumorigenesis can only be studied in xenografts using immunodeficient mice that fail
to develop a complex TME with the immune subsets seen in patient tumors.
Ovarian cancers are rich resources for easily accessible cancer and immune cells from ascites fluid.
Ascites fluid is remarkably immunosuppressive, containing high levels of Tregs and MDSCs [47,143].
Ascites have been a source for NK cells, where ex vivo expansion restored their cytotoxicity against
autologous CD45-EpCAM+ cells [189]. Nounamo and colleagues showed that myxoma virus can
prevent the secretion of IL-10 from ascites-derived CD14+ myeloid cells, thereby providing in vitro
evidence that myxoma virus may remodel the ascites microenvironment to facilitate stronger antitumor
immunity [143]. An interesting approach was developed by Freedman and colleagues using an
oncolytic adenovirus expressing a bispecific T cell engager (BiTE) that targets autologous CD8+ T
cells to EpCAM+ ascites cells and pleural effusions. Remarkably, even in the presence of ascitic fluid,
EnAdEpCAMBiTE stimulated T cell proliferation and cytotoxicity against EpCAM+ ascites cells [190].
A co-culture system has also been developed to assess the efficacy of CAR-T cell therapy by culturing
dissociated primary ovarian tumors with autologous derived anti-5T4 CAR-T cells [34]. Even though
the use of human samples has limitations for studying the ovarian cancer TME, they offer invaluable
resources to determine the specificity of both innate and adaptive targeted immunotherapies.
7. Summary
Further studies about EOC TME evolution during disease and treatment are needed. Importantly,
heterogeneity among metastatic and primary tumors within a single patient can coexist [191], and this
heterogeneity can influence the immune cell landscape, thereby affecting prognosis and therapeutic
responses. Similarly, the ascites TME can respond differently to therapy, because EOC ascites contain
another complex immunosuppressive network. Therefore, the challenges of tumor heterogeneity must
be considered when designing therapeutic strategies for EOC patients.
In this review, we described some of the current emerging immunotherapies that have
shown promising results in animal models and other cancer types and that could be exploited
in EOC. The major barrier in EOC immunotherapy is the highly immunosuppressive TME.
Thus, therapies aiming to decrease immunosuppression as a first line therapy combined with
immunostimulating strategies could succeed in the fight against EOC.
We have also highlighted spontaneous and GEMM syngeneic models of ovarian cancer that
offer promising characteristics for use in immunotherapy research. In moving forward, it will be
important to characterize many of these models for immune infiltration, neoantigen burden, TAA,
and immune checkpoint expression, as well as stromal features, in order to generate meaningful data
for the immunotherapy field that goes beyond survival. Models using dominant immunogens such as
SV40TAg should proceed with caution and require validation in separate models. The use of ovalbumin
may offer a superior model that allows for the modulation of the ovarian cancer TME. Thus far, the ID8
model has been the most widely used, but given recent findings on the weak immunogenicity of ID8
cells [147], novel therapeutics should be tested in both spontaneous and GEMM models that cover a
wide range of the tumor heterogeneity seen in the clinic.
New sequencing technologies have enhanced our ability to look deeper into tumors, stroma, and
TIL compartments. These studies have revealed the impact of genetic heterogeneity and epigenetic
plasticity in cancer evolution during treatment (drug resistance) and clinical outcome [192,193].
At present, we know that a tumor is not a single entity determined solely by genetic alterations,
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but a whole complex network that affects surrounding healthy cells provoking tumorigenesis
advantage. Thus, in order to achieve significant responses to eradicate neoplastic cells, TME screening
(TIL composition and quality) must be considered to better assign a therapeutic strategy to a patient,
especially in advanced EOC stages. The detection of key biomarkers allowing the prediction of
responsiveness to an immunotherapeutic approach is also necessary to select the best strategies and
combined therapies that have the maximum potential to fully eradicate cancers [1].
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Špíšek, R.; Fialová, A. Expression of tumor antigens on primary ovarian cancer cells compared to established
ovarian cancer cell lines. Oncotarget 2016, 7, 46120–46126. [CrossRef] [PubMed]
189. Nham, T.; Poznanski, S.M.; Fan, I.Y.; Shenouda, M.M.; Chew, M.V.; Lee, A.J.; Vahedi, F.; Karimi, Y.; Butcher, M.;
Lee, D.A.; et al. Ex vivo-expanded NK cells from blood and ascites of ovarian cancer patients are cytotoxic
against autologous primary ovarian cancer cells. Cancer Immunol. Immunother. 2018, 67, 575–587. [CrossRef]
[PubMed]
190. Freedman, J.D.; Hagel, J.; Scott, E.M.; Psallidas, I.; Gupta, A.; Spiers, L.; Miller, P.; Kanellakis, N.; Ashfield, R.;
Fisher, K.D.; et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer
biopsies. EMBO Mol. Med. 2017, 9, 1067–1087. [CrossRef] [PubMed]
191. Jiménez-Sánchez, A.; Memon, D.; Pourpe, S.; Veeraraghavan, H.; Li, Y.; Vargas, H.A.; Gill, M.B.; Park, K.J.;
Zivanovic, O.; Konner, J.; et al. Heterogeneous tumor-immune microenvironments among differentially
growing metastases in an ovarian cancer patient. Cell 2017, 170, 927–938. [CrossRef] [PubMed]
184
Cancers 2018, 10, 244
192. Greaves, M. Evolutionary determinants of cancer. Cancer Discov. 2015, 5, 806–820. [CrossRef] [PubMed]
193. McGranahan, N.; Swanton, C. Cancer evolution constrained by the immune microenvironment. Cell 2017,
170, 825–827. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution




Regulation of Ovarian Cancer Prognosis by Immune
Cells in the Tumor Microenvironment
Maureen L. Drakes * and Patrick J. Stiff
Cardinal Bernardin Cancer Center, Department of Medicine, Loyola University Chicago, Building 112,
2160 South First Avenue, Maywood, IL 60153, USA; pstiff@lumc.edu
* Correspondence: mdrakes@luc.edu; Tel.: +1-708-327-3125
Received: 8 August 2018; Accepted: 29 August 2018; Published: 1 September 2018
Abstract: It is estimated that in the United States in 2018 there will be 22,240 new cases of ovarian
cancer and 14,070 deaths due to this malignancy. The most common subgroup of this disease is
high-grade serous ovarian cancer (HGSOC), which is known for its aggressiveness, high recurrence
rate, metastasis to other sites, and the development of resistance to conventional therapy. It is
important to understand the ovarian cancer tumor microenvironment (TME) from the viewpoint of
the function of pre-existing immune cells, as immunocompetent cells are crucial to mounting robust
antitumor responses to prevent visible tumor lesions, disease progression, or recurrence. Networks
consisting of innate and adaptive immune cells, metabolic pathways, intracellular signaling molecules,
and a vast array of soluble factors, shape the pathogenic nature of the TME and are useful prognostic
indicators of responses to conventional therapy and immunotherapy, and subsequent survival rates.
This review highlights key immune cells and soluble molecules in the TME of ovarian cancer, which
are important in the development of effective antitumor immunity, as well as those that impair
effector T cell activity. A more insightful knowledge of the HGSOC TME will reveal potential immune
biomarkers to aid in the early detection of this disease, as well as biomarkers that may be targeted to
advance the design of novel therapies that induce potent antitumor immunity and survival benefit.
Keywords: tumor microenvironment; immune inhibition; tumor-infiltrating lymphocytes;
tumor-associated macrophages; dendritic cells; antitumor immunity; immunotherapy
1. Introduction
Ovarian cancer may be divided into six subgroups, namely, serous, mucinous, endometroid,
transitional-cell, clear-cell, and squamous carcinoma [1]. The most common group is high-grade
serous ovarian carcinoma (HGSOC), a disease that escapes detection and diagnosis until after it
is disseminated to areas of the abdomen and beyond. At this advanced stage, survival is dismal,
with only about twenty percent of patients diagnosed at International Federation of Gynecology and
Obstetrics (FIGO) stage III or IV disease fortunate enough to reach a five-year survival time point,
since most of these individuals become resistant to conventional therapy and succumb to disease.
This disease grows aggressively, often recurs at the primary or metastatic sites, and is the most deadly
of gynecologic cancers [2,3].
HGSOC is believed to arise from the ovarian-surface epithelium and/or the fallopian
epithelium [4]. Most patients (96%) with this disease have TP53 mutations, with BRCA1/2
(22% patients) mutations also common [5,6]. An accompanying feature of HGSOC is an accumulation
of ascites fluid in the peritoneal cavity, which allows the adhesion of cancer cells to the omentum
(connective and fatty tissue covering the ventral surface of the intestines) and serous membranes lining
the peritoneal organs [7], thereby increasing the potential of cancer lesions at these sites soon after the
primary disease is established [8,9].
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The tumor microenvironment (TME) in HGSOC is comprised of an intricate system of immune
cells, including subsets of T cells, dendritic cells, macrophages, and NK cells, as well as soluble factors
elaborated by myriads of existing cell types, both spontaneously and as a result of their networking
interactions [10,11]. Studies on the ovarian TME in HGSOC have been prompted by the need to
understand the disease biology, with the goal of targeting cancer-promoting immune mechanisms,
and providing effective therapies for the management and ultimately a cure for HGSOC. The full
significance of the ovarian TME in determining disease progression, recurrence, or regression is yet to
be revealed. This review focuses on the dynamic and diverse immune components in the ovarian TME
and how they mediate the balance between protumor and antitumor immunity, and patient survival.
2. Immune Regulation by T Cells in the TME
Tumor-associated/infiltrated lymphocytes (TILs) are found in the tumor stroma or in the tumor
islets (intraepithelial TILs). CD3+, CD4+, and CD8+ TILs are usually associated with a positive
outcome [12–16]. Notably, in a study of 186 samples of advanced-stage ovarian cancer, it was found
that 55% patients with CD3+ TILs had a five-year survival of 38%, whereas only 4.5% patients without
detectable TILs reached his survival mark. Moreover, taking into consideration patients who had
surgical debulking and platinum-based chemotherapy, 73.9% of patients with pre-existing TILs had
complete response (CR), while only 11.9% patients without TILs exhibited CR [15].
Some groups have demonstrated that in ovarian-cancer tumor-tissue sections, intraepithelial
CD8+ TILs correlate with good outcome, and others have shown that a high ratio of CD8+/FoxP3+ T
regulatory cells (Tregs) is beneficial to survival [17]. In a meta-analysis of 10 studies and 1815 patients,
both CD3 and CD8 TILS were found to be associated with survival, but CD8+ TILS were the more
significant of these two subsets. Interestingly, in these studies the prognostic value of TILS was more
significant in some geographic regions studied compared with others, raising the possibility that
genetic factors or different levels of access to healthcare may also be relevant factors to consider when
measuring survival in such studies [13].
In detailed investigations with over 5500 patients, including 3196 with HGSOC, it was found
that among the five invasive histotypes studied, HGSOC showed the most infiltration of CD8+ T cells.
Patients were followed over 24,650 person-years. Analysis of CD8+ TILS in the tumor epithelium on a
scale of negative, low, moderate, and high revealed distinct survival differences in HGSOC patients
based on the density of CD8+ TILS in the epithelial components of tumor islets. The median survival
for patients with no CD8+ TILS was 2.8 years, whereas with low, moderate, or high TILS, survival was
3.0 years, 3.8 years, and 5.1 years, respectively. The presence of CD8+ TILS was favorable to outcome
regardless of extent of residual disease, standard therapy or BRCA1 mutation [18].
Others report that the CD8+CD103+ T cell subset are found in abundance in the ovarian-cancer
epithelium, and are associated with a better outcome [19,20]. Together, these studies of CD8+ T cells in
the ovarian TME further emphasize the relevance of these TILS as a prognostic indicator in HGSOC.
Another subset of TILs populating the HGSOC TME are FoxP3+ T regulatory cells. These cells
were initially regarded as a potent immunosuppressive mechanism, limiting the potency of antitumor
immune responses. CD4+CD25+FoxP3+ T regulatory cells may act by elaborating protumor cytokines
such as IL-10 or TGF-β, or by cell–cell contact mechanisms [21]. Despite several early reports
associating this subset of T regulatory cells with a poor outcome [22,23], a meta-analysis of 869 patients
over several studies did not conclude that FoxP3 Tregs in the tumors of ovarian-cancer patients
are a significant prognostic indicator of survival [24]. Yet there are other T cell subsets in the
ovarian TME that may negatively impact survival. These include T cells expressing cytotoxic T
lymphocyte-associated antigen 4 (CTLA-4), glucocorticoid-induced TNF receptor family-related
protein (GITR), or CCR4, CD8+CD28- T regs [25–28], as well as exhausted CD8+T cells expressing
immune checkpoint inhibitory molecules programmed cell death-1 (PD-1) or lymphocyte activation
gene-3 (LAG-3; CD223) [29–31]. These cells may all confer immunosuppression in the TME or limit
antitumor responses (Figure 1). There is still debate in the literature concerning the role of the
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Th17 CD4+ T cell subset in ovarian cancer, but some have reported that these cells have an inverse
relationship with Tregs, and correlate with survival [32,33].
Figure 1. Schematic representation of the primary immune components in the tumor microenvironment
(TME). Several cell types in the TME of high-grade serous ovarian carcinoma (HGSOC) elaborate factors
that can lead to immune dysregulation and inhibition of antitumor responses. The ascites of these
patients is rich in TGF-β, IL-6, IL-8, IL-10, vascular endothelial growth factor (VEGF), and CCL22
and other factors released by contributing cell types as shown in the graphic. CCL22 (the ligand
for CCR4) preferentially recruits Tregs into tumors. Exhausted CD8 T cells in tumors express PD-1
and LAG-3 and secrete low quantities of IFN-γ. Several Treg subsets exist in the TME, each bearing
some of the phenotypic markers, CD4, CD8, CCR4, FoxP3, CD25, GITR, or CTLA-4, and primarily
release TGF-β and IL-10. Molecules such as recepteur d’origine nantais (RON) on tumor cells are
associated with invasiveness, and tumor associated antigens (TAAs) such as New York Esophageal
antigen-1 (NY-ESO-1), human epidermal growth factor receptor 2 (HER-2), and Wilm’s tumor-1 (WT-1)
are immunogenic targets. Immune-suppressive mechanisms in the TME that foster tumor initiation,
progression, and recurrence may be reversed with combinations of conventional and novel therapies,
designed to potentiate antitumor immune responses. Parameters consistent with disease improvement
include CD8+ T cells secreting IFN-γ, perforin, and granzyme B, which facilitate the killing of tumor
cells. Additionally, DC-secreted chemokines, such as CXCL9 and CXCL10, can recruit CD4+ and CD8+
immunocompetent T cells, and IL-16-a-cytokine secreted by T cells, macrophages, and dendritic cells,
is a primary chemoattractant for CD4+T cells in ovarian cancer.
188
Cancers 2018, 10, 302
In addition to their prime role in immune surveillance limiting the initiation of ovarian cancer
and other cancers [34–37], immunocompetent TILs can recognize cancer antigens or overexpressed
self-antigens that have been processed by antigen-presenting cells, and mount potent antitumor
immune responses. CD4+ TILs can recruit dendritic cells that can prime T cells to exert their cytotoxic
effects by secreting perforin, granzyme B, or Fas ligand (cell death receptor ligand; FasL; CD95L),
which may directly kill cancer cells. Both cytotoxic CD8+ and CD4+ TILs cells secrete cytokines such as
IFN-γ and IL-2 [38] that can induce other cells in the TME to mount antitumor immunity, and promote
longer survival. In the ovarian tumor, IL-16, primarily a Th1 cytokine, has been reported to be a critical
chemoattractant for the recruitment of CD4+ T cells into the tumor [39].
However, there is an ongoing interplay between TILs and the TME, and by suppressing the
function and limiting the infiltration of CD3+, CD4+, or CD8+ TILs, tumors can circumvent antitumor
immunity, especially in TME where TILs were already low in numbers at the time of diagnosis.
Exclusion or inhibitory mechanisms imposed on TILs in the ovarian TME are as follows. Increased
angiogenesis in ovarian-cancer cells presents a great barrier to the infiltration of tumor-specific
T cells, thereby reducing the numbers of TILs in patients’ tumors. TGF-β increases angiogenesis
directly as well as suppresses the proliferation and activation of TILs [40,41]. Overexpressed
vascular endothelial growth factor (VEGF) can enhance the proliferation, migration, and invasion
of endothelial cells and is associated with poor outcomes in ovarian cancer [42]. VEGF-A decreases
the adhesive interaction between lymphocytes and tumor vascular endothelial cells, and reduces TIL
penetration through deregulation of intercellular adhesion molecule-1 (ICAM-1) and vascular cell
adhesion-molecule-1 (VCAM-1) [43]. Furthermore, VEGF-A in concert with IL-10 and PGE2 induces
FasL in endothelial cells. Increased FasL in endothelial cells favors the selective trafficking of Tregs
above CD8+ immunocompetent T cells [44]. Several other molecules in the tumor endothelium, such as
programmed cell death-1 ligand (PD-L1), B7-H3, arginase-1 (ARG-1), indoleamine 2,3, dioxygenase
(IDO), IL-10, and PGE2, released by endothelial cells, downregulate TIL function or kill CD8+ effector
TILs [45–49].
The density of TILs in tumors has recently been used to categorize tumors. Tumors are termed
“hot” or immunogenic if they consist of high numbers of TILs, whereas “cold tumors” have much
fewer TILs [50,51], and patients in this latter group are likely to have a poor response to therapy.
An understanding of T cell subsets in relation to inhibitory mechanisms in the ovarian TME at baseline
diagnosis is crucial to effectively designing novel therapies for HGSOC, and to predict outcome
after treatment regimens, as T cells (especially CD8+ T cells) may be the critical antitumor effector
mechanism in the disease. The success of these therapies may depend largely on the ability of T cells
to reverse immune dysregulation at the site of the disease.
3. Multifaceted Nature of Macrophages in the TME
In contrast to immunocompetent T cells, the majority of myeloid lineage cells in the ovarian TME
are generally of a protumor propensity [52,53]. Subpopulations of myeloid lineage cells in the TME of
patients consist of a variety of phenotypes and nomenclature [54,55] (Table 1).
Tumor-associated macrophages (TAMS) are the major subpopulation of this lineage cells in the
ovarian TME. TAMS can readily change phenotype and function in the presence of soluble molecules
in the surrounding milieu [56,57]. These cells can be recruited from blood monocytes, or arise from
resident peritoneal macrophages [54,58–60]. TAMS from both of these origins have some phenotypes
in common such as the expression of molecules CD163 and CD206, as well as similar levels of genes
for phagocytosis and antigen presentation. However, a distinctive feature of TAMS in the TME is an
upregulation of genes linked to extracellular-matrix (ECM) remodeling [61]. In ovarian cancer, TAMS
are mostly immunosuppressive, and associated with tumor cell invasion, angiogenesis, metastasis and
early relapse [11,62,63].
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Table 1. Phenotypic characterization of myeloid lineage cells in the ovarian TME.




Inflammatory monocyte CD14+, HLA-DR high, CD11c+, CD64+
M1 macrophage HLA-DR+, CD68+, CD80+, CD86+
M2 macrophage HLA-DR+, CD68+, CD163+, CD206+, CD200R
M-MDSC CD11b+, CD33+, CD14+, HLA-DR low
G-MDSC CD11b+, CD33+, CD15+, CD66b+, HLA-DR low
Dendritic cells
Immature DC CD80 low, CD86 low, CD40 low, CD14+, CXCR3+
Mature DC C80 high, CD86 high, CD40 high, CD83+, HLADR high, CCR7+, CD103+
a The primary identification markers of TAM subsets and of myeloid DC in the TME are shown.
In tumors, the benign-to-malignant state is associated with angiogenesis (increase in
vascularization). VEGF, TGF-β, matrix metalloproteinases (MMPs), hypoxia-inducible factor (HIF),
and adrenomedullin (ADM) secreted by TAMS enhance the process of vascularization [64–66].
TAMS are also critical in mediating epithelial–mesenchymal transition (EMT), which is essential
to tumor progression. In this process, polarized epithelial cells change their phenotype to motile
mesenchymal cells. The downregulation of epithelial markers, such as E-cadherin, is replaced by
the upregulation of mesenchymal markers such as vimentin, Slug, Snail, fibronectin, zinc-finger
E-box binding homeobox 1 (ZEB1), ZEB2, and α-smooth muscle actin, allowing cells to migrate
and invade [61,66,67]. These changes correlate with metastasis, recurrence, chemoresistant tumors,
and poor outcome. EMT is mediated by several TAM products, such as TGF-β, hepatocyte growth
factor (HGF), and epidermal growth factor (EGF) [66,68–71].
Studies in ovarian-cancer tissue showed that there is a significant elevation in the numbers of
CD68+ and CD206+ TAMS, and of MMPs expression, in comparison with benign ovarian tissues [72].
This difference was due to higher levels of these parameters in patients with stage III/IV in comparison
with those at stage I/II disease. Furthermore, in patients with positive lymphatic invasion, the numbers
of CD68+, CD206+, and MMP-positive cells was significantly higher than in patients without lymphatic
invasion [72]. Additional studies with SKOV3 ovarian-tumor cells demonstrated that TAMS promoted
upregulation of TLRs 1, 2, 4 and 6, MMP-2, MMP-9, and MMP-10 expression. Ovarian-cancer cell
invasion was enhanced via TLRs signaling pathway and activation of downstream nuclear transcription
factor (NF)-KB p65 and microtubule-associated proteins (MAPs) kinases pathway in SKOV3 cells [72].
In other studies, TAMS enhanced spheroid formation and tumor growth and early ovarian-cancer
metastasis by secreting EGF [62]. TAMS can also be high secretors of CCL18, a chemokine that promotes
tumor migration and metastasis in ovarian cancer [73]. IFN-γ treatment reduces CCL18 secretion and
can switch TAMS to an immunostimulatory phenotype [74]. TAMS in the ovarian-cancer TME are
very low IL-12 secreting, a cytokine that is positively associated with outcome in this disease [61,75,76].
A brief summary of the primary protumor processes regulated by TAMS in the TME is outlined in
Table 2. A more detailed account of TAM activities in the TME is reported elsewhere [66,70].
Table 2. Immune dysregulation by TAMS in the TME.
Mediators a Cell Targets Major Actions
IL-10 CTL Inhibits activation
TGF-β Treg Induces differentiation
TGF-β, HGF, collagen, cathepsin
and serine proteases, EGF, CSF-1 Tumor Increases adhesion, invasion, and EMT
IL-6, TNF-α, WNT, JAG Tumor Promotes survival, growth, stemness
ADM, VEGF, COX-2, MMPs,
HIF-1α, TGF-β Endothelial Angiogenesis
a TAMS elaborate a range of immune molecules and soluble mediators that are involved in the initiation and
progression of cancer.
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Macrophages and monocytes in the ovarian tumor may exhibit polarization to an M2, protumor,
and immunosuppressive state, under the influence of colony-stimulating factor (CSF), IL-4, IL-13,
IL-10, TGF-β and other soluble molecules. M2 (alternatively activated) macrophages secrete IL-10 and
TGF-β and play an active role in tissue remodeling and tumor progression [77,78].
The presence of CD4+ or CD8+ T cells secreting IFN-γ in the tumor can promote the presence of
M1 immunocompetent classically activated macrophages, above an M2 phenotype. M1 macrophages
are stimulated by Toll-like receptors (TLR) ligands and by IFN-γ to give a Th1 response secreting IL-12,
IL-23, and TNF-α. M1 macrophages are highly potent against micro-organisms and tumors, and are
associated with survival in HGSOC [79].
Another subgroup of TAMS that also merits special mention is the myeloid-derived suppressor
cell (MDSC, M-MDSC). This is a group of immature myeloid cells in the TME that correlate well with
heightened disease, increased tumor burden, and resistance to immune therapy in HGSOC [80,81].
These cells have a role in enhancing stemness and promoting metastasis of ovarian-cancer cells by
inducing miRNA101 expression, subsequently repressing the corepressor gene C-terminal binding
protein-2 (CtBP2) [82].
MDSC are also recruited to the ovarian TME under the influence of chemokine receptor CXCR4.
PGE2 is required for the production of chemokine CXCL12, and for the expression of its binding
receptor CXCR4 in these cells [83]. The CXCR4–CXCL12 axis and PGE2 are critical to the progression
of HGSOC [84–86], and negatively impact the function of several immune cells in the TME, as we will
discuss in the subsequent text.
Cyclooxygenase-2 (COX-2, an enzyme required for PGE2 synthesis) and PGE2 drive the differentiation
of CD1a+ DC to CD14+CD33+CD34+ MDSC, and induce the expression of immunosuppressive molecules
IDO, arginase-1 (ARG-1), IL-10, nitric oxide synthase-2 (NOS-2) and COX-2 by MDSC, molecules that limit
CD8+ cytotoxic T cell responses [49,87,88]. Blocking COX-2/PGE2 suppression in MDSC prevents the
accumulation of MDSC and enhances antitumor immunity [85]. Additional stimuli that may recruit
MDSC to the ovarian TME are soluble factors such as VEGF, which are secreted by tumor cells in the
microenvironment [81]. Granulocytic-MDSC (G-MDSC) are also of the myeloid lineage but do not
appear to be a critical factor in the progression of most cancers.
Taken together, TAMS play critical roles in the establishment of cancers, including HGSOC.
Targeting of these cells with anti-CCL2 antibody, anti-CSF-IR inhibitors, anti-CD52 antibody,
and anti-CD11b antibody for therapy of ovarian cancer has been investigated in preclinical models of
ovarian cancer [89–91]. There has also been a limited number of Phase I/II clinical trials blocking TAM
activity in patients [92,93], but to date there is no such approved therapy.
4. Dendritic Cell Function in the Ovarian TME
Dendritic cells capture antigen, process and present antigenic peptide to cells in the immune
system [94]. DC present exogenously captured peptides to CD4+ T cells via MHC class-II,
and endogenous peptide antigens via major histocompatibility complex class-I (MHC-I) to CD8+
T cells. DC can also present exogenously captured antigens as MHC class I associated peptides (cross
presentation), consequently facilitating more efficient CD4+ and CD8+ T cell activity [95,96]. Potent
activation of T cells requires a cognate antigen (signal 1), costimulatory molecules (such as CD80,
CD86, CD40) on DC or other antigen-presenting cells (signal 2), and proinflammatory cytokines
(signal 3). If this process is sequential and efficient the outcome is Th1 (antitumor) immunity by CD4+
and CD8+ T cells. Lack of any of these signals can result in Th2 immunity or immune suppression
mediated by Tregs [97–101]. Tumors can disrupt these signals by strategies such as loss of tumor
antigens, and by the abundance of immunosuppressive soluble factors in the TME that can induce DC
dysfunction [102,103].
Immature myeloid DC are derived from hematopoietic bone-marrow (BM) progenitor cells.
These cells leave the BM enter the bloodstream and reside in lymph nodes or other tissue. They express
costimulatory molecules at low levels, release low levels of cytokines, and are capable of mounting
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only limited immune responses. These cells express chemokine receptors CXCR3, CXCR4, CCR1, 2, 5,
and 6. On stimulation by antigen, immature DC migrate to lymph nodes from tissues and present the
specific antigen to other immune cells [104,105].
DC exposed to antigen undergo a process of maturation, characterized by an increase in
costimulatory molecules, downregulation of existing chemokine receptors, and the acquisition of
CCR7, the latter of which recruits DC to LN, attracted by CCL19 (MIP-3β) and CCL21, chemokines
secreted by DC. Mature DC can activate naïve CD8+ T cells, crosslink with CD40 ligand on other cells,
and secrete IL-12 [94,104–107].
Myeloid DC in tumors are found in low numbers and exhibit many features of immature
DC. The immune-suppressive environment in the ovarian tumor, rich in TGF-β, IL-10, VEGF,
ARG-1, along with inhibitory molecules such as IDO, PD-1, and PD-L1, drives the differentiation of
CD14+CD1a- immature myeloid cells, anergic T cells and Tregs, induces tolerance, and promotes
tumor growth [49,108,109]. In one study, depletion of DC in mice at advanced stages of ovarian cancer
delayed tumor growth [110]. The benefit of mature myeloid DC function in inducing antitumor
immune responses has been exploited in DC vaccine therapy clinical trials in ovarian and other cancers
(NCT00703105) [111–113].
Recent evidence indicates that in melanoma, tumor-residing CD103+ DC were necessary for
CD8+ effector T cell recruitment in the TME. These CD103+ DC have high expression of CXCR3 and
of the transcription molecule Batf3, which possibly controls the development and maintenance of
the DC1 lineage [114–116]. The presence of Baft3-lineage CD103+ DC correlated with the presence
of CXCR3-binding chemokines CXCL9, 10 and 11, which increase the trafficking of effector T cells
into tumors, and are associated with survival in cancers such as HGSOC [117,118]. The lack of
conventional DC as in Batf3 −/− mice abolishes the rejection of immunogenic tumors, the response to
adoptive T cell therapy, and to immune checkpoint blockade [114,115,119,120]. It is plausible that in
the ovarian TME a similar mechanism of recruitment of effector T cells by this DC lineage would be an
immune-enhancing mechanism to counteract the underlying immunosuppressive myeloid networks
that favor disease progression, recurrence, and death.
In addition to immature myeloid-derived DC, plasmacytoid DC also contribute to the
immunosuppressive network in HGSOC. CXCR4 expressing plasmacytoid DC (pDC) precursor cells
are recruited into the ovarian TME by CXCL12 and IL-10 in the tumor [121]. Plasmacytoid DC
(CD4+CD123+BDCA2+) in tumors such as HGSOC are often tolerogenic, and are noted for the release
of IDO, an enzyme that catalyzes tryptophan degradation [47,48]. IDO promotes tumor angiogenesis
and metastasis, and downregulates the proliferation and other functions of TILS [122].
In ovarian cancer, pDC induced IL-10 secreting CD4+ and CD8+ Tregs and enhanced angiogenesis,
mediated by the secretion of TNF-α and IL-8. Tumor pDC produced low quantities of IL-6, TNF-α,
IFN-α, macrophage inflammatory protein-1β (MIP-1β), and RANTES (CCL5) in response to TLR
stimulation, in contrast to pDC from ascites or peripheral blood. In a cohort of 44 ovarian-cancer
patients, pDC were the most abundant DC subset in tumor and malignant ascites, but they were
almost depleted in peripheral blood. The presence of pDC in the tumor only (but not in ascites) was
associated with early relapse [123].
5. Tumor-Associated Neutrophils
Polymorphonuclear neutrophils (PMNS, neutrophils) are of the myeloid lineage of cells and
exhibit some of the phenotypes of G-MDSC (CD33+CD66b+). However, transcriptome analysis shows
these cell types to be two distinct populations [124]. Neutrophils are a heterogenous group of cells
that may be classified into two main functional groups, antitumor (N1) and protumor (N2) [125].
Neutrophils move into tissues from blood under the influence of CXCL1 and CXCL2 and other
mediators [126,127].
The role of tumor-associated neutrophils (TANS) in the ovarian TME is not yet fully elucidated.
Recent investigations showed that coincubation of ovarian-cancer SKOV3 cells with either PMNS
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or PMN lysate changed the polygonal epithelial phenotype of the cells to a spindle shape, causing
a cribform cell growth. This PMN-induced alteration was due to elastase, a prominent protease of
PMN. PMN elastase induced changes in cells were consistent with an EMT process of the cancer
cells, and a more migratory phenotype. These authors also studied 213 HGSOC patient samples and
showed that PMN are a significant portion of TILS in many patients. Some biopsies showed a definite
clustering of PMN and ZEB1 (EMT transcription factor)-positive cancer cells, especially in areas of
low E-cadherin [128]. Transition from an epithelial to mesenchymal profile is characteristic of a more
aggressive nature in cancers.
In the TME, TGF-β appears to be the predominant soluble molecule responsible for tumor
associated neutrophil (TAN) polarization, and inhibition of this molecule favors the accumulation of N1
TANS [125,129]. Neutrophils have a prime role in the initiation of tumors as they act to alter the ECM
and the TME. MMP-9 secreted by neutrophils is a key upregulator of carcinogenesis [130]. Additional
destructive roles of neutrophils in the TME, such as contributing to angiogenesis, extravasation, and
metastases, and suppression of the adaptive immune response are well-reported, as summarized
elsewhere [131–133].
N1 TANS exhibit protection against tumor development through several mechanisms. They may
directly kill tumor cells, or they can promote CD8+ T cell recruitment and activation by elaborating
T cell-attracting chemokines such as CXCL9 and CXCL10, and Th1 cytokines such as IL-12 [134–137].
Several other mechanisms whereby N1 TANS potentiate antitumor immunity have also been
reported [133,138].
The prognostic value of neutrophils in ovarian cancer is further underscored by the findings
of a recent meta-analysis study, which showed that a high neutrophil-to-lymphocyte ratio (NLR)
was associated with worse overall survival (O/S) in some groups of patients (Asians, but not in
Caucasians) [139].
6. Natural Killer Cells
Natural killer (NK) cells are an integral part of the innate immune system. These cells do not
rely on HLA-mediated recognition of tumor targets, rather, the CD16 receptor, the NKG2D receptor
and the NKp30 cytotoxicity receptor on NK cells mediate the death of tumor cells. CD56 high CD16-
NK cells have low cytotoxic potential, whereas CD56 low CD16+ NK cells are more efficient at killing
tumor cells. In ovarian cancer, there may be defects in NK-cell function such as aberrant receptor
or ligand expression, fewer NK cells, or inability of these cells to effectively secrete cytotoxicity
molecules or cytokines, which are all possible mechanisms of immune escape [58]. For example,
cancer cells from ovarian cancer ascites fluid release macrophage migration inhibitory factor (MIF),
a chemokine that stimulates tumor-cell proliferation, migration, and metastasis. MIF transcriptionally
downregulates NKG2D in NK cells and lowers the ability of these cells to kill tumor cells [140].
Additionally, high expression of soluble B7-H6 (a ligand for the NKp30 receptor) was associated with
lowered NKp30 expression on NK cells and reduced NK-cell activity [141]. It has also been reported
that lower B7-H6 expression correlates with reduced metastasis and disease progression, and better
overall survival in ovarian cancer [142].
In the presence of IL-18, NK cells can release chemokines CCL3 and CCL4, which attract immature
DC. Efficient NK–DC interaction in the tumor can lead to increase of CXCR3 and CCR5 on DC,
which can recruit CD8+ effector T cells to tumors, in the presence of chemokines CXCL9, CXCL10,
and CCL5 [143]. Gene-analysis expression from the Immunological Genome Project showed that NK
cells can secrete CCL5, CCL3, XCL1, CXCL1, CCL4, and CCL27A [144,145]. In tumors, NK cells were
strong inducers of conventional DC chemoattractants XCL1 and CCL5. Tumor production of PGE2
could disrupt this process and the ability of DC to secrete chemokines [145]. Taken together, NK cells
can directly regulate tumor-cell numbers through cytotoxic mechanisms, or NK cells can potentiate the
efficacy of antitumor T cell responses through adaptive immune mechanisms.
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Investigations have been conducted using an IL-15 superagonist complex, IL-15N72D/IL-15Rα-Fc
(ALT-803; Altor Bioscience Corporation, FL, USA), which inhibits complement activation, and includes
the addition of a domain to mediate IL-15/IL-15Rα transpresentation to NK cells. In this study,
NOD/SCID/γc−/− (NSG, which do not contain NK/NKT/γδ T/B cells) mice were xenografted
with firefly luciferase-expressing MA148 tumor cells, and sublethally irradiated. Mice were then
administered overnight activated human NK cells, followed by ALT-803, and analyzed for tumor cells
at different time points. When mice were euthanized, a peritoneal lavage was performed and NK-cell
function evaluated [146].
Mice treated with ALT-803 resulted in an NK-dependent significant decrease in tumor. ALT-803
also enhanced the cytotoxic function (as measured by increases in CD107a, IFN-γ, and TNF-α) of NK
cells from PBMC or ascites, when coincubated with ovarian-cancer cell lines [146]. Targeting of NK
cells in a clinical setting may be a promising therapy strategy in HGSOC.
7. Other Components of the Ovarian TME
7.1. TME Architecture
An underlying factor in metastasis involves the attachment of ovarian-cancer cells in ascites to
areas of the abdomen. The mesothelium, the squamous epithelium that covers organs of the peritoneal
cavity, consists of a single layer of mesothelial cells, below which is a basement membrane of collagen,
fibronectin, and laminin, components of the ECM. Some studies showed that cancer cells from ascites
preferentially attach to the basement membrane rather than to mesothelial cells [147], suggesting that
this mesothelial layer may be a limited frontline defence against ovarian-cancer progression. However,
it is also known that ovarian-cancer cells also directly attach to mesothelial cells via β1 integrin and
CD44 [71,148–150]. During this process, ovarian-cancer cells upregulate mesenchymal genes such
as TWIST1 and ZEB1 [149], and decrease the expression of genes such as CDH1, an epithelial gene
for E-cadherin [71]. There are several other processes whereby ovarian-cancer cells may invade the
mesothelial cell layer, such as by actively killing mesothelial cells. In colon-cancer cells for example,
a Fas (expressed on mesothelial cell)- Fas ligand (expressed on cancer cells) mediated mechanism of
killing mesothelial cells has been described [150].
As earlier addressed, TAMS also play a central role in altering the ECM, thereby contributing
to the adhesion, invasion, and proliferation of ovarian-cancer cells. Additionally, adipocytes of the
omentum contribute to a protumor TME by secreting IL-6, IL-8, CCL2, and adiponectin, which support
ovarian-cancer cell metastasis [151].
Cancer-associated fibroblasts (CAFs) contribute to excessive deposition and alteration of the ECM,
creating a barrier that blocks efficient delivery of anticancer drugs and enhancing chemoresistance [152].
CAFs also secrete a range of protumor molecules that create an immunosuppressive milieu in the
ovarian TME, and support the proliferation, invasion, and migration of cancer cells [153–157]. In an
epithelial ovarian-cancer (EOC) xenograft model, human bone-marrow mesenchymal stem cells were
shown to give rise to CAFs that produced IL-6 to enhance tumor growth [158].
7.2. Exosomal Vesicles (EVs)
These vesicles are released by tumor cells and most other cells types of the TME [159,160].
They mediate the transfer of proteins, lipids, and nucleic acids such as DNAs, mRNAs, and miRNAs
between tumor and stroma [161]. EVs range from 30 to 150 nm, whereas microvesicular bodies (MVBs)
are 100 nm to 1 μm [162]. EVs carry molecules such as CD24, and epithelial cell adhesion molecule
(EPCAM1), which directly regulate cancer-cell migration, proteases (MMP2, MMP9), which promote
ECM degradation and cancer invasiveness [160,163,164], or EV-associated mRNAs, such as miR21,
which may induce resistance to paclitaxel [163,165,166].
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8. Interactive Communication in the TME
Characteristics of HGSOC are aggressive growth and recurrence of tumors within the peritoneal
cavity as well as metastasis to other sites. Novel therapy to manage ovarian cancer is tailored
to overcome immune suppressive mechanisms in the TME that contribute to reduced immune
surveillance and immune evasion by tumor cells. Since the TME in each HGSOC patient is both
heterogenous and unique [167], there is the need for a better understanding of the contribution of
the TME to disease outcome, and more adequate tools to evaluate patients in this present era of
personalized therapy.
Blank and colleagues [168] proposed an immunogram model, consisting of seven parameters,
which describes interactions between cancers and the immune system that may occur in individual
patients. In this framework, the assumption is that T cell activity is the ultimate effector mechanism
in therapy response, and that even though other cells, or other factors such as modulation of the
microbiome, may contribute to outcome, the contribution to disease improvement will ultimately
be mediated by enhanced T cell activity. In some patients, overcoming T cell inhibition may be the
only factor that needs to be addressed for disease improvement. The parameters addressed in this
immunogram model, as briefly outlined below, are also helpful for understanding the interactions
between other solid cancers and the immune system.
Tumor foreignness: for example, it is reported that the outcome to anti-CTLA-4 blockade therapy
correlates with increased tumor mutational burden (a measure of neoantigen load) [169].
General Immune status: this may include a study of changes in immune cells in peripheral
blood [170].
Immune cell infiltration: chemokines CXCL9 and CXCL10 that recruit CD8+ effector T cells are
part of a gene signature associated with improved outcome to PD-1 blockade [18,171,172].
Checkpoint molecules: molecules such as PD-1 and PD-L1 on tumor cells or immune cells present
potent immunosupression in TMEs [173–175].
Soluble inhibitors: IDO, a soluble molecule produced by TAMS or pDC, interferes with
anti-CTLA-4 antibody efficacy in mice [176].
Absence of inhibitory tumor metabolism: high serum lactate dehydrogenase concentrations
correlate with poor outcome to anti-CTLA-4 and anti-PD-1 antibody immunotherapy [177].
Tumor sensitivity to immune effectors: Tumor cells have developed several immune evasion
mechanisms, such as inactivation of antigen-presentation machinery [102]. Additionally, by epigenetic
post-translational mechanisms, the TME can select for cancer cells that can downregulate the expression
of some tumor antigens, which would normally be recognized by T cells [178].
Other factors in the TME that regulate communication between cancers and the immune system
include many of the parameters outlined in the preceding text, such as the maturation level and
function of DC, the density and immunosuppressive nature of TAMS, NK-cell activity, and the TME
architecture (Figure 1).
9. Conclusions and Perspectives
A better understanding of the TME in HGSOC will reveal useful diagnostic and prognostic
biomarkers, and advance the development of suitable bioassays for routine clinical use for the detection
and diagnosis of this malignancy. With such a heterogenous disease and multiple immune and
biochemical networks, success in diagnosing this disease and predicting outcome will require multiple
biomarkers, and more sensitive and precise methods of imaging to detect early lesions.
Current tools used to study the TME involve the use of genomics to investigate gene-expression
signatures in the tumors of HGSOC. Verkaak and colleagues described four different gene classifications
in a study of ovarian tumors as differentiated, immunoreactive, mesenchymal, and proliferative [179].
By IHC, the immunoreactive group had increased T lymphocytes, whereas desmoplasia associated
with infiltrating stromal cells was in the mesenchymal group. Patients in the immunoreactive group
had the best survival outcome. Some tumors also exhibited more than one of the 4 gene clusters.
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Findings were validated on an independent dataset of 879 HGSOC-expression profiles. Additional
information to survival outcome and platinum resistance rates was obtained by using survival-outcome
prediction models for association with BRCA1/2 mutation status, residual disease after surgery and
stage of disease [179]. Similar gene-classification models may be useful for the selection of patients
for targeted or immunotherapy, or to predict patient outcome. It is likely that patients exhibiting
mesenchymal signatures may respond better to treatments such as angiogenesis inhibitors.
Additional methods to study the HGSOC TME include combinations of proteomic and
other genomic data output [180,181] and a study approach addressing multiple parameters (such
as gene expression, matrix proteomics, cytokine and chemokine expression, ECM parameters,
and biomechanical properties) on a single biopsy sample for a better understanding of the events
occurring in tumor tissue [182]. Other novel tools to study the ovarian TME include the use of artificial
microenvironments to monitor ovarian-cancer progressiveness [183].
The HGSOC TME is a complex and dynamic interactive entity, which may vary between the
primary disease and at the time of recurrence, and in the quest for more effective therapy design
one needs to take into account pre-existing immunosuppression, as well as emerging resistance
mechanisms with therapy [184]. Attempts to manage ovarian cancer with immunotherapy has not
been as successful as for some other cancers [174,185]. We are hopeful that combining immunotherapy,
such as PD-1 blockade, with other checkpoint inhibitory molecules (such as anti-CTLA-4, anti-TIM-3,
anti-LAG-3), PARP inhibitors, kinase inhibitors, chemotherapeutics [186], dendritic-cell vaccines,
CAR T cell therapy [187,188], or other treatments, will prove to be successful measures to overcome the
multiple immunosuppressive mechanisms in the TME. As a cautionary measure, combination therapy
will require optimizing doses and schedules of regimens, while limiting adverse effects. However,
we anticipate that a combined therapy approach will be the way forward, towards providing effective
therapy for improved survival, and ultimately a cure for HGSOC.
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Abstract: Heated intraperitoneal chemotherapy (HIPEC) has several potential benefits. Higher doses
of chemotherapy can be used with HIPEC because the plasma-peritoneal barrier results in little
absorption into the blood stream. HIPEC offers higher peritoneal penetration in comparison to
an intravenous (IV) regimen and does not have the traditional normothermic intraperitoneal (IP)
regimen limitation of post-operative adhesions. Hyperthermia itself has cytotoxic effects and can
potentiate antineoplastic effects of chemotherapy in part by increasing the depth of tumor penetration
by up to 3 mm. For the treatment of ovarian cancer, HIPEC has been evaluated in the recurrent setting
with secondary cytoreduction. Recent studies, including a prospective trial, have evaluated its role
in primary management of ovarian cancer. This review summarizes previous and ongoing studies
regarding the use of HIPEC in the management of ovarian cancer.
Keywords: ovarian cancer; heated intraperitoneal chemotherapy (HIPEC); intraperitoneal
chemotherapy (IP); cytoreductive surgery; secondary cytoreduction; interval cytoreduction
1. Introduction
Epithelial ovarian cancer (EOC) is the deadliest gynecologic malignancy [1]. The majority of
women are diagnosed at advanced stage with widely metastatic peritoneal disease. Standard of care
involves a combination of surgery and chemotherapy. The ability to surgically resect tumors with
optimal cytoreduction surgery (CRS), ideally to no gross residual disease (R0), is an important positive
prognostic factor [2]. Despite the improvements seen in median survival time with the current standard
of radical tumor CRS and IV carboplatin and paclitaxel, long term survival rates for patients with
advanced epithelial ovarian carcinoma remain disappointing and efforts continue to develop more
effective primary therapy.
For most patients with EOC, the majority of disease burden is in the peritoneal cavity and can
be quantified by the peritoneal cancer index (PCI) [3]. The PCI is a measure of the extent of disease
burden in the peritoneal cavity. Due to this location, normothermic IP chemotherapy has been studied
in prospective clinical trials in the post-operative treatment of primary EOC, and NCCN has noted the
combined IV/IP regimen as preferred regimen for optimally cytoreduced Stage III EOC. In the setting
of recurrence, treatment guidelines are determined by the time to recurrence and location of metastatic
disease. HIPEC during CRS for EOC has been gaining more attention in the treatment of metastatic
peritoneal disease. Specifically, HIPEC has more frequently been utilized in the recurrent setting with
secondary CRS, but recent studies have evaluated its role in primary management of ovarian cancer.
The aim of this article is to review previous and ongoing studies regarding the use of HIPEC in context
of the overall use of IP chemotherapy for the treatment of EOC.
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2. Normothermic Intraperitoneal Chemotherapy
In normothermic IP chemotherapy, cisplatin and paclitaxel are injected into the patient’s peritoneal
cavity through an intraabdominal port. IP chemotherapy is administered in the post-operative period
over a course of up to six cycles. Three large prospective randomized studies support the use of IP
chemotherapy in the primary treatment of EOC. In the Gynecologic Oncology Group (GOG) 104 study,
patients were randomized to two arms: the control arm of cisplatin and cyclophosphamide IV and the
experimental arm of cisplatin IP and cyclophosphamide IV. While there was a statistically significant
overall survival (OS) benefit to the IP regimen of 49 months in comparison to 41 months for the
IV regimen, consensus was the benefits of IP chemo are not greater than the benefits of new agent
paclitaxel [4]. In GOG 114, patients in the control arm received six cycles of cisplatin and paclitaxel IV
with an OS of 52.5 months and the experimental arm received two cycles of carboplatin IV, followed
by six cycles of cisplatin and paclitaxel IP with an OS of 63.2 months. Progression free survival (PFS)
and OS were statistically significant, but were partially attributed to the addition of two extra cycles of
chemotherapy in the IP arm [5].
GOG 172 influenced practice patterns in the United States. The IV/IP regimen of IP cisplatin and
paclitaxel, plus IV paclitaxel demonstrated the longest median OS compared to IV carboplatin and
paclitaxel in patients with optimally cytoreduced stage III ovarian cancer. The median PFS for the
IV alone and IV/IP regimens was 18.3 and 23.8 months, respectively. The median OS for the IV and
the IP regimens was 49.7 and 66.9 months, respectively. Due to chemotherapy-associated toxicities,
only 42% of women on the IP regimen actually received six cycles of therapy, and 49% received three
or fewer IP cycles [6]. Because the OS benefit outweighed the toxicity of the regimen, the NCI Clinical
Announcement recognized the superiority of IP chemotherapy in the optimal disease setting [7].
In a follow up analysis of the mature data of GOG 114 and GOG 172 combined, an OS benefit
remains significant for IP regimens after 10 years of follow up. This benefit in OS was most pronounced
in patients who underwent optimal CRS to R0 treated with the IP regimen. Specifically, in GOG 172,
the OS was 127 months in this subset of patients [8]. There was also a correlation noted between
survival and the number of IP cycles completed in a separate follow up analysis [9].
Despite the favorable OS for IP chemotherapy, the IP cisplatin-based chemotherapy regimen has
not been universally accepted as a standard treatment for EOC secondary to regimen toxicity and IP
catheter access device problems. A more recent large prospective trial, GOG 252, compared weekly IV
chemotherapy regimens to varying dose reduced IP regimens. All arms of the trial had bevacizumab
added during treatment and as maintenance. No significant differences in PFS were observed between
the three arms. In comparison to GOG 172, more patients were able to complete the IP regimens,
but all arms had excessive toxicity. One concern in interpreting the data from GOG 252 is the addition
of bevacizumab to all arms could have influenced the results and analysis [10]. With the inability
to replicate the results from GOG 172 and the limitation to access IP chemotherapy outside of the
tertiary setting, there has been increased interest in HIPEC as a treatment alternative in the primary
and recurrent ovarian cancer setting.
3. HIPEC
In HIPEC, heated intraabdominal chemotherapy is administered at the time of CRS. HIPEC
has several potential benefits. High-dose chemotherapy can be used because the plasma-peritoneal
barrier results in little absorption into the blood stream [11,12]. In addition, there is higher peritoneal
penetration in comparison to IV regimen, and HIPEC does not have the limitation of traditional IP
regimen of post-operative adhesions [13,14]. Hyperthermia itself has cytotoxic effects and can increase
the depth of tumor penetration by the chemotherapeutic agent up to 3 mm and moreover can potentiate
its antineoplastic effects [15–18].
A major historic limitation to HIPEC is the previously reported morbidity and mortality and
thus its use was often discouraged [19]. To proceed with HIPEC, CRS to R0, CC0 (non-visible disease
remaining) or CC1 (less than 2.5 mm visible disease remaining) is required and involves radical
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and complex surgeries that are associated with higher complication rates. Currently, particularly in
high-volume centers with HIPEC specialists, morbidity and mortality has drastically improved [20,21].
One large retrospective review of 694 patients, treated between 2005 and 2011, utilizing the American
College of Surgeons National Surgical Quality Improvement Program (ACS NSQUIP) database,
demonstrated a complication rate of 33% and 30-day mortality of 2.3%, both rates consistent with
outcomes for other major complex abdominal operations [21].
In EOC, HIPEC has been evaluated in the primary and recurrent setting. The majority of published
data regarding this treatment modality is retrospective, but recently some prospective data has been
published. Here we will review study outcomes with HIPEC in the management of primary and
recurrent ovarian cancer as well as review ongoing trials.
4. HIPEC in the Primary Treatment of Ovarian Cancer
The largest prospective randomized clinical trial demonstrated a survival advantage for patients
who received HIPEC, compared to standard IV chemotherapy, for the treatment of primary EOC.
(Table 1) All patients received neoadjuvant chemotherapy after determining they were not eligible
for primary CRS and had to have at least stable disease after receiving up-front IV chemotherapy.
The control arm received standard IV chemotherapy before and after CRS (PFS = 10.7 months,
OS = 33.9 months). The experimental arm received the same standard IV chemotherapy but also
received HIPEC with cisplatin during CRS (PFS = 14.2 months (p = 0.01), OS = 45.7 months (p = 0.02)).
Over 90% of patients completed full six cycles of IV chemotherapy in both arms [22]. While the PFS
and OS in this trial are shorter than the previous mentioned normothermic IP trials, it should be noted
that this is a different patient population. The PFS and OS survival in the control arm of this trial
are similar to established data in patients receiving NACT and interval CRS [23]. Similarly, a large
retrospective study from Italy showed improved outcomes in patients who underwent HIPEC after
having a complete or partial response to neoadjuvant IV chemotherapy in comparison to HIPEC at
primary CRS. [24,25] In addition to standardizing the HIPEC procedure, the time of administration of
HIPEC is another important factor.
Table 1. HIPEC primary trials.
Author Study type N 1 Chemotherapy PFS OS
Van Driel, et al. [23] Prospective 245 Cisplatin 14.2 months 45.7 months
Bakrin, et al. [26] Retrospectivecohort 92 Cisplatin (80%)
2 n/a CC0: 41.5months
Gonzalez Bayon, et al. [27] Prospective 15 Cisplatin andDoxorubicin n/a 77.8 months
Cascales-Campos, et al. [28] RetrospectiveSeries 52 Paclitaxel
1 year: 81%
3 years: 63% n/a
Bae, et al. [29] RetrospectiveCase Control 67
Carboplatin or
Paclitaxel 3 years: 56.3% 3 years: 66.1%
1: Number of HIPEC patients in trial. 2: Chemotherapy included in analysis: included cisplatin, doxorubicin,
oxaliplatin, mitomycin, cisplatin and mitomycin, and cisplatin and doxorubicin
A retrospective cohort study from France looked at 92 patients receiving HIPEC for primary EOC
treatment. The majority (60.8%) received consolidation HIPEC treatment after receiving 6–9 cycles of IV
carboplatin and paclitaxel. The rest received HIPEC at primary CRS (13%) and at interval CRS (26.1%.)
The majority of patients received cisplatin HIPEC (80.4%,) but 35.9% did receive a second agent
with HIPEC, either doxorubicin (19.6%) or mitomycin (18.5%). Significant to survival were timing
of HIPEC, peritoneal cancer index (PCI), and R0 CRS. Longest median OS was seen in the primary
CRS group at 52.7 months, followed by interval CRS at 36.5 months and then consolidation HIPEC at
33.4 months (p = 0.03.) Of all primary HIPEC patients, those able to be optimally cytoreduced to less
than 2.5 millimeters (mm) had a median survival of 41.5 months compared to 21.2 months in those
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with residual disease greater than 2.5 mm (p < 0.01) [26]. Again, this is a different patient population
than was evaluated in previous normothermic IP trials; therefore we cannot make direct comparisons.
A trial from Spain prospectively evaluated a smaller series of primary, first recurrence and
second recurrence EOC patients. Fifteen patients received HIPEC in the primary setting, and all
received neoadjuvant chemotherapy. All patients received a combination of cisplatin and doxorubicin
chemotherapy during HIPEC. The majority (73%) of patients were optimally cytoreduced to no
gross residual cancer, and the median OS was remarkably 77.8 months in this patient population.
This survival is similar to previously published normothermic IP chemotherapy data, but, again,
we cannot compare such a small series of patients with different parameters [27].
Another larger trial from Spain was a case control series evaluating HIPEC in both the primary
and interval CRS setting. Twenty three patients underwent primary cytoreduction with HIPEC and
29 patients underwent neoadjuvant chemotherapy and then interval CRS with HIPEC. All patients had
CC0 CRS to no visible residual disease. Interestingly, the PCI was significantly higher in the HIPEC
arm meaning that these patients had a larger tumor burden at the beginning of surgery. Also, a higher
rate of bowel anastomosis and peritoneal stripping was observed in the HIPEC arm, but these cases
were performed after data was published showing that aggressive CRS is associated with improved
survival. In contrast, most of the control arm cases were performed before this time period. While the
ovarian histology was not categorized, they did identify tumor grade. Up to 30% of tumors in the
HIPEC arm were low grade which is a higher than typical ratio. No information was provided of how
many cycles of IV chemotherapy was completed. While unable to complete analysis of OS, the disease
free survival (DFS) was followed at 1, 2 and 3 years. In the control arm, respectively, the DFS was 66%,
33%, 18%; and in the HIPEC arm, the DFS was 81%, 67%, 63% (p < 0.01). It was noted that the survival
benefit of HIPEC was not significant in undifferentiated tumors [28].
A retrospective review from South Korea evaluated the role of HIPEC as consolidation treatment
at the end of primary IV chemotherapy. All patients underwent primary CRS (included both CC0 and
suboptimal patients in analysis) then received adjuvant IV chemotherapy. Patients then underwent a
planned secondary CRS. There were 29 patients in the control arm and 67 in the HIPEC arm. HIPEC
patients received either single agent carboplatin or paclitaxel at time of CRS. Early stage EOC did
not show a survival advantage with HIPEC treatment. However, for stage III control and HIPEC
patients, PFS at 3 years was, respectively, 16.7 % and 56.3% (p < 0.01) and OS 32.8% and 66.1% (p < 0.01.)
There was no survival difference between the carboplatin HIPEC and paclitaxel HIPEC subgroups.
A higher hematologic toxicity was seen in the carboplatin HIPEC arm, however [29].
5. HIPEC in the Treatment of Recurrent Ovarian Cancer
Substantially more studies have been published regarding the use of HIPEC in the management
of recurrent ovarian cancer. Although, a significant amount are retrospective, evaluating a small series
of patients or inconsistent with patient parameters and HIPEC dosing. Platinum agents are one of the
most commonly used during HIPEC for ovarian cancer, but the dose varies in trials. A phase I trial
was published regarding the maximum tolerated dose of (MTD) of cisplatin for HIPEC at time of first
recurrence (Table 2). The MTD established was 100 mg/m2 with 25% of patients experiencing Gr 3–4
toxicity. Notably no severe hematologic toxicity at this dose, and over 90% of patients completed all
6 cycles of adjuvant IV chemotherapy. The median PFS of 13.6 months was comparable to previously
published PFS in recurrent ovarian patients treated with IV chemotherapy alone. Peritoneal platinum
concentration was significantly elevated in comparison to plasma levels, and platinum DNA adducts
were found in tumor biopsies after HIPEC confirming cytotoxic activity immediately after a single
dose of cisplatin. A Phase II trial is currently open to further evaluate the efficacy of this dose and
regimen [30].
The retrospective cohort study from France also looked at the role of HIPEC in recurrent ovarian
cancer. The paper included 247 chemo-sensitive (defined as a recurrence interval of greater than six
months after completing IV chemotherapy) and 223 chemo-resistant (defined as a recurrence interval of
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less than six months) EOC patients. Similarly, the majority of patients received cisplatin HIPEC (75.3%,)
but 36.4% did receive a second agent with HIPEC, either doxorubicin (28.1%) or mitomycin (9.1%).
Significant to survival were lower PCI and CC0 CRS. Longest median OS was in patients with PCI score
of 0–8, 59.3 months, followed by patients achieving CC0 CRS, 51.5 months. Interestingly, there was not
a significant difference in survival between the chemo-sensitive (42.2 months) and chemo-resistant
(48.0 months) subgroups. This could signify the benefit of hyperthermia in chemo-resistant tumors [26].
Other studies, however, have shown no benefit to HIPEC in chemo-resistant patients, and this needs
to be further evaluated [25].
The previous trial from Spain prospectively evaluated a smaller series of primary, as well as 19 first
recurrence and eight second recurrence EOC patients. All patients received a combination of cisplatin
and doxorubicin chemotherapy during HIPEC. The majority (74%, 75% respectively) of patients were
optimally CRS to CC0. The median OS was 62.8 months in the first recurrence group and 35.7 months
in the second recurrence group. There was no difference in survival between patients reduced to no
gross residual disease (CC0) and those with less than 2.5 mm of disease (CC1) [27]. The survival in
this study is similar to previously published data of patients being treated with secondary surgery for
recurrent ovarian cancer [31,32].
In a second trial from Spain, a case control review was performed on chemo-sensitive disease at
first recurrence. Chemo-sensitive defined as recurrence greater than 12 months from completion of
treatment. Twenty two patients underwent CRS solely and 39 patients underwent CRS with HIPEC.
All patients included underwent CC0 CRS to no residual disease. Median PFS was 22 months in the
CRS alone group and 21 months in the CRS with HIPEC group. While both groups were optimally
cytoreduced, the HIPEC had a significantly higher PCI score. This could indicate a more aggressive
group of tumors and explain the similar PFS even with the addition of HIPEC. Also, paclitaxel rather
than a platinum agent was used in the trial, and, due to the cell cycle dependent mechanism of action,
it was theorized that it may not be the most effective agent for use during HIPEC. Reassuringly, both
groups had similar post-operative toxicity [33].
Table 2. HIPEC recurrent trials in ovarian cancer.
Author Study type N 1 Chemotherapy PFS OS
Zivanovic et al. [30] Phase Iprospective 12 Cisplatin 13.6 months n/a
Bakrin et al. [26] RetrospectiveCohort 470 Cisplatin (76%)
2 n/a CC0: 51.5months





Cascales-Campos et al. [28] Case control 39 Paclitaxel 21 months n/a
Fagotti et al. [34] Case Control 30 Oxaliplatin 26 months 5 years: 42.7%
Spiliotis et al. [35] Prospective 60 Multiagent 3 n/a 26.7 months
1: Number of HIPEC patients in trial. 2: Chemotherapy included in analysis: included cisplatin, doxorubicin,
oxaliplatin, mitomycin, cisplatin and mitomycin, and cisplatin and doxorubicin. 3: Chemo-sensitive—Cisplatin and
paclitaxel; Chemo-resistant—Doxorubicin with paclitaxel or mitomycin
A similar patient population was studied in Italy. A case control study with 37 patient controls
receiving either CRS and IV chemotherapy (13 patients) or IV chemotherapy alone (24 patients) versus
30 patients undergoing CRS and HIPEC. All patients were experiencing a first recurrence, and the
initial PFS was similar in both the control and case arms. The only significant difference between the
arms was pattern of recurrence. The control arm had significantly more patients with single nodule or
localized recurrence. All control patients achieved CC0 CRS, and 96.7% of HIPEC patients achieved
CC0 CRS. PFS was 15 months in the control arm and 26 months in the HIPEC arm. Interestingly,
over half of the HIPEC patients had a longer secondary PFS after HIPEC than the primary PFS after
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initial treatment. The HIPEC patients had significantly longer OS, secondary PFS, and deaths than the
control group [34].
A prospective trial from Greece evaluated the role of HIPEC at first recurrence. Sixty patients
were randomized to each arm; CRS followed by IV chemotherapy versus CRS with HIPEC followed by
IV chemotherapy. The trial included both chemo-sensitive and chemo-resistant patients. The HIPEC
chemo-sensitive patients were treated with cisplatin and paclitaxel during CRS and the chemo-resistant
were treated with doxorubicin and paclitaxel or mitomycin. Mean OS was 26.7 months in the HIPEC
group versus 13.4 months in the control group (p < 0.01.) The OS was similar in both the HIPEC
chemo-sensitive (26.8 months) and chemo-resistant (26.6 months) subgroups. In comparison, the OS
was significantly different in the control arm chemo-sensitive (15.2 months) and chemo-resistant
(10.2 months) subgroups (p < 0.01.) Both arms achieved similar rates of CC0 CRS. However, the overall
survival in the HIPEC CC0 group was significantly higher (30.9 months) than the control CC0 group
(16.9 months) [35].
6. Discussion
Ovarian cancer is the deadliest gynecologic malignancy in the United States. Normothermic IP
chemotherapy for primary EOC has a known benefit in the optimal CRS setting. Unfortunately,
widespread use has not occurred due to concern for toxicity and patient access to tertiary care
centers. Due to these concerns, there is interest in HIPEC therapy for the management of primary and
recurrent EOC.
The largest HIPEC study published to date was in the setting of primary EOC. A survival benefit
in patients undergoing interval CRS was found with the addition of HIPEC, and there was no difference
in toxicity between the control and HIPEC arms [22]. A critique of the study is that it did not have an
IP chemotherapy arm for comparison. The role of normothermic IP chemotherapy is unclear in the
interval CRS patient population. A phase II randomized trial, OV21/PETROC, was completed and the
IP regimen was found to be well tolerated with reasonable toxicity and no reduction in QOL. There was
a noted decrease in progression of disease at nine months in the IP group, however, as the study was
underpowered, there was no difference found in PFS and OS between the IV and IP arms [36].
More studies have been published in the recurrent setting, however, most are small and
retrospective. A primary critique of HIPEC therapy in EOC is that there is not a standardized regimen.
Platinum agents, specifically cisplatin, are frequently used but at varying doses. The phase I trial
published defining cisplatin 100 mg/m2 as the maximum tolerated dose (MTD) will be important to
consider when moving forward with designing HIPEC trials in EOC. This was the same dose utilized
in the above mentioned primary EOC prospective trial.
Along with varying doses in the recurrent setting, there were varying responses to HIPEC therapy.
Prolonged disease free intervals have been shown in both the first and second recurrence settings.
Interestingly, some trials have shown similar response in both chemo-sensitive and chemo-resistant
recurrences [26]. In one study, the HIPEC arm of patients had a significantly higher PCI at time of CRS
yet similar survival to the control arm [33]. A higher PCI is concerning for a more aggressive tumor
biology, and could mean that the HIPEC played a role in the similar survival. Overall, there has been a
positive significant survival response to HIPEC in the recurrent setting, but almost all published data
is from small, retrospective studies.
A significant concern of HIPEC is the toxicity associated with the regimen. Prospective data
published shows HIPEC to have similar toxicity to CRS followed by IV therapy [22,33]. Again,
these are a limited number of studies, and further evaluation of morbidity and mortality needs to be
performed. Another concern of HIPEC therapy is the increased cost associated with frequent ICU
admissions and length of hospital stay. The inpatient IP regimen was found not cost effective in the
short term in comparison to the traditional IV regimen, but when long term survival analysis was
considered it became more cost effective due to the improved survival [37]. There has been no cost
analysis performed for HIPEC in EOC. The addition of targeted or immunotherapies to IV regimens
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is another popular treatment option being considered. The addition of bevacizumab has been found
not cost effective when considering all advanced stage EOC receiving IV therapy [38]. However,
the cost effectiveness of bevacizumab was improved when looking at a subgroup of patients [39].
This illustrates the significance of identifying appropriate patient populations for specific treatment
modalities. It will be important in future trials to perform comparative cost analysis, especially if
survival outcomes are similar.
7. Conclusions
In conclusion, there is now high quality prospective data suggesting a survival benefit to HIPEC
therapy for patients undergoing primary treatment of EOC after receipt of neoadjuvant chemotherapy
and optimal cytoreduction. Poorer quality data exists supporting its use in other clinical contexts such
as recurrent disease. This treatment has not been studied in multiple clinical contexts, the regimen
and toxicity management has not been standardized and HIPEC has not yet been compared to other
standard treatments such as normothermic IP chemotherapy. Therefore, the treatment of EOC with
HIPEC outside of clinical trial would not be recommended. Further trials are undergoing (Table 3) and
are needed to assess the appropriate patient population and mechanisms of action for HIPEC therapy.
Table 3. Ongoing randomized HIPEC trials in ovarian cancer.
Country PI Phase Time Point Sample Size Chemotherapy
Clinicaltrials.gov
Identifier
South Korea Chang N/A Primary 204 Paclitaxel NCT03448354
United States Momeni 1 Recurrent 20 Carboplatin NCT02672098
Italy Not provided N/A Recurrent 158 Cisplatin NCT01538785
Spain Villarejo Campos 3 Primary orrecurrent 94 Paclitaxel NCT02681432
China Cui 3 Primary orrecurrent 214
Paclitaxeland
cisplatin NCT03373058
United States Jewell 2 Primary 20 Cisplatin NCT03321188
Italy, Germany Ansaloni 3 Primary 94 Cisplatin andpaclitaxel NCT01628380
Mexico Salcedo-Hernandez 2 Primary 100 Cisplatin anddoxorubicin NCT03275194
Spain Villarejo Campos 3 Primary orrecurrent 32 Cisplatin NCT02328716
Belgium, France,
Spain Classe 3 Recurrent 444 Cisplatin NCT01376752
France not provided 3 Recurrent 220 Cisplatin NCT03220932
United States Zivanovic 2 Recurrent 98 Carboplatin NCT01767675
India Solanki N/A Primary orrecurrent 150 Not provided NCT02754115
United States Sardi 2 Primary 48 Carboplatin NCT02124421
United States Kelly 2 Primary orrecurrent 40 Carboplatin NCT03188432
United States Dellinger 1 Primary orrecurrent 5 Cisplatin NCT01970722
Norway Flatmark Observational Primary orrecurrent 200 Not provided NCT02073500
Belgium Ceelen 2 Primary orrecurrent 48 Cisplatin NCT02567253
United States Lilja 2 Recurrent 200 Cisplatin NCT02349958
France Bereder N/A Primary orrecurrent 44 Not provided NCT02803515
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Abstract: Ovarian cancer, a rare but fatal disease, has been a challenging area in the field of
gynecological cancer. Ovarian cancer is characterized by peritoneal metastasis, which is facilitated by
a cross-talk between tumor cells and other cells in the tumor microenvironment (TME). In epithelial
ovarian cancer, tumor-associated macrophages (TAMs) constitute over 50% of cells in the peritoneal
TME and malignant ascites, and are potential targets for therapy. Here, we review the bipolar nature
of TAMs and the evolving strategies to target TAMs in ovarian cancer.
Keywords: ovarian cancer; tumor-associated macrophages; peritoneal metastasis;
tumor microenvironment
1. Introduction
Ovarian cancer is a rare but often fatal disease. Despite accounting for only 2.5% of all female
cancers, ovarian cancer represents 5% of cancer deaths, and is the leading cause of gynecologic cancer
death, in the United States [1,2]. The primary cause of death and the most common presence, in
a high-grade serous epithelial ovarian cancer, is a peritoneal metastasis. Metastasis in epithelial
ovarian cancer is characterized by ascites and tumor implants, that typically disseminate throughout
the peritoneal cavity, along the lining of the peritoneum, the omentum, and the serosal surfaces of
the viscera.
Peritoneal metastasis is regulated by cross-talk between tumor cells and the tumor
microenvironment (TME). The TME is a dynamic cellular environment within an extracellular matrix
surrounding the tumors, which contain a heterogeneous group of cells, including macrophages,
lymphocytes, mesenchymal stem cells, fibroblasts, blood vessels, pericytes, and adipocytes [3,4].
Macrophages are converted into tumor-associated macrophages (TAMs), primarily through the release
of cytokines, chemokines, and growth factors, secreted from tumor cells and other cells in the TME.
In epithelial ovarian cancer, TAMs constitute over 50% of cells in the peritoneal tumor implants
and the ascites. TAMs are plastic and heterogeneous. Depending on the TME and the extracellular
stimuli, macrophages exhibit two main phenotypes along a spectrum, the anti-tumorigenic (M1-like)
and the pro-tumorigenic (M2-like). M2-like macrophages contribute to an immune suppressive TME
and promote cross-talk between tumor cells and other cells leading to an enhanced tumor-cell growth,
invasion, and metastasis [3,4]. This bipolar and plastic nature of the TAMs has the potential to be
harnessed for therapeutic purposes. Indeed, the concept of re-educating M2-like macrophages to
convert them into M1-like tumoricidal phenotypes was introduced as a therapeutic strategy, almost
two decades ago [5]. Here, we review the bipolar nature of the TAMs and the evolving strategies to
target TAMs in ovarian cancer.
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2. Macrophages in Epithelial Ovarian Cancer
Macrophages are of myeloid lineage. They contribute to physiological homeostasis and constitute
critical components of the innate immune response. Macrophages are involved in antigen presentation,
phagocytosis, and other immuno-modulatory processes. Epithelial ovarian cancer TAMs originate from
two main sources: (1) resident macrophages that arise from the embryonic yolk sac during development
and (2) infiltrating macrophages that arise from the bone marrow monocytes (Figure 1) [6–8]. Both
resident and infiltrating macrophages are heavily influenced by their cellular niche and transform into
specific phenotypes, based on the signals they receive from the TME.
Figure 1. The ontogeny and polarization of M1 and M2 macrophages. Tissue-resident macrophages
are mainly derived from yolk sac during development. Tumor-associated macrophages (TAMs)
are derived from tissue-resident macrophages, or by differentiation of monocytes from the bone
marrow. TAMs are polarized into M1-like or M2-like phenotypes based on signals received from the
microenvironment (TME).
Resident macrophages are long-lived and maintained by local signals and the primary colony
stimulating factor 1 (CSF-1), via the CSF-1 receptor (CSF-1R). Resident macrophages regulate immune
responses and metabolic functions in a tissue-specific manner [9]. In ovarian cancer in mouse models,
resident macrophages in the peritoneum are associated with GATA-6 [10]. In the omentum, one
of the favored sites of the ovarian cancer peritoneal metastasis, resident macrophages are found in
leukocyte-rich “milky spots” [11] and contribute to ovarian cancer cell invasion, both in the omentum
and the rest of the peritoneal cavity [12,13]. In a mouse model of ovarian cancer, omental macrophages
serve as a source of retinoic acid and other inducers to transport resident macrophages from the
omentum to the peritoneum [10].
Infiltrating macrophages are short-lived and recruited from bone marrow monocytes. Infiltrating
macrophages arrive in local tissue microenvironment and differentiate further into tissue-specific
macrophages, which under homeostatic conditions, abide by the signals they receive from the
surrounding microenvironment. In cancer, both the resident and the infiltrating macrophages in
the TME, typically differentiate into pro-tumorigenic M2-like phenotypes.
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Ascites is a hallmark of epithelial ovarian cancer, and its presence and volume are negatively
related to prognosis [14]. TAMs, representing both the resident macrophages and the infiltrating
macrophages, constitute a major fraction of the cells in epithelial ovarian cancer ascites [3,15,16].
TAMs in ovarian cancer ascites are primarily M2-like and pro-tumorigenic, with features similar to
resident peritoneal macrophages, expressing genes involved in extracellular matrix remodeling, such
as PCOLCE2 [17]. A sub-set of TAMS, found in ascites, are more similar to infiltrating macrophages.
These are M1-like, expressing high levels of IFN- , which induces an IL-12-mediated cytotoxic response
against tumor cells [18].
3. Bipolar Macrophages
A mixed population of TAMs exists in the TME of epithelial ovarian cancer [19]. Classically
activated M1 and alternatively activated M2 are the two main phenotypes that represent a spectrum
of functions (Figure 1 and Table 1) [20–22]. TAMs in the peritoneal cavity and ascites are primarily
M2-like and are pro-tumorigenic. This polarization of TAMs towards M2 and M2/M1 ratios, has the
potential use as a predictive and prognostic marker. For example, the ratio of M1/M2 is associated with
an improved ovarian cancer prognosis [23]. In contrast, the ratio of CD163+ M2-like macrophages to
the total CD68 macrophages (CD163/CD68) is a poor prognostic factor [24]. In addition, higher levels
of CD163+ M2-like macrophages correlates with elevated IL6, and IL-10, and a shorter relapse-free
survival [25].
Table 1. Comparison of characteristics of M1 and M2 macrophages. Adapted from Krishnan, 2018 [19],
Mantovani, 2002 [21], and Mantovani, 2004 [22].
Characteristics M1 Macrophage M2 Macrophage
Activation pathway Th1 (Classical) Th2 (Alternative)
Tumor relation Anti-tumorigenic Pro-tumorigenic
Inducers LPS, IFN-gamma, IL-12 IL4, IL10, IL13, TGF-β, CCL2,CXCL4
Chemokines CXCL9, CXCL10, CCL4, CCL10,CCL11 CCL17, CCL22, CCL24
Markers CD86, CD80, iNOS, TLR2, TLR4,IL-1R, MHC-II
CD163, CD206, CCl18, IL-1RII,
TGM2










Abbreviations: Major histocompatibility complex (MHC); signal transducer and activator or transcription 1 (STAT1);
Nitric oxide (NO).
3.1. M1 Macrophages
M1-like polarized macrophages are classically activated via the Th1 immune pathway. Th1 cells
are mainly type 1 immune cells, which secrete cytokines, such as IFN- , IL-12, and TNF. They activate
macrophages to induce inflammatory signaling pathways that exert tumoricidal effects [26]. Thus,
the role of M1 macrophages is primarily pro-inflammatory, and they aid in killing pathogens and
cancer cells.
M1 macrophages are critical for recruiting tumor-infiltrating lymphocytes that exhibit tumoricidal
properties [27]. M1 macrophages secrete chemokines and cytokines to recruit T cells. Tumors with
T cells have 14 times higher levels of macrophage-secreted chemokine mRNA levels, compared to
tumors without T cells. Macrophage-derived chemokines delay the recurrence of ovarian cancer from
6 months to later than 40 months. Patients diagnosed with metastatic ovarian cancer, and tumors that
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contain tumor-infiltrating T cells, have a significantly improved clinical response to treatment, and
a 38% overall five-year survival rate, as compared to a 4.5% survival rate in patients whose tumors
had no T cells [27,28]. Tumor-infiltrating T cells recruited by M1-like macrophages induce tumors to
express high levels of IFN-γ, IL-2, and other anti-tumorigenic cytokines. Tumors devoid of T cells
have high levels of vascular endothelial growth factor (VEGF) expression, which contributes to the
angiogenesis and a pro-tumorigenic TME. Glypican-3 (GPC3) enhances M1 macrophage recruitment
and increases the secretion of IL-12 and TNF-alpha in ascites of GPC3 expressing mouse models
of ovarian cancer [29]. Further, GPC3 is associated with an increased CD8+ T cell infiltration into
the TME, induction of apoptosis of tumor cells, decreased ascites formation, and improved survival.
Thus, M1 macrophage-derived chemokines, play a key role in recruiting cytotoxic T cells into the
tumor microenvironment.
3.2. M2 Macrophages
M2-like macrophages are alternatively activated via the type 2 (Th2) immune pathway. Th2
immune cells secrete cytokines such as IL-4 and IL-5, that induce antibody formation. In general, M2
macrophages are anti-inflammatory and are involved in wound healing via tissue remodeling and the
secretion of the extracellular matrix. In the setting of the TME in ovarian cancer, TAMs are primarily
M2-like and are pro-tumorigenic. M2 TAMs support angiogenesis, tumor cell growth, migration,
invasion, and metastasis [30,31]. This observation was supported by another group that showed that
advanced ovarian cancers, with infiltration of M2 macrophages, are associated with poor survival [32].
M2 macrophages enhance cell proliferation in epithelial ovarian cancer cells via the
MMP9/HB-EGF axis [33]. Sphere-forming ability is one of the hallmarks of cancer cells that are
capable of metastasis. TAMs aid sphere formation and tumor growth, by secreting the epidermal
growth factor (EGF) [34]. The EGF leads to integrin (αMβ2) upregulation, on TAMs, and an increased
EGFR and ICAM-1 expression, on cancer cells. The elevated EGFR, in tumors, further activates the
VEGF/VEGFR pathway in neighboring tumor cells, and thus supports cell proliferation and metastasis.
M2-like macrophages facilitate the cell adhesion of ovarian cancer cells to mesothelial cells by causing
the mesothelial cells to over-express P-selectin [35]. This mechanism likely supports the epithelial
ovarian cancer spread, along the mesothelial-lined peritoneal cavity.
3.3. Molecular Mechanisms of Macrophage Polarization
The precise mechanism that regulates TAM polarization is an area of ongoing investigation.
Although interferon regulatory factor IRF5 is the main transcription factor for M1 macrophages [36],
an advanced transcriptome analysis unveiled additional transcription factors including, IRF3, Signal
transducer, and activator of transcription (STAT) STAT1, STAT5. Hypoxia-inducible factor (HIF-1),
nuclear factor kappa B (NF-κB) heterodimer, containing p65–p50, are major regulators of inflammatory
chemokines and cytokines that polarize macrophages M1 phenotypes [37].
The main transcription factor for M2 polarization is IRF4 [38]. Proteomic analysis, comparing the
proteins and transcripts of the resting and the M2 macrophages, revealed other transcription factors,
such as STAT3 and STAT6, the NF-κB homodimer p50–p50, HIF-2, PI3K, AKT, and transglutaminase 2
(TGM2), which were associated with M2 polarization [39]. TGM2 is an enzyme with multiple functions,
including cross-linking proteins, cell proliferation, and apoptosis [40]. Together, these transcription
factors produce anti-inflammatory cytokines and chemokines typical of Th2 type immune cells.
MicroRNAs are also involved in macrophage polarization [41]. miR-216a is associated with
M1 macrophage polarization, through telomerase activation, via the Smad3/NF-κB pathway [42].
Interestingly, miR-216a enhances p53 and p16 expression, which are suppressed in ovarian cancer.
This suggests that increasing miR-216a through indirect means could be exploited therapeutically, in
ovarian cancer. Reactive oxygen species (ROS) polarize macrophages to M1-like phenotypes [43,44].
HOXA9 polarizes peritoneal macrophages to M2-like phenotypes [45]. Thus, these molecular pathways
offer additional means for therapeutically exploiting the bipolar nature of macrophages.
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4. Inflammation and TAMs in Ovarian Cancer
Inflammation is one of the classic characteristics of cancer and is integral to cancer initiation,
progression, and metastasis. Macrophages facilitate ovarian cancer peritoneal metastasis, via
inflammatory pathways, mediated by cytokines and chemokines [46]. The NF-κB pathway provides
an important link between inflammation and many types of cancer, including ovarian cancer [47].
Ascites derived from a syngeneic mouse model of ovarian cancer, contains macrophages as
dominant cell populations [48]. Macrophage cell density increases proportionately to the volume
of ascites and tumor progression. In this model, tumor cells at advanced stages have enhanced
NF-κB activation. The peritoneal spread of cancer cells during tumor progression is associated with
an increase in the number of M2 macrophages, but had a marginal effect on the number of M1
macrophages. Further, M2 macrophage levels are reduced by inhibiting NF-κB, in the tumors. The p50
component of NF-κB regulates M2-dependent inflammation and a lack of p50, leads to the elevated
M1-associated inflammatory processes [49]. This provides an encouraging evidence that the ratio of
M1/M2 macrophages can be shifted by targeting NF-κB.
Other factors linking inflammation and epithelial ovarian cancer, include serum amyloid A
(SAA1/2) and macrophage migration inhibitory factors (MIF). Accumulation of serum amyloid A
(SAA1/2) is associated with inflammation in epithelial ovarian cancer, via the TNF-alpha mediated
activation of NF-κB [50]. Normal human ovarian tissues express little or no SAA1/2, whereas, ovarian
cancers express high levels of SAA1/2 [43]. Elevated levels of MIF are found in ascites and in the
circulation of ovarian cancer patients [51,52]. MIF levels correlate with the histological grade of the
cancer tissue, disease prognosis, and platinum sensitivity [53]. MIF reduces natural-killer group
2, member D (NKG2D) expression, and prevents the natural killer (NK) cells from exerting their
tumoricidal effects. NKG2D, under normal circumstances, activate the tumoricidal properties of NK
and T cells. TME releases ligands for NKG2D and depletes NK cells, which in turn, increases the ratio
of anti-tumorigenic CD163+ CD206+ M2-like macrophages in the TME. Soluble NKG2D ligands in
ovarian cancer ascites indicated poor prognosis and decreased memory effector T cells [54].
5. TAMs as Therapeutic Targets
TAMs play a critical role in epithelial ovarian cancer tumorigenesis and, therefore, are promising
targets for therapy. Evolving therapeutic approaches fall into three broad categories, that include
strategies to (1) Block migration of monocytes to the TME; (2) re-polarize macrophages to increase the
ratio of M1 to M2-like macrophages; and (3) inhibit immune-signaling pathways in macrophages.
5.1. Block Migration of Monocytes to the TME
Tumor cells and other cells in the TME release cytokines, chemokines, and growth factors that
attract monocytes to the TME. This has been demonstrated, in vitro, using ovarian cancer cell lines, as
well as, in vivo, using mouse models and some clinical settings.
5.1.1. CSF-1 and CSF-1R
In clinical studies, CSF-1 and CSF-1R expression upregulation in epithelial ovarian cancer have
been associated with poor prognosis [55]. The survival, proliferation, and differentiation of monocytes
and macrophages are dependent on the CSF1R pathway [56]. In the syngeneic mouse model of
ovarian cancer, GW2580, a selective CSF1R kinase inhibitor significantly reduces ascites fluid buildup
and the infiltration of M2 TAMs [57]. Further, inhibiting the CSF-1R, partly overcomes anti-VEGF
resistance [58], and the CSF-1R disruption results in macrophage depletion, which supports a direct
role of the CSF-1R in macrophage recruitment [59]. Currently, active clinical trials targeting CSF1R
on M2 macrophages, involve PLX3397, in combination with anti-PD-1 pembrolizumab (Clinical
trial # NCT02452424), and Cabiralizumab (antibody against CSF1R), in combination with anti-PD-1
monoclonal antibody Nivolumab (NCT02526017). A clinical trial using LY3022855, a CSF1R inhibitor
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in combination with anti-PDl1 monoclonal antibody Durvalumab, or anti-cytotoxic T-lymphocyte
associated protein 4 monoclonal antibody Tremelimumab, is currently recruiting (NCT02718911).
5.1.2. CCL2
CCL2 is also known as MCP-1 (CC motif ligand 2 or macrophage chemoattractant protein-1),
is a chemokine that plays a key role in monocyte recruitment to the TME. Epithelial ovarian cancer
cells release CCL2/MCP-1 to attract monocytes and convert them to TAMs, within the TME [60].
A plant-derived product, 9-hydroxycanthin-6-one reduces the MCP-1 expression in ovarian cancer
cells and inhibits macrophage recruitment [61]. Interestingly, using a mouse model, it was seen that
CCL2/MCP-1 is crucial for Th2 immune responses. MCP-1-/- mice do not induce the Th2 response
and express low levels of IL-4, IL-5, and IL-10 [62]. Monocytes and macrophages express CCR2, which
is a receptor for CCL2. Thus, the CCL2/CCR2 axis represents an attractive target for ovarian cancer
therapy. A CCR2 antagonist RS504303 that is under development, significantly reduces bone-marrow
derived monocyte cell migration, in mouse [63]. A clinical trial using an anti-CCl2 antibody, known
as CNTO 888, in combination with gemcitabine or paclitaxel, and carboplatin or docetaxel, has been
completed (NCT01204996).
5.1.3. Drugs
Bisphosphonates deplete monocytes/macrophages in ovarian cancer. In a syngeneic mouse
model of ovarian cancer, clodronate reduces TAMs by inhibiting cytokine secretion, which decreases
angiogenesis [64]. In patients with epithelial ovarian cancer, transient depletion of peritoneal
macrophages using liposomal alendronic acid potentiates an adoptive immunotherapy [65].
Trabectedin, a marine-derived anti-tumor compound, depletes macrophages in mouse models [66].
A phase 2 clinical trial of trabectedin in ovarian cancer patients, showed a significant depletion of blood
monocytes, as well as a reduction in CCL2 levels, in TAMs and ovarian tumor cells [67]. However,
trabectedin as a single agent has limited efficacy. An alternate strategy to deplete TAMs is to exploit
elevated expression levels of folate receptor-2 (FOLR2) that has been found in human and murine
ovarian cancer TAMs, and use G-5 methotrexate nanoparticles to target these TAMs [68].
5.2. Re-Polarize Macrophages to Increase the Ratio of M1 to M2-Like Macrophages
Notch signaling plays a crucial role in M1 polarization in a mouse model, where macrophages
with an active Notch display anti-tumor properties. Most of the following studies, unless otherwise
stated, were carried out using a mouse model. When Notch signaling is blocked, M2 macrophages
are polarized and resist M1 activators [69]. CCL2, apart from recruiting monocytes, enhances
M2 polarization as well [70]. Activation of the peroxisome proliferator-activated receptor
(PPAR )/NF-κB axis, in ovarian cancer stem cells, induces M2 polarization [71].
An unexpected observation made by our group revealed that inhibition of NF-κB in a syngeneic
mouse model of ovarian cancer, increased pro-tumorigenic M2 macrophages, which promoted ascites,
an increased expression of pro-tumorigenic soluble factors (such as VEGF in ascites fluid), and an
infiltration of more M2 macrophages into the TME [48,72]. These results suggest that the activation of
NF-κB in TAMs, not tumor cells, could be a viable therapeutic strategy. Indeed, NF-κB transfected
TAMs, display anti-tumorigenic properties in mice harboring solid tumors, which on treatment showed
elevated M1 phenotype favoring Th1 cytokines and reduced Th2 cytokines [73].
Antibiotics and natural products modulate macrophages. Doxycycline is a common antibiotic
that reduces pro-angiogenic properties of M2 macrophages, in neovascular age-related macular
degeneration models [74]. Among natural products, deoxyschizandrin, a phytochemical extracted from
berries, significantly reduces the pro-tumorigenic activity of TAMs by inhibiting M2 macrophages [75].
In addition to blocking macrophage recruitment to tumor sites, 9-hydroxycanthin-6-one, inhibits M2
polarization in ovarian cancer [61]. Neferine, another plant-derived product, was found to inhibit
M2-macrophages in an OVHM xenograft mouse model [76].
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5.3. Inhibit Immune Signaling Pathways in Macrophages
The tumor-associated PD-L1 expression has been investigated by several investigators [77,78].
In addition, macrophages associated with primary and metastatic high-grade serous, ovarian cancer
express PD-L1 [77]. A comparison of the TME of primary and recurrent epithelial ovarian cancer
showed interesting trends, regarding the effect of T cells and macrophages, on survival. Recurrent
tumor TME, with higher immune cell recruitment and higher TAMs, have better survival [79]. In
clinical studies, expression of PD-L1, by both immune cells and tumor cells in recurrent tumors, leads
to an active immune response and imparts better survival in recurrent cancer, as compared to primary
cancer, where only the immune cells express PD-L1.
They further explained that the phenotype of regulatory T cells (Tregs), in primary and recurrent
cancer, is different, with recurrent cancer expressing more CD25+ Tregs, which are indicators of better
prognosis. Thus, they concluded that the dynamics between TAM PD-L1 expression and cytotoxic vs.
Tregs create an imbalance that favors survival. PD-L1 expression was significantly higher in ovarian
cancer than in other cancers and coincided with poor prognosis [78]. Although PD-L2 expression was
associated with poor prognosis, there was no significant difference in PD-L2 between primary and
recurrent ovarian cancer. Their most interesting finding was that the tumor cell PD-L1 expression
was inversely proportional to the CD8 expression of intraepithelial tumor-infiltrating lymphocytes
(TILs). Further, their findings supported CD8+ TILs as a positive predictor of overall survival and
progression-free survival, in ovarian cancer. B7-H4 protein and mRNA is highly expressed in ovarian
cancers and is involved in epithelial cell transformation [80]. B7-H4 inhibits T cell activation, thereby,
halting host anti-tumor response, leading to a tumor escape from immune surveillance. Earlier reports
from this group showed that B7-H4 is also expressed in ovarian tumor-associated macrophages, and
similar to tumor B7-H4, these macrophages also suppress tumor immunity [81]. When normal blood
monocytes were incubated with tumor ascites, elevated levels of B7-H4 was observed, whereas, the
serum-free medium showed no such effect, thereby suggesting that B7-H4 expression is regulated by
the tumor microenvironment, specifically IL-6 and IL-7.
Current clinical trials that target PDL1/2 and PD1/2 axis include patients diagnosed with
ovarian cancer. A clinical trial for platinum-resistant ovarian cancers involves a combination of
the anti-PD-L1 antibody Atezoliuzub with Bevacizumab (NCT02659384). Another clinical trial, for
advanced ovarian tumors and recurrent ovarian cancer is investigating a combination of an anti-PDL1
antibody MEDI4736 with Olaparib and/or Cedinarib (NCT024844004). Designing strategies to alleviate
immune suppression, by reducing monocyte recruitment, decreasing the M2/M1 ratio, and targeting
TAMs in combination with with immune checkpoint inhibitors, could represent attractive targets that
switch the innate immunity balance in favor of tumor cell death (Figure 2).
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Figure 2. Strategies for targeting TAMs in ovarian cancer. (A) Block monocyte recruitment to the tumor
niche. (B) Chemical intervention to increase M1/M2 ratio by inhibiting M2 polarization, increasing
M1 polarization by using Interferon gamma (IFN- , Lipopolysaccharide (LPS)) or by repolarizing M2
to M1 by adding IFN- or regulating the Notch, NF-κB. (C) Inhibit immune signaling pathways on
macrophages, for e.g., CSF-1, VEGFR, which promotes angiogenesis, and PD-L1, which inhibits T
cell activity.
6. Conclusions
In epithelial ovarian cancer, TAMs mediate progressive ovarian cancer and thus present an
attractive target to develop anti-cancer regimens, as they are involved in all stages of ovarian
cancer development. M1 macrophages, on the other hand, represent anti-tumorigenic TAMs. An
advantage of using TAMs as anti-cancer targets is their genomic stability, which could provide a
means of alleviating drug resistance. A deeper understanding of mechanisms behind macrophage
polarization, will aid in developing strategies to enhance M1 macrophage polarization or shift the
balance between M1 and M2 towards anti-tumorigenic M1 macrophage population. TAMs represent a
plastic immune cell population amenable to manipulation and re-education and repolarizing M2 to
M1 tumoricidal phenotypes. The affinity of TAMs to the peritoneal TME and the ascites in epithelial
ovarian cancer, offers a future potential for targeted intraperitoneal treatment, in combination with
chemotherapy drugs.
Despite their promise, clinical implementation of macrophage-based therapies has been limited.
The main challenges in targeting TAMs, are their complexity and heterogeneity in the context of
the TME and the likely need to combine macrophage-based therapies with other anti-tumor agents.
Cross-talk between tumor cells and other cells in the TME is complex. Ongoing research to ‘deconvolute’
elements of the TME will lead to a better understanding of how to strategically target dominant cell
populations, such as macrophages in different TME niches [4]. Classic definitions of M1 and M2 do
not fully encompass the full spectrum of macrophage function. Next generation single cell sequencing
and flow methods will be required to better understand the most important functions of the sub-types
of TAMs, in ovarian cancer.
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Abstract: High-grade serous ovarian cancer, also known as high-grade serous carcinoma (HGSC),
is the most common and deadliest type of ovarian cancer. HGSC appears to arise from the ovary,
fallopian tube, or peritoneum. As most HGSC cases present with widespread peritoneal metastases,
it is often not clear where HGSC truly originates. Traditionally, the ovarian surface epithelium (OSE)
was long believed to be the origin of HGSC. Since the late 1990s, the fallopian tube epithelium has
emerged as a potential primary origin of HGSC. Particularly, serous tubal intraepithelial carcinoma
(STIC), a noninvasive tumor lesion formed preferentially in the distal fallopian tube epithelium,
was proposed as a precursor for HGSC. It was hypothesized that STIC lesions would progress,
over time, to malignant and metastatic HGSC, arising from the fallopian tube or after implanting
on the ovary or peritoneum. Many clinical studies and several mouse models support the fallopian
tube STIC origin of HGSC. Current evidence indicates that STIC may serve as a precursor for HGSC
in high-risk women carrying germline BRCA1 or 2 mutations. Yet not all STIC lesions appear
to progress to clinical HGSCs, nor would all HGSCs arise from STIC lesions, even in high-risk
women. Moreover, the clinical importance of STIC remains less clear in women in the general
population, in which 85–90% of all HGSCs arise. Recently, increasing attention has been brought
to the possibility that many potential precursor or premalignant lesions, though composed of
microscopically—and genetically—cancerous cells, do not advance to malignant tumors or lethal
malignancies. Hence, rigorous causal evidence would be crucial to establish that STIC is a bona fide
premalignant lesion for metastatic HGSC. While not all STICs may transform into malignant tumors,
these lesions are clearly associated with increased risk for HGSC. Identification of the molecular
characteristics of STICs that predict their malignant potential and clinical behavior would bolster the
clinical importance of STIC. Also, as STIC lesions alone cannot account for all HGSCs, other potential
cellular origins of HGSC need to be investigated. The fallopian tube stroma in mice, for instance,
has been shown to be capable of giving rise to metastatic HGSC, which faithfully recapitulates the
clinical behavior and molecular aspect of human HGSC. Elucidating the precise cell(s) of origin of
HGSC will be critical for improving the early detection and prevention of ovarian cancer, ultimately
reducing ovarian cancer mortality.
Keywords: ovarian cancer; epithelial ovarian cancer; high-grade serous ovarian cancer (HGSOC);
high-grade serous carcinoma (HGSC); ovarian cancer origin; fallopian tube; ovarian surface
epithelium (OSE); serous tubal intraepithelial carcinoma (STIC)
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1. Ovarian Cancer
“Ovarian cancer” is an umbrella term that refers to a heterogeneous group of malignancies
arising from or involving the ovary [1–3]. Morphologically, ovarian cancer is classified into two broad
categories: (i) non-epithelial ovarian cancer (NEOC) and (ii) epithelial ovarian cancer (EOC). There are
two types of NEOC: germ-cell tumors (GCT) and sex cord-stromal tumors (SCST) [4–6]. While 10–15%
of ovarian cancer cases are NEOC [4,5], the vast majority (85–90%) belong to EOC [2,3]. According
to morphology, molecular alterations, and clinical behavior, EOC is further divided into two groups:
type I and type II [7]. Type I tumors are low-grade, slow-growing ovarian carcinomas. Type II tumors
are high-grade, aggressive malignancies. The most common type II malignancy is high-grade serous
ovarian cancer, also known as high-grade serous carcinoma (HGSC). Hence, an alternative, clinically
useful way to categorize EOCs would be to simply split them into two groups: high-grade serous
ovarian cancer (HGSC) and non-high-grade-serous ovarian cancer (non-HGSC). Though both are
epithelial ovarian cancers, these two groups are biologically-distinct malignancies [8]. Non-HGSCs
are mostly indolent tumors confined to the ovary at the time of diagnosis [9]. In contrast, HGSC
is an inherently aggressive malignancy, which commonly presents as advanced-stage disease and
accounts for the majority of ovarian cancer deaths [9–14]. Thus, “ovarian cancer” is also largely
synonymous with “high-grade serous ovarian cancer (HGSC).” While significant tumor burden often
involves the ovaries at the time of diagnosis, also typical is widespread metastatic disease involving
the fallopian tubes, peritoneal surfaces, and omentum, obscuring the tissue and cell of origin of
ovarian cancer [7,15,16].
1.1. Non-Epithelial Ovarian Cancer (NEOC)
Implicit in the name, “ovarian cancer” was thought to be tumors originating in the ovary [17–19].
Certainly, the ovary can be a site of tumor origin. The ovary is composed of follicles, each containing
an egg, embedded in interstitial (stromal) tissue and encircled by a single layer of the ovarian surface
epithelium (OSE) [20,21]. During each menstrual cycle, in response to the pituitary gonadotropins
follicle-stimulating hormone (FSH) and luteinizing hormone (LH), a cohort of preantral follicles
in the ovary grow to become antral follicles with multiple layers of granulosa cells and theca
cells [21–27]. In antral follicles, the granulosa cells, theca cells, and stromal cells together make
up somatic cells of the ovary [21]. These ovarian somatic cells, particularly granulosa cells (90% of
SCSTs) as well as theca cells, can transform into sex cord-stromal tumors (SCST), which represent
5–8% of all primary ovarian tumors [4,28–30]. Ovarian tumors can also arise from the egg, which
leads to germ-cell tumors (GCT) [6,31–33]. Germ-cell tumors and sex cord-stromal tumors are major
types of non-epithelial ovarian malignancies, which account for 10–15% of all ovarian tumors [4,5].
Non-epithelial ovarian cancer (NEOC) is generally diagnosed at an early stage, where tumors
are confined to the ovary without distant metastasis (GCT: 60–70%; SCST: 60–95% of cases) [4,5].
Early-stage diagnosis and chemosensitivity present a favorable prognosis to patients with NEOC
(five-year survival rates: 90–100%) [4,5,28,34].
1.2. Epithelial Ovarian Cancer (EOC)
Besides non-epithelial tumors, epithelial tumors can form in the ovary. The vast majority
of ovarian tumors are epithelial ovarian cancer (EOC), which accounts for 85–90% of ovarian
malignancies [2,3]. According to morphologic resemblance to normal epithelial cells lining the
reproductive tract, EOC can be subdivided into four major types: serous (~70%), endometrioid
(10%), mucinous (3–10%), and clear-cell carcinomas (10%) [2,3,10,11,14,35]. Serous carcinoma cells
resemble fallopian tube epithelium; endometrioid carcinoma is likened to endometrial epithelium;
mucinous carcinoma resembles the epithelium in the endocervix; and clear-cell carcinoma is similar to
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clumps of normal glycogen-rich epithelial cells found in the vagina [2,3]. Also, serous carcinomas are
of two types: high grade (90–96%) and low grade (4–10%) [7,14].
Recent advances in molecular and genetic analyses on ovarian carcinomas, in conjunction
with clinical behavior and histopathology, have EOCs classified into type I and type II [7,36–38].
Type I tumors are low grade, indolent (slow growing), genetically stable, and devoid of p53
(TP53) mutations, mostly presenting at early stage. They include low-grade serous carcinoma,
low-grade endometrioid carcinoma, clear-cell carcinoma, mucinous carcinoma, and malignant Brenner
tumors [7,36]. Type I tumors are associated with wild-type p53 (TP53), but often contain mutations in
genes such as KRAS, BRAF, PTEN, and β-catenin [7,36,39]. In contrast, Type II tumors are high grade,
inherently aggressive, genetically unstable, typically harboring p53 (TP53) mutations, and presenting
at advanced stage [40,41]. Included in this group are high-grade serous carcinoma (HGSC), high-grade
endometrioid carcinoma, undifferentiated carcinomas, and malignant mixed-mesodermal tumors
(MMMT; carcinosarcoma) [7,36]. Low-grade cancers resemble normal cells cytologically, whereas
high-grade cancers show variation in cellular size and shape, large and irregular nuclei, more frequent
mitoses, and loss of polarity [42].
Unlike non-epithelial ovarian tumors, EOCs are diagnosed predominantly at advanced stage
(stage III or IV: 60–80%) with widespread metastases throughout the peritoneal cavity, which is
associated with high mortality [11,14,43]. In contrast, a smaller fraction of EOCs (20–40% of EOCs) are
diagnosed at early stage (stage I or II) [8,11,14]. A recent, large comprehensive histotype analysis of
28,118 cases of EOCs—diagnosed in 2004–2014, drawn from the U.S. Surveillance, Epidemiology,
and End Results (SEER) cancer registry data—indicates that 39.2% (11,009/28,118) of EOCs are
diagnosed in early stages (stage I and II) and 60.8% (17,109/28,118) of EOCs in advanced stages
(stage III and IV) [14]. These early-stage tumors are dominated by type I (low-grade) tumors (61.1%:
6728/11,009) [14] (~85%) [11]: low-grade serous, endometrioid, mucinous, and clear-cell carcinomas.
Two-thirds (75.6%: 6728/8900) of the type I, low-grade carcinomas are diagnosed in early stages [14,44].
Generally, the type I tumors are clinically indolent tumors, and thus a relatively minor contributor to
ovarian cancer deaths [9,45]. Still, type I tumors account for 18.6% (2235/12,045) of EOC deaths [14].
In contrast, while constituting a minor fraction (38.9%: 4281/11,009) of early-stage EOCs, type II tumors
(HGSC and carcinosarcoma) account for the vast majority (87.3%: 14,937/17,109) of advanced-stage
EOCs and for most EOC deaths (81.4%: 9810/12,045) [14]. Among the type II tumors, HGSC is the
predominant type. HGSC alone accounts for 81.1% (13,898/17,109) of all advanced-stage EOCs and is
responsible for nearly three-quarters (73.9%: 8900/12,045) of all EOC deaths [14].
Overall, high-grade serous carcinoma (HGSC), also known as high-grade serous ovarian cancer,
is estimated to be 50–60% of all ovarian malignancies [10,11]. Moreover, HGSC accounts for a large
majority (63.4%: 7837/28,118) of all ovarian carcinomas, and advanced-stage HGSC represents nearly
a half (49.4%: 13,898/28,118) of all EOCs [14]. Hence, when the term “ovarian cancer” or “epithelial
ovarian cancer” is used without specific subtype elaboration, most often, it refers to “high-grade serous
ovarian cancer (HGSC)”.
High-Grade Serous Ovarian Cancer (High-Grade Serous Carcinoma: HGSC)
High-grade serous ovarian cancer refers to the HGSC arising from the ovary, fallopian tube,
or peritoneum [9,46] (Figure 1). Yet HGSC (high-grade serous ovarian cancer) should be distinguished
from (high-grade) endometrial serous carcinoma. Serous carcinoma arising from the endometrium
is also classified as high-grade serous carcinoma, but of uterine origin; hence, it is an endometrial
cancer, not an ovarian cancer [47]. This uterine cancer is also commonly called uterine papillary serous
carcinoma (UPSC). To distinguish from (high-grade) endometrial serous carcinoma (UPSC), the HGSC
of primary ovarian, tubal, or peritoneal malignancy is also called high-grade pelvic (nonuterine) serous
carcinoma [48]. HGSC accounts for more than 60% of epithelial ovarian cancers and over 70% of
all ovarian cancer deaths [10,14,41]. Thus, HGSC is not only the most common, but also deadliest
ovarian cancer [41].
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Figure 1. Cells of origin for high-grade serous ovarian cancer (HGSC).
The primary reason for the high mortality associated with HGSC is its diagnosis predominantly
at advanced stage [11,14,45,49]. Generally, despite overall high mortality, ovarian cancer has a much
better prognosis when diagnosed in the early stages [50]. When ovarian cancer is diagnosed in stage I,
and when tumors are still localized to the ovary (15–20% of all cases [2]), the five-year survival rate is
92.3% after treatment with conventional surgery and platinum-based chemotherapy [50]. The five-year
survival is still 74.5%, even when the disease has spread to the pelvis in stage II. For advanced-stage
ovarian cancer, however, the five-year survival falls to 29.2% [50]. These observation suggest that
early detection of ovarian cancer would improve treatment outcomes and survival [51]. Challenging
this seemingly obvious notion, however, is the fact that most of early-stage diagnoses are indolent
tumors [8,11,44]. The vast majority (>80%) of ovarian cancers detected in stage I are non-epithelial
tumors and low-grade epithelial tumors, which are mostly indolent, portending a favorable
prognosis [8,11,44]. In contrast, HGSC, which accounts for the majority of ovarian cancer deaths,
is not frequently detected in early stages (<25%), with most cases of HGSC being diagnosed in stage III
or IV (>75%) [11,14,45,49]. As HGSC account for more than 80% of advanced-stage (III–IV) ovarian
cancers and over 70% of ovarian cancer deaths, effective early detection would require detection of
a greater fraction of HGSC in early stages prior to distant metastasis [14,45].
HGSC can be detected in early stages. In the Normal Risk Ovarian Cancer Screening Study
(NROSS) in the US with more than 5000 women [52], 21 operations were prompted by the screening
strategy to detect 13 ovarian cancers with 9 in early stage (I/II). Two of the 9 were borderline,
and 7 were invasive. Of the 7 invasive early-stage ovarian cancers detected, 6 were high-grade
serous or endometrioid. While the numbers are small, these updated results from the NROSS suggest
that HGSC can be detected in the early stage, although there is clearly room to improve the sensitivity
of currently-available serum biomarkers and imaging techniques [52].
In addition, early-stage diagnosis of HGSC is not rare. In the large study of the U.S SEER data,
HGSC accounts for more than a third (35.8%: 3939/11,009) of early-stage (I and II) EOCs: 19.1%
(88/4621) in stage IA/IB (localized) and 47.9% (3057/6388) in stage IC/II (regional) [14]. This study
also shows that patients with advanced-stage HGSC have a poor prognosis: 32.1% for 5-year survival
and 15% for 10-year survival. In contrast, in patients diagnosed with early-stage HGSC, survival rates
improve to 71.4% (5-year) and 53% (10-year), respectively. These improvements in survival among
patients with early-stage HGSCs are fairly comparable to survival rates in patients with early-stage
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type I (indolent) tumors (80.4% for 5-year and 68.0% for 10-year survival). This suggests that effective
early-stage detections of HGSC could improve overall patient survival in ovarian cancer.
By far, the largest screening trial of ovarian cancer has been a randomized clinical trial from the
United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) [53], in which a total
of 202,638 postmenopausal women ages 50 to 74 had been followed for a median of 11.1 years and
evaluated for ovarian cancer mortality, after a randomization into a control (no screening) group and
two screening groups: (i) serum CA125 and (ii) transvaginal ultrasound (TVUS). The primary analysis
shows no significant reduction in ovarian cancer mortality, though ovarian mortality rates are reduced
in screening groups by 15% (CA125) and 11% (TVUS), compared with no screening group. There is
no difference in all-cause mortality between screening and control groups. Curiously, a secondary
analysis, after exclusion of deaths in years 0–7, produces a mortality reduction of 21% in the CA125
group (p = 0.021; 95% confidence interval: −2 to 40%). Overall, the results are in line with those
from previous ovarian cancer screening trials, which have not shown a significant decrease in ovarian
cancer mortality [44,51,54–56].
As HGSC is responsible for more than 70% of ovarian cancer deaths and over 80% of
advanced-stage ovarian cancer diagnoses, key to effective ovarian cancer screening is an effective
detection of early-stage HGSC. This appears to be challenging. When women with symptoms were
promptly diagnosed by CA125 blood test and TVUS, seven of nine (78%) HGSC cases were already in
advanced stages (III–IV) with two HGSC cases (22%) in early stages [49], illustrating the challenge of
diagnosing HGSC at an early stage with the currently available detection methods.
In principle, the goal of cancer screening is straightforward: detection of cancer at an early, curable
stage to reduce cancer mortality and improve patient survival. In practice, however, it is profoundly
challenging to detect eventual life-threatening malignancies in their early stages among asymptomatic
individuals, who may be at average risk or genetically high risk. Considering the relatively low
incidence of ovarian cancer (lifetime risk: 1.3% for ovarian cancer vs. e.g., 12.4% for breast cancer),
an effective screening test needs to be equipped with high sensitivity as well as robust specificity.
Presently, less than a quarter (22.1%: 3939/17,837) of HGSCs are diagnosed in early stages, while more
than three-quarters (77.9%: 13,898/17,837) of HGSCs are not diagnosed until advanced stage [14].
The future success of ovarian cancer screening will therefore depend on how effectively these
advanced-stage diagnoses of HGSC could be shifted to early-stage diagnoses.
Achieving effective early-stage detection of HGSC will also require a better understanding
of the mechanism of HGSC, particularly early mechanisms, including the cell(s) of origin, cancer
initiation and development, early progression, and metastatic transition. As ovarian cancer, particularly
HGSC, presents mostly as an advanced-stage disease with widespread peritoneal metastases, it would
often not be clear, at the time of diagnosis, where the tumors actually originate in a given patient.
Nevertheless, ovarian cancer, including HGSC, was presumed, by convention, to originate in
the ovary [18,19,57].
2. Origins of High-Grade Serous Ovarian Cancer (HGSC)
2.1. Ovary
Ovarian Surface Epithelium (OSE)
Epithelial ovarian cancer has been thought to arise from epithelium in the ovary—the ovarian
surface epithelium (OSE). Most ovarian cancer patients present with advanced-stage disease, in which
tumors are found in the ovary and other peritoneal tissues, including the fallopian tube, mesentery,
omentum, and diaphragm. In some patients, however, tumors are confined to the ovary. Though
observed in different patients, viewing these tumors as different phases of the same malignancy,
ovarian cancer with advanced-stage disease was assumed to have originated in the ovary [18,19,57].
The vast majority of advanced-stage ovarian cancers are high-grade serous carcinoma (HGSC). Hence,
HGSC is also thought to arise from the ovary [18,58]. In the ovary, epithelial cells reside in the OSE.
234
Cancers 2018, 10, 433
During ovulation, as the mature ovarian follicle ruptures and releases the egg, it also causes a local
breakage of the OSE at the ruptured site. As the ruptured follicle differentiates into a corpus luteum,
the damaged OSE may invaginate during the repair process. The inward movement of the damaged
OSE toward the ovarian cortex (stroma) could result in the formation of a cyst with an epithelial lining
inside (termed an “inclusion cyst”) [57,59,60]. Alternatively, it was suggested that inclusion cysts could
form, without ovulation, as a result of an interaction between the OSE and the ovarian stroma [57].
It has been theorized that OSE and cortical inclusion cysts derived from the OSE may be the origin of
all epithelial ovarian cancers [18,19,57,58].
OSE: Developmental View
The OSE is a single layer of squamous (flattened) epithelial cells derived from the coelomic
epithelium, which lines the body cavity (coelom) of a developing embryo [59]. In the peritoneal
cavity, the coelomic epithelium differentiates into mesothelium, the epithelial cells lining the
peritoneum [45]. The part of the coelomic epithelium overlying the gonadal ridge, in which the
ovary forms, differentiates into the OSE [59,61]. The OSE is thus a type of mesothelium covering
the ovary; hence, the OSE is also known as ovarian mesothelium (OM) [59]. Interestingly, though
both tissues are histologically mesothelium, the peritoneal mesothelium and the ovarian mesothelium
(OSE) give rise to distinct malignancies. When the mesothelium lining the peritoneum undergoes
a malignant transformation, the resulting tumor is called (peritoneal) mesothelioma [45]. On the other
hand, transformation of the OSE (ovarian mesothelium) leads to ovarian carcinoma.
The coelomic epithelium also invaginates at the upper lateral part of the gonadal ridge, forming
the Müllerian ducts [19,59]. The Müllerian ducts give rise to the epithelia of the fallopian tube, uterine
endometrium, and endocervix (the upper part of the cervix) [19,59]. Thus, the peritoneal mesothelium,
the ovarian surface epithelium (ovarian mesothelium), and the epithelium derived from the Müllerian
ducts share the same embryonic origin: the coelomic epithelium [19,59]. Despite this, the peritoneal
and ovarian mesothelium and the Müllerian duct-derived epithelium are phenotypically different [19].
The normal epithelial cells in the fallopian tube, uterus, and endocervix are columnar (tall) epithelium,
whereas the peritoneal and ovarian mesothelium are flat-to-cuboidal epithelial cells [59]. Unlike the
peritoneal mesothelium, the OSE (ovarian mesothelium) is prone to metaplasia (replacement of one
mature cell type with another mature cell type) [19,57]. The OSE tends to spontaneously undergo
metaplasia to resemble the normal epithelium of the fallopian tube, uterus, and endocervix [19,57].
This metaplastic capability of OSE to Müllerian epithelium, when combined with gene mutations,
could prompt the formation of ovarian carcinomas bearing a morphological similarity to the normal
epithelium of the fallopian tube, uterus, and endocervix [62]. Hence, though not naturally resembling
the cellular morphology (Müllerian epithelium) of ovarian carcinomas, the OSE appears to have the
capacity to transform into ovarian carcinomas bearing the morphology of Müllerian epithelium.
OSE: Mouse Models
Mouse studies have provided abundant evidence that the OSE can transform into ovarian
carcinomas resembling the morphology of Müllerian epithelium [62–68] (Table 1). In an allograft study,
individual expression of Hoxa9, 10, and 11 in the transformed mouse OSE results in ovarian carcinomas
resembling serous, endometrioid, and mucinous ovarian carcinoma, respectively, when these
Hoxa-expressing OSE cells are injected into mice [62]. The OSE has also been genetically modified
by targeted mutations in genetically engineered mouse models. When Pten is inactivated and
simultaneously Kras G12D mutant is expressed specifically in the OSE by a delivery of adenovirus-cre to
the ovarian bursa, these mice develop endometrioid ovarian carcinoma with peritoneal metastases [66].
Adenovirus-cre-mediated inactivation of Pten and Apc in the murine OSE leads to endometrioid ovarian
carcinoma [68]. When Pten deletion and KrasG12D expression are induced by Amhr2 cre/+, the OSE
transforms to produce low-grade serous carcinoma [67]. With an addition of p53 (Trp53) R172H/+
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mutant expression to Pten deletion and KrasG12D expression, these mice form mucinous carcinomas
from the OSE, coexisting with cells of serous features [69].
Table 1. Mouse models of ovarian cancer: ovarian origins.
Targeted Genes Promoter Ovarian Tumor Metastasis Ascites Ref.
p53, Myc, Kras G12D;
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Lkb1, Pten Amhr2 cre/+ HGSC: 100% (12/12) No description
25%
(3/12) [74]














53.3% (19/35) No [75]
?: information not described in the cited reference.
Ovarian carcinomas histopathologically resembling human HGSC can also arise from the
OSE [65,72,74] (Table 1). Mutations in the p53 gene (TP53 in humans; Trp53 in mice) is the most
common genetic event observed in human HGSC [41]. Inactivation of p53 (Trp53) and Rb1 in
the OSE, via an intrabursal injection of recombinant adenovirus cre, leads to metastatic serous
ovarian carcinoma [65]. In this model, nearly all mice (97%: 33/34) develop ovarian tumors which
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may be histologically classified as serous or undifferentiated carcinoma. Though the majority
of these ovarian tumors appear to remain at stage I, 27% (9/33) of the mice exhibit peritoneal
metastases with accompanying ascites. Lung metastases are noted in 18% (6/33) of the mice, and 6%
(one mouse) develop liver metastases. This reported phenotype, however, was not reproducible in
another independent study [70,71]. In this second study, the same experimental approach produced
leiomyosarcoma in the ovary—a smooth muscle tumor—instead of the reported metastatic (high-grade)
serous ovarian carcinoma [70]. In another mouse study, adenovirus cre was delivered inside the bursa
to delete or express in the OSE the following genes: (i) inactivation of Rb1, p53, and Brca1; (ii) expression
of a p53 mutant (p53R172H) with Rb1 and Brca1/2 deletion [72]. These mice developed ovarian tumors
with high-grade serous morphology, ranging from stage I to IV [72]. Examined closely, some of these
ovarian tumors remained at stage I or II (29%: 21–32%), lacking metastatic capability. Peritoneal
metastases were not common: 16% (0–26%) of the mice were at stage III. Without accompanying
peritoneal metastasis, liver, lung, or plural metastases were observed in 17% (0–25%) of the mice.
In another model, loss of Lkb1 and Pten in the OSE leads to ovarian HGSC (100%: 12/12),
but with seemingly weak metastatic potential: ascites noted in 25% (3/12) of the mice [74]. In addition,
in a transgenic mouse model expressing SV40 large T antigen (TAg) in the OSE, ~50% of the mice
produce metastatic ovarian carcinoma of serous morphology [63]. Also, ovarian carcinoma with
peritoneal metastasis is formed in an allograft model, in which mice are injected with the OSE
harboring p53-null mutation and any two oncogenic mutations of Myc, KrasG12D, and Akt [64].
Evidently, the mouse OSE, incited by gene mutations, is capable of transforming into an ovarian
carcinoma histopathologically resembling human HGSC. Yet, the OSE-derived HGSCs from mouse
models seem to exhibit weak metastatic potential. Conversely, human HGSC appears to be inherently
aggressive, and to be capable of metastasis from a relatively early stage of development [8,9].
It is possible that additional mutations could enable aggressiveness of OSE-derived murine HGSCs.
However, a number of mouse models, exhibiting generally weak or deficient metastatic ability of
OSE-derived HGSCs, also suggest another possibility: though likely serving as the origin for some
HGSCs, the OSE may not be the only primary site from which human HGSC arises [9,73,75–79].
2.2. Fallopian Tube
2.2.1. Serous Tubal Intraepithelial Carcinoma (STIC)
Beginning in the late 1990s, the fallopian tube has emerged as another likely site of origin for
high-grade serous carcinoma (HGSC) [9,76,80–82]. This insight came from studies of women carrying
germline BRCA1 or 2 mutations, which make these women more prone to malignancies, particularly
ovarian cancer as well as breast cancer [83–85]. In these BRCA carriers, the lifetime risk of ovarian
cancer ranges from 40–60% for BRCA1 and 10–30% for BRCA2, respectively [2,76,84,86]. The most
common type of ovarian cancer noted in these BRCA1 or 2 carriers is HGSC [87,88]. When BRCA
mutations were first recognized as conferring high risk for ovarian cancer, ovarian cancer was believed
to arise solely from the ovary. Further evaluation, however, demonstrated that BRCA carriers were also
susceptible to peritoneal and fallopian tube malignancies, as well as ovarian cancer [89–94]. Hence,
the standard risk-reducing prophylactic procedure has become surgical removal of the ovaries and
fallopian tubes (bilateral salpingo-oophorectomy), preferably by age 40 [84,95].
An early observation implicating the fallopian tube as a site of origin for HGSC came from a study
of the fallopian tubes, prophylactically removed by surgery, from high-risk women including BRCA1
carriers [80]. In this study, half of the high-risk women (6/12) exhibited dysplasia (preneoplastic
change) in the epithelium of their fallopian tubes [80]. In contrast, little abnormality was found in
the prophylactically-removed ovaries from BRCA1 carriers [96,97]. These observations prompted
more extensive histopathological examinations of the ovaries and fallopian tubes prophylactically
removed from germline BRCA-mutation-carrying women [96]. These studies had led to the discovery
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of a potential premalignant lesion in the epithelium of the distal fallopian tube (fimbria), termed
“serous tubal intraepithelial carcinoma (STIC)” [98,99].
STIC: Clinical and Molecular Observations
STIC is a noninvasive premalignant lesion with malignant cellular features [45,48], including
enlarged nuclei, dark staining of the nucleus (hyperchromasia), coarse chromatin aggregates,
and prominent nucleoli, which are also characteristic histopathological features of HGSC [9].
STIC is closely associated with HGSC. STIC lesions are found in prophylactically removed fallopian
tubes from asymptomatic germline BRCA-mutation carriers (0–11.5%) [100–103]. In addition,
STICs are also identified in the fallopian tubes of patients with sporadic (nonhereditary) HGSC
(21–59%) [45,48,104–106], as well as germline-BRCA-mutation-positive women with hereditary HGSC
(3–31%) [107,108]. Most STICs exhibit robust immunostaining of p53 [109,110] and harbor p53
mutations [111] (collectively termed the “p53 signature”). The p53 signature refers to benign-appearing
secretory cells in the distal fallopian tube that exhibit intense nuclear p53 (TP53) staining, positive
γ-H2AX staining (indicative of DNA damage), and lack of Ki-67 (MIB-1) staining (indicative of
minimal proliferative activity) [98,109,112,113]. As p53 signatures lack histological features of STIC,
p53 signatures are considered earlier lesions preceding STICs [101,114]. Besides the histopathological
resemblance and the association of its occurrence to HGSC, STIC lesions also exhibit genomic instability,
a characteristic genomic feature of HGSC, indicating genetic similarity to HGSC [114,115]. In addition,
genomic analysis of STIC lesions, fallopian tube tumors, ovarian tumors, and peritoneal metastases
from the same patients reveals an evolutionary relationship, suggesting that STICs and p53 signatures
are likely early events in the progression of HGSC [114,116]. Furthermore, the evolutionary analysis of
genetic changes observed in these various tumor tissues has identified alterations in BRCA1, BRCA2,
TP53, and PTEN as critical early events in the initiation of STICs and subsequent development
of HGSC [114]. Also, gene-expression profile of HGSC exhibits a greater similarity to that of the
fallopian tube epithelium than to the ovarian surface epithelium, suggesting a fallopian tube origin of
HGSC [117]. Together, these observations have led to the hypothesis that the fallopian tube STIC is
a precursor of HGSC arising from the ovary, fallopian tube, or peritoneum [9,76,118,119].
According to this hypothesis, STICs could develop into invasive tumors (HGSC) in the fallopian
tube, and the fallopian tube HGSCs then spread to the ovary and peritoneal cavity. Alternatively,
STICs could shed and implant on the surface of the ovary or peritoneum where they could progress
to HGSC [9,120].
STIC: Mouse Models
Crucial to this hypothesis is the demonstration of a cause-effect relationship between STIC
and HGSC: i.e., whether STIC can transform into malignant and metastatic HGSC. Partial evidence
has come from studies with genetically engineered mice, in which the fallopian tube epithelium is
preferentially, or in combination with other tissues, targeted with gene mutations [78,79,121–125]
(Table 2). In one mouse study, expression of mutant p53 (Trp53) and inactivation of Pten and Brca1/2,
together, generated STICs (83.9%: 26/31 mice) as well as HGSCs in the ovary (73.1%: 19/26) and
peritoneum (73.1%: 19/26) [78]. In another study, STIC formed in 35% (28/80) of mice harboring
the inactivation of four genes (Brca1, p53, Rb1, and Nf1: 48 mice) or three genes (Brca1, p53, and Rb1:
29 mice; Brca1, p53, and Nf1: 3 mice) in the fallopian tube epithelium [79]. Also, in this study, more
than two-thirds of the mice (68.8%: 55/80) formed fallopian tube tumors (STIC, early-stage HGSC,
and HGSC); some of these mice also developed ovarian tumors (38.2%: 21/55) or peritoneal tumors
(12.7%: 7/55) or ascites (12.7%: 7/55), or a combination of the three [79]. In the same study [79],
inactivation of Brca1, p53, and Pten in the fallopian tube epithelium also produced STIC or early-stage
HGSC or both or HGSC in the fallopian tube in 90% of mice: STIC (40%: 4/10 mice); early-stage HGSC
(60%: 6/10); and HGSC (20%: 2/10). In these mouse models [78,79], as the gene mutations occur in the
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fallopian tube epithelium—but not in the ovary or peritoneum—ovarian and peritoneal HGSCs are
likely tumors resulting from STICs formed in the fallopian tube.
Table 2. Mouse models of ovarian cancer: fallopian tube origins.















- Monitoring of tumor development: 6–13 weeks of age
Brca1, p53 R172H,
Pten
Pax8 100%(4/4) No 25% (1/4)
25% (1/4):
peritoneal mass No [78]
- Monitoring of tumor development: 5–7 weeks of age
Brca2, p53 R172H,
Pten
Pax8 75%(9/12) No 75% (9/12)
67% (8/12):
peritoneal mass No [78]
- Monitoring of tumor development: 7–15 weeks of age
p53 R172H, Pten Pax8
67%
(4/6) No 0% (0/6) 0% (0/6) No [78]
- Monitoring of tumor development: 19–38 weeks of age
SV40 TAg Ovgp1 Yes(?%) No
Adeno-carcinoma
(56%) No No [123]















- Monitoring of tumor development: 3.5–26 months of age





0% 0% 0% [125]
- Monitoring of tumor development: 3.5–26 months of age








33% (1/3) 0% [125]
- Monitoring of tumor development: 3.5–26 months of age









- Monitoring of tumor development: 3–8 months of age












- Survival range: 6.2–13 months of age (mean survival = 9.4 months; n = 24)
MMMT: malignant mixed mesodermal tumor (carcinosarcoma); HGSC: high-grade serous carcinoma or high-grade
serous ovarian cancer; p53: Trp53; ?: information not described in the cited reference.
Overall, these mouse models, targeting fallopian tube epithelium with gene mutations, develop
STICs and HGSCs which closely recapitulate many of clinical and molecular features of STIC and
HGSC in humans. Also, notably, Brca1 or 2 inactivation appears to be necessary for STIC to advance
to HGSC in mice [78]. These mouse models therefore support a notion that STIC can be a precursor
lesion for HGSC in genetically high-risk women carrying germline BRCA1/2 mutations.
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It remains unclear, however, whether STIC could also serve as a precursor for sporadic
(nonhereditary) HGSCs, which account for 85–90% of all HGSC cases [2,76]. In mouse models without
Brca1 or 2 mutation, p53 mutation and Pten deletion together can produce STIC lesions in the fallopian
tube epithelium (67%: 4/6 mice) (Table 2) [78]. Yet these STICs do not progress to invasive or metastatic
HGSCs in the ovary or peritoneal cavity [78]. In another study, expression of the SV40 large T antigen
(TAg), driven by the oviductal glycoprotein 1 (Ovgp1) promoter, also results in STIC lesions in the
fallopian tube epithelium along with adenocarcinoma in the ovary in some mice [123]. As Ovgp1
is highly expressed in the fallopian tube and TAg expression is not detected in the ovarian surface
epithelium, this ovarian carcinoma is presumed to have resulted from the spread and transformation of
fallopian tube STICs in the ovary [123]. Nevertheless, these STIC lesions do not advance to peritoneal
HGSC [123]. Thus, these mouse studies suggest that many STIC lesions may not progress to invasive,
and more critically, metastatic malignancies [78,79,123]. Studies of human HGSCs also note that most
STIC lesions likely do not advance to metastatic HGSC, and may thus be classified as low grade [98,126].
Hence, it remains to be elucidated whether STIC could be a bona fide precursor lesion for HGSC
in women in the general population who are at average risk, and yet who account for most cases
of HGSC.
STIC: Clinical Significance
Overall, though existence of STIC and its association to HGSC are extensively described in human
and mouse studies, the clinical significance of STIC remains uncertain [127]. In the early studies, in
which the fallopian tube was first proposed as a potential primary origin of HGSC, tubal dysplastic
lesions, later termed STICs, were reported in 37% and 50% of high-risk women whose fallopian tubes
were prophylactically removed [80,118] (Table 3). In most clinical studies, however, including ones
with larger sample sizes, the prevalence of STICs (or occult tubal carcinomas) in high-risk women
generally varies from 0–11.5% [100–103,128–139] (Table 3). It is unknown what proportion of the STICs
would progress to malignant and metastatic HGSC. It is possible that HGSC could also develop from
precursors distinct from STICs. Human and murine studies have indicated that metastatic HGSC can
arise from the fallopian tube without evidence of STIC [77,79,120].
Table 3. Incidence of STIC in high-risk women and in the general population.
Sample Tissue Population









50% (6) 12 Piek et al., 2001 [80]
37% (16?) 44 Piek et al., 2003 [118]
6.7% (4) 60 Colgan et al., 2001 [133]
10% (3) 30 Leeper et al., 2002 [93]
6% (4) 67 Powell et al., 2005 [137]
8% (4) 50 Carcangiu et al., 2006 [131]
3.8% (6) 159 Finch et al., 2006 [100]
5.7% (7) 122 Callahan et al., 2007 [130]
8.5% (15) 176 Shaw et al., 2009 [101]
8.9% (4) 45 Hirst et al., 2009 [134]
8.1% (9) 111 Powell et al., 2011 [128]
8.5% (10) 117 Manchanda et al., 2011 [135]
7.1% (16) 226 Mingels et al., 2012 [136]
1.7% (5) 303 Reitsma et al., 2013 [138]
4.2% (17) 405 Powell et al., 2013 [129]
2.0% (12) 593 Wethington et al., 2013 [102]
11.5% (9) 78 Cass et al., 2014 [132]
2.6% (25) 966 Sherman et al., 2014 [139]
0% (0) 111 Seidman et al., 2016 [140]
5.6% (2) 36 Lee et al., 2017 [103]
Fallopian tubes from
HGSC cases
High risk 30.8% (8) 26 Howitt et al., 2015 [108]
3.3% (2) 60 Malmberg et al., 2016 [107]
240
Cancers 2018, 10, 433
Table 3. Cont.
Sample Tissue Population








47.6% (20) 42 Kindelberger et al., 2007 [104]
58.5% (24) 41 Przybycin et al., 2010 [48]
37.3% (19) 51 Seidman et al., 2011 [45]
20.5% (8) 39 Tang et al., 2012 [106]
38.3% (23) 60 Mingels et al., 2014 [141]
38.2% (13) 34 Koc et al., 2014 [105]





3.1% (2) 64 Shaw et al., 2009 [101]
0.8% (4) 522 Rabban et al., 2014 [142]





22.7% (5) 22 Jarboe et al., 2009 [47]
21.8% (12) 55 Stewart et al., 2010 [143]
14.3% (4) 28 Tang et al., 2012 [106]




General 1.7% (3) 175 Seidman et al., 2016 [140]
?: information not described in the cited reference.
Also, STIC lesions may not be unique to HGSC. Though STICs are associated chiefly with
HGSC, they are not exclusive to HGSCs of the ovary, fallopian tube, and peritoneum. STICs are
also found in the fallopian tubes of patients with (high-grade) endometrial serous carcinoma
(8–23%) [47,106,143,144], as well as ones from patients with nonserous endometrial carcinoma or
endometrial hyperplasia (1.1%) [140] (Table 3). STICs are also found in the fallopian tubes of 3%
(2/64) of women undergoing surgery not related to ovarian, tubal, or peritoneal malignancy [101].
In addition, STIC lesions are not found in a large fraction of clinical HGSC cases. In advanced
human HGSC, the occurrence of STIC ranges from 21–59% in sporadic HGSC [45,48,104–106,141]
and 3–31% in (germline-BRCA-mutation-positive) hereditary HGSC [107,108]. These findings suggest
that a significant number of HGSCs may derive from precursors independent of STICs [36,108].
Also, p53 (TP53) signatures, another potential precursor lesions in the fallopian tube closely associated
with STICs, is not unique to high-risk women, but is also commonly seen in women who are at low
risk of ovarian cancer [101,109]. The p53 (TP53) signatures were present in the fallopian tubes of
19% (12/64) and 33% (19/58) of women who are at average risk of ovarian cancer, compared with
11% (19/176) and 24% (10/41) of high-risk women undergoing risk-reducing salpingo-oophorectomy
(RRSO) [101,109]. The fact that STIC and p53 (TP53) signatures are not unique to HGSC and HGSC can
arise without evidence of STIC suggests that there may exist additional, yet undiscovered, precursor
lesions for HGSC [36]. Given the highly aggressive nature of HGSC, the existence of novel precursor
lesions would not be inconceivable.
STIC is evidently a risk factor for HGSC. Yet, more causal evidence would be needed to affirm that
STIC is a bona fide precursor lesion for hereditary (10–15%) and sporadic (85–90%) HGSCs in women.
The key issue is whether STIC, a lesion of noninvasive neoplastic cells, could evolve into an invasive
tumor and advance to aggressive metastatic HGSC. In the aforementioned mouse models [78,79],
though some fallopian tube STICs lead to ovarian and peritoneal HGSCs, the extent and spectrum of
metastases do not appear to fully match the clinical metastases observed in human HGSC.
Regarding the fallopian tube as an origin of HGSC, currently available data indicate that
STIC likely serves as a premalignant lesion that could develop into metastatic HGSC in high-risk
women carrying germline BRCA1/2 mutations [145]. The overall fraction of ovarian cancers that
originate in the fallopian tube is not known. In one study examining specimens from risk-reducing
salpingo-oophorectomy (RRSO), microscopic HGSC was identified in the fallopian tube in six (4.5%)
of 133 BRCA1/2 carriers [113]. Four of the HGSCs were confined to the fallopian tube, one to the
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ovary only, and one was identified from peritoneal washings only. In contrast, when early-stage
(I and II) HGSCs (14/131) from BRCA1/2 carriers were examined, the majority of early-stage HGSCs
(78.6%: 11/14) were diagnosed as ovarian primaries, while three cases (21.4%: 3/14) as fallopian
tube primaries [113]. These results suggest that the fallopian tube may be the primary site of origin
of HGSC, but the ovary is a preferred site of tumor growth and progression in high-risk women.
Temptingly, this notion might be extended to HGSC in the general population, but there is not yet
sufficient causal evidence [127].
It seems logical to predict that a precursor lesion such as STIC, which exhibits malignant
morphological and genetic features, would gradually progress and eventually manifest as a full-blown
metastatic malignancy [146]. However, it is also increasingly recognized that many of microscopically
cancerous precursor or early-tumor lesions may not proceed to clinical, lethal malignancies [81,147–150].
Thus, rigorous evaluations of the causal relationship between STIC and metastatic HGSC would be
critical for establishing STIC as an origin of metastatic HGSC.
Insights from Ductal Carcinoma In Situ (DCIS) in Breast Cancer
Ductal carcinoma in situ (DCIS), a microscopic malignancy confined to the breast ductal
epithelium without invasion of the duct wall, is widely believed to be a precursor or premalignant
lesion for all breast cancer malignancies [151]. In 2018, DCIS was estimated to be 24% (63,960) of
newly diagnosed breast tumors (266,120) [152]. Since the 1970s, when screening mammography was
introduced, detection of DCIS had risen by 700% from 1976 to 2008 (7 DCIS/100,000 women in 1976
and 56 in 2008) [153]. An additional 573,000 cases of DCIS were estimated to be diagnosed during the
three decades. If DCIS is a true premalignant lesion for invasive and lethal breast cancer, more cases of
DCIS should lead to a proportional decline in the incidence of advanced-stage breast cancer. However,
late-stage breast cancer cases had fallen by only 8% during the same period (102/100,000 women in
1976 and 94 in 2008; diagnosis of additional 573,000 cases of DCIS vs. an estimated decrease of 67,000
cases of late-stage breast cancer during this period) [153]. These clinical observations suggest that
though some DCIS can advance to invasive breast cancer, the vast majority of DCIS lesions are unlikely
to progress to metastatic, life-threatening malignancies [154].
In an autopsy study in which women died from causes other than breast cancer, DCIS was
identified in about 30% of women between the ages of 40 and 54 years [155]. As one in eight women
(12.4%) develops breast cancer during her lifetime in the U.S. [156], this common occurrence of DCIS in
the general population also bolsters the notion that many DCIS lesions do not lead to malignant breast
cancers [155]. Some DCIS lesions do proceed to invasive, metastatic breast cancer [157]. It is unknown,
however, which DCIS would advance to invasive, metastatic cancer and which would not; the estimates
vary widely from 0–50% [154,157,158]. For this reason, though noninvasive, DCIS is still regarded as
breast cancer (stage 0) and treated as aggressively as invasive breast cancer with surgery and hormonal
therapy [154]. There is a growing perception that the rise of DCIS diagnoses has led to overdiagnosis
and overtreatment [147,159].
Reflecting an increasing awareness of the overdiagnosis and overtreatment, there has also been
a growing level of recognition that many of premalignant lesions, albeit histopathologically classified
as cancer, often do not progress to invasive or metastatic tumors [81,147,148]. Hence, it has been
proposed that premalignant lesions, such as ductal carcinoma in situ (DCIS), not be labeled as cancer
or carcinoma [147]. Instead, they may be reclassified using a more appropriate term reflecting their
indolent clinical behavior, such as “indolent lesions of epithelial origin (IDLE)” [147]. Also, appreciating
the generally low malignant potential of most STICs, a new term, such as “low-grade serous tubal
intraepithelial neoplasia,” was suggested in place of “STIC” [81].
Like DCIS, STIC is also a noninvasive tumor of epithelial origin [45,48]. Though not invasive,
these STIC lesions possess malignant cellular features [98] as well as widespread genomic alterations,
and are therefore considered preinvasive or premalignant lesions [114–116]. It is intuitive to assume
that these lesions would eventually become invasive in the local tissue and ultimately spread to
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other parts of the body. Yet many microscopic cancers may not, though some do, proceed to
clinical malignancy [149,150,160,161]. Current evidence suggests that some STIC lesions would be
capable of progressing to invasive tumors leading to peritoneal metastases in the context of germline
BRCA-mutation carriers [78,79]. Other STIC lesions may not undergo malignant transformation,
remaining noninvasive [78,79,123]. Particularly critical, yet unknown, is the clinical significance of
STIC in the general population where 85–90% of HGSC cases occur. The information on the prevalence
of STICs in the general population is limited, but several studies suggest that it could vary from
0.8–3.1% [101,140,142], while the lifetime risk of ovarian cancer is 1.3% (one in 78 women) [50,162].
Like DCIS, most likely, some STICs would possess malignant potential, while more STICs would not.
Advances in technology would increasingly facilitate detection of these noninvasive yet potentially
cancerous lesions, such as DCIS and STIC, in the general population as well as high-risk individuals.
The challenge is to be able to predict how these potential precancerous lesions would behave in the
course of tumor progression: would these precancerous lesions cause little harm or turn deadly if left
untreated? As STIC has emerged as a potential precursor for human HGSC, it is crucial to elucidate the
natural progression of STIC in the context of HGSC development at the molecular as well as biological
levels. A deeper understanding of the natural history of STIC would help develop ways to clinically
assess the malignant potential of STIC lesions.
2.2.2. Fallopian Tube Stroma
Fallopian tube origin of HGSC is also supported by a serendipitous phenotype in a mouse
model, in which Dicer1 and Pten are inactivated in the fallopian tube [77] (Table 2). These Dicer1-Pten
double-knockout (DKO) mice faithfully and reliably reproduce the clinical behavior of human HGSC
with 100% penetrance [77]. In these mice, HGSC forms in the fallopian tube, and then spreads to
envelop the ovaries, and also aggressively metastasizes throughout the peritoneal cavity. Peritoneal
metastases occur preferentially to the omentum and diaphragm with widespread tumors in the
mesentery and peritoneal membrane, invariably accompanied by ascites. All of the mice die from
peritoneal metastases of fallopian tube HGSC (n = 24/24; 6.2–13 months of age; mean survival:
9.4 months) [77]. Though metastases are generally confined to the peritoneal cavity in these mice,
occasionally, HGSC metastasizes to the lungs (stage IV), as well as the peritoneal cavity (stage III).
Besides phenotypic and histopathologic resemblance, there are also significant correlations in gene
expression between mouse and human HGSCs [77]. Moreover, these mouse HGSCs also exhibit
widespread genomic instability resembling human HGSC (unpublished).
However, while modeling the clinical behavior of human HGSC, histopathologically classified
as HGSC, exhibiting marked genomic disarray, and unmistakably stemming from the fallopian tube,
the HGSC in this model does not appear to originate in the fallopian tube epithelium, but rather,
in the fallopian tube stroma [77]. In this model, Amhr2-cre (Amhr2cre/+), in which the insertion of cre
recombinase gene is targeted to an endogenous Amhr2 locus, would direct the deletion of Dicer1 and
Pten specific to the fallopian tube stroma, not in the epithelium [163]. Accordingly, no histopathologic
abnormality or STIC lesions were present in fallopian tube epithelium [77]. In this mouse model,
in the absence of Dicer1 and Pten, stromal stem cells residing in the fallopian tube [163] may transform
into HGSC in the fallopian tube, leading to widespread peritoneal metastases as well as the ovarian
metastasis. Thus, despite fallopian tube origin, the stromal origin of HGSC in this mouse model is
at odds with the STIC hypothesis, which predicts that the fallopian epithelium, particularly distal
tubal epithelium, is the primary cell of origin of metastatic HGSC in humans. There is yet no clinical
evidence that human HGSC could originate in the stroma of the fallopian tube.
Also, the genetic relevance of DICER1 and PTEN in human HGSC is not clear. Low expression
of DICER1 is associated with advanced stages and reduced survival in human ovarian cancer
(HGSC) [164], suggesting that DICER1 may function as a tumor suppressor. Yet the role of DICER1
loss in ovarian cancer remains to be clarified. In human HGSC, homozygous deletion of DICER1
(DICER1−/−) is extremely rare (0.3%: 1/316 patients) [41,165,166]. Relatively common, however,
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is a single-copy loss of DICER1 (44%). Similarly, PTEN deletion is found in 38.9% of the cases
for combined homozygous (6.6%) and heterozygous losses (32.3%) [41]. Though PI3K signaling
is frequently activated in human HGSC, it is not clear how this partial loss of PTEN impacts the
development of HGSC.
Thus, most cases of human HGSC are unlikely to occur as a direct consequence of loss of DICER1
and PTEN. Rather, this mouse model reveals critical pathways—activated by loss of Dicer1 and
Pten—what are essential to the development of metastatic HGSC. Accordingly, this mouse HGSC
reveals significant alterations of known critical pathways for HGSC [41], including PI3K signaling [77],
FOXM1 signaling (unpublished), and homologous recombination (unpublished).
Despite many features in common between this mouse model and human HGSC—most notably,
the striking clinical resemblance to human HGSC—the major limitation of this model is the precise cell
origin of this murine HGSC: fallopian tube stroma. According to current understanding, it is difficult
to envision that human HGSC, an epithelial malignancy, could originate, not in epithelium, but rather
in stroma. In the mouse uterus, a fraction of stromal cells of Amhr2 lineage, likely stromal stem
cells, are capable of differentiating into epithelial cells during the endometrial regeneration after
parturition [163]. Plausibly, stem cells residing in the fallopian tube stroma, in the absence of Dicer1
and Pten, transform into HGSC. Whether this potential stromal-to-epithelial transition could occur
during the development of human HGSC remains to be clarified. Nevertheless, it should also be
acknowledged that the natural course of human HGSC—initiation, development, early progression,
and ultimate peritoneal metastasis—remains poorly understood.
Rarely does an animal model manifest a full spectrum of clinical disease of a human disorder.
If an animal model, however, develops a cancer that behaves like the human cancer with a nearly
identical metastatic pattern, one could reason that the mouse and human malignancies likely share
similar mechanisms of development and tumor progression. This mouse model could be a valuable
tool in understanding the mechanisms underlying the development, early progression, and metastatic
progression of human HGSC—and also serve as a useful preclinical model for evaluating new therapies.
2.2.3. Ovarian Cancer Prevention: Salpingo-Oophorectomy vs. Salpingectomy
Over the last decade, clinical and mouse studies have bolstered the idea that the fallopian tube is
the predominant origin of HGSC. This novel concept has spawned new thinking in ovarian cancer
prevention in women at high genetic risk and also in the general population.
Salpingo-oophorectomy—surgical removal of the ovaries and fallopian tubes—is the standard
preventive surgery recommended for germline BRCA1/2 carriers, who are at high risk of ovarian
cancer [9,85,167,168]. This prophylactic surgery has proven to be highly effective, as it reduces the risk of
ovarian cancer by 72–96% [86,89,169], ovarian-cancer-specific mortality by 79–95% [86,170], and overall
mortality by 60–66% [86,170]. Besides ovarian cancer protection, oophorectomy also significantly
decreases the risk of breast cancer (50% risk reduction) in BRCA1/2 carriers [84,86,89,170–173] (though
some studies indicate no difference in breast cancer risk, or a selective risk reduction only among
BRCA2 carriers [174,175]).
Despite the proven benefits of risk and mortality reductions in ovarian and breast cancer,
salpingo-oophorectomy has a major drawback of premature menopause, which hinders wider acceptance.
Prophylactic surgery involves removal of the ovaries and fallopian tubes, and is recommended between
the ages of 35 and 40 years, when women are premenopausal [84,95,168,176]. Consequently, these women
undergo premature surgical menopause with an increased risk of experiencing postmenopausal
symptoms, including hot flashes, sleep disturbance, mood changes, vaginal dryness, sexual dysfunction,
cognitive decline, osteoporosis, and cardiovascular disease [177–179]. To avoid these adverse health
outcomes, approximately 30–50% of BRCA1 and 2 carriers choose not to undergo prophylactic
salpingo-oophorectomy even after completion of child bearing [95,180–185].
With the emerging concept of the fallopian tube as the principal site of origin for HGSC,
an alternative preventive approach has been proposed to mitigate the adverse consequences of ovary
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removal in women at high genetic risk. A two-step surgery has been proposed, in which salpingectomy
(removal of the fallopian tubes) is performed early upon completion of childbearing, followed by
subsequent oophorectomy (removal of the ovaries) at ages 40–45 for BRCA1 and ages 45–50 for BRCA2
carriers [180,186,187]. Although salpingectomy alone with ovary conservation could theoretically
reduce the risk of HGSC, this approach warrants careful consideration.
While the majority of HGSCs arise in the fallopian tube, it may not be that all originate
there [113,139]. Thus, retaining the ovaries with salpingectomy alone would continue to pose ovarian
cancer risk to some high-risk women until the completion of oophorectomy [180,188]. Another concern
is a delay in oophorectomy. Breast cancer protection appears to occur when oophorectomy is performed
before menopause in high-risk women [86,89,170,172,173]. Delaying ovary removal may diminish the
benefit of breast cancer protection [176,188]. Ovarian cancer risk appears to be higher in salpingectomy
alone than salpingo-oophorectomy in the general population [189,190]. Clinical trials are underway to
evaluate the effectiveness of salpingectomy alone or salpingectomy followed by delayed oophorectomy
in high-risk women [176,186]. Presently, bilateral salpingo-oophorectomy is still the recommended
prophylactic surgery for high-risk women carrying germline BRCA1 or 2 mutations [176].
This new paradigm of fallopian tube origin also presents the option for an opportunistic
salpingectomy as an alternative preventive measure in the general population (who are at average
risk) undergoing hysterectomy for benign disease or pelvic surgery [95,191–193]. In the United States,
approximately 600,000 women undergo a hysterectomy for benign (uterine) disease [194]. About half
(300,000) the women undergoing hysterectomy also opt for a prophylactic salpingo-oophorectomy for
a variety of health reasons, including risk reduction of ovarian cancer; the other half choose to retain
their ovaries and fallopian tubes to avert the adverse health consequences associated with removal of
the ovaries [191,195]. As expected, the risk of developing ovarian and breast cancer is reduced (by 96%
and 25%, respectively) in average-risk women undergoing hysterectomy and salpingo-oophorectomy,
compared with women undergoing hysterectomy but conserving the ovaries [196]. However, adverse
effects of ovary removal are also pronounced in these women. Beyond premature menopausal
symptoms, ovary removal has also been associated, in some studies, with increased mortality in
women with hysterectomy (28% increase in the risk of death for coronary heart disease, and 12%
increase in overall mortality), compared with women whose ovaries are retained at the time of
hysterectomy [195,196]. Observational studies suggest that ovary removal may do more harm than
good in average-risk women in the general population [195].
Germline BRCA1/2 carriers have high risk of both ovarian and breast cancer (lifetime risk: 10–60%
for ovarian cancer [2,86]; 66–82% for breast cancer [84,85]). In these high-risk women, removal of the
ovaries offers dual benefits: not only does it prevent ovarian cancer, it also significantly lowers breast
cancer risk (by 47–64%) [84,86,171] and mortality (by 56–90%) [84,86,170]. The benefits of removing the
ovaries (as well as the fallopian tubes), therefore, appear to be evident in these women at high genetic
risk. In the general population, however, women are at average risk for ovarian and breast cancer
(lifetime risk: 1.3% for ovarian cancer [50,162]; 12.4% for breast cancer [50,152]). In these average-risk
women, though ovary removal appears to reduce the risk of breast cancer, it seems to have little impact
on breast cancer mortality [195,196]. In contrast to a clear risk reduction in high-risk women, ovary
removal seems to bring to average-risk women a relatively modest benefit in relation to breast cancer.
These average-risk women may benefit from fallopian tube removal alone and retaining the
ovaries. Salpingectomy alone is shown to reduce the risk of ovarian cancer by 35–64% in the general
population [189,190]. Conservation of the ovaries would improve quality of life by averting premature
menopausal symptoms, and also extend overall survival by reducing ovary-loss-associated mortality.
Hence, salpingectomy with ovary retention, in lieu of salpingo-oophorectomy, can be an option to
these average-risk women undergoing hysterectomy or pelvic surgery [95,193].
In summary, in high-risk women, until further evidence is available, risk-reducing
salpingo-oophorectomy (RRSO) is recommended by age 40 for BRCA1 mutation carriers and by
age 45 for BRCA2 mutation carriers [95,176]. On the other hand, for women at average risk of ovarian
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and breast cancer, salpingectomy alone—and keeping the ovaries—may be a prophylactic option to
consider when undergoing hysterectomy or pelvic surgery [193].
2.3. Other Potential Origins of HGSC
2.3.1. Secondary Müllerian System
Epithelial ovarian cancer may also arise in the secondary Müllerian system [197], which refers to
the presence of Müllerian epithelium (i.e., epithelium of the fallopian tube, uterus, and endocervix)
outside the indigenous locations (i.e., the fallopian tube, uterus, and endocervix). The secondary
Müllerian system includes endometriosis (endometrium-like tissue present outside the uterus),
endosalpingiosis (fallopian tube-epithelium-like epithelium on or beneath the peritoneal surface),
and the rete ovarii (Müllerian epithelium-resembling tubular structures near the ovarian hilum, a
junctional area between the ovary and the fallopian tube). As HGSC resembles normal fallopian
tube epithelium, the secondary Müllerian system could serve as an origin of HGSC [198]. After
prophylactic removal of the ovaries, some of these ovary-deficient high-risk women develop HGSC in
the peritoneum [89,199]. This primary peritoneal HGSC is believed to arise from endosalpingiosis [45]
or Müllerian metaplasia of peritoneal mesothelium [76].
2.3.2. Ovarian Hilum
In addition, the epithelium (particularly stem cells) lining the hilum, a junctional area between
the ovary and the fallopian tube, has been suggested to be a cell of origin for HGSC [61,73]. In a mouse
allograft study, epithelial cells in the mouse ovarian hilum that are also positive for stem-cell markers
are isolated and cultured followed by inactivation of p53 (Trp53) and Rb1 [73]. When injected into the
peritoneal cavity of mice, these hilum-derived potential stem cells lacking p53 and Rb1 are able to form
HGSC in the ovary (n = 7/8 mice) [73]. However, the metastatic behavior of this HGSC does not seem
to align with the typical metastatic pattern of human HGSC, which is characterized by widespread
peritoneal metastases. Though five (71%) of the seven mice with ovarian HGSC also developed lung
metastasis, there seem no other peritoneal tumors besides the tumors formed in the ovary [73]. While it
is intriguing to see that hilum-derived, stem-cell-like epithelial cells lacking p53 and Rb1 have potential
to form serous carcinoma in the ovary, this serous tumor appears to lack peritoneal metastatic potential,
a characteristic clinical feature of human HGSC [43].
3. Conclusions
Once it seemed obvious to think that all ovarian cancers, including high-grade serous ovarian
cancer (HGSC), originated in the ovarian surface epithelium (OSE) [18,19,57]. Presently, it seems
equally compelling to think that HGSC arises from serous tubal intraepithelial carcinoma (STIC) formed
in the distal fallopian tube epithelium [9,46,200]. Both may be the cell of origin in different fractions
of cases. Abundant clinical observations, genetic evidence, and increasing consensus in the field all
point to STIC as the precursor lesion, particularly in women at increased genetic risk [9,76,114,116].
Yet, it is still imperative to rigorously establish a cause-effect relationship between STIC and clinical
HGSC: i.e., whether STICs progress to malignant and metastatic HGSCs. Particularly, the clinical
significance of STIC remains uncertain in women in the general population, who account for 85–90% of
HGSC cases. Undoubtedly, STICs pose high risk for HGSC, and certain STIC lesions could transform
into clinical HGSC. However, logical and intuitive as it may seem, many of precursor or premalignant
lesions, despite consisting of microscopically and genetically cancerous cells, would not progress to
lethal malignancies [147,149,150]. Hence, it is crucial to understand the natural progression of STIC
lesions at the molecular and biological levels. In particular, the focus should be directed toward
assessing the clinical consequences of STIC lesions: i.e., those likely to remain benign vs. those with
the ability to undergo full malignant transformation, progressing to metastatic HGSC. A deeper and
more comprehensive molecular characterization of STICs in different stages of HGSC may help predict
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or determine the malignant and metastatic potential of STICs. Also, as STICs do not account for all
HGSCs, it is also important to search for other potential cell origins for HGSC. The fallopian tube
stroma in mice, for instance, has the capability to develop metastatic HGSC which faithfully reproduces
the clinical metastasis of human HGSC.
Determining the precise cell(s) of origin of HGSC is crucial for improving early-detection and
prevention rates of ovarian cancer, and could offer insight into devising effective treatment against
advanced ovarian cancer.
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Abstract: Epithelial ovarian carcinoma is the most predominant type of ovarian carcinoma,
the deadliest gynecologic malignancy. It is typically diagnosed late when the cancer has already
metastasized. Transcoelomic metastasis is the most predominant mechanism of dissemination
from epithelial ovarian carcinoma, although both hematogenously and lymphogenously spread
metastases also occur. In this review, we describe molecular mechanisms known to regulate
organ-specific metastasis from epithelial ovarian carcinoma. We begin by discussing the sites
colonized by metastatic ovarian carcinoma and rank them in the order of prevalence. Next, we review
the mechanisms regulating the transcoelomic metastasis. Within this chapter, we specifically focus on
the mechanisms that were demonstrated to regulate peritoneal adhesion—one of the first steps in
the transcoelomic metastatic cascade. Furthermore, we describe mechanisms of the transcoelomic
metastasis known to regulate colonization of specific sites within the peritoneal cavity, including the
omentum. Mechanisms underlying hematogenous and lymphogenous metastatic spread are less
comprehensively studied in ovarian cancer, and we summarize mechanisms that were identified
to date. Lastly, we discuss the outcomes of the clinical trials that attempted to target some of the
mechanisms described in this review.
Keywords: ovarian cancer; organ-specific metastases; peritoneal adhesion; mesothelium; omentum;
peritoneal wall; lymph node; liver; lung; gene expression
1. Introduction
Ovarian carcinoma is the fifth leading cause of death from female cancers [1] and comprises
several malignancies of epithelial and non-epithelial origins. Epithelial ovarian carcinoma (EOC) is the
most predominant type, which, in turn, encompasses several distinct histotypes that are thought to
originate in epithelial cells of the female reproductive tract [2–4]. High-grade serous ovarian carcinoma
(HGSOC) is the most predominant histotype of EOC, and is thought to originate in epithelial cells of
the ovaries and fallopian tubes.
HGSOC metastases spread via several distinct routes, including transcoelomic, hematogenous,
and lymphogenous, with the former being the most predominant [5,6]. Transcoelomic spread refers to
a route of tumor metastasis across a body cavity, such as the peritoneal cavity, as in the case of ovarian
cancer. Transcoelomic metastases from ovarian cancer primarily seed the viscera of organs and tissues
of the peritoneal cavity; metastasizing cells first attach to the mesothelial monolayer of intraperitoneal
tissues and subsequently invade the extracellular matrix of the underlying stroma. The majority of
patients with EOC are first diagnosed when peritoneal metastases have already formed, because the
disease at early stages (when the tumor is confined to the ovary) is nearly asymptomatic.
These patients are typically treated by surgery and neoadjuvant chemotherapy (NACT) consisting
of a combination of a platinum drug and a taxane. The Gynecologic Oncology Group defined optimal
debulking as residual implants less than 1 cm [7]. Optimal debulking is often not possible due
Cancers 2018, 10, 444; doi:10.3390/cancers10110444 www.mdpi.com/journal/cancers258
Cancers 2018, 10, 444
to the vast spread of metastatic lesions across the viscera of the peritoneal cavity [8]. Analysis of
3126 patients demonstrated that one-third each had complete resection, a small residual tumor
burden of 1–10 mm, or macroscopic residual disease >1 cm in diameter [9], indicating that
optimal resection could be achieved in approximately two-thirds of patients. In cases when optimal
debulking is not feasible, the preferred treatment route includes interval debulking surgery after
NACT [10,11]. Although most cases are initially responsive to chemotherapy, most become less and
less sensitive with every recurrence, and eventually develop chemoresistance [12,13]. Moreover,
metastatic ovarian cancer is thought to contain a subpopulation of cells with self-renewing capacity,
or cancer stem cells, which are not affected by cytotoxic chemotherapy [14,15]. Patients who
relapse more than six months after completion of platinum/taxane initial therapy are considered
platinum-sensitive. Patients who respond to primary treatment and relapse within six months are
characterized as platinum-resistant. Patients who relapse within 3 months of treatment are regarded
as platinum-refractory [16]. The five-year survival for patients with advanced EOC is below 30%.
Recurrent chemotherapy-resistant EOC is incurable. Moreover, peritoneal metastases are known to
cause malnutrition and cachexia, which is associated with metabolic changes and bowel obstruction in
patients with ovarian carcinoma [17–19]. Cachexia is strongly associated with worse prognosis [20–22].
For these reasons, the mechanisms regulating peritoneal metastasis from EOC are studied most
extensively with the aim of identifying ways of preventing re-colonization of mesothelial linings
and blocking or retarding the growth of intraperitoneal lesions using novel targeted molecular
therapies that could be applied either alone or in conjunction with conventional chemotherapies.
The hematogenous route of metastatic colonization also contributes to formation of intraperitoneal
metastases [23,24]. The lymphatic system is often involved by the disseminating EOC cells as
well [25–28]. Formation of thoracic metastases from EOC is thought to occur, in part, via direct
extension of the peritoneal metastases or via lymphatics, although the relative contribution of these
mechanisms is yet to be experimentally established.
In this review, we focus on the molecular mechanisms currently known to underlie the formation
and development of organ-specific metastases from EOC.
2. Sites of EOC Metastases
Several studies assessed the patterns of metastatic spread from EOC at relapse, as well as at
autopsy. These studies demonstrated that, although EOC typically colonized a wide variety of organs
and tissues, there was not one single metastatic site that was always involved by metastasis in all
studied cases. The main site of metastasis was the peritoneum, including the parietal and visceral
peritoneum and omentum, which was involved in 77% of cases on average among several reports
(ranging between 53% and 99%, Table 1) [25–27,29–31]. Other commonly colonized sites identified
by autopsy studies included lymph nodes (38–77% of cases), large and small intestine (44–86% of
cases), liver parenchyma (45–59% of cases), and lung (33–39% of cases). Pancreas, spleen, stomach,
and ureter were involved in 3–24% of cases, while organs, such as the thyroid, bone, brain, skin,
heart, breast, and kidney were typically colonized in 1–12% of the cases [25–27,32]. Notably, although
distant metastases are rarely the main cause of death from metastatic EOC, their presence usually
indicates worse prognosis [33,34]. For example, the presence of parenchymal splenic metastasis was an
independent predictor of decreased overall survival [35]. Brain metastasis also correlated with worse
prognosis among older patients [36,37].
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Table 1. Prevalence of peritoneal metastasis in patients with epithelial ovarian carcinoma (EOC).


















100 Autopsy 73 (73%) At autopsy [25]
USA, National
Cancer Institute 73 Autopsy 39 (53%) At autopsy [26]
Switzerland,












49 (70%) At relapse [31]
* The number of cases with epithelial ovarian carcinoma only. ** The number of patients who were analyzed. ***
The number of cases for which complete imaging data are available. **** The number of cases with recurrent
ovarian cancer.
Interestingly, the mutational status of tumor protein P53 (TP53) is linked with the propensity to
seed either mainly peritoneal or peritoneal and distant metastases. Ninety-six percent of all cases
belonging to HGSOC carry mutations in the tp53 gene, which could occur at multiple locations
within the gene sequence [34,38,39]. Null mutations of p53 were predictive of distant metastasis to
liver, thorax, spleen, brain, and lymph nodes at initial diagnosis, and they occurred eightfold more
frequently compared with cases containing either missense mutations of tp53 or those expressing
wild-type TP53 [34], although the detailed mechanisms are not known. Furthermore, cases with
serous histology displayed slightly higher preponderance to having distant metastases (22 out of 66) in
comparison to cases with other histologies, in which seven out of 35 cases had distant metastases [34].
In summary, the studies showed that metastases from ovarian carcinoma predominantly formed
locally within the peritoneal cavity (peritoneum, omentum, and mesothelium); however, a large
number of cases also presented with distant metastases, most commonly at lymph nodes, liver,
and lung.
3. Mechanisms Regulating Transcoelomic Metastasis from EOC
Transcoelomic dissemination is thought to be the major route via which EOC metastasis
spreads [6]. Peritoneal metastases can reach very large sizes and are often accompanied by the presence
of the malignant ascites. These metastases are seeded by individual cells and multicellular aggregates
or spheroids, which first adhere to mesothelial cells outlining the peritoneal cavity and then invade
the submesothelial extracellular matrix (Figure 1). Studies of cell cultures of ovarian cancer cell
lines demonstrated that cells could spontaneously detach from monolayers and remain as individual
cells or form spheroids [40,41]. Recent in vivo studies demonstrated that spheroids predominantly
formed by collective detachment from the primary tumor [40]. Mechanistically, it was suggested that a
membrane type-1 matrix metalloproteinase plays a pivotal role in the spontaneous release of cell–cell
adherent sheets, which later form spheroids [42]. Another study showed that individual cells could
also aggregate together prior to mesothelial adhesion [43].
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Figure 1. A scheme of the peritoneal metastasis through the transcoelomic route. Disseminating
epithelial ovarian carcinoma (EOC) cells and spheroids are shown in mauve, mesothelial cells are shown
in green, the basement membrane is shown in orange, stromal cells are shown in grey, parenchymal
cells are shown in yellow, and the extracellular matrix is shown in grey.
Progression of ovarian carcinoma is often accompanied by the presence of the malignant ascites,
a fluid that accumulates within the peritoneal cavity [44,45]. It was estimated that more than one-third
of ovarian cancer patients present with ascites at diagnosis, and nearly all contain ascites at the time of
recurrence [46]. It is thought that ascites forms as a result of impaired drainage of the peritoneal cavity
due to the obstruction of the lymphatic system by metastasizing tumor cells or an increased filtration
rate to the peritoneal cavity [44]. The presence of the malignant ascites predicts poor prognosis in
different ovarian cancer patient cohorts irrespective of the tumor’s histological type [47–50]. Ascites
contains many soluble molecules, such as survival factors, including cytokines, chemokines, growth
factors, and fragments of the extracellular matrix (ECM). In addition, ascites is an abundant source of
the cells of the immune system, stromal and mesothelial cells, and cancer stem cells [46]. It is thought
that the microenvironment within the ascites contributes to survival of the metastasizing ovarian
cancer cells, provides support for tumor growth, and contributes to tumor heterogeneity [51].
3.1. Mechanisms Regulating Peritoneal Adhesion
The peritoneal mesothelium is a monolayer of mesothelial cells that lines the abdominal cavity [52].
Disseminating individual cells and spheroids adhere to the mesothelial lining of the intraperitoneal
cavity to establish metastatic lesions. Studies described below demonstrated that both ovarian cancer
and mesothelial cells play active roles in this process.
Mesothelial cells produce hyaluronan, which is thought to serve as a protective layer preventing
attachment of the malignant EOC cells [53]. Inflammation associated with cancer may result
in production of low-molecular-weight hyaluronan fragments and destruction of the protective
hyaluronan coat consisting of the high-molecular-weight hyaluronan [54]. Different molecular
pathways associated with both mesothelial and disseminating tumor cells could participate in
promoting peritoneal adhesion.
The majority of EOC cases affect the elderly, as the median age at diagnosis is 63 [55]. Thus,
several studies focused on characterization of senescent stromal cells, including peritoneal mesothelial
cells in the metastatic process. Senescent mesothelial cells play a critical role in the development
of peritoneal carcinomatosis in several cancer models, including ovarian cancer [56]. In studies of
syngeneic ovarian cancer models, aged mice were more prone to formation of metastases than their
younger counterparts [57]. Increased metastatic burden in aged mice also corresponded to significant
changes in the cellular composition of the native immune system within the peritoneal adipose tissue
such that the presence of tumor-infiltrating lymphocytes was higher and B-cell-related pathways were
altered in comparison to younger mice [57].
EOC cells can co-opt mesothelial cells in order to facilitate peritoneal adhesion. It was demonstrated
that EOC cells can secrete exosomes enriched for CD44 molecule (CD44). These exosomes could be
internalized by mesothelial cells, resulting in the secretion of matrix metallopeptidase 9 (MMP-9),
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which helps EOC with cell invasion [58]. Mesothelial cells also secrete lysophosphatidic acid (LPA),
which aids in mesothelial adhesion of EOC cells expressing receptors for LPA [59].
Numerous in vitro and in vivo studies used different experimental approaches to show that
disseminating ovarian cancer cells themselves express a number of membranous receptors and
adhesion molecules that facilitate their adhesion to mesothelial cells expressing ligands for these
receptors (Figure 2).
Figure 2. Molecular mechanisms regulating peritoneal adhesion. Disseminating epithelial ovarian
cancer cells and spheroids are shown in mauve, mesothelial cells are shown in green, the basement
membrane is shown in orange, stromal cells are shown in grey, parenchymal cells are shown in
yellow, and the extracellular matrix is shown in grey. Only one interaction between a cancer cell
and a mesothelial cell is shown for simplicity and a clearer presentation of the known mechanisms.
CD44: CD44 molecule; CA125: mucin 16, cell surface associated or ovarian carcinoma antigen CA125;
L1CAM: L1 cell adhesion molecule; CX3CL1: C-X3-C motif chemokine ligand 1; CX3CR1: C-X3-C motif
chemokine receptor 1; CD24: CD24 molecule.
The first interaction reported to facilitate peritoneal adhesion was between hyaluronan (HA)
expressed by mesothelial cells and CD44 expressed by EOC cells [60,61]. It was also reported that
extracellular tissue transglutaminase (TG2) expressed by ovarian cancer cells results in upregulation
of CD44, which further promotes peritoneal adhesion [62]. Reduction of expression of a secreted
glycoprotein, versican, which is thought to facilitate the CD44–HA interaction, in EOC cells,
resulted in reduction of tumor formation by individual cells and abrogation of metastatic ability
of spheroids [63,64]. These studies revealed an important role of CD44 and molecular interactions
supporting its function, notably, TG2 and versican, in mesothelial adhesion. Further studies indicated
that treatment with neutralizing anti-CD44 antibodies reduced tumor burden on the peritoneal wall
and diaphragm in a xenograft mouse model [65], suggesting that targeting CD44 is a promising
approach for the reduction of peritoneal tumor.
Other molecular interactions supporting peritoneal adhesion are fostered by a glycoprotein on
the surface of EOC cells, ovarian carcinoma antigen CA125 (MUC16), and mesothelin expressed on
the surface of mesothelial cells, both of which were demonstrated by in vitro studies using EOC cell
lines [66,67].
A series of in vitro studies that utilized EOC cell lines and mesothelial cells demonstrated that
neuropilin-1 expressed in mesothelial cells can interact with a glycoprotein expressed in EOC cells,
the L1 adhesion molecule (L1CAM) [68].
Both in vitro studies of EOC and mesothelial cell co-cultures and in vivo studies of short-term
adhesion and survival xenograft studies showed that a chemokine receptor fractalkine (CX3CR1)
expressed in EOC cells can interact with its ligand CX3CL1 expressed (in its transmembrane form) by
peritoneal mesothelial cells [69,70].
Studies using co-cultures of EOC cells and mesothelial cells pre-treated with β1-integrin-specific
neutralizing antibodies demonstrated that β1-integrins expressed by EOC cells could interact with
fibronectin expressed by mesothelial cells [71]. The role of α5β1-integrin-mediated adhesion of
262
Cancers 2018, 10, 444
EOC cells to fibronectin-expressing mesothelial cells was further confirmed with a series of in vitro
experiments utilizing primary mesothelial cells as well as in vivo using xenograft models of the
disease [72]. The latter study highlighted the role of EOC cells in inducing fibronectin expression in
mesothelial cells via transforming growth factor beta 1 (TGFβ1)-mediated signaling.
Another interactive loop facilitating peritoneal adhesion is initiated by alternatively activated
macrophages (AAMs) occurring in the peritoneal microenvironment of EOC, which involved
stimulation of expression of a calcium-dependent receptor, P-selectin, on mesothelial cells by a C–C
motif chemokine ligand 4 (CCL4 or MIP-1β) secreted by the AAMs; EOC cells expressing CD24
interacted with P-selectin-expressing mesothelial cells, as demonstrated by ex vivo and in vivo studies
of a syngeneic ovarian cancer model [73].
Once metastasizing EOC cells adhered to the mesothelial monolayer, to anchor metastatic
lesions, they need to disrupt the mesothelial lining and invade submesothelial parenchymal tissues
consisting of the ECM, stromal cells, and cells of the organ parenchyma. EOC cells express various
molecules that assist their invasion into the parenchyma of the organs and tissues to which they have
adhered. Overexpression of alcohol dehydrogenase 1B (ADH1B) was demonstrated to regulate EOC
cell attachment and clearance of the mesothelial lining, as well as subsequent matrix invasion [74].
Adherent spheroids could utilize integrin- and talin-dependent activation of myosin and traction force
to clear the mesothelial monolayer [75]. Expression of a transmembrane glycoprotein prominin-1
(PROM1) correlated with the ability of EOC cells to adhere to and clear the mesothelial monolayer
as well [76]. It was shown that N-cadherin, but not E-cadherin, is essential for the lateral dispersal of
spheroids onto extracellular matrix and invasion; individual cells also depended on N-cadherin for
their dispersal and penetration into the collagen gels [77].
After breaching the mesothelial monolayer, ovarian cancer cells quickly adhere to the
submesothelial matrix, which is predominantly composed of collagens type I and III, using both
α2β1- and α3β1-integrins [78,79]. MT1-MMP is a major interstitial collagenase enabling invasion
and anchorage of metastatic ovarian cancer cells in the submesothelial matrix [80].Three-dimensional
collagen I is instrumental in upregulating the transmembrane collagenase membrane type 1 matrix
metalloproteinase (MT1-MMP) via several mechanisms, including integrin-dependent activation of an
Src proto-oncogene, non-receptor tyrosine kinase (Src)-dependent pathway, and subsequent induction
of a transcription factor early growth response 1 (EGR1), as well as matrix rigidity-dependent activation
of wingless (Wnt) signaling through downregulation of dickkopf-1 expression [81,82]. Epidermal
growth factor receptor (EGFR)-dependent modulation of MT1-MMP surface dynamics was also found
to contribute to transition to a more invasive phenotype of ovarian cancer cells [83].
In summary, several molecular interactions between cancer and mesothelial cells establish
successful cell–cell adhesion during mesothelial adhesion. Disseminating cancer cells take advantage
of secreted molecules produced by mesothelial cells and can reprogram their gene expression to
aid peritoneal adhesion. Likewise, aging can amplify the process of peritoneal carcinomatosis by
providing more permissive conditions for cancer cell adhesion. Importantly, EOC cells themselves
express proteins that enable their attachment and tissue invasion.
3.2. Mechanisms Regulating the Transcoelomic Omental Metastasis
The omentum is a peritoneal fold that connects the stomach with abdominal organs [84].
The omentum functions to protect and support abdominal organs and to limit intraperitoneal infection.
In addition to a mesothelial monolayer covering this tissue, omentum mainly consists of adipocytes.
Other prominent structures within the omentum are milky spots that are the areas of lymphoid tissue
containing macrophages, lymphocytes, and mast cells [85]. The omentum also contains other stromal
cells, such as fibroblasts, and it is supplied by the gastroepiploic arteries [86]. Studies showed that
invading EOC cells successfully establish metastatic lesions in the omentum by taking advantage of
the unique microenvironment within this tissue [87,88].
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In metastasis from EOC, omentum plays a central role as one of the major tissues hosting peritoneal
metastatic lesions [5,25,27,32]. Omentum is also a major site of recurrent metastasis in patients whose
omentum was not completely resected. According to the current standard of care, omentum may
be partially or completely resected in medically fit patients in the process of the debulking surgery
depending on the degree of its involvement with the metastasis [89]. Due to the importance of
omentum as a major secondary site, several studies addressed the mechanisms supporting survival
and proliferation of metastatic EOC cells within the omental tissues, and uncovered the role of various
omental stromal cells in supporting this process.
Recent studies suggested that, as cells detach from the primary tumor and become suspended in
the ascites, they undergo a metabolic shift from glycolysis to lipid metabolism, which later affords and
facilitates their survival within the omental tissue [90]. Metastasizing EOC cells are also attracted to
the omentum by adipokines expressed by the adipocytes, such as adiponectin, interleukin-6 (IL-6),
interleukin-8 (IL-8), C–X–C motif chemokine ligand 1 (CXCL1, GRO-α), and others [87,91].
Milky spots are mainly composed of macrophages and lymphocytes, and represent initial
lymphatics of the omentum that drain into lymph collectors [92]. Preclinical studies that used ex vivo
and in vivo syngeneic and xenograft mouse models demonstrated that disseminating EOC cells can
lodge onto milky spots and further spread through the adipose-rich tissue [88,93]. In vivo studies
with both syngeneic (ID8 mouse-derived ovarian cancer cell line in C57BL/6 mice) and xenograft
(Caov-3, HEYA8, and SKOV3i.p.1 human-derived ovarian cancer cell lines in athymic nude mice)
models of ovarian carcinoma suggested that disseminating cells preferentially lodge onto milky
spot-containing adipose tissue as opposed to peritoneal fat, while the number and size of the milky
spots did not depend on the mouse genetic background [93]. The study also showed that conditioned
media collected from milky spot-containing adipose tissue significantly increased cell migration in
comparison to the conditioned media from milky spot-deficient adipose tissue [93].
Once EOC cells lodge onto the omentum, proximity to adipocytes results in upregulation of
fatty-acid-binding protein 4 (FABP4) and a fatty-acid receptor CD36, followed by transfer of lipids
from adipocytes to EOC cells, and induction of lipolysis in adipocytes and β-oxidation in cancer
cells [87,94]. Interaction of EOC cells with mesothelial cells reduced expression of microRNA-193
(miR-193) in the former, resulting in increased ability to colonize the omentum [95]. Consistent with
cancer cell utilization of lipids stored in adipocytes as an energy source, a study that described the role
of milky spots in metastatic colonization of the omentum also reported reduction of the adipose tissue
as the tumors grew over time [93].
Fibroblasts in omentum also play a prominent role in regulating this organ-specific metastasis.
A study uncovered interaction between tumor necrosis factor alpha (TNFα), transforming growth
factor alpha (TGFα), and epidermal growth factor receptor (EGFR); this TNFα–TGFα–EGFR interacting
loop is thought to form between EOC cells and fibroblasts that reside in omentum, and it is suggested
that it functions to promote peritoneal metastasis [96].
Interactions between chemokine receptors expressed by cancer cells and their corresponding
chemokines at the metastatic sites was suggested to regulate homing of metastasizing cells to their
niches. Among these interactions, association between the C–X–C motif chemokine receptor 4 (CXCR4)
and its ligand, stromal-derived factor 1, was demonstrated to regulate pro-metastatic functions of cells
from several cancer types, including ovarian [97–100]. A specific inhibitor of CXCR4, AMD3100, nearly
completely blocked EOC cell dissemination to the omentum in a rodent syngeneic model, supporting
the importance of this chemokine axis in development of the omental metastasis [101]. Another study
demonstrated that omentum-secreted IL-8 and GRO-α can activate C-X-C motif chemokine receptor 2
(CXCR2) in ovarian carcinoma cells and facilitate EOC cell spreading in the peritoneal cavity [91].
Thus, studies of the mechanisms of omental metastasis to date demonstrated important roles
of the omentum itself and metastasizing EOC cells in facilitating formation and development of this
major type of metastatic lesions.
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3.3. Mechanisms Regulating Transcoelomic Metastasis to Other Intraperitoneal Organs and Tissues
The mechanisms regulating organ-specific intraperitoneal dissemination to other organs,
including peritoneal wall, viscera of the bowels, viscera of the liver, etc., are less well understood
as compared to the mechanisms regulating formation of the omental metastasis. Several studies
uncovered the pivotal role of the chemokine–receptor interactions in regulating these organ-specific
metastases. Inhibition of CXCR4 with AMD3100 significantly reduced colonization of the colon,
peritoneal wall, diaphragm, and liver [101]. Downregulation of another chemokine receptor, X-C motif
chemokine receptor 1, or lymphotactin (XCR1), almost completely abrogated colonization of diaphragm
and peritoneal wall [102]. Further, it was demonstrated that yet another chemokine axis, between
fractalkine (CX3CL1) and its receptor (CX3CR1), regulates dissemination of the CX3CR1-positive
EOC cells to the surfaces of the CX3CL1-positive tissues, including peritoneal wall, diaphragm, liver,
mesentery, and retroperitoneal kidneys [69,70].
4. Mechanisms Regulating Hematogenous Metastasis from EOC
Peritoneovenous shunting is a procedure in which a shunt could be used to return the peritoneal
fluid from the peritoneal cavity into veins, such as the superior vena cava or the internal jugular vein,
by means of a one-way valved anastomosis [103–105]. This method was attempted on a cohort of
patients with ovarian cancer and other malignancies who had intractable ascites for the purpose of
palliative care [106,107]. A study that described the autopsy findings of the patients that underwent
this procedure concluded that most patients either did not develop distant metastases or grew
very small isolated lesions as a result of this procedure [108]. In the ovarian cancer field, this was
interpreted as suggesting that the hematogenous route has little relevance as a mechanism via which
the metastasis forms. However, a close examination of the presented data suggests that this conclusion
was overgeneralized. Eight out of nine ovarian cancer patients did not survive longer than about
four months on average (survival ranged from one to seven months) after the initiation of this
procedure; moreover, even over this short period of survival, evidence of distant metastases at lung,
liver, spleen, brain, and other distant sites was found in three of the eight patients. Only one out of
nine ovarian cancer patients survived for 27 months after the procedure without developing distant
metastasis [108,109]. Importantly, although distant metastases were not the cause of death in this study,
they did occur, even though all but one patient survived between one and seven months after insertion
of the shunts.
In another patient-based study that focused on investigating the outcomes of inferior vena
cava filter placement in patients with epithelial ovarian, fallopian, and primary peritoneal cancer,
the authors reported that patients who underwent this procedure had significantly lower survival and
significantly higher incidence of deep vein thrombosis and distant metastasis [110], supporting the
role of a hematogenous route in seeding distant metastases from EOC. Additionally, seeding of distant
organs, including brain [36], is likely to occur via this mechanism.
Experimentally, evidence of development of the hematogenous metastasis within the omentum
was recently presented [23]. A novel parabiosis mouse model was used to demonstrate that the
molecular interaction between the Erb-B2 receptor tyrosine kinase 3 (ERBB3) expressed by ovarian
cancer cells and its ligand neuregulin-1 expressed by the omentum is the main driving force of the
hematogenously spread omental metastasis. Parabiosis is a surgical union of two organisms that
allows sharing of the blood circulation [111]. In the study on ovarian carcinoma, the parabiosis model
was created by excising the skin of female mice from the shoulder to the hip joint followed by surgical
anastomosis to make new connections between blood vessels of pairs of mice [23].
In another study, three approaches were employed to investigate the role of the hematogenous
route of EOC metastases, including an intravascular tail-vein injection of ovarian cancer cells, as
well as subcutaneous engraftment of murine and human tumors. Primary ovarian cancer cells were
co-injected with mesenchymal stem cells subcutaneously. To promote formation of blood vessels in
the tumor, human infantile hemangioma stem cells were co-injected as well. This protocol resulted in
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100% engraftment rate and macroscopic ovarian metastases by the time of sacrifice [24]. The authors
observed development of tumors not only within the ovary, but also at other distant sites, including
the lung [24], further supporting existence of mechanisms driving hematogenous dissemination to
different organ sites. A study on the role of CXCR4 in EOC metastases showed that downregulation of
CXCR4 by short hairpin RNA (shRNA) resulted in a robust reduction of the circulating tumor cells,
suggesting a possible role of the stromal cell-derived factor 1 (SDF1)/CXCR4 axis in the hematogenous
route of dissemination [112].
In summary, many patient studies reported occurrence of the distant metastasis, which could
have arrived at these sites, notably the brain, likely via the hematogenous route. Although these
distant hematogenously spread metastases are not considered to be the cause of death from EOC by
themselves, their presence is significantly correlated with worse survival. Presently, the peritoneal
metastases from EOC is still an unsolved problem in clinical management of this disease. However,
it is very likely that continuous progress in the treatment of the peritoneal metastasis and increased
survival could allow for more time for development of the distant metastasis, which could become
clinically relevant in long-term survivors of metastatic EOC.
5. Mechanisms Regulating Lymphatic Metastasis from EOC
The International Federation of Gynecology and Obstetrics (FIGO) ovarian cancer staging states
that metastatic involvement of the retroperitoneal lymph nodes indicates FIGO Stage IIIC of the
disease, and colonization of the inguinal lymph nodes and lymph nodes outside of the abdominal
cavity by metastases signifies Stage IVB of the disease [113]. Although EOC metastases frequently
involve lymph nodes, autopsy studies reported that the frequency of colonization differed by their
anatomic location with the abdominal lymph nodes being most frequently colonized among others
(Table 2).
Table 2. Most frequently colonized lymph nodes identified in EOC patients by autopsy studies.
Study Abdominal Lymph Nodes Pelvic Lymph Node Thoracic Lymph Node
[27] 58% 48% 28%
[25] 47% 17% 29%
[32] 74.1% 27.7 34.9
Average number of patients
with indicated metastasis 60 31 31
Vascular endothelial growth factor receptor 3 (VEGFR3) is the major receptor involved in
lymphangiogenesis and maintenance of the lymphatic endothelium [114]. The ligands activating
this receptor are vascular endothelial growth factors C and D (VEGFC, VEGFD). Immunohistochemical
analysis of expression of VEGFA, VEGFC and VEGFD in ovarian carcinoma patients, most of
which (92/100) were diagnosed with FIGO Stage III disease with retroperitoneal metastases or
those with predominantly intraperitoneal metastasis, demonstrated that high expression of VEGFC
corresponded to the presence of the retroperitoneal metastasis, while low VEGFC correlated with
mostly intraperitoneal metastatic spread, supporting the role of VEGFC–VEGFR3 interaction in EOC
cell tropism to the lymph node. High VEGFC also correlated with shorter overall survival [115].
Another study was performed to characterize the patterns of expression of the ubiquitin-specific
protease 7 (USP7); it was found that high expression of USP7 significantly correlated with lymph node
metastases [116]. Upregulation of focal adhesion kinase (FAK) in EOC cells strongly correlated with
incidence of lymph node metastases as well [117].
In summary, lymphatic involvement is correlated with worse outcomes. Patient studies
demonstrated preferential colonization of the abdominal over other lymph nodes in the human body.
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6. Targeted Therapies in Ovarian Cancer
Development of targeted therapies against ovarian carcinoma, although still mainly at the stage of
characterization of new potential targets, is an actively growing field. Several proteins that were
demonstrated to play a role in progression and metastasis of ovarian cancer were or currently
are investigated as novel drug targets in clinical trials. The targeting agents used in these studies
vary widely from small-molecule inhibitors to monoclonal antibodies, antibody–drug conjugates,
and immunotherapy.
For example, a CD44-targeting compound SPL-108 is being investigated in conjunction with
paclitaxel in a phase I trial against epithelial ovarian carcinoma (ClinicalTrials.gov identifier:
NCT03078400).
Several clinical trials are attempting to target mesothelin. Among those, one clinical trial
(ClinicalTrials.gov identifier: NCT03692637) that is currently in phase I is aiming to use anti-mesothelin
chimeric antigen receptor (CAR) natural killer (NK) cells in epithelial ovarian carcinoma. This study is
taking advantage of the new targeting technology based on the use of CAR-NK therapy consisting of
chimeric antigen receptor (CAR)-expressing natural killer cells of the immune system [118]. Another
mesothelin-targeting approach is being investigated in a phase I clinical trial involving patients
with recurrent mesothelin-expressing platinum-resistant ovarian cancer, and this study will test
the efficacy of anetumab ravtansine in combination with polyethylene glycol (PEG) PEGylated
liposomal doxorubicin (ClinicalTrials.gov identifier: NCT02751918). Anetumab ravtansine is an
antibody–drug conjugate, in which an anti-mesothelin antibody (anetumab) is attached to a tubulin
inhibitor (ravtansine) [119].
As β1-integrins play a pivotal role in different mechanisms underlying progression of ovarian
carcinoma, they are targeted in clinical trials in ovarian carcinoma. Volociximab, a chimeric monoclonal
antibody that binds to and inhibits the functional activity of α5β1-integrins, was studied in a phase
II trial as a monotherapy in patients with platinum-resistant advanced epithelial ovarian or primary
peritoneal cancer. Although the agent alone did not provide sufficient clinical activity, it was well
tolerated, prompting the development of improved strategies to target α5β1-integrins [120]. A phase
II clinical trial (ClinicalTrials.gov identifier: NCT00635193) was conducted in patients with advanced
ovarian cancer or those who relapsed after platinum/taxane therapy that tested volociximab in a
combination with liposomal doxorubicin. Preliminary data from this trial suggest that the combination
was well tolerated [121], while no data on the efficacy against the relapsed disease was reported.
Epidermal growth factor receptor (EGFR) is overexpressed in epithelial ovarian carcinoma and its
high expression is associated with poor prognosis [122]. EGFR is important in progression of many
cancer types [123]; thus, it became one of the major targets in cancer following the development of
several targeting agents [124,125]. Therefore, many clinical trials addressed targeting EGFR using
tyrosine kinase inhibitors or antibodies as monotherapy in ovarian cancer, although the results of
these trials demonstrated no difference in survival [126]. While new EGFR-targeting agents, such
as a monoclonal antibody matuzumab (EMD 72000), are still being investigated as monotherapy
(ClinicalTrials.gov identifier: NCT00073541), combinations of EGFR-targeting therapy with the
standard chemotherapy are being tested in other clinical trials. In one such combination trial, gefitinib
(Iressa), a small-molecule inhibitor of EGFR, is being investigated in combination with topotecan,
a topoisomerase inhibitor, in patients with relapsed ovarian, peritoneal, and fallopian tube cancers
(ClinicalTrials.gov identifier: NCT00317772).
A small-molecule inhibitor of CXCR4, plerixafor (Mozobil), will be investigated in patients
with advanced cancers, including ovarian (ClinicalTrials.gov identifier: NCT02179970). VEGFRs were
studied as targets of angiogenesis in ovarian carcinoma, resulting in approval of a monoclonal antibody
against VEGFA, bevacizumab (Avastin), by The Food and Drug Administration in 2014 [127]; however,
these agents were not directed at targeting the lymphogenous spread.
In summary, although many targeted therapies directed at mechanisms described in this review
are yet to show any advantage in the treatment of relapsed ovarian carcinoma when given as a
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monotherapy, optimism still remains that their combinations with other chemotherapeutic agents
will benefit the patients at terminal stages of the disease. The successes behind targeted therapies
for breast cancer gene (BRCA)-deficient ovarian carcinoma with the inhibitors of poly (ADP)-ribose
polymerase [128] provide further confidence in the approach.
7. Conclusions
Many studies addressed mechanisms regulating the formation and development of intraperitoneal
metastases. Foremost, the findings demonstrate the importance of the receptor–ligand interactions
between metastatic EOC cells with other cells and molecules in the microenvironment, such as
mesothelial cells, omental adipocytes, fibroblasts, ECM, and others, in the development of metastatic
lesions. Disseminating EOC cells are endowed with expression of several types of receptors, including
those for chemokines, tyrosine kinases, integrins, and glycoproteins. Expression of these receptors
proved to be essential for successful colonization of the various tissues and organs. These findings
pointed research efforts toward the development of targeted therapies against disseminating EOC cells.
However, further studies into EOC metastasis-related mechanisms are crucial for the development
of personalized therapies against this highly heterogeneous and deadly disease. Several studies
highlighted the role of the microenvironment and stromal cells (both naïve and tumor-associated)
in the intraperitoneal milieu, as well as the role of the molecular changes during aging that support
peritoneal metastases. Thus, these causal aspects of the microenvironment should also be viewed as
potential molecular targets for reduction of the metastatic spread and prevention of recurrences. Both
hematogenous and lymphatic routes of dissemination are relatively less studied due to their perceived
limited impact on the outcomes, as most EOC patients succumb to the intraperitoneal metastasis.
Nonetheless, it is likely that their clinical relevance, however unfortunate for the patients, will increase
as treatment of the intraperitoneal metastasis improves in the future. Therefore, understanding of the
mechanisms regulating the distant metastasis is essential for ultimately blocking this deadly metastatic
disease. Overall, a more comprehensive characterization of the mechanisms regulating metastatic
ovarian carcinoma and therapy response is required for the development of new targeted therapies
and improvement of currently used treatment regimens.
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Abstract: As one of the important cancer hallmarks, metabolism reprogramming, including lipid
metabolism alterations, occurs in tumor cells and the tumor microenvironment (TME). It plays an
important role in tumorigenesis, progression, and metastasis. Lipids, and several lysophospholipids
in particular, are elevated in the blood, ascites, and/or epithelial ovarian cancer (EOC) tissues,
making them not only useful biomarkers, but also potential therapeutic targets. While the roles
and signaling of these lipids in tumor cells are extensively studied, there is a significant gap in our
understanding of their regulations and functions in the context of the microenvironment. This review
focuses on the recent study development in several oncolipids, including lysophosphatidic acid and
sphingosine-1-phosphate, with emphasis on TME in ovarian cancer.
Keywords: lipids; lysophospholipids (LPLs); lysophosphatidic acid (LPA); sphingosine-1-phosphate;
tumor microenvironment (TME); epithelial ovarian cancer (EOC)
1. Introduction
The tumor microenvironment (TME) for epithelial ovarian cancer (EOC) is rather unique. It
is mainly confined within the peritoneal cavity and frequently associated with ascetic fluid [1–6].
The TME consists of many stromal cell types including: tumor-associated macrophages (TAMs),
T cells (e.g., regulatory T cells), tumor associated fibroblasts (TAFs), mesothelial cells, adipocytes,
endothelial cells (ECs), myeloid-derived suppressor cells (MDSCs), pericytes, platelets, extracellular
matrix components (EMCs), and cell-free factors [1–6].
The presence of ascetic fluid provides a mobile, easy access, and more dynamic environment
for tumor–stromal interactions. In addition to tumor and stromal cells, EOC ascites is rich in
cell-free inflammatory cytokines, chemokines, matrix metalloproteinases, integrins, and other secreted
molecules, including bioactive lipid factors. These factors are generated by and mutually function
in both tumor and stromal cells via autocrine/paracrine mechanisms. They may exist in either
extracellular vesicles (EVs) or in “free” forms, including bond forms to proteins or other molecules [7].
EVs are membrane surrounded structures released by cells in an evolutionally conserved manner, but
their release, contents, and/or up-take may be abnormally regulated in cancer. The major populations
include microvesicles (MVs, 100–1000 nm), exosomes (30–100 nm), and apoptotic bodies [8]. Exosomes
have emerged as new as diagnostic markers, as well as cell-to-cell communication vehicles, with
therapeutic applications [4,9,10]. The compositions of exosomes from different cell types are complex,
containing ~200 lipids, >3000 proteins, ~1600 mRNA and ~800 microRNAs [11–13].
Metabolic reprogramming is one of the major cancer hallmarks [14] that is critical for cancer cells
to adapt to stress from TME and the increased nutritional requirements during their growth. These
modifications occur through cross-talk between tumor and stroma cells in TME in a dynamic network
that connects different molecular processes, such as energy production, inflammatory response, and
drug resistance [15]. In particular, primary EOC is characterized by abnormal lipid metabolism and
Cancers 2018, 10, 227; doi:10.3390/cancers10070227 www.mdpi.com/journal/cancers276
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energy disorders. In addition, recurrent EOC patients have been shown to have increased amino acid
and lipid metabolism compared with primary EOC patients [16].
Compared to other major living cell components, including DNA, RNA (all composed by
four bases), proteins (all composed of 20 amino acids), and carbohydrates (all have the basic element
CH2O with ring, chain, and branched structures), lipids are very diverse in both their respective
structures and functions. These diverse compounds are grouped into classes; glycerophospholipids
(PLs) (including lysophospholipids (LPLs)) sphingolipids, sterol lipids, prenol lipids, saccharolipids,
and polyketides [17]. The functional involvement of many of these lipids in EOC, PLs, LPLs,
sphingophospholipids (SPLs), fatty acids, cholesterol, vitamins, and triglycerides (TGs) in particular,
have been covered by many reviews [3,18–23]. This review will focus on recent development of
signaling LPLs with an emphasis on TME in EOC.
2. LPLs
Compared to PLs, which have two fatty acid chains, LPLs only have one fatty acid chain and thus
have reduced hydrophobicity (Figure 1). In addition, many LPLs are either negatively or positively
charged, increasing their polarity and solubility in water. With these chemical properties, LPLs are
synthesized and/or secreted extracellularly and many of them function as signaling molecules through
their specific membrane receptors. In addition, several of these LPLs have tumor promoting activities
and are thus termed as “oncolipids” [24]. They are accumulated in the TME. LPA is a prototype of the
LPL signaling molecules. It exhibits pleiomorphic functions in almost all cell lineages tested. Since our
early report on LPA’s effect in EOC [25,26], more than 1000 papers have been published reporting the
roles and signaling mechanisms of LPA in various cancer types [24,27].
 
Figure 1. Structures of glycerophospholipids (PLs), lysophospholipids (LPLs only have R1 or R2) and
the action sites of phospholipases.
2.1. LPA
Lysophosphatidic acids (LPAs) are a group of compounds with various fatty acid side chains,
differing in their length (commonly 14–22 carbons) and number of double bonds (commonly from zero
to six in most tissues). In addition, the chemical linkages of the fatty acid chain to the glycerol backbone
can be differently grouped as acyl-, alkyl-, and alkenyl-LPAs [28]. We have originally identified LPA as
an EOC growth factor, termed ovarian cancer activating factor [26,29]. Numerous papers have now
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been published to show that LPA induces a broad range of tumor promoting activities in EOC and
LPA is a therapeutic target for EOC [30–32].
2.1.1. Increased LPA Levels in EOC
We have initially reported LPA as a potential marker for EOC [33]. Blinded [34] and numerous
independent studies have confirmed that LPA is elevated in the blood from EOC patients, when
compare to those with benign diseases and/or healthy controls [35–42]. The mean values of
physiological and pathologic concentrations of plasma LPA in healthy women and EOC patients
are 0.6–0.9 μM and 2.0–22 μM, respectively [33,34]. The mean values of benign and malignant
ascites acyl-LPA concentrations are 2.9 μM and 19–95 μM, respectively [28,43]. The mean non-acyl
(both alkyl-, and alkenyl)-LPA levels are 3.7 ± 1.7 and 0.9 ± 0.7 μM for benign and malignant ascites,
respectively [28] (Table 1). The concentrations of LPA and other lipids mentioned below were measured
in cell-free plasma or ascites. In most reports, it is unclear whether these lipids are associated with
MVs, as mentioned in the Introduction, in a protein bound, or a “free” form. In an attempt to
test this, we have separated different MVs and the cell- and vesicle-free (S4) portion of ascites via
step-wise centrifugation. We found that human EOC ascites S4 portion potently promotes proliferation,
migration, and invasion of human EOC cells in a PLA2-dependent manner, suggesting that LPA, and
maybe other LPLs, may present in a protein bound or a “free” form [44]. However, this issue needs to
be more systematically investigated and lipid association with different extracellular components may
also be cell-type and context dependent.
The challenges to move LPA or other lipid molecules as cancer markers into clinics are several fold.
First, as metabolites, these molecules have quick turnover times by their producing and degradation
enzymes. In addition, their levels are likely to be affected by other physiological/pathologic
conditions—such as diet, smoking, and drinking—which have not been completely investigated.
Secondly, due to their chemical properties, the different extraction, storage and detection
conditions/methods used in different labs significantly affect the levels detected. However, there
are no standard procedures established. Finally, the best detecting method for these lipid markers is
electrospray-mass spectrometry (ESI-MS), which is not a routine setting in clinics currently. These
challenges have made cross-examination and validation of these markers difficult. Studies to
standardize the procedures of collection, extraction, storage, and measurements of lipid marker
are critical. Nevertheless, technique advancements are emerging. In particular, mass spectrometry will
likely become a routine technique in regular clinic settings in the near future.
2.1.2. LPA Production and Regulation
LPA is produced from secreted enzymes from lysophosphatidylcholine (LPC) by autotaxin (ATX),
as well as phospholipase A2 (PLA2) by either providing the substrate LPC for ATX, or directly produce
LPA from phosphatidic acid (PA) [49–53]. LPA is degraded outside cells by a family of three enzymes
called the lipid phosphate phosphatases (LPPs) (Figure 1). Imbalanced expression and/or activity
levels of ATX, PLA2s, and/or LPPs are involved in EOC [54] (see Figure 1 in [54]). The ATX/LPA axis
has received increasing interest as a target in cancers, fibrotic diseases, autoimmune diseases, arthritis,
chronic hepatitis, obesity, and impaired glucose homeostasis [55]. At least one of the synthetic ATX
selective inhibitors is in clinical trials for idiopathic pulmonary disease [55].
EOC cells may produce LPA upon stimulations [50–52]. However, the tissues and cells in EOC
TME are likely to be the major source of elevated LPA in EOC. The cell types involved in LPA
production include, but are not limited to, platelets, adipocytes, mesothelial cells, and immune cells.
Platelet activation generated LPA used to be considered the major source of plasma LPA [56,57].
Paraneoplastic thrombocytosis has been recognized as a prevalent phenomenon in patients with
ovarian cancer since the early 1970s [58]. Cancer patients have a ~4-fold increased risk of
venous thromboembolism compared with the general population and this is associated with
significant morbidity and mortality [59,60]. The preventative and therapeutic significance of
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blocking thrombopoietic factors (cytokines and lipids) have been noted as an interesting direction
in EOC research [60–62]. Tumor cells hijack platelet functions by activating them though platelet
aggregation [63]. Activated platelets may help tumor cells survive immune surveillance by acting as
protective “cloaks” against immune destruction. However, the major tumor cell beneficiary activities
are likely mediated by the factors secreted from platelets after activation. These factors include
cytokines (such as interleukin-6 (IL-6)), TGF-β, and lipid factors, which mediate the inflammatory,
proliferative, and proangiogenic activities of platelets to promote tumor growth, tissue invasion,
and metastasis [63]. Increased platelet counts and platelet activation associated with EOC are likely
to be important contributors for the elevated LPA levels in EOC TME. In addition, LPA promotes
platelet aggregation [64,65] and blocking platelet function leads to inhibition of metastasis of breast
cancer through decreased LPA signaling. ATX is detected in platelet α-granules. Functionally active
ATX is eventually released following tumor cell-induced platelet aggregation, thereby promoting
metastasis [66].
EOC cells preferentially metastasize to omentum, the adipose tissue, which secretes many
chemotactic cytokines and growth factors, including LPA [67–69]. Adipocytes promote ovarian
cancer metastasis and provide energy for rapid tumor growth [70]. Since the identification of ATX as
the major LPA producing enzyme [21,71] and studies conducted using mouse ATX knockout models,
it has become clear that adipose tissue are at least one of the major tissues in EOC TME that produces
LPA [72,73]. Approximately 40% of body ATX is produced by adipocytes, and this is further increased
by inflammation [74,75]. The use of ATX inhibitors seems an attractive strategy to produce novel
medicinal agents, for example anticancer agents [55].
EOC cells that metastasize within the peritoneal cavity wall and the organs enclosed are coved
by a layer of peritoneal mesothelial cells. We have shown that human peritoneal mesothelial
cells constitutively produce LPA, which accounts for a significant portion of the chemotactic
activity of the conditioned medium from peritoneal mesothelial cells to ovarian cancer cells [76].
The calcium-independent phospholipase A2 (iPLA2), and cytosolic PLA2 (cPLA2) are involved in this
production and LPA’s tumor promoting activities [76].
Although many types of immune and endothelial cells are involved in EOC TME, their
contributions to LPA production and/or degradation are less known. Steady-state ATX is expressed
by only a few tissues, including high endothelial venules in lymph nodes, but inflammatory signals
(enriched in EOC TME) can upregulate ATX expression in different tissues [77]. In addition, when
ECs are con-cultured with EOC cells, coherent and non-cell line specific changes in fatty acids,
glycerophospholipids, and carbohydrates, induced by endothelial cell contact are observed over
time [78]. Wong and Reinartz et al. have reported that macrophage-derived phospholipase PLA2G7,
which may produce extracellular LPA, is involved in EOC and associated with early relapse of EOC.
It is a secreted enzyme that may produce LPA and arachidonic acid [79,80].
Mice with homozygous deletion of LPP1 (a LPA degradation enzyme) in stromal cells result in
elevated levels and decreased turnover of LPA in vivo. In turn, enhanced tumor seeding in the LPP1
KO mice compared to wild type was observed [81].
Taken together, the host cells play an important role in producing and degradation LPA, which
may be present in cell free forms in either exosome and/or EV-free forms [44].
2.1.3. Major Cellular Functions and Signaling Mechanisms of LPA in EOC
LPA stimulates almost every aspects of tumor promoting activities, including cell proliferation
or differentiation, prevents apoptosis induced by stress or stimuli, induces platelet aggregation
stimulates cell morphology changes, cell adhesion, cell migration, and cell invasion. It also stimulates
tumorigenesis and metastasis in vivo [25,26,30–32,50,51,76,82–99].
LPA regulates many pro-tumorigenic and pro-inflammatory factors, including vascular
endothelial growth factor (VEGF), matrix metalloproteinases (MMPs), urokinase plasminogen
activator, IL-6, IL-8, CXC motif chemokine ligand 12/CXC receptor 4, COX2, cyclin D1, Hippo–YAP,
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and growth-regulated oncogene alpha. These regulations are at the transcriptional, translational,
and epigenetic levels [19,34,44,51,76,82–84,86,88–91,94,95,100–105]. LPA induces loss of junctional
β-catenin, stimulates clustering of β1 integrins, and enhances the conformationally active population
of surface β1 integrins. Furthermore, LPA treatment initiates nuclear translocation of β-catenin and
transcriptional activation of Wnt/β-catenin target genes, resulting in gain of mesenchymal marker
expression [106]. Gglycodelin, a glycoprotein, is over-expressed in various malignancies, including
EOC, and its expression correlates with the diagnosis and prognosis of cancer patients. The expression
of glycodelin can be regulated by stromal cells and LPA [107]. While LPA’s function and signaling in
EOC has been rather extensively reviewed [19,100,108], several notions and recent developments are
specifically noted here.
Firstly, LPA is a confirmed mitogen in many cell types. However, MTT dye reduction is not a good
method to measure this effect. LPA affected MTT dye reduction with an unknown mechanism in EOC
cells [109], making it an unreliable indicator for cell number changes. In addition, MTT dye reduction
may not be sensitive enough to detect DNA replication as [3H]tymidine incorporation [25,26,29].
Secondly, the most potent roles of LPA in EOC and other cancer cells are likely to be cell migration
and invasion. This action is mediated by LPARs and Gi and G12/13 [30,51,76,83,89,95,104]. This
is correlated to LPA’s in vivo effects, where LPA mainly stimulates metastasis, instead of primary
tumor growth [89,95]. In comparison, EGF and other growth factors are likely to be more effective
in cell proliferation than LPA, but the latter is more effective in induction of cell migration and
invasion [30,51,89,90,93,95].
Thirdly, LPA has been recently shown to be involved in cancer stem cells (CSC) in EOC [84,110].
Seo et al. have shown that EOC CSC produces LPA, which augments CSC characteristics
such as sphere-forming ability, resistance to anticancer drugs, tumorigenic potential in xenograft
transplantation, and high expression of CSC-associated genes, including OCT4, SOX2, and aldehyde
dehydrogenase 1 (ALDH1). These actions are mediated by LPAR1. ATX is highly secreted from ovarian
CSCs. Inhibition or knockdown of ATX markedly attenuates the LPA-producing, tumorigenic, and
drug resistance potentials of CSCs. In addition, clinicopathological analysis shows a significant survival
disadvantage of patients with positive staining of ATX. In addition, LPA is involved in the crosstalk
between CSC in TME. EOC cells secrete LPA that activates the expression and secretion of CXCL12 by
mesenchymal stem cells (MSCs), enhancing the resistance of OVCA cells to hyperthermia [23].
Fourthly, the majority of LPA signaling is mediated by its six G protein couples receptors
(GPCRs) [100,111]. Among them, LPAR1–3 belong to the endothelial differentiation gene (Edg) family
of GPCR and LPAR4–6 belong to the purinergic P2Y family of GPCRs [111,112]. While LPAR1–3 in
general mediate LPA’s tumor promoting activities [76,113,114], limited reports showed that LPAR1
may represent a negative regulatory LPA receptor inducing apoptosis in ovarian cancer cells [96].
At least three compounds blocking these receptors have passed phase I and phase II clinical trials [115].
Compared to LPAR1–3, LPAR4–6 are less studied. Both pro- and anticancer effects mediated by LPA4–6
in various cancers have been reported, with the majority of them reporting anti-cancer effects [116–118].
Finally, LPA has also been identified as a ligand for the nuclear receptor peroxisome
proliferator-activated receptor gamma (PPARγ) [119,120]. However, the LPA-PPARγ studies are
mainly limited to the vascular and metabolic processes [121,122]. The roles of PPARγ-mediated LPA
effects in cancer are essentially unknown until recently. Emerging evidence, however, suggest that this
is an important missing opportunity in cancer research. We have recently shown that LPA dose- and
time-dependently upregulated SOX9 in EOC cells. This upregulation is mediated by PPARγ. SOX9
was involved in cellular activities related to Cancer Stem Cells (CSC), including anokis-resistance,
regulation of CSC marker CD44, and spheroid-formation [85]. In addition, we have shown that LPA
effectively upregulates ZIP4 (a zinc transporter) expression via by PPARγ and LPA’s promoting effects
in CSC-related activities in HGSOC cells is at least partially mediated by ZIP4 in an extracellular
zinc-independent manner [84]. These findings emphasize the importance of targeting by PPARγ for
LPA’s tumorigenic actions.
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2.1.4. LPA in the Immune System
The ATX-LPA axis has emerged as a novel regulator of lymphocyte homing and inflammation.
LPARs are expressed by T cells and LPA enhances the motility of human and mouse T cells in vitro,
although generally not in a direct manner [77]. Cancer cells must evade the immune system during
metastasis. LPA facilitates this important process by inhibiting CD8+ T cell activation [75]. LPA also
regulates macrophage differentiation and T cell motility [123,124]. Although EOC cells mainly express
the LPAR1–3, LPAR6 is the main LPA receptor on TAM and tumor-associated T cells [123].
ATX is expressed by lymphoid organ high endothelial venule. LPARs receptors are expressed by
NK cells, mast cells, eosinophils, and B cells [77]. In addition, tumor-associated macrophages (TAMs)
produce LPA [123]. However, how LPA signaling in stroma cells, and in immune cells in EOC in
particular, remains to be further investigated.
In summary, LPA, a simple molecule that mediates a plethora of biological effects, may be
targeted at its levels of production by ATX or PLA2s, LPA receptors, including PPARγ, or through
LPA degradation by lipid phosphate phosphatases (LPPs). The targeting strategy should take TME
into serious consideration. Drugs for these applications have been and will soon be entering clinical
practice [27].
2.2. LPC
Compared to LPA, plasma LPC levels are usually 10 to 100-fold higher and are in the 100–200 μM
range in human subjects [34] (Table 1). LPC levels have been shown to be significantly elevated
in the plasma of ovarian cancer patients [34,125,126]. On the other hand, others and we have
shown that patients with malignant cancer diseases have attenuated LPC plasma levels [127–131].
Moreover, different phospholipase A2 enzymes, which mainly convert phosphatidylcholine (PC) to
LPC have been shown to be functionally involved in EOC and/or as markers for various cancer
types [7,44,50,51,91,126,132,133].
LPC is present at the highest concentrations among LPLs. Its role in signing is still debatable.
Although both of its tumor-promoting and suppressing activities have been reported in various
cancers [96,129,134,135], specific attention should be paid that LPC is not present in a free form in
most physiological and pathologic conditions. It binds to albumin and other carrier proteins [136,137].
The bound form of LPC may not have many of the effects reported previously [91,137]. In particular,
when high concentrations (>20 μM) of free LPC are used, it may have non-specific and detergent-like
effects, which are unlikely to be physiologically or pathologically significant. LPC may function as a
component of cell membrane and carrier to deliver choline to tissues and LPC is the precursor/substrate
for ATX to produce LPA. However, its levels are hardly rate-limiting. This fact is also pertinent to
developing ATX inhibitors. Those ATX substrate analog inhibitors are difficult to work in vivo, due to
the competitive high concentrations of LPC present in the human blood and/or other tissues.
Table 1. Concentrations (in μM) of major lysophospholipids (LPLs) involved in epithelial ovarian
cancer (EOC).
Lipid EOC or BC Plasma Healthy Control Plasma EOC Ascites Benign Ascites
Acyl-LPA 2–22 [33,34] 0.6–0.9 [33,34] 19–95 [28,43] 2.9 [28,43]
Alkyl-, and alkenyl-LPA 3.7 ± 1.7 [28] 0.9 ± 0.7 [28]
LPI to 3.0 [28,35] 0–1.5 [28,35] 14.7 ± 9.7 [28,35] 2.9 ± 2.0 [28,35]
LPC 120 ± 0.30 [45]117–153 [34]
128 ± 46 [45]
122 [34]






Cancers 2018, 10, 227
2.3. Lysophosphatidylinositol (LPI) and Other LPLs
While phosphatidylinositol (PI) is the substrate of PI3K, one of the most pertinent signaling
pathways in cancer [138], LPI as a signaling molecule is much less studied. We have shown that
the plasma and ascites levels of LPI in EOC are elevated. In healthy controls, the plasma levels of
LPI are in the range of 0–1.5 μM in healthy subjects, which are increased to 1.1–3.0 μM in patients
with EOC [28,35]. The means and SDs levels of LPI in non-malignant ascites vs. malignant EOC
are 2.9 ± 2.0 μM and 14.7 ± 9.7 μM respectively (Table 1). However, in our lab, unlike LPA and
sphingosine-1-phosphate (S1P), neither positive nor negative effects of LPI have been detected in EOC
cells. A very recent report has shown that LPC and LPI regulate gene expression, including adhesion
molecules, cytokines, and chemokines, as well as those involved in cholesterol biosynthesis (by LPC),
or gene transcripts critical for the metabolism of glucose, lipids, and amino acids (by LPI) in human
aortic endothelial cells (HAECs). Moreover, LPC and LPI share the ability to transdifferentiate HAECs
into innate immune cells [139].
Although a specific receptor of LPI has been reported [140], they warrant further validation
for their rules and signaling in cancers. We and others also detected several other LPLs in EOC
plasma and/or ascites, including lysophosphatidylethanolamine (LPE), lysophosphatidylglycerol
(LPG), lysophosphatidylserine (LPS), lyso-platelet activating factor (lyso-PAF), and PAF [28,35,45,141].
However, the role and signaling of these LPLs in EOC are much less studied.
2.4. Sphingosine-1-Phosphate (S1P)
2.4.1. S1P Levels and Production
S1P is the orthologue of LPA with a different backbone (a sphingoid base vs. a glycerol backbone).
The physiological and pathologic concentrations of S1P is approximately one order of magnitude
lower than that of LPA and is usually present in sub-μM to low μM range [45–48] (Table 1).
In contrast to LPA, S1P is mainly produced intracellularly by two sphingosine kinases
(SphK1 and SphK2; see Figure 1 in [142] and Figure 2 in [143]). S1P may be irreversibly degraded by
S1P lyase (SPL) or dephosphorylated by S1P phosphatases (SPPs). Since the S1P lyase level in the blood
was much lower than that in tissues and erythrocytes, as well as platelets lack SPL and SPP activity
when they mature, higher S1P levels in the blood and lower amounts in tissues are present [144].
Intracellularly produced S1P is exported out of the cell either by the specific transporter Spinster
2 (Spns2) or by several members of the ABC transporter family [145]. This autocrine and/or paracrine
action of S1P is known as “inside-out signaling”. In the last few years, it has become evident that
S1P also exerts intracellular functions by targeting different molecules, including the PPARγ family
factors [145].
2.4.2. S1P Functions and Signaling Mechanisms in EOC
Over the past two decades, increasing evidence demonstrates a strong link between S1P and both
normal physiology and progression of different diseases, including cancer and inflammation. S1P may
affect survival, proliferation, angiogenesis, and metastatic spread of cancer [144,146].
LPA and S1P share structural similarity. In addition, LPAR1–3 and S1PR1–5 belong to the same
edg-receptor family [147]. Moreover, S1P has been shown to have many similar tumor promoting
activities as LPA, and is considered as a cancer treatment target [148,149], which has been reviewed
extensively [32,144,146,150,151] (Figure 2). However, there are several major differences between LPA
and S1P. Most of all, while LPA displays, in most cases, tumor promoting activities; S1P is multi-facet
at several levels, which is emphasized as follows.
Firstly, S1P has strong concentration dependent differential effects. As mentioned above, the
physiological/pathological concentrations of S1P are in general lower than those of LPA [46–48].
The effects of S1P in EOC cells tested are highly concentration-dependent [152–157]. While lower
concentrations of S1P (≤1 μM) are usually stimulatory, higher concentrations (10–30 μM) of S1P are
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inhibitory. The S1P effects are also dependent on cell culture conditions. For example, S1P (10 μM)
induced cell death when cells were in suspension but stimulated cell growth when cells were attached.
The calcium-dependent induction of cell death by S1P is apparently associated with its inhibitory effect
on cell attachment and cell adhesion [152]. N-cadherin, γ- and β-catenins, FAK, and integrin β1 are
among the proteins affected by S1P and/or LPA [152,156].
 
Figure 2. Diagram illustration of LPA receptors, signaling pathways and functions shown in EOC.
LPA stimulates almost every aspect of tumor promoting activities [24,25,29–31,44,45,70,77–94]. This figure
illuminates updated information related to LPA receptors (LPAR1 to LPAR6, and PPARγ), signaling
pathways, and functions shown in EOC, modified from a previous review article by Yung et al. [94].
In particular, the nuclear receptor for LPA, PPARγ is included. While Gα12/13, Gαq, and Gαi mediate
tumor promoting activities in most cases, Gαs is likely to be a negative regulator counter-reacting Gαi
actions. Abbreviations: autotaxin (ATX); LIM kinase (LIMK); lysophospholipids (LPLs); myosin light
chain (MLC) phosphatidic acid (PA); phospholipids (PLs); phospholipase D (PLD); phospholipase A1
(PLA1); and phospholipase A2 (PLA2).
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Based on chemically measured S1P concentrations in biological fluids and the binding affinities of
S1P to its receptors (in nM to low μM range [158]), the effects of low concentrations of S1P (≤1 μM)
may be more pathophysiologically relevant. The effects of high concentrations of S1P (10–30 μM) may
be more artificial and/or non-specific.
Secondly, SphK1 and SphK2 have distinct cellular locations, regulations and functions. In general,
SphK1 is tumor promoting and SphK2 is suppressive; SphK1 is upregulated in cancer, while SphK2
is downregulated [151,159,160]. Numerous tumor promoting agonists including TNF-α and other
inflammatory signaling molecules, such as IL-1β, IFN-γ, IgE, and C5a, stimulate cytosolic SphK1,
which translocates to the plasma membrane and uses sphingosine as a substrate to generate S1P.
Elevated SphK1 has been shown in EOC cells and functionally involved in drug-resistance and other
tumor promoting activities [161,162]. In contrast, SphK2 is located in cytosol or in the nucleus [144].
S1P produced by SphK2 inhibits histone deacetylases (HDACs), which modulates the dynamic balance
of histone acetylation and influences the epigenetic regulation of specific target genes [163]. The two
SphKs are also likely to have cooperative roles as evidence by knockout mice. Double-knockout
animals were embryonic lethal, due to the incomplete maturation of the vascular system and brain,
although mice deficient in either SphK1 or SphK2 had no obvious abnormalities [151].
Thirdly, different and opposing effects are mediated by different S1PRs. S1P receptors have
been identified so far and named S1PR1–5 (formerly referred to as endothelial differentiation gene
(Edg1, 5, 3, 6, 8) [147]. Following receptor activation, multiple signaling cascades are activated, which
are very similar to or opposing to those stimulated by LPA [164,165]. Among the five S1PRs,
S1PR1/S1PR3 and S1PR2 receptors may mediate opposing effects [149,151,153,154,157,159,160]. S1PR1
and S1PR3 mediate S1P’s tumor promoting activities, such as cell migration and invasion via activation
of Rac. Blockage of SphK1, but not SphK2, or S1PR1/3 could attenuate ovarian cancer angiogenesis and
inhibit angiogenic factor expression in a mouse model [159]. S1PR1 is upregulated in ovarian cancer
tissues and cell lines, which is negatively regulated by miR-148a in EOC cells [166]. On the other
hand, S1PR2 generally mediates the inhibitory effect via Rho-mediated inhibition of Rac [160]. S1PR2
is also involved in negative regulation of tumor angiogenesis and tumor growth in vivo via RhoC
activation [167], although one study has shown that the growth of SKOV3 cells could be decreased
by S1PR2 inhibition in vitro and in vivo [168]. In addition, S1PR2 has an inhibitor role in macrophage
recruitment during inflammation [169]. Goetzl et al. reported that both S1PR2 and S1PR3 are expressed
higher in ovarian surface epithelial cells than in ovarian cancer cells [170].
Finally, S1P may have profound regulator effects on inflammation and in the immune system.
The SphKs/S1P/S1PR1 axis plays an important role in the immune regulation. It is involved in the
mature vascular system; pathological angiogenesis; immune cell egress from tissue compartments;
hematopoietic, vascular, and stem cell survival; and cytokine production. In particular, S1P induces
STAT3 activation in tumor-associated myeloid derived suppressing cells (MDSCs) [151]. In addition,
the roles of LPA and S1P on angiogenesis are likely to be different. S1P may have a direct proangiogenic
role on ECs [159]. S1P and its receptors are involved in vessel morphogenesis and angiogenesis
during embryonic development and in the adult organism both under normal and pathological
conditions [171,172]. On the other hand, LPA’s role on ECs may be indirect and mediated by its effect
on tumor and/or TME cells via releasing proangiogenic factors, such as IL-8 [92,94,173].
SphK1 is highly expressed in the tumor stroma of high grade serous ovarian cancer (HGSOC)
and is required for the differentiation and tumor promoting function of cancer-associated fibroblasts
(CAFs) [174]. While increasing S1P catabolism or inhibiting S1P biosynthesis could become a new way
to treat cancer, some studies found that the inhibition of S1P raised secondary malignancy [151,175].
A biospecific monoclonal antibody to S1P (S1P mAb) has been developed and investigated for its
role in tumorigenesis. The anti-S1P mAb substantially reduced tumor progression and in some cases
eliminated measurable tumors in murine xenograft and allograft models. Tumor growth inhibition
was attributed to antiangiogenic and antitumorigenic effects of the antibody [176]. The anti-S1P mAb
blocked EC migration and resulting capillary formation, inhibited blood vessel formation induced by
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VEGF and bFGF, and arrested tumor-associated angiogenesis [176]. In this study, SKOV3 cells were
used for ovarian cancer, but they are not cells from HGSOC, which accounts for about 70% of EOC
cases, with less than 30% of patients currently surviving more than five years after diagnosis with little
improvement in overall survival over the past 40 years [177–179]. Hence, the therapeutic significance
of targeting S1P in EOC warrants further studies.
In summary, the role of S1P in the pathogenesis of ovarian cancer remains unclear and
controversial and more studies are clearly required. Due to the multi-faceted nature of S1P’s roles and
signaling, targeting S1P signaling may be a double-edged sword.
2.5. Sphingosylphosphorylcholine (SPC)
SPC is an orthologue of LPC with a different backbone (a sphingoid base vs. a glycerol backbone).
The levels of SPC in EOC vs. non-malignant ascites is low: 71.5 ± 50.8 nM vs. 17.9 ± 10.1 nM,
respectively [28]. The levels of plasma SPC are also at nM range [45]. SPC is a potential calcium-release
inducer in EOC cells [25,26,29]. SPC also shows other cellular activities in EOC cells, including
regulation of IL-8 expression in EOC cells [94]. However, high concentrations (at μM level) of SPC
is very toxic to cells. SPC induces dendritic cells (DC) chemotaxis and stimulates the production of
IL-12 from DC [180,181]. However, the real physiological or pathological roles of SPC in EOC are still
very elusive.
3. Conclusions
The reciprocal interplay of cancer cells and TME is an indispensable prerequisite for tumor growth
and progression. Ovarian cancer, the most lethal of all gynecological malignancies, is characterized
by a unique TME that enables specific and efficient metastatic mechanisms/routes, impairs immune
surveillance, and mediates therapy resistance. More specifically, detached cancer cells—as well as
large numbers of T cells, TAMs, and other host cells—cooperate with resident host cells to support
tumor progression and immune evasion. The presence of the peritoneal fluid (ascites) enables more
efficient tumor-stromal cell interactions and the transcoelomic spread of tumor cells to other pelvic
and peritoneal organs. In particular, this fluid is rich in tumor-promoting soluble factors including
elevated LPLs, either in EV or non-EV forms. Several important future directions and unresolved
questions include, but are not limited to: development of standard and uniform methods for lipid
extraction and analyses; further characterization of LPL regulation (both production and degradation)
and their signaling mechanisms; development of strategies for cancer-specific targeting those tumor
promoting lipids; and conducting more studies on their extracellular associations in order to better
develop markers and targeting. Overall, it is critical to take TME into consideration to develop the
next generation of therapeutic strategies.
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Abstract: Aerobic glycolysis is an important metabolic adaptation of cancer cells. There is growing
evidence that oxidative phosphorylation is also an active metabolic pathway in many tumors,
including in high grade serous ovarian cancer. Metastasized ovarian tumors use fatty acids for
their energy needs. There is also evidence of ovarian cancer stem cells privileging oxidative
phosphorylation (OXPHOS) for their metabolic needs. Metformin and thiazolidinediones such as
rosiglitazone restrict tumor growth by inhibiting specific steps in the mitochondrial electron transport
chain. These observations suggest that strategies to interfere with oxidative phosphorylation should
be considered for the treatment of ovarian tumors. Here, we review the literature that supports this
hypothesis and describe potential agents and critical control points in the oxidative phosphorylation
pathway that can be targeted using small molecule agents. In this review, we also discuss potential
barriers that can reduce the efficacy of the inhibitors of oxidative phosphorylation.
Keywords: high grade serous ovarian cancer; metabolism; mitochondria; oxidative phosphorylation;
oxidative stress; biguanides; atovaquone; plumbagin; thiazolidinediones; ubiquinone; Nrf-2
1. Introduction
Metabolic adaptations allow tumors to maintain a highly proliferative state. Evidence in support
of such adaptations was obtained nearly a century ago by Otto Warburg, and Carl and Gert Cori and
their colleagues when they demonstrated an increased uptake of glucose by tumors as compared to
normal tissues [1,2]. Warburg further demonstrated that even when sufficient oxygen was available,
tumors used glycolysis to metabolize glucose to lactic acid [3,4]. In this respect, glucose metabolism
in tumor cells resembles that occurring under anaerobic conditions. However, because glucose was
being metabolized to lactate in the presence of oxygen, Warburg coined the term “aerobic glycolysis”
to accurately describe this metabolic process in tumors [3]. Although glucose breakdown through
oxidative phosphorylation (OXPHOS) yields maximum number of ATP, curtailing the metabolism
to glycolysis provides the necessary biomolecule precursors needed by the tumors to maintain a
high level of proliferation [5–8]. Several key enzymes in the glycolytic pathway and tricarboxylic
acid cycle, (pyruvate kinase M2, pyruvate dehydrogenase kinase, isocitrate dehydrogenase, succinate
dehydrogenase, lactate dehydrogenase and others (representative articles include [9–17]) are targets
for anti-cancer drugs.
A rapidly growing body of evidence is demonstrating that an adaptation to aerobic glycolysis does
not entail a complete shutdown of oxidative phosphorylation (OXPHOS) in tumors. Active electron
transport occurs in cancer cells that trigger tumor recurrence and in cancer stem cells [18–20]. Here, we
review evidence supporting the importance of OXPHOS in high grade serous ovarian cancer (HGSOC),
discuss small molecule inhibitors of OXPHOS, their mechanism of action, and potential barriers to the
use of such agents for the treatment of HGSOC.
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2. Oxphos As Target for Hgsoc Therapy
Ovarian cancer is classified into type I and II diseases [21–23]. Clear cell cancer and low grade
endometrioid are major types of ovarian tumors classified as Type I malignancies with mutations in
ARID1A (AT-rich interactive domain-containing protein 1A), K-Ras (Kirsten rat sarcoma) and PTEN
(phosphatase and tensin homolog). High grade serous ovarian cancer (HGSOC), the predominant
subtype, is classified as Type II disease and is characterized by mutations in p53 and copy number
variations [24–29]. In the majority of the patients, HGSOC is detected at an advanced stage when the
tumor has progressed to sites beyond the ovaries. While cytoreductive surgery and chemotherapy
with platinum and taxanes are initially effective, they fail to prevent recurrence of HGSOC. Recurrent
HGSOC responds poorly to most established and experimental therapies. While PARP (ADP ribose
polymerase) inhibitors have extended overall survival [30–33], there remains a need for additional
novel therapeutic approaches to treat HGSOC. In this review, we make the case that OXPHOS be
considered as a druggable pathway while developing novel therapies against HGSOC.
In normal cells, glucose is metabolized through glycolysis, tricarboxylic acid cycle and OXPHOS
to produce 34–38 molecules of ATP per molecule of glucose (Figure 1). In cancer and other highly
proliferative and activated cells (immune cells, for example), the end product of glycolysis, pyruvate,
is not transferred to the mitochondria and consumed in the tricarboxylic acid cycle, but instead
is converted to lactate (Figure 1). This conversion to lactate allows the cells to regenerate NAD
(Nicotinamide Adenosine Dinucleotide) needed to drive the conversion of glyceraldehyde-3-phosphate
to 1,3-bisphosphoglycerate in glycolysis.
 
Figure 1. Oxidative phosphorylation. Aerobic glycolysis metabolizes glucose to lactic acid. Oxidative
phosphorylation (OXPHOS) occurs in mitochondria and leads to efficient generation of ATP. OXPHOS
is an active pathway in tumors and cancer stem cells. Several inhibitors or the various subunits of the
mitochondrial electron transport complexes can serve as candidates for tumor therapy. Prominent drug
candidates for HGSOC are shown. CytC, Cytochrome C, ETC, Electron Transport Chain, LDH, Lactate
Dehydrogenase, Q, unbiquinone, QH2, Ubiquinol, TCA, Tricarboxylic Acid Cycle, FADH2, Flavine
Adenine Dinucleotide, NADH, Nicotinamide Adenine Dinucleotide.
An active glycolytic pathway supplies the biochemical precursors required for protein, nucleotide
and lipid synthesis. This is an important reason why cancer cells limit glucose metabolism to glycolysis
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even when there is sufficient availability of oxygen. Ovarian tumors also show metabolic adaptation
to aerobic glycolysis that allows them to maintain an increased proliferative capacity and survive
under anchorage dependent conditions [34–36]. Adaptation of the ovarian cancer cells to aerobic
glycolysis is supported by the increased expression of the glycolytic enzymes pyruvate kinase isoform
M2 (PKM2), hexokinase II, and lactate dehydrogenase A (LDHA). PKM2 catalyzes the conversion
of phosphoenolpyruvate to pyruvate and regulates the flux of acetyl coA available to enter the
tricarboxylic aid cycle. Elevated expression of PKM2 correlates with decreased progression free
survival in HGSOC although overall survival is not affected [37]. Hexokinase II is also upregulated
in HGSOC [38,39]. Elevated hexokinase II expression contributes to chemoresistance in ovarian
tumors [40].
The metabolic shift to aerobic glycolysis provides the precursors for synthesis of proteins,
nucleotides and lipids, at the expense of ATP. To compensate, cancer cells overexpress glucose
transporters. As a result, there is an increased uptake of glucose that is catabolized through aerobic
glycolysis. Serous ovarian tumors express high levels of glucose transporters GLUT1, GLUT3 and
GLUT4, as compared to healthy and benign ovarian tissues [41,42]. Increased uptake of glucose
through the upregulation of glucose transporters (GLUT) is a hallmark of HGSOC allowing their
imaging by 18-fluoro-deoxyglucose positron emission tomography (FDG-PET) [43,44].
The molecular mechanisms responsible for the metabolic reprogramming in cancer are under
investigation. One mechanism is through the regulation of pyruvate kinase M2 isoform (PKM2)
activity through its interactions with growth factor receptors [45]. There is emerging evidence
that mutated BRCA1 [46] and mutated p53 (reviewed in [47]), two genes that are most frequently
mutated in HGSOC, also contribute to the shift to aerobic glycolysis. In HGSOC, the sulfatase,
h-Sulf-1 is downregulated [48]. Loss of h-sulf-1 in HGSOC increases glycolytic activity through the
phosphorylation of pyruvate dehydrogenase causing a decrease in availability of pyruvate in the
tricarboxylic acid cycle [49]. All of these results clearly demonstrate that glycolysis is a major metabolic
adaptation occurring in HGSOC.
2.1. Relevance of OXPHOS in Solid Tumors
While aerobic glycolysis is an important adaptation in HGSOC, OXPHOS is also an active pathway
in cancer cells [50–56]. Initial data in support of this observation was gained from experiments with the
tetracycline-inducible K-Ras (G12D) mouse model for pancreatic cancer [57]. Withdrawal of doxycycline
caused regression of the pancreatic ductal carcinomas [55]. However, tumor recurrence was observed
in the mice 4–5 months after doxycycline withdrawal. Tumor relapse was attributed to cancer stem cells
surviving the ablation of mutant K-Ras. These surviving cancer stem cells had increased mitochondrial
biogenesis with higher OXPHOS activity but impaired glycolysis. The relapsing tumors were responsive
to the OXPHOS inhibitor, oligomycin [55].
Tumor cells that utilize aerobic glycolysis, coexist with cancer cells with active OXPHOS.
A recent report by Yu et al [58] developed a model to predict the predominant metabolic pathway
utilized by normal and cancer cells. Glycolysis is indicated by high expression of HIF-1α (Hypoxia
inducible factor-1α) and low levels of phospho-5’ AMP-activated protein kinase (pAMPK), whereas
OXPHOS-reliant tumors have low levels of HIF-1α and high levels of pAMPK. Some cancer cells
express high levels of both HIF-1α and pAMPK indicating active glycolysis as well as OXPHOS.
There are, however, some indicators that active mitochondrial metabolism may have a favorable
outcome. The Bioenergetic Cellular (BEC) index, a ratio β-F1ATPase (F1 portion of adenosine
triphosphate synthase) to HSP60 (Heat Shock Protein 60) and GAPDH (Glyceraldehyde 3-Phosphate
dehydrogenase) expression, predicts the metabolic state of a cell [59]. A higher BEC is an indicator
of active OXPHOS. In one study, thirty six of 55 HGSOC patients had a BEC of less than 2.65 [60].
Progression free survival was higher in patients with <2.65 compared to the 19 patients with higher
BEC (9.8 versus 5.3 months). However, the BEC does not account for metabolic heterogeneity and
therefore these observations do not rule out the presence of tumor foci with active OXPHOS. There is
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evidence that agents targeting OXPHOS can be used to target cancer initiating cells, chemoresistant
tumors as well as non-tumor cells from the tumor microenvironment.
2.2. Reliance of Ovarian Cancer Stem Cells on OXPHOS
Perhaps the largest impact of OXPHOS is in the survival and proliferation of cancer initiating
stem cells. Tumor initiating cells isolated from tumorigenic murine ovarian surface epithelial
(MOSE) cells showed increased expression of glucose transporters and an overactive glycolytic
pathway [61,62]. However, these tumor initiating cells also had a higher capacity than non-tumor
initiating tumor-forming MOSE cells for mitochondrial oxygen consumption. The tumor initiating
MOSE cells also exhibited higher survivability when cultured in media that did not contain glucose
but was supplemented with glutamine and fatty acids. The observation that the tumor initiating cells
are better able to survive on glutamine-supplemented media suggests that they are less dependent
on glycolysis and, through the entry of glutamine in the tricarboxylic acid cycle are able to generate
sufficient NADH (Nicotinamide Adenine Dinucleotide) and FADH2 (Flavine Adenine Dinucleotide).
The higher mitochondrial capacity facilitates production of sufficient levels of ATP that drive
their proliferation.
CD44+/CD117+ cancer stem cells isolated from the peritoneal fluid of HGSOC patients that
had the ability to form tumors in mice, showed decreased levels of pyruvate dehydrogenase kinase
(PDHK1) and increased expression of isocitrate dehydrogenase (IDH2) [18]. This observation is in stark
contrast to the non-cancer stem cells (CD44+/CD117−) from HGSOC patients where the PDHK1 was
upregulated and IDH2 was significantly lower. PDHK1 negatively regulates pyruvate dehydrogenase
and as a result controls the amount of acetyl-CoA (Coenzyme A) available for the tricarboxylic acid
cycle. The decrease in PDHK1 and increase in IDH2 in the CD44+/CD117+ ovarian cancer stem
cell population are indicators of enhanced tricarboxylic acid cycle. The CD44+/CD117+ cancer stem
cells produced higher levels of oxygen radicals and had enhanced OXPHOS than the non-stem cell
(CD44+/CD117−) population. RAG2−/− mice implanted with HGSOC tumors when maintained on a
diet supplemented with the glycolysis inhibitor, 2-deoxyglucose, instead of glucose, showed a decrease
in tumor size. However, the surviving tumors from these mice were enriched in CD44+/CD117+ cancer
stem cells [18].
2.3. OXPHOS in Chemoresistant HGSOC
There is also evidence that OXPHOS is an important pathway to target in chemoresistant tumors.
Tumor necrosis factor receptor-associated protein 1 (TRAP1) is a mitochondrial chaperone from the
Hsp90 family [63]. Increase in TRAP1 expression elevates aerobic glycolysis in ovarian cancer cell
lines [64]. HGSOC lines with lower expression of TRAP1 or silencing of this gene increased the oxygen
consumption rate and decreased extracellular acidification (a measure of aerobic glycolysis) [65].
Low expression of TRAP1 results in higher reliance on OXPHOS and is associated with resistance
to platinum [64]. Chemoresistant ovarian cancer cells show increased OXPHOS activity and survive
under limiting glucose levels or when the resistant tumors were implanted in mice that were fed
2-deoxyglucose [34].
2.4. OXPHOS and the Tumor Microenvironment
Tumor cells produce high levels of lactic acid in the tumor microenvironment. While the lactic
acid can be transported by cancer cells through monocarboxylic acid transporters (MCTs) and used to
promote tumor proliferation, the effect of the acidic environment on the non-malignant cells is also an
important factor to consider when determining the metabolic profile of the tumor. For example, the
lactic acid in the tumor microenvironment can regulate the activity of immune cells infiltrating the
tumor microenvironment (reviewed in [66]).
Such crosstalk in the tumor microenvironment is not unidirectional as the tumor cells can also
be affected by the metabolic status of the fibroblasts from the microenvironment. For example, Ras
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(glycine at position 12 mutated to valine) mutations alter metabolism in cancer cells and increase
the release of oxygen radicals [67]. These radicals induce oxidative stress in the intratumoral stroma,
forcing a catabolic state that produces lactate, ketones, glutamine and fatty acids that serve as fuel to
the cancer.
Stromal cells from the tumor microenvironment express low levels of caveolin 1 and high
MCT4 allowing them to expel lactate into the tumor microenvironment [68–70]. In a recent study,
patients with BRCA1 mutated breast cancers were treated with the anti-oxidant, N-acetyl cysteine [71].
Pathological examination showed a reversal in the expression of caveolin 1 and MCT4 by the stromal
cells suggesting that neutralization of the oxygen radicals can inhibit the symbiotic relationship
between the cancer cells and the stromal cells in the microenvironment. Additionally, this study also
observed a decrease in ki67 stained cancer cells. Since the mitochondria are the major source for oxygen
radicals, it can be argued that the stromal cells from the tumor microenvironment are OXPHOS-active
and the oxygen radicals generated by these cells promote the proliferation of cancer cells. Therefore,
inhibitors of OXPHOS can not only be successful because of their direct cytotoxic effects on cancer
cells but also through the potential modulation of metabolism in stromal and other non-cancer cells
from the tumor microenvironment.
3. OXPHOS Provides Multiple Targets for Drug Development
High energy electrons from NADH and FADH2 are harvested in OXPHOS and transferred to
molecular oxygen. Four multiprotein complexes located in the inner membrane of the mitochondria
(Complexes I-IV) are required for electron transport (Figure 1). Electrons from NADH and FADH2
are extracted in complex I and complex II, respectively. Electrons from complex I and II are delivered
to complex III via the electron carrier, ubiquinone (coenzyme 10, CoQ10). The quinone head group
of CoQ10 participates in two electron redox reactions. Addition of one electron to CoQ10 yields
semiquinone and further reduction of this intermediate leads to formation of ubiquinol. The electron
transfer from NADH/FADH2 to ubiquinone occurs at the ubiquinone and ubiquinol binding sites,
Q0 and Qi, in the mitochondrial complexes I-III. Electron transport from complex III to complex IV
is aided by cytochrome C (Cyt C). In complex IV, the electrons are delivered to molecular oxygen to
form water.
The transfer of electrons is coupled with pumping of protons from the matrix to the intermembrane
of the mitochondria. This transfer of protons leads to the maintenance of a proton gradient (ΔΨpion).
The proton efflux from the matrix helps maintain a negative charge in the matrix and contributes to
an electrical potential gradient (ΔΨm). The electromotive force generated through proton transport
provides the energy necessary for the fifth mitochondrial complex, the ATP synthase, to convert ADP
to ATP.
Complex chemical reactions and biochemical control points are required to regulate OXPHOS.
From the standpoint of cancer drug discovery, this situation provides opportunities for the
development of novel therapeutic strategies. Agents that interfere with electron transport, maintenance
of the proton gradient (ΔΨpion and ΔΨm) and transfer of electrons to oxygen and ATP synthesis can
be developed as cancer therapeutics. While small molecules are likely the preferred agents to target
OXPHOS, efforts are also underway to develop peptides that can specifically target this mitochondrial
metabolic pathway (reviewed in Reference [72]). In the subsequent sections, we will discuss small
molecule agents that interfere with OXPHOS.
4. OXPHOS Inhibitors
4.1. Complex I Inhibiting Biguanides
Metformin and proguanil are biguanides with complex I inhibitory activities (Figure 1). Regular use
of metformin reduces risk of ovarian cancer (OR 0.61, 95% CI 0.3–1.25) [73]. Nearly 70% of HGSOC
patients using metformin survived for 5 years. In comparison, only 47% of HGSOC patients who
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were not on metformin survived for 5-years or more [74]. Romero and colleagues have analyzed
the positive benefits of metformin use in HGSOC patients with diabetes. Approximately 51% of the
diabetic patients who regularly used metformin had progression-free survival at 5-years post initial
diagnosis of the cancer. In contrast, 23% of the nondiabetic metformin users and only 8% of non-diabetic
non-metformin users had progression free survival at 5-years postdiagnosis [75]. The overall survival
at 5-years post initial diagnosis of HGSOC was reported to be 63%, 37% and 23%, respectively, for these
three cohorts [75].
Metformin inhibits complex I and thereby reduces ATP production. As a result of decreased
ATP levels, AMPK is activated in cancer cells along with inhibition of mTORC1 (mammalian Target
of Rapamycin Complex). Millimolar concentrations of metformin are required to inhibit complex
I activity and there remains an active question of whether such high levels of metformin can be
achieved in solid tumors. Proguanil inhibits complex I activity in the malarial parasite and is therefore
administered in conjunction with atovaquone, a complex III inhibitor. However, proguanil has limited
effect on human complex I and is therefore not suitable for cancer therapy [76,77]. Another bigiuanide,
phenformin triggers lactic acidosis and therefore has major clinical toxicity.
A novel agent, IACS-0107059, that likely mimics the biguanide functional group has been
investigated as therapy for acute myeloid leukemia [78–82]. This compound blocks complex I at
subnanomolar-nanomolar range and inhibits proliferation of HGSOC cells. Clinical trials are currently
underway to test this compound against AML and solid tumors.
Eight clinical trials are currently posted in clinicaltrials.gov to test the effect of metformin in
ovarian cancer patients. The majority of these trials are evaluating the combination of metformin with
chemotherapy and are currently recruiting patients. Results from one trial (NCT01579812) showed that
metformin was well tolerated. Ex vivo evaluation of the tumors showed significant decrease in viable
cancer stem cell population. Additional studies are needed to determine if these positive benefits are
due to the OXPHOS inhibitory effects of metformin. As demonstrated by Yu et al. [58], monitoring
pAMPK and HIF-1α levels in the metformin clinical trials can potentially be used as biomarkers for the
status of OXPHOS versus aerobic glycolysis in tumors providing insight into the metabolic adaptations
occurring in the tumors in response to this biguanide.
4.2. Oxidative Stress Inducers
Oxidative stress results from an imbalance between the processes responsible for generation and
sequestration of reactive oxygen radicals (ROS) [83]. Since the transfer of electrons to molecular oxygen
is an integral step of the electron transport chain, the OXPHOS pathway is a major generator of oxygen
radicals (Figure 2). A rapid increase in intracellular levels of oxygen radicals causes cellular damage
and cell death. Atovaquone, a Food and Drug Administration (FDA) approved anti-malarial agent
that inhibits complex III activity, is being repurposed for treatment of solid tumors [84–86].
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Figure 2. Uncontrolled oxidative stress is cytotoxic to cancer cells. OXPHOS is a major producer of
oxygen radicals. While oxygen radicals have positive benefits in cells, a rapid and uncontrolled rise in
hydroxyl radicals can lead to cancer cell death. PRX, peroxiredoxin, GPX, glutathione peroxidase, CAT,
catalase, SOD, superoxide dismutase, and NOX, NADPH oxidase.
Unpublished results from our group are demonstrating that atovaquone should be investigated
for treatment of HGSOC. The naphthoquinone unit of atovaquone engages in redox reactions and
interferes with electron transport mediated by ubiquinone [84–86].
There are several naturally occurring and synthetic molecules that contain the quinone,
naphthoquinone or anthroquinone head groups. Plumbagin and juglone are examples of such
compounds. Treatment of HGSOC cells with plumbagin results in an immediate increase in
intracellular oxygen radical flux [87]. Plumbagin also inhibits oxygen consumption rate, decreases ATP
synthesis and increases the redox ratio (NADH/FAD) and extracellular acidification rate (ECAR) [87].
These results indicate that plumbagin is likely to be an inhibitor of mitochondrial electron transport.
Molecules that interfere with ubiquinone-mediated electron transport induce severe oxidative
stress. There are at three major types of reactive oxygen species (superoxide anion O2−, hydrogen
peroxide H2O2 and hydroxyl radicals OH·) that are formed due to incomplete transfer of electrons to
molecular oxygen (Figure 2).
4.3. Superoxide Anion (O2−)
The primary source of superoxide anions is the electron transport chain in the mitochondria [88,89].
Leakage of electrons travelling through the multiple complexes in the electron transport chain results
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in one-electron reduction of oxygen to produce the superoxide anions. The second major producer of
the superoxide anion are the NADPH oxidases (NOXs) which are transmembrane enzymes present
at the different membranes in the cell (Figure 2) [90]. Superoxide anions are restricted in the cellular
damage they can cause because they typically only react with peptide epitopes located near the iron
sulfur complexes and hence do not cause indiscriminate cellular damage [91].
4.4. Hydrogen Peroxide (H2O2)
Reduction of the superoxide anions by superoxide dismutases (SODs) yields hydrogen peroxide
(H2O2). H2O2, existing at nanomolar concentration in the cell, is the main ROS signaling molecule
of the cell. It functions by oxidizing the thiolate anion (Cys-S−) of a cysteine to its sulfenic form
(Cys-SO−). Oxidation of the cysteine thiol affects the formation of Inter- and Intramolecular disulfide
bonds and has serious consequences on the biological properties of proteins [92]. This oxidation is
reversed by the enzymatic action of thioredoxin (TRX) and glutaredoxin (GRX), which themselves
are reduced back by thioredoxin reductase (TR). These set of enzymes essentially constitute the main
group of molecules executing the redox signaling in the cell [93]. At abnormally high concentrations of
H2O2 (as those observed during oxidative stress), the sulfenic form (Cys-SO−) is irreversibly oxidized
to higher oxidized states of sulfinic (Cys-SO2−) and sulfonic (Cys-SO3−), which cannot be repaired
through redox control and hence can cause significant cellular damage.
4.5. Hydroxyl Radical (OH·)
The hydroxyl radical (OH·) is the most reactive of the three ROS molecules described in this
section. H2O2 reacts with metal cations (Fe2+, Cu+) present in the cytosol in a reaction called Fenton
reaction, to produce OH·. Additionally, nitric oxide synthases (NOS) also produce OH· along with
NO2· under limiting concentration of cofactors and co-substrates. OH· reacts indiscriminately with
various substrates such as lipids, proteins and DNA and leads to genomic instability [94]. Presence of
OH· is abnormal and therefore, an indicator of high oxidative stress in the cell.
Oxidative stress induces pleiotropic effects in the cells. These include, but are not restricted to,
activation of p53, inhibition of NFκB (Nuclear Factor kappa-B), activation of protein kinases and other
signaling molecules, and decrease in the expression of survivin. Molecules such as plumbagin that
increase intracellular oxygen radicals, are often thought to mediate pleiotropic effects that culminate
in cancer cell death. However, it is important to consider that such molecules may also be specific in
their ability to compete with ubiquinone and inhibit electron transport in the mitochondria and can
therefore serve as important OXPHOS-targeting agents.
5. Barriers to Using OXPHOS Inhibitors for HGSOC Therapy
5.1. Potential Toxicity of OXPHOS Inhibitors
Our studies with plumbagin clearly show that inhibition of electron transport results in a rapid
increase in harmful oxygen radicals that cause significant cellular damage [87]. With OXPHOS serving
as a major mechanism for energy generation, there is significant risk that inhibitors of this pathway
may damage healthy tissues. Toxicity of the OXPHOS inhibitors is therefore a major concern that may
curtail their use for the treatment of HGSOC and other tumors. It should be noted, however, that
plumbagin did not produce major toxicity in pre-clinical studies in mouse models [95,96]. Additionally,
metformin is generally a safe drug with minimum toxicity. While proguanil is effective inhibitor of
the OXPHOS pathway in the malarial and other parasites, its specific activity as OXPHOS inhibitor
is reduced in human cells [76,77]. This experience with atovaquone and proguanil suggests that
rational drug development approaches can be applied to develop inhibitors that have higher potency
against human OXPHOS complexes. Given the higher susceptibility of cancer cells to oxidative stress,
well-designed and more potent inhibitors can potentially be used at lower concentrations to produce
optimum activity in tumors while reducing toxicity in healthy tissues. Additionally, the OXPHOS
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inhibitors can also be functionalized with folate and other tumor targeting moieties to facilitate selective
delivery of these agents to the tumor, thereby achieving higher efficacy with lower toxicity.
5.2. Anti-Oxidant Mechanisms and Chemoresistance
There are elaborate antioxidant mechanisms to maintain steady state levels of oxygen radicals in all
cells. Superoxide dismutase, catalase, peroxiredoxins, glutathione, glutathione reductase, thioredoxins
and others form the network of anti-oxidant mechanisms that control oxidative stress. This network
is controlled by a master regulatory transcription factor, Nrf-2. Cancer cells respond to inhibition of
complex III by atovaquone, (unpublished observation) and plumbagin [87] by increasing the expression
of Nrf-2. Therefore, the oxidative stress triggered by these agents is relatively short lived and therefore
attenuates their cytolytic activity. The rise in Nrf-2 should therefore be considered as a chemoresistance
mechanism to oxidative stress-inducing OXPHOS inhibitors. Combining these OXPHOS inhibitors
with Nrf-2 modulators such as brusatol, results in a synergistic increase in inhibition of cancer cell
proliferation [87]. Agents that enhance Nrf-2 activity are being developed to control oxidative damage
in neurologic diseases. Similar efforts are needed to develop Nrf-2 inhibitors to enhance oxidative
stress in HGSOC and other tumors.
Use of Nrf-2 inhibitors for cancer treatment also raises the possibility that such approaches may
inhibit the natural protection against oxygen radicals in healthy tissues. Rational drug design, targeted
delivery and specific drug formulations will be required to maximize the effect of Nrf-2 inhibitors in
cancer cells while attenuating the side-effects of such drugs in healthy tissues.
5.3. Mitochondrial Adaptations to Oxidative Stress
The extensive use of atovaquone has led to the realization that some malarial parasites have
developed resistance to this drug through mutations in cytochrome B (Cyt B), an essential component
of complex III [97–100]. Cyt B is encoded by the mitochondrial genome. The mitochondrial population
with mutated Cyt B is likely to be exposed to minimum oxidative damage in response to atovaquone
and will therefore show enrichment through successive mitochondrial replications. A similar situation
can also be envisioned in cancer where oxidative stress-inducing OXPHOS inhibitors may result in an
increase in the drug-resistant mitochondrial pool. Studies are needed to determine the contributions of
such mitochondrial adaptations to chemoresistance against OXPHOS inhibitors.
6. Conclusions
Inhibition of glucose metabolism will result in significantly curtailing the ability of cancer cells
to proliferate and modulate the tumor microenvironment through the release of lactic acid and other
intermediates. OXPHOS pathway in tumors, cancer stem cells and the stromal and immune cells in
the tumor microenvironment is recognized as a target for development of novel anti-cancer therapies.
The multimeric complexes of the OXPHOS pathway are targets for small molecule inhibitors that can
inhibit metabolism as well as induce oxidative damage and cancer cell death. OXPHOS inhibitors can
be paired with immunologic and other therapies. While the development of novel OXPHOS inhibitors
will be necessary, it will be important that these agents are specifically targeted to the cancer or the
tumor microenvironment in order to reduce toxicity in healthy tissues. Finally, the use of OXPHOS
inhibitors may result in Nrf-2 activation and mitochondrial adaptations that may pose as pathways that
are typically not considered to contribute towards chemoresistance. Studies on atovaquone, proguanil,
metformin have provided the foundation that will support the development of additional and more
potent OXPHOS inhibitors for the treatment of HGSOC and other tumors.
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Abstract: Ovarian cancer progression involves multifaceted and variable tumor microenvironments
(TMEs), from the in situ carcinoma in the fallopian tube or ovary to dissemination into the peritoneal
cavity as single cells or spheroids and attachment to the mesothelial-lined surfaces of the omentum,
bowel, and abdominal wall. The TME comprises the tumor vasculature and lymphatics (including
endothelial cells and pericytes), in addition to mesothelial cells, fibroblasts, immune cells, adipocytes
and extracellular matrix (ECM) proteins. When generating 3D models of the ovarian cancer TME,
researchers must incorporate the most relevant stromal components depending on the TME in
question (e.g., early or late disease). Such complexity cannot be captured by monolayer 2D culture
systems. Moreover, immortalized stromal cell lines, such as mesothelial or fibroblast cell lines, do not
always behave the same as primary cells whose response in functional assays may vary from donor to
donor; 3D models with primary stromal cells may have more physiological relevance than those using
stromal cell lines. In the current review, we discuss the latest developments in organotypic 3D models
of the ovarian cancer early metastatic microenvironment. Organotypic culture models comprise
two or more interacting cell types from a particular tissue. We focus on organotypic 3D models
that include at least one type of primary stromal cell type in an ECM background, such as collagen
or fibronectin, plus ovarian cancer cells. We provide an overview of the two most comprehensive
current models—a 3D model of the omental mesothelium and a microfluidic model. We describe the
cellular and non-cellular components of the models, the incorporation of mechanical forces, and how
the models have been adapted and utilized in functional assays. Finally, we review a number of 3D
models that do not incorporate primary stromal cells and summarize how integration of current
models may be the next essential step in tackling the complexity of the different ovarian cancer TMEs.
Keywords: ovarian cancer; tumor microenvironment; 3D models
1. Introduction
From tumor initiation to metastasis, intricate and reciprocal interactions between ovarian cancer
cells and the stromal components of their surrounding milieu create complex and fluctuating tumor
microenvironments (TMEs) [1,2]. Stromal components of the TME include the tumor vasculature and
lymphatics (including endothelial cells and pericytes), mesothelial cells, fibroblasts, immune cells,
and extracellular matrix (ECM) proteins. Mechanical forces such as sheer stress caused by increased
peritoneal fluid flow also contribute to this environment, inducing changes in cell morphology and
gene expression [3,4]. All of these elements are associated with specific facets of tumorigenesis
and metastasis, and their involvement cannot be accurately captured by traditional 2D cell culture
systems. Cancer cell cultures in 3D microenvironments are far more representative of disease than
traditional 2D systems. Three-dimensional systems provide 1) conditions which are structurally
Cancers 2018, 10, 265; doi:10.3390/cancers10080265 www.mdpi.com/journal/cancers310
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similar to the in vivo environment and are amenable to changes in oxygen and growth factor gradients
(e.g., cell spheroids) [5] and 2) cell–cell and cell–ECM communication (e.g., scaffold-based models) [6,7].
Ovarian cancer progression involves detachment of cancer cells from the in situ carcinoma in the
fallopian tube or the primary ovarian tumor, dissemination into the peritoneal cavity as single cells or
spheroids, and attachment to the mesothelial-lined surfaces of the omentum, bowel, and abdominal
wall [8,9] (Figure 1). Ovarian cancer complexity and heterogeneity has meant that development of
in vitro 3D ovarian cancer TME models to recapitulate in vivo pathophysiological features has been
challenging. Our group has previously published comprehensive reviews of the different 3D culture
methods used to study the ovarian cancer TME [10–12]. In the current review, we focus on the latest
organotypic 3D models that utilize primary stromal cells, in particular a 3D model of the omental
mesothelium and a microfluidic model. We provide an overview of these models, both of which are
used to study the early steps of ovarian cancer metastasis, describing the cellular and non-cellular
components, the consideration of mechanical forces, and their utilization. We discuss the challenges
and limitations associated with the current models and put forward the essential steps to establish an
archetype model that will faithfully recreate the in vivo scenario.
Figure 1. Pathogenesis of the ovarian cancer disease.
2. Three-Dimensional Modelling of Early Metastasis TME Interactions in Ovarian Cancer
Organotypic models refer to 3D models, usually containing ECM, that are comprised of two
or more cell types to mimic the complex interactions within a tissue. For this review, we focus
on organotypic models of the ovarian cancer TME that comprise a 3D culture containing at least
one primary stromal cell type in an ECM background, such as collagen or fibronectin, plus ovarian
cancer cells.
Ovarian cancer cells have a special predilection for the peritoneum and the omentum as sites
of metastasis [8]. The outer lining of these sites consists of a single layer of mesothelial cells with
an underlying ECM. During the metastatic process, microscopic non-invasive omental metastases
proliferate on top of this layer of mesothelial cells. As the metastases increase in size, the cancer cells
induce pro-tumorigenic changes in the stromal cells of the microenvironment, including an increase
in the number of fibroblasts and a more rigid basement membrane [13]. Tumor cells then invade the
omental adipose tissue. In 1985, Niedbala et al. were the first to establish an organotypic culture of the
ovarian cancer TME and investigate the mechanism through which ovarian cancer cells infiltrate the
mesothelial cell layer and attach to the ECM [14]. Human primary mesothelial cells (HPMCs) were
grown in a monolayer on ECM derived from bovine corneal endothelial cells, onto which ovarian
cancer cells derived from patient ascites were seeded. A current version of this organotypic model of
the ovarian cancer TME was developed by Kenny et al. This model allows examination of the role that
the ECM, HPMCs and fibroblasts play in the initial adhesion, migration, invasion and proliferation of
ovarian cancer cells during early metastasis to the mesothelium [13]; it is referred to in this review as
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the “mesothelium model”. Adding a different element, other models recreate the dynamic mechanical
forces that act upon ovarian cancer spheroids in the peritoneal cavity using microfluidic devices [15,16].
3. Three-Dimensional Organotypic Model of Human Mesothelium
The 3D organotypic mesothelium model was created to elucidate the role of specific cellular and
non-cellular components, namely fibroblasts, HPMCs, and different ECM proteins, in early ovarian
cancer metastasis to the omentum [13]. Two key factors set this mesothelium model apart from other
3D cultures: (1) prior to construction of the model, the authors analyzed hematoxylin and eosin (H&E)
stains of normal omental biopsies to form the best picture of the physiological framework of normal
omentum and (2) the authors included two types of primary stromal cells, HPMCs and fibroblasts.
Using primary HPMCs and fibroblasts at early passages extracted from fresh biopsies of omentum
obtained during surgery, the authors recreated the omental ovarian cancer TME in vitro (Figure 2A).
Primary human omental fibroblasts were embedded in ECM and overlaid with a layer of HPMCs
(1:5 ratio of fibroblasts and HPMCs). With the addition of ovarian cancer cells or immortalized ovarian
surface epithelial cells, this highly reproducible construction was used to determine the role of each of
the TME components, including different ECM proteins, during ovarian cancer adhesion and invasion.
Results from the model showed that both HPMCs and fibroblasts play key roles in these processes.
Customization of the model with different ECM proteins revealed that ovarian cancer cell adhesion
and invasion is greatest in the presence of collagen, compared with vitronectin, fibronectin, or laminin.
This tool was also shared as a JoVE video article to improve dissemination of the protocol and as a
resource for other scientists in the ovarian cancer field [17].
Figure 2. Three-dimensional organotypic model of human mesothelium. (A) Layered model for investigating
ovarian cancer adhesion, migration, invasion and proliferation in a metastatic microenvironment. In this
layered model, the extracellular matrix (ECM) and fibroblasts are cultured together prior to the sequential
addition of mesothelial cells and cancer cells. (B) Model for high-throughput screening (HTS) to identify
compounds that inhibit ovarian cancer adhesion/invasion or proliferation. In this HTS model, ECM,
fibroblasts and mesothelial cells are plated simultaneously, followed by the addition of cancer cells
and compounds.
This modular mesothelium model has been used in numerous publications that further illuminate
the mechanisms involved in early ovarian cancer metastasis [18–24]. Kenny and colleagues proceeded
to show that ovarian cancer cells recruit HPMCs to establish metastatic colonies by inducing
an upregulation in the levels of fibronectin 1 (FN1) mRNA and protein in HPMCs which
promote cell adhesion [18]. They also demonstrated that adhering ovarian cancer cells express
matrix-metalloproteinase, which cleaves matrix proteins into smaller fragments, thereby facilitating
invasion [19,20]. Other functional assays using the model and an antibody against the urokinase
plasminogen activator (uPA) receptor (u-PAR) revealed that targeting the uPA/u-PAR proteolytic
system reduced metastasis and induced apoptosis of ovarian cancer cells [21]. Building on this,
Mitra et al. used the mesothelium model to identify miRNAs involved in omental colonization,
demonstrating that upregulation of uPA in ovarian cancer cells is due to downregulation in miR-193b
levels, which is in turn due to ovarian cancer cell interaction with HPMCs on the surface of the
omentum [22]. More recently, a study by Caroline Ford’s group used this model to expand on the
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synergistic role of Wnt receptors ROR1 and ROR2 in early ovarian cancer metastasis, specifically their
role in ovarian cancer cell adhesion to the omentum [23].
The ability to customize the mesothelium model led to its reshaping and utilization in high
throughput screening (HTS) assays. Through optimization of parameters such as incubation time,
plating sequence, number of ovarian cancer cells, HPMCs, fibroblasts, and ECM, the model was
adapted for use in reproducible 384- and 1536- multi-well HTS assays [25] (Figure 2B). Fully automated
3D HTS assays were carried out to screen small molecule inhibitors that could potentially target
ovarian cancer adhesion/invasion or proliferation [25,26]. The effect of oncology drugs from three
small molecule compound libraries, the National Center for Advancing Translational Sciences
(NCATS) Mechanism Interrogation PlatE oncology collection, the Prestwick library, and the Library
of Pharmacologically Active Compounds (LOPAC1280) on ovarian cancer adhesion/invasion or
proliferation was investigated. These assays were followed by confirmatory, counter, and secondary
biological assays utilizing the 3D organotypic model of human mesothelium to identify lead
compounds. Ultimately, inhibitory activity of the lead compounds on ovarian cancer metastasis was
validated in different in vivo xenograft models. A key takeaway from the HTS assays was that many
of the compounds screened were active in cancer cells on plastic (>90%), but only a few compounds
were effective in the 3D HTS platform (<1%) which directly translated to in vivo activity in xenograft
mouse models. Differences in drug response between 2D cultures and 3D organotypic models have
also been demonstrated in studies of skin melanoma. These studies reported that treatment with
tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in combination with either UVB or
cisplatin killed melanoma cells in 2D cultures, but only the TRAIL plus cisplatin combination was
effective in their layered 3D organotypic skin melanoma spheroid model [27–29]. These differences
further highlight the value of 3D organotypic models that can accurately represent the complexity of
the ovarian cancer TME.
This mesothelium model is a first step at recapitulating the metastatic microenvironment of
ovarian cancer, but it still lacks other in vivo factors such as vasculature, adipocytes, and host immune
cells. However, it represents a significantly more complex experimental system than ovarian cancer
cells grown in monolayer to analyze the complex mechanisms of tumorigenesis and to potentially
identify new therapeutics. Omental cells from different patients in the 3D organotypic cultures reveal
a broader picture of donor-to-donor variability in terms of drug response, cellular function and
cell signaling.
4. Three-Dimensional Organotypic Model of Cancer Cells Circulating in Ascites
Peritoneal dissemination of ovarian cancer spheroids and their interactions with omental
mesothelial cells are not static processes. Hydrodynamic forces generated by increased production
of fluid in the peritoneal cavity must be considered in addition to the 3D culture itself. To recreate
this aspect of the ovarian cancer TME, Li et al. developed a 3D microfluidic-based platform in which
living cells are infused into micrometer-sized chambers [15]. These platforms enable accurate control
of the cellular microenvironment, allowing a continuous release of growth factors or nutrients. In their
device, Li et al. plated mesothelial cells on fibronectin, and added fluorescently labelled ovarian cancer
spheroids under continuous fluidic flow to mimic the flow of peritoneal fluid induced by ovarian
cancer in the clinical setting (Figure 3).
Figure 3. Three-dimensional organotypic model of cancer cells circulating in ascites.
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A 2018 publication by Carroll et al. added another layer of complexity by investigating the
interactions between alternatively activated macrophages (AAMs), mesothelial cells, and ovarian
cancer cells in dynamic flow experiments of ovarian cancer cell adhesion [16]. The authors first
determined, under static 3D conditions, that AAM-secreted macrophage inflammatory protein-1
induced expression of P-selectin in mesothelial cell lines, which in turn increased ovarian cancer
cell adhesion to the mesothelial cells. Using a parallel-plate flow chamber, which simulates fluid
sheer stress on cells, the authors went on to demonstrate that these increased levels of P-selectin in
mesothelial cell lines led to increased rolling of ovarian cancer cells.
Compared with experiments under static conditions, experiments performed under flow
conditions provided valuable insights into features of transcoelomic metastasis that cannot be
reproduced in standard static cultures, such as increased adhesion under flow conditions [16].
Although these microfluidic 3D models contained only one stromal cell type, their modularity means
that they can be customized to include other stromal cells or ECM components for use in functional
assays such as adhesion, invasion, and proliferation.
5. Other 3D Models of the Ovarian Cancer TME
5.1. Organoids
Identification of precursor lesions in the fallopian tube fimbria of ovarian cancer patients and
BRCA mutation carriers point towards the fimbria as the likely site of origin of high-grade serous
ovarian cancer [30–32], but the fallopian tube TME has not been well explored. Organoids are
in vitro cellular clusters (3D) derived from primary tissue that use ECM hydrogels to self-assemble
with architecture, histology, and genetic features resembling the original tissue [33]. Kessler et al.
re-constructed the microenvironmental milieu with growth factors and Matrigel to successfully culture
fallopian tube organoids from fallopian tube epithelial stem cells [34]. By supplementing this culture
with a selection of growth factors, the authors determined that both Notch and Wnt regulate stemness
and differentiation in fallopian tube organoids.
Fallopian tube organoid in vitro models have also been generated from induced pluripotent stem
cells (iPSCs). Yucer et al. guided differentiation of iPSC lines into fallopian tube epithelium precursor
cells through exposure to BMP4 and WNT4 followed by follistatin, an activin-binding protein that
bio-neutralizes members of the TGF-β superfamily [35]. When spheroids of these differentiated cells
were grown on Matrigel and supplemented with estrogen, progesterone, and crucially, conditioned
media from primary fallopian tube epithelial cells, they self-organized into luminal structures
representative of the fallopian tube architecture with ciliated and secretory components.
Organoids do not contain any stromal components, but can be incorporated into organotypic
culture systems to study the interactions between the organoid cells and the cells of their
microenvironment. Taking this concept a step further, one could envision a model in which transformed
fallopian tube epithelial cells [36] are propagated in organoids and integrated into an organotypic
model to investigate the early ovarian cancer TME.
5.2. Explant Cultures
While not a model in the sense that models are constructed, explants of omentum, ovary or
fallopian tube pieces cultured in the presence of ovarian cancer cells represent another form of 3D
culture. In particular, mouse omentum, ovarian and fallopian tube organ pieces can be cultured for
up to two weeks [37–39]. Human omentum and fallopian tube explants have been cultured for up
to five days with ovarian cancer cells [19,40], and ultimately revealed that ovarian cancer cells could
metastasize to the fallopian tube. In addition, these explant cultures can be used to test the effect of
different drugs or treatments on ovarian cancer adhesion, migration, invasion and proliferation by
targeting either the cancer or stromal cells.
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5.3. Cell Line Spheroids
For most researchers studying the ovarian cancer TME, access to patient tissue to obtain primary
cells will be the limiting factor. A number of valuable 3D models that do not include primary cells have
been published and utilized in functional assays. These non-organotypic endeavors to recapitulate
the primary ovarian cancer TME in vitro include ovarian cancer cell spheroid cultures on synthetic
matrices [41], on ECM [9], in low-adherent plastics, in hanging-drops, or in spinner flasks [42–44].
While these 3D systems lack a primary stromal cell component, their multi-component concept is
more faithful to the TME than cells grown in a monolayer on plastic. Utilization of such systems in
numerous studies elucidating the mechanisms of drug resistance demonstrate that they can be used as
predictive preclinical models [41,45–48].
6. Challenges and Future Perspectives
6.1. Picturing the Prototype Ovarian Cancer TME Model
Developing an ideal model for the ovarian cancer TME is not straightforward. Multiple TMEs with
varying components mean that a minimum of four models are likely required: in situ carcinoma in the fallopian
tube; dissemination in the peritoneal cavity; early metastatic attachment to the mesothelial-lined
surfaces of the omentum, bowel, and abdominal wall; and late chemoresistant metastases. Each
complete model will first require the comprehensive characterization (e.g., by immunohistochemistry)
of the associated stromal cells and ECM components, the growth factor and metabolite milieu, and,
if applicable, the flow rate. Once the components of each TME have been characterized, the primary
cells and ECM will need to be isolated, followed by reconstruction of the tissue of interest, with the
aid of a bioprinter or synthetic matrices that can be degraded by cells once they form their own ECM
architecture. Functionality of the model will then have to be verified. One option for this may be to
confirm that the in vitro secreted proteins are analogous to those of the in vivo secretome, for example
in terms of drug response or activation of immune cells. Each of these phases of model development is
a significant undertaking, and the current models do not come close to the in vivo scenario in terms of
the variety of cell types that are involved in each TME.
6.2. Future Directions
Multiple potential sites of origin and the continuously changing microenvironments at each
stage of the disease demand the development of more diverse (i.e., fallopian tube, ovary, peritoneum)
and complex 3D models of the ovarian cancer TME. Each phase of progression has a distinct TME
with specific components; for example, models of chemoresistance would include cancer-associated
fibroblasts [49], which are not included in the models of early metastasis discussed here. Each of the
models presented has its own advantages and limitations, leading us to propose that integration of
these models will be a first step towards a more accurate model.
Currently, the mesothelium model is the only 3D organotypic model of the ovarian cancer TME
that is utilized by multiple research groups [13]. The mesothelium model was designed to mimic the
tissue organization of the mesothelium that lines the human omentum and peritoneum. It recapitulates
the initial adhesion, migration, invasion and proliferation of ovarian cancer cells on the mesothelium
lining. This platform has been modified to investigate the individual and cooperative role of different
cell types in the TME on ovarian cancer progression. It has evolved and been adapted for HTS of over
100,000 small molecule compounds which could potentially identify new therapeutics for prevention
of ovarian cancer metastasis.
The organotypic models discussed here are restrained from reaching their full potential due
to the limitations of working with primary tissue, including access to the tissue and the lifespan of
the 3D models, the absence of other essential primary features such as vasculature [50,51], and the
inclusion of artificial ECM components. Vascularization appears to be next obvious step in advancing
the organotypic models towards the in vivo scenario. An elegant model of a vascularized TME
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was recently published by Magdeldin et al., in which the authors created a 3D model of the tumor
stroma using colorectal cancer cell spheroids, collagen hydrogels, the basement membrane protein
laminin, human dermal fibroblasts, and human umbilical vein endothelial cells (HUVECs) [52].
Customization of the stromal composition revealed that laminin was critical for regulating vascular
network formation, while the addition of the cancer cells to the model disrupted the interconnectivity
of the network. Jeon et al. reported on an organ-specific 3D microfluidic model to study human
breast cancer cell extravasation during metastasis [53]. In their microfluidic model, primary bone
marrow-derived mesenchymal stem cells (hBM-MSCs), osteo-differentiated primary hBM-MSCs,
and primary GFP-HUVECs were embedded in a fibrin gel in the microfluidic device. The endothelial
cells formed the vasculature, and the other cells contributed to a microenvironment that mimicked bone,
a frequent site of metastasis in advanced breast cancer. Addition of breast cancer cells to this modular
model enabled the authors to investigate the roles of the different components in extravasation.
Matrices incorporated into the models presented here are purified from other human, rat, or mouse
sources. Scaffold properties [54], including the concentration of ECM proteins, can affect the stiffness
of the artificial matrix; therefore, the accessibility of drugs in in vitro screening must also be considered
and optimized. Incorporation of perictyes and endothelial cells, as well as ECM from patient-matched
mesothelium or prolonged cultures where the microenvironmental cells secrete and organize their
own ECM, could clarify key mechanisms of metastasis, chemoresistance and recurrence. Bioprinting
has emerged as a very promising approach to in vitro 3D cancer models owing to its ability to create
complex 3D architectures [55].
Ultimately, 3D organotypic models of ovarian cancer aim to recapitulate but systematically
simplify the in vivo human microenvironment. Our hope is that by increasing the physiological
relevance of 3D organotypic microenvironment models of tumor initiation, primary tumor growth,
circulating tumor multi-cellular aggregates, different metastatic sites, and chemoresistant ovarian
cancer, the clinical significance of ovarian cancer research will be improved. If we want to offer
personalized medicine for ovarian cancer patients, we will also need to successfully establish ovarian
cancer organoids for biobanking, as observed with the establishment of organoid cultures in breast,
bladder and colorectal cancers [56–58]. By recreating the different TMEs in vitro, we can clarify the role
of the TME in the transformation of the original epithelial stem cells into metastatic and chemoresistant
cancer cells to ultimately prevent and effectively treat ovarian cancer.
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Abstract: Inflammation plays a role in the initiation and development of many types of cancers,
including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a type of
EOC. There are connections between EOC and both peritoneal and ovulation-induced inflammation.
Additionally, EOCs have an inflammatory component that contributes to their progression. At sites
of inflammation, epithelial cells are exposed to increased levels of inflammatory mediators such as
reactive oxygen species, cytokines, prostaglandins, and growth factors that contribute to increased cell
division, and genetic and epigenetic changes. These exposure-induced changes promote excessive cell
proliferation, increased survival, malignant transformation, and cancer development. Furthermore,
the pro-inflammatory tumor microenvironment environment (TME) contributes to EOC metastasis
and chemoresistance. In this review we will discuss the roles inflammation and inflammatory
mediators play in the development, progression, metastasis, and chemoresistance of EOC.
Keywords: inflammation; epithelial ovarian cancer; cytokines; reactive oxygen species; growth factors
1. Inflammation and EOC
Inflammation is part of the immune response that protects against foreign pathogens and aids
in healing. Inflammation is elicited in response to cellular damage either by infection, exposure
to foreign particles (pollutants or irritants), or an increase in cellular stress [1]. The ultimate goal
of the inflammatory response is to restore tissue homeostasis, either by destruction or healing of
the damaged tissue. The acute or immediate inflammatory response involves modification of the
vasculature surrounding the site of stress or damage to increase blood flow. This alteration is then
followed by activation of innate immune cells already present in the tissue, including macrophages,
dendritic cells (DC), and mast cells, and an increase in infiltration of additional innate immune cells
into the affected tissue. At sites of inflammation there are high levels of reactive oxygen species (ROS),
cytokines, chemokines, and growth factors that are produced by the immune cells and other cells in the
tissue. Acute inflammation is essential for tissue homeostasis and to protect against normal exposure
to pathogens. However, in certain cases the body is unable to resolve this response or is subjected to
repeated stimulation resulting in chronic inflammation.
Ovarian cancer (OC) is the fifth leading cause of cancer-related deaths in women in the United
States [2] and can originate in the germ cells, sex-cord stroma, the fallopian tube (FT), or ovary
epithelium. Epithelial ovarian cancer (EOC) which originates from the ovary or fallopian tube
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epithelium, accounts for 85–90% of all OCs. Chronic inflammation is an important risk factor associated
for EOC and high grade serous ovarian cancer (HGSC), the most malignant subtype of EOC. Chronic
inflammation results in activation of signaling pathways, transcription factors, and the innate and
adaptive immune responses [3,4]. In this review we primarily focus on inflammation as a risk factor
for invasive EOC, but have also included supportive evidence from other OC subtypes, studies that do
not define the subtype of OC, and other tumor types as indicated.
1.1. Signaling Pathways and Transcription Factors
Several signaling pathways and transcription factors involved in the inflammatory response also
play critical roles in EOC. Here we briefly introduce relevant pathways that will be linked to OC
formation in later sections. Cytokines produced during inflammation bind to and activate toll like
receptors (TLRs) on cell surfaces, which results in activation of the signaling pathways involving
mitogen-activated protein kinases (MAPKs) p38 and JNK (c-Jun N-terminal kinase) and transcription
factors including nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and the signal
transducer and activator of transcription (STATs). The MAPK pathway regulates cellular processes
like proliferation, differentiation, growth, migration, and cell death by upregulating the expression
of transcription factors like AP-1, c-Jun, FOS and by activating NF-κB and STATs, that either by
themselves or along with AP-1 or c-Jun regulate expression of pro-survival and pro-growth genes.
NF-κB and AP-1 also regulate production of cytokines like IL-6 [5–7].
During inflammation these transcription factors play an important role to maintain tissue
homeostasis. However, in case of chronic inflammation, the signaling pathways are continuously
stimulated, which can contribute to tumorigenesis.
1.2. Innate Immune Response
Inflammation activates the innate immune response, which signals macrophages and DCs
to secrete chemoattractants like Interleukin-8 (IL-8), monocyte chemotactic protein-1 (MCP-1),
and various other inflammatory mediators. These chemoattractants in turn result in recruitment
of neutrophils, lymphocytes, and natural killer (NK) cells to the site of damage. All of these cells
then secrete cytokines like IL-1, IL-3, IL-6, IL-8, tumor necrosis factor alpha (TNF-α), interferon (IFN)
α, and colony-stimulating factors (CSF) like granulocyte macrophage CSF (GM-CSF). The cytokines
bind to transmembrane receptors on the cell surfaces of other cells to activate transcription factors
that regulate gene expression downstream of the cytokine activated pathway. This creates a
pro-inflammatory environment resulting in recruitment of other immune cells, migration of endothelial
cells, and proliferation of fibroblasts. Activation of macrophages and NK cells results in the production
of high levels of ROS and reactive nitrogen species (RNS), which are used by these cells to kill foreign
pathogens, but also end up damaging neighboring normal cells [8]. The lymphocytes also secrete
growth factors like platelet derived growth factor (PDGF), transforming growth factor beta (TGF-β),
and fibroblast growth factor (FGF), which facilitate wound healing. Overall the acute immune response
is a rapid response that typically only lasts a few days. It results in removal of the pathogen, release of
proteolytic enzymes to destroy damaged tissue, or stimulation of the proliferation of fibroblasts and
epithelial cells to repair the tissue [1].
1.3. Adaptive Immune Response
If the infection is not resolved by the innate immune response, the adaptive immune response
is activated, which is less inflammatory in nature. The adaptive immune response also provides
longstanding protection against specific pathogens and/or antigens. B cells and T cells are the
effector cells of the adaptive immune system that are derived from lymphocytes when they are
presented with specific antigens by the antigen presenting cells (APC). T cells respond to the APCs by
producing IL-2, which induces expression of transcription factors that facilitate T cells to differentiate
into T regulatory (Tregs) and T effector (Teff) cells. There are two major classes of T effector cells;
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CD8+ cytotoxic T cells and CD4+ T helper (Th) cells. Th cells are further differentiated into Th1, Th2,
or Th17 depending on the ILs secreted and the transcription factors expressed. IFN-y activates STAT1
to induce formation of Th1 and IL-6, and TGF-β can induce Th17 cell formation. Th1 and Th17 secrete
ILs and activate macrophages and B cells to create a pro-inflammatory microenvironment (ME) that
can be protumorigenic depending on the context. Tregs are immunosuppressive cells that turn off the
immune response [1,9,10].
2. Inflammation as a Risk Factor for EOC
Amongst other factors such as hereditary, environmental, and lifestyle, inflammation emerges
as an important risk factor for EOC. EOC arises either in the epithelial layer surrounding the ovary
or in the epithelium of the distal FT, which could then spread to the ovary. A significant portion
of HGSC is thought to originate in the FT, in part because removal of the FT significantly reduces
OC risk [11]. Interestingly, while surgical specimens from mutation carriers rarely had premalignant
ovarian epithelial changes, early lesions called serous tubal intraepithelial carcinomas (STICs) were
found in the FTs of 5–10% of the patients. Copy number and mutational analysis suggest that STICs
shed cells with metastatic potential that then colonize the ovary to form HGSC. STICs are mostly
found in the fimbriae, the distal end of the FT that shares a ME with the ovary. During a woman’s
lifetime, the repeated secretion of ROS, cytokines, and other growth factors by the ovaries and immune
cells creates a chronic inflammatory ME in the peritoneum that in turn potentiates the initiation of
normal cells to malignant ones in the FT and the ovary, supports tumor progression, metastasis,
and development of resistance to chemotherapy.
During ovulation, infection and other causes of inflammation ovary and FT tissue is damaged and
undergoes repair. We will briefly discuss how each of these processes evoke or involve an inflammatory
response that can persist, leading to a cytokine and growth factor rich environment in the peritoneum
and contribute to EOC.
2.1. Ovulation
The process of ovulation itself is comparable to that of inflammation as described in the early 20th
century. The development of the follicle to its rupture and release of the egg results in recruitment of
activated immune cells to the ovary and production of enormous amounts of chemokines, cytokines,
and growth factors. Ovulation is initiated by a surge of Luteinizing hormones (LH) that results in
increased blood flow to the ovarian follicles. Before release of the egg, the surge of LH hormone recruits
neutrophils and macrophages to the graafian follicles [12–14]. Macrophages in the theca have been
shown to support growth of follicles [15]. During ovulation macrophages secrete growth factors like
hepatocyte growth factor (HGF), TGF-β, and epidermal growth factor (EGF), which stimulate cellular
proliferation and follicle growth. Simultaneously the macrophages also secrete ROS, TNF-α, and IL1β,
which stimulate local apoptosis resulting in rupture of the follicle, which bathes the ovarian surface
and fimbriae with follicular fluid. Exposure of FT cells to follicular fluid results in altered expression
of genes associated with inflammation, including increased expression of IL8 and cyclooxygenase-2
(COX-2) [16]. Quiescent fibroblasts are present in the thecal layer surrounding the follicles. Exposure
to growth factors stimulates their proliferation and they then secrete prostaglandins, collagenases,
and plasminogen activator. In the corpus luteum, after the follicle is released, the macrophages secrete
prostaglandins, ROS, and TNF-α, which stimulate apoptosis of the corpus luteum cells. Therefore,
ovulation results in the cyclic exposure of FT and ovarian epithelial cells to high levels of ROS,
cytokines, and growth factors [17] Although the other causes of inflammation discussed below are
important and result in increased overall risk for EOC, the process of ovulation itself occurs often in
the lifetime of the majority of women and may be the most important inflammation-related risk factor
for EOC. This hypothesis is corroborated by the laying hen model, which is commonly used to study
ovarian cancer [18]. In this model, hens develop spontaneous EOC, likely due to their high ovulation
rate, thus linking ovulation directly as an increased risk factor for EOC. Delayed onset of menarche
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and early onset of menopause have been shown to be inversely related to the risk of OC, likely due
to the reduction in number of ovulation cycles in a woman’s lifetime [19,20]. Further, ovulation has
also been connected to EOC because contraceptive pills, pregnancy, and breastfeeding reduce the
risk of OC. These factors reduce, halt, or delay overall ovulation cycles, respectively, which in turn
reduces overall exposure to inflammation of the ovary and FT. The associations of parity and oral
contraceptive use with invasive EOC were recently confirmed in a large, prospective study using
the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort that found only
limited heterogeneity in the risk between reproductive factors and EOC subtypes [21]. Hysterectomy,
tube ligation, and removal of ovaries are also protective against development of OC [22,23].
2.2. Infection
Pelvic inflammatory disorder (PID) is the infection of the female reproductive organs like cervix,
uterus, FTs, and ovaries. It is a significant risk factor for OC and is caused by various bacteria and virus
such as Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae, human papilloma virus,
and cytomegalovirus [24,25]. Infection by these microbes results in DNA damage and production of
ROS and induces a pro-inflammatory response, which involves secretion of cytokines and migration of
immune cells [24]. PID is generally resolved with antibiotics within 48–72 hours of detection. However,
repeated infection and unresolved inflammation can lead to chronic inflammation that is a risk factor
for EOC.
2.3. Other Sources of Inflammation
The other causes of inflammation in the ovaries and/or FTs are endometriosis, obesity, Polycystic
Ovarian Syndrome (PCOS), and talc exposure. Endometriosis is defined as presence of stroma and
endometrial gland tissues in the pelvic peritoneum, rectovaginal septum, and ovaries [26]. Retrograde
menstruation is the most commonly accepted theory for endometriosis. Retrograde menstruation
results in aberrant accumulation of red blood cells (RBCs) and tissue, which can trigger an inflammatory
response, activating the macrophages in the peritoneal cavity [27,28]. The macrophages lyse the
RBCs, resulting in an increase in iron accumulation in the endometric implants and peritoneal fluid.
The accumulated iron can catalyze formation of free radicals like RNS and ROS in the peritoneum
and results in increased oxidative stress (OS). OS can activate NF-κB, in macrophages resulting in
secretion of growth factors, cytokines, and IFNs. Around one third of women are affected by mild
endometriosis, which resolves on its own over time. For the remaining cases, endometriosis results in
chronic pain and inflammation, which can be resolved by excision of affected tissue or the outgrowth.
However, in 45% of these cases, the endometriosis reoccurs resulting in repeated bouts of chronic
inflammation [29,30].
Obese women have higher risks of EOC and HGSC and pro-inflammatory cytokines are associated
with higher body mass index (BMI) levels. Adipose tissues secrete the cytokines TNF-α, IL-6, IL-8,
and MCP-1, which can induce an inflammatory reaction in the peritoneum [31]. Continuous secretion
of these cytokines leads to a state of chronic inflammation, which includes activation of macrophages
and recruitment of NK cells and results in high levels of OS. Once the tumor has been initiated,
the continuous secretion of cytokines by adipose tissue or omentum can facilitate migration of cancer
cells to the omentum, promoting metastasis of the tumor into the peritoneum [30]. High levels
(>10 mg/L) of C-reactive protein (CRP), a marker of global inflammation, are associated with an
increased risk of EOC [32,33]. IL-6 itself is not a risk factor for EOC but in obese women IL-6 and CRP
may be associated with increased EOC risk [33].
PCOS also contributes to inflammation in women and may increase risk of EOC [34]. PCOS
is a hormonal disorder occurring in reproductive aged women during which ovaries may develop
numerous small collections of fluid and fail to release eggs properly. Obesity, hyperandrogenism,
and increased insulin resistance further characterize PCOS. Increased C-Reactive protein (CRP) and
MCP-1 levels, indicative of low-level chronic inflammation, are elevated in women with PCOS [35–38].
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Simultaneously chemokines like IL-18, IL-6, and TNF-α are also increased in circulation in women with
PCOS [39–42]. The increase in inflammatory mediators correlates positively with BMI, suggesting that
increased obesity in women with PCOS may be the source of inflammation. Increased DNA damage
and OS is observed in women with PCOS, which may also increase risk for EOC [43]. Evidence linking
PCOS directly to EOC is limited due to small study sizes, PCOS being associated with other EOC risk
factors such as obesity, and PCOS possibly being only associated with one subtype of EOC, borderline
serous [44].
Talc is a silicate mineral and exposure to it can cause inflammation of the ovaries and poses a
risk hazard for development of EOC [45]. It has been proposed that talc from talcum powder used
for dusting and from condoms and vaginal diaphragms can migrate up to the ovaries via retrograde
flow of fluids and mucous and get lodged in the ovaries. Tubal ligation, which is protective for EOC,
is thought to block the transport off talc from the lower genital tract. Talc behaves as a foreign particle,
triggering an inflammatory response [46,47]. The talc attracts macrophages, which try to phagocytose
it. The macrophages then send chemotactic signals to other immune response mediators and initiate a
wound healing process. Since talc is not degradable by the body, it inhibits the wound healing process,
resulting in chronic inflammation.
2.4. NSAIDS and Reduced Risk of EOC
Further connecting inflammation to EOC are several studies that demonstrate that intake of
non-steroidal anti-inflammatory drugs (NSAIDs), specifically of aspirin, correlates inversely with risk
of OC and endometrial cancer [48–52]. In vitro studies with OC cell lines and NSAIDS show that
NSAIDs and COX-2 inhibitors facilitate apoptosis, however this effect is not dependent on COX-2
and may be due to upregulation of p21, a protein important for cell cycle arrest [53]. Another study
by Arango et al., demonstrates that acetylsalicylic acid or aspirin resulted in increased apoptosis via
downregulation of Bcl2 in an endometrial cancer cell line [54]. A third study has shown that a selective
COX-2 inhibitor, JTE-522, can inhibit proliferation and increase apoptosis of endometrial cancer cells
by increasing levels of p53 and p21 and decreasing phosphorylation of retinoblastoma (Rb) protein,
which results in its activation; all of which results in cell cycle arrest [55,56]. Simultaneously, there was
an increase in caspase-3 activity, which is indicative of increased apoptosis. Another mechanism by
which aspirin could facilitate its chemopreventive nature is by inhibiting oxidative induced DNA
damage [57]. COX-1 is also expressed in normal ovaries of the laying hen, with expression increasing
in post-ovulatory follicles suggesting its importance for or a role in ovulation. With the onset of
OC, COX-1 expression is increased [58] and COX-1 inhibition and NSAIDs have shown to decrease
proliferation of ascites in the laying hen OC model [59]. Further, when 0.1% aspirin was included
in their diet for one year, although the onset of OC was not different, the progression of cancer was
slower when compared to hens fed with regular diet [60].
As discussed, inflammation results in secretion of ROS, growth factors, cytokines, and chemokines
into the shared environment surrounding the ovary and distal FT. Exposure of normal tissue to
these inflammatory mediators results in activation of downstream signaling that can promote the
transformation of normal cells or survival of already transformed cells. Once EOC has already
formed further exposure of cancer cells to these inflammatory mediators also results in activation of
downstream signaling within the cancer cell and in the surrounding tissue, creating an inflammatory
environment that can further promote EOC (Figure 1). We will discuss in more detail how key
inflammatory mediators contribute to EOC initiation, progression, metastasis, and chemoresistance.
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Figure 1. Sources of inflammation in the ovary and fimbriae. Ovulation, retrograde menstruation,
endometriosis, infections, exposure to talc, Polycystic Ovarian Syndrome (PCOS), and obesity result
in exposure of the ovary and fimbriae to reactive oxygen species (ROS), oxidative stress, cytokines,
and growth factors, generating an inflammatory response that leads to additional production of ROS
and cytokines in the ovary. Unresolved, chronic inflammation is a critical risk factor for tumor initiation.
3. Inflammation and EOC Initiation and Progression
Tumorigenesis is a multistep process that requires cells to gain the ability to evade apoptosis and
antigrowth signals, proliferate independently of stimuli, develop a support system (angiogenesis),
and have the capacity to invade and metastasize. Tumorigenesis is initiated by the transformation of a
normal cell to a malignant one. The deregulation of the above mentioned processes in the malignant
cell could potentiate its progression to cancer.
One mechanism of cancer initiation is genomic instability due to DNA damage [61] and EOCs
exhibit a high number of chromosomal aberrations and genomic instability [62]. The most common
gene mutations in HGSCs include BRCA, TP53, and genes in involved in mismatch repair and the DNA
damage response [63]. A pro-inflammatory ME can also contribute to genetic instability and therefore
play a role in EOC cancer initiation. A pro-inflammatory ME, which is continuously supplemented
by ROS, cytokines, and growth factors, can cause DNA damage in epithelial ovarian and FT cells,
switch on antiapoptotic pathways, and initiate transformation of normal cells. When cells transformed
either by oncogenic alterations or by exposure to inflammation are in a pro-inflammatory ME they
are able to turn on pro-survival signaling pathways rather than the senescence pathways that are
normally induced by oncogene expression in normal cells. For example, disruption of the RAS
pathway results in activated NF-κB signaling and upregulation of its downstream targets including
cytokines like IL-1β, IL-6, and IL-8. These cytokines are upregulated in EOC patients and their
increased levels correlate with decreased survival [64–71]. The inflammatory mediators like cytokines,
chemokines, growth factors, and prostaglandins secreted by the transformed epithelial cells further
promote a pro-inflammatory environment, which can reprogram the surrounding cells to form the TME.
The TME is mainly composed of endothelial cells, cancer associated fibroblasts (CAFs), adipocytes,
tumor associated macrophages (TAMs), regulatory T-cells, pericytes, infiltrated immune cells such as
neutrophils, lymphocytes, and various other cells that further secrete growth factors and cytokines
which potentiate tumor progression (Figure 2, Table 1). Furthermore, OC-initiating cells (OCICs)
have been identified in tumors and ascites that exhibit stem cell like properties and are capable of
forming tumors [65,66,72]. Cytokines can promote self-renewal of CD133+ OCICs to potentiate tumor
progression [73].
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Figure 2. Inflammatory mediators contributing to EOC progression, metastasis, and angiogenesis.
EOC cells produce ROS, chemokines, cytokines, and growth factors that can: (1) Lead to recruitment of
immune cells like Dentric cells (DC), Natural killer cells (NK), Tumor associated macrophages (TAMs),
and T-regulatory (Treg) cells into the TME, which generate additional cytokines, ROS, and growth
factors, resulting in chronic inflammation. (2) Stimulate the tumor cells themselves, the TAMs, and the
surrounding fibroblasts (also known as cancer associated fibroblasts or CAFs) to proliferate and secrete
growth factors like TGF-β and FGF that stimulate production of integrins and Matrix Metalloproteins
(MMPs), resulting in migration of the tumor cell via degradation of the extra cellular matrix (ECM).
(3) Stimulate endothelial cells (EC) to produce growth factors like PDGF and EGF and factors like
VEGF that stimulate angiogenesis. The double arrows indicate that the cells are a source of the factor
as well as stimulated by it.
The innate immune response can prevent tumorigenesis by recognizing and eliminating
transformed cells. However, chronic inflammation can contribute to the ability of premalignant
cells to evade apoptosis, escape the immune surveillance, and continue to grow, resulting in tumor
formation. As mentioned, EOC can originate from either distal FT or ovarian epithelial cells. Since both
the ovary and fimbria are exposed to the same ME, exposures reviewed here are relevant to initiation
in either tissue. [74]. In this section we will review the role of OS and some specific pro-inflammatory
mediators and signaling pathways in the initiation and progression of EOC.
3.1. ROS and Oxidative Stress
ROS plays an important role in the normal female reproductive cycle, from affecting maturation of
the oocyte to ovulation, apoptosis of cells in corpus luteum, and embryo development [75]. Ovulation
results in increased levels of DNA damage in the FT epithelium that is likely a result of the ROS
generated during ovulation or the ovulation-associated increase in numbers of infiltrating macrophages
in the FT [17]. Additionally, during infection and inflammatory responses immune and damaged cells
produce ROS resulting in continuous exposure of the ovaries, FTs, and peritoneal cavity to ROS [76–78].
ROS exposure could potentially lead to epithelial cells in the ovary and FT undergoing transformative
changes, as has been demonstrated for ovarian surface epithelium cells grown in 3D culture [79].
Elevated ROS and RNS levels beyond the level that cells can neutralize results in OS. Increased OS
results in DNA damage, activation of signaling cascades, and epigenetic alterations.
DNA damage in a cell results in stimulation of DNA damage repair pathways. These repair
pathways can be inactivated or be erroneous, which results in increased genotoxic stress and mutated
DNA. Secretory tubal epithelial cells in the FT, a cell of origin for HGSC, are particularly susceptible to
genotoxic injury with persistent DNA damage that could lead to mutation and STIC formation [80].
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Mutations in tumor oncogenes and suppressors result in overexpression, constitutive activation of
the protein, loss of expression, or expression of nonfunctional proteins, resulting in a transformed cell.
Follicular fluid may have transformative properties as it has been demonstrated that bathing fimbriae
with follicular fluid containing high levels of ROS results in increased levels of DNA damage. Bathing
fimbriae that have loss of p53 and Rb with this follicular fluid results in evasion of apoptosis and cells
with persistent DNA damage [81].
ROS can activate pro-survival intracellular tyrosine phosphorylation signaling cascades, mainly
regulated by the MAPKs and redox sensitive kinases. Activation of c-Jun, JNK, ERK (extracellular
signal-regulated kinase), and p38-MAPK signaling cascades results in upregulation of cell cycle
proteins that enhances proliferation. Activation of JNK can also activate NF-κB, which can suppress
apoptosis. The MAPK pathway inhibits apoptosis and regulates differentiation. When activated in
transformed cells these pathways are important for tumor initiation. ROS affects redox sensitive
factors like thioreoxin, which is also found elevated in OC cell lines [82]. Thioredoxin is involved in
redox regulation of transcription factors such as NF-κB, NRF2, forkhead box class O (FOXO) proteins,
reducing factor-1 (ref-1), and hypoxia inducible factor (HIF-1α), thereby increasing their binding to
the DNA. Most of these transcription factors promote tumor growth and progression by regulating
expression of genes that affect cell survival and growth [83,84]. For example, FOXO, NRF2, and ref-1
transcription factors upregulate transcription of anti-oxidant proteins that scavenge free radicals and
allow survival of damaged or transformed cells [85]. HIF-1α upregulates the antiapoptotic factor,
bcl-2 as well as vascular endothelial growth factor (VEGF), a factor important for angiogenesis.
OS has also been shown to facilitate epigenetic mechanisms in many cancers, including EOC [86].
Innate immune-mediated inflammation drives epigenetic silencing of tumor suppressor genes
(TSGs) [87]. At sites of inflammation high levels of OS result in oxidative DNA damage that is
recognized by the mismatch repair proteins mutS homolog MSH2 and MSH6. MSH2 and MSH6 then
recruit epigenetic silencing proteins, including DNA methyltransferase 1 (DNMT1) to the sites of
damage [88]. In an in vivo model of inflammation-driven colon tumorigenesis this early recruitment
to sites of oxidative DNA damage results in permanent methylation of TSGs in tumors that form
at the sites of inflammation [89]. While such a mechanism has not been directly proven in EOC
models, Sapoznik et al. have demonstrated that exposure to follicular fluid or inflammation can
induce Activation-Induced Cytidine Deaminase (AIDS) in fallopian tube epithelial cells, which results
in epigenetic and genetic changes, increase in DNA damage and genotoxic stress and may be a
contributing factor to EOC [90].
3.2. TNF-α
The cytokine TNF-α plays an important role in the process of ovulation and in removal of
damaged corpus luteum. TNF-α ligand and its receptors, TNFRI and TNFRII are upregulated in
ovarian tumors compared to normal ovarian tissue and high levels of TNF-α are found in ascites from
OC patients [91–93]. OC cells have also been shown to secrete high levels of TNF-α as compared to
normal ovarian epithelial cells resulting in autocrine upregulation of TNF-α mRNA and in expression
of other pro-inflammatory cytokines, chemokines, and angiogenic factors like IL-6, M-CSF, CXCL2,
CCL2, and VEGF [93,94]. Kellie et al. have shown using mouse models that TNF-α stimulates
IL-17 production via TNFRI resulting in myeloid cell recruitment to the ovarian TME and increased
tumor growth [95]. TNF-α, also upregulates AIDS transcript levels which can contribute to genotoxic
stress [90].
3.3. IL-6
The cytokine IL-6 has been associated with poor survival in OC and is emerging as a potential
therapeutic target for EOC [67,68,96,97]. IL-6 is normally produced by ovarian epithelial and OC cells.
Macrophage migration inhibitory factor (MIF), EGF, and Transglutaminase secreted by OC cells can
stimulate IL-6 production via activation of NF-κB [98–100]. IL-6 increases proliferation of OC cells by
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facilitating their exit from G1 into S phase of the cell cycle and by activation of the MAPK-ERK-Akt
(protein kinase B) growth promoting signaling pathway [101]. ERK activation can promote formation
of ascites by increasing the migration of tumor cells [70]. IL-6 production by M2 macrophages present
in ascites in later stages of EOC can also stimulate cancer cell proliferation via STAT3 activation [102].
High levels of IL-6 can result in immune suppression by downregulation of IL-2, which stimulates Teff
cell production [103]. IL-6 also stimulates production of Metallomatrix proteins (MMPs) in OC cells,
which increases their invasive properties and promotes tumorigenesis [101,104].
3.4. IL-8
IL-8 a member of C-X-C chemokine family is present in the preovulatory follicle [105] where it
may play a role in increasing leukocyte infiltration [106]. It is also elevated in ovarian cysts and in
OC patients compared to healthy controls [107,108]. IL-8 has been found to be present in significantly
higher levels in the ascites of patients with OC in comparison to patients with benign gynecological
disorders [109]. Increased IL-8 expression has been associated with poor prognosis in OC patients [107].
Treatment of EOC cells with IL-8 results in their increased proliferation, which is accompanied by an
increase in cyclins B1 and D1 and is dependent on phosphorylation of Akt and ERK [110]. Cyclins B1
and D1 are important for cell cycle progression, and an increase in their expression leads to increased
cell growth. On the other hand, two independent studies have demonstrated that IL-8 inhibits EOC
growth by increasing neutrophil infiltration [111,112].
3.5. Lyophosphotidic Acid (LPA)
LPA is a phospholipid that binds to and activates the endothelial differentiation gene (Edg) family
of receptors. LPA is present in ovarian follicular fluid and it stimulates IL-6 and IL-8 production in the
corpus luteum [113,114]. OC cells have been shown to produce LPA, which functions like a growth
factor [115–119]. Plasma and ascites of OC patients have elevated levels of LPA that contribute to OC
progression via upregulation of COX-2 and MMP2 [115,120,121]. LPA can bind to LPA2 receptor and
induce expression of IL-6 and IL-8 via activation of NF-κB and AP-1 in OC cell lines [122]. It can induce
ROS dependent Akt and ERK phosphorylation and inhibition of LPA can increase apoptosis of EOC
cells [123]. ERK phosphorylation can induce phosphorylation of HIF-1α, which then can upregulate
VEGF and promote tumorigenesis. Another group demonstrated that stimulating EOC cells with
ether-linked LPA resulted in their increased proliferation and survival by increased synthesis of DNA
and activation of Akt via PI3K, which contributes to tumor progression [124].
3.6. Prostaglandins and COX-1 and COX-2
Prostaglandins are secreted in the ovary, FT, and uterus. They are important for maturation
of the oocyte and facilitate the movement of the FT so that the mature oocyte can move from the
ovary to the uterus. In the uterus prostaglandins help regulate and maintain uterine blood flow.
COX-1 and COX-2 are enzymes that catalyze the production of prostaglandins from arachidonic
acid and are overexpressed in OC patients [22,125,126]. High COX levels positively correlate with
increased cell proliferation, angiogenesis, and malignancy in ovarian tumors [126,127]. COX-1 and
COX-2 are normally involved in the acute inflammatory response but can become dysregulated in
chronic inflammatory or TMEs. Obermajer et al. have demonstrated that prostaglandins produced
by COX-2 can stimulate production of CXCR4 and its ligand Stromal cell derived factor 1 (SDF1)
CXCL12 in myeloid derived suppressor cells (MDSC), which stimulates them to migrate towards
OC ascites [128]. MDSCs inhibit the proliferation and differentiation of T cells, resulting in overall
immune suppression, which allows the tumor cells to escape immune surveillance and continue to
grow. Genetically engineered mouse models of EOC; one harboring the p53 and Rb deletion and other
the KRASG12D mutation and Pten deletion, demonstrate increased COX-1 levels, thus suggestive that
COX-1 could be used as a potential biomarker and therapeutic target for EOC [129]. Further when
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COX-1 was inhibited in EOC cells, it led to reduction in prostacyclin (a type of prostaglandin) synthesis
and reduced tumor growth by enhanced apoptosis [130].
4. Inflammation and EOC Angiogenesis
Angiogenesis is required for the growth of both primary and metastatic tumors [131]. The process
of angiogenesis is a complex multi-step process reviewed previously [132]. It is regulated by a balance
between pro-angiogenic and antiangiogenic factors. Hypoxic and ischemic areas are present at sites
of inflammation and also in tumors mainly due to obstruction of local blood vessels, differences
in pace of growth of blood vessels and growth of the tumor and/or infiltration of immune cells.
Macrophages accumulate at hypoxic sites and alter their gene expression profiles in response to the
hypoxic conditions. One of the important genes for angiogenesis that is upregulated by hypoxia is
VEGF [133,134]. The rate-limiting step in angiogenesis is VEGF signaling in endothelial cells (ECs) [135].
VEGF functions via tyrosine kinase receptors VEGF-1 and VEGF-2 and promotes migration, survival,
proliferation of ECs, and formation of new blood vessels [136–138]. Many of the inflammatory
mediators discussed so far are also involved in promoting angiogenesis in EOC as detailed below
(Figure 2, Table 1).
4.1. TNF-α
TNF-α creates a pro-inflammatory TME and has also been associated with promoting angiogenesis.
It has been hypothesized that TNF-α induces the production of soluble factors that promote tumor
angiogenesis. Culture supernatants from TNF-α expressing cells induce the growth of mouse
lung endothelial cells in vitro while culture supernatants from TNF-α lacking cells do not exert
the same effect [94]. In pituitary adenomas TNF-α is known to induce VEGF that in turn induces
CXCL12 [139,140]. VEGF and CXCL12 synergistically induce angiogenesis in EOC [141]. Mice injected
with OC cells lacking TNF-α have reduced vascular density in their tumors and reduced formation of
blood vessels in the peritoneal deposits. These mice also did not have accumulation of ascetic fluid
suggesting the importance of TNF-α in angiogenesis and EOC progression [94].
4.2. IL-6
In physiological conditions, IL-6 is involved in angiogenesis in the ovary during the development
of ovarian follicles [142]. IL-6 induces the phosphorylation of STAT3 and MAPK in ovarian endothelial
cells thereby enhancing their migratory ability, a key step in angiogenesis [143]. As explained before,
OC cells also secrete increased amounts of IL-6. Some OC cells also secrete an alternative splice variant
of IL-6Rα, the soluble form sIL-6R, which consists of only the ectodomain of the transmembrane
receptor. By a process called trans-signaling, the sIL-6R-IL-6 complex initiates signaling in cells in the
ME that do not express the transmembrane receptor facilitating angiogenesis [144].
4.3. IL-8
Several studies have clearly established the role of IL-8 in promoting angiogenesis. Hu et al.,
demonstrated that IL-8 plays a role in angiogenesis using a rat sponge model [145]. IL-8 was also
able to induce angiogenesis in the rat cornea, which is normally avascular [146]. As explained in
the previous section, there are several sources of IL-8 in ovarian TME. Overexpression of IL-8 in
A2780 (non-IL-8 expressing) OC cells has been shown to increase the expression of VEGF, MMP-2,
and MMP-9; while depletion of IL-8 in SKOV3 (IL-8 expressing) cells has been shown to reduce VEGF,
MMP-2, and MMP-9 [110]. The process of angiogenesis involves degradation of extracellular matrix
components and proliferation and migration of endothelial cells. MMPs are a family of endopeptidases
that breakdown components of extracellular matrix and have been implicated in angiogenesis [147].
Because of the importance of VEGF and MMPs in angiogenesis these findings suggest that IL-8 in the
ovarian TME will promote the formation of new blood vessels in EOC. Targeting IL-8 using mouse
models reduces EOC growth and decreases angiogenesis [112].
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4.4. LPA
In addition to playing a role in initiation, and progression, LPA has also been implicated in
angiogenesis in OC. LPA has been shown to induce transcriptional activation of VEGF in EOC cell
lines [163]. Transcriptional activation of VEGF primarily occurs through HIF-1α under oxygen limiting
conditions in Hep3B hepatocellular carcinoma cells [164]. LPA mediated induction of VEGF expression
has been shown to be independent of HIF-1α in EOC cell lines. Transition metal cobalt treatment also
leads to stabilization of HIF1α similar to hypoxia. Combination treatment of EOC cells with cobalt
and LPA additively increased VEGF production suggesting the effect of two different pathways [155].
LPA activates c-Myc and Sp-1, which induce VEGF expression through consensus binding sites in the
VEGF promoter that have been implicated in HIFα independent induction of VEGF [155].
5. Inflammation and EOC Metastasis
Tumor metastasis is the major cause of mortality in most cancers, including EOC. Most EOC
patients are diagnosed at an advanced stage when the cancer has already metastasized [165].
Dissemination of cancer cells to distant sites is a complex multi-step process called the
invasion-metastasis cascade and is reviewed in detail in previous papers [166–168]. Briefly, some major
steps in metastasis are—invasion through the basement membrane, intravasation into the lymphatics
and circulation, survival of disseminating cancer cells in circulation, extravasation into surrounding
tissues, colonization, and finally, formation of micro and macro metastases. However, unlike other
epithelial malignancies, EOC has a different pattern of metastasis. EOC cells directly shed from the
primary tumor into the peritoneal space and disseminate to organs in the peritoneal cavity. One of the
prerequisites for cancer cells to metastasize is to undergo a process called epithelial to mesenchymal
transition (EMT) where they lose their ability to attach to the basement membrane and acquire
a mesenchymal phenotype and characteristics. Several recent evidences have indicated that the
TME aids tumor cells to acquire these properties facilitating the metastatic cascade. An example of
the ME promoting metastasis is the presence of STICs in the distal part of the FT, which shares
its ME with ovary. Yang-Hartwich et al. have demonstrated that granulosa cells in the ovary
secrete SDF-1 (stromal cell-derived factor 1) [169]. SDF-1 functions as a chemoattractant and recruits
malignant FT cells to the ovary suggesting that the ovary is a primary site of metastasis, not the
primary tumor site. Russo et al. demonstrated that loss of PTEN (phosphatase and tensin homolog)
by the malignant FT cells and upregulation of WNT4 (wingless-related MMTV integration site 4)
is crucial for initial metastasis to the ovary thereby supporting the tubal origin of EOC and the
ovary as the primary site of metastasis [170]. The cells that make up the TME also secrete various
inflammatory mediators, which facilitate progression and metastasis of OC cells (Figure 2, Table 1).
These factors enable tumor metastasis by deregulating signal transduction pathways. Examples include
the PI3-Akt and RAS-ERK pathways, which control migration and invasion through downstream
effectors like Rho family GTPases, extracellular proteases, integrins, matrix associated proteins like
focal adhesion kinases (FAK), and transcription factors like ETS2 and AP-1 [171–173]. Robinson-Smith
et al. demonstrated that peritoneal inflammation correlated with dissemination of cancer cells from the
ovaries in SCID mice. Augmenting the inflammatory response using thioglycolate accelerated ascites
formation and metastasis while suppressing the inflammation using acetyl salicyclic acid impeded
ascites formation and reduced metastasis. This inflammation-induced metastasis of OC cells was
found to be primarily mediated by macrophages and not neutrophils or NK cells [174]. As explained
in one of the previous sections a pro-inflammatory environment can be created in the peritoneum
due to secretion of cytokines like IL-6 and TNF-α by adipose cells [31]. Omentum, the primary site of
metastasis of OC, is largely composed of adipose cells. In addition to adipocytes, omentum also consists
of blood and lymph vessels, immune cells, and stromal cells [175]. Adipocytes have been shown to
increase migration, invasion, and proliferation of EOC cells. Upregulation of SUSD2 a secreted tumor
suppressor by adipocytes by guadecitabine treatment reduced EOC migration and invasion. This
finding suggests that epigenetic changes in the stromal cells in addition to EOC cells can facilitate EOC
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metastasis [176]. Omentum has aggregates of immune cells around the vasculature commonly referred
to as milky spots [177]. Melanoma, lung carcinoma, ovarian carcinoma, and mammary carcinoma
cell lines have been shown to specifically metastasize to the immune cell aggregates in the omentum
when injected intraperitonealy into C57BL/6 mice [178]. These milky spots in the omentum have
also been shown to facilitate metastatic colonization of the OC cells. Clark et al. have suggested that
both adipocytes and milky spots have specific and important roles in metastatic colonization of OC
cells [179]. These evidences imply that omentum potentially provides a good niche for the growth of
ovarian cancer cells. Here we will specifically discuss how inflammatory mediators promote tumor
metastasis in EOC.
5.1. ROS
EOC cells produce a large amount of ROS [180]. Loss of E-cadherin is one of the characteristic
features of tumor cells with increased ability to migrate and invade. Wang et al. demonstrated that
ROS leads to HIFα mediated activation of lysl oxidase. Lysl oxidase was shown to inversely correlate
with E-cadherin expression promoting migration and invasion in EOC cells [181]. Tumor cells treated
with sub-lethal doses of H2O2 failed to attach to the extracellular matrix components fibronectin and
laminin and had increased metastatic colonization of lung, thereby establishing a role for ROS in tumor
cell metastasis [182].
5.2. TNF-α
TNF-α provides a good example of how interactions between cancer and stroma aid in OC
metastasis. Ascitic fluid and OCs contain a large number infiltrating macrophages in part because
OCs constitutively produce M-CSF, which functions as a chemoattractant for monocytes [183].
These infiltrating monocytes produce many cytokines one of which is TNF-α [184,185]. OC cells also
have elevated TNF-α expression that is regulated by DNA hypomethylation and chromatin remodeling
of the TNF-α promoter. Increased TNF-α produced by OC cells and macrophages stimulates increased
expression of TGF-α in stromal fibroblasts. TGF-α secreting stromal fibroblasts promote peritoneal
metastasis of OC via EGF receptor signaling [148].
Furthermore, in EOC cells and clinical biopsies TNF-α expression correlates with one of the most
commonly expressed cytokine receptors CXCR4. TNF-α stimulation of EOC cells enhanced their
migration toward the only CXCR4 ligand, CXCL12. Stimulation of EOC cells by CXCL12 induced
mRNA and protein expression of TNF-α. Therefore, a positive feedback loop has been suggested
where in CXCL12 induced TNF-α potentially acts on the cancer cells and induces CXCR4 expression
thereby enhancing tumor cell migration [149,150].
5.3. IL-6
IL-6 has also been implicated in metastasis of OC. Elevated levels of IL-6 found in serum and
peritoneal fluid of EOC and OC patients have many sources [186–188]. Mesothelial cells in the
peritoneum, TAMs, and EOC cells all secrete IL-6 [67]. M2 polarized macrophages in the ovarian
TME induce proliferation and invasion of EOC cells by secretion of IL-6 [189]. Increased IL-6 present
in ascites from OC patients enhanced the invasive ability of OC cells via the JAK-STAT signaling
pathway. Canonically IL-6 signaling occurs by binding of the ligand to its transmembrane receptor
IL-6Rα. The effect of IL-6 on invasion of OC cells correlated with their IL-6R expression [151]. Because
through trans-signaling, the sIL-6R–IL-6 complex initiates signaling in cells that do not express the
transmembrane receptor [144], we hypothesize that IL-6 produced by macrophages could also promote
invasion of OC cells similar to the mechanism of induction of angiogenesis.
5.4. IL-8
Increased proliferation, anchorage independent growth, and angiogenic potential are some
prerequisites for cells to metastasize. IL-8 increases the proliferation of OC cells and upregulates VEGF
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and MMP2 and 9 via activation of NF-κB, which results in enhanced invasive phenotype of OC cells.
IL-8 has been shown to activate TAK1/NF-κB signaling via CXCR2, thereby facilitating the seeding
and growth of OC cells in the peritoneal cavity during metastasis [153].
5.5. LPA
LPA promotes proliferation, survival, and metastasis of EOC cells by inducing the expression of
c-Myc, VEGF, IL-8, MMPs and COX-2 [163,190–193]. LPA acts through its receptors LPAR1-3, which are
members of G-protein coupled receptor superfamily. Invasive EOC cells have significantly higher
expression of LPAR1 in comparison to non-invasive cell lines and LPA induces EOC cell invasion
specifically through LPAR1 and not through LPAR2 or LPAR3 [194]. It can also induce secretion
of urokinase in EOC cells, which has been shown to play a role in metastasis and its high levels
correlate with advanced OC and poor survival in patients. LPA has been shown to increase promoter
activity, mRNA levels, protein levels, and enzyme activity of Urokinase plasminogen activator (uPA)
possibly via the edg-4 LPA receptor [156]. uPA is involved in converting plasminogen to plasmin,
which facilitates the degradation of basement membrane and extracellular membrane proteins like
fibronection aiding in metastasis [157].
5.6. TGF-β
TGF-β initiates signaling by dimerization of serine/threonine kinase receptors. The dimerization
of receptors results in their phosphorylation, which then relays signals downstream via SMAD
dependent and SMAD independent pathways. Phosphorylation by the TGF-β receptor causes
R-SMADs to bind to Co-SMAD and translocate to the nucleus, where they activate transcription
of genes that promote invasion, migration. Bone morphogenic proteins (BMPs) are cytokines that
belong to TGF-β family and have been associated with progression of many different cancer types.
Their mechanism of promoting tumor progression depends on the TME in which the cancer grows
and their mode of metastatic spread [195]. Specifically, BMP-2 overexpression has been associated
with poor prognosis in OC [196]. Additionally, TGF-β could potentially modify the TME to promote
tumorigenesis. Veriscan (VCAN), an extracellular matrix associated protein, was upregulated by TGF-β
through TGF-β receptor II (TGFBR2) and SMAD signaling making the EOC cells more aggressive.
Increased VCAN expression enhanced motility and invasion of EOC cells by activating NF-κB signaling,
increased expression of MMP-9, and hyaluronidase mediated motility receptor [160]. CAFs have higher
expression of TGF-β receptors in comparison to normal ovarian fibroblasts and EOC cells suggesting
that CAFs within the TME are more responsive to TGF-β then the other cell types [160].
6. Inflammation and EOC Chemoresistance
The standard treatment for EOC patients is cytoreductive surgery followed by platinum/
taxane-based chemotherapy [197]. The main obstacle in treatment of EOC patients is development
of chemoresistance. Resistance to chemotherapy can be either intrinsic or acquired. Inherent gene
expression patterns harbored by chemo-naïve tumor cells contribute to intrinsic resistance. Acquired
resistance is a consequence of different alterations induced after exposure to chemotherapeutic
agents [198]. Different mechanisms, including increased drug efflux, decreased uptake of the drug,
inactivation of the drug, increased DNA repair, and reduced apoptotic response, have been implicated
in development of platinum resistance [199]. Several recent studies have demonstrated that the TME
contributes to both intrinsic and acquired resistance. One type of intrinsic drug resistance influenced
by the TME is referred to as environment mediated drug resistance (EMDR). In EMDR, factors and
cells present in the TME activate diverse signaling events, transiently protecting the tumor cells
from undergoing apoptosis in response to chemotherapeutic agents [200,201]. Another type of drug
resistance induced by cytokines, chemokines, and growth factors secreted by fibroblast cells in the
tumor stroma is called soluble factor mediated drug resistance (SFM-DR). A good example of SFM-DR
is IL-6 mediated drug resistance in multiple myeloma. IL-6 is important for growth of multiple
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myeloma cells. IL-6 activates STAT3 signaling in these cells and protects them from Fas mediated
apoptosis by upregulating antiapoptotic protein Bcl-XL [202]. Myeloma cells that produced IL-6 in
an autocrine manner were found to be resistant to dexamethasone induced apoptosis while non-IL-6
producing cells were sensitive [203]. Cell adhesion mediated drug resistance (CAM-DR) occurs due to
adhesion of tumor cells to extracellular matrix components like laminin, collagen, and fibronectin or
due to fibroblasts present in the tumor stroma [204]. An example of this type of resistance is when drug
sensitive myeloma cells were adhered to an extracellular matrix component fibronectin, they exhibited
a reversible drug resistant phenotype which was not due reduced drug accumulation or increase in
antiapoptotic proteins like Bcl-XL [201]. Here we will discuss specific inflammatory mediators and
their role in OC chemoresistance (Figure 3).
Figure 3. Inflammatory mediators contribute to chemoresistance of EOC. A combination of platinum
and taxane drugs is currently used as chemotherapy for OC. ROS, Lyophosphotidic Acid (LPA),
cytokines, and growth factors like TGF-β and EGF increase tumor cell survival by upregulating
antiapoptotic genes, by stimulating stemness and proliferation of cancer initiating cells, by increasing
repair of damaged DNA, or by increasing efflux of the drug. The resistant tumor cells and the cancer
initiating cells can then proliferate under the influence of growth factors and cytokines resulting in a
recurrent chemoresistant tumor.
6.1. ROS
ROS are abundant in the pro-inflammatory TME. Malignant EOC tissues have been shown
to have 96% higher ROS levels than normal controls [205]. OC stem like cells or OCICs are more
drug resistant and responsible for relapse of chemoresistant tumors [66]. OCICs produce ROS and
superoxide. This ROS induces the expression of peroxisome proliferator-activated receptor-gamma
coactivator (PCG)-1α, which regulates mitochondrial biogenesis and is required for expression of
detoxifying enzymes [206,207]. PCG1α increases the aldehyde dehydrogenase (ALDH) activity and
expression of multidrug resistance gene (MDR1). MDR1 is an ATP dependent transporter that has
been associated with efflux of platinum based drugs from OC cells contributing to platinum resistance.
Scavenging ROS reduced expression of PCG1α and drug resistant related genes thereby linking ROS
to development of chemoresistance [207].
6.2. IL-6
IL-6 in the OC TME is associated with increased chemoresistance. Wang et al. demonstrated
that autocrine production of IL-6 by EOC cells makes them resistant to cisplatin and paclitaxel by
causing decreased proteolytic cleavage of capase-3. Paclitaxel resistant EOC cells have increased
expression of IL-6 and one of its downstream effectors STAT3 [208,209]. IL-6 producing OC cells also
had increased expression of multidrug resistant genes MDR1 and GSTpi and anti-apoptotic genes
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Bcl-2, Bcl-xL, and XIAP, suggesting that IL6 promotes drug resistance by increasing drug efflux and
reducing apoptosis [152].
6.3. IL-8
IL-8 blocks TRAIL-induced apoptosis and reduces caspase cleavage in EOC cell lines by decreasing
the expression of death receptor (DR) 4 [210]. TRAIL is a cell death inducing ligand that belongs to
the TNF superfamily and has been shown to induce apoptosis specifically in tumor cells and not in
nontransformed cells [211,212]. Combination of TRAIL and the chemotherapeutic drugs—cisplatin,
doxorubicin, and paclitaxel has been shown to induce apoptosis in chemoresistant EOC cell lines by
causing increased caspase and PARP cleavage [154]. This finding suggests that IL8 may contribute to
chemoresistance by blocking TRAIL.
6.4. LPA
LPA has been shown to contribute to platinum resistance by preventing cells from undergoing
cisplatin-induced apoptosis without affecting their proliferation rate. The mechanism of how LPA
inhibits apoptosis in EOC cells in response to cisplatin is not yet clearly understood [161].
6.5. TGF-β and EGF
Recurrent OC show significantly higher expression of TGF-β1 and TGF-β3 in comparison to
primary tumors and normal ovary tissue [213]. Inhibition of TGF-β by the inhibitor LY2109761
sensitizes resistant SKOV3 cells to cisplatin suggesting that TGF-β contributes to the development
of platinum resistance in EOC cells [162]. Cisplatin resistant A2780P cells had hypomethylation
and upregulation of TGFBR2 confirming the involvement of the pathway in acquisition of platinum
resistance [214]. An elevated level of EGF receptor (EGFR) has also been associated with poor prognosis
in OC patients [215]. EGF has been shown to stimulate the growth of EOC cells expressing EGFR and
alters their cell cycle distribution [216]. EGF similar to LPA has been shown to protect EOC cells from
undergoing cisplatin induced apoptosis [161].
6.6. COX-2
In addition to being associated with tumor initiation and progression, COX-2 has also been
associated with chemoresistance. Ferrandina et al. reported that a statistically significant higher
percentage of primary OC patients unresponsive to platinum-containing chemotherapy were positive
for COX-2 than responsive patients (84.6% versus 34.6%, respectively) [217]. The percentage of positive
COX-2 staining per tumor area in COX-2 positive patients ranged from 15 to 45%. The results from
this study suggest that COX-2 levels may influence the response of patients to different chemotherapy
regimens, but the sample size of this study was small and the results need to be confirmed in a larger
group of patients. Furthermore, this association needs to be corroborated biochemically [217]. In both
patients groups undergoing cytoreductive surgery and explorative laparotomy, COX-2 expression was
higher in nonresponders [218]. Using lung, colon, and prostate cancer models, COX-2 has been shown
to induce Bcl-2 and promote tumor growth by facilitating the formation of new blood vessels [158,159].
These findings suggest that COX-2 may contribute to chemoresistance by inhibiting apoptosis and
promoting angiogenesis in OC as well.
7. Treatment Strategies Targeting Inflammatory Mediators in EOC
As discussed, development of resistance to available chemotherapeutic drugs remains the major
obstacle in management of OC patients. While several immunotherapies have been developed to
improve the antitumor response of T-cells and/or modulate the immune response, here we will
discuss EOC treatment strategies that specifically target the inflammatory mediators that have been
reviewed above.
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A monoclonal antibody directed at VEGF, bevacizumab, has been widely studied and is a
promising target in EOC [219]. Bevacizumab is a recombinant humanized monoclonal antibody and
has been approved by the FDA for treatment of metastatic breast, non-small cell lung, and colorectal
cancer. Phase II clinical studies have shown that it is active in treatment of recurrent OC patients [220].
OCEANS trial was a randomized phase III clinical trial that evaluated the safety and efficacy of
bevacizumab in combination with gemcitabine and carboplatin (GC) in comparison with GC alone
in recurrent platinum sensitive ovarian, primary peritoneal, or FT cancer. This trial demonstrated
that bevacizumab was able to prolong the PFS in platinum-sensitive recurrent EOC patients [221].
In addition to OCEANS, GOG218, and ICON7 have also shown that bevacizumab prolongs the PFS in
OC patients confirming the promise this therapeutic target holds for management of OC [222,223].
We have discussed some mechanisms by which the pro-inflammatory cytokine TNF-α promotes
OC metastasis and angiogenesis making it a good target for development of therapeutic agents.
The safety profile and biological activity of a monoclonal anti-TNF-α antibody, Infliximab was assessed
in a clinical study consisting of patients with advanced solid tumors, including OC. Infliximab
did not have any toxic effects and was well tolerated by these patients. Reduced plasma levels
of IL-6 and CCL12 in these patients was observed 24 h and 48 h after administration of Infliximab,
while neutralization of TNF-α was detected after an hour indicating some biological activity [224].
This response warrants further study of Infliximab as a therapeutic agent for treatment of OC.
IL-6/STAT3 signaling has been implicated at different stages of OC progression and is a promising
target although most agents are still in preclinical or early clinical trial stages. Siltuximab, an anti-IL-6
antibody, suppresses IL-6-induced STAT3 phosphorylation and nuclear translocation in OC cell lines.
Siltuximab treatment also reduced the level of pro-survival proteins like Bcl-XL and Survivin, which are
downstream of STAT3. Siltuximab was able to sensitize paclitaxel resistant OC cell lines, but did not
show the same effect in vivo [225]. sc144 is a novel small molecule inhibitor has shown significant
promise in preclinical studies. sc144 binds gp130, which is a signal transducer in STAT3 signaling.
It causes phosphorylation of gp130 leading to its deglycosylation. This abrogates downstream STAT3
phosphorylation and nuclear translocation inhibiting transcription of downstream genes. sc144
has increased potency in EOC cells in comparison to normal epithelial cells and slows down the
growth of tumors in xenograft models of EOC [226]. A phase I clinical trial combining carboplatin,
the monoclonal antibody Tocilizumab, which blocks IL-6R, and immune enhancer INF-α showed good
promise. The EOC patients who received the highest dose of Tocilizumab had increased serum levels
of IL-6 and sIL-6R and also showed longer median overall survival [227].
We have discussed the role of TGF-β in EOC tumor progression substantiating it as a good
therapeutic target. A preclinical study of LY2109761 (TGFβRI and TGFβRII kinase inhibitor) in
combination with cisplatin was conducted by Gao et al. This inhibitor significantly increased apoptosis
in cisplatin resistant cells. Combining LY2109761 with cisplatin had antiproliferative effects and
increased the rate of apoptosis in parental and cisplatin resistant xenograft models [162]. In triple
negative breast cancer, LY2157299 a TGF-β1 receptor kinase inhibitor, prevented recurrence of tumors
in xenograft models after treatment with paclitaxel [228]. Early phase clinical trials of LY2157299 in
patients with advanced or metastasized pancreatic cancer have been completed. Early phase trials
in triple negative metastatic breast cancer, unresectable hepatocellular carcinoma, and metastatic
castration resistant prostate cancer are underway [229].
EGF has also been associated with chemoresistance in EOC. Cetuximab, a chimerized monoclonal
antibody that targets EGFR, was tested in combination with carboplatin in patients with recurrent
platinum sensitive OC. Cetuximab showed modest activity in these patients [230]. Panitumumab,
a human monoclonal antibody specific to EGFR, in combination with carboplatin did not improve
efficacy or progression free survival in platinum sensitive EOC patients [231].
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8. Conclusions and Future Perspectives
Several studies in the last decade have associated increased inflammation and inflammatory
mediators with increased EOC risk and reduced survival in EOC patients. We have presented
published evidence suggesting that inflammation and inflammatory mediators promote ovarian
tumorigenesis. However the mechanisms by which the process of inflammation culminates in ovarian
tumor initiation need to be further understood. Such links have been established in colon and
pancreatic cancer. Understanding these mechanisms is important for developing ways to target
inflammatory mediators and reduce OC risk. Furthermore, epidemiological studies of NSAIDs and
early clinical trials targeting IL-6 and TNF-α have shown significant promise, thus suggesting that
targeting inflammatory mediators as treatment for OC warrants future research.
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Abstract: Women with endometriosis are at increased risk of developing ovarian cancer,
specifically ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma. An important
clinical caveat to the association of endometriosis with ovarian cancer is the improved prognosis for
women with endometriosis at time of ovarian cancer staging. Whether endometriosis-associated
ovarian cancers develop from the molecular transformation of endometriosis or develop because
of the endometriotic tumor microenvironment remain unknown. Additionally, how the presence
of endometriosis improves prognosis is also undefined, but likely relies on the endometriotic
microenvironment. The unique tumor microenvironment of endometriosis is composed of epithelial,
stromal, and immune cells, which adapt to survive in hypoxic conditions with high levels of iron,
estrogen, and inflammatory cytokines and chemokines. Understanding the unique molecular features
of the endometriotic tumor microenvironment may lead to impactful precision therapies and/or
modalities for prevention. A challenge to this important study is the rarity of well-characterized
clinical samples and the limited model systems. In this review, we will describe the unique molecular
features of endometriosis-associated ovarian cancers, the endometriotic tumor microenvironment,
and available model systems for endometriosis-associated ovarian cancers. Continued research on
these unique ovarian cancers may lead to improved prevention and treatment options.
Keywords: ovarian cancer; endometriosis; tumor microenvironment; miRNA molecules; genes;
hypoxia; inflammation; model systems
1. Introduction
Endometriosis is a debilitating disease that is estimated to affect up to 5 million U.S. women and
girls. Endometriosis results in considerable morbidity, including pelvic pain, multiple operations,
infertility, and negative effects on psychosocial quality of life [1–5]. Unfortunately, endometriosis is
also a significant risk factor for development of ovarian cancer [6]. The presence of endometriosis
increases the risk of ovarian endometrioid, low-grade serous, and clear-cell adenocarcinoma by
up to 8.9-fold but not high-grade serous adenocarcinoma [7–12]. Thus, ovarian endometrioid,
low-grade serous, and clear-cell adenocarcinomas are considered endometriosis-associated ovarian
cancers. Ovarian cancer is considered a top-five cancer killer in U.S. women, claiming more than
14,000 lives in 2015 [13]. Therefore, 5 million U.S. women and girls with endometriosis are at risk for
developing deadly ovarian cancer. Fortunately, ovarian endometrioid and clear-cell adenocarcinoma
represent roughly 20% of all ovarian cancers and account for less than 10% of deaths [14–16]. Clinically,
studies suggest that co-occurrence of endometriosis with ovarian cancer is associated with an improved
prognosis [17–20]. Important factors in this improved prognosis include discovery at early age and
early stage disease in women with endometriosis at time of ovarian cancer staging [21–24], but may
also represent the unique biology from the endometriotic tumor microenvironment. This review will
focus on the contributions of the endometriotic tumor microenvironment to ovarian cancer biology.
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2. Unique Molecular Features of Endometriosis-Associated Ovarian Cancer
Each histotype of epithelial ovarian cancer is thought to arise from a distinct precursor lesion.
For example, endometriosis is thought to give rise to both ovarian endometrioid and clear-cell
adenocarcinomas [25]. Recently, sophisticated proteomic tracing studies suggest that ovarian
endometrioid adenocarcinomas arise from secretory cells of endometriosis or the endometrium,
while ovarian clear-cell adenocarcinomas arise from ciliated cells. Importantly, it is hypothesized that
the unique cellular environment dictates the development of ciliated or secretory cells, which then
gain mutations to become malignant [26]. Recently, next-generation sequencing studies showed
mutations in cancer-driver genes (i.e., AT-rich interaction domain 1A (ARID1A), Phosphatidylinositol-4,
5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and Kirsten rat sarcoma viral oncogene
homolog (KRAS)) in deep infiltrating endometriotic lesions, supporting the idea that the endometriotic
microenvironment facilitates mutations [27]. Because deep infiltrating endometriotic lesions do not
pose a risk of malignant transformation, the unique contributions of driver mutations in these particular
endometriotic lesions are still relatively unknown [27]. Interestingly, these mutations in cancer-driver
genes were only present in glandular epithelium and not underlying stroma [27]. These data support
the idea that both epithelium and stromal populations of deep infiltrating endometriosis do not
represent similar clonal populations. Further, this data may represent the idea that unique stromal
populations are recruited to the area [28,29]. Detailed studies of unique genetic contributions of both
epithelial and/or stromal compartments in malignant transformation are needed.
Studies examining endometriotic lesions and ovarian cancer from the same patient have shown
concordant mutations in ARID1A, phosphatase and tensin homolog (PTEN), PIK3CA, and KRAS,
suggesting that mutations in endometriosis cause a predisposition to ovarian cancer [30–33].
Mutations in KRAS and ARID1A have been discovered in endometriosis, including ovarian
endometriosis and deep infiltrating endometriosis [27,34]. Loss of ARID1A is higher in atypical
endometriosis and non-atypical endometriosis adjacent to ovarian cancer than non-atypical
endometriotic distal lesions [30,32,35–39]. In general, both endometrioid and clear cell ovarian
cancer with or without endometriosis have common high frequency mutations in ARID1A, PIK3CA,
catenin betat 1 (CTNNB1), PTEN, and KRAS [33,40–45]. In terms of unique molecular features, 29% of
low-grade ovarian endometrioid adenocarcinomas with concurrent endometriosis contained mutations
in KRAS compared to 3% of low-grade endometrioid adenocarcinomas lacking endometriosis [33].
Importantly, Ishikawa et al. showed high frequency of ARID1A mutations and one patient with both
ARID1A and KRAS mutations in endometriosis-associated ovarian cancers [43]. The contributions of
both ARID1A and KRAS warrant further study in terms of endometriosis, the endometriotic tumor
microenvironment, and endometriosis-associated ovarian cancer.
In terms of low-grade serous tumors, an A to T substitution in BRAF has been identified in
36–68% of low-grade serous ovarian cancers and is associated with improved prognosis [46–48].
Additionally, increased expression of B-raf proto-oncogene, serine/threonine kinase (BRAF) was also
noted in eutopic and ectopic endometrium of women with endometriosis when compared to control
endometrium [49]. The contributions of BRAF to endometriosis and endometriosis-associated ovarian
cancers, specifically, low-grade serous ovarian cancers are understudied.
In addition to mutational changes, epigenetic changes play a role in both endometriosis
and endometriosis-associated ovarian cancers. Methylation changes in both endometriosis and
endometriosis-associated ovarian cancer have recently been reviewed [50,51]. Along those lines,
endometriosis tissues have decrease expression of ten-eleven translocation genes (TET1, TET2,
and TET3), which convert 5-methylcytosine to 5-hydroxymethlcytosine and play a role in changes
in levels of 5-hydroxymethylcytosine marks in endometriosis tissues and blood [52]. Unfortunately,
the authors did not assess 5-hydroxymethlcytosine marks in specific genes. Further studies are needed
in endometriosis-associated ovarian cancer to examine changes in these and other alternative DNA
marks. MicroRNA (miRNA) molecules, which are also considered epigenetic changes, are dysregulated
in endometriosis (reviewed in [53]). While dysregulated miRNAs in epithelial ovarian cancers have
351
Cancers 2018, 10, 261
been recently reviewed [54,55], dysregulated miRNA molecules in endometriosis-associated ovarian
cancers have not been individually reviewed. Given that miRNA molecules can be secreted from cells,
we have included miRNA molecules under endometriotic tumor microenvironment (below).
A challenge to studies on the endometriotic tumor microenvironment is the rarity of clinical
samples of ovarian cancer with concurrent endometriosis and the rigor of details provided for
patient characterization. Given over 22,000 women will be diagnosed with ovarian cancer in
2016 [13], only 10% will be endometrioid and roughly 10% will be clear-cell [14–16]. Additionally,
a majority of women with endometriosis-associated ovarian cancers do not have endometriosis
at time of staging. Roughly 30% of ovarian endometrioid or clear-cell adenocarcinomas will
have concurrent endometriosis, further narrowing the number of tumors to study with concurrent
endometriosis [56–59]. Many studies do not describe the patient population in terms of absence or
presence of endometriosis, leaving readers to believe that the women may not have endometriosis,
which may not be accurate. Efforts for data harmonization for rare tumors may improve
reproducibility. Using well-characterized samples, Banz et al. used transcriptome microarray analysis
to evaluate normal ovary, endometriomas, and endometrioid ovarian cancer with and without
endometriosis [60]. The results showed a small group of cytokines dysregulated in ovarian cancers
with endometriosis, consistent with the inflammatory milieu of endometriosis [60]. Additionally,
Zhang et al. showed a unique gene signature in ovarian endometrioid adenocarcinoma with
concurrent endometriosis compared to ovarian endometrioid adenocarcinoma without concurrent
endometriosis [61]. Highly dysregulated signaling pathways included nuclear factor kappa B
(NFkB), transforming growth factor beta (TGFβ), and KRAS signaling [61]. Most likely there are
contributions from genetics and epigenetics that may be mediated from the endometriotic tumor
microenvironment [62]. However, further studies are needed to examine how endometriosis affects
ovarian cancer.
3. The Unique Endometriotic Tumor Microenvironment
While the pathogenesis of endometriosis is still largely poorly understood, the most
accepted theory is the implantation theory following retrograde menstruation (reviewed in [63]).
Most menstruating women have retrograde menstruation [64], but only 10% have endometriosis [1–3],
suggesting that unique conditions occur in women with endometriosis. The endometriotic
microenvironment contains multiple cell types—endometrial epithelial cells, stromal fibroblasts,
endothelial cells, and immune cells—as well as inflammatory mediators, metabolic waste products
such as iron from the breakdown of red blood cells, steroid hormones, and small RNA molecules. Thus,
it is not surprising that the conditions found in endometriosis are also advantageous to the growth and
development of ovarian cancer. However, very little is known about how these stressful conditions
directly affect ovarian cancer. In this section, we will describe these important factors within the scope
of endometriosis and how these important factors pertain to ovarian cancer. Figure 1 summarizes
graphically key players in the endometriotic tumor microenvironment as it pertains to ovarian cancer.
3.1. Hypoxia and Endothelial Cells
Hypoxia is thought to be critical to the survival and invasion of endometriotic cells through
multiple mechanisms including autophagy [65–68], TGFβ signaling [69], and signal transducer
and activator of transcription 3 (STAT3) signaling [70–72]. In endometriosis, hypoxia stabilizes
hypoxia inducible factor-1α (HIF1A) which downregulates dual-specificity phosphatase-2 (DUSP2)
directly and indirectly through miR-20a [73]. Ultimately, this downregulation leads to increased
angiogenesis and proliferation through activation of extracellular signal-regulated kinase (ERK)
signaling cascades [73,74]. As such, molecular immunohistochemistry shows a high correlation
between precursor endometriosis lesions and matched clear-cell adenocarcinomas for expression of
HIF1A and phosphorylated mechanistic target of rapamycin kinase (P-mTOR) [75]. Importantly,
vascular endothelial growth factor (VEGF), leptin (LEP), cysteine rich angiongenic inducer 61
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(CYR61), and osteopontin (SPP1) work together in response to hypoxia to establish a local vascular
network within the endometriotic lesion [74]. In addition to neoangiogenesis mediated through
HIF1A, as endometriotic lesions undergo hypoxia and inflammation from repeated menstrual cycles,
the expression of tissue factor increases. Tissue factor is a critical protein for extrinsic coagulation
cascade, leading to hypercoagulation. Clinically, women with clear-cell ovarian cancer have more
frequent venous thromboembolism [76]. Hypoxia may also lead to cellular proliferation through
estrogen receptor, leptin, and prostaglandin modulation [77]. These studies suggest that the hypoxic
microenvironment of endometriosis plays a role in not only the potentiation of endometriosis by
promoting cell proliferation and nutrient availability through vascularization but may also play
roles in outcomes for women with clear-cell ovarian cancer. The increased expression of HIF1A in
endometriosis may represent a novel therapeutic target for endometriosis or ovarian cancer [78].
3.2. Fibroblasts and Extracellular Matrix Components
Endometriosis is pathologically complex, containing endometrial epithelial and stromal fibroblasts
outside the uterine cavity, alongside invading hemosiderin-laden macrophages [79]. The endometriotic
extracellular matrix (ECM) plays a significant role in paracrine/autocrine signaling between
epithelial and stromal cells [80–83]. Studies have shown unique functional properties of primary
cultures of human endometrial stromal fibroblasts from women with endometriosis compared to
cultures from women without endometriosis. Specifically, fibroblast cultures from women with
endometriosis have a deficiency in decidualization, the differentiation process by which the uterus
prepares for pregnancy [84]. Additionally, these fibroblasts from women with endometriosis have
increased ERK signaling, high proliferative potential from progesterone resistance, and acquire an
inflammatory phenotype [85–89]. While the importance of stromal-epithelial crosstalk is noted in
embryo implantation in the uterus [80], the role of similar crosstalk in endometriosis or epithelial
ovarian cancers is still understudied but may represent a key component of the endometriotic
tumor microenvironment.
To examine the tumor microenvironment in ovarian cancer, Zhang et al. used computer-aided
image analysis and showed that the number of cancer-associated fibroblasts, as indicated by cells
positive for smooth muscle antigen, was higher in epithelial ovarian cancers compared to benign
adnexal masses. Unfortunately, the specific histology of ovarian cancers and the pathology of the
benign adnexal masses were not described in these studies. Large numbers of similarly staining
cancer-associated fibroblasts were also found in omental metastatic lesions [90]. Co-culture of
cancer-associated fibroblast with ovarian cancer cell lines (SKOV3, CAOV3) led to increased invasion
and migration when compared to ovarian cancer cell lines grown in co-culture with normal
fibroblasts [90]. One of the main questions regarding cancer-associated fibroblasts is how and why
they are becoming activated to benefit tumor cells. Mitra et al. proposed that ovarian cancer cells
reprogram fibroblasts into cancer-associated fibroblasts through miRNA expression changes [91].
Specifically, cancer-associated fibroblasts have a significant downregulation of miR-31 and miR-214
and upregulation of miR-155. C-C motif ligand 5 (CCL5), a chemokine known to be highly upregulated
in ovarian cancers, is a direct target of miR-214. Similarly, endometriomas have high expression of
chemokines and dysregulated miRNA expression [92]. Advancements in the understanding of the
role of non-epithelial ovarian cancer cells in ovarian cancer may lead to better treatments which block
tumor promotion brought on by tumor adjacent cells.
3.3. Immune Cells and Inflammatory Mediators
Dysregulated inflammation plays a key role in endometriosis-associated pathology [93].
For example, Capobianco and Rovere-Querini provide an in-depth review of the role of macrophages
in endometriosis, showing a relationship between components of the endometriotic microenvironment
such as high iron, hypoxia, and angiogenesis with macrophage recruitment and activation [94].
Additionally, a syngeneic mouse model of endometriosis showed that endometriotic lesions failed to
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grow without macrophages, and if macrophages were removed after implantation, angiogenesis was
halted, blocking the progression of the endometriotic lesion [95]. Further, Canet et al. suggest
that retainment of a specific macrophage population in endometriomas, the cell division cycle 42
(CDC42)-positive population, protects endometriomas from malignant transformation [96]. Similarly,
platelet factor 4 (PF4) also known as chemokine (C-X-C Motif) ligand 4 (CXCL4) is highly expressed
on macrophages in endometriomas, but not on tumor-associated macrophages of clear cell ovarian
cancers [97]. Thus, specific details of the macrophage population in endometriosis and ovarian cancer
are important and require further study.
Transcriptomic work on endometriomas showed that the inflammatory cytokine transforming
growth factor beta 1 (TGFβ1), regulates other inflammatory mediators relevant to endometriosis,
including tumor necrosis factor alpha (TNFα) and interleukin-6 (IL6) [92]. These inflammatory
mediators are highly elevated in peritoneal fluid from women with endometriosis [98–101]. The acute
and chronic inflammation of endometriosis is a response to the invading tissue, leading to the release
of regulated on activation normal T cell expressed and secreted (RANTES), monocyte chemotactic
protein-1 (MCP1), and interleukin-8 (IL8), which act as chemoattractants recruiting more macrophages
to the area [102]. In terms of the endometriotic tumor microenvironment, the promotion
of tumor invasion via macrophages may be dependent on TNFα [103], which is elevated in
women with endometriosis [98,99]. Along the same lines, work using an estrogen receptor
beta (ERβ)-overexpressing syngeneic mouse model of endometriosis suggests that non-genomic
effects of ERβ play a role in the TNFα-mediated dysregulation of endometriosis progression [104].
Encouragingly, treatment of a syngeneic mouse model of endometriosis with a long-acting
TNFα-blocking agent decreased endometriotic implant size [105]. However, treatment of women with
rectovaginal nodules with infliximab, a TNFα monoclonal antibody, had no improved clinical effect
over placebo [106]. Understanding the immune response to misplaced endometrial tissue will be a large
factor in understanding the onset and progression of endometriosis and lead to a better understanding
of how endometriosis creates a unique and potentially tumor-promoting microenvironment.
3.4. Altered Metabolism
Endometriotic cysts contain blood. When blood is metabolized, heme and iron are released
into the microenvironment [107]. Because of this, endometriotic cysts contain higher iron levels than
other benign ovarian cysts [108]. Consequently, an iron-rich microenvironment can lead to increased
proliferation, DNA synthesis, and adhesion, and promote chronic inflammation, allowing for the
spread of endometriosis [107]. High iron also leads to excessive oxidative stress, which creates a
microenvironment conducive to the induction of mutations and has been linked to cancer development
in the liver and lung [107,109]. Shigetomi et al. outlines how endometriotic cells under oxidative
stress from excess iron are able to bypass cell cycle checkpoints after DNA damage by overexpressing
hepatocyte nuclear factor-1 beta (HNF1B), which activates forkhead box transcription factors and alters
miRNA expression promoting cell survival [110]. Due to the excess iron exposure, endometriotic cysts
have higher expression of lactose dehydogenase, lipid peroxidase, and 8-hydroxy-2′-deoxyguanosine.
High expression of these markers of oxidative stress link endometriosis, high iron, and higher
frequencies of gene mutations [108]. These data corroborate the hypothesis that endometriosis
produces a high iron microenvironment that may lead to increased DNA damage through oxidative
stress, but also promotes cell survival, leading to a highly mutated subpopulation of cells that continue
to grow [111].
Alongside high iron levels, endometriotic peritoneal fluid has elevated lactate. Further,
endometriotic lesions express high levels of glycolysis genes compared to eutopic endometrium [112].
Increased expression of HNF1α in the endometriotic peritoneum leads to the conversion of glucose to
lactate in a process known as the “Warburg Effect,” known for its promotion of cell survival in stressful
microenvironments [113]. Lipidomics has also been pursued for understanding the metabolomic
profile of the endometriotic microenvironment. Lipid profiling studies on endometrial aspirates
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have shown a reduction of saturated diacylglycerols and triacylglycerols in endometriosis patients
compared to healthy controls [114]. In fact, this study generated a panel of 123 metabolites which
were differentially expressed in endometriosis women and correctly identified 86% of samples to
either the endometriosis or control group [114]. A similar study on endometrial biopsies used five
lipid metabolites as biomarkers and were able to predict endometriosis with 75% specificity and
90.5% sensitivity [115]. A true model of the endometriotic tumor microenvironment should include
increased iron levels, higher levels of glycolysis-associated proteins, and endometriosis-associated
lipidomic profiles.
Figure 1. Composition of the endometriotic tumor microenvironment. Endometriosis represents a
pathologically benign disease. Endometriosis may be classified into endometriomas, superficial peritoneal
disease, or deep infiltrating endometriosis (invasion > 5 mm). Although deep infiltrating endometriosis
is invading, typically into the muscularis layer of the bowel, it is clinically not associated with
ovarian cancer. Endometriomas are epithelial lined cysts of the ovary, which can be filled with a
brown cyst fluid, and thus the name “chocolate cysts.” Endometriomas can be associated with
ovarian cancer, with atypical endometriomas having a higher risk of malignant transformation.
Atypical endometriomas are characterized by epithelial cells with enlarged hyperchromatic and
pleomorphic nuclei, with cellular crowding and high nuclear-to-cytoplasmic ratio. The altered
endometriotic tumor microenvironment may lead to malignant transformation or propagation of
proliferative potential [107]. RANTES: regulated on activation normal T cell expressed and secreted;
MCP1: monocyte chemotactic protein-1; IL: interleukin; TGFβ1: transforming growth factor beta 1;
TNFα: tumor necrosis factor alpha; CDC42: cell division cycle 42; CXCL4: chemokine (C-X-C motif)
ligand 4.
3.5. Steroid Hormones
Endometriosis is an estrogen-responsive disorder with lesion-level hyperestrogenism. Specifically,
endometriotic tissue differs from eutopic endometrial tissue by the high expression of aromatase
(CYP19A1) and 17β-hydroxysteroid-dehydrogenase (17β-HSD) type 1 and the absence of 17β-HSD
type 2 [107,116]. Aromatase converts androstenedione or testosterone to estrone and estradiol at
the level of the endometriotic microenvironment. High levels of estradiol have been linked to IL8
and RANTES production, which facilitate proliferation, inflammation, and feedback to increased
expression of aromatase [107,117]. Aromatase activity is also stimulated through prostaglandin E2,
an inflammatory product of cyclooxygenase 1 and 2 (COX1/2), found in endometriotic lesions in
high levels [118]. Inhibitors of prostaglandin E2 receptor show promising effects in a xenograft model
of endometriosis [119]. At the endometriotic lesion level, there is significant feed forward production
and maintenance of estrogen, associated with pro-tumorigenic qualities. Medical management
of endometriosis with oral contraceptives lowers overall steroid hormone levels. This may explain
why the protection from combined oral contraceptive therapy on ovarian cancer risk is more robust
for women with endometriosis (odds ratio 0.21 (0.08–0.58), p = 0.003) compared to non-endometriosis
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population (odds ratio 0.47 (0.37–0.61, p < 0.001)) [120]. Thus, the role of steroid hormones on
endometriosis-associated ovarian cancers needs further study.
3.6. Small RNA Molecules
Small RNA molecules are non-coding RNA molecules that can play an important role in the
post-transcriptional regulation of gene expression. Multiple groups of small RNAs have been
identified, such as microRNAs (miRNAs), small nucleolar RNA (snoRNAs), small interfering
RNAs (siRNAs), and Piwi-interacting RNA (piRNAs) [121]. The most studied type of small RNA
molecules in endometriosis-associated ovarian cancers are miRNAs. In general, miRNAs regulate
gene expression by mRNA cleavage and translational repression [122,123]. Studies have shown
that miRNAs are frequently dysregulated in endometriosis and endometriosis-associated ovarian
cancers (reviewed in [53–55]). Compilation of dysregulated miRNAs in ovarian endometrioid and
clear-cell adenocarcinomas, as well as endometriosis (Supplemental Table S1) shows dysregulated
miRNA molecules for each tissue type [53,55,124–133]. Figure 2 shows the number of miRNAs
dysregulated in ovarian clear-cell and endometrioid adenocarcinomas, and endometriosis tissues.
Supplemental Table S1 details the specific miRNA molecules in the each unique and overlapping
group. MiR-126 was found downregulated in all three groups. While the function of miR-126 is
still unknown, miR-126 was significantly downregulated in endometriosis compared with eutopic
endometrium [134]. Additionally, downregulation of miR-126 induced non-ovarian cancer cell
proliferation, migration, and invasion, mediated through numerous validated targets, such as PI3K,
KRAS, and VEGF. Reduced levels of miR-126 were a significant predictor of poor survival of cancer
patients, although women with ovarian cancer were not included in the study [135]. Thus, miR-126 may
play a role in endometriosis and ovarian cancer, even though these functional studies did not have
ovarian cancer samples with concurrent endometriosis.
Figure 2. Venn diagram of overlap of number of miRNAs differentially expressed in endometriosis and
ovarian clear-cell and endometrioid adenocarcinoma. The miRNAs differentially expressed are depicted
in three overlapping circles. The numbers indicate the miRNA counts that are unique or in common
between the groups. (A) Upregulated miRNAs; (B) downregulated miRNAs. Supplemental Table S1
details the miRNAs in each group above.
MiR-30a, miR-30c, miR-31, miR-532-5p, and miR-885-5p were upregulated in clear cell ovarian
cancer by multiple studies [124–127,131,132]. MiR-30 was found to be 5-fold overexpressed in
ovarian clear-cell adenocarcinoma [132]. Sestito et al. showed that overexpression of miR-30a
delayed tumor formation in xenograft tumors, and overexpression of miR-30a sensitized ovarian
cancer cells to chemotherapy [136]. Downregulation of miR-532 was associated with poor survival
in women with ovarian cancer, and overexpression of miR-532 suppressed the proliferative and
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invasive capacity of the ovarian cancer cell lines, ES2 and SKOV-3, and inhibited tumor growth
in vivo [137]. Endometrioid ovarian cancer had the shortest list of dysregulated miRNAs (Figure 2
and Supplemental Table S1). MiR-200 family miRNAs (miR-200a, -200b, -200c, -141, and -429) were
upregulated in ovarian cancer and may play crucial roles in ovarian cancer metastasis, diagnosis,
and treatment [126,129,130,138].
4. Model Systems for Studying Rare Ovarian Cancers
Multiple model systems have been employed to study endometriosis and endometriosis-
associated ovarian cancers (reviewed in [139,140]). This review will highlight the tumor microenvironment
of the genetically engineered mouse models of endometriosis-associated ovarian cancers. We have
chosen to focus on spontaneous models instead of transplant models (reviewed in [140]). Because there
has yet to be a comprehensive mouse model that replicates ovarian cancer with endometriosis,
this review will also focus on the role of immortalized cell lines, xenograft models, co-culture systems,
and three-dimensional (3D) models.
4.1. Genetically Engineered Mouse Models
4.1.1. Candidate Genes in Genetically Engineered Mouse Models
High-grade serous ovarian cancer is a genomically complex disease [141] and although neither
endometrioid nor clear-cell ovarian cancer have been as extensively profiled, they are likely complex
as well. For the study of genetically engineered mouse models, fortunately, both endometrioid and
clear cell ovarian cancer have high frequency mutations in only a handful of genes: ARID1A, PIK3CA,
CTNNB1, PTEN, and KRAS [33,40–42,44,45]. Use of traditional Cre recombinase technology with
candidate-gene floxed alleles has had mixed results in terms of single gene knockout developing
endometriosis-associated ovarian cancers. Table 1 lists the promoters driving Cre recombinase,
and Table 2 details the brief rationale behind the use of specific genes in these mouse models. Table 3
lists these genes with combinations of tissue-specific promoters driving Cre recombinase. Despite the
promising allele targets and the tissue-specific promoters driving Cre recombinase, there are no genetic
mouse models of endometriosis and concurrent ovarian cancer. Investigators have created genetically
engineered mouse models, which developed ovarian low-grade serous, clear-cell, or endometrioid
adenocarcinoma (Table 3). However, none of these models have concurrent endometriosis.
This suggests that different genetic combinations are required to model concurrent endometriosis
and ovarian cancer. The discussion below highlights the role of the microenvironment of each model,
and how this microenvironment may be playing a role in ovarian cancer development. Even though
the presented models do not completely represent the endometriotic tumor microenvironment, they are
still useful for understanding development of endometrioid or clear-cell ovarian cancer.
Table 1. Cre recombinase promoters and site of effects.
Cre Gene Promoter Location of Expression Ref.
Adenovirus (Ad) Cytomegalovirus Injection site [142]
Amhr2 Anti-Mullërian hormonereceptor type 2
Oviduct: stroma
Uterus: stroma and smooth muscle cells
Ovary: granulosa cells and ovarian surface epithelium
[143,144]
Cyp19 Cytochrome P450 family 19 Granulosa cells of antral follicles and luteal cells [145]
Ovgp1 Oviductal glycoprotein 1 Non-ciliated oviductal epithelial cells [146]
Pax8 Paired box gene 8 Fallopian tube, cervix, uterus, and endometrium [147]
Pgr Progesterone receptor
Oviduct: epithelium
Uterus: epithelium, stroma, myometrium
Ovary: time-limited granulosa cells
[148]
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4.1.2. Endometriosis
The only genetically engineered mouse model to spontaneously develop endometriosis with a
single gene change is a highly innovative mouse model developed by Dinulescu et al. [162]. Using an
oncogenic KRAS knock-in allele mouse (KrasG12D), peritoneal endometriosis developed after injection
of adenovirus-driven Cre (AdCre) through the uterotubal junction to infect the ovarian bursa. This true
peritoneal endometriosis model contained glandular epithelium and stromal components validated
by molecular immunohistochemistry to cytokeratin 7, 8, and 20, estrogen receptor, progesterone
receptor, smooth muscle actin, and CD10 [162]. Conversely, when AdCre was injected through the
infundibulum to the ovarian bursa, the model develops ovarian endometriosis-like lesions without
the stromal component [162]. A transplantation experiment hints that the peritoneal endometriosis is
uterine or tubal in origin while the ovarian endometriosis-like lesions are ovarian surface epithelium
derived [162]. While long-term follow up showed no development of ovarian cancer, future studies
into the molecular lineage using secretory or ciliary markers may allow better definition of cell of
origin [26,62]. A similar mouse model adds human mucin 1 (MUC1) to oncogenic KrasG12D with
AdCre intrabursal injection [168]. This mouse model similarly exhibits endometriosis-like lesions of
the ovary. Importantly, these mice developed an immune response to MUC1 with high numbers of
CD4+ Foxp3+ regulatory T cells in para-aortic lymph nodes compared to uninjected mice without
lesions [168]. Models which recapitulate the immune response are needed to study the endometriotic
tumor microenvironment.
Because mice do not normally menstruate, modeling retrograde menstruation requires significant
manipulation. In homologous mouse models of endometriosis, endometrium from an estrogen-
primed donor mouse is injected into a syngeneic estrogen-treated recipient mouse. However,
homologous mouse models such as these grow poorly without exogenous estrogen [162]. A variation
is the menstrual mouse model. In this model, the donor mouse undergoes significant hormonal
manipulation followed by a stimulation of the uterus leading to decidualization. Hormone withdrawal
leads to degeneration of the endometrium with leukocyte invasion, similar to menstruation in
women [169–171]. Donor sloughed endometrium is then placed into recipient syngeneic mouse.
Using this approach, Cheng et al. placed oncogenic KrasG12V endometrial tissue into the subcuticular
ventral abdomen of syngeneic mice without exogenous hormonal stimulation or matrix [172].
These lesions contained glandular epithelium, stroma, immune cells, extracellular matrix, and blood
vessels with both estrogen receptor alpha and beta expression [172]. Similarly, Greaves et al. used a
similar approach with endometrial tissue from a menstrual model of wild type mice. Using hormonally
stimulated receptor mice, injection of tissue intraperitoneal with this non-genetically modified
endometrial tissue leads to peritoneal endometriosis [173]. Again, these tissues were histologically
and molecularly similar to human endometriosis [173]. Hormonal levels (i.e., endogenous versus
exogenous high levels), tissue placement (i.e., subcuticular versus intraperitoneal), and genetic changes
important to endometriosis-associated ovarian cancers (i.e., oncogenic KRAS, loss of function ARID1A)
must be considered when using these menstrual endometriosis models. Additionally, genetically
engineered mouse models that are unable to undergo decidualization such as PgrCre;Arid1af/f mice [160]
do not allow such studies.
4.1.3. Clear Cell Ovarian Cancer
Poorly differentiated clear-cell ovarian carcinoma develops at 7.5 weeks post-injection in
AdCre;Arid1af/f;Pik3ca*H1047R female mice with 77% penetrance and with 57% of injected mice having
peritoneal metastasis [157]. Similar deletion of ARID1A alone or with knock-in of Pik3ca mutations
showed ovarian surface epithelium hyperplasia but no endometriosis [157,158]. Although clear cell
features are present two weeks post-injection, endometriotic-like lesions are not described [157].
Microarray analysis, comparing primary ovarian tumors to contralateral un-injected ovary,
found almost 600 genes dysregulated with significant enrichment in immune system function [157].
Consistent with an endometriotic tumor microenvironment, IL6 signaling was found to be increased
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in the primary tumors, peritoneal metastases, body fluids, and ascites [157]. IL6 signaling and
tumor cell growth was blocked with IL6 neutralizing antibodies. While IL6 expression was also
implicated in normal ovarian surface epithelium hyperplasia with ARID1A deletion or Pik3ca mutation
alone, the combination further enhanced IL6 production [157]. Cross-species, global gene expression
profiling showed similar dysregulated genes in this mouse model compared to ovarian clear-cell
adenocarcinoma from women [174]. Together these data suggest that the deletion of ARID1A
and mutation in Pik3ca*H1057R results in increased IL6 expression leading to the ovarian surface
epithelial hyperplasia and eventually clear cell ovarian cancer. These tumor cells perpetuate IL6
production, creating a positive feedback loop of increased IL6 and increased cell (normal and cancerous)
proliferation [157,174]. This interaction highlights how the tumor and its microenvironment can interact
with one another to generate a more tumor-promoting environment.
4.1.4. Endometrioid
ARID1A, PIK3CA, CTNNB1, PTEN, and KRAS [33,40–42,44,45] are commonly mutated in
both endometrioid and clear cell ovarian cancers from women. However, manipulation of
these genes in mice typically results in endometrioid but not clear cell ovarian cancer.
On injection of adenovirus-driven Cre (AdCre) into the ovarian bursa through the infundibulum
of Ptenf/f;KrasG12D female mice generated female mice with 100% penetrance of highly aggressive
and metastatic endometrioid ovarian cancer at 12 weeks. Interestingly, this mouse model has ovarian
endometriosis-like lesions with either addition of oncogenic KrasG12D or deletion of Pten alone, but only
results in endometrioid ovarian cancer when both Pten and KrasG12D are simultaneously mutated [162].
A mouse model targeting both Pten and Apc resulted in endometrioid ovarian cancer with high
penetrance and metastatic disease [161]. Unfortunately, this conditional knockout (AdCre) did not result
in endometriosis, which may be due to the early (6-week post-injection) tumor development [161].
Another model of endometrioid carcinoma in mice utilized a double conditional knockout of Pten and
Arid1a and intrabursal AdCre injection to show a progression of ovarian surface epithelium hyperplasia,
endometrioid carcinoma, and finally poorly differentiated carcinoma [158]. The well-differentiated
endometrioid carcinoma was confined to the ovaries, suggesting the place of origin, while the
undifferentiated tumors had metastasized into the peritoneal cavity [158]. Guan et al. hypothesizes
that ARID1A plays a role in both tumor initiation and progression but requires the collaborative second
hit of Pten to produce tumors [158]. Although the hyperplasia was not linked to endometriosis in these
mice, it does speak to an environment of uncontrolled cellular proliferation giving rise to endometrioid
ovarian cancer when left untreated.
High nuclear β-catenin levels have uniquely been found in endometrioid ovarian cancer
from women, where this nuclear accumulation leads to activation of the WNT pathway [149].
Gain-of-function deletion of exon 3 of Ctnnb1 leads to stable β-catenin expression in mice [175].
Amhr2CreCtnnb1f/f female mice have aggressive endometrioid ovarian cancers with 100% penetrance
by 6 months. Addition of Pten deletion to this model allows for tumors that are even more aggressive
by 6 weeks [165]. Similar to deletion of exon 3 of Ctnnb1, deletion of Apc leads to stable β-catenin and
WNT signaling activation [149]. Only with deletion of Pten did mice develop ovarian tumors [161].
To model the progression of type I tumors to the more aggressive type II tumors, Wu et al. (2013)
added Pik3caE545K/+ to Apcf/f Ptenf/f mice with AdCre and showed peritoneal and lung metastasis [167].
While these models used Amhr2Cre or AdCre to focus genetic changes in the ovarian surface
epithelium, other studies have created conditional genetic changes in the oviduct. When Apc and
Pten were concurrently deleted in the fallopian tube using Ovgp1Cre, endometrioid tumors of the
ovaries developed in 10 of 15 mice, with 50% of those resulting in metastasis to the lungs or
omentum [146]. Deletion of Pten in the fallopian tube by Pax8Cre also resulted in endometrioid tumors.
Specifically, 75% of female mice developed primary tumors in the fallopian tube by 7 months, and 75%
of tumor-burdened mice had metastasis to the ovaries [147]. Deletion of Apc with PgrCre female
mice revealed tumors in both the oviduct and ovaries. Specifically, 25 of 40 female mice developed
361
Cancers 2018, 10, 261
endometrioid oviductal tumors, one of 43 developed granulosa cell tumors, and 12 of 43 developed
endometrioid ovarian tumors. While these female mice had simple ovarian cysts, the authors did not
specifically denominate them as endometriosis [166]. Taken together, these mouse models suggest that
the oviduct and/or the ovary may be involved in endometrioid cancer development in the mouse.
4.1.5. Low-Grade Serous Ovarian Cancer
Addition of oncogenic Kras (KrasG12D) with either Amhr2Cre or Cyp19Cre resulted in ovaries
with abnormal follicles, which were non-tumorigenic but also non-mitotic and non-apoptotic [145].
Deletion of Pten using Amhr2Cre did result in increased proliferation and increased cell survival
of ovarian surface epithelium [163]. However, the loss of the tumor suppressor Pten alone is
not tumorigenic in somatic cells of the ovary. When Pten is deleted in the context of oncogenic
Kras with Amhr2Cre, there is development of low-grade serous papillary cystadenocarcinoma [163].
Although no endometriosis was noted, these mice were shown to have ovarian surface epithelium
hyperplasia and abnormal follicle-derived ovarian lesions. Mullany et al. continued work on the
KrasG12D;Ptenf/f;Amhr2Cre mice and showed that ovarian surface epithelium cells, removed from mutant
mice prior to tumor formation, developed into tumors when grown in soft agar [143]. This key result
suggests that Kras and Pte// play a significant role in the development of tumors in the ovarian surface
epithelium, and the genetic mutations are the primary driver, since tumor formation occurred even
outside of the ovarian microenvironment [143].
4.2. Other Models
4.2.1. Immortalized Cell Lines
Immortalized human ovarian cancer cell lines have been widely used for studying molecular
mechanisms of ovarian cancer. Ovarian cancer cell lines are used to study cancer biology,
connecting genetic and epigenetic alterations to cancer development, progression, and drug response.
Importantly, ovarian cancer cell lines have been developed from different histological and molecular
subtypes of ovarian cancer. Unfortunately, molecular characterization has revealed that common
ovarian cancer cell lines (i.e., SKOV3, HEYA8) do not molecularly represent the histology of tumor
of origin. The number of cell lines derived from either endometrioid or clear cell ovarian cancers is
more limited than high-grade serous cell lines. However, molecular profiling, including attention to
gene mutations common in these endometriosis-associated ovarian cancers (i.e., ARID1A, PIK3CA,
CTNNB1, PTEN, and KRAS) and mutations common in high-grade serous (i.e., TP53), have allowed
better molecular and biological distinction [176–182]. Table 4 shows the common endometrioid and
clear-cell ovarian cancer cell lines, including lines that were not derived from endometriosis-associated
ovarian cancers, but which may molecularly represent non-high grade serous cell lines. Even fewer cell
endometriotic cell lines exist, with 12Z cells being the only widely shared epithelial-like endometriosis
immortalized cell line [183]. For rigor and reproducibility, additional well-characterized endometriotic
cell lines and possibly ovarian cancer cell lines derived from women with endometriosis need to
be created.
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4.2.2. Xenograft Models
Implantation of immortalized human cell lines typically requires immunocompromised mice.
A Japanese group created telomerase transformed endometriosis epithelial cell lines and confirmed
cellular growth, steroid hormone response, and lack of malignant transformation in nude mice [185].
Further, these cells have been used in xenograft models to study treatment effects of small molecular
inhibitors in endometriosis [104,200]. However, limited distribution outside Japan has restricted the
use of these cells for studies of endometriosis-associated ovarian cancers. A similarly developed
endometriotic epithelial cell line (EEC16) does not grow in SCID mice [184].
In terms of the endometriotic tumor microenvironment, Komiyama et al. placed normal
endometrium of women without endometriosis into SCID mice. RMG-1 cells, a clear-cell ovarian
cancer cell line, were grown in mice then transplanted into mice with or without endometrial implants.
Although the tumors weighed less when grown with endometrium, proliferation was significantly
higher in mice with transplanted endometrium. Additionally, these tumors expressed high levels
of TGFβ and IL6. Addition of normal human endometrium changed the xenograft model to a more
endometriotic microenvironment [201].
4.2.3. Three Dimensional (3D) and Co-Culture Models
Immortalized cell lines in monolayer two-dimensional (2D) culture fail to recapitulate the
complexity of tumor tissue. Tumors are three-dimensional (3D) structures, surrounded by other
cell types and a unique extracellular matrix (ECM) that is biologically optimized for growth of each
cell type [202]. To recapitulate this for in vitro model systems, immortalized cell lines can be grown
in Matrigel, ultra-low-adhesive plates, or a hanging drop. Using these methods, many immortalized
cell lines will form 3D spheroids. Three-dimensional spheroid models can be highly instructive
towards the understanding of current drug resistance and new therapeutics because they better
mimic the way 3D tumors or de novo spheroids interact with the surrounding microenvironment.
Specifically, the architecture of spheroids results in non-heterogeneity of nutrient and drug penetration,
which can cause differential responses to varying layers of the spheroid. For example, Lee et al.
compared 31 ovarian cancer cell lines in both 2D monolayer and 3D spheroids to primary tumors.
Three-dimensional spheroids showed slower rates of proliferation and decreased drug sensitivity
than the same cells grown in 2D [202]. Additionally, these 3D spheroids mimicked histological
characteristics of primary tumors. Although the authors did not perform genome-wide transcriptomic
analysis, candidate biomarkers such as mucin 16, cell surface associated (CA125), Wilms Tumor 1
(WT1), estrogen receptor, Paired box gene 8 (PAX8), and β-catenin were examined by IHC on a
tissue microarray composed of 2D and 3D samples. The expression of these biomarkers correlated
well with expression in primary tumors [202]. These data suggest that 3D spheroid models alter
the microenvironment in a potentially more biological way compared to other in vitro systems.
Additionally, Lal-Nag et al. used high-throughput screening to test multiple oncological drugs
against the HEYA8 cell line. The cells responded differently to various drugs if they were grown
in monolayer, in the process of forming spheroids, or already in pre-formed spheroids. This work
establishes that the dimensionality of ovarian cancer cells plays a role in how they respond to their
environment [203]. Similarly, Chowwanadisai et al. created cisplatin-resistant ovarian cancer spheroids
by treating cells with sub-threshold doses of cisplatin, which resulted in a mesenchymal-enriched
gene expression signature [204]. While molecular changes within spheroids may play a role in
chemotherapy resistance, size of spheroids, similar to remaining disease after debulking surgery,
plays a role in response. Tanenbaum et al. [205] showed that small spheroids treated with either
short-term high-dose or prolonged low-dose cisplatin underwent significant shrinkage. Importantly,
large spheroids preferentially responded to short-term high doses of cisplatin [205]. The investigators
did not explore if the remaining cells became chemotherapy-resistant [205]. Although immortalized
cell lines from endometrioid or clear cell ovarian cancers have not been extensively tested in 3D culture,
we anticipate that they would behave similarly.
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In addition to single cell types within 3D spheroids, co-culture systems can be useful. For example,
endometrial epithelial cells are inhibited at a rate of 65–80% when grown in co-culture with
endometrial stromal cells, highlighting the need for complex co-culture models [206]. Additionally,
co-culture models of epithelial and stromal endometriosis cells show that stromal cells are responsible
for metabolism of iron. The authors hypothesize that storage of iron by stromal cells is protective
against malignant transformation of epithelial cells. Specifically, a lack of stromal cells and an
abundance of epithelial cells, which cannot metabolize iron, leads to oxidative damage and oncogenic
change [207]. This hypothesis fits with data from Anglesio et al. showing tumorigenic mutations in
KRAS in epithelial cells of endometriosis but not stromal cells [27]. Similarly, co-culture of macrophages
with endometriotic epithelial or endometriotic stromal cells leads to an increase in invasion that is more
robust in epithelial than stromal cells [208]. Three-dimensional organoids made from endometrium
and decidua have been developed simultaneously by two independent laboratories and represent
promising models for in vitro study [209,210]. Development of additional endometriotic tumor
microenvironment models are needed to study ovarian cancer cells within spheroids, 3D organoids,
or co-culture systems.
5. Future of Precision Therapy for/or Prevention of Ovarian Cancer
Endometriosis is a known risk factor for ovarian cancer [41]. However, early treatment of
endometriosis represents a known prevention strategy for ovarian cancer. For example, a woman
on oral contraceptive therapy has a more robust protection against ovarian cancer if she has
endometriosis than if she does not [120]. While treatment of endometriosis with contraceptives
is effective, women desiring fertility do not enjoy the side of effects of contraception, and when medical
management is stopped, 73% of women have return of symptoms. Additionally, surgical treatment of
endometriosis with removal of one or both ovaries results in significant decrease in ovarian cancer
risk. However, 55% of women undergoing local resection of endometriosis will have at least one more
surgery over the course of seven years [211,212]. Morbidity associated with multiple operations makes
selection of timing for endometriosis surgery important in pre-menopausal women. New treatments
for endometriosis are needed. Importantly, discovery of new treatments for endometriosis should be a
priority for ovarian cancer funding agencies as these therapies may lead to prevention of ovarian cancer.
In terms of therapy highlighting the importance of the molecular signaling between cells within
tumors, Mok et al. used a systems biology approach to study individual cell types. Machine learning
with large databases of drugs and molecular effects highlighted an FDA-approved drug for potential
targeted treatment. While this study used high-grade serous ovarian tumors, it brings forward the
importance of non-epithelial ovarian cancer cells in cancer treatment [213]. Importantly, the study
focused on TGFβ signaling pathways [213]. Endometriosis also has dysregulated TGFβ signaling
pathways [92]. Similar treatment of endometriosis may prevent ovarian cancer.
6. Conclusions
The Gynecologic Cancers Steering Committee of the National Institutes of Health (NIH)
proposed strategic priorities for ovarian cancer. These research priorities focus on discovery of
biomarkers, identification of cancer subsets to drive treatment recommendations, immunotherapy,
combination therapies, and manipulation of the host-tumor microenvironment. While these priorities
are not specific for a particular histotype, they are highly applicable to both the more common
high-grade serous and less common endometriosis-associated ovarian cancers and warrant further
study in endometriosis-associated ovarian cancer models.
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Abstract: Ovarian cancer is the most lethal gynecological malignancy. Poor overall survival,
particularly for patients with high grade serous (HGS) ovarian cancer, is often attributed to late
stage at diagnosis and relapse following chemotherapy. HGS ovarian cancer is a heterogenous disease
in that few genes are consistently mutated between patients. Additionally, HGS ovarian cancer
is characterized by high genomic instability. For these reasons, personalized approaches may be
necessary for effective treatment and cure. Understanding the molecular mechanisms that contribute
to tumor metastasis and chemoresistance are essential to improve survival rates. One favored model
for tumor metastasis and chemoresistance is the cancer stem cell (CSC) model. CSCs are cells with
enhanced self-renewal properties that are enriched following chemotherapy. Elimination of this
cell population is thought to be a mechanism to increase therapeutic response. Therefore, accurate
identification of stem cell populations that are most clinically relevant is necessary. While many CSC
identifiers (ALDH, OCT4, CD133, and side population) have been established, it is still not clear
which population(s) will be most beneficial to target in patients. Therefore, there is a critical need to
characterize CSCs with reliable markers and find their weaknesses that will make the CSCs amenable
to therapy. Many signaling pathways are implicated for their roles in CSC initiation and maintenance.
Therapeutically targeting pathways needed for CSC initiation or maintenance may be an effective
way of treating HGS ovarian cancer patients. In conclusion, the prognosis for HGS ovarian cancer
may be improved by combining CSC phenotyping with targeted therapies for pathways involved in
CSC maintenance.
Keywords: ovarian cancer; cancer stem cells; signaling; chemoresistance; metastasis
1. Introduction
In the United States, ovarian cancer is the fifth leading cause of cancer death in women [1].
The American Cancer Society (ACS) estimates that this year approximately 22,240 women will be
newly diagnosed with ovarian cancer, and ~14,075 women will die as a result of the disease, making it
the most lethal gynecologic malignancy (ACS Facts and Figures 2018). The vagueness of symptoms
(bloating, abdominal/pelvic pain, difficulty eating/feeling of fullness, and frequent urination) and the
lack of early detection methods contribute to the majority of patients (70–75%) receiving diagnoses in
advanced stages (stage III or stage IV) when the cancer has metastasized throughout the peritoneal
cavity [1,2]. The five-year survival rate for women with advanced-stage ovarian cancer is ~25% [3,4].
There are several major ovarian cancer subtypes. Additionally, there is mutational and gene
expression heterogeneity within each subgenre. Mutational and gene expression heterogeneity is also
Cancers 2018, 10, 241; doi:10.3390/cancers10080241 www.mdpi.com/journal/cancers379
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found in different subpopulations within a single tumor. Patients with the same pathological diagnosis,
such as high grade serous (HGS) carcinoma, often vary greatly with respect to gene expression
and specific genetic mutations [3,5,6]. The lack of consistent mutations or mis-expressed genes
makes developing novel targeted therapeutics difficult. The current standard of care is a “one size
fits all” approach consisting of aggressive debulking surgery to resect visible tumor followed by
platinum and taxane combination chemotherapy [1,7–9]. Residual tumor implants measuring less
than 1 cm are considered indicative of optimal debulking [1]. Debulking surgery performed by
a gynecological oncologist improves the chance of survival; however, many patients are not treated
by gynecological oncologists [1,7,8]. Therefore, in some cases, chemotherapy prior to surgery is
equally effective as primary debulking [4]. Chemotherapy treatment is initially effective in 70–80%
of patients [2,10,11]. However, recurrence of the disease will occur in the majority of patients
(80–90%) within 5 years, and the tumors often acquire resistance to the chemotherapeutics [1,9,11].
The presence of microscopic tumors left behind during surgical debulking and the limitations of current
chemotherapeutics contribute to the likelihood of relapse. The presence or enrichment of cancer stem
cells (CSCs), which are defined as tumor cells that survive and/or accumulate after chemotherapy,
have activation of self-renewing signaling pathways, and exhibit increased tumor-initiating properties,
may contribute to relapse [11–13]. We will discuss how CSC properties contribute to chemoresistance
and how investigating these properties may lead to novel therapeutics to eliminate ovarian cancer and
prevent relapse.
2. Histologic Types of Ovarian Cancer
Ovarian tumors are divided into three types: epithelial (60%), germ cell (30%), and specialized
stromal cells tumors (8%) [3,14]. Epithelial tumors comprise the majority of malignant ovarian tumors
(80–90%) [10,14]. Within the epithelial tumors there are four major subtypes: serous, endometrioid,
clear cell, and mucinous [5,15,16]. Serous tumors are the most common of the epithelial subtypes and
comprise two-thirds of all cases [2,3,5,15]. Historically, serous ovarian cancer is classified according
to three different three-tiered systems based on morphology/histology. The three systems are the
FIGO (the International Federation of Gynecology and Obstetrics) system based on architectural
features, the World Health Organization system based on architectural and cytological features, and the
Shimizu/Silverberg system based on architectural features, degree of atypical cytological features, and
mitotic index, with the most common system being the FIGO system [17]. Within the FIGO system,
serous ovarian carcinomas are classified as low grade (Grade 1), intermediate grade (Grade 2), and high
grade (Grade 3) [16]. Historically, low grade and high grade serous ovarian tumors were considered to
be different grades of the same tumor [5]. However, molecular and genetic studies suggest that it is
likely low grade and HGS tumors are distinct diseases with different genetic mutations and different
prognoses [5,15,18]. A newer two-tier system combines the current histopathological classification
system with molecular genetic findings and clinical features. In this system, ovarian tumors are
designated as Type I or Type II [17,19] (Figure 1).
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Figure 1. Classification of the Epithelial Ovarian Cancer histological subtype according to the two
tier system. Type I tumors include endometroid, clear cell carcinoma, mucinous, and low grade
serous. Type II tumors are mostly comprised of high grade serous but also include carcinosarcoma and
undefined carcinomas [5,15,18,20].
Low grade serous, mucinous, endometrioid, and clear cell carcinomas fall within the Type
I classification [5]. These tumors arise from endometrial tissue, fallopian tube tissue, germ cells,
and transitional epithelium [5,14,15,18,21,22]. Type I tumors grow more slowly (are indolent) and are
considered to be more genetically stable [5,14,20]. Type II tumors typically have a higher disease volume
throughout the peritoneal cavity and a higher incidence of ascites than Type I tumors [20]. They appear
to follow a stepwise pattern from a benign precursor to a malignancy with genetic changes in specific
cell signaling pathways [2]. Type I tumors are predominantly of non-serous type [10]. Low grade serous
ovarian cancer accounts for approximately 5–10% of all serous ovarian cancers [2,10,16]. The most
common pathway disrupted in low grade serous ovarian cancer is the mitogen-activated protein kinase
(MAPK) pathway [5,6,16,17]. Specifically, activating mutations in BRAF and KRAS are common [2,10,23].
An active MAPK pathway is found in 80% of low grade serous tumors as well as in 78% of their putative
precursor lesions (borderline tumors) [16]. Other genes/pathways that are commonly altered in Type I
tumors include PTEN, PI3K, ARID1A, Wnt/β-catenin, and ERRB2 [2,6,15,18,20,24,25] (Figure 2).
 
Figure 2. Pathway for Type I tumor formation. Type I tumors appear to form in a stepwise manner
from benign precursor lesions. Progression from a borderline ovarian tumors to low grade serous
carcinoma commonly includes activating mutations in one of the following members of the MAPK
pathway: KRAS, BRAF, or ERBB2.
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Prognosis for early-stage tumors is good with a >80% 5-year survival rate with chemotherapy [9].
When dividing all ovarian tumors between stages, Type I tumors are heavily represented in stage
I/II (clear cell, 26%; endometrioid, 27%; mucinous, 8%). Only about 36% of early stage tumors are
serous [18]. Treatment options for Type I ovarian tumors are identical to those used for Type II
tumors and include debulking surgery followed by chemotherapy [17,18]. The response of Type I
tumors to chemotherapy is poor due to the relative insensitivity to drug regimens and lack of targeted
therapies [7,26]. Low grade serous ovarian tumors have a low response rate to platinum-based
therapies with 4% showing a complete response, none with a partial response, 88% with stable disease,
and 8% with progression [27]. Another study demonstrated that low grade serous tumors are less
responsive than HGS tumors to both paclitaxel (69% vs. 14%) and carboplatin (50% vs. 17%) [27,28].
Type I tumors account for only 10% of ovarian cancer deaths [20]. The poor response of Type I
tumors to therapy and the chemoresistance that arises in Type II tumors highlight the need for novel
treatment strategies.
HGS tumors comprise 75% of all Type II tumors [3]. HGS neoplasms are typically aggressive
and develop rapidly (high mitotic activity) [5,18,20]. Previously, it was thought that HGS ovarian
cancer was derived from the ovarian surface epithelium or from cortical inclusion cysts [18,29].
Recent molecular and mouse studies suggest that these tumors likely arise from the epithelium of the
distal fallopian tube and that serous tubal intra-epithelial carcinoma (STIC) lesions are the precursors to
HGS ovarian cancer [29–31]. One study examined histological sections from fallopian tubes of ovarian
cancer patients for evidence of STIC lesions. STIC lesions were identified in 61% of the fallopian
tubes from HGS patients with 92% of the lesions being in the fimbriated end of the fallopian tube [32].
Kroeger et al. compiled a list of 15 studies showing that approximately 50–60% of HGS tumors are
associated with STIC lesions in the fimbriated end of the fallopian tube [3]. Furthermore, in a molecular
profiling analysis, HGS tumors with and without STIC lesions exhibited molecular profiles similar
to fallopian tube epithelium [29]. To establish if HGS ovarian cancer can be recapitulated in the
mouse, transgenic mouse models have been developed. Dicer and PTEN were conditionally deleted in
the reproductive tract using anti-Müllerian hormone receptor type 2-directed Cre (Amhr2-Cre) [33].
These mice exhibited abnormal proliferation in the stromal compartment of the fallopian tube [33].
Primary and metastatic tumors that developed in the mice were histologically serous carcinoma,
and they shared a similar gene expression profile with human HGS tumors [33]. In another model,
Pax8-Cre was used to drive the deletion of Brca/Pten/Tp53 in the fallopian tube. These mice developed
STIC lesions and serous carcinomas [31]. Interestingly, loss of PTEN alone in the fallopian tube
(via Pax-8-Cre) was sufficient to generate endometrioid and serous borderline tumors [34]. This raises
the possibility of fallopian tube origins for some Type I tumors and non-HGS tumors. While it is
possible that a portion of HGS tumors arise from the ovarian surface epithelium, it is likely that a major
site of origin for HGS tumors is the fallopian tube [30,35].
Unlike Type I tumors, there is a significant amount of genetic instability within the Type II
subgroup, and few genes are consistently mutated [5,14]. The main exception is that in Type II
tumors, TP53 mutations are common (both inactivating and gain of function) [36,37]. TP53 mutations
are rare in Type I tumors [6]. Type II tumors often exhibit active DNA damage repair mechanisms
(e.g., PARP) [3,20]. Overexpression of oncogenes ERRB2 (20–67%) and AKT (12–30%) also occur in
some cases [6]. Other common mutations in Type II tumors are BRCA1 or BRCA2. Epithelial ovarian
cancer is sporadic in 90% of cases with the remaining 10% being hereditary [2]. In 90–95% of hereditary
Type II ovarian tumors, there are germline mutations in BRCA1 or BRCA2 [2]. Importantly, BRCA1 and
BRCA2 are often mutated or inactivated in spontaneous ovarian cancer. BRCA1 and BRCA2 mutations
are detected in around 5–9% and 3–4% of spontaneous ovarian cancer, respectively [38–42]. Loss of
BRCA function through other means, particularly promoter methylation, is common in ovarian cancer
(particularly when mutations are not present) [43,44]. Therefore, the p53 and BRCA1/2 pathways are
highly implicated in development of HGS ovarian cancer.
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Most Type II tumors are found in advanced stages of the disease, which leads to a poor overall
prognosis. While Type II tumors respond well to chemotherapy (70–80%) initially, almost all patients
relapse and Type II tumors result in 90% of all deaths from ovarian cancer [20]. The advanced
stage of disease and development of chemoresistance with Type II tumors results in high mortality.
A contributing factor to tumor metastasis and chemoresistance is the presence or enrichment of
tumor-initiating/cancer stem cells (CSCs) [45]. Devising new treatments that eliminate this cell
demographic is of particular interest for HGS ovarian cancer.
3. Definition of Ovarian Cancer Stem Cells
Heterogeneity is a common feature in ovarian cancer tumors. Different models are proposed
to explain tumor heterogeneity. In the stochastic or clonal model, tumors arise from a group of
homogeneous cells (clonal). Tumor heterogeneity then occurs through random (stochastic) events
within this population. Any of the cells within this population can be tumor initiating provided they
possess the necessary genetic mutations, epigenetic changes, and a receptive microenvironment [46–50].
The second model (CSC model) recapitulates the stem cell hierarchy found in development of tissues
like the hematopoietic system. In this model, tumors are made of groups of heterogeneous cells that all
arise from precursor cells with stem-like properties. These “stem-like” precursors differentiate and/or
acquire different mutations that lead to diverse activation of pathways. The resultant cells have unique
phenotypes and a hierarchical pattern of inheritance from the initiating CSCs [47,49–52] (Figure 3).
 
Figure 3. Models of tumor development and heterogeneity. (A) The clonal evolution model for tumor
initiation. A genetic event occurs in a cell giving rise to a mutant cell population. Any cell is capable of
becoming a tumor cell if there is an initiating genetic event. Tumor heterogeneity is due to propagation
of cells carrying mutations that are the result of multiple genetic events. (B) The cancer stem cell model
for tumor initiation. Either a normal stem cell has a genetic event resulting in a cancer stem cell capable
of indefinite self-renewal and/or differentiation or a differentiated cell has a genetic event that activates
a stem like program within the cell resulting in a cancer stem cell. Tumor cells have a hierarchical
inheritance pattern from their cancer stem cell but develop different phenotypes as they acquire further
mutations as they differentiate resulting in tumor heterogeneity.
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Normal stem cells divide asymmetrically, allowing for self-renewal. One daughter cell retains
all the characteristics and programing of the parent cell while the other daughter cell differentiates
or acquires new properties [53]. To maintain their undifferentiated state and the ability to self-renew,
stem cells reside in a “stem cell niche” comprising various stromal cells, vascular support, and soluble
factors that provide a permissive environment [49,54]. CSCs display self-renewal characteristics and
retain the ability to produce cells that are highly proliferative and invasive [47,53]. Other characteristics
of CSCs include significant DNA repair capability and resistance to therapy [49,53]. In fact,
ovarian CSCs (CD133+ and Sca1+) persisted following chemotherapy in a mouse model of ovarian
cancer and in cells treated with carboplatin in vitro [45,55]. Moreover, these cells express stem cell
markers and maintain tumor initiating potential [45]. Additionally, in vitro studies demonstrated that
treatment of ovarian cancer cells with chemotherapy enriches the stem cell pool [56–58]. These studies
imply that CSCs are protected from chemotherapy and may be initiators of tumor relapse.
4. Stem Cell Identification in Ovarian Cancer
In 2005, Bapat et al. described the first example of a putative ovarian CSC. A single cell
was taken from the ascites of an ovarian cancer patient. Once propagated, the cell was able to
form anchorage-independent spheroids in culture and was able to seed tumors in mice via serial
transplantation over several generations, illustrating the stem-like capabilities of the cell [59]. Since this
initial study, many other investigations have been conducted to identify and validate ovarian CSCS.
Identification of CSCs relies on the presence of markers (cell surface and intracellular) that are unique
to this particular subset of tumor cells [46,47,50]. In ovarian cancer, a variety of markers are used to
denote the presence of CSCs. Cells isolated based on these markers can be tested for “stemness” in vitro
via spheroid forming assays, resistance to chemotherapeutics, and in vivo with limiting dilution assays
(LDAs) to examine the tumorgenicity of the sample [52]. In the LDA, mice are injected with a defined
number of cells from a mixed population of cells or cells isolated that express the stem cell markers.
The population that is more stem-like will initiate tumors from significantly fewer cells [60]. Table 1
contains a list of some putative ovarian CSC markers.
Table 1. Putative Ovarian Cancer Stem Cell Markers.
Marker Type of Protein Suspected Role in Stem Cells References
CD24 Cell surface transmembrane glycoprotein Stem gene expression, tumor initiation,chemoresistance, stem cell maintenance [46,53,61,62]
CD44 Cell surface transmembrane glycoprotein(hyaluronic acid receptor)
Chemoresistance, tumor initiation, stem gene
expression, spheroid formation [13,46,53,61–67]
cKit/CD117 Tyrosine kinase receptor Chemoresistance, stem cell maintenance,tumor initiation [11,53,59,61,68,69]
PROM1/CD133 Cell surface transmembrane glycoprotein Tumor initiation, chemoresistance,spheroid formation, high cell proliferation [13,46,53,61,62,70–76]
ALDH1 Cytosolic aldehydedehydrogenase enzyme
Tumor initiation, chemoresistance,
spheroid formation [46,53,61,75,77,78]
ROR1 Tyrosine kinase receptor Spheroid formation, tumor initiation,proliferation [79,80]
SOX2 Transcription factor Stem cell maintenance, self-renewal [8,81–84]
NANOG Transcription factor Stem cell maintenance, self-renewal,chemoresistance [8,53,61,66,81–83]
POU5F1/OCT4 Transcription factor Tumor initiation, chemoresistance [8,53,61,81–83]
MYC Transcription factor Tumor initiation, chemoresistance [85,86]
EpCAM Cell surface membrane glycoprotein Tumor initiation, spheroid formation,proliferation [13,46,53,61,62]
MDR1/ABCB1 ATP binding cassette transporter Chemoresistance [46,49,53,61,66,87–91]
ABCG2 ATP binding cassette transporter Chemoresistance [46,49,53,61,87,88,90,91]
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4.1. Side Population
One way in which ovarian CSCs are identified is by their ability to efflux DNA-binding
dyes such as Hoechst 33342 and Rhodamine 123 resulting in a side population (SP) using flow
cytometry. The ability to efflux these dyes identifies a CSC population that overexpress ATP
binding cassette transporters such as MDR1/ABCB1 and ABCG2 that can efflux chemotherapeutic
agents [46,49,61,87,88]. This SP demonstrates stem cell properties including the ability to repopulate
tumors in an LDA and resistance to chemotherapy. Expression of ABCB1 and ABCG2 correlates with
resistance to cisplatin and paclitaxel in ovarian cancer cell lines (2008, KF28, TU-OM-1, OVCAR3,
SKOV3) and in cells from patient and mouse ascites [89–91]. However, the SP of cells is heterogeneous
and can display different combinations of other stem cell markers, so it may be unknown which cells
within this population is most “stem-like” or which population(s) are reconstituting the tumor [53].
4.2. Cell Surface Markers
Cell surface makers are essential in the identification of CSCs for multiple tumor types.
When Bapat et al. first described ovarian CSCs, CD117 was demonstrated to be a cell surface marker
for the ovarian CSCs [59]. Human serous ovarian cancer patient-derived xenografts (PDXs) showed
that CD117+ cells isolated from the xenografts were able to recapitulate a tumor with only 10,000 cells;
this was a 100-fold increase in tumor initiating capability compared with the CD117− cells [68].
CD117+ cells were also successful at generating tumors when serially transplanted [68]. Other ovarian
CSC surface markers include CD24, CD44, EpCAM, and CD133 [13,46,53,61,62]. One of the most
commonly reported ovarian CSC markers is CD133. CD133 expression correlates with poor prognosis
in ovarian cancer and increased chemoresistance [70–72]. In cell lines, CD133 promotes a number
of stem characteristics. CD133+ and CD133− cells were single cell isolated and expanded from
A2780 and PEO1 cell lines [73]. The CD133− cells only produced CD133− cells while CD133+ cells
divided asymmetrically to produce both CD133+ and CD133− cells, suggesting that the CD133+ cells
retain stem cell properties [73]. CD133+ cells exhibit increased resistance to cisplatin and were more
tumorigenic in xenograft and serial transplantation studies [73,74]. Another one of the common CSC
markers is CD44. CD44 is the hyaluronate receptor and is important in adhesion. In ovarian cancer,
CD44 correlates with chemoresistance and tumor progression [63–65]. One function of CD44 is to
activate Stat3 [66]. CD44 is commonly used as a stem cell marker in combination with CD117, MyD88,
E-cadherin/CD34, and CD24/EpCAM. Each of these CD44+ cell populations has been demonstrated
to have stem-like properties (reviewed in Klemba et al.) [67]. In conclusion, there are multiple surface
markers used to identify CSCs in ovarian cancer. Some investigations use these surface markers alone
or in combination with other markers. However, we are still uncertain if there is a definitive ovarian
CSC marker/population, if multiple CSC populations co-exist, or if CSC identity varies by patient.
4.3. ALDH Activity
In addition to cell surface markers, CSCs often are identified using the expression of the enzyme
aldehyde dehydrogenase 1 (ALDH1) and its activity. The enzymatic activity of ALDH1 is used to
identify and define CSCs in cancer types including breast, colon, liver, and ovarian [46]. Several studies
suggest that ALDH1 expression correlates with poor prognosis. In one study of ovarian cancer
patients, ALDH1A1 expression was found in 72.9% of tumors, and this expression correlated with
decreased progression-free survival (6.05 vs. 13.81 months) [77]. A second study demonstrated that
patients with high ALDH1 expression (by immunohistochemistry in >50% of the tumor section)
exhibited poorer prognosis [78]. Cell lines with high ALDH1 exhibited increased chemoresistance and
tumorgenicity [78]. Silva et al. examined 13 primary human ovarian tumors and 5 ascites samples
for various putative CSC markers. ALDH1 was expressed in all cases [75]. Ovarian cancer cell
lines were then examined for these CSC markers. Each of the cell lines examined (A2008, SKOV3,
HEY-1, A2780, OVCAR8, OVCAR3, and OVCAR432) had a subpopulation of cells with ALDH1
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expression [75]. Conversely, knockdown of ALDH1A1 in an orthotopic mouse model (from both
taxane- and platinum-resistant cell lines) sensitized the tumors to treatment, resulting in reduced
tumor growth [77]. The expression and activity of ALDH1 alone or in combination with cell surface
stem cell markers is a popular and accepted method for identifying ovarian CSCs.
4.4. Transcription Factors
Pluripotency transcription factors necessary for normal stem cell maintenance are commonly
expressed in ovarian CSCs [53,81–83]. In addition to being markers for ovarian CSCs,
transcription factors such as OCT4, SOX2, and NANOG are expressed during development and
are essential for normal stem cell maintenance and proliferation [62,66,84,92–95]. Aberrant expression
of stem cell genes in differentiated cells, progenitor cells, or stem cell populations can lead to enhanced
self-renewal and proliferative capability [96]. Expression of stem cell transcription factors not only
provides evidence for the CSC model of tumor development, it also explains in part how stem cell
properties of self-renewal and asymmetric division are maintained in CSCs. By comparing normal
stem cell populations to CSCs we can gain insight into tumor initiation and regulation of the CSC
phenotype. In embryonic stem cells (ESCs) the pluripotency transcription factors form a protein
interaction network [83]. Many of these interactions are critical for stem cell functions. In addition,
expression of pluripotency factors and protein–protein interactions are retained in CSCs. Among these
factors is ARID3B. ARID3B and its paralog ARID3A are expressed in ESCs in a complex with NANOG,
OCT4, and NAC1 [83]. ARID3B is overexpressed in serous ovarian cancer and its expression in
the nucleus correlates with relapse following chemotherapy [58,97]. ARID3B increases expression
of stem cell markers [76]. In particular, ARID3B induces expression of the stem cell marker Prom1
(CD133) [58]. ARID3B additionally increases the pool of CD133+ cells, suggesting that it has a role
in promoting a stem cell phenotype [58,76]. In fact, ARID3A and ARID3B co-localize with CD133 in
ovarian cancer tumor sections. Additionally, ARID3B is enriched in ovarian cancer ascites sorted for
CD133+ cells (Figure 4). These data suggest that ARID3B+ cells are found in a stem cell niche (Figure 4).
Future studies on pluripotency factors common in ovarian CSCs including OCT4, MYC, and ARID3B
will provide clarity for how cancer stemness is maintained [85,86].
Figure 4. ARID3B expression correlates with CD133-stem cell niche. (A) IHC shows nuclear ARID3A
and ARID3B co-localize with CD133+ regions in serial HGSOC sections. (B) HGSOC patient ascites
was sorted for CD133+ cells. RT-qPCR was conducted for Prom1(CD133) and ARID3B on unsorted and
independent sorts [98].
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Different stem cell markers may confer different selective advantages to different pools of “CSCs”.
Patients may have more than one pool of stem cells and different patients may have CSCs with different
phenotypes. An example is included in Figure 5. To enrich for CSCs, OVCA429 and Kuramochi cells
were untreated or treated with cisplatin and paclitaxel and then cultured on nonadherent plates in
stem cell media [56]. Flow cytometry was performed for CD117 (gene = CKIT) and CD133. OVCA429
cells have a clear CD117+CD133− population of CSCs that is enriched following chemotherapy
treatment. Following chemotherapy treatment, multiple cell populations are expanded in Kuramochi
cells including CD133+/CD117−, CD133+/CD117+, and CD117+/CD133−. These experiments suggest
that different stem cell pools may be more prevalent in an individual cell type or patient tumor.
Importantly, each of the CSC markers may have its own each unique function. The kinase activity of
CD117 may provide a survival advantage over CD117− cells [69]. However, CD133+ cells may have
an adhesion or metastatic advantage over cells lacking CD133 [76]. Although we can detect cell-to-cell
variation in the expression of markers, we do not know if these different CSC lineages arise from
common progenitors. CSC lineage tracing to define the hierarchy of cells in a stem cell population has
not been conducted for all putative ovarian CSC subtypes. Additionally, LDAs need to be conducted
to verify stem cell potential for each putative ovarian CSC population. In order for studies of CSCs to
be translational, we will need to define how the different CSC populations pertain to patient prognosis,
relapse, and response to therapy. Moving forward, we need to establish the clinical significance of
different ovarian CSC marker profiles [47,52,53,61,99]. Comparing survival and relapse potential for
patients based on these different marker profiles is essential for us to develop effective treatments for
the clinically relevant ovarian CSC populations.
Figure 5. Flow cytometry for the stem cell markers CD117 and CD133 on ovarian cancer cells before
and after CSC enrichment. Untreated OVCA429 and Kuramochi cells or cells enriched for CSCs
(by treatment with cisplatin and paclitaxel followed by culturing CSCs in stem cell media on ultra low
adhesion plates) [56] were stained for stem cell markers CD117 (cKIT is the gene that encodes CD117)
(X-axis) and CD133 (Y-axis).
5. Pathways That Promote Stemness and Chemoresistance in HGSOC
We chose to focus on the major pathways that drive both stemness and chemoresistance in HGS
ovarian cancer. These properties of highly metastatic HGS ovarian cancer are inextricably linked.
Understanding the pathways that are most pertinent to metastatic HGS ovarian cancer will provide
us with putative targets to develop efficacious therapeutic agents. As there are numerous pathways
involved in stemness and chemoresistance, we will highlight the ones that have a clear role in ovarian
cancer and are potentially targetable.
5.1. PI3K/PTEN/AKT Signaling
Aberrant PI3K/PTEN/AKT signaling often results from genomic alterations in many cancers
including clear cell ovarian cancer. In HGS carcinoma, there are few mutations in the components of
the PI3K/PTEN/AKT pathway, but by immunohistochemistry (IHC) about half of the HGS tumors
have evidence of pathway activation [100,101]. A meta-analysis of the literature reports that both
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univariate and multivariate analysis show that high expression of activated AKT (pAKT) is associated
with poor progression-free survival and poor overall survival [102]. Due to mutations in many parts
of the PI3K/PTEN/AKT pathway, activated AKT signaling is highly relevant for ovarian cancer
development and progression.
The PI3K/PTEN/AKT pathway is also implicated in ovarian CSCs. PI3K/PTEN/AKT signaling
regulates enrichment of CSCs, maintenance of a CSC phenotype, and chemoresistance [103–106].
Spheroids derived from SKOV3 and HO8910 cell lines expressed elevated phosphorylated AKT1 and
decreased expression of PTEN [103]. The spheroids exhibited increased resistance to paclitaxel [103].
Conversely, inhibiting AKT1 activation decreased spheroid formation and migration [104]. Knockdown
of AKT1 via siRNA resulted in the loss of CSC marker expression (OCT4, SOX2, ALDH1, and ABCG2)
as well as loss of spheroid formation and paclitaxel resistance [104]. These studies demonstrate the
importance of the PI3K/PTEN/AKT pathway in CSC formation, maintenance, and chemoresistance
to paclitaxel.
The PI3K/PTEN/AKT pathway also regulates cisplatin resistance in ovarian cancer.
In cisplatin-resistant A2780 cells (A2780-CP), AKT regulates the expression of PPM1D [105].
PPM1D inhibits the DNA damage and apoptotic response after DNA damage occurs [105].
Downregulation of AKT activity results in loss of PPM1D stability and increases its degradation [105].
Loss of PPM1D increases the response of the A2780-CP cells to cisplatin [105].
The PI3K/PTEN/AKT signaling pathway promotes the enrichment of ovarian CSC populations
and regulates ovarian CSC chemoresistance, thus making it an ideal target for therapeutics to
eliminate ovarian CSCs. There are currently PI3K/PTEN/AKT inhibitors such as BKM120, Everdimus,
and Perifosine that are being used to treat cancer patients [100]. Future efforts to stratify patients that
are likely to benefit from PI3K/PTEN/AKT inhibition will be needed for this therapy to be effective in
ovarian cancer patients.
5.2. Jak2/STAT3
Proliferation, survival, and differentiation are all regulated by the Jak2/STAT3 pathway in
several solid tumors [107]. In ovarian cancer, the Jak/STAT pathway is constitutively active in
most cases [108]. Jak/STAT is implicated for having a key role in the development of HGS ovarian
cancer. Activation of STAT3 via phosphorylation at Tyr705 and the loss of the STAT3 inhibitor PIAS3
may serve as a tumor-initiating event in the distal fallopian tube for the formation of HGS ovarian
cancer [109]. Phosphorylated STAT3 is expressed in 86% of ovarian tumors examined (from different
histotypes) and constitutive pSTAT3 expression is expressed in 63% of the HGS tumors examined [110].
Phosphorylated, nuclear STAT3 is associated with poor prognosis [110]. In tissue microarrays (TMAs),
patients whose tumors had high nuclear pSTAT3 staining (>10% nuclei stained) had poorer survival
rates than women with low nuclear pSTAT3 staining (<10% nuclei stained) [110]. These patient
findings implicate the Jak/STAT pathway as being highly important for ovarian cancer initiation
and progression.
The Jak/STAT pathway also regulates ovarian CSCs. CD24+ ovarian CSCs require Jak2/STAT3
signaling for growth and metastasis [111]. Primary tumors generated in the Apc−; Pten−; Trp53−
(transgenic mouse model in which APC, PTEN, and Trp53 are conditionally deleted in the ovarian
surface epithelium) were collected, dissociated, and sorted via fluorescence-activated cell sorting
(FACS) using stem cell markers [111]. LDAs confirmed that the CD24+ cells isolated were a CSC
population [111]. This population of cells expressed elevated pSTAT3 and stem cell marker NANOG,
which is required for stem cell renewal [111]. CD24+ cells were injected into mice and the mice
were then treated with cisplatin or with cisplatin+TG101209, a Jak2 inhibitor [111]. The mice
treated with cisplatin+TG101209 showed significantly increased survival and almost no metastases
(1 out of 14) [111].
Other studies show a role for the Jak/STAT pathway in ovarian CSC maintenance and
chemoresistance. Abubaker et al. collected tumor cells from patient ascites or the HEY8 ovarian
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cancer cell line and treated them with paclitaxel [108]. Treatment with paclitaxel induced the
expression of CSC markers CD117, OCT4, and EpCAM in ascites and HEY8 cells [108]. In both the
paclitaxel-treated ascites and HEY8 cells, the Jak2/STAT3 pathway was activated [108]. This suggests
that the Jak2/STAT3 pathway regulates the expression of stem-like genes necessary for CSC
maintenance. Moreover, paclitaxel-treated cells were also treated with the Jak2-specific small molecule
inhibitor (CYT387), which resulted in inhibition of the Jak2/STAT3 pathway activation, loss of
stem cell marker expression, and increased sensitivity of the cells to paclitaxel treatment [108].
When paclitaxel-treated and paclitaxel+CYT387-treated cells were injected into mice, the mice injected
with the paclitaxel+CYT387-treated cells showed a reduced tumor burden and enhanced sensitivity
to paclitaxel [108]. These studies demonstrate that in models of ovarian cancer, Jak2 inhibitors are
effective at reducing stem cell characteristics and inhibiting tumor growth. These inhibitors also
increase survival and response to therapy. Because the Jak/STAT pathway promotes stemness and
chemoresistance in the CSC population, it is a viable target for therapies aimed at reducing ovarian
CSC populations.
5.3. NFκB
The NFκB pathway plays a role in normal cellular processes such as survival, proliferation,
and apoptosis. In cancer the NFκB pathway is implicated in invasion and metastasis.
However, the pathway is also involved in CSC maintenance [112]. In ovarian cancer, both the
canonical and noncanonical NFκB pathways are active. A CD44+ ovarian CSC population isolated
from patient ascites exhibited constitutive NFκB pathway activation via a luciferase reporter assay,
formed spheroids in culture, and formed tumors when injected into mice [13]. Another study showed
that CD44+ CSCs from SKOV3 cells (that also express NANOG, SOX2, and OCT4) exhibited increased
expression of NFκB pathway members RelA, RelB, and IKKα [113]. Inhibition of the NFκB pathway
with a dominant-negative form of IκBα resulted in a decrease in the CD44+ CSC population with
a reduction from 65.3% CD44+ cells to just 27.7% [113]. These data suggest that NFκB signaling
regulates expression of stemness genes.
The NFκB pathway is also involved in ovarian CSC chemoresistance. CD44+ ovarian CSCs
from patient ascites have constitutively active NFkB [13]. When treated with TNFα, the CD44+ cells
showed increased NFκB activity and cytokine production as well as resistance to TNFα-induced
apoptosis [13]. The resistance to apoptotic pathway activation suggests a mechanism for ovarian
CSC survival when treated with chemotherapeutics. Treatment of ovarian CSCs with Eriocalyxin
B (EriB) inhibits the NFκB pathway and induces cell death in ovarian CSCs [114]. EriB inhibited
the TNFα-induced NFκB activity and cytokine production and sensitized the cells to TNFα- and
FasL-induced cell death [114]. This suggests that inhibition of the canonical NFκB pathway could
sensitize ovarian CSCs to therapy [114].
While many studies focused on the canonical NFκB pathway, the noncanonical pathway is also
active in promoting stemness and chemoresistance in ovarian cancer. RelB in particular is important for
ovarian CSC regulation. RelB is overexpressed in ovarian CSC populations including CD44+ SKOV3
cells and ALDH+/CD133+ OV90 and ACI23 cell lines [113,115]. In the OV90 and ACI23 cells, ALDH1
activity and expression of RelB both increase with carboplatin treatment [115]. This suggests a role for
the noncanonical NFκB pathway and RelB in promoting stemness and chemoresistance. Knockdown
of RelB with shRNA reduced the number of ALDH+/CD133+ CSCs in vitro in both cell lines and
in xenografts by 50% [115]. The RelB knockdown decreased expression of other stem cell markers
(NANOG and CD44) and increased sensitivity to carboplatin [115]. In addition, ACI23 and OV90 cells,
when stably transfected with inducible shRNA for RelB, showed reduced spheroid formation and
reduced tumorgenicity [115]. The noncanonical pathway through RelB promotes tumor growth as well
as the expression of stemness genes [115]. RelB also regulates chemoresistance in ovarian CSCs [115].
Thus, both the canonical and noncanonical NFκB pathways are excellent targets for therapeutics to
reduce the CSC population.
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5.4. Notch
Notch signaling has a role in multiple cellular processes. Notch is a critical component
in regulating progenitor cell maintenance, differentiation, cell proliferation, and apoptosis.
Notch is also important for cell–cell communication [116,117]. In HGS ovarian cancer, Notch3
expression is amplified/overexpressed [118]. By analyzing 31 fresh HGS ovarian cancer samples,
Notch3 amplification correlated with protein expression [118]. Notch3 was overexpressed more often
in high grade tumors (66%) than in low grade tumors (33%) [118]. Further, according to The Cancer
Genome Atlas (TCGA), Notch3 is amplified in 17% of HGS tumors. The most highly expressed Notch3
ligand in ovarian serous carcinoma is Jagged 1, which is predominantly expressed in the mesothelial
cells within the tumor microenvironment, suggesting a role for Notch3/Jagged 1 signaling in cell
adhesion and proliferation [119].
In the majority of patients with recurrent HGS ovarian cancer, Notch3 is overexpressed [120].
Tumors from patients with either primary disease or recurrent disease were examined for Notch3
overexpression and survival [120]. In the group with primary disease, there was no difference in
survival between those with Notch3 overexpression and those without [120]. Those in the group with
recurrent disease did show a difference. Those expressing high Notch3 levels had decreased overall
survival (22 vs. 37 months) and decreased progression-free survival (3 vs. 8 months) suggesting that
Notch3 expression is a factor in the recurrence of ovarian cancer as well as a prognostic indicator in
recurrent disease [120].
Chemoresistance is a hallmark of CSCs and disease recurrence/relapse, and Notch3 expression
affects the expression of stemness factors as well as chemoresistance. The transcription factor
OCT4 promotes self-renewal of ovarian CSCs while SOX2 is required for their maintenance [84,92].
Overexpression of Notch3 in ovarian cancer cell lines (IOSE-80pc and MPSC1) enhances expression of
stem cell markers (NANOG, OCT4, and SOX2) and increases expression of the ABCB1 transporter
protein [120]. The ABCB1 transporter increases chemoresistance in these ovarian CSCs and NANOG
promotes the epithelial to mesenchymal transition (EMT) in ovarian cancer [121]. To demonstrate
the role of Notch3 on chemoresistance, Nocth3 was knocked down in OVCAR3 cells using shRNA
resulting in reduced IC50 compared to control cells [120]. These studies all implicate Notch3 signaling
in ovarian CSC chemoresistance.
Other Notch signaling molecules are also implicated in stemness and chemoresistance including
Jagged 1 and downstream signaling molecules. Downregulation of Jagged 1 in SKOV3TRip2 cells
via siRNA increased sensitivity of cells to docetaxel [122]. In ovarian cancer cells isolated for the
SP, Notch pathway genes (FPTG, ST3GAL6, and ADAM19), stem cell markers NANOG and OCT4,
and three ABC transporter genes (ABCG2 [both lines], ABCC4 [SKOV3 only], and ABCB1 [A224 only])
were induced [95]. Collectively, the data suggest that Notch signaling is involved in promoting
stemness and chemoresistance, and expression of Notch3 in particular may serve as a prognostic
indicator for patients with recurrent disease. Notch signaling is an attractive target for therapeutics
aimed at ovarian CSCs. Currently, there are experimental γ-secretase inhibitors, γ-secretase modifiers,
Notch soluble decoys, and negative regulatory region monoclonal antibodies that are already being
developed [116].
5.5. Wnt
Wnt signaling is particularly important during development where it regulates cell fate
determination during embryogenesis including the cardiovascular system, central nervous system,
and craniofacial development [116,123]. In adults, Wnt signaling is critical for self-renewal in tissues
(e.g., bone growth plate, hair follicles, colon, etc.) [116,124,125]. The major processes regulated by
noncanonical Wnt signaling include cell polarity and motility; however, Wnt also plays a role in
maintaining stem cells, quiescence, and chemoresistance [126]. Wnt signaling is complex and many
components of Wnt signaling are implicated in ovarian CSCs and chemoresistance (Figure 6).
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Figure 6. Wnt Signaling Cascade. (A) Basal state without the presence of Wnt ligand activation.
β-catenin is ubiquitinated and sent to the proteosome for destruction. (B) Activation of the Wnt
pathway via binding of a Wnt ligand to the Frizzled receptor and LRP5/6 resulting in recruitment of
Disheveled (Dvl) and axin to the cell membrane. β-catenin is released from the destruction complex
and translocates to the nucleus to act as a co-transcription factor.
With regards to ovarian cancer, Wnt signaling is involved in normal development of the ovarian
and fallopian tube stem cells. Wnt signaling also has functions in tumor development. LGR5 is a stem
cell marker for ovarian stem cells and LGR6 is a stem cell marker for the fallopian tube, and expression
of either one is a sign of elevated Wnt signaling [127–129]. LGR5 and LGR6 are expressed in HGS
tumors [127]. LGR5+ cell-driven lineage tracing was performed in mice, illustrating the importance of
LGR5 and Wnt signaling in embryonic and adult ovarian stem cells for homeostasis and regenerative
repair and self-renewal [130]. Since the fimbria of the fallopian tube are implicated as a site of origin
in HGS tumors, fallopian tube stems cells also must be examined [129]. Using a Tcf-eGFP reporter
and confocal microscopy on fallopian tube organoid cultures, active Wnt signaling was needed for
the expression of stem cell factors to support organoid growth [129]. Understanding how abnormal
regulation of Wnt signaling drives initiation or maintenance of ovarian CSCs is critical.
Disregulation of Wnt signaling is frequently involved in the development of cancer [123,131].
In ovarian cancer, aberrant Wnt signaling differs by histotype. Wnt signaling stabilization and
subsequent nuclear translocation of β-catenin leads to activation of Wnt target genes including those
involved in stemness. β-catenin is frequently mutated at GSK3β phosphorylation sites that allow
β-catenin to be ubiquinated and degraded in the absence of Wnt signaling (54%) resulting in nuclear
localization in approximately 70% of cases of low grade endometrioid ovarian carcinomas [132].
Activating mutations of proteins in the Wnt pathway are rare in serous ovarian carcinomas [132].
However, there is evidence of nuclear β-catenin in HGS [132]. With regards to the noncanonical Wnt
pathway, Wnt5A was highly expressed in a collection of 583 ovarian tumors and it is found in the
ascites [126,132]. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) (a pseudokinase and receptor
for Wnt5A) is expressed in ovarian cancer and is correlated with poor outcomes [79]. Survival analysis
showed that patients with high expression of ROR1 had significantly reduced progression-free survival
and overall survival [79]. Cells isolated from ROR1+ patient-derived xenografts exhibited stem-like
qualities including ALDH1 expression, ability to form spheroids, and increased tumorgenicity [80].
These data suggest that ROR1 is a potential CSC marker for ovarian cancer and that noncanonical Wnt
signaling is a component of ovarian cancer stemness.
In ovarian CSCs, Wnt signaling helps promote both stemness and chemoresistance. The CSC
marker/receptor tyrosine kinase, CD117, is upregulated in ovarian CSCs. Many factors contribute to
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acquisition of CD117 expression including the hypoxic microenvironment of the stem cell niche [106].
CD117 leads to activation of AKT and the phosphorylation of GSK3β and nuclear expression of
β-catenin [106]. β-catenin activity induces expression of ABCG2, a drug transporter which increases
cisplatin and paclitaxel resistance [106]. Therefore, the hypoxic niche supports stemness by activation
of Wnt target genes.
Wnt signaling in ovarian cancer CSCs is complex. Collectively, the patient studies combined with
cell culture and animal models suggest that multiple Wnt signaling pathways contribute to stemness
and chemoresistance in ovarian cancer. A number of potential molecules in the Wnt pathways
may be viable targets for therapeutic intervention. Wnt inhibitors such as compounds that target
Disheveled (NSC668036 and FJ9), Frizzled receptor antibody, Thiazolidinedione (target β-catenin
reverse transport), and Sulindac (unknown action but potentially effects β-catenin proteasomal
degradation) are being examined for use in cancer treatment [116]. Deciphering the cross-talk between
Wnt and other pathways in addition to more sophisticated assessment of the contribution of particular
Wnt molecules and pathways will enable development of future Wnt-targeted drugs that can be used
in ovarian cancer treatment.
5.6. Hedgehog
During embryogenesis, Hedgehog signaling (Hh) regulates tissue polarity as well as patterning
and stem cell maintenance [116]. In cancer, the Hh pathway is dysregulated in one of two ways:
(1) constitutive expression of endogenous ligand (e.g., Sonic hedgehog [Shh]) or (2) mutations of
proteins within the pathway (Patched, SMO, SUFU) [133]. We will explore the ways Hedgehog
signaling has emerged as an important regulator of proliferation, chemoresistance, and stemness in
ovarian cancer [133,134].
Overexpression of Gli1 (a transcription factor activated by Hh signaling) as well as PTCH
(Hh receptor) is correlated with poor prognosis and survival in patients [133]. Eighty cases of epithelial
ovarian tumor were examined by IHC [133]. All cases expressed PTCH, though PTCH was highly
expressed in 34.1% of cases [133]. Gli1 expression varied by histotype of the tumor with high Gli1
expression being most common in serous tumors [133]. High expression of either Gli1 or PTCH
correlated with poor survival compared to those patients with low expression [133]. These data
suggest that Gli1 and/or PTCH expression may be prognostic indicators for ovarian cancer patients.
Gli1 antagonists such as HPI 1–4 that are currently being developed as well as drugs targeting PTCH
may be useful therapies for ovarian cancer patients with activated Hh signaling.
In ovarian cancer, Gli1 appears to be a critical contributor. Gli1 is a regulator of proliferation
and tumor growth in ovarian cancer. Gli1 is elevated in several ovarian cancer cell lines (OVCAR5,
OV-202, and OV-167) compared with normal ovarian surface epithelium [135]. Inhibition of the Hh
pathway with cyclopamine resulted in Gli1 decreasing in a dose-dependent manner (60–80%) [135].
The decrease in Gli1 mRNA and protein correlated with a decrease in proliferation in all three cancer
lines [135]. In addition to the in vitro results, a mouse xenograft model using OVCAR5 cells found
that cyclopamine significantly inhibited tumor growth [135]. In agreement with these findings,
exogenous expression of Gli1 in ovarian cancer cell lines SKOV3, OVCAR3, and OVCA433 increased
cell proliferation 2-fold and increased invasiveness 200–500% over control; whereas knockdown of
Gli1 with siRNA suppressed proliferation and invasiveness (40–60%) [133]. These studies suggest that
Gli1 is an important regulator of proliferation and tumor growth in ovarian cancer.
The Hh pathway regulates stemness in ovarian cancer. In one study, ES2, SKOV3, and TOV112D
cells were treated with recombinant Shh and Ihh, both Hh pathway agonists [134]. In all three cell
lines, spheroid formation increased significantly [134]. When treated with cyclopamine, there was
significant impairment of spheroid formation [134]. This demonstrates a role for the Hh pathway in
maintaining stemness in ovarian cancer.
Gli1 also is implicated in chemoresistance in ovarian cancer cells. Gli1 has an interesting role
in the DNA damage response following cisplatin treatment [136]. In cisplatin-resistant A2780 cells
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(A2780-CP), cells with anti-Gli1 shRNA or a scrambled shRNA were treated with cisplatin and then
DNA repair was assessed [136]. After 12 h the control cells had repaired 78% of the DNA adducts
compared to 33% in cells treated with anti-Gli1 shRNA [136]. In addition to impairing the cell’s ability
to repair the cisplatin adducts, pretreatment with the anti-Gli1 shRNA sensitized the cells to cisplatin
resulting, in a shift of the IC50 from 30 μM to 5 μM [136]. This suggests that Gli1 regulates DNA
adduct repair and sensitivity to cisplatin in ovarian cancer. Additionally, Gli1, SMO, and PTCH are
overexpressed in borderline and malignant ovarian cancer [137]. Moreover, Gli1 and SMO were highly
overexpressed in platinum-resistant ovarian cancer [137]. Both cell culture and patient studies suggest
an important role for Gli1 and Hh signaling in ovarian cancer chemoresistance.
While Hh signaling is studied in regard to other cancer types, Hh signaling in ovarian cancer
is relatively understudied. Current findings suggest that Gli1 has an important role in ovarian
cancer stemness, tumorigenicity, and chemoresistance. Further studies on the role of Hh signaling
in ovarian cancer will allow for personalized medicine approaches for those patients with active Hh.
Future therapy options could include the Hh inhibitor GDC-0449 that is currently in clinical trials for
use in ovarian cancer [138].
5.7. Developing Therapeutics Targeting Ovarian Cancer Stem Cells
There are multiple pathways involved in promoting a stem cell phenotype and chemoresistance
in ovarian cancer. Each pathway has the potential to be therapeutically targeted. However, a major
challenge is defining which population of cells needs to be targeted with pathway inhibitors.
If a therapeutic goal is to eliminate the CSC population, more studies are needed to define CSC
populations, markers, and critical pathways that are required for stem cell maintenance (Table 2:
Summary of targetable genes).
Table 2. Summary of targetable genes.















Notch3 γ-secretase inhibitors, γ-secretase modifiers, Notch soluble decoys,
negative regulatory region monoclonal antibodiesJagged1
Wnt
β-catenin







HPI-1, HPI-2, HPI-3, HPI-4, GDC-0449Gli1
6. Future Studies
Ovarian CSCs in HGS ovarian cancer are an attractive target for therapeutics in order to prevent
relapse following chemotherapy. Prior to targeting these insidious cells, a number of issues should
be considered. One complication in treating patients with HGS ovarian cancer is the amount of
heterogeneity found within the tumors. Additionally, HGS is characterized by genomic instability
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rather than specific driving mutations. This level of heterogeneity makes identifying drug targets
that help a wide population of HGS ovarian cancer patients difficult. More phenotypic, genetic,
and epigenetic studies of patient CSCs need to be conducted to assess which CSC populations are
the most critical ones to target. Hierarchical lineage tracing efforts will allow us to decipher if
different CSC populations arise from a common progenitor cell. Detailing the mechanisms that
are required for CSC maintenance is critical. Delineating the role of the microenvironment in CSC
maintenance is also important. Do these varying marker profiles denote differing niches for the CSCs
and, therefore, different survival and renewal pathways that are active in different populations of CSCs?
Are different CSC subpopulations present at different times during cancer progression? These questions
underscore the need for personalized medicine in the treatment of ovarian cancer. Three potential
targets for new therapeutics include stem cell markers, stem cell signaling pathways needed for
renewal and/or survival, and the stem cell niche. Careful studies examining the contribution of
CSC subpopulations and signaling pathways to CSC survival and maintenance will lead to directed
therapeutic target design.
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Abstract: Cancer–stroma interactions play a key role in cancer progression and response to standard
chemotherapy. Here, we provide a summary of the mechanisms by which the major cellular
components of the ovarian cancer (OC) tumor microenvironment (TME) including cancer-associated
fibroblasts (CAFs), myeloid, immune, endothelial, and mesothelial cells potentiate cancer progression.
High-grade serous ovarian cancer (HGSOC) is characterized by a pro-inflammatory and angiogenic
signature. This profile is correlated with clinical outcomes and can be a target for therapy.
Accumulation of malignant ascites in the peritoneal cavity allows for secreted factors to fuel paracrine
and autocrine circuits that augment cancer cell proliferation and invasiveness. Adhesion of cancer
cells to the mesothelial matrix promotes peritoneal tumor dissemination and represents another
attractive target to prevent metastasis. The immunosuppressed tumor milieu of HGSOC is permissive
for tumor growth and can be modulated therapeutically. Results of emerging preclinical and clinical
trials testing TME-modulating therapeutics for the treatment of OC are highlighted.
Keywords: high-grade serous ovarian cancer; tumor microenvironment; angiogenesis; immune
response; metastasis; therapeutic targeting strategies
1. Introduction
High-grade serous ovarian cancer (HGSOC) comprises the majority of epithelial ovarian tumors,
is associated with a p53-mutated signature and is characterized by initial sensitivity to platinum and
a unique pattern of dissemination in the peritoneal space. The peritoneum consists of mesothelial
cells that cover and protect the viscera. The sub-peritoneal stroma contains a collagen-based matrix,
activated fibroblasts, blood vessels, and lymphatics. This unique milieu permits accumulation of factors
secreted by both cancer and stromal cells and enables metastatic seeding and tumor proliferation.
The immune component of the peritoneal milieu consists of monocytes/macrophages and cytotoxic
T cells. Several studies have demonstrated an “activated” phenotype of the peritoneal environment
associated with ovarian cancer (OC), as opposed to its quiescent state in benign conditions [1].
The pro-inflammatory signature associated with cancer favors angiogenesis and exerts chemotactic
and protective effects on cancer cells. Chemokines, cytokines, and growth factors commonly secreted
in the tumor microenvironment (TME) include the stromal cell-derived factor (SDF1), interleukin-6
(IL-6), interleukin (IL-8), monocyte chemoattractant protein 1 (MCP1), Chemokine (C-C motif) ligand
5 and 7 (CCL5 and CCL7), transforming growth factor-β1 TGF β1, tumor necrosis factor-α (TNFα),
fibroblast growth factor (FGF), and others [1–4]. While tumor cells play a role in the secretion of factors
that modulate angiogenesis, non-transformed tumor infiltrating cells such as fibroblasts, myeloid cells,
immune cells, and endothelial precursors also play a crucial role modulating neo-vascularization [5].
OC metastasis commonly involves the omentum, an adipocyte-rich organ. Lipid transfer between
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Cancers 2018, 10, 266
adipocytes and cancer cells mediated by fatty acid binding protein 4 (FABP4), through a “symbiotic”
process between cancer cells and the fatty microenvironment was described as a key regulator of
peritoneal metastasis [6]. As the rich TME protects cancer cells from noxious stimuli promoting tumor
growth (Figure 1), its disruption through targeted therapy could arrest cancer progression. Indeed,
over the past decade, several classes of novel agents targeting the ovarian TME have been developed
and tested clinically. The most active agents are antiangiogenic therapies, which have been recently
approved by the Food and Drug Administraton FDA for OC. Other emerging strategies, particularly
immunotherapy, are in various stages of development. Here, several targeted therapies directed
against the main components of the TME will be reviewed.
Figure 1. The interplay between cancer and stromal cells in the tumor microenvironent TME regulates
tumor growth and metastasis: as tumors grow, hypoxic stress and low nutrient availability drives the
release of tumor-secreted growth factors and cytokines that exert paracrine effects on the surrounding
stroma. Sustained exposure to tumor-derived transforming growth factor-β (TGF-β), platelet-derived
growth factor (PDGF), fibroblast growth factor (FGF) and vascular endothelial growth factor (VEGF)
drives fibroblasts trans-differentiation into (cancer associated fibroblasts) CAFs. These factors also
act upon endothelial cells, pericytes and immune cells to stimulate angiogenesis. CAF-derived
FGF and hepatocyte growth factor (HGF) promote tumor cell proliferation, CAF-derived matrix
metalloproteinases (MMPs) promote invasion while chemokine ligand 14 (CXCL14) and transforming
growth factor-α (TGF-α) enhance metastasis. Ovarian cancer (OC) cell-derived TGF-β1 upregulates
fibronectin secretion in mesothelial cells, which in turn enhances spheroid adhesion to the peritoneal
wall. Adipocytes facilitate cells proliferation by providing energy dense lipids to the metastasized
cancer cells. Cancer cells expressing Snail and chemokine (C-X-C motif) ligand 1/2 (CXCL1/2) recruit
myeloid-derived suppressor cells (MDSCs) to the tumor site; conversely MDSC-secreted microRNA101
reprograms tumor cells to a stemness phenotype.
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2. Fibroblasts
Fibroblasts represent the preeminent cellular component of connective tissues, the structural
scaffold of many organs in the body. They are a heterogeneous population of mesenchymal-derived
cells that maintain the composition of the extracellular matrix (ECM) [7,8]. As such, fibroblasts produce
and deposit most of the proteins that comprise the ECM, including collagens, proteoglycans, tenascin,
fibronectin, and laminin. Tissue homeostasis involves a tightly orchestrated balance of ECM synthesis
and metabolism; in addition to ECM production, fibroblasts are also responsible for matrix metabolism.
They produce several ECM-degrading matrix metalloproteinases (MMPs) and their inhibitors, tissue
inhibitors of metalloproteinases (TIMPs) [9]. It has been observed that fibroblasts within the tumor
milieu are phenotypically similar to activated fibroblasts associated with granulating tissue (wound
healing) [10]. These cancer-associated fibroblasts (CAFs) function as tumor-promoting cells; playing
important roles in tumor initiation and progression [11–13]. Although resident fibroblasts are a major
source of CAFs, they can also arise from the trans-differentiation of other cell populations including
epithelial cells, endothelial cells, pericytes, adipocytes and bone marrow-derived mesenchymal stem
cells [14]. During tumorigenesis the trans-differentiation of the aforementioned cells into CAFs is
driven by sustained exposure to tumor-derived factors including TGF-β, PDGF-BB, basic fibroblast
growth factor (bFGF), vascular endothelial growth factor (VEGF), as well as microRNAs, reactive
oxygen species (ROS), matrix metalloproteases (MMPs) and extracellular vesicles [15–19].
Current evidence suggests the mechanisms/downstream effectors that coordinate CAF activation
vary and are contingent on CAF origin. For example, it was shown that SKOV3 cells stimulate
normal fibroblasts conversion through TGF-β mediated induction of ROS and CLIC4, which led to the
subsequent increase in the expression CAF markers αSMA and FAP. On the other hand, Jeon et al.,
demonstrated that cancer cell-derived lysophosphatidic acid induced TGF-β in adipose tissue-derived
mesenchymal stem cells which then promoted their trans-differentiation into CAFs [18,20]. Likewise,
expression of HOXA9, a differentiation related gene, was linked to paracrine secretion of TGF-β2 by
OC cells, inducing adipose and mesenchymal stem cells to become CAFs [21]. It is unknown whether
other stromal cells such as pericytes and endothelial could also contribute to the reactive stroma
associated with HGSOC.
The role of fibroblasts in cancer progression is complex. Early studies provided evidence that
fibroblasts possess anti-tumorigenic function by forming a restrictive stroma. However, the atypical
cancer-stroma interactions promote fibroblasts to develop tumor-permissive properties [22–24]. Recent
reports illustrate how the reciprocal cancer cell–fibroblast communication potentiates tumor growth
and progression in OC models. For example, CAFs have been shown to suppress the immune response
through miR141/200a-mediated expression of CAF-derived CXCL12. This chemokine promotes
infiltration of immunosuppressive CD25+ FOXP3+ T lymphocytes in the HGSOC milieu, which in turn
allows tumor growth [25]. CAFs have also been shown to drive tumor cell proliferation, migration
and invasion by producing high amounts of mitogenic factors, hepatocyte growth factor (HGF) and
FGF [26–28]. Additionally, CAF-secreted IL-8 and SDF-1 drive angiogenesis to facilitate oxygen and
nutrients delivery to the tumor tissue [29,30]. Fibroblasts treated with SKOV3-derived extracellular
vesicles acquired an activated phenotype; in turn these fibroblast enhanced tumor and endothelial cells
proliferation [17]. In another study, OC cell-derived TNF-α induced TGF-α transcription in stromal
fibroblasts. In turn, TGF-α secreted by these fibroblasts promoted metastasis via induction of EGFR
signaling in cancer cells [31]. CAFs also produce metabolites that are essential to cancer cells’ survival,
such as lactate that is absorbed and utilized by oxidative phosphorylation in adjacent cancer cells [32].
The chemokine ligand 14 (CXCL14) is a CAFs secreted protein that is associated with a poor prognosis
in OC. It was discovered that CXCL14 induced LINC00092 expression in OC cells, which resulted
enhanced metastasis. LINC0009 interacted with 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase
2 (PFKFB2) to induce a glycolytic phenotype in ovarian cancer cells. These interactions are necessary
for maintaining the CAF-phenotype, thereby unearthing a positive feedback loop between CAF-cancer
cells interactions that sustain a tumor-permissive microenvironment [33].
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Cancer invasion and metastasis is also closely associated with MMPs secreted by CAFs and tumor
cells and increased MMP expression has been associated with poor prognosis for various cancers [34].
In addition to modifying the ECM, MMPs can facilitate tumor growth and invasion by increasing the
bioavailability of ECM tethered growth factors. For instance, CAF-secreted matrix metalloproteinase-13
(MMP-13) enhanced tumor cells invasion through proteolytic cleavage of matrix-bound VEGF and
angiogenesis [35].
An additional factor involved in CAF-tumor cell cross-talk is the fibroblast activation protein
(FAP). FAP is exclusively expressed on activated fibroblasts, and increased expression is associated
with poor prognosis in many tumors [36]. In OC, FAP promoted HO-8910PM tumor cell proliferation,
invasion and migration via interactions with integrin α3β1 and urokinase-type plasminogen activator
receptor (uPAR) signaling complex [37]. Moreover, elevated stromal FAP expression was a strong
predictive marker of platinum resistance and relapse [38]. Due to the adverse effects of CAFs on
cancer recurrence and patient survival, there has been extensive investment in developing strategies to
effectively target CAFs.
3. Therapies Targeting Fibroblasts
FAP is overexpressed in many epithelial cancers including OC, and its expression is often
associated with poor prognosis [36,38], cancer cell migration, invasion and immunosuppression [39–41].
As such, FAP has emerged as a potential therapeutic target to abate the tumor promoting effects of CAFs.
The catalytic activity of FAP was shown to be necessary for tumor proliferation. However, inhibition of
FAP enzymatic activity by small molecules has had little success in clinical trials [42,43]. In a transgenic
mouse model, targeted depletion of FAP-expressing CAFs resulted in increased cancer cell death.
Mechanistically, this effect was dependent on TNF-α and IFN-γ, which are known to be involved
in CD8+ T cell mediated cancer cell death [41]. Furthermore, pre-clinical studies using vaccines
against FAP showed promising results for colon and lung cancer. Vaccines targeting FAP-expressing
cells significantly suppressed tumor growth by eliciting CD8+ or a combined CD8+ and CD4+-T cell
response respectively [40,44].
TGF-β, a cytokine abundantly secreted by fibroblasts and detectable in ascites fluid, contributes
to the development of a tumor-promoting microenvironment. Several TGF-β targeting agents have
been evaluated in clinical trials. These include small molecule kinase, antisense oligonucleotides, and
TGF-β-ligand traps [45,46]. In a mouse model of peritoneal metastasis, the TGF-β inhibitor A-83-01
improved overall survival [47,48]. Likewise, the transforming growth factor-β receptor 1 (TβRI)
kinase inhibitor galunisertib inhibited tumor growth in a partly TME-dependent manner in various
PDX tumors [49]. TGF-β inhibitors have also been shown to enhance the efficacy of conventional
therapeutics. For example, combination treatment with TGF-β receptor inhibitor LY2109761 and
cisplatin significantly blocked the growth of cisplatin-resistant ovarian xenografts [50]. Despite
promising initial preclinical results, advancement of TGF-β signaling inhibitors to the clinical arena
has been slow, marred by initial concerns over systemic (cardiac) toxicity, which fortunately appears to
be limited in humans [51].
Several other tyrosine kinase inhibitors (TKI) have been employed to mitigate the pro-tumorigenic
effects of growth factors secreted by fibroblasts in the tumor milieu, such as the platelet derived growth
factor (PDGF) and fibroblast growth factor (FGF). PDGF-D over-expression was associated with lymph
node metastasis and platinum resistance in ovarian cancer [52] and imatinib, a PDGFR inhibitor, was
shown to inhibit OC cell growth [53]. While the precise effects of imatinib on ovarian stroma are
not well defined, previous research demonstrated that this TKI suppressed angiogenesis in cervical
tumors [54]. Dasatinib, another FDA approved TKI, which also targets the PDGF receptor has been
shown to partially revert lung cancer-derived CAFs to a normal phenotype [55]. Clinical trials tested
the PDGFR inhibitors imatinib and sorafenib in patients with recurrent platinum resistant OC and
demonstrated modest clinical activity [56,57].
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4. Angiogenesis
Angiogenesis is the process whereby new blood vessels sprout from the pre-existing vasculature.
Angiogenesis is a tightly regulated and transient process observed in biological processes such
as development, wound healing and reproduction [58]. However, pathological angiogenesis is
a rate-limiting event in metastasis. As tumors increase in size (>1–2 mm2), nutrient and oxygen
availability are reduced and an angiogenic switch is activated; the newly formed blood vessels are
able to deliver nutrients and oxygen necessary for cancer cell proliferation, facilitate waste expulsion,
and also provide the primary route by which cancer cells migrate to secondary sites (metastasis) [59].
In fact, tumor vascularity serves as an indicator of metastatic potential for many cancers with highly
vascularized tumors having greater incidence of metastasis and reduced survival [60,61]. In cancers,
angiogenesis is driven by reduced levels of anti-angiogenic factors, and sustained overproduction of
pro-angiogenic molecules by tumor and host cells [58]. Angiogenesis is triggered by growth factors
such as VEGF, PDGF, (FGF), angiopoietin (Ang), as well as the chemokines IL-8 and interleukin-6
(IL-6) [59,62,63]. The association between HGSOC and an angiogenic signature was recognized more
than two decades ago and has remained a staple in the study of this tumor’s biology. VEGF is the most
extensively studied angiogenic factor in pathological angiogenesis; it is overexpressed in HGSOC and
secreted into malignant ascites [64–67]. Increased VEGF expression is associated with reduced survival
rates in patients with OC [68–70]. In a cohort of 222 HGSOC specimens, high levels of VEGF-A were
correlated with increased microvessel density and with infiltration by immune cells [71]. Interestingly,
high levels of VEGF-A were associated with BRCA-mutated ovarian tumors [71]. Although cancer cells
are a major source of angiogenic factors, non-neoplastic cells (immune cells, adipocytes, and CAFs) in
the TME also produce the angiogenic factors required to sustain tumor growth and progression [72]. As
such, there has been considerable focus on developing therapeutics to inhibit the angiogenic signaling
as a means of mitigating cancer progression.
5. Anti-Angiogenic Therapy (AAT)
VEGF is the most extensively studied pro-angiogenic factor and therapies targeting this pathway
use either inhibition of the ligand or of its receptor, vascular endothelial growth factor receptor
(VEGFR). VEGF-A is a secreted glycoprotein that belongs a family of related growth factors that
includes VEGF-B, VEGF-C, VEGF-D and VEGF-E and placental growth factor (PLGF), which have
varying functions in angiogenesis [73]. The VEGF system functions as a mitogenic factor for endothelial
cells, induces endothelial cell migration and differentiation, and protects immature endothelial cell
against apoptosis [74,75]. VEGF exerts these functions by binding to the tyrosine kinase receptors
VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1) on the cell surface, causing them to dimerize and become
activated [76]. Bevacizumab (Avastin, Roche, Basel, Switzerland), is a humanized monoclonal
antibody against VEGF that binds and inactivates VEGF, thus inhibiting endothelial cell activation
and proliferation. Bevacizumab was shown to reduce tumor growth and prolong survival in murine
ovarian cancer models [77,78]. Clinical trials using bevacizumab as a single agent and in combination
with other therapeutics have been successful and bevacizumab is currently FDA approved for use in
the front-line setting, as well as in recurrent disease [79,80].
The first clinical trial to test the efficacy of bevacizumab in OC was performed by the
Gynecologic Oncology Group (protocol GOG 170D) and tested the drug in 62 patients with recurrent,
platinum-resistant disease. In this trial, 21% of patients exhibited objective clinical responses and 40.3%
survived progression-free for at least 6 months. Median progression-free survival (PFS) and overall
survival (OS) were 4.7 and 17 months respectively [81]. This initial success led to the development
of combination therapies using bevacizumab with chemotherapy. In the ICON7 phase III trial, the
efficacy of bevacizumab in combination with platinum and paclitaxel was tested in patients with
advanced or metastatic epithelial ovarian cancer after cytoreductive surgery. Bevacizumab was
continued for 12 additional cycles or until progression of disease. Progression-free survival at 42
months was increased from 22.4 months with chemotherapy alone to 24.1 months with combination
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treatment (p = 0.04). Interestingly, PFS and OS were most significantly increased in patients at high
risk for progression. In this group, survival at 42 months was 28.8 months for patients receiving
standard therapy vs. 36.6 months for patients receiving carboplatin/platinum and bevacizumab [82].
Similar results were observed in GOG protocol 218, where chemotherapy plus bevacizumab followed
by bevacizumab maintenance improved PFS (but not OS) compared to platinum and paclitaxel
alone after cytoreductive surgery [79]. In another randomized phase III clinical trial (AURELIA
Trial), bevacizumab in combination with physician’s choice chemotherapy was tested in women
with recurrent platinum-resistant OC. The median PFS was 3.4 months for patients who received
chemotherapy alone versus 6.7 months for patients treated with bevacizumab and chemotherapy [83].
These results summarized in Table 1 led to the approval and widespread clinical use of the first therapy
targeting the ovarian cancer TME.
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Other modalities to block this pathway are in development. For example, aflibercept is a
recombinant fusion protein of VEGFR1 and VEGFR 2 extracellular domain, which functions as a
decoy receptor and inhibits VEGF-mediated signaling by trapping VEGF-A, VEGF-B, placental growth
factor-1 (PlGF-1) and (PlGF-2). Aflibercept was shown to reduce ascites and decrease the peritoneal
dissemination of OC xenograft models [53,84–86]. A phase II trial tested the efficacy of aflibercept in
patients with advanced platinum-resistant OC and malignant ascites. Patients who required three or
more previous paracenteses per month were given intravenous aflibercept 4 mg/kg every two weeks.
The primary study endpoint was repeat paracentesis response rate (RPRR), and a response was defined
as a minimum two-fold increase in time to repeat paracentesis compared with the baseline interval.
Ten out of 16 patients treated achieved a response; RPRR was 62.5% (95% CI 35.4–84.8%). Median time
to repeat paracentesis was 76.0 days (95% CI 64.0–178.0), 4.5 times longer than the baseline (16.8 days)
and the median PFS was 59.5 days (95% CI 41.0–83.0) [87], demonstrating that targeting this growth
factor in the TME leads to appreciable clinical benefits.
However, angiogenesis is a complex phenomenon tightly regulated by complementary and
cross-talking pathways, which allows for the development of resistance [88]. Thus, inhibitors that
concurrently block multiple receptors were tested in an effort to improve the efficacy of AAT. Cediranib
(AZD2171, AstraZeneca) is a receptor tyrosine kinase inhibitor that inhibits vascular endothelial
receptor 1–3 (VEGFR 1–3), platelet-derived growth factor-α and β (PDGFR-α and -β), and c-kit. A
phase II clinical trial assessed the efficacy of cediranib in patients with recurrent gynecologic cancers
who had received less than two lines of platinum-based chemotherapy. Of 46 patients treated, eight
patients (17%) had partial responses (PR), six patients (13%) stable disease (SD), and there were
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no complete responses (CRs) [89]. In another phase II trial, the efficacy of single-agent cediranib
was assessed in 74 patients with persistent/recurrent OC following one round of platinum-based
chemotherapy. The patients were stratified into two groups; 39 platinum-sensitive (PL-S) and 35
platinum-resistant (PL-R), and the primary endpoint was objective response rate at 16 weeks. In
the platinum sensitive (PL-S) group, 10 patients (26%) demonstrated partial responses (PR) and 20
(51%) had stable disease (SD). There were no confirmed PR in the platinum resistant (PL-R) group
and 23 patients (66%) had SD. The median PFS was 7.2 months for PL-S and 3.7 months for PL-R
groups, and the median OS was 27.7 and 11.9 months respectively [90]. Currently cediranib is being
evaluated in combination with olaparib, a poly (ADP-ribose) polymerase PARP inhibitor in women
with recurrent OC.
Nintedanib is another tyrosine kinase inhibitor for VEGFR-1-3, FGFR 1-3, PDGFR α and β.
Nintedanib was tested as maintenance treatment after chemotherapy in a randomized trial. PFS at
36-weeks was 5.0% vs. 16.3% in placebo and nintedanib treated patients [91]. However, in a subsequent
phase III trial (AGO-OVAR 12) nintedanib combined with platinum-based therapy did not induce a
significant survival advantage after debulking surgery. The median PFS was 17.2 vs. 16.6 months for
patients treated with nintedanib and placebo, respectively. A post-hoc analysis showed that nintedanib
and platinum-based therapy combination improved PFS in non-high-risk patients [92]. Pazopanib
(GW786034) is tyrosine kinase inhibitor for VEGFR-1, -2 and -3 PDGFR-α and -β and c-kit. An ongoing
clinical phase II trial (MITO-11) is evaluating the safety and activity of pazopanib in combination with
paclitaxel in patients with platinum-resistant or refractory OC. The median progression-free survival
was 3.5 months in patients treated with weekly paclitaxel vs. 6.3 months in patients treated with
weekly paclitaxel and pazopanib. The median overall survival was 14.8 months in paclitaxel treated vs.
18.7 months in patients treated with paclitaxel and pazopanib [93]. In all, these and other trials have
convincingly demonstrated the activity of AAT in HGSOC, leading to the approval of bevacizumab
for treatment in both the adjuvant and recurrent settings. New trials are evaluating the efficacy of
anti-angiogenic drugs in combination with immune modulators or PARP inhibitors for treatment of
gynecologic malignancies.
6. Interactions with the Mesothelial Matrix
In order to form secondary tumors, disseminated OC cell spheroids floating in the peritoneal cavity
rely on their capacity to adhere to the mesothelial lining covering the peritoneal cavity and abdominal
organs. During dissemination from the primary site, OC cells lose E-cadherin expression (Figure 2,
upper left) and upregulate α5 integrin, which was proposed as a therapeutic target [94]. Secondary
site invasion occurs upon displacement of the mesothelial monolayer cells (Figure 2, lower right), with
cancer cells invading and submerging into the subjacent environment. The clearance of mesothelial cells
is enabled by traction forces mediated by myosin and generated by the adhesion complex molecules,
α5 integrin and talin-1, and is more efficiently accomplished by reprogrammed mesenchymal-like OC
cells [95,96]. Other receptors that play a role in OC cell adhesion to mesothelium include CD44 and
β1 integrin (Iβ1) [97]. OC cell-derived TGF-β1 upregulates fibronectin (FN) expression in mesotheial
cells [98]. The adhesion of OC cells to the FN matrix secreted by mesothelial cells [98] is dependent
upon α5β1 integrin clustering and talin recruitment to stabilize the adhesions (Figure 2) [95]. Integrin
clustering is induced by secreted tissue transglutaminase (TG2), which forms a bridge connecting
Iβ1 and FN together at the cell surface [99]. This event induces downstream RhoA activation and
suppression of Src–p190RhoGAP signaling. A focus of our laboratory’s work was to understand the
role played by the TG2-Iβ1-FN ternary complex in the process of OC metastasis and to test it as a
new therapeutic target. By using OC orthotopic and ip xenografts, we showed that TG2 knock-down
blocked peritoneal dissemination of ovarian tumors through a mechanism dependent on β1-integrin
mediated cell adhesion and signaling [100,101]. Our recent results also demonstrate that engagement
of integrin β1 facilitated by TG2 activates β-catenin signaling and stemness associated pathways in
in vivo and organoid models of HGSOC [102,103].
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Figure 2. Ovarian cancer cells adhere to the mesothelial lining during tumor dissemination in the
peritoneal cavity. Upon activation of EMT (epithelial-to-mesenchymal transition), cells progressively
shed from the primary tumor into the peritoneal cavity (blue square). During the EMT process,
there is a decrease in E-cadherin expression and increase in proteins associated to a mesenchymal
phenotype, such as vimentin, tissue transglutaminase (TG2) and integrins. Cells that survive in the
environment of the peritoneal cavity form spheroids. Spheroids attach to the fibronectin (FN) rich
matrix secreted by the mesothelial cells, clear the subjacent monolayer and invade the underling tissue.
These adhesion and invasion processes are mediated by interactions of integrin-β1 receptors with
the FN fibrils in the ECM. Upon FN binding, α5β1 integrin receptors undergo clustering, which is
enhanced by molecular bridges with TG2. Next, talin is recruited to the adhesion complex and provides
the necessary traction force for the mesothelial monolayer displacement (red dotted bottom square).
Also, “outside-in” signaling downstream of β1 integrin is activated, inducing focal adhesion kinase
(FAK) phosphorylation. Therapeutic strategies targeting the TG2-FN-Iβ1 complex aim at interfering
with the cell adhesion process and consequently preventing OC metastasis (red dotted top square).
7. Targeting Ovarian Cancer Cell Adhesion to the Peritoneal Matrix
Several strategies have been tested in an effort to block OC peritoneal dissemination. Treatment
with blocking antibodies against integrins and the CD44 receptor were shown to inhibit OC cells
adhesion to the mesothelial layer for short time intervals [104–106]. As α5β1 integrin is expressed
on both OC cells as well as on the endothelial cells forming microvessels [107], it was expected that
targeting this heterodimer (Figure 2, top square) will interfere with tumor growth and metastasis in
many types of solid cancers, including OC [108]. Currently several drugs targeting integrins are under
development (reviewed in [109]).
Volociximab, a chimeric antibody that binds α5β1 integrin with high affinity, was shown to
block growth and dissemination of OC xenograft models [94]. However, the phase II clinical
trial testing volociximab in patients with recurrent, platinum-resistant OC failed to demonstrate
benefit although the drug was well tolerated [110]. Intetumumab (CNTO-95), a human αv-integrin
specific monoclonal antibody that targets both αvβ3- and αvβ5-integrins showed anti-tumor and
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anti-angiogenic effects in xenografts models of breast cancer [111,112]. In a phase I clinical trial
including patients with advanced solid tumors, one patient with ovarian carcinosarcoma had stable
disease for six months [113]. Other integrin-blocking antibodies, such as etaracizumab, the humanized
version of anti-αvβ3-integrin LM609 had minimal therapeutic benefit in other cancers [114]. Cilengitide
is a stable cyclic pentapeptide containing an Arg-Gly-Asp (RGD) motif which allows selective binding
to αvβ3 and αvβ5 integrins [115]. Cilengitide was tested in brain tumors and was found to not increase
OS in glioblastoma patients during a phase III trial [116]. Given that αvβ3 integrin expression by
tumor cells correlates with a favorable prognosis in OC patients [117], targeting this integrin might be
a less appropriate strategy for OC. The initial disappointment with integrin targeting strategies may
be related to their prior testing in the recurrent, advanced setting as single agents. Development of
combination regimens and testing of these blocking antibodies in patients with low volume metastatic
disease might overcome the lack of clinical success with this intervention.
FN is one of the most abundant ECM proteins in the omentum and peritoneum [118]. Adhesion of
OC cells to FN via α5β1 integrin impacts “outside-in signaling” by inducing phosphorylation of focal
adhesion kinase (FAK) either directly [119] or through c-Met [108]. This can further lead to activation of
mitogenic pathways [120] which support tumor growth [121]. The β1 integrin–FN interaction is further
enhanced by the bridging activity of TG2, a protein we discovered to be overexpressed in OC [122].
Previous work in our group has emphasized the importance of TG2 in the OC metastatic process, by
providing evidence of its involvement in promoting OC cells’ epithelial-to-mesenchymal transition
through activation of non-canonical NF-κB [123], increasing cell proliferation by regulating β-catenin
signaling [102], enhancing peritoneal dissemination [100], and increasing invasion by regulating
MMP-2 [124]. As proof of principle that the TG2-FN-Iβ1 complex represents an interesting target in
OC, we used a function-blocking antibody which targeted the FN binding domain of TG2, and showed
that this antibody blocked OC spheroid proliferation and tumor initiating capacity by disrupting the
interaction between OC stem cells and their niche [103].
To discover potent and selective TG2-FN inhibitors we used both virtual docking and high
throughput screening strategies. Through an initial in silico docking approach, we identified a small
molecule inhibitor capable of disrupting this complex and of blocking cancer cell adhesion to the
FN matrix [125]. Subsequent efforts used an AlphaLISA-based assay adapted to high-throughput
screening and applied to the ChemDiv library leading to the discovery and validation of several small
molecules [126]. One hit selected from this screen (TG53) was validated in vitro to be an efficient
inhibitor of OC cell adhesion to FN, migration and invasion. Future efforts focus on optimizing this
compound through structure–activity relationship-based strategies to generate more selective, potent
and drug-like compounds which block the TG2-FN protein–protein interaction and ultimately prevent
OC metastasis.
8. Tumor Immune Response in Ovarian Cancer
Preclinical models and retrospective cohort analyses of human tumor specimens have
demonstrated that the interaction between cancer cells and the host immune defense plays an
important role harnessing tumor progression. There are several immune cell subsets relevant for
tumor progression and response to immunotherapy [127]. These are classified in two categories:
immune reactive and immune suppressive cells. The immune reactive cells include primarily cytotoxic
T lymphocytes and activated CD4+ T cells. The immune suppressive cells are myeloid lineage
subpopulations known as myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages
(TAMs, especially M2 subtype), dendritic cells (DCs) and the lymphocyte subsets of T helper cells (Th2
subtype) and T regulatory cells (Tregs). A seminal study showed that the presence of CD3+ tumor
infiltrating lymphocytes (TILs) in OC is associated with increased survival [128]. The 5-year overall
survival (OS) was 38% for patients whose tumors contained T cells compared to 4.5% for those whose
tumors were devoid of T cells. Subsequently, a strong association between the presence of CD8+ TILs
and favorable clinical outcomes of HGSOC was recognized [129–131]. The CD8+ to T regulatory (Tregs)
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cells ratio was also shown to correlate with increased survival of OC patients [130]. More recently,
the presence of CD8+ cells expressing the TNFR-family receptor CD137 (4-1BB) was reported as a
prognostic marker associated with improved survival of OC patients [132]. A recent study evaluated
the immune TME landscape in differentially growing metastases after several therapy cycles in an
OC patient and reported heterogeneity in immune infiltrates that explained the evolution of tumor
masses over nine years period [133]. This unique report revealed a correlation between the regressing
or stable metastases and the presence of oligoclonal expanding T cells. Conversely, progressing tumors
showed a lack of infiltration with anti-cancer lymphocytes. This study reinforces the importance of the
tumor immune microenvironment to the outcome of OC disease. In all, these and other studies [134]
strongly support the role of anti-tumor immunity as a key regulator in the evolution of the disease.
Enhancing the naturally occurring immune defense could therefore play an important
role harnessing disease progression. Immunotherapy has demonstrated efficacy in various
malignancies [135,136]. Several immune modulatory approaches (vaccines, IL2, CTLA-4 directed
antibodies, adoptive transfer of activated T cells) have been tested in OC, with promising results in
early interventions [137,138]. However, the impact of immunotherapy on the survival of OC patients
remains unproven and predictive markers of positive outcomes remain undefined, highlighting the
need to further optimize such strategies.
9. Immune Checkpoint Inhibitors
Recent advances have brought attention to the programmed cell death protein-1 (PD-1)
mechanism used by cancer cells to evade immune surveillance, which can be effectively targeted
by inhibitory antibodies [139]. This strategy demonstrated impressive clinical activity in several
solid tumors (melanoma, lymphoma, renal, lung, and bladder cancer) leading to new FDA-approved
interventions [140–142]. PD-1 signaling blocks T-cell activation keeping nascent T-cells in check and
preventing immune responses against normal tissues. During cancer progression, this inhibitory
pathway is activated by upregulating the expression of PD ligands (PD-L1 and PD-L2) on tumor
and immune cells and permits evasion from immune surveillance [139]. The significance of the PD1
pathway to OC progression has been investigated; however, the emerging evidence is conflicting. On
one hand, initial studies showed that the increased PD-L1 expression in ovarian tumors correlates with
decreased intra-tumoral CD8+ lymphocytes and worse patient survival [143]. Presence of dendritic
cells expressing PD1 in the OC microenvironment was also found to be associated with decreased
numbers of TILs and suppressed T cell activity [144], consistent with the concept that PD-L1 represents
an escape mechanism. On the other hand, more recent studies using specific PD1 and PD-L1 detection
antibodies provide evidence to the contrary. Two reports showed that expression of PD-L1 on immune
cells in the tumor milieu, including on tumor associated macrophages (TAMs), is associated with
increased total numbers of TILs and better survival in HGSOC [145,146]. It remains unresolved how
expression of the PD1 pathway elements can be causally linked to a favorable prognosis in OC. It is
possible that expression of PD-L1 reflects an active immune TME (defined by increased TILs density)
able to attack and eliminate the tumor, or that PD-L1+ TILs have a yet to be defined regulatory role in
the immune response mechanism. Additional support for clinical interventions targeting this pathway
includes that PD-1/PD-L1 blockade restored anti-tumor immunity in an OC xenograft model [147].
Two recent clinical trials tested PD-1 (pembrolizumab) and PD-L1 (avelumab) inhibitory antibodies in
women with recurrent OC, reporting response rates of 11% (pembrolizumab) and 10% (avelumab),
with 23% and 40% additional patients experiencing stable disease, respectively [148,149]. These early
data suggest that immune checkpoint blockade in OC has defined, albeit modest activity.
Another emerging concept refers to the tumor neoantigen load as an important regulator of
anti-tumor immune response and a marker for response to treatment [150,151]. Along these lines,
a recent study showed that BRCA 1 and 2 mutated ovarian tumors are characterized by increased
neoantigen load and that this correlates with increased number of TILs, increased expression of
PD1 and PDL1, and is linked to improved clinical outcome [152]. These data support exploring
411
Cancers 2018, 10, 266
PD1 blockade in OC and continued investigation of the complex immune milieu associated with
ovarian tumors. Therefore, identifying rational combinations to enhance the activity of PD1 blocking
antibodies in OC and further analysis of the immune tumor milieu to identify predictive markers is
necessary. Our group is exploring the combination of the PD1 inhibitor pembrolizumab and the DNA
hypomethylating agent guadecitabine in women with recurrent platinum-resistant ovarian cancer
(NCT02901899), testing the hypothesis that epigenomic priming will enhance the activity of immune
checkpoint inhibitors.
10. Targeting Tumor Associated Macrophages (TAMs) and Myeloid-Derived Suppressor
Cells (MDSCs)
Myeloid cells are frequently observed in the stroma of growing tumors [153]. The role of myeloid
suppressor cells has been recognized first in late 1970s. In 2007, the term myeloid-derived suppressor
cells (MDSCs) was coined for “bone marrow-derived cells of myeloid lineage comprising myeloid
precursors and immature macrophages, granulocytes, and DCs, characterized by their high potential
to suppress T cells” [154]. Immature myeloid suppressor cells were shown even earlier to accumulate
in a variety of immune-related diseases, including cancer [155,156]. MDSC subsets were found to
be responsible for immune suppression in 10 pre-clinical models of tumorigenesis [157]. In OC,
macrophages are mainly found in ascites or infiltrate of the omentum. TAMs in the omentum were
shown to harbor predominantly the M2 phenotype and to facilitate tumor progression [158,159].
Peritoneal TAMs support this process by secreting cytokines such as IL-6 and IL-8 [160]. In the
ascites, M2 macrophage-like TAMs were found in the center of spheroids, where they participated in
mechanisms supporting tumor cell proliferation and migration during OC metastasis [161]. The main
signaling pathway involved in TAMs cross-talk to floating spheroid cancer cells was EGF–EGFR.
TAMs promoted cancer cell invasiveness by activating the NF-κB and JNK signaling pathways [162].
Reversely, peritoneal macrophages were shown to adopt the M2 phenotype under the influence of OC
cells expressing homeobox gene HOXA9 [163]. PD-L1 was primarily expressed by CD68+ TAMs rather
than tumor cells in HGSOC, and often colocalized with both cytotoxic T cells as well as T regulatory
cells and was a positive prognostic marker [146].
The contribution of MDSCs defined as harboring Lin−CD45+CD33+ markers combination was
studied in a cohort of patients with HGSOC [164]. MDSCs comprised 37% of non-neoplastic cells in
the TME and were responsible for inhibiting T-cell immunity, by blocking both T cell proliferation and
effector function. Increased tumor MDSCs inversely correlated with CD8+ TILs and overall survival
in advanced OC [165]. Interestingly, the corresponding Lin−CD45+CD33+ fraction in patients’ blood
did not have the same properties. MDSCs were shown to support metastasis and a cancer stem
cell phenotype. Mechanistically, it was shown that tumor-resident MDSCs enhance stemness via
microRNA101, which targets co-repressor gene C-terminal binding protein-2 (CtBP2) 3’-UTR region
and interferes with its binding at NANOG, OCT4/3, and SOX2 promoters in primary OC cells [164].
Primary ovarian tumors expressing high levels of Snail were shown to recruit increased number
of CD33+ MDSCs through secretion of the CXCR2 ligands CXCL1/2 [166,167]. Therefore, blocking
CXCR2 would represent a therapeutic approach for Snail-high OC tumors.
Targeting immature myeloid cells and their cross-talk with other immune cells and cancer cells is
a potential strategy of combating tumor progression. Several classes of therapeutics targeting MDSCs
or TAMs have been described and were recently reviewed [167]. They include agents which promote
MDSCs apoptosis, antibodies that induce MDSCs and/or TAMs depletion, compounds that induce
immature myeloid cells differentiation (such as retinoic acid, vitamin D3 or HDACi), inhibitors of
immune suppression function (sildenafil, triterpenoids, inhibitors of COX-2, inducible nitric oxide),
compounds which block recruitment (by targeting chemokines and chemokine receptors) or MDSCs
proliferation, and lastly TAM reprogramming factors. Given that TAMs and MDSCs mediate resistance
to immunotherapy targeting, this immune suppressive cell population could increase the success rate
of checkpoint blockade inhibitors [168].
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Several strategies have been tested in preclinical models, but progress towards clinical is still
ongoing. For example, almetuzumab, which targets CD52 expressed by vascular leukocytes and
Tie2+ monocytes, was shown to have anti-myeloid and anti-angiogenic properties in OC models [169].
Anti-CD52 therapy decreased tumor growth in an OC murine model. Additionally, ovarian TAMs
express high levels of folate receptor-2, which can be targeted by using methotrexate loaded
G5-dendrimers (G5-MTX) [170]. Noteworthy, these G5-MTX nanoparticles were shown to overcome
resistance to anti-VEGF-A therapy in OC preclinical models. Epigenetic modulators have also been
shown to alter the myeloid population, triggering anti-tumor immune responses. For example,
the bromodomain inhibitor JQ1 significantly reduced PD-L1 expression on TAMs and dendritic
cells, induced increased T cell cytotoxic activity and suppressed OC tumor growth in preclinical
models [171]. A combination of histone deacetylase inhibitors (HDACi) and DNA methyltransferase
inhibitor (DNMTi) was shown to reduce TAMs and increase T and NK cell activation, delaying tumor
progression in preclinical models [172]. The combination of DNMTi/HDACi also synergized with the
immune checkpoint inhibitors. Clinical trials testing HDACi and DNMTi with anti-PD1 therapy in
patients with recurrent OC are ongoing. Lastly, catumaxomab is a humanized antibody that targets
three different cell types: tumor cells (via epithelial cell adhesion molecule (EpCAM) binding); T-cells
(via CD3 binding); and accessory cells (macrophages, dendritic cells, and natural killer cells) via type
I, IIa, and III Fcγ receptors (FcγR). Subsequently, catumaxomab induces several effects, including
T-cell-mediated tumor lysis, antibody-dependent cell-mediated cytotoxicity, and phagocytosis via
activation of NK cells and TAMs. Catumaxomab is administered intra-peritoneally and was shown
to be clinically active in patients with malignant ascites, leading to its approval in Europe for the
treatment of EpCAM+ tumors associated with ascites, including HGSOC [173].
11. Conclusions
New targets at the interface between HGSOC cells and the TME have been characterized. Targeted
treatments, alone or in combination with chemotherapy, are emerging and, in some situations, are
already impacting clinical outcomes in women with HGSOC. Anti-angiogenic therapy in combination
with chemotherapy has significantly improved the survival of women with advanced OC and has
become part of the standard approach. In contrast, CAFs-directed strategies or therapeutics targeting
cell adhesion to the matrix remain less impressive. Future development of combination and sequencing
strategies based on a refined understanding of tumor biology and cross-talking pathways is critically
needed. While immune interventions are still being optimized, early results suggest that combination
strategies are needed to overcome the immune tolerant milieu of HGSOC. This could be due to
silencing of tumor antigen and low tumor mutational burden, which render the ovarian tumors to
be “cold”, or to an infiltration of immunosuppressive cells. Therefore, current approaches investigate
dual immune targeting or combinations with interventions that de-repress tumor antigens through
epigenetic reprogramming or which increase the tumor mutational burden by inducing DNA damage.
It is clear that in order to improve clinical outcomes in this fatal malignancy, interventions affecting
both cancer cells and the stroma need to be implemented. Thus, we anticipate that clinical trials
will continue to explore rationally designed combinations and/or sequences of therapies targeting
vulnerabilities of both tumor cells and the TME.
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